UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
FORM 10-K  

þ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017 .
or
¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.            
Commission File Number: 000-08185
CHEMICAL FINANCIAL CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Michigan
 
38-2022454
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
235 E. Main Street
Midland, Michigan
 
48640
(Address of Principal Executive Offices)
 
(Zip Code)
(989) 839-5350
(Registrant's Telephone Number, Including Area Code)
Securities Registered Pursuant to Section 12(b) of the Act:
Common Stock, $1 Par Value Per Share
 
The NASDAQ Stock Market
(Title of Class)
 
(Name of each exchange on which registered)
Securities Registered Pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  þ No  ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ¨ No  þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  þ No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  þ No  ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer þ
 
Accelerated filer ¨
 
Non-accelerated filer ¨
 
Smaller reporting company ¨
Emerging growth company ¨
 
 
 
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   þ
The aggregate market value of the registrant's outstanding voting common stock held by non-affiliates of the registrant as of June 30, 2017 , determined using the closing price of the registrant's common stock on June 30, 2017 of $48.41 per share, as reported on The NASDAQ Stock Market ® , was $3.34 billion . The number of shares outstanding of the registrant's Common Stock, $1 par value per share, as of February 26, 2018 , was 71,302,847 shares.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the definitive Proxy Statement of Chemical Financial Corporation for the April 25, 2018 annual shareholders' meeting are incorporated by reference into Part III of this Form 10-K.
 
 
 
 
 



CHEMICAL FINANCIAL CORPORATION
ANNUAL REPORT ON FORM 10-K
Table of Contents
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2


FORWARD-LOOKING STATEMENTS
This Annual Report contains forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates and projections about the financial services industry, the economy and us. Words and phrases such as "anticipates," "believes," "continue," "estimates," "expects," "forecasts," "future," "intends," "is likely," "judgment," "look ahead," "look forward," "on schedule," "opinion," "opportunity," "plans," "potential," "predicts," "probable," "projects," "should," "strategic," "trend," "will," and variations of such words and phrases or similar expressions are intended to identify such forward-looking statements. These statements include, among others, statements related to: our expectation to continue to pay quarterly dividends through 2018, our planned restructuring efforts, our strategic plan to develop customer relationships that will drive core deposit growth and stability, management's belief that our commercial and commercial real estate loan portfolios are generally well-secured, management's opinion that our borrowing capacity could be expanded, the impact of projected changes in net interest income assuming changes to short-term market interest rates, statements regarding our risk exposure in our primary markets, as well as statements related to the anticipated effects on results of operations and financial condition from expected developments. All statements referencing future time periods are forward-looking.

Management's determination of the provision and allowance for loan losses; the carrying value of acquired loans, goodwill and mortgage servicing rights; the fair value of investment securities (including whether any impairment on any investment security is temporary or other-than-temporary and the amount of any impairment); and management's assumptions concerning pension and other postretirement benefit plans involve judgments that are inherently forward-looking. There can be no assurance that future loan losses will be limited to the amounts estimated. All of the information concerning interest rate sensitivity is forward-looking. The future effect of changes in the financial and credit markets and the national and regional economies on the banking industry, generally, and on us, specifically, are also inherently uncertain.

Forward-looking statements are based upon current beliefs and expectations and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Accordingly, such statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions ("risk factors") that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements. We undertake no obligation to update, amend or clarify forward-looking statements, whether as a result of new information, future events or otherwise. Risk factors include, without limitation:

our ability to attract and retain new commercial lenders and other bankers as well as key operations staff in light of competition for experienced employees in the banking industry;
our ability to grow deposits while reducing the number of physical branches that we operate;
negative reactions to our branch closures by our customers, employees and other counterparties;
economic conditions (both generally and in our markets) may be less favorable than expected, which could result in, among other things, a deterioration in credit quality, a reduction in demand for credit and a decline in real estate values;
a general decline in the real estate and lending markets, particularly in our market areas, could negatively affect our financial results;
increased cybersecurity risk, including potential network breaches, business disruptions, or financial losses;
current or future restrictions or conditions imposed by our regulators on our operations may make it more difficult for us to achieve our goals;
legislative or regulatory changes, including changes in accounting standards and compliance requirements, may adversely affect us;
changes in the interest rate environment may reduce margins or the volumes or values of the loans we make or have acquired;
economic, governmental, or other factors may prevent the projected population, residential, and commercial growth in the markets in which we operate; and
operational and regulatory challenges associated with our information technology systems and policies and procedures in light of our rapid growth and pending system conversion in 2018.

In addition, risk factors include, but are not limited to, the risk factors described in Item 1A of this Annual Report. These and other factors are representative of the risk factors that may emerge and could cause a difference between an ultimate actual outcome and a preceding forward-looking statement.
    

3


PART I.
Item 1. Business.
Overview
Chemical Financial Corporation (the "Corporation"), headquartered in Midland, Michigan, is a financial holding company registered under the Bank Holding Company Act of 1956, as amended, that was incorporated in the State of Michigan in August 1973. Our common stock is listed on the NASDAQ under the symbol "CHFC." On June 30, 1974, the Corporation acquired Chemical Bank and Trust Company pursuant to a reorganization in which the former shareholders of Chemical Bank and Trust Company became shareholders of the Corporation. Chemical Bank and Trust Company's name was changed to Chemical Bank on December 31, 2005. In this Annual Report, unless the context indicates otherwise, all references to "we," "us," and "our" refer to Chemical Financial Corporation and Chemical Bank.
Since our acquisition of Chemical Bank and Trust Company, we have acquired 25 community banks and 36 other branch bank offices through December 31, 2017 . Our most recent transactions include our merger with Talmer Bancorp, Inc. ("Talmer") during the third quarter of 2016 and the acquisitions of Lake Michigan Financial Corporation ("Lake Michigan") and Monarch Community Bancorp, Inc. ("Monarch") during the second quarter of 2015, and the acquisition of Northwestern Bancorp, Inc. ("Northwestern") during the fourth quarter of 2014. These transactions are discussed in more detail under the subheading "Mergers, Acquisitions and Branch Closings" included in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this Annual Report.
Our business is concentrated in a single industry segment, commercial banking, which is conducted through our single commercial bank subsidiary, Chemical Bank. We offer a full range of traditional banking and fiduciary products and services to residents and business customers in our geographical market areas. These products and services include business and personal checking accounts, savings and individual retirement accounts, time deposit instruments, electronically accessed banking products, residential and commercial real estate financing, commercial lending, consumer financing, debit cards, safe deposit box services, money transfer services, automated teller machines, access to insurance and investment products, corporate and personal wealth management services, mortgage banking and other banking services. Chemical Bank operated through an internal organizational structure of seven regional banking units, organized by geography, as of December 31, 2017 . In addition, we own, directly or indirectly, various non-bank operating and non-operating subsidiaries.
At December 31, 2017 , we had consolidated total assets of $19.28 billion , total loans of $14.16 billion , total deposits of $13.64 billion and shareholders' equity of $2.67 billion . For more information about our financial condition and results of operations, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our Consolidated Financial Statements and related notes included in this Annual Report.
Our Market Area     
Our principal market concentrations are in Michigan, Northeast Ohio and Northern Indiana where Chemical Bank's branches are located and the areas surrounding these communities. As of December 31, 2017 , we served these markets through 212 banking offices. In addition to the banking offices, Chemical Bank operated seven loan production offices and over 245 automated teller machines, both on- and off-bank premises, as of December 31, 2017 .
Lending Activities
We offer a range of lending services including both commercial and consumer loans. Our commercial loan portfolio is comprised of commercial, commercial real estate loans and real estate construction and land development loans. Our consumer loan portfolio is comprised of residential mortgage, consumer installment and home equity loans. Our customers are generally commercial businesses, professional services and retail consumers within our market areas. At December 31, 2017 , total loans, net of allowance for loan losses, were $14.06 billion , representing 72.9% of our total assets.

4



A summary of the composition of our loan portfolio at December 31, 2017 , 2016 and 2015 follows:
 
December 31,
 
2017
 
2016
 
2015
 
Amount
 
Percent of Total
 
Amount
 
Percent of Total
 
Amount
 
Percent of Total
(Dollars in thousands)
 
Composition of Loans:
 
 
 
 
 
 
 
 
 
 
 
Commercial
$
3,385,642

 
24
%
 
$
3,217,300

 
25
%
 
$
1,905,879

 
26
%
Commercial real estate
4,500,670

 
32

 
3,973,140

 
30

 
2,112,162

 
29

Real estate construction and land development
574,215

 
4

 
403,772

 
3

 
232,076

 
3

Residential mortgage
3,252,487

 
23

 
3,086,474

 
24

 
1,429,636

 
20

Consumer installment
1,613,008

 
11

 
1,433,884

 
11

 
877,457

 
12

Home equity
829,245

 
6

 
876,209

 
7

 
713,937

 
10

Total composition of loans
$
14,155,267

 
100
%
 
$
12,990,779

 
100
%
 
$
7,271,147

 
100
%
    
Commercial Loan Portfolio
Commercial loans
We offer commercial loans and lines of credit to varying types of businesses, including for profit businesses, municipalities, school districts and nonprofit organizations, for the purpose of supporting working capital and operational needs and term financing of equipment. Our commercial loan portfolio is well diversified across business lines and has no concentration in any one industry.
In our credit underwriting process, we carefully evaluate the borrower's industry, management skills, operating performance, liquidity and financial condition. We underwrite commercial loans based on a multiple of repayment sources, including operating cash flow, liquidation of collateral and guarantor support, if any. We closely monitor the operating performance, liquidity and financial condition of the borrowers through analysis of required periodic financial statements and meetings with the borrower's management. We generally secure our commercial loans with inventory, accounts receivable, equipment, personal guarantees of the owner or other sources of repayment, although we may also obtain real estate as collateral.
Commercial Real Estate Loans
Our commercial real estate loans include loans that are secured by real estate occupied by the borrower for ongoing operations, non-owner occupied real estate leased to one or more tenants and vacant land that has been acquired for investment or future land development. Commercial real estate loans are subject to the same general risks and additionally are particularly sensitive to fluctuations in the value of real estate and typically involve larger loan balances concentrated in a single borrower. In addition, the payment experience on loans secured by income-producing properties and vacant land loans is typically dependent on the success of the operation of the related project and is typically affected by adverse conditions in the real estate market and in the economy. Fluctuations in the value of real estate, as well as other factors arising after a loan has been made, could negatively affect a borrower’s cash flow, creditworthiness and ability to repay the loan. When we make new real estate loans, we obtain a security interest in real estate whenever possible, in addition to any other available collateral, to increase the likelihood of the ultimate repayment of the loan. We generally attempt to mitigate the risks associated with commercial real estate loans by, among other things, lending primarily in our market areas, lending across industry lines, not developing a concentration in any one line of business and using prudent loan-to-value ratios in our underwriting process.
Each commercial real estate borrower is evaluated on an individual basis to determine the business risks and credit profile of each borrower and we generally require that a borrower maintain specific debt service covenants. To ensure secondary sources of payment and liquidity to support a loan, we review the financial statements of the operating company and the personal financial statements of the principal owners and may require their personal guarantees.
Real Estate Construction and Land Development Loans
Our real estate construction loans are primarily originated for construction of commercial properties and often convert to a commercial real estate loan at the completion of the construction period. Our land development loans include loans made to developers for the purpose of infrastructure improvements to vacant land to create finished marketable residential and commercial lots/land. A majority of our land development loans consist of loans to develop residential real estate. Land development loans

5


are generally originated as interest only with the intention that the loan principal balance will be repaid through the sale of finished properties by the developers within twelve months of the completion date.
Real estate construction and land development lending involves a higher degree of risk than commercial real estate lending and residential mortgage lending because of the uncertainties of construction, including the possibility of costs exceeding the initial estimates, the need to obtain a tenant or purchaser of the property if it will not be owner-occupied or the need to sell developed properties. We generally attempt to mitigate the risks associated with real estate construction and land development lending by, among other things, lending primarily in our market areas, using prudent underwriting guidelines and closely monitoring the construction process.

Consumer Loan Portfolio

Residential Mortgage   

Our residential mortgage loans consist primarily of one- to four-family residential loans with fixed interest rates of 15 years or less, with amortization periods generally from 15 to 30 years. The loan-to-value ratio at the time of origination is generally 80% or less. Loans with more than an 80% loan-to-value ratio generally require private mortgage insurance. Residential mortgage loans also include loans to consumers for the construction of single family residences that are secured by these properties.

The mortgage loans that we originate to be held by us in our portfolio have generally been priced competitively with current market rates for such loans. We currently offer a number of ARM loans with terms of up to 30 years and interest rates that adjust at scheduled intervals based on the product selected. These interest rates can adjust annually, or remain fixed for an initial period of three, five or seven years and thereafter adjust annually. The interest rates for ARM loans are generally indexed to the one-year U.S. Treasury Index or the one year LIBOR rate. The ARM loans generally provide for periodic (not more than 2%) and overall (not more than 6%) caps on the increase or decrease in the interest rate at any adjustment date and over the life of the loan.
Because the majority of loans originated and retained in the residential portfolio are adjustable-rate one- to four-family mortgage loans, we limit our exposure to fluctuations in interest income due to rising interest rates. However, adjustable-rate loans generally pose credit risks not inherent in fixed-rate loans, primarily because as interest rates rise, the underlying payments of the borrower rise, thereby increasing the potential for default. Periodic and lifetime caps on interest rate increases help to reduce the credit risks associated with adjustable-rate loans but also limit the interest rate sensitivity of such loans. We require that adjustable-rate loans held in the loan portfolio have payments sufficient to amortize the loan over its term and the loans do not have negative principal amortization.
Consumer Installment
Our consumer installment loans consist of relatively small loan amounts to consumers to finance personal items (primarily automobiles, recreational vehicles and marine vehicles) and are comprised primarily of indirect loans purchased from dealerships. We originate consumer installment loans utilizing a computer-based credit scoring analysis to supplement the underwriting process. Consumer rates are both fixed and variable, with negotiable terms. Our consumer installment loans typically amortize over periods up to 60 months. Although we typically require monthly payments of interest and a portion of the principal on our loan products, we may offer consumer loans with a single maturity date when a specific source of repayment is available. Consumer loans not secured by real estate are generally considered to have greater risk than first or second mortgages on real estate because they may be unsecured, or, if they are secured, the value of the collateral may be difficult to assess and more likely to decrease in value, and is more difficult to control, than real estate.
Home Equity Loans and Lines of Credit
Our home equity loans and lines of credit are comprised of loans to consumers who utilize equity in their personal residence, including junior lien mortgages, as collateral to secure the loan or line-of-credit. The majority of our home equity lines of credit are comprised of loans with payments of interest only and original maturities of up to ten years. These home equity lines of credit include junior lien mortgages whereby the first lien mortgage is held by a nonaffiliated financial institution. We also originate home equity loans utilizing a computer-based credit scoring analysis to supplement the underwriting process.
Mortgage Banking Activity
Sale of Residential Real Estate Loans
We engage in mortgage banking as part of an overall strategy to deliver loan products to customers. As a result, we sell a large portion of the residential loans we originate to Fannie Mae, Freddie Mac or, to a lesser extent, private investors, while

6


typically retaining the rights to provide loan servicing to our customers. As part of our overall asset/liability management strategic objectives, we may also originate and retain certain adjustable-rate residential loans. To reduce the interest rate risk associated with commitments made to borrowers for mortgage loans that have not yet been closed and that we intend to sell in the secondary markets, we routinely enter into commitments to sell loans or mortgage-backed securities, considered to be derivatives, to limit our exposure to potential movements in market interest rates. We monitor our interest rate risk position daily to maintain appropriate coverage of our loan commitments made to borrowers.
We use derivative instruments to mitigate the interest rate risk associated with commitments to make mortgage loans that we intend to sell. We also enter into contracts for the future delivery of residential mortgage loans in order to economically hedge potential adverse effects of changes in interest rates. These contracts are also derivative instruments. Derivative instruments are recognized at fair value in our consolidated balance sheets as either assets or liabilities.
Loan Servicing
We service residential and commercial mortgage loans for investors under contracts where we receive a fee for performing mortgage servicing activities on mortgage loans that are not owned by us and are not included on our balance sheet. This process involves collecting monthly mortgage payments on behalf of investors, reporting information to those investors on a timely basis and maintaining custodial escrow accounts for the payment of principal and interest to investors, and property taxes and insurance premiums on behalf of borrowers.
As compensation for our mortgage servicing activities, we receive weighted average servicing fees of approximately 0.25% per year of the loan balances serviced, plus any late charges collected from the delinquent borrowers and other fees incidental to the services provided, offset by applicable subservicing fees. In the event of a default by the borrower, we receive no servicing fees until the default is cured. In times when interest rates are rising or at high levels, servicing mortgage loans can represent a steady source of noninterest income and can, at times, offset decreases in mortgage banking gains. Conversely, in times when interest rates are falling or at very low levels, servicing mortgage loans can become comparatively less profitable due to the rapid payoff of loans and the negative impact due to the change in fair value of the asset. We account for our mortgage servicing rights at fair value. The amount of mortgage servicing rights initially recorded is based on the fair value of the mortgage servicing rights determined on the date when the underlying loan is sold. Our determination of fair value and the amount we record is based on a valuation model using discounted cash-flow analysis and available market pricing. Third party valuations of the mortgage servicing rights portfolio are obtained on a regular basis and are used to determine the fair value of the servicing rights at the end of the reporting period. Estimates of fair value reflect the following variables:
anticipated prepayment speeds;
product type (i.e., conventional, government, balloon);
fixed or adjustable rate of interest;
interest rate;
servicing costs per loan;
discounted yield rate;
estimate of ancillary income; and
geographic location of the loan.

We monitor the level of our investment in mortgage servicing rights in relation to our other mortgage banking activities in order to limit our exposure to significant fluctuations in loan servicing income. Nonetheless, we remain exposed to significant potential volatility in the value of our mortgage servicing rights. Accordingly, in the future, we may sell mortgage servicing rights depending on a variety of factors, including capital sufficiency, the size of the mortgage servicing rights portfolio relative to total assets and current market conditions.
Credit Administration and Loan Review
Certain credit risks are inherent in making loans. These include repayment risks, risks resulting from uncertainties in the future value of collateral, risks resulting from changes in economic and industry conditions and risks inherent in dealing with individual borrowers. We attempt to mitigate repayment risks by adhering to internal credit policies and procedures. We employ consistent analysis and underwriting to examine credit information and prepare underwriting documentation. We monitor and approve exceptions to policy as required, and we also track and address technical exceptions.
Wealth Management
We offer services through the Wealth Management department of Chemical Bank. These services include investment management and custodial services; trust services; financial and estate planning; and retirement planning and employee benefit

7


programs. The Wealth Management department earns revenue largely from fees based on the market value of those assets under management, which can fluctuate as the market fluctuates. The Wealth Management department had assets under custodial and management arrangements of $5.13 billion at December 31, 2017 , $4.41 billion at December 31, 2016 and $3.71 billion at December 31, 2015 . The Wealth Management department also sells investment products (largely annuity products and mutual funds) through its Chemical Financial Advisors program. Customer assets within the Chemical Financial Advisors program were $1.31 billion at December 31, 2017 , $1.15 billion at December 31, 2016 and $0.87 billion at December 31, 2015 .
Deposit Products
We offer a full range of deposit services that are typically available from most banks and savings institutions, including checking accounts, commercial accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. Transaction accounts and time deposits are tailored to and offered at rates competitive with those offered in our primary market areas. In addition, we offer certain retirement account services. We solicit accounts from individuals, businesses, associations, organizations and governmental authorities. We believe that our significant branch network will assist us in continuing to attract deposits from local customers in our market areas.
Employees
At December 31, 2017, we had approximately 3,000  full-time equivalent employees.
Competition
The business of banking is highly competitive. The principal methods of competition for financial services are price (interest rates paid on deposits, interest rates charged on loans and fees charged for services) and service (convenience and quality of services rendered to customers). In addition to competition from other commercial banks, we face significant competition from non-bank financial institutions, including savings and loan associations, credit unions, finance companies, insurance companies and investment firms. Credit unions and finance companies are particularly significant competitors in the consumer loan market. The financial services industry has become more competitive as technology advances have lowered barriers to entry, enabling more companies, including nonbank companies, to provide financial services. Technological advances may diminish the importance of depository institutions and other financial institutions. Mergers and acquisitions have also led to increased concentration in the banking industry, placing added competitive pressure on our core banking products and services as we see competitors enter some of our markets or offer similar products. We also compete for deposits with a broad range of other types of investments, including mutual funds and annuities.
The growth of our deposits can be impacted by competition from other investment products, such as mutual funds and various annuity products. These investment products are sold by a wide spectrum of organizations, such as brokerage and insurance companies, as well as by financial institutions. In response to the competition for other investment products, we, through our Chemical Financial Advisors program, offer a wide array of mutual funds, annuity products and marketable securities through an alliance with an independent, registered broker/dealer. We also compete with credit unions in most of our markets. These institutions are challenging competitors, as credit unions are exempt from federal income taxes, allowing them to potentially offer higher deposit rates.
Mergers, Acquisitions, Consolidations and Divestitures
Our current strategy for growth includes strengthening our presence in core markets, expanding into contiguous markets and broadening our product offerings, while taking into account the integration and other risks of growth. We evaluate strategic acquisition opportunities and conduct due diligence activities in connection with possible transactions. As a result, discussions, and in some cases, negotiations and transactions may take place and future acquisitions involving cash, debt or equity securities may occur, including future acquisitions that may extend beyond contiguous markets. These generally involve payment of a premium over book value and current market price, and therefore, dilution of book value per share will likely occur with any future transaction.
For more information, see the information under the heading "Mergers, Acquisitions and Branch Closings" included in Management's Discussion and Analysis of Financial Condition and Results of Operations, which is here incorporated by reference.
Availability of Information
We file reports with the Securities and Exchange Commission (SEC). Those reports include the annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements. The public may read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an internet

8


site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.     
Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, including the financial statements and the financial statement schedules, but not including exhibits to those reports, may be obtained without charge upon written request to Dennis L. Klaeser, Chief Financial Officer of the Corporation, at P.O. Box 569, Midland, Michigan 48640-0569 and are accessible at no cost on our website at www.chemicalbank.com in the "Investor Information" section, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. No information contained on our website is intended to be included as part of, or incorporated by reference into, this Annual Report on Form 10-K. Copies of exhibits may be requested at the cost of 30 cents per page from our corporate offices.
Supervision and Regulation
Chemical Financial Corporation and Chemical Bank are subject to extensive supervision and regulation under various federal and state laws and regulations. The supervisory and regulatory framework is intended primarily for the protection of depositors and the banking system as a whole, and not for the protection of shareholders and creditors.
Banks are subject to a number of federal and state laws and regulations that have a material impact on their business. These include, among others, minimum capital requirements, state usury laws, state laws relating to fiduciaries, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (Dodd-Frank Act), the Truth in Lending Act, the Truth in Savings Act, the Equal Credit Opportunity Act, the Fair Housing Act, the Fair Credit Reporting Act, the Servicemembers Civil Relief Act, the Expedited Funds Availability Act, the Community Reinvestment Act, the Real Estate Settlement Procedures Act, the U.S.A. PATRIOT Act, the Bank Secrecy Act, the Foreign Account Tax Compliance Act, Office of Foreign Assets Controls regulations, electronic funds transfer laws, redlining laws, predatory lending laws, laws prohibiting unfair and deceptive acts or practices, antitrust laws, environmental laws, anti-money laundering laws and privacy laws. These laws and regulations can have a significant effect on the operating and financial results of banks.
A summary of significant elements of some of the laws, regulations and regulatory policies applicable to the Corporation and Chemical Bank follows below. The descriptions are qualified in their entirety by reference to the full text of the statutes, regulations and policies that are described. The following discussion is not intended to be a complete list of all of the activities regulated by the banking laws or of the impact of those laws and regulations on our operations. It is intended only to briefly summarize some material provisions. These statutes, regulations and policies are continually subject to review by Congress, state legislatures and federal and state regulatory agencies. Changes in applicable laws or regulations may have a material effect on our business and prospects. Our operations may be affected by legislative changes and the policies of various regulatory authorities. We cannot predict the effect that fiscal or monetary policies, economic conditions or new federal or state legislation may have on our business and earnings in the future.
Regulatory Agencies
The Corporation is a legal entity separate and distinct from Chemical Bank. The Corporation is regulated by the Federal Reserve Board ("FRB") as a financial holding company and a bank holding company under the Bank Holding Company Act of 1956 ("BHC Act"). The BHC Act provides for general regulation of financial holding companies by the FRB and functional regulation of banking activities by banking regulators. The Corporation is also under the jurisdiction of the Securities and Exchange Commission ("SEC") and is subject to the disclosure and regulatory requirements of the Securities Act of 1933 and the Securities Exchange Act of 1934. The Corporation's common stock is traded on The NASDAQ Stock Market ® ("NASDAQ") under the symbol CHFC and is subject to the NASDAQ Listing Rules.
Chemical Bank is chartered by the State of Michigan and supervised, examined and regulated by the Michigan Department of Insurance and Financial Services ("DIFS"). Chemical Bank, as a member of the Federal Reserve System, is also supervised, examined and regulated by the FRB. Chemical Bank is also subject to regulation by the Consumer Financial Protection Bureau, which has responsibility for enforcing the principal federal consumer protection laws, such as the Truth in Lending Act, the Equal Credit Opportunity Act, and Real Estate Settlement Procedures Act, and the Truth in Savings Act, among others, for institutions that have assets in excess of $10 billion. Deposits of Chemical Bank are insured by the Federal Deposit Insurance Corporation ("FDIC") to the maximum extent provided by law.
Bank Holding Company Activities
In general, the BHC Act limits the business of bank holding companies to banking, managing or controlling banks and other activities that the FRB has determined to be closely related to the business of banking. In addition, bank holding companies that qualify and elect to be financial holding companies may engage in any activities that are financial in nature or complementary

9


to a financial activity and do not pose a substantial risk to the safety and soundness of depository institutions or the financial system without prior approval of the FRB. Activities that are financial in nature include securities underwriting and dealing, insurance underwriting and making merchant banking investments.
In order for the Corporation to maintain financial holding company status, both the Corporation and Chemical Bank must be categorized as "well-capitalized" and "well-managed" under applicable regulatory guidelines. If the Corporation or Chemical Bank ceases to meet these requirements, the FRB may impose corrective capital and/or managerial requirements and place limitations on the Corporation's ability to conduct the broader financial activities permissible for financial holding companies. In addition, if the deficiencies persist, the FRB may require the Corporation to divest of Chemical Bank. The Corporation and Chemical Bank were both categorized as "well-capitalized" and "well-managed" as of December 31, 2017 .
The BHC Act requires prior approval of the FRB for any direct or indirect acquisition of more than 5% of the voting shares of a commercial bank or its parent holding company by the Corporation. In reviewing applications seeking approval of merger and acquisition transactions, the bank regulatory authorities will consider, among other things, the competitive effect and public benefits of the transactions, the capital position of the combined organization, the Corporation's performance record under the Community Reinvestment Act of 1977 ("CRA"), the Corporation's adherence to banking regulations and fair lending laws and the effectiveness of the subject organizations in combating money laundering activities.
Interstate Banking and Branching
Bank holding companies may acquire banks located in any state in the United States without regard to geographic restrictions or reciprocity requirements imposed by state law. Banks may establish interstate branch networks through acquisitions of other banks. The establishment of de novo interstate branches or the acquisition of individual branches of a bank in another state (rather than the acquisition of an out-of-state bank in its entirety) is allowed to the extent that state law would permit a bank chartered in that state to establish such a branch.
Michigan permits both U.S. and non-U.S. banks to establish branch offices in Michigan. The Michigan Banking Code permits, in appropriate circumstances and with the approval of the DIFS, (1) acquisition of Michigan banks by FDIC-insured banks, savings banks or savings and loan associations located in other states, (2) sale by a Michigan bank of branches to an FDIC-insured bank, savings bank or savings and loan association located in a state in which a Michigan bank could purchase branches of the purchasing entity, (3) consolidation of Michigan banks and FDIC-insured banks, savings banks or savings and loan associations located in other states having laws permitting such consolidation, (4) establishment of branches in Michigan by FDIC-insured banks located in other states, the District of Columbia or U.S. territories or protectorates having laws permitting a Michigan bank to establish a branch in such jurisdiction, and (5) establishment by foreign banks of branches located in Michigan. A Michigan bank holding company may acquire a non-Michigan bank and a non-Michigan bank holding company may acquire a Michigan bank.
Dividends
The Corporation's primary source of funds available to pay dividends to shareholders is from dividends paid to it by Chemical Bank. Federal and state banking laws and regulations limit both the extent to which Chemical Bank can lend or otherwise supply funds to the Corporation and also place certain restrictions on the amount of dividends Chemical Bank may pay to the Corporation.
The Corporation and Chemical Bank are subject to regulatory policies and requirements relating to the payment of dividends, including requirements to maintain capital above regulatory minimums, which could prohibit the payment of dividends under circumstances where the payment could be deemed an unsafe and unsound banking practice. Chemical Bank is required to obtain prior approval from the FRB for the declaration and payment of dividends to the Corporation if the total of all dividends declared in any calendar year will exceed the total of (i) Chemical Bank's net income (as defined by regulation) for that year plus (ii) the retained net income (as defined by regulation) for the preceding two years. In addition, federal regulatory authorities have stated that banking organizations should generally pay dividends only out of current operating earnings. Further, the FRB has indicated that bank holding companies should carefully review their dividend policy and has discouraged payment ratios that are at maximum allowable levels unless both asset quality and capital are very strong. Chemical Bank declared and paid dividends to the Corporation of $165.0 million and $110.5 million in 2017 and 2016 , respectively. The Corporation utilized proceeds from the dividend from Chemical Bank in 2016 to fund a portion of the cash component of the merger consideration in the Talmer transaction. The Corporation utilized a portion of the proceeds from the dividend from Chemical Bank in 2015 to pay off subordinated debentures, which were acquired as part of the Lake Michigan transaction, during the first quarter of 2016. Dividends received from Chemical Bank in the past are not necessarily indicative of amounts that may be paid or available to be paid in the future.

10


Source of Strength
Under FRB policy, the Corporation is expected to act as a source of financial strength to Chemical Bank and to commit resources to support Chemical Bank. In addition, if DIFS deems Chemical Bank's capital to be impaired, DIFS may require Chemical Bank to restore its capital by a special assessment on the Corporation as Chemical Bank's only shareholder. If the Corporation failed to pay any assessment, the Corporation's directors would be required, under Michigan law, to sell the shares of Chemical Bank's stock owned by the Corporation to the highest bidder at either a public or private auction and use the proceeds of the sale to restore Chemical Bank's capital.
Capital Requirements
The Corporation and Chemical Bank are subject to regulatory "risk-based" capital guidelines. Failure to meet these capital guidelines could subject the Corporation or Chemical Bank to a variety of enforcement remedies, including issuance of a capital directive, the termination of deposit insurance by the FDIC, a prohibition on accepting brokered deposits, and other restrictions on its business. In addition, Chemical Bank would generally not receive regulatory approval of any application that requires the consideration of capital adequacy, such as a branch or merger application, unless it could demonstrate a reasonable plan to meet the capital requirement within a reasonable period of time.
The Federal Deposit Insurance Corporation Improvement Act ("FDICIA") requires, among other things, federal banking agencies to take "prompt corrective action" in respect of depository institutions that do not meet minimum capital requirements. FDICIA sets forth the following five capital categories: "well-capitalized," "adequately-capitalized," "undercapitalized," "significantly-undercapitalized" and "critically-undercapitalized." A depository institution's capital category will depend upon how its capital levels compare with various relevant capital measures as established by regulation, which include Tier 1 and total risk-based capital ratio measures and a leverage capital ratio measure.
Federal banking regulators are required to take specified mandatory supervisory actions and are authorized to take other discretionary actions with respect to institutions in the three undercapitalized categories. The severity of the action depends upon the capital category in which the institution is placed. Subject to a narrow exception, the banking regulator must generally appoint a receiver or conservator for an institution that is critically undercapitalized. An institution in any of the undercapitalized categories is required to submit an acceptable capital restoration plan to its appropriate federal banking agency. An undercapitalized institution is also generally prohibited from paying any dividends, increasing its average total assets, making acquisitions, establishing any branches, accepting or renewing any brokered deposits or engaging in any new line of business, except under an accepted capital restoration plan or with FDIC approval.
In July 2013, the FRB and the FDIC approved final rules implementing the Basel Committee on Banking Supervision's (BCBS) capital guidelines for U.S. banks (commonly known as Basel III). Under Basel III, which began for the Corporation and Chemical Bank on January 1, 2015 and are subject to a phase-in period through January 1, 2019, minimum capital requirements were increased for both the quantity and quality of capital held by the Corporation and Chemical Bank. Basel III added a new common equity Tier 1 capital to risk-weighted assets ratio (CET ratio) of 4.5% and a capital conservation buffer of 2.5% of risk-weighted assets, which when fully phased-in, effectively results in a minimum CET ratio of 7.0%. Basel III also raised the minimum ratio of Tier 1 capital to risk-weighted assets from 4.0% to 6.0% (which, with the capital conservation buffer, effectively results in a minimum Tier 1 capital ratio of 8.5% when fully phased-in) and requires a minimum leverage ratio of 4.0%.
A summary of the actual and minimum Basel III regulatory capital ratios for the Corporation and Chemical Bank as of December 31, 2017 follows:
 
Leverage Ratio
 
Common Equity Tier 1 Capital Ratio
 
Tier 1 Risk-Based Capital Ratio
 
Total Risk-Based Capital Ratio
 
 
 
 
 
 
 
 
Actual Capital Ratios:
 
 
 
 
 
 
 
Chemical Financial Corporation
8.3%
 
10.2%
 
10.2%
 
11.0%
Chemical Bank
8.4%
 
10.3%
 
10.3%
 
11.0%
Minimum for capital adequacy purposes
4.0%
 
4.5%
 
6.0%
 
8.0%
Minimum to be well capitalized under prompt corrective action regulations
5.0%
 
6.5%
 
8.0%
 
10.0%
Minimum for capital adequacy, including capital conservation buffer (1)
4.0%
 
7.0%
 
8.5%
 
10.5%
(1)
Assumes fully phased in capital conservation buffer of 2.5%. The capital conservation buffer will be phased in beginning January1, 2016 at 0.625% and increasing by the same amount each year until fully implemented in January 2019. Failure to maintain the required capital conservation buffer may limit the Corporation's and Chemical Bank's ability to pay dividends or discretionary bonuses, among other things.

11


At December 31, 2017 , the capital ratios of the Corporation and Chemical Bank exceeded the regulatory guidelines for institutions to be categorized as "well-capitalized." Under certain circumstances, the appropriate banking agency may treat a well- capitalized, adequately capitalized or undercapitalized institution as if the institution were in the next lower capital category. Additional information on the Corporation and Chemical Bank's capital ratios may be found under Note 20 to our Consolidated Financial Statements under Item 8 of this Annual Report.
FDIC Insurance
The FDIC formed the Deposit Insurance Fund ("DIF") in accordance with the Federal Deposit Insurance Reform Act of 2005 (Reform Act). The FDIC implemented the Reform Act to create a stronger and more stable insurance system. The FDIC maintains the insurance reserves of the DIF by assessing depository institutions an insurance premium. The DIF insures deposit accounts of Chemical Bank up to a maximum amount per separately insured depositor. Under the Dodd-Frank Act, the maximum amount of federal deposit insurance coverage permanently increased from $100,000 to $250,000 per depositor, per institution.
FDIC insured depository institutions are required to pay deposit insurance premiums based on an insured depository institution’s assessment base, calculated as its average consolidated total assets minus its average tangible equity. Chemical Bank’s current annualized premium assessments can range from $0.15 to $0.40 for each $100 of its assessment base. The rate charged depends on Chemical Bank’s performance on the FDIC’s "large and highly complex institution" risk-assessment scorecard, which includes factors such as Chemical Bank’s regulatory rating, its ability to withstand asset and funding-related stress, and the relative magnitude of potential losses to the FDIC in the event of Chemical Bank’s failure. The Corporation's FDIC DIF insurance premiums were $11.2 million in 2017 , compared to $7.4 million in 2016 and $5.5 million in 2015 .

In March 2016, the FDIC adopted rules to impose a surcharge, as required by the Dodd-Frank Act, on the quarterly deposit insurance assessments of insured depository institutions having total consolidated assets of at least $10 billion (like Chemical Bank). The surcharge would begin the calendar quarter after the DIF reserve ratio first reaches or exceeds 1.15% and would continue through the quarter that it first reaches or exceeds 1.35%. Effective July 1, 2016, the FDIC began to assess large institution surcharges under this new rule. Large banks will pay a quarterly surcharge, in addition to regular assessments, equal to an annual rate of 4.5 basis points. The assessment base for the surcharge will be a large bank's regular assessment base reduced by $10 billion (and subject to adjustment for affiliated banks). The surcharge will remain in place through the quarter that the DIF reserve ratio first reaches or exceeds 1.35%, but no later than December 31, 2018. If the DIF reserve ratio has not reached 1.35% by that date, the FDIC will impose a shortfall assessment on large banks in the first quarter of 2019, and collect it on June 30, 2019.

Safety and Soundness Standards
As required by FDICIA, the federal banking agencies' prompt corrective action powers impose progressively more restrictive constraints on operations, management and capital distributions, depending on the category in which an institution is classified. These actions can include: requiring an insured depository institution to adopt a capital restoration plan guaranteed by the institution's parent company; placing limits on asset growth and restrictions on activities, including restrictions on transactions with affiliates; restricting the interest rates the institution may pay on deposits; prohibiting the payment of principal or interest on subordinated debt; prohibiting the holding company from making capital distributions without prior regulatory approval; and, ultimately, appointing a receiver for the institution.
The federal banking agencies also have adopted guidelines prescribing safety and soundness standards relating to internal controls and information systems, internal audit systems, loan documentation, credit underwriting, interest rate exposure, asset growth, and compensation and benefits. The federal regulatory agencies may take action against a financial institution that does not meet such standards.
Depositor Preference
The Federal Deposit Insurance Act provides that, in the event of the "liquidation or other resolution" of an insured depository institution, the claims of depositors of the institution, including the claims of the FDIC on behalf of insured depositors, and certain claims for administrative expenses of the FDIC as a receiver, will have priority over other general unsecured claims against the institution. If an insured depository institution fails, insured and uninsured depositors, along with the FDIC, will have priority in payment ahead of unsecured, non-deposit creditors, including depositors whose deposits are payable only outside of the United States and the parent bank holding company, with respect to any extensions of credit they have made to such insured depository institution.
The Dodd-Frank Act
The Dodd-Frank Act, enacted in July 2010, represents a comprehensive overhaul of the financial services industry within the United States, including establishing the federal Consumer Financial Protection Bureau ("CFPB") and requiring the CFPB and other federal agencies to implement many new and significant rules and regulations. The CFPB has issued significant new

12


regulations, which became effective in January 2014, that impact consumer mortgage lending and servicing. In addition, the CFPB has issued regulations, which became effective October 1, 2015, that change the disclosure requirements and forms used under the Truth in Lending Act and the Real Estate Settlement Procedures Act. Compliance with these new laws and regulations and other regulations under consideration by the CFPB have and will likely result in additional costs and could change the products and/or services that are currently being offered, which could be significant and could adversely impact the Corporation's results of operations, financial condition or liquidity.
Enhanced Prudential Standards
A publicly traded bank holding company with $10 billion or more in consolidated assets must comply with certain provisions of the Federal Reserve's enhanced prudential standards (EPS). The holding company is required to establish a stand-alone, board level risk committee that must have a formal written charter approved by the board of directors. The risk committee is charged with approving and periodically reviewing the risk-management policies of the company and overseeing the operation of its global risk-management framework. The Corporation has a Standing Risk Management Committee of the board of directors.
Stress Tests
The Dodd-Frank Act mandates company-run stress tests requirements for U.S. bank holding companies with total consolidated assets of $10 billion to $50 billion. The Dodd-Frank Act Stress Test ("DFAST") require bank holding companies to assess the potential impact of three macroeconomic scenarios - baseline, adverse, and seriously adverse - on the company's consolidated losses, revenues, balance sheet (including risk-weighted assets) and capital. The rules also require each banking organization to establish and maintain a system of controls, oversight and documentation, including policies and procedures, designed to ensure that the DFAST procedures used by the banking organization are effective in meeting the requirements of the rules. Chemical will be required to submit a stress test report in 2018.
The Durbin Amendment
The Dodd-Frank Act included provisions that require that interchange fees in debit card transactions be "reasonable and proportionate" in relation to the cost of the transaction incurred by the card issuer (the "Durbin Amendment"). Under rules issued by the Federal Reserve, interchange fees on a debit card transaction are capped at $0.21 per transaction plus five basis points multiplied by that amount of the transaction are conclusively determined to be reasonable and proportionate. In addition, an issuer may charge up to 1 cent on each debit card transaction as a fraud prevention adjustment if the issuer meets certain fraud prevention standards. The interchange fee restrictions in the Durbin Amendment apply to debit card issuers with $10 billion or more in total consolidated assets. Chemical Bank became subject to these interchange restrictions beginning on January 1, 2017.
The Volcker Rule
The Volcker Rule implements Section 619 of the Dodd-Frank Act. The Volcker Rule prohibits "banking entities," such as the Corporation, Chemical Bank and their affiliates and subsidiaries, from owning, sponsoring, or having certain relationships with hedge funds and private equity funds (referred to as "covered funds") and engaging in short-term proprietary trading of securities, derivatives, commodity futures and options on these instruments.
The Volcker Rule excepts certain transactions from the general prohibition against proprietary trading, including transactions in government securities (e.g., U.S. Treasuries or any instruments issued by the GNMA, FNMA, FHLMC, a Federal Home Loan Bank, or any state or a political division of any state, among others); transactions in connection with underwriting or market-making activities; and, transactions as a fiduciary on behalf of customers. Banking entities may also engage in risk-mitigating hedges if the entity can demonstrate that the hedge reduces or mitigates a specific, identifiable risk or aggregate risk position of the entity. The banking entity is required to conduct an analysis supporting its hedging strategy and the effectiveness of the hedges must be monitored and, if necessary, adjusted on an ongoing basis. Banking entities with more than $50 billion in total consolidated assets and liabilities that engage in permitted trading transactions are required to implement enhanced compliance programs, to regularly report data on trading activities to the regulators, and to provide a CEO attestation that the entity’s compliance program is reasonably designed to comply with the Volcker Rule.
Although the Volcker Rule became effective on April 1, 2014, the Federal Reserve exercised its unilateral authority to extend the compliance deadline until July 21, 2017, with respect to covered funds. This period has ended and the Corporation, Chemical Bank and their affiliates and subsidiaries must be in compliance with the Volcker Rule.

13


Community Reinvestment Act
Banks are subject to the provisions of the CRA. Under the terms of the CRA, the appropriate federal bank regulatory agency is required, in connection with its examination of a bank, to assess such bank's record in meeting the credit needs of the community served by that bank, including low and moderate income neighborhoods, consistent with the safe and sound operation of the institution. Under the CRA, institutions are assigned a rating of "outstanding," "satisfactory," "needs to improve," or "substantial non-compliance." The regulatory agency's assessment of the bank's record is made available to the public. Further, a bank's federal regulatory agency is required to assess the CRA compliance record of any bank that has applied to: (1) obtain deposit insurance coverage for a newly chartered institution, (2) establish a new branch office that will accept deposits, (3) relocate an office, or (4) merge or consolidate with, or acquire the assets or assume the liabilities of, a federally regulated financial institution. In the case of a bank holding company applying for approval to acquire a bank or another bank holding company, the FRB will assess the CRA compliance record of each subsidiary bank of the applicant bank holding company, and such compliance records may be the basis for denying the application. Upon receiving notice that a subsidiary bank is rated less than "satisfactory," a financial holding company will be prohibited from additional activities that are permitted to a financial holding company and from acquiring any company engaged in such activities. Chemical Bank's CRA rating was "outstanding" as of December 31, 2017 .
Loans to One Borrower
Under the Home Owners Loan Act ("HOLA"), savings associations are generally subject to the national bank limits on loans to one borrower. Generally, savings associations may not make a loan or extend credit to a single or related group of borrowers in excess of 15 percent of the institution’s unimpaired capital and surplus (as defined by HOLA). Additional amounts may be loaned if such loans or extensions of credit are secured by readily-marketable collateral, but in no case may they be in excess of an additional 10 percent of unimpaired capital and surplus. We have established an internal lending threshold that is more conservative than the limits required by HOLA.
Financial Privacy
Federal banking regulations limit the ability of banks and other financial institutions to disclose non-public information about consumers to nonaffiliated third parties. These limitations require disclosure of privacy policies to consumers and, in some circumstances, allow consumers to prevent disclosure of certain personal information to a nonaffiliated third party. These regulations affect how consumer information is transmitted through diversified financial companies and conveyed to outside vendors.
Chemical Bank is also subject to regulatory guidelines establishing standards for safeguarding customer information. These guidelines describe the federal banking agencies’ expectation for the creation, implementation and maintenance of an information security program, which would include administrative, technical and physical safeguards appropriate to the size and complexity of the institution and the nature and scope of its activities. The standards set forth in the guidelines are intended to ensure the security and confidentiality of customer records and information, protect against any anticipated threats or hazards to the security or integrity of such records and protect against unauthorized access to or use of such records or information that could result in substantial harm or inconvenience to any customer.

Anti-Money Laundering and the USA Patriot Act

A major focus of governmental policy on financial institutions has been aimed at combating money laundering and terrorist financing. The Bank Secrecy Act of 1970 ("BSA") and subsequent laws and regulations require the bank to take steps to prevent the use of the bank or its systems to facilitate the flow of illegal or illicit money or terrorist funds. Those requirements include ensuring effective board and management oversight, establishing policies and procedures, performing comprehensive risk assessments, developing effective monitoring and reporting capabilities, ensuring adequate training and establishing a comprehensive independent audit of BSA compliance activities. The USA PATRIOT Act of 2001 (USA Patriot Act) substantially broadened the scope of United States anti-money laundering laws and regulations by imposing significant compliance and due diligence obligations, creating new crimes and penalties and expanding the extra-territorial jurisdiction of the United States. The United States Treasury Department has issued, and in some cases proposed, a number of regulations that apply various requirements of the USA Patriot Act to financial institutions. These regulations impose obligations on financial institutions to maintain appropriate policies, procedures and controls to detect, prevent and report money laundering and terrorist financing and to verify the identity of their customers. Certain of those regulations impose specific due diligence requirements on financial institutions that maintain correspondent or private banking relationships with non-U.S. financial institutions or persons. Failure of a financial institution to maintain and implement adequate programs to combat money laundering and terrorist financing, or to comply with all of the relevant laws or regulations, could have serious legal and reputational consequences for the institution.


14


Office of Foreign Assets Control Regulation

The United States Treasury Department Office of Foreign Assets Control ("OFAC") has imposed economic sanctions that affect transactions with designated foreign countries, nationals and others. OFAC sanctions targeting countries take many different forms. Generally, however, they contain one or more of the following elements: (i) restrictions on trade with or investment in a sanctioned country, including prohibitions on "U.S. persons" engaging in financial transactions relating to making investments in, or providing investment-related advice or assistance to, a sanctioned country; and (ii) a blocking of assets in which the government or specially designated nationals of the sanctioned country have an interest, by prohibiting transfers of property subject to U.S. jurisdiction (including property in the possession or control of U.S. persons). Blocked assets (e.g., property and bank deposits) cannot be paid out, withdrawn, set off or transferred in any manner without a license from OFAC. Failure to comply with these sanctions could have serious legal and reputational consequences.
Incentive Compensation
The regulatory agencies have issued comprehensive guidance on incentive compensation policies intended to ensure that the incentive compensation policies of banking organizations do not undermine the safety and soundness of such organizations by encouraging excessive risk-taking. The guidance, which covers all employees that have the ability to materially affect the risk profile of an organization, either individually or as part of a group, is based upon the key principles that a banking organization's incentive compensation arrangements should (i) provide incentives that do not encourage risk-taking beyond the organization's ability to effectively identify and manage risks, (ii) be compatible with effective internal controls and risk management and (iii) be supported by strong corporate governance, including active and effective oversight by the organization's board of directors.
The FRB reviews, as part of the regular, risk-focused examination process, the incentive compensation arrangements of banking organizations, such as the Corporation, that are not "large, complex banking organizations." The findings will be included in reports of examination. Deficiencies will be incorporated into the organization's supervisory ratings, which can affect the organization's ability to make acquisitions and take other actions. Enforcement actions may be taken against a banking organization if its incentive compensation arrangements, or related risk-management control or governance processes, pose a risk to the organization's safety and soundness and the organization is not taking prompt and effective measures to correct the deficiencies.

Item 1A. Risk Factors.
Our business is subject to many risks and uncertainties, including those described below. Although we seek ways to manage these risks, we ultimately cannot predict the future or control all of the risks to which we are subject. Actual results may differ materially from management's expectations. Some of these significant risks and uncertainties are discussed below. The risks and uncertainties described below are not the only ones that we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that adversely affect us and our business. If any of these risks were to occur, our business, financial condition or results of operations could be materially and adversely affected. If this were to happen, the market price of the Corporation's common stock could decline significantly. More detailed information concerning these risks is contained in other sections of this Annual Report, including "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."
Risks Related to our Business

If we fail to effectively manage credit risk, our business and financial condition will suffer.

We must effectively manage credit risk. As a lender, we are exposed to the risk that our borrowers will be unable to repay their loans according to their terms, and that the collateral securing repayment of their loans, if any, may not be sufficient to ensure repayment. In addition, there are risks inherent in making any loan, including risks relating to proper loan underwriting, risks resulting from changes in economic and industry conditions and risks inherent in dealing with individual borrowers, including the risk that a borrower may not provide information to us about its business in a timely manner, and/or may present inaccurate or incomplete information to us, and risks relating to the value of collateral. Collateral values are adversely affected by changes in prevailing economic, environmental and other conditions, including declines in the value of real estate, changes in interest rates, changes in monetary and fiscal policies of the federal government, terrorist activity, environmental contamination and other external events. In order to manage credit risk successfully, we must, among other things, maintain disciplined and prudent underwriting standards and ensure that our lenders follow those standards. The weakening of these standards for any reason, such as an attempt to attract higher yielding loans, a lack of discipline or diligence by our employees in underwriting and monitoring loans, the inability of our employees to adequately adapt policies and procedures to changes in economic or any other conditions affecting borrowers and the quality of our loan portfolio, may result in loan defaults, foreclosures and additional charge-offs and may necessitate that we significantly increase our allowance for loan losses, each of which could adversely affect our net income. As

15


a result, our inability to successfully manage credit risk could have a material adverse effect on our business, financial condition or results of operations.

Our allowance for loan losses, and fair value adjustments with respect to loans acquired in our acquisitions, may prove to be insufficient to absorb actual losses in our loan portfolio, which may adversely affect our business, financial condition and results of operations.

We maintain an allowance for loan losses, which is a reserve established through a provision for loan losses charged to net income that represents management's estimate of probable losses that have been incurred within our existing loan portfolio. The level of the allowance for loan losses reflects management's continuing evaluation of specific credit risks, loan loss experience, current loan portfolio quality, the value of real estate, present economic, political and regulatory conditions and unidentified losses inherent in the current loan portfolio. The determination of the appropriate level of the allowance for loan losses inherently involves a high degree of subjectivity and requires us to make significant estimates of current credit risks and future trends, all of which may undergo material changes. Deterioration in economic conditions and declines in real estate values affecting borrowers, new information regarding existing loans, identification of additional problem loans and other factors, both within and outside of our control, may require an increase in the allowance for loan losses.

The application of the purchase method of accounting in our acquisitions (and any future acquisitions) will impact our allowance for loan losses. Under the purchase method of accounting, all acquired loans were recorded in our Consolidated Financial Statements at their estimated fair value at the time of acquisition and any related allowance for loan loss was eliminated because credit quality, among other factors, was considered in the determination of fair value. To the extent that our estimates of fair value are too high, we will incur losses associated with the acquired loans. The allowance associated with our purchased credit impaired loans reflects deterioration in cash flows since acquisition resulting from our quarterly re-estimation of cash flows which involves complex cash flow projections and significant judgment on timing of loan resolution.

If our analysis or assumptions prove to be incorrect, our current allowance may not be sufficient, and adjustments may be necessary to allow for different economic conditions or adverse developments in our loan portfolio. Material additions to the allowance for loan losses would materially decrease our net income and adversely affect our general financial condition.

In addition, our regulators, as an integral part of their periodic examination, review our allowance for loan losses and may require an increase in the allowance for loan losses or the recognition of further loan charge-offs, based on judgments different than those of management.

Finally, the measure of our allowance for loan losses is dependent on the adoption and interpretation of accounting standards. The Financial Accounting Standards Board, or FASB, recently issued a new credit impairment model, the Current Expected Credit Loss, or CECL model, which will become applicable to us in 2020. Under the CECL model, we will be required to present certain financial assets carried at amortized cost, such as loans held for investment and held-to-maturity debt securities, at the net amount expected to be collected. The measurement of expected credit losses is to be based on information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This measurement will take place at the time the financial asset is first added to the balance sheet and periodically thereafter. This differs significantly from the “incurred loss” model currently required under GAAP, which delays recognition until it is probable a loss has been incurred. Accordingly, we expect that the adoption of the CECL model will materially affect how we determine our allowance for loan losses and could require us to significantly increase our allowance. Moreover, the CECL model may create more volatility in the level of our allowance for loan losses. If we are required to materially increase our level of allowance for loan losses for any reason, such increase could adversely affect our business, financial condition and results of operations.

See the sections captioned "Allowance for Loan Losses" in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and Note 5 - Loans in the notes to our Consolidated Financial Statements in Item 8. Financial Statements and Supplementary Data, located elsewhere in this Annual Report for further discussion related to the Corporation's process for determining the appropriate level of the allowance for loan losses.

We may be adversely affected by risks associated with future acquisitions, including execution risk, which could disrupt our business and dilute shareholder value.
    
We plan to growth our business both organically and through acquisitions. We periodically evaluate merger and acquisition opportunities and conduct due diligence activities related to possible transactions with other financial institutions and financial services companies. As a result, we may engage in discussions or negotiations that, if they were to result in a transaction, could have a material effect on our operating results and financial condition, including short- and long-term liquidity. Our acquisition

16


activities could be material and could require us to use a substantial amount of common stock, cash, other liquid assets, and/or incur debt. Acquisitions and mergers typically involve the payment of a premium over book value, and, therefore, dilution of our tangible book value and ownership interest may occur in connection with any future transaction. Furthermore, failure to realize the expected revenue increases, cost savings, increases in geographic or product presence, and/or other projected benefits from an acquisition could have a material adverse effect on our financial condition and results of operations, including net income per common share.

Our acquisition activities could involve a number of additional risks, including the risks of:
delay in completing an acquisition or merger due to litigation or the regulatory approval process;
the recording of assets and liabilities of the acquired or merged company at fair value may materially dilute shareholder value at the transaction date and could have a material adverse effect on our financial condition and results of operations;
incurring the time and costs associated with identifying and evaluating potential acquisition or merger targets;
difficulty or unanticipated expense associated with converting the operating systems of the acquired or merged company into ours:
potential exposure to unknown or contingent liabilities of the acquired or merged company;
our estimates and judgments used to evaluate credit, operations, management and market risks with respect to the acquired or merged company may not be accurate;
our exposure to potential asset quality issues of the acquired or merged company;
the time and costs of evaluating new markets, hiring experienced local management and opening new offices, and the time lags between these activities and the generation of sufficient assets and deposits to support the costs of the expansion;
diversion of our management's attention to the negotiation of a transaction, and the integration of the operations and personnel of the combining businesses;
the introduction of new products and services into our business;
potential disruption to our business;
the incurrence and possible impairment of goodwill and other intangible assets associated with an acquisition or merger and possible adverse short-term effects on our results of operations;
the possible loss of key employees and customers of the acquired or merged company;
difficulty in estimating the value of the acquired or merged company; and
potential changes in banking or tax laws or regulations that may affect the acquired or merged company.

Failure to successfully address these and other issues related to acquisitions and mergers could have a material adverse effect on our financial condition and results of operations, and could adversely affect our ability to successfully implement our business strategy.
Future acquisitions may be delayed, impeded, or prohibited due to regulatory issues.
Our future acquisitions, particularly those of financial institutions, are subject to approval by a variety of federal and state regulatory agencies. The process for obtaining these required regulatory approvals has become substantially more difficult in recent years. Regulatory approvals could be delayed, impeded, restrictively conditioned or denied due to existing or new regulatory issues we have, or may have, with regulatory agencies, including, without limitation, issues related to anti-money laundering/Bank Secrecy Act compliance, fair lending laws, fair housing laws, consumer protection laws, unfair, deceptive, or abusive acts or practices regulations, Community Reinvestment Act issues, and other similar laws and regulations. We may fail to pursue, evaluate or complete strategic and competitively significant acquisition opportunities as a result of our inability, or perceived or anticipated inability, to obtain regulatory approvals in a timely manner, under reasonable conditions or at all. Difficulties associated with potential acquisitions that may result from these factors could have a material adverse effect on our business, and, in turn, our financial condition and results of operations.

17


We face a risk of noncompliance with the Bank Secrecy Act and other anti-money laundering statutes and regulations and corresponding enforcement proceedings.

The federal Bank Secrecy Act, the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (which we refer to as the “PATRIOT Act”) and other laws and regulations require financial institutions, among other duties, to institute and maintain effective anti-money laundering programs and to file suspicious activity and currency transaction reports as appropriate. FinCEN, established by the U.S. Treasury Department to administer the Bank Secrecy Act, is authorized to impose significant civil money penalties for violations of those requirements and has engaged in coordinated enforcement efforts with the individual federal banking regulators, as well as the U.S. Department of Justice, Drug Enforcement Administration and Internal Revenue Service. There is also increased scrutiny of compliance with the rules enforced by the OFAC. Federal and state bank regulators also have focused on compliance with Bank Secrecy Act and anti-money laundering regulations. If our policies, procedures and systems are deemed deficient or the policies, procedures and systems of the financial institutions that we have already acquired or may acquire in the future are deficient, we would be subject to liability, including fines and regulatory actions such as restrictions on our ability to pay dividends and the necessity to obtain regulatory approvals to proceed with certain aspects of our business plan, including our acquisition plans, which would negatively impact our business, financial condition, results of operations and prospects. Sanctions that the regulators have imposed on banks that have not complied with all requirements have been especially severe. Failure to maintain and implement adequate programs to combat money laundering and terrorist financing could also have serious reputational consequences for us.

Litigation filed against Talmer, its board of directors and the Corporation could result in the payment of damages.
    
In connection with the Talmer merger transaction, purported Talmer stockholders have filed putative class action lawsuits against Talmer, its board of directors and the Corporation. These lawsuits could result in substantial costs to us, including any costs associated with indemnification. The defense or settlement of the lawsuits may adversely affect our business, financial condition, results of operations, cash flows and market price.

Because our total assets exceed $10 billion, we are subject to additional regulation, increased supervision and increased costs.

The Dodd-Frank Act imposes additional regulatory requirements on financial institutions with $10 billion or more in total assets, such as us. We crossed $10 billion in total assets as a result of our merger with Talmer in August 2016, and we had $19.28 billion in total assets as of December 31, 2017. As a result, we are now subject to the following additional requirements:

supervision, examination and enforcement by the CFPB with respect to consumer financial protection laws;
regulatory stress testing requirements, whereby we are required to conduct an annual stress test (using assumptions for baseline, adverse and severely adverse scenarios);
a modified methodology for calculating FDIC insurance assessments and potentially higher assessment rates as a result of institutions with $10 billion or more in assets being required to bear a greater portion of the cost of raising the reserve ratio to 1.35% as required by the Dodd-Frank Act;
heightened compliance standards under the Volcker Rule; and
enhanced supervision as a larger financial institution.

In addition, under the Durbin Amendment to the Dodd-Frank Act, institutions with $10 billion or more in assets are subject to a cap on the interchange fees that may be charged in certain electronic debit and prepaid card transactions. The maximum permissible interchange fee for electronic debit transactions is the sum of 21 cents per transaction and five basis points multiplied by the value of the transaction. In addition, an issuer may charge up to one cent on each transaction as a fraud prevention adjustment if the issuer meets certain fraud prevention standards.

The imposition of these regulatory requirements and increased supervision may require additional commitment of financial resources to regulatory compliance and may increase our cost of operations. Further, the results of the stress testing process may lead us to retain additional capital or alter the mix of its capital components.

Our core banking system conversion process could expose us to operating and financial risks.
We are currently in the process of converting our core banking system. Although we do not anticipate any material complications associated with this conversion process, we can give no assurances that the new core banking system will be operational within the timeline currently contemplated or that the additional expenses allocated to implement the new system will be sufficient. Since the core banking system is integral to our operations, any delays or increased costs beyond those budgeted could adversely impact our operations and profitability. Even if implemented within the scheduled timeline and within the expected budget, the change to our core banking system could expose us to new risks associated with new systems and new vendors. Further,

18


potential problems with new systems could involve regulatory compliance risk, potentially resulting in higher operating costs or limitations on our operating activities.

We may face increased pressure from purchasers of our residential mortgage loans to repurchase those loans or reimburse purchasers for losses related to those loans.

We sell fixed rate long-term residential mortgage loans we originate in the secondary market. Purchasers of residential mortgage loans, such as government sponsored entities, require sellers of residential mortgage loans to either repurchase loans previously sold or reimburse purchasers for losses related to loans previously sold when losses are incurred on a loan previously sold due to actual or alleged failure to strictly conform to the purchaser's purchase criteria. As a result, we may face increased pressure from purchasers of our residential mortgage loans to repurchase those loans or reimburse purchasers for losses related to those loans and we may face increasing expenses to defend against such claims. If we are required in the future to repurchase loans previously sold, reimburse purchasers for losses related to loans previously sold, or if we incur increasing expenses to defend against such claims, our financial condition and results of operations would be negatively affected.

We hold general obligation municipal bonds in our investment securities portfolio. If one or more issuers of these bonds were to become insolvent and default on its obligations under the bonds, it could have a negative effect on our financial condition and results of operations.

We held general obligation municipal bonds totaling $782.1 million at December 31, 2017, which were issued by many different municipalities with no significant concentration in any single municipality. There can be no assurance that the financial conditions of these municipalities will not be materially and adversely affected by future economic conditions. If one or more of the issuers of these bonds were to become insolvent and default on their obligations under the bonds, it could have a negative effect on our financial condition and results of operations.

We are subject to liquidity risk in our operations, which could adversely affect our ability to fund our various obligations and jeopardize our business, financial condition and results of operations.

Liquidity risk is the possibility that we will not be able to meet our obligations as they come due or capitalize on growth opportunities as they arise because of an inability to liquidate assets or obtain adequate funding on a timely basis, at a reasonable cost and within acceptable risk tolerances. Liquidity is required to fund various obligations, including credit obligations to borrowers, loan originations, withdrawals by depositors, repayment of debt, dividends to shareholders, operating expenses and capital expenditures. Liquidity is derived primarily from retail deposit growth and earnings retention, principal and interest payments on loans and investment securities, net cash provided from operations and access to other funding. If we are unable to continue to attract and retain core deposits, to obtain third party financing on favorable terms, or to have access to interbank or other liquidity sources, we may not be able to grow our assets as quickly as we have historically. If customers move money out of bank deposits into other investments, we could lose a relatively low cost source of funds. This loss would require us to seek other funding alternatives, including wholesale funding, in order to continue to grow, thereby increasing our funding costs and reducing our net interest income and net income. If we are unable to maintain adequate liquidity, then our business, financial condition and results of operations would be negatively affected.

General economic conditions, and in particular conditions in our core markets in Michigan, Ohio and Indiana, affect our business.

Our business is affected by general economic conditions in the United States, although most directly within our core markets in Michigan, Ohio and Indiana. Our success depends primarily on the general economic conditions in the States of Michigan, Ohio and Indiana and the specific local markets in which we operate. The economic conditions in these local markets have a significant impact on the demand for our products and services as well as the ability of our customers to repay loans, the value of the collateral securing loans and the stability of our deposit funding sources. A significant majority of our loans are to individuals and businesses in Michigan. Consequently, any prolonged decline in Michigan's economy could have a materially adverse effect on our financial condition and results of operations. While economic conditions have improved since the end of the economic recession, a return of recessionary conditions could impact the United States and our local markets which, in turn, could have a material adverse effect on our financial condition and results of operations.


19


The impacts of recent tax reform are not yet fully known, and these and other tax regulations could be subject to potential legislative, administrative or judicial changes or interpretations.

The Tax Cuts and Jobs Act, which was signed into law on December 22, 2017, has had, and is expected to continue to have, far-reaching and significant effects on us, our customers and the U.S. economy. The act lowered the corporate federal statutory tax rate and eliminated or limited certain federal corporate deductions. While it is too early to evaluate all of the potential consequences of the act, such consequences could include lower commercial customer borrowings, either due to the increase in cash flows as a result of the reduction in the corporate statutory tax rate or the utilization by businesses in certain sectors of alternative non-debt financing and/or early retirement of existing debt. Further, there can be no assurance that any benefits realized as a result of the reduction in the corporate federal statutory tax rate will ultimately result in increased net income, whether due to decreased loan yields as a result of competition or other factors. Uncertainty also exists related to state and other taxing jurisdictions' response to federal tax reform, which we will continue to monitor and evaluate. Federal income tax treatment of corporations may be further clarified and modified by other legislative, administrative or judicial changes or interpretations at any time. Any such changes could adversely affect our business, financial condition and results of operations.

If we do not adjust to changes in the financial services industry, our financial performance may suffer.

The Corporation's ability to maintain its financial performance and return on investment to shareholders will depend largely on its ability to continue to grow its loan portfolio and also, in part, on its ability to maintain and grow its core deposit customer base and expand its financial services to its existing and/or new customers. In addition to other banks, competitors include savings and loan associations, credit unions, securities dealers, brokers, mortgage bankers, investment advisors and finance and insurance companies. The increasingly competitive environment is, in part, a result of changes in the economic environment within the states in which the Corporation does business, regulation, and changes in technology and product delivery systems. New competitors may emerge to increase the degree of competition for the Corporation's customers and services. Financial services and products are also constantly changing. The Corporation's financial performance will also depend, in part, upon customer demand for its products and services and its ability to develop and offer competitive financial products and service.

Consumers may decide not to use banks to complete their financial transactions.

Technology and other changes are allowing customers to complete financial transactions without the involvement of banks. For example, consumers can now pay bills and transfer funds directly without banks. The process of eliminating banks as intermediaries in financial transactions, known as disintermediation, could result in the loss of fee income, the loss of customer deposits and income generated from those deposits and lending opportunities.

Changes in interest rates could reduce our net income and cash flow.

Our net income and cash flow depends, to a great extent, on the difference between the interest we earn on loans and securities and the interest we pay on deposits and other borrowings. Market interest rates are beyond our control, and they fluctuate in response to general economic conditions, the policies of various governmental and regulatory agencies and competition. Changes in monetary policy, including changes in interest rates and interest rate relationships, will influence the origination of loans, the purchase of investments, the generation of deposits, the interest received on loans and securities and the interest paid on deposits and other borrowings. Any significant adverse effects of changes in interest rates on the our results of operations, or any substantial, unexpected, prolonged change in market interest rates could have a material adverse effect on our financial condition and results of operations. See the sections captioned "Net Interest Income" in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and "Market Risk" in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, located elsewhere in this Annual Report, for further discussion related to our management of interest rate risk.

We may be required to pay additional deposit insurance premiums to the FDIC, which could negatively impact earnings.

The FDIC insures deposits at FDIC-insured depository institutions, such as Chemical Bank, up to $250,000 per account. The amount of a particular institution’s deposit insurance assessment is based on that institution’s risk classification under an FDIC risk-based assessment system. Depending upon the magnitude of future losses that the FDIC deposit insurance fund suffers, there can be no assurance that there will not be additional premium increases or assessments in order to replenish the fund. The FDIC may need to set a higher base rate schedule based on future financial institution failures and updated failure and loss projections. Potentially higher FDIC assessment rates than those currently projected or special assessments could have an adverse impact on our financial condition and results of operations.

20


Our evaluation of investment securities for other-than-temporary impairment involves subjective determinations and could materially impact our financial condition and results of operations.

Our evaluation of impairments in our investment securities portfolio involved a quantitative and qualitative process, which is subject to risks and uncertainties and is intended to determine whether declines in the fair value of such investments should be recognized in current period earnings. The risks and uncertainties include changes in general economic conditions, the issuer's net income, projected net income and financial condition or future recovery prospects, the effects of changes in interest rates or credit spreads and the expected recovery period. Estimating future cash flows involves incorporating information received from third-party sources and making internal assumptions and judgments regarding the future performance of the underlying collateral and/or value of the underlying asset and also assessing the probability that an adverse change in future cash flows has occurred. The determination of the amount of other-than-temporary impairments is based upon our quarterly evaluation and assessment of known and inherent risks associated with the respective asset class. Such evaluations and assessments are revised as conditions change and new information becomes available.

Additionally, our management considers a wide range of factors about the security issuer and uses judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for recovery. Inherent in management's evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations in the impairment evaluation process include, but are not limited to: (i) the length of time and the extent to which the market value has been less than cost or amortized cost; (ii) the potential for impairments of securities when the issuer is experiencing significant financial difficulties; (iii) the potential for impairments in an entire industry sector or sub-sector; (iv) the potential for impairments in certain economically depressed geographic locations; (v) the potential for impairments of securities where the issuer, series of issuers or industry has suffered a catastrophic type of loss or has exhausted natural resources; (vi) our intent and ability to retain the investment for a period of time sufficient to allow for the recovery of its value; (vii) unfavorable changes in forecasted cash flows on residential mortgage-backed and asset-backed securities; and (viii) other subjective factors, including concentrations and information obtained from regulators and rating agencies. Impairments to the carrying value of our investment securities may need to be taken in the future, which could have a material adverse effect on our financial condition and results of operations.

We may be required to recognize an impairment of our goodwill or core deposit intangible assets, or to establish a valuation allowance against our deferred income tax assets, which could have a material adverse effect on our financial condition and results of operations.

Goodwill represents the excess of the amounts paid to acquire subsidiaries over the fair value of their net assets at the date of acquisition. We test goodwill at least annually for impairment. Substantially all of our goodwill at December 31, 2017 was recorded on the books of Chemical Bank. The fair value of Chemical Bank is impacted by the performance of its business and other factors. Core deposit intangible (CDI) assets represent the estimated value of stable customer deposits, excluding time deposits, acquired in business combinations, that provide a source of funds that are below market interest rates. We amortize our CDI assets over the estimated period the corresponding customer deposits are expect to exist. We test our CDI assets periodically for impairment. If we experience higher than expected deposit run-off, our CDI assets could be impaired. If we determined that our goodwill or CDI assets have been impaired, we must recognize a write-down by the amount of the impairment, with a corresponding charge to net income. Such write-downs could have a material adverse effect on our financial condition and results of operations. At December 31, 2017, we had $1.13 billion of goodwill, representing 42.5% of shareholders' equity. We had $34.3 million of CDI assets at December 31, 2017.

Deferred income tax represents the tax effect of the differences between the book and tax basis of assets and liabilities. Deferred tax assets are assessed periodically by management to determine if they are realizable. Factors in management's determination include our performance, including the ability to generate taxable net income. If, based on available information, it is more-likely-than-not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to net income. As of December 31, 2017, we carried a valuation allowance against our deferred tax assets of $1.2 million . Charges to establish a valuation allowance with respect to our deferred tax assets could have a material adverse effect on the financial condition and results of operations.

We may be a defendant in a variety of litigation and other actions, which may have a material adverse effect on our financial condition and results of operations.
We are regularly involved in a variety of litigation arising out of the normal course of our business. Our insurance may not cover all claims that may be asserted against us, and any claims asserted against us, regardless of merit or eventual outcome, may harm our reputation or cause us to incur unexpected expenses, which could be material in amount. Should the ultimate expenses, judgments or settlements in any litigation exceed our insurance coverage, they could have a material adverse effect on

21


our financial condition and results of operations. In addition, we may not be able to obtain appropriate types or levels of insurance in the future, nor may we be able to obtain adequate replacement policies with acceptable terms, if at all.
We are subject to the Community Reinvestment Act and federal and state fair lending laws, and failure to comply with these laws could lead to material penalties.

The Community Reinvestment Act, the Equal Credit Opportunity Act and the Fair Housing Act impose nondiscriminatory lending requirements on financial institutions. The Federal Reserve, the CFPB, the Department of Justice, and other federal and state agencies are responsible for enforcing these laws and regulations. Private parties may also have the ability to challenge an institution’s performance under fair lending laws in private class action litigation. A successful challenge to our performance under the fair lending laws and regulations could adversely impact our rating under the Community Reinvestment Act and result in a wide variety of sanctions, including the required payment of damages and civil money penalties, injunctive relief, imposition of restrictions on merger and acquisition activity and restrictions on expansion activity, which could negatively impact our reputation, business, financial condition and results of operations.

We are exposed to risk of environmental liabilities with respect to real properties that we may acquire.

In the course of our business, we may acquire, through foreclosure, properties securing loans we have originated or purchased that are in default. Particularly in commercial real estate lending, there is a risk that hazardous substances could be discovered on these properties. In this event, we might be required to remove these substances from the affected properties at our sole cost and expense. The cost of this removal could substantially exceed the value of the affected properties. In addition, if we are the owner or former owner of a contaminated site, we may be subject to common law claims by third parties seeking damages for environmental contamination emanating from the site. We may not have adequate remedies against the prior owner or other responsible parties and could find it difficult or impossible to sell the affected properties. If we were to become subject to significant environmental liabilities or costs, our business, results of operations and financial condition could be materially and adversely affected.

We depend on the accuracy and completeness of information about our customers and counterparties.
In deciding whether to extend credit or enter into other transactions, and in evaluating and monitoring our loan portfolio on an ongoing basis, we rely on information provided to us by or on behalf of our customers and counterparties, including financial statements, credit reports and other financial information. We may also rely on representations of those customers and counterparties or of other third parties, such as independent auditors, as to the accuracy and completeness of that information. Reliance on inaccurate, incomplete, fraudulent or misleading financial statements, credit reports or other financial or business information, or the failure to receive such information on a timely basis, could result in loan losses, reputational damage or other effects that could have a material adverse effect on our business, financial condition or results of operations.

We operate in a highly competitive industry and market area.

We face substantial competition in all areas of our operations from a variety of different competitors, many of which are larger and may have more financial resources than us. We compete with commercial banks, credit unions, savings and loan associations, mortgage banking firms, other financial service businesses, including investment advisory and wealth management firms, mutual fund companies, and securities brokerage and investment banking firms, as well as super-regional, national and international financial institutions that operate offices in our primary market areas and elsewhere. The financial services industry could become even more competitive as a result of legislative, regulatory and technological changes and continued consolidation. As customers preferences and expectations continue to evolve, technology has lowered barriers to entry and made it possible for banks to expand their geographic reach by providing services over the Internet and for non-banks to offer products and services traditionally provided by banks, such as automatic transfer and automatic payment systems. Because of this rapidly changing technology, our future success will depend in part on our ability to address our customers’ needs by using technology.

We compete with these institutions both in attracting deposits and assets under management, and in making new loans. We may not be able to compete successfully with other financial institutions in our markets, particularly with larger financial institutions operating in our markets that have significantly greater resources than us and offer financial products and services that we are unable to offer, putting us at a disadvantage in competing with them for loans and deposits and investment management clients, and we may have to pay higher interest rates to attract deposits, accept lower yields on loans to attract loans and pay higher wages for new employees, resulting in lower net interest margin and reduced profitability. In addition, many of our competitors have fewer regulatory constraints and may have lower cost structures, such as credit unions that are not subject to federal income tax.


22


Our ability to compete successfully depends on a number of factors, including, among other things:

our ability to develop, maintain and build long-term customer relationships based on quality service, high ethical standards and safe, sound assets;
our ability to expand our market position;
our ability to keep up-to-date with technological advancements in both delivering new products and maintaining existing products, while continuing to invest in cybersecurity and control operating costs;
the scope, relevance and pricing of products and services we offer to meet customer needs and demands;
the rate at which we introduce new products and services relative to our competitors;
customer satisfaction with our level of service; and
industry and general economic trends.

Failure to perform in any of these areas could significantly weaken our competitive position, which could adversely affect our growth and profitability and have a material adverse effect on our financial condition and results of operations.

We depend on our executive officers and other key employees to continue the implementation of our long-term business strategy, and we could be harmed by the unexpected loss of their services.

We believe that our continued growth and future success will depend in large part on the skills of our executive officers and other key employees and our ability to motivate and retain these individuals, as well as our ability to attract, motivate and retain highly qualified senior and middle management and other skilled employees. Competition for employees is intense, and the process of locating key personnel with the combination of skills and attributes required to execute our business strategy may be lengthy. We may not be successful in retaining our key personnel, and the unexpected loss of services of one or more of our key personnel could have a material adverse effect on our business because of their skill, knowledge of our primary markets, years of industry experience and the difficulty of promptly finding qualified replacement personnel. If the services of any of our of key personnel should become unavailable for any reason, we may not be able to identify and hire qualified persons on terms acceptable to us, or at all, which could have a material adverse effect on our business, financial condition, results of operation and future prospects.

The banking industry is heavily regulated and that regulation, together with any future legislation or regulatory changes, could limit or restrict our activities and adversely affect our operations or financial results.

We operate in an extensively regulated industry and we are subject to examination, supervision, and comprehensive regulation by various federal and state agencies. Our compliance with banking regulations is costly and restricts some of our activities, including payment of dividends, mergers and acquisitions, investments, loans and interest rates and locations of offices. We are also subject to capitalization guidelines established by our regulators, which require us to maintain adequate capital to support our business.

Since the recession ended, federal and state banking laws and regulations, as well as interpretations and implementations of these laws and regulations, have undergone substantial review and change. In particular, the Dodd-Frank Act drastically revised the laws and regulations under which we operate. The burden of regulatory compliance has increased under the Dodd-Frank Act and has increased our costs of doing business and, as a result, may create an advantage for our competitors who may not be subject to similar legislative and regulatory requirements. Any future changes in federal and state laws and regulations, as well as the interpretation and implementation of such laws and regulations, could affect us in substantial and unpredictable ways, including those listed above or other ways that could have a material adverse effect on our business, financial condition or results of operations.

Furthermore, our regulators also have the ability to compel us to take certain actions, or restrict us from taking certain actions entirely, such as actions that our regulators deem to constitute an unsafe or unsound banking practice. Our failure to comply with any applicable laws or regulations, or regulatory policies and interpretations of such laws and regulations, could result in sanctions by regulatory agencies, civil money penalties or damage to our reputation, all of which could have a material adverse effect on our business, financial condition or results of operations.

Our business needs and future growth may require us to raise additional capital, but that capital may not be available or may be dilutive.
    
We are required by federal and state regulatory authorities to maintain specified levels of capital to support our operations. We may need to raise additional capital, in the form of debt or equity, in the future to have sufficient capital resources to meet our commitments and to fund our business needs and future growth, particularly if the quality of our assets or earnings were to deteriorate significantly. In addition, we are required by federal regulatory authorities to maintain adequate levels of capital to

23


support our operations. Our ability to raise additional capital will depend on conditions in the capital markets at that time, which are outside of our control, and on our financial performance. We cannot assure that we will be able to raise additional capital in the future on terms acceptable to us or at all. Any occurrence that limits our access to capital, may adversely affect our capital costs and our ability to raise capital and, in turn, our liquidity. Any inability to raise capital on acceptable terms when needed could have a material adverse effect on our business, financial condition and results of operations and could be dilutive to both tangible book value and our share price.

In addition, an inability to raise capital when needed may subject us to increased regulatory supervision and the imposition of restrictions on our growth and business. These restrictions could negatively affect our ability to operate or further expand our operations through loan growth, acquisitions or the establishment of additional branches. These restrictions may also result in increases in operating expenses and reductions in revenues that could have a material adverse effect on our financial condition, results of operations and our share price.

The soundness of other financial institutions could adversely affect us.

Our ability to engage in routine funding transactions could be adversely affected by the actions and commercial soundness of other financial institutions. Financial services institutions are interrelated as a result of trading, clearing, counterparty or other relationships. We have exposure to many different industries and counterparties, and we routinely execute transactions with counterparties in the financial services industry. As a result, defaults by, or even rumors or questions about, one or more financial services institutions, or the financial services industry generally, could lead to losses or defaults by us or by other institutions. Many of these transactions expose us to credit risk in the event of default of our counterparty or client. In addition, our credit risk may be exacerbated when the collateral that we hold cannot be realized or is liquidated at prices insufficient to recover the full amount of the loan. We can give no assurance that any such losses would not materially and adversely affect our business, financial condition or results of operations.

Our controls and procedures may fail or be circumvented.

Management regularly reviews and updates our internal controls and corporate governance policies and procedures. Any system of controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. A significant failure or circumvention of our controls and procedures or failure to comply with regulations related to controls and procedures could have a material adverse effect on our business, results of operations and financial condition.

A failure in or breach of our operational or security systems or infrastructure, or those of our third party vendors and other service providers or other third parties, including as a result of cyberattacks, could disrupt our businesses, result in the disclosure or misuse of confidential or proprietary information, damage our reputation, increase our costs and cause losses.

Our operations rely on the secure processing, storage and transmission of confidential and other sensitive business and consumer information on our computer systems and networks and third party providers. Under various federal and state laws, we are responsible for safeguarding such information. For example, our business is subject to the Gramm-Leach-Bliley Act which, among other things: (1) imposes certain limitations on our ability to share nonpublic personal information about our customers with nonaffiliated third parties; (2) requires that we provide certain disclosures to customers about our information collection, sharing and security practices and afford customers the right to “opt out” of any information sharing by us with nonaffiliated third parties (with certain exceptions); and (3) requires that we develop, implement and maintain a written comprehensive information security program containing appropriate safeguards based on our size and complexity, the nature and scope of our activities, and the sensitivity of customer information we process, as well as plans for responding to data security breaches. Ensuring that our collection, use, transfer and storage of personal information complies with all applicable laws and regulations can increase our costs.

Although we take protective measures to maintain the confidentiality, integrity and availability of information across all geographic and product lines, and endeavor to modify these protective measures as circumstances warrant, the nature of the threats continues to evolve. As a result, our computer systems, software and networks may be vulnerable to unauthorized access, loss or destruction of data (including confidential client information), account takeovers, unavailability of service, computer viruses or other malicious code, cyber-attacks and other events that could have an adverse security impact. Despite the defensive measures we take to manage our internal technological and operational infrastructure, these threats may originate externally from third parties such as foreign governments, organized crime and other hackers, and outsource or infrastructure-support providers and application developers, or may originate internally from within our organization. Furthermore, we may not be able to ensure that all of our clients, suppliers, counterparties and other third parties have appropriate controls in place to protect the confidentiality of the information that they exchange with us, particularly where such information is transmitted by electronic means. Given the

24


increasingly high volume of our transactions, certain errors may be repeated or compounded before they can be discovered and rectified. In addition, the increasing reliance on technology systems and networks and the occurrence and potential adverse impact of attacks on such systems and networks, both generally and in the financial services industry, have enhanced government and regulatory scrutiny of the measures taken by companies to protect against cyber-security threats. As these threats, and government and regulatory oversight of associated risks, continue to evolve, we may be required to expend additional resources to enhance or expand upon the security measures we currently maintain.

In particular, information pertaining to us and our customers is maintained, and transactions are executed, on the networks and systems of us, our customers and certain of our third-party partners, such as our online banking or reporting systems. The secure maintenance and transmission of confidential information, as well as execution of transactions over these systems, are essential to protect us and our customers against fraud and security breaches and to maintain our clients’ confidence. While we have not experienced any material breaches of information security, such breaches may occur through intentional or unintentional acts by those having access or gaining access to our systems or our customers’ or counterparties’ confidential information, including employees. In addition, increases in criminal activity levels and sophistication, advances in computer capabilities, new discoveries, vulnerabilities in third-party technologies (including browsers and operating systems) or other developments could result in a compromise or breach of the technology, processes and controls that we use to prevent fraudulent transactions and to protect data about us, our customers and underlying transactions, as well as the technology used by our customers to access our systems. We cannot be certain that the security measures we or processors have in place to protect this sensitive data will be successful or sufficient to protect against all current and emerging threats designed to breach our systems or those of processors. Although we have developed, and continue to invest in, systems and processes that are designed to detect and prevent security breaches and cyber-attacks and periodically test our security, a breach of our systems, or those of processors, could result in losses to us or our customers; loss of business and/or customers; damage to our reputation; the incurrence of additional expenses (including the cost of notification to consumers, credit monitoring and forensics, and fees and fines imposed by the card networks); disruption to our business; our inability to grow our online services or other businesses; additional regulatory scrutiny or penalties; or our exposure to civil litigation and possible financial liability-any of which could have a material adverse effect on our business, financial condition and results of operations.

We depend on information technology and telecommunications systems of third-party servicers, and systems failures, interruptions or breaches of security involving these systems could have an adverse effect on our operations, financial condition and results of operations.

Our business is highly dependent on the successful and uninterrupted functioning of our information technology and telecommunications systems, third-party servicers accounting systems and mobile and online banking platforms. We outsource some of our major systems, such as payment processing systems, and online banking platforms. To revise based on outsourced systems. The failure of these systems, or the termination of a third-party software license or service agreement on which any of these systems is based, could interrupt our operations. Because our information technology and telecommunications systems interface with and depend on third-party systems, we could experience service denials if demand for such services exceeds capacity or such third-party systems fail or experience interruptions. If sustained or repeated, a system failure or service denial could result in a deterioration of our ability to process new and renewal loans, gather deposits and provide customer service, compromise our ability to operate effectively, damage our reputation, result in a loss of customer business and/or subject us to additional regulatory scrutiny and possible financial liability, any of which could have a material adverse effect on our financial condition and results of operations. In addition, failure of third parties to comply with applicable laws and regulations, or fraud or misconduct on the part of employees of any of these third parties could disrupt our operations or adversely affect our reputation.

It may be difficult for us to replace some of our third party vendors, particularly vendors providing our core banking, debit card services and information services, in a timely manner if they are unwilling or unable to provide us with these services in the future for any reason and even if we are able to replace them, it may be at higher cost or result in the loss of customers. Any such events could have a material adverse effect on our business, financial condition or results of operations.

Our operations rely heavily on the secure processing, storage and transmission of information and the monitoring of a large number of transactions on a minute-by-minute basis, and even a short interruption in service could have significant consequences. We also interact with and rely financial counterparties and regulators. Each of these third parties may be targets of the same types of fraudulent activity, computer break-ins and other cyber security breaches described above or herein, and the cyber security measures that they maintain to mitigate the risk of such activity may be different than our own and may be inadequate.

As a result of financial entities and technology systems becoming more interdependent and complex, a cyber incident, information breach or loss, or technology failure that compromises the systems or data of one or more financial entities could have a material impact on counterparties or other market participants, including ourselves. Although we review business continuity and backup plans for our vendors and take other safeguards to support our operations, such plans or safeguards may be inadequate.

25


As a result of the foregoing, our ability to conduct business may be adversely affected by any significant disruptions to us or to third parties with whom we interact.

Additionally, regulators expect financial institutions to be responsible for all aspects of their performance, including aspects which they delegate to third parties. Disruptions or failures in the physical infrastructure or operating systems that support our businesses and clients, or cyber-attacks or security breaches of the networks, systems, devices, or software that our clients use to access our products and services could result in client attrition, regulatory fines, penalties or intervention, reputational damage, reimbursement or other compensation costs, and additional compliance costs, any of which could materially adversely affect our results of operations or financial condition.

We rely on quantitative models to manage certain accounting, risk management and capital planning functions.

We use quantitative models to help manage certain aspects of our business and to assist with certain business decisions, including estimating probable loan losses, measuring the fair value of financial instruments when reliable market prices are unavailable, estimating the effects of changing interest rates and other market measures on our financial condition and results of operations, risk management and for capital planning purposes. Our modeling methodologies rely on many assumptions, historical analyses and correlations. These assumptions may be incorrect, particularly in times of market distress, and the historical correlations on which we rely may no longer be relevant. Additionally, as businesses and markets evolve, our measurements may not accurately reflect this evolution. Even if the underlying assumptions and historical correlations used in our models are adequate, our models may be deficient due to errors in computer code, bad data, misuse of data, or the use of a model for a purpose outside the scope of the model’s design.

All models have certain limitations. Reliance on models presents the risk that our business decisions based on information incorporated from models will be adversely affected due to incorrect, missing or misleading information. In addition, our models may not capture or fully express the risks we face, may suggest that we have sufficient capitalization when we do not, or may lead us to misjudge the business and economic environment in which we will operate. If our models fail to produce reliable results on an ongoing basis, we may not make appropriate risk management, capital planning, or other business or financial decisions. Strategies that we employ to manage and govern the risks associated with our use of models may not be effective or fully reliable, and as a result, we may realize losses or other lapses. Also, information that we provide to the public or regulators based on poorly designed models could be inaccurate or misleading.

Banking regulators continue to focus on the models used by banks and bank holding companies in their businesses. Some of our decisions that the regulators evaluate, including distributions to our shareholders, could be affected adversely due to their perception that the quality of the models used to generate the relevant information is insufficient. Accordingly, the failure or inadequacy of a model may result in increased regulatory scrutiny on us or may result in an enforcement action or proceeding against us by one of our regulators.

Our ability to maintain our reputation is critical to the success of our business, including our ability to attract and retain customer relationships, and failure to do so may materially adversely affect our performance.

The reputation of Chemical Bank is one of the most valuable components of our business. As such, we strive to conduct our business in a manner that enhances our reputation. Damage to our reputation could undermine the confidence of our current and potential clients in our ability to provide financial services. Such damage could also impair the confidence of our investors, counterparties and business partners, and ultimately affect our ability to effect transactions or maintain or hire qualified management and personnel. Maintenance of our reputation depends not only on our success in controlling and mitigating the various risks described herein, but also on our success in identifying and appropriately addressing issues that may arise in areas such as potential conflicts of interest, anti-money laundering, client personal information and privacy issues, record-keeping, regulatory investigations and any litigation that may arise from the failure or perceived failure of us to comply with legal and regulatory requirements. If our reputation is negatively affected, by the actions of our employees or otherwise, our business and, therefore, our operating results may be materially adversely affected. Further, negative public opinion can expose us to litigation and regulatory action, which would adversely affect our business, financial condition and results of operations.

Severe weather, natural disasters, acts of war or terrorism and other external events could significantly impact the our business.

Severe weather, natural disasters, acts of war or terrorism and other adverse external events could have a significant impact on our ability to conduct business. Such events could affect the stability of our deposit base, impair the ability of borrowers to repay outstanding loans, impair the value of collateral securing loans, cause significant property damage, result in loss of revenue and/or cause us to incur additional expenses. Although management has established disaster recovery policies and procedures, the

26


occurrence of any such event in the future could have a material adverse effect on our business, financial condition and results of operations.

Risks Related to Our Common Stock

Investments in our common stock involve risk.

The market price of our common stock may fluctuate significantly in response to a number of factors, including, among other things:

Variations in quarterly or annual results of operations
Changes in dividends paid per share
Deterioration in asset quality, including declining real estate values
Changes in interest rates
Changes in tax laws
Significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by, or involving, the Corporation or its competitors
Failure to integrate acquisitions or realize anticipated benefits from acquisitions
Regulatory actions, including changes to regulatory capital levels, the components of regulatory capital and how regulatory capital is calculated
New regulations that limit or significantly change the Corporation's ability to continue to offer existing banking products
Volatility of stock market prices and volumes
Issuance of additional shares of common stock or other debt or equity securities of the Corporation
Changes in market valuations of similar companies
Uncertainties, disruptions and fluctuations in the credit and financial markets, either nationally or globally
Changes in securities analysts' estimates of financial performance or recommendations
New litigation or contingencies or changes in existing litigation or contingencies
New technology used, or services offered, by competitors
Breaches in information security systems of the Corporation and/or its customers and competitors
Changes in accounting policies or procedures required by standard setting or other regulatory agencies
New developments in the financial services industry
News reports relating to trends, concerns and other issues in the financial services industry
Perceptions in the marketplace regarding the financial services industry, the Corporation and/or its competitors
Rumors or erroneous information
Geopolitical conditions such as acts or threats of terrorism or military conflicts

We may issue debt and equity securities that are senior to our common stock as to distributions and in liquidation, which could negatively affect the value of our common stock.

In the future, we may increase our capital resources by entering into debt or debt-like financing or issuing debt or equity securities, which could include issuances of senior notes, subordinated notes, preferred stock or common stock. In the event of our liquidation, our lenders and holders of our debt securities and preferred stock would receive a distribution of our available assets before distributions to the holders of our common stock. Our decision to incur debt and issue securities in future offerings may depend on market conditions and other factors beyond our control. We cannot predict or estimate the amount, timing or nature of our future offerings and debt financings, if any. Future offerings could reduce the value of shares of our common stock and dilute a shareholder's interest in the Corporation.

The Corporation relies on dividends from Chemical Bank for most of its revenue.

The Corporation is a separate and distinct legal entity from Chemical Bank. It receives substantially all of its revenue from dividends from Chemical Bank. These dividends are the principal source of funds to pay cash dividends on the Corporation's common stock. Various federal and/or state laws and regulations limit the amount of dividends that Chemical Bank may pay to the Corporation. In the event Chemical Bank is unable to pay dividends to the Corporation, the Corporation may not be able to pay cash dividends on its common stock. The earnings of Chemical Bank have been the principal source of funds to pay cash dividends to shareholders. Over the long-term, cash dividends to shareholders are dependent upon earnings, as well as capital requirements, regulatory restraints and other factors affecting Chemical Bank. See the section captioned "Supervision and Regulation" in Item 1. Business and Note 20 - Regulatory Capital and Reserve Requirements in the notes to our Consolidated

27


Financial Statements included in Item 8. Financial Statements and Supplementary Data, which are located elsewhere in this Annual Report.

Shares of our common stock are not insured deposits.

Shares of our common stock are not bank deposits and are not insured or guaranteed by the FDIC or any other governmental agency, and are subject to investment risk, including the possible loss of principal.
Item 1B. Unresolved Staff Comments.
None.  
Item 2. Properties.
Our executive offices are located at 235 E. Main Street in downtown Midland, Michigan, in an office building that is owned by us. The main branch office of Chemical Bank is located at 333 E. Main Street in downtown Midland, Michigan, in an office building that we own.
We conduct business through 212 banking offices and seven loan production offices as of December 31, 2017 . We have 186 banking offices located in Michigan, 24 banking offices located in Ohio and two banking offices located in Indiana through which we operate. Of our 212 banking offices, 40 are leased properties. Management believes the terms of the various leases are consistent with market standards and were arrived at through arm's-length bargaining.
We consider our properties to be suitable and adequate for operating our banking business.
Item 3. Legal Proceedings.
On February 22, 2016, two putative class action and derivative complaints were filed in the Circuit Court for Oakland County, Michigan by individuals purporting to be a shareholder of Talmer. The actions are styled  Regina Gertel Lee v. Chemical Financial Corporation, et. al. , Case No. 2016-151642-CB and  City of Livonia Employees’ Retirement System v. Chemical Financial Corporation et. al.,  Case No. 2016-151641-CB. These complaints purport to be brought derivatively on behalf of Talmer against the individual defendants, and individually and on behalf of all others similarly situated against Talmer and the Corporation (collectively, the "Defendants"). The complaints allege, among other things, that the directors of Talmer breached their fiduciary duties to Talmer’s shareholders in connection with the merger by approving a transaction pursuant to an allegedly inadequate process that undervalues Talmer and includes preclusive deal protection provisions, and that the Corporation allegedly aided and abetted the Talmer directors in breaching their duties to Talmer’s shareholders. The complaints also allege that the individual defendants have been unjustly enriched. Both complaints seek various remedies on behalf of the putative class (consisting of all shareholders of Talmer who are not related to or affiliated with any defendant). They request, among other things, that the Court enjoin the merger from being consummated in accordance with its agreed-upon terms, direct the Talmer directors to exercise their fiduciary duties, rescind the merger agreement to the extent that it is already implemented, award the plaintiff all costs and disbursements in each respective action (including reasonable attorneys’ and experts’ fees), and grant such further relief as the court deems just and proper. The  City of Livonia  plaintiff amended its complaint on April 21, 2016 to add additional factual allegations, including but not limited to allegations that Keefe Bruyette & Woods, Inc. ("KBW") served as a financial advisor for the proposed merger despite an alleged conflict of interest, that Talmer’s board acted under actual or potential conflicts of interest, and that the defendants omitted and/or misrepresented material information about the proposed merger in the Form S-4 Registration Statement relating to the proposed merger. These two cases were consolidated as  In re Talmer Bancorp Shareholder Litigation , case number 2016-151641-CB, per an order entered on May 12, 2016. On October 31, 2016, the plaintiffs in this consolidated action again amended their complaint, adding additional factual allegations, adding KBW as a defendant, and asserting that KBW acted in concert with the Corporation to aid and abet breaches of fiduciary duty by Talmer's directors. The Defendants all filed motions for summary disposition seeking dismissal of all claims with prejudice. The Court issued an opinion and order on those motions on May 4, 2017 and granted dismissal to the Corporation, but denied the motions filed by KBW and the individual defendants. KBW and the individual defendants filed an application seeking leave to appeal the Court's ruling to the Michigan Court of Appeals. That application was denied by the Michigan Court of Appeals on August 16, 2017. On June 8, 2017, the Defendants filed a notice with the Court that the plaintiffs had failed to timely certify a class as required by the Michigan Court Rules. Upon the filing of that notice, the City of Livonia case became an individual action brought by the two named plaintiffs, and cannot proceed as a class action. On October 19, 2017, the Defendants filed motions for summary disposition under MCR 2.116(C) (10) in the City of Livonia case, again seeking the dismissal of the case. A hearing on those motions is scheduled for April 11, 2018. KBW and the individual defendants all believe that the claims asserted against each of them in the above-described consolidated action are without merit and intend to vigorously defend against these consolidated lawsuits.
On June 16, 2016, the same putative class plaintiff that filed the City of Livonia state court action discussed in the preceding paragraph filed a complaint in the United States District Court for the Eastern District of Michigan , styled  City of Livonia Employees’

28


Retirement System v Chemical Financial Corporation, et. al.,  Docket No. 1:16-cv-12229. The plaintiff purports to bring this action " individually and on behalf of all others similarly situated, " and requests certification as a class action. The Complaint alleges violations of Section 14(a) and 20(a) of the Securities Exchange Act of 1934 and alleges, among other things, that the Defendants issued materially incomplete and misleading disclosures in the Form S-4 Registration Statement relating to the proposed merger. The Complaint contains requests for relief that include, among other things, that the Court enjoin the proposed transaction unless and until additional information is provided to Talmer’s shareholders, declare that the Defendants violated the securities laws in connection with the proposed merger, award compensatory damages, interest, attorneys’ and experts’ fees, and that the Court grant such other relief as it deems just and proper. Talmer, the Corporation, and the individual defendants all believe that the claims asserted against each of them in this lawsuit are without merit and intend to vigorously defend against this lawsuit. On October 18, 2016, the Federal Court entered a stipulated order staying this action until the Oakland County Circuit Court issues rulings on motions for summary disposition In re Talmer Bancorp Shareholder Litigation , case number 2016-151641-CB. Following the Oakland County Circuit Court's denial of the Motions by KBW and the individual defendants and their ensuing application for leave to appeal that ruling, the Federal Court issued an order extending the stay of this action. On November 13, 2017, the Federal Court issued an Order Directing Plaintiff To Show Cause Why The Stay Should Not Be Lifted. On January 8, 2018, the plaintiff filed a reply to the show cause order, and asked that the stay be continued. The Defendants oppose continuation of the stay, and filed a reply to that effect on January 22, 2018. Further action by the Court is awaited.
In response to the failure of the City of Livonia case to qualify as a class action, on July 31, 2017, the same attorneys who filed the City of Livonia action field a new lawsuit in the Oakland County, Michigan Circuit Court, based on the Talmer transaction. That case is styled Kevin Nicholl v Gary Torgow et al, Case No. 2017-160058-CB. The Nicholl case makes substantially the same claims as were brought in the City of Livonia case, and seeks certification of a shareholder class. The Nicholl case has been assigned to Judge Wendy Potts, the same judge presiding over the City of Livonia case. On November 22, 2017, the plaintiff filed a First Amended Complaint purporting to add the City of Livonia Employees’ Retirement System and Regina Gertel Lee as additional named plaintiffs in the case. The Defendants have filed motions for summary disposition in the Nicholl case, seeking dismissal of the Nicholl case. Argument on these motions will be heard on April 11, 2018, which is the same date the summary disposition motions of the Defendants will be argued in the City of Livonia case.
On January 3, 2018, the plaintiffs in the City of Livonia case filed a Motion For Voluntary Dismissal Without Prejudice. Defendants filed an opposition to that motion. The Court has set hearing on the plaintiff’s motion for April 11, 2018.
In addition, we are subject to certain legal actions arising in the ordinary course of business. In the opinion of management, after consultation with legal counsel, the ultimate disposition of these matters is not expected to have a material adverse effect on our Consolidated Financial Condition or Results of Operations.    
Item 4. Mine Safety Disclosures.
Not applicable.

29


PART II.

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock is traded on The NASDAQ Stock Market ® under the symbol CHFC. As of December 31, 2017 , there were approximately 71.2 million shares of our common stock issued and outstanding, held by approximately 4,797  shareholders of record. The table below sets forth the range of high and low sales prices for transactions reported on The NASDAQ Stock Market ® for our common stock for the periods indicated.
 
2017
 
2016
 
High
 
Low
 
High
 
Low
First quarter
$
54.98

 
$
47.52

 
$
36.45

 
$
29.40

Second quarter
51.52

 
44.22

 
40.14

 
34.29

Third quarter
53.17

 
43.61

 
47.62

 
35.73

Fourth quarter
58.17

 
50.39

 
55.55

 
40.93

The earnings of Chemical Bank are the principal source of funds to pay cash dividends to our shareholders. Accordingly, cash dividends are dependent upon the earnings, capital needs, regulatory constraints, and other factors affecting Chemical Bank. See Note 20 to our Consolidated Financial Statements in Item 8 of this Annual Report for a discussion of such limitations. We have paid regular cash dividends every quarter since we began operation as a bank holding company in 1973. Based on our financial condition at December 31, 2017 , management expects to continue to pay quarterly cash dividends on our common shares in 2018 . However, there can be no assurance as to future dividends because they are dependent on our future earnings, capital requirements and financial condition, and may require regulatory approval. On January 23, 2018 , we declared a first quarter 2018 cash dividend of $0.28 per share, payable on March 16, 2018 .
The following table summarizes the quarterly cash dividends paid to shareholders over the past five years.
 
Years Ended December 31,
 
2017
 
2016
 
2015
 
2014
 
2013
First quarter
$
0.27

 
$
0.26

 
$
0.24

 
$
0.23

 
$
0.21

Second quarter
0.27

 
0.26

 
0.24

 
0.23

 
0.21

Third quarter
0.28

 
0.27

 
0.26

 
0.24

 
0.22

Fourth quarter
0.28

 
0.27

 
0.26

 
0.24

 
0.23

Total
$
1.10

 
$
1.06

 
$
1.00

 
$
0.94

 
$
0.87


30


Shareholder Return
The following line graph compares our cumulative total shareholder return on our common stock over the last five years, assuming the reinvestment of dividends, to the Standard and Poor's (S&P) 500 Stock Index and the KBW Nasdaq Regional Banking Index (Ticker: KRX). Both of these indices are based upon total return (including reinvestment of dividends) and are market-capitalization-weighted indices. The S&P 500 Stock Index is a broad equity market index published by S&P. The KBW Nasdaq Regional Banking Index is published by Keefe, Bruyette & Woods, Inc. (KBW), an investment banking firm that specializes in the banking industry. The KBW Nasdaq Regional Banking Index is composed of 50 small and mid-cap U.S. regional banks or thrifts that are publicly traded. The line graph assumes $100 was invested on December 31, 2012 .
CHART-5CB1436A5A6E55CBB0A.JPG
The dollar values for total shareholder return plotted in the above graph are shown below:
 
 
December 31,
 
 
2012
 
2013
 
2014
 
2015
 
2016
 
2017
Chemical Financial Corporation
 
$
100.00

 
$
137.66

 
$
137.55

 
$
158.74

 
$
257.24

 
$
259.57

KBW NASDAQ Regional Banking Index
 
100.00

 
146.85

 
150.41

 
159.31

 
221.46

 
225.34

S&P 500 Stock Index
 
100.00

 
132.39

 
150.51

 
152.59

 
170.84

 
208.14




31


Equity Compensation Plans
Information about our equity compensation plans as of December 31, 2017 is set forth in Part III, Item 12 of this Annual Report, and is here incorporated by reference.
Purchases of Equity Securities
The following schedule summarizes total monthly share repurchase activity for the fourth quarter of 2017 :
 
 
Issuer Purchases of Equity Securities
Period
 
Total Number of Shares Purchased (1)
 
Average Price Paid Per Share
 
Total Number of Shares Purchased as Part of Publicly Announced
 Plans or Programs
 
Maximum Number of Shares that May Yet Be Purchased Under
Plans or Programs
October 1, 2017 to October 31, 2017
 
11,687

 
$
53.26

 

 
500,000
November 1, 2017 to November 30, 2017
 
30,630

 
55.92

 

 
500,000
December 1, 2017 to December 31, 2017
 
6,602

 
56.04

 

 
500,000
    Total
 
48,919

 
$
55.30

 

 

(1)
Represents shares delivered or attested in satisfaction of the exercise price and/or tax withholding obligations by employees who received shares of our common stock in 2017 under our share-based compensation plans, as these plans permit employees to use our stock to satisfy such obligations based on the market value of our stock on the date of vesting or date of exercise, as applicable.

32


Item 6. Selected Financial Data.
The following table sets forth our selected historical consolidated financial information for the periods and as of the dates indicated. We derived our balance sheet and income statement data for the years ended December 31, 2017 , 2016 , 2015 , 2014 and 2013 from our audited Consolidated Financial Statements. You should read this information together with Management's Discussion and Analysis of Financial Condition and Results of Operations and our audited Consolidated Financial Statements and the related notes thereto, which are included elsewhere in this Annual Report. As noted in the following table, we have included certain non-GAAP financial measures, which should be read in conjunction with the section entitled “Non-GAAP Financial Measures” and the accompanying table entitled “Reconciliation of Non-GAAP Operating Results,” for reconciliation of non-GAAP measures to the most directly comparable GAAP financial measure. The financial information includes the impact of our merger with Talmer on August 31, 2016, our acquisitions of Lake Michigan on May 31, 2015, Monarch on April 1, 2015 and Northwestern on October 31, 2014. See Note 2 to our Consolidated Financial Statements in Item 8 of this Annual Report for additional information regarding our acquisitions. Our historical results shown in the following table and elsewhere in this Annual Report are not necessarily indicative of our future performance.
 
As of and for the years ended December 31,
(Dollars in thousands, except per share data)
2017
 
2016
 
2015
 
2014
 
2013
Summary of Operations
 
 
 
 
 
 
 
 
 
Interest income
$
632,135

 
$
410,379

 
$
291,789

 
$
227,261

 
$
214,061

Interest expense
74,557

 
29,298

 
17,781

 
14,710

 
17,414

Net interest income
557,578

 
381,081

 
274,008

 
212,551

 
196,647

Provision for loan losses
23,300

 
14,875

 
6,500

 
6,100

 
11,000

Net interest income after provision for loan losses
534,278

 
366,206

 
267,508

 
206,451

 
185,647

Noninterest income
144,019

 
122,350

 
80,216

 
63,095

 
60,409

Operating expenses, core (non-GAAP) (1)(2)
384,340

 
277,284

 
216,090

 
173,537

 
164,948

Merger and restructuring expenses
28,402

 
61,134

 
7,804

 
6,388

 

Impairment of income tax credits
9,252

 

 

 

 

Income before income taxes
256,303

 
150,138

 
123,830

 
89,621

 
81,108

Income tax expense
106,780

 
42,106

 
37,000

 
27,500

 
24,300

Net income
$
149,523

 
$
108,032

 
$
86,830

 
$
62,121

 
$
56,808

Significant items, net of tax(non-GAAP) (1)(3)
70,033

 
35,695

 
5,484

 
4,555

 

Net income, excluding significant items(non-GAAP) (1)(3)
$
219,556


$
143,727


$
92,314


$
66,676


$
56,808

Per Common Share Data
 
 
 
 
 
 
 
 
 
Net Income
 
 
 
 
 
 
 
 
 
Basic
$
2.11

 
$
2.21

 
$
2.41

 
$
1.98

 
$
2.02

Diluted
2.08

 
2.17

 
2.39

 
1.97

 
2.00

Diluted, excluding significant items (non-GAAP) (1)(3)
3.06

 
2.88

 
2.54

 
2.11

 
2.00

Cash dividends declared and paid
1.10

 
1.06

 
1.00

 
0.94

 
0.87

Book value at end of period
37.48

 
36.57

 
26.62

 
24.32

 
23.38

Tangible book value per share (non-GAAP) (1)
21.21

 
20.20

 
18.73

 
18.57

 
19.17

Market value at end of period
53.47

 
54.17

 
34.27

 
30.64

 
31.67

Common shares outstanding (in thousands)
71,207

 
70,599

 
38,168

 
32,774

 
29,790

Average diluted common shares (in thousands)
71,513

 
49,603

 
36,353

 
31,588

 
28,352

(1)
Denotes a non-GAAP Financial Measure. Please refer to section entitled " Non-GAAP Financial Measures " included within this Management's Discussion and Analysis of Financial Condition and Results of Operations for a reconciliation to the most directly comparable GAAP financial measure.
(2)
Excludes merger expenses, restructuring expenses and impairment of income tax credits.
(3)
For 2017, "significant items" are defined to include the fourth quarter of 2017 charge to income tax expense resulting from the revaluation of our net deferred tax assets completed following the signing of the Tax Cuts and Jobs Act in December 2017, merger expenses, restructuring expenses and fourth quarter of 2017 losses on sales of investment securities as part of our treasury and tax management objectives. For years prior to 2017, "significant items" are defined to include merger expenses and gain on sales of branch offices.


33


 
As of and for the years ended December 31,
(Dollars in thousands, except per share data)
2017
 
2016
 
2015
 
2014
 
2013
Balance Sheet Data
 
 
 
 
 
 
 
 
 
Total assets
$
19,280,873

 
$
17,355,179

 
$
9,188,797

 
$
7,322,143

 
$
6,184,708

Investment securities
2,640,639

 
1,858,391

 
1,063,702

 
1,065,277

 
958,475

Total loans
14,155,267

 
12,990,779

 
7,271,147

 
5,688,230

 
4,647,621

Total deposits
13,642,803

 
12,873,122

 
7,456,767

 
6,078,971

 
5,122,385

Total liabilities
16,612,124

 
14,773,653

 
8,172,823

 
6,525,010

 
5,488,208

Total shareholders' equity
2,668,749

 
2,581,526

 
1,015,974

 
797,133

 
696,500

Tangible shareholders' equity (non-GAAP) (1)
1,510,011

 
1,425,998

 
714,901

 
606,419

 
571,947

Balance Sheet Averages
 
 
 
 
 
 
 
 
 
Total assets
$
18,465,156

 
$
12,037,155

 
$
8,481,228

 
$
6,473,144

 
$
5,964,592

Total earning assets
16,400,425

 
10,856,795

 
7,851,134

 
6,095,064

 
5,628,969

Total loans
13,607,683

 
9,304,573

 
6,583,846

 
4,976,563

 
4,355,152

Total deposits
13,255,366

 
9,397,562

 
6,958,667

 
5,339,422

 
4,964,082

Total interest-bearing liabilities
12,142,292

 
7,821,366

 
5,704,205

 
4,349,977

 
4,181,921

Total shareholders' equity
2,627,862

 
1,546,721

 
919,328

 
754,211

 
626,555

Performance Ratios
 
 
 
 
 
 
 
 
 
Net interest margin
3.40
%
 
3.51
%
 
3.49
%
 
3.49
%
 
3.49
%
Net interest margin(fully taxable equivalent)(Non-GAAP) (1)(2)
3.48
%
 
3.60
%
 
3.58
%
 
3.59
%
 
3.59
%
Return on average assets
0.81
%
 
0.90
%
 
1.02
%
 
0.96
%
 
0.95
%
Return on average shareholders' equity
5.7
%
 
7.0
%
 
9.4
%
 
8.2
%
 
9.1
%
Return on average tangible shareholders' equity (Non-GAAP) (1)
10.2
%
 
11.2
%
 
12.9
%
 
10.4
%
 
11.4
%
Average shareholders' equity as a percent of average assets
14.2
%
 
12.8
%
 
10.8
%
 
11.7
%
 
10.5
%
Efficiency ratio (GAAP)
60.1
%
 
67.2
%
 
63.2
%
 
65.3
%
 
64.2
%
Efficiency ratio adjusted (non-GAAP) (1)
51.9
%
 
54.4
%
 
58.7
%
 
60.9
%
 
62.4
%
Dividend payout ratio
52.9
%
 
48.8
%
 
41.8
%
 
47.7
%
 
43.5
%
Consolidated Capital Ratios
 
 
 
 
 
 
 
 
 
Shareholders' equity as a percentage of total assets
13.8
%
 
14.9
%
 
11.1
%
 
10.9
%
 
11.3
%
Tangible shareholders' equity as a percentage of tangible assets (non-GAAP) (1)
8.3
%
 
8.8
%
 
8.0
%
 
8.5
%
 
9.4
%
Common equity tier 1 capital (3)
10.2
%
 
10.7
%
 
10.6
%
 
N/A

 
N/A

Tier 1 leverage ratio (3)
8.3
%
 
9.0
%
 
8.6
%
 
9.3
%
 
9.9
%
Tier 1 risk-based capital ratio (3)
10.2
%
 
10.7
%
 
10.7
%
 
11.1
%
 
12.7
%
Total risk-based capital ratio (3)
11.0
%
 
11.5
%
 
11.8
%
 
12.4
%
 
14.0
%
Asset Quality
 
 
 
 
 
 
 
 
 
Net loan charge-offs
$
9,681

 
$
9,935

 
$
8,855

 
$
9,489

 
$
16,419

Net loan charge-offs as a percentage of average loans
0.07
%
 
0.11
%
 
0.13
%
 
0.19
%
 
0.38
%
Year end balances:
 
 
 
 
 
 
 
 
 
Allowance for loan losses — originated loans
$
91,887

 
$
78,268

 
$
73,328

 
$
75,183

 
$
78,572

Allowance for loan losses — acquired loans

 

 

 
500

 
500

Total nonaccrual loans
63,095

 
44,334

 
62,225

 
50,644

 
61,897

Total nonperforming assets
71,902

 
61,521

 
72,160

 
64,849

 
71,673

Year end ratios:
 
 
 
 
 
 
 
 
 
Allowance for loan losses as a percentage of total originated loans
0.94
%
 
1.05
%
 
1.26
%
 
1.51
%
 
1.81
%
Allowance for loan losses as a percentage of nonaccrual loans
145.6
%
 
176.5
%
 
117.8
%
 
148.5
%
 
126.9
%
Nonaccrual loans as a percentage of total loans
0.45
%
 
0.34
%
 
0.86
%
 
0.89
%
 
1.33
%
Nonperforming assets as a percentage of total assets
0.37
%
 
0.35
%
 
0.79
%
 
0.89
%
 
1.16
%
(1)
Denotes a non-GAAP Financial Measure. Please refer to section entitled " Non-GAAP Financial Measures " included within "Management's Discussion and Analysis of Financial Condition and Results of Operations" for a reconciliation to the most directly comparable GAAP financial measure.
(2)
Presented on a tax equivalent basis using a 35% tax rate for all periods presented.
(3)
The years ended December 31, 2017, 2016 and 2015 are under Basel III transitional and the years ended December 31, 2014 and 2013 are under Basel I.

34


Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion describes our results of operations for the years ended December 31, 2017 , 2016 and 2015 and also analyzes our financial condition as of December 31, 2017 , as compared to December 31, 2016 . This discussion should be read in conjunction with the " Selected Financial Data " and our audited Consolidated Financial Statements and accompanying footnotes thereto included elsewhere in this Annual Report. Historical results of operations and the percentage relationships among any amounts included, and any trends that may appear, may not indicate trends in operations or results of operations for any future periods.
We have made, and will continue to make, various forward-looking statements with respect to financial and business matters. Comments regarding our business that are not historical facts are considered forward-looking statements that involve inherent risks and uncertainties. Actual results may differ materially from those contained in these forward-looking statements. For additional information regarding our cautionary disclosures, see " Forward-Looking Statements " of this Annual Report.
Business Overview
Chemical Financial Corporation is a financial holding company headquartered in Midland, Michigan with its business concentrated in a single industry segment - commercial banking. We, through our wholly-owned subsidiary bank, Chemical Bank (the "Bank"), offer a full range of traditional banking and fiduciary products and services. These products and services include business and personal checking accounts, savings and individual retirement accounts, time deposit instruments, electronically accessed banking products, residential and commercial real estate financing, commercial lending, consumer financing, debit cards, safe deposit box services, money transfer services, automated teller machines, access to insurance and investment products, corporate and personal wealth management services, mortgage banking and other banking services.
The principal markets for our products and services are communities in Michigan, Northeast Ohio and Northern Indiana where our bank branches are located and the areas surrounding these communities. As of December 31, 2017 , we served these markets through 186 banking offices located in Michigan, 24 branches located in Northeast Ohio and two branches located in Northern Indiana. In addition to our banking offices, we operated seven loan production offices and 245 automated teller machines, both on- and off-bank premises. Chemical Bank operates through an internal organizational structure of seven regional banking units which are collections of branch banking offices organized by geographical region.
Our principal source of revenue is interest and fees on loans, which accounted for 81.7% of total revenue in 2017 , 76.2% of total revenue in 2016 and 76.7% of total revenue in 2015 . Interest on investment securities, service charges and fees on deposit accounts, wealth management revenue and mortgage banking revenue are also significant sources of revenue, which combined, accounted for 20.3% of total revenue in 2017 , 19.0% of total revenue in 2016 and 19.8% of total revenue in 2015 . Revenue is influenced by overall economic factors including market interest rates, business and consumer spending, consumer confidence and competitive conditions in the marketplace.
During the third quarter of 2017, we launched a project to identify strategies that could be deployed to drive revenue growth and steps to be taken to further improve operating efficiency as part of an effort to refine and clarify our overall strategic plan of how we allocate our capital across the organization and better position us for growth. The project resulted in restructuring efforts including a reduction of approximately 7% in total employees and consolidation of 25 branches completed during the fourth quarter of 2017 in addition to 13 branches that were consolidated during the third quarter of 2017. Under the restructuring efforts, we additionally discontinued our title insurance services and reduced resources devoted to indirect auto lending. The restructuring efforts produced more than $20 million of annualized savings, while half, or more, is planned to be reinvested in the hiring of new commercial bankers and key operational staff as well as making investment to enhance our core operating systems.

35


Mergers, Acquisitions and Branch Closings
Merger with Talmer Bancorp, Inc.
On August 31, 2016, we acquired all the outstanding stock of Talmer Bancorp, Inc. ("Talmer") for total consideration of $1.61 billion , which included stock consideration of $1.50 billion and cash consideration of $107.6 million . As a result of the merger, we issued 32.1 million shares of our common stock based on an exchange ratio of 0.4725 shares of our common stock, and paid $ 1.61 in cash, for each share of Talmer common stock outstanding. Talmer, a bank holding company, owned Talmer Bank and Trust, which was consolidated with and into Chemical Bank effective November 10, 2016. Talmer Bank and Trust operated a full service community bank offering a full suite of commercial banking, retail banking, mortgage banking, wealth management and trust services to small and medium-sized businesses and individuals through 80 full service banking offices located primarily within southeast Michigan and northeast Ohio, as well as in west Michigan, northeast Michigan, and northern Indiana. The merger with Talmer resulted in increases in our total assets of $7.71 billion , including total loans of $4.88 billion , total deposits of $5.29 billion and investment securities of $810.6 million . In connection with the merger with Talmer, we recorded $847.7 million of goodwill, which was primarily due to the synergies and economies of scale expected from combining our operations with those of Talmer. In addition, we recorded $19.1 million of core deposit intangibles in conjunction with the merger.
We incurred $8.5 million and $61.1 million of merger and acquisition-related transaction expenses during the years ended December 31, 2017 and 2016 , respectively, primarily related to the merger with Talmer, which reduced diluted earnings per share by $0.08 in 2017 and $0.81 in 2016.
Acquisition of Lake Michigan Financial Corporation
On May 31, 2015, we acquired all of the outstanding stock of Lake Michigan Financial Corporation (Lake Michigan) for total consideration of $187.4 million , which included stock consideration of $132.9 million and cash consideration of $54.5 million. As a result of the acquisition, we issued approximately 4.3 million shares of our common stock, based on an exchange ratio of 1.326 shares of our common stock, and paid $16.64 in cash, for each share of Lake Michigan common stock outstanding. Lake Michigan, a bank holding company, owned The Bank of Holland and The Bank of Northern Michigan, which combined operated five banking offices in Holland, Grand Haven, Grand Rapids, Petoskey and Traverse City, Michigan. The Bank of Holland and The Bank of Northern Michigan were consolidated with and into Chemical Bank on November 13, 2015. The acquisition of Lake Michigan resulted in increases in total assets of $1.24 billion , including total loans of $985.5 million , and total deposits of $924.7 million , as of the acquisition date. In connection with the acquisition of Lake Michigan, we recorded $101.1 million of goodwill, which was primarily attributable to the synergies and economies of scale expected from combining our operations with those of Lake Michigan. In addition, we recorded $8.6 million of core deposit and other intangible assets in conjunction with the acquisition.
Acquisition expenses associated with the acquisition of Lake Michigan totaled $5.5 million during 2015, which reduced net income per common share by $0.11 in 2015.
Acquisition of Monarch Community Bancorp, Inc.
On April 1, 2015, we acquired all of the outstanding stock of Monarch Community Bancorp, Inc. (Monarch) in an all-stock transaction valued at $27.2 million . As a result of the acquisition, we issued 860,575 shares of our common stock based on an exchange ratio of 0.0982 shares of our common stock for each share of Monarch common stock outstanding. Monarch, a bank holding company, owned Monarch Community Bank, which operated five full service branch offices in Coldwater, Marshall, Hillsdale and Union City, Michigan. Monarch Community Bank was consolidated with and into Chemical Bank on May 8, 2015. The acquisition of Monarch resulted in increases in our total assets of $182.8 million , including total loans of $121.8 million , and total deposits of $144.3 million , as of the acquisition date. In connection with the acquisition of Monarch, we recorded $5.3 million of goodwill, which was primarily attributable to the synergies and economies of scale expected from combining our operations with Monarch. In addition, we recorded $1.9 million of core deposit intangible assets in conjunction with the acquisition.
Acquisition expenses associated with the acquisition of Monarch totaled $2.3 million during 2015, which reduced net income per common share by $0.04 in 2015.
Acquisition of Northwestern Bancorp, Inc.
On October 31, 2014, we acquired all of the outstanding stock of Northwestern Bancorp, Inc. (Northwestern) for total cash consideration of $121.0 million . Northwestern, a bank holding company which owned Northwestern Bank, provided traditional banking services and products through 25 banking offices serving communities in the northwestern lower peninsula of Michigan. At the acquisition date, Northwestern added total assets of $815.0 million, including total loans of $475.3 million , and total deposits of $794.4 million , to our operations. Northwestern Bank was consolidated with and into Chemical Bank as of the acquisition date. In connection with the acquisition of Northwestern, we recorded $60.3 million of goodwill, which was primarily attributable to

36


the synergies and economies of scale expected from combining our operations with those of Northwestern. In addition, we recorded $12.9 million of core deposit intangible assets in conjunction with the acquisition.
Acquisition expenses associated with the acquisition of Northwestern totaled $5.8 million during 2014, which reduced net income per common share by $0.14 in 2014.
Branch Closings
On April 15, 2016, we closed eleven branch locations which were identified as having a small core deposit base and/or were in close proximity to other Chemical Bank branch locations.
In conjunction with the consolidation of Talmer Bank and Trust with and into Chemical Bank during the fourth quarter of 2016, we closed seven branches in communities where Talmer Bank and Trust and Chemical Bank had overlapping branches.
Expenses associated with the closing of the aforementioned branch office locations were not significant, with the exception of $1.0 million of fair value write-downs recognized in the second quarter of 2016 related to the eleven branch locations that were closed, as the majority of the employees of these closed branch offices were transferred to other nearby Chemical Bank branch locations or other open positions within Chemical Bank.
In the third quarter of 2017, we initiated restructuring efforts that included the consolidation of 25 branches in the fourth quarter of 2017. These branch consolidations were in addition to the 13 branches consolidated during the third quarter 2017. The expense related to branch closings was approximately $5.1 million during the year ended December 31, 2017, included in "restructuring expenses" on our Consolidated Statements of Income. At December 31, 2017, we operated a total of 212 branches.
Branch Sales
On October 28, 2016, Talmer Bank and Trust completed the sale of its single branch office in Chicago, Illinois to Old Second National Bank, a wholly owned subsidiary of Old Second Bancorp, Inc. Old Second National Bank assumed approximately $48.9 million of deposits and purchased approximately $233.6 million of loans and paid a $6.5 million premium in the transaction.
On November 4, 2016, Talmer Bank and Trust completed the sale of its single branch office in Las Vegas, Nevada to First Savings Bank. First Savings Bank assumed approximately $88.1 million of deposits and purchased approximately $0.1 million of loans and paid a $1.0 million premium in the transaction.

Critical Accounting Policies
    
Our Consolidated Financial Statements are prepared in accordance with United States generally accepted accounting principles (GAAP), Securities and Exchange Commission (SEC) rules and interpretive releases and general practices within the industry in which we operate. Application of these principles requires management to make estimates, assumptions and complex judgments that affect the amounts reported in our Consolidated Financial Statements and accompanying notes. These estimates, assumptions and judgments are based on information available as of the date of the financial statements; accordingly, as this information changes, our Consolidated Financial Statements could reflect different estimates, assumptions and judgments. Actual results could differ significantly from those estimates. Certain policies inherently have a greater reliance on the use of estimates, assumptions and judgments and, as such, have a greater possibility of producing results that could be materially different than originally reported. We utilize third-party sources to assist with developing estimates, assumptions and judgments regarding certain amounts reported in our Consolidated Financial Statements and accompanying notes. When third-party sources are utilized, our management remains responsible for complying with GAAP. To execute management's responsibilities, we have processes in place to develop an understanding of the third-party methodologies and to design and implement specific internal controls over valuation.

The significant accounting policies we follow are presented in Note 1 to our Consolidated Financial Statements included in Item 8 of this Annual Report. These policies, along with the disclosures presented in the other notes to our Consolidated Financial Statements and in "Management's Discussion and Analysis of Financial Condition and Results of Operations," provide information on how significant assets and liabilities are measured in our Consolidated Financial Statements and how those measurements are determined. Based on the techniques used and the sensitivity of financial statement amounts to the methods, estimates and assumptions underlying those amounts, management has identified the determination of the allowance for loan losses, accounting for acquired loans, income and other taxes and the valuation of loan servicing rights to be the accounting areas that require the most subjective or complex judgments, and as such, could be most subject to revision as new or additional information becomes available or circumstances change, including overall changes in the economic climate and/or market interest rates. Management reviews the following critical accounting policies with the Audit Committee of the board of directors at least annually.


37


Allowance for Loan Losses

We use a defined methodology to quantify the necessary allowance for loan losses ("allowance") and related provision for loan losses, but there can be no assurance that the methodology will successfully identify and estimate all of the losses that are inherent in the loan portfolio. Such methodology utilizes historical loss experience (net charge-offs) adjusted for qualitative factors, including trends in credit quality, composition of and growth in our loan portfolio, and the overall economic environment in our markets. These qualitative factors include many estimates and judgments. As a result, we could record future provisions for loan losses that may be significantly different than the levels that have been recorded in the three-year period ended December 31, 2017 . Notes 1 and 5 to our Consolidated Financial Statements further describe the methodology used to determine the allowance. In addition, a discussion of the factors driving changes in the amount of the allowance is included under the subheading "Allowance for Loan Losses" in "Management's Discussion and Analysis of Financial Condition and Results of Operations."

The allowance consists of two components: the allowance for loan losses (including both the originated and acquired loan portfolios) and the reserve for unfunded credit commitments. Unfunded credit commitments include items such as letters of credit, financial guarantees and binding unfunded loan commitments. The allowance represents management’s estimate of probable credit losses inherent in the loan and credit commitment portfolios as of period end.

The allowance is calculated with the objective of maintaining a reserve sufficient to absorb losses inherent in the loan portfolio. The determination of the amount of the allowance is considered a critical accounting estimate because it requires significant judgment and the use of estimates related to the amount and timing of expected cash flows on acquired loans and impaired loans, collateral values on impaired loans, and estimated losses on pools of homogeneous loans based on historical loss experience, and consideration of current economic trends and conditions, all of which may be susceptible to significant change. The principal assumption used in deriving the allowance is the estimate of a loss percentage for each type of loan.

In determining the allowance for the originated loan portfolio and the related provision for loan losses, we considers three principal elements: (i) valuation allowances based upon probable losses identified during the review of impaired loans, (ii) reserves, by loan classes, on all other loans based on a six-year historical loan loss experience, loan loss trends and giving consideration to estimated loss emergence periods, and (iii) a reserve for qualitative factors that take into consideration risks inherent in the originated loan portfolio that differ from historical loan loss experience.

We have a loan review function that is independent of the loan origination function. At least annually, the loan review function performs a detailed credit quality review, including analysis of collateral values, of the majority of loans in the commercial loan portfolio, particularly focusing on larger balance loans and loans that have deteriorated below certain levels of credit risk. In many cases, the estimate of collateral values includes significant judgments and assumptions.

The following section, "Accounting for Acquired Loans", describes the process for determining the allowance for the acquired loan portfolio.

Accounting for Acquired Loans

ASC Topic 310-30, Loans and Debt Securities Acquired with Deteriorated Credit Quality (ASC 310-30), provides the GAAP guidance for accounting for loans acquired in a business combination that have experienced a deterioration in credit quality from origination to acquisition for which it is probable that the purchaser will be unable to collect all contractually required payments receivable, including both principal and interest.

Loans purchased with evidence of credit deterioration since origination and for which it is probable that all contractually required payments will not be collected are considered to be impaired. In the assessment of credit quality deterioration, we must make numerous assumptions, interpretations and judgments using internal and third-party credit quality information to determine whether or not it is probable that we will be able to collect all contractually required payments. This is a point in time assessment and inherently subjective due to the nature of the available information and judgment involved. Evidence of credit quality deterioration as of the acquisition date may include statistics such as past due and nonaccrual status, recent borrower credit scores and loan-to-value percentages. Those loans that qualify under ASC 310-30 are recorded at fair value at acquisition, which involves estimating the expected cash flows to be received, both principal and interest, expected to be collected, discounted at the prevailing market rate of interest. Accordingly, the associated allowance for loan losses related to these loans is not carried over at the acquisition date. ASC 310-30 also allows purchasers to aggregate acquired loans into loan pools that have common risk characteristics and use a composite interest rate and expectation of cash flows to be collected for the loan pools. We elected to apply ASC 310-30, by analogy, to loans acquired in the Talmer, Lake Michigan, Monarch, Northwestern and OAK acquisitions that were determined not to have deteriorated credit quality, and therefore, did not meet the scope criteria of ASC 310-30.

38


Accordingly, we follow the accounting and disclosure guidance of ASC 310-30 for these loans, even though they are not purchased impaired loans.

The excess of cash flows of a loan, or pool of loans, expected to be collected over the estimated fair value is referred to as the "accretable yield" and is recognized into interest income over the estimated remaining life of the loan, or pool of loans, on a level-yield basis. The difference between the contractually required payments of a loan, or pool of loans, and the cash flows expected to be collected at acquisition, considering the impact of prepayments and estimates of future credit losses expected to be incurred over the life of the loan, or pool of loans, is referred to as the "nonaccretable difference" and is particularly sensitive to changes in loan credit quality.

We evaluate estimates of cash flows expected to be collected from acquired loans quarterly. These evaluations require the continued usage of key assumptions and estimates, similar to the initial estimate of fair value. Decreases in the estimates of expected cash flows will generally result in a charge to the provision for loan losses and a resulting increase to the allowance for loan losses. Increases in the estimates of expected cash flows will first reverse any previously established allowance for loan losses and then result in adjustments to the accretable yield, which will increase amounts recognized in interest income in subsequent periods. Dispositions of acquired loans, which may include sales of loans to third parties, receipt of payments in full or in part by the borrower and foreclosure of the collateral, result in removal of the loan from the acquired loan portfolio at its carrying amount. As a result of the significant amount of judgment involved in estimating future cash flows expected to be collected for acquired loans, the adequacy of the allowance for loan losses could be significantly impacted by changes in expected cash flows resulting from changes in credit quality of acquired loans.

Acquired loans that were classified as nonperforming loans prior to being acquired and acquired loans that are not performing in accordance with contractual terms subsequent to acquisition are not classified as nonperforming loans subsequent to acquisition because the loans are recorded in pools at net realizable value based on the principal and interest we expect to collect on such loans. Judgment is required to estimate the timing and amount of cash flows expected to be collected when the loans are not performing in accordance with the original contractual terms.

Notes 1, 2 and 5 to our Consolidated Financial Statements contain additional information related to acquired loans.

Income and Other Taxes

We are subject to the income and other tax laws of the United States, the States of Michigan, Ohio, Indiana and other states where nexus has been created. These laws are complex and are subject to different interpretations by the taxpayer and the various taxing authorities. In determining the provisions for income and other taxes, management must make judgments and estimates about the application of these inherently complex laws, related regulations and case law. In the process of preparing our tax returns, management attempts to make reasonable interpretations of enacted tax laws. These interpretations are subject to challenge by the tax authorities upon audit or to reinterpretation based on management's ongoing assessment of facts and evolving case law. On December 22, 2017, H.R.1, referred to as the "Tax Cuts and Jobs Act", was signed into law. The Tax Cuts and Jobs Act, among other items, reduces the corporate income tax rate from 35% to 21%, effective January 1, 2018. As such, we completed a revaluation of the net deferred tax assets and estimated a reduction in our deferred tax asset as of December 31, 2017 .

When income and expenses are recognized in different periods for tax purposes than for book purposes, applicable deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date.
    
On a quarterly basis, management assesses the reasonableness of its effective federal tax rate based upon its estimate of taxable income and the applicable taxes expected for the full year, including the impact of any discrete items that have occurred. Deferred tax assets and liabilities are reassessed on a quarterly basis, including the need for a valuation allowance for deferred tax assets. The need for reserves for uncertain tax positions is reviewed quarterly based upon developments in tax law and the status of examinations or audits.
    

39


Valuation of Loan Servicing Rights
    
We recognize as assets the rights to service mortgage loans for others, known as loan servicing rights (“LSRs”). As of January 1, 2017, we elected to account for LSRs under the fair value option. Prior to January 1, 2017, we accounted for LSRs at the lower of cost or fair value. To determine the fair value of LSRs, we use an independent third party valuation model requiring the incorporation of assumptions that market participants would use in estimating future net servicing income, which include estimates of prepayment speeds, discount rate, cost to service and escrow account earnings. Changes in the fair value of LSRs directly impacts earnings. See Notes 3 and 9 to our Consolidated Financial Statements for more information on fair value measurements.

Accounting Standards Updates

See Note 1 to our Consolidated Financial Statements included in this Annual Report for details of accounting pronouncements adopted during 2017 . See the following section for a description of pronouncements that have been released but not yet adopted.

Pending Accounting Pronouncements

Revenue Recognition

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which implements a common revenue standard that clarifies the principles for recognizing revenue and supersedes most current revenue recognition guidance. The core principle of the revenue standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU is intended to clarify and converge the revenue recognition principles under GAAP and International Financial Reporting Standards and to streamline revenue recognition requirements in addition to expanding required revenue recognition disclosures. In August 2015, the FASB issued ASU 2015-14, Deferral of the Effective Date, which provides a one year deferral to the effective date, therefore, ASU 2014-09 is effective for public companies for annual periods, and interim periods within those annual periods, beginning on or after December 15, 2017. As such, we will adopt ASU 2014-09 as of January 1, 2018 and intend to use the modified transition approach. Approximately 79% of our revenues are derived from net interest income on financial assets and liabilities, which are excluded from the scope of the amended guidance. Following detailed review of our revenue streams not derived from net interest income on financial assets and liabilities, we identified the recognition of gains from other real estate sales financed by us to be in the scope of this amended guidance as the new standard is largely consistent with the existing guidance and current practices applied by our businesses. The cumulative effect of recognizing the deferred gain recorded under previous GAAP increases retained earnings by $1.2 million upon adoption as of January 1, 2018.

Recognition and Measurement

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). ASU 2016-01 amends current guidance by: (i) requiring equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income; (ii) allowing an entity to measure equity investments that do not have readily determinable fair values at either fair value or cost minus impairment, if any, plus or minus changes in observable prices, with changes in measurement recognized in net income; (iii) simplifying the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; (iv) eliminating the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost on the balance sheet; (v) requiring use the of exit price notion when measuring the fair value of financial instruments for disclosure purposes; (vi) requiring recognition of changes in the fair value related to instrument-specific credit risk in other comprehensive income if the fair value option for financial liabilities is elected; (vii) requiring separate presentation in the financial statements of financial assets and financial liabilities by measurement category; and (viii) clarifying that an entity should evaluate the need for a valuation allowance on deferred tax assets related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for interim and annual reporting periods beginning after December 15, 2017. The adoption of ASU 2016-01 as of January 1, 2018 will not have a material impact on our consolidated financial condition or results of operations.


40


Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). Under ASU 2016-02, we will be required to recognize the following for all leases (with the exception of short-term leases): (i) a right to use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term and (ii) a lease liability, which is a liability that represents the lessee's obligation to make lease payments arising from a lease, measured on a discounted basis. ASU 2016-02 requires a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. ASU 2016-02 is effective for public companies for interim and annual periods beginning after December 15, 2018 with early adoption allowed. We are currently evaluating the impact on our results of operations, financial position, and liquidity and have identified key players from our organization to assess and implement the standard. Based on preliminary evaluation, the adoption of ASU 2016-02 is not expected to have a material impact on our results of operations, but it is anticipated to result in a material increase in our assets and liabilities and will depend on our inventory of leases at adoption date.

Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income.

ASU 2016-13 requires an entity to measure expected credit losses for financial assets over the estimated lifetime of expected credit loss and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard includes the following core concepts in determining the expected credit loss estimate it must: (a) be based on an asset’s amortized cost (including premiums or discounts, net deferred fees and costs, foreign exchange and fair value hedge accounting adjustments), (b) reflect losses expected over the remaining contractual life of an asset (considering the effect of voluntary prepayments), (c) consider available relevant information about the estimated collectibility of cash flows (including information about past events, current conditions, and reasonable and supportable forecasts), and (d) reflect the risk of loss, even when that risk is remote.

ASU 2016-13 also amends the recording of purchased credit-impaired assets. Under the new guidance, an allowance will be recognized at acquisition through a gross-up approach whereby an entity will record as the initial amortized cost the sum of (a) the purchase price and (b) an estimate of credit losses as of the date of acquisition. In addition, the guidance also requires immediate recognition in earnings of any subsequent changes, both favorable and unfavorable, in expected cash flows by adjusting this allowance.

ASU 2016-13 amends the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on an available-for-sale debt security is a credit loss. Management may not use the length of time a security has been in an unrealized loss position as a factor in concluding whether a credit loss exists, as is currently permitted. In addition, an entity will recognize an allowance for credit losses on available-for-sale debt securities as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment, as is currently required. As a result, entities will recognize improvements to credit losses on available-for-sale debt securities immediately in earnings rather than as interest income over time under current practice.

New disclosures required by ASU 2016-13 include: (a) for financial assets measured at amortized cost, an entity will be required to disclose information about how it developed its allowance, including changes in the factors that influenced management’s estimate of expected credit losses and the reasons for those changes, (b) for financial receivables and net investments in leases measured at amortized cost, an entity will be required to further disaggregate the information it currently discloses about the credit quality of these assets by year or the asset’s origination or vintage for as many as five annual periods, and (c) for available-for-sale debt securities, an entity will be required to provide a roll-forward of the allowance for credit losses and an aging analysis for securities that are past due.

Upon adoption of ASU 2016-13, a cumulative-effect adjustment to retained earnings will be recorded as of the beginning of the first reporting period in which the guidance is effective. ASU 2016-13 is effective for public companies for interim and annual periods beginning after December 15, 2019, with early adoption permitted for annual periods beginning after December 15, 2018. We are currently evaluating the provisions of ASU 2016-13 to determine the impact on our consolidated financial condition and results of operations. The impact ASU 2016-13 will depend upon the state of the economy and the nature of our portfolios at the date of adoption.


41


Statement of Cash Flows

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"), which clarifies guidance on the classification of eight specific cash flow issues. ASU 2016-15 was issued to reduce diversity in practice and prevent financial statement restatements. Cash flow issues include: debt prepayment or debt extinguishment costs, settlement of zero-coupon bonds, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies and bank-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions and separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Under the provision, entities must apply the guidance retrospectively to all periods presented but may apply it prospectively if retrospective application would be impracticable. The adoption of ASU 2016-15 as of January 1, 2018 will not have a material impact on our consolidated financial condition or results of operations.

Mergers and Acquisitions

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business ("ASU 2017-01"), which narrows the definition of a business and provides a framework that gives entities a basis for making reasonable judgments about whether a transaction involves an asset or a business. ASU 2017-01 is effective for public business entities in annual periods beginning after December 15, 2017, including interim periods therein. The adoption of ASU 2017-01 will not have a material impact on our consolidated financial condition or results of operations.

Goodwill Impairment Measurement

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment, which simplifies the accounting for goodwill impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Subsequent to adoption of ASU 2017-04, goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance largely remains unchanged. ASU 2017-04 will be applied prospectively, and is effective for public business entities for annual and interim goodwill impairment tests beginning after December 15, 2019. The adoption of ASU 2017-04 is not expected to have a material impact on our consolidated financial condition or results of operations.

Pension and Other Post Retirement Benefit Plans

In February 2017, the FASB issued ASU No. 2017-06, Plan Accounting: Defined Benefit Pension Plans (Topic 960); Defined Contribution Pension Plans (Topic 962); Health and Welfare Benefit Plans (Topic 965) - Employee Benefit Plan Master Trust Reporting ("ASU 2017-06"). This update clarifies the reporting requirements by an employee benefit plan for its interest in a master trust and removes redundancy relating to 401(h) account disclosures. The new guidance requires a plan's interest in a master trust to be presented in separate line items in the statement of net assets available and in the statement of changes in net assets available. The amendment removes the requirement to disclose the percentage interest in the master trust, and instead requires disclosure of the dollar amount of interest in each investment type. ASU 2017-06 is effective for fiscal years beginning after December 15, 2018, and will be applied retrospectively to each period where financial statements are presented. As such, we will adopt ASU 2017-06 as of January 1, 2019 and we do not expect a material impact on our consolidated financial condition or results of operations.

In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost ("ASU 2017-07"). ASU 2017-07 improves the income statement presentation of net periodic benefit cost for an entity's pension and postretirement plans. The new standard requires employers to disaggregate current-service-costs from other components of net benefit cost and present it with other compensation costs in the income statement, and outside of income from operations if presented. The amendment also allows only the service-cost component of net benefit cost to be eligible for capitalization. ASU 2017-07 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early adoption allowed within the first interim period. We will adopt ASU 2017-07 as of January 1, 2018. Under the provision, entities must use a retrospective transition method to adopt the separate income statement presentation of the service costs and other components, and a prospective transition method for the capitalization of the service-cost component. We are currently evaluating the portion of net benefits cost that continue to be eligible for capitalization and the portion that is not eligible. The adoption of ASU 2017-07 will not have a material impact on our consolidated financial condition or results of operations.


42


Stock Compensation

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU 2017-09"), which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 clarifies and reduces diversity, cost and complexity by limiting circumstances in which an entity applies modification accounting. The new guidance stipulates that when an award is amended, modified accounting should not be applied if the fair value, vesting conditions and classification as an equity or liability instrument of the modified award are the same as the original award immediately before modification. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted for any interim period. Under the provision, entities must apply the guidance retrospectively for all awards modified on or after the modification date. The adoption of ASU 2017-09 will not have a material impact on our consolidated financial condition or results of operations.

Derivatives

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), which better align an entity's risk management activities and financial reporting for hedging relationships. ASU 2017-12 eliminates the separate measurement of hedge ineffectiveness as well as the benchmark interest rate concept when applying hedge risk to variable-rate instruments. In addition, the standard update allows a company to elect to perform subsequent effectiveness assessments qualitatively if the initial quantitative hedge effectiveness assessment is found to be highly effective. ASU 2017-12 is effective for all entities for annual periods, and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted for any interim period. We plan to early adopt ASU 2017-12 as of January 1, 2018 using a modified retrospective transition, as required, with a cumulative effect adjustment recorded to reduce retained earnings by $3 thousand.
Non-GAAP Financial Measures
This Annual Report contains references to financial measures that are not defined in GAAP. Such non-GAAP financial measures include our operating expenses, core (which excludes merger expenses, restructuring expenses and impairment of income tax credits); tangible book value per share; tangible shareholders' equity; presentation of net interest income and net interest margin on a fully taxable equivalent (FTE) basis; operating expenses and efficiency ratio (which excludes merger expenses, restructuring expenses, impairment of income tax credits and amortization of intangibles); the adjusted efficiency ratio (which excludes significant items, impairment of income tax credits, amortization of intangibles, net interest FTE adjustments, the change in fair value of loan servicing rights and gains and losses from sale of investment securities) and other information presented excluding significant items including net income, diluted earnings per share, return on average assets, return on average shareholders' equity and return on average tangible shareholders' equity. Management believes that the presentation of these non-GAAP financial measures (a) provides important supplemental information that contributes to a proper understanding of our operating performance, (b) enables a more complete understanding of factor and trends affecting our business, and (c) allows investors to evaluate our performance in a manner similar to management, the financial services industry, bank stock analysts, and bank regulators. Management uses non-GAAP measures as follows: in the preparation of our operating budgets, monthly financial performance reporting, and in our presentation to investors of our performance. However, we acknowledge that these non-GAAP financial measures have a number of limitations. Limitations associated with non-GAAP financial measures include the risk that persons might disagree as to the appropriateness of items comprising these measures and that different companies might calculate these measures differently. These disclosures should not be considered an alternative to our GAAP results.

A reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is presented below. A reconciliation of net interest income and net interest margin (FTE) to the most directly comparable GAAP financial measure can be found under the subheading "Average Balances, Fully Taxable Equivalent (FTE) Interest and Effective Yields and Rates" of this Annual Report.

43


 
 
Year Ended December 31,
(Dollars in thousands, except per share data)
 
2017
 
2016
 
2015
 
2014
 
2013
Reconciliation of Non-GAAP Operating Results
 
 
 
 
 
 
 
 
 
 
Net Income
 
 
 
 
 
 
 
 
 
 
Net income, as reported
 
$
149,523

 
$
108,032

 
$
86,830

 
$
62,121

 
$
56,808

Merger expenses
 
8,522

 
61,134

 
7,804

 
6,388

 

Restructuring expenses
 
19,880

 

 

 

 

Gain on sales of branch offices
 

 
(7,391
)
 

 

 

Losses on sales of investment securities (1)
 
7,556

 

 

 

 

Significant items
 
35,958

 
53,743

 
7,804

 
6,388

 

Income tax benefit (2)
 
(12,585
)
 
(18,048
)
 
(2,320
)
 
(1,833
)
 

Revaluation of net deferred tax assets
 
46,660

 

 

 

 

Significant items, net of tax
 
70,033

 
35,695

 
5,484

 
4,555

 

Net income, excluding significant items
 
$
219,556

 
$
143,727

 
$
92,314

 
$
66,676

 
$
56,808

Diluted Earnings Per Share
 
 
 
 
 
 
 
 
 
 
Diluted earnings per share, as reported
 
$
2.08

 
$
2.17

 
$
2.39

 
$
1.97

 
$
2.00

Effect of significant items, net of tax
 
0.98

 
0.71

 
0.15

 
0.14

 

Diluted earnings per share, excluding significant items
 
$
3.06

 
$
2.88

 
$
2.54

 
$
2.11

 
$
2.00

Return on Average Assets
 
 
 
 
 
 
 
 
 
 
Return on average assets, as reported
 
0.81
%
 
0.90
%
 
1.02
%
 
0.96
%
 
0.95
%
Effect of significant items, net of tax
 
0.38

 
0.29

 
0.07

 
0.07

 

Return on average assets, excluding significant items
 
1.19
%
 
1.19
%
 
1.09
%
 
1.03
%
 
0.95
%
Return on Average Shareholders' Equity
 
 
 
 
 
 
 
 
 
 
Return on average shareholders' equity, as reported
 
5.7
%
 
7.0
%
 
9.4
%
 
8.2
%
 
9.1
%
Effect of significant items, net of tax
 
2.7

 
2.3

 
0.6

 
0.6

 

Return on average shareholders' equity, excluding significant items
 
8.4
%
 
9.3
%
 
10.0
%
 
8.8
%
 
9.1
%
Return on Average Tangible Shareholders' Equity
 
 
 
 
 
 
 
 
 
 
Average shareholders' equity
 
$
2,627,862

 
$
1,546,721

 
$
919,328

 
$
754,211

 
$
626,555

Average goodwill, CDI and noncompete agreements, net of tax
 
1,155,734

 
582,536

 
245,894

 
157,634

 
127,363

Average tangible shareholders' equity
 
$
1,472,128

 
$
964,185

 
$
673,434

 
$
596,577

 
$
499,192

Return on average tangible shareholders' equity
 
10.2
%
 
11.2
%
 
12.9
%
 
10.4
%
 
11.4
%
Efficiency Ratio
 
 
 
 
 
 
 
 
 
 
Net interest income
 
$
557,578

 
$
381,081

 
$
274,008

 
$
212,551

 
$
196,647

Noninterest income
 
144,019

 
122,350

 
80,216

 
63,095

 
60,409

Total revenue - GAAP
 
701,597

 
503,431

 
354,224

 
275,646

 
257,056

Net interest income FTE adjustment
 
13,077

 
9,642

 
7,452

 
5,975

 
5,355

Loan servicing rights change in fair value (gains) losses
 
6,375

 
(5,112
)


 

 

Gains on sale of branch offices
 

 
(7,391
)


 

 

Gains from closed branch locations and sale of investment securities
 
7,388

 
(669
)
 
(779
)
 

 
(1,133
)
Total revenue - non-GAAP
 
$
728,437

 
$
499,901

 
$
360,897

 
$
281,621

 
$
261,278

Operating expenses - GAAP
 
$
421,994

 
$
338,418

 
$
223,894

 
$
179,925

 
$
164,948

Merger expenses
 
(8,522
)
 
(61,134
)
 
(7,804
)
 
(6,388
)
 

Restructuring expenses
 
(19,880
)
 

 

 

 

Impairment of federal income tax credits (3)
 
(9,252
)
 

 

 

 

Operating expense, core - Non-GAAP
 
384,340

 
277,284

 
216,090

 
173,537

 
164,948

Amortization of intangibles
 
(6,089
)
 
(5,524
)
 
(4,389
)
 
(2,029
)
 
(1,909
)
Operating expenses, efficiency ratio - Non-GAAP
 
$
378,251

 
$
271,760

 
$
211,701

 
$
171,508

 
$
163,039

Efficiency ratio - GAAP
 
60.1
%
 
67.2
%
 
63.2
%
 
65.3
%
 
64.2
%
Efficiency ratio - adjusted Non-GAAP
 
51.9
%
 
54.4
%
 
58.7
%
 
60.9
%
 
62.4
%
(1) Fourth quarter of 2017 losses on sales of investment securities are deemed a significant item for 2017 as they were taken as part of our treasury and tax management objectives associated with the Tax Cuts and Jobs Act.
(2)    Assumes merger expenses are deductible at an income tax rate of 35%, except for the impact of estimated nondeductible expenses incurred in periods when merger and acquisition transactions are completed.
(3)  The impairment of federal income tax credits is related to federal historic tax credits placed into service during the period that provide a reduction to our income tax expense. The impairment, included within other operating expenses, is more than offset by a reduction to our income tax expense related to the same tax credits included within other operating expenses.

44


 
 
December 31,
(Dollars in thousands, except per share data)
 
2017
 
2016
 
2015
 
2014
 
2013
Tangible Book Value
 
 
 
 
 
 
 
 
 
 
Shareholders' equity, as reported
 
$
2,668,749

 
$
2,581,526

 
$
1,015,974

 
$
797,133

 
$
696,500

Goodwill, CDI and noncompete agreements, net of tax
 
(1,158,738
)
 
(1,155,528
)
 
(301,073
)
 
(190,714
)
 
(124,553
)
Tangible shareholders' equity
 
$
1,510,011


$
1,425,998


$
714,901


$
606,419


$
571,947

Common shares outstanding
 
71,207

 
70,599

 
38,168

 
32,774

 
29,790

Book value per share (shareholders' equity, as reported, divided by common shares outstanding)
 
$
37.48

 
$
36.57

 
$
26.62

 
$
24.32

 
$
23.38

Tangible book value per share (tangible shareholders' equity divided by common shares outstanding)
 
$
21.21

 
$
20.20

 
$
18.73

 
$
18.50

 
$
19.20

Tangible Shareholders' Equity to Tangible Assets
 
 
 
 
 
 
 
 
 
 
Total assets, as reported
 
$
19,280,873

 
$
17,355,179

 
$
9,188,797

 
$
7,322,143

 
$
6,184,708

Goodwill, CDI and noncompete agreements, net of tax
 
(1,158,738
)
 
(1,155,528
)
 
(301,073
)
 
(190,714
)
 
(124,553
)
Tangible assets
 
$
18,122,135

 
$
16,199,651

 
$
8,887,724

 
$
7,131,429

 
$
6,060,155

Shareholders' equity to total assets
 
13.8
%
 
14.9
%
 
11.1
%
 
10.9
%
 
11.3
%
Tangible shareholders' equity to tangible assets
 
8.3
%
 
8.8
%
 
8.0
%
 
8.5
%
 
9.4
%

Balance Sheet Review
Overview
Total assets were $19.28 billion at December 31, 2017 , an increase of $1.93 billion , or 11.1% , from total assets at December 31, 2016 of $17.36 billion . The increase in total assets during 2017 was primarily attributable to an increase in loans and investment securities funded by an increase in FHLB advances and customer deposit growth. The $8.17 billion increase in total assets during 2016 was primarily attributable to the merger with Talmer, which increased total assets by $7.71 billion as of the merger date in addition to organic loan growth.
Average assets were $18.47 billion during 2017 , an increase of $6.43 billion , or 53.4% , from average assets of $12.04 billion during 2016 . Average assets during 2016 increased $3.56 billion , or 41.9% , from average assets of $8.48 billion during 2015 . The increase in average assets during 2017 , as compared to 2016 , was attributable to the merger with Talmer effective August 31, 2016, originated loan growth and an increase in investment securities. The increase in average assets during 2016 , as compared to 2015 , was attributable to a combination of the $7.71 billion of assets acquired in the merger with Talmer completed August 31, 2016 and additional organic loan growth.

45


Investment Securities
The following table summarizes the maturities and yields of the carrying value of investment securities by investment category, and fair value by investment category, at December 31, 2017 and 2016 :
 
Maturity as of December 31, 2017 (1)
 
 
 
 
 
 
 
Within
One Year
 
After One
but Within
Five Years
 
After Five
but Within
Ten Years
 
After
Ten Years
 
Total
Carrying
Value (2)
 
Total
Fair
Value
(Dollars in thousands)
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Available-for-Sale:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government sponsored agencies
$
30,241

 
2.29
%
 
$
81,106

 
2.39
%
 
$
61,461

 
2.43
%
 
$
30,108

 
2.43
%
 
$
202,916

 
2.39
%
 
$
202,916

State and political subdivisions
9,219

 
2.55

 
60,691

 
2.14

 
115,622

 
2.63

 
160,437

 
3.70

 
345,970

 
3.04

 
345,970

Residential mortgage-backed securities
21,922

 
2.44

 
66,510

 
2.46

 
38,595

 
2.52

 
23,105

 
2.58

 
150,131

 
2.49

 
150,131

Collateralized mortgage obligations
223,295

 
2.65

 
500,467

 
2.61

 
231,658

 
2.74

 
78,425

 
2.98

 
1,033,845

 
2.68

 
1,033,845

Corporate bonds
13,968

 
1.73

 
37,308

 
2.01

 
141,518

 
3.68

 

 

 
192,794

 
3.22

 
192,794

Preferred stock and trust preferred securities

 

 

 

 
22,968

 
3.62

 
14,923

 
3.34

 
37,890

 
3.51

 
37,890

Total investment securities available-for-sale
298,645

 
2.55

 
746,082

 
2.50

 
611,822

 
2.92

 
306,998

 
3.29

 
1,963,546

 
2.77

 
1,963,546

Held-to-Maturity:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
State and political subdivisions
89,359

 
2.33

 
237,113

 
3.12

 
152,299

 
3.92

 
197,822

 
3.64

 
676,593

 
3.35

 
662,516

Trust preferred securities

 

 

 

 

 

 
500

 
4.75

 
500

 
4.75

 
390

Total investment securities held-to-maturity
89,359

 
2.33

 
237,113

 
3.12

 
152,299

 
3.92

 
198,322

 
3.64

 
677,093

 
3.35

 
662,906

Total investment securities
$
388,004

 
2.50
%
 
$
983,195

 
2.65
%
 
$
764,121

 
3.12
%
 
$
505,320

 
3.43
%
 
$
2,640,639

 
2.92
%
 
$
2,626,452

(1)
Residential mortgage-backed securities, collateralized mortgage obligations and certain government sponsored agencies are based on scheduled principal maturity. All other investment securities are based on final contractual maturity.
(2)
The aggregate book value of securities issued by any single issuer, other than the U.S. government and government sponsored agencies, did not exceed 10% of our shareholders' equity.
(3)
Yields are weighted by amount and time to contractual maturity, are on a taxable equivalent basis using a 35% federal income tax rate and are based on carrying value. Yields disclosed are actual yields based on carrying value at December 31, 2017. Approximately 4% of investment securities at December 31, 2017 were variable-rate financial instruments.

46


 
Maturity as of December 31, 2016 (1)
 
 
 
 
 
 
 
Within
One Year
 
After One
but Within
Five Years
 
After Five
but Within
Ten Years
 
After
Ten Years
 
Total
Carrying
Value (2)
 
Total
Fair
Value
(Dollars in thousands)
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Amount
 
Yield (3)
 
Available-for-Sale:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury securities
$
5,793

 
0.95
%
 
$

 
%
 
$

 
%
 
$

 
%
 
$
5,793

 
0.95
%
 
$
5,793

Government sponsored agencies
71,233

 
1.11

 
82,888

 
1.43

 
56,363

 
1.78

 
4,527

 
1.85

 
215,011

 
1.42

 
215,011

State and political subdivisions
9,438

 
2.53

 
70,435

 
2.11

 
116,239

 
2.39

 
103,976

 
2.94

 
300,088

 
2.52

 
300,088

Residential mortgage-backed securities
54,204

 
1.55

 
143,937

 
1.60

 
48,400

 
2.08

 
25,741

 
2.31

 
272,282

 
1.74

 
272,282

Collateralized mortgage obligations
87,400

 
2.04

 
135,646

 
2.26

 
79,496

 
2.42

 
17,483

 
2.58

 
320,025

 
2.26

 
320,025

Corporate bonds
7,778

 
1.47

 
52,315

 
1.85

 
29,381

 
3.66

 

 

 
89,474

 
2.41

 
89,474

Preferred stock and trust preferred securities

 

 

 

 

 

 
32,291

 
2.95

 
32,291

 
2.95

 
32,291

Total investment securities available-for-sale
235,846

 
1.62

 
485,221

 
1.86

 
329,879

 
2.36

 
184,018

 
2.79

 
1,234,964

 
2.09

 
1,234,964

Held-to-Maturity:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
State and political subdivisions
66,090

 
2.18

 
262,136

 
2.74

 
145,225

 
3.90

 
149,476

 
3.13

 
622,927

 
3.04

 
608,221

Trust preferred securities

 

 

 

 

 

 
500

 
4.00

 
500

 
4.00

 
310

Total investment securities held-to-maturity
66,090

 
2.18

 
262,136

 
2.74

 
145,225

 
3.90

 
149,976

 
3.13

 
623,427

 
3.05

 
608,531

Total investment securities
$
301,936

 
1.74
%
 
$
747,357

 
2.17
%
 
$
475,104

 
2.83
%
 
$
333,994

 
2.95
%
 
$
1,858,391

 
2.41
%
 
$
1,843,495

(1)
Residential mortgage-backed securities, collateralized mortgage obligations and certain government sponsored agencies are based on scheduled principal maturity. All other investment securities are based on final contractual maturity.

(2)
The aggregate book value of securities issued by any single issuer, other than the U.S. government and government sponsored agencies, did not exceed 10% of our shareholders' equity.

(3)
Yields are weighted by amount and time to contractual maturity, are on a taxable equivalent basis using a 35% federal income tax rate and are based on carrying value. Yields disclosed are actual yields based on carrying value at December 31, 2016. Approximately 10% of our investment securities at December 31, 2016 were variable-rate financial instruments.
We utilize third-party pricing services to obtain market value prices for our investment securities portfolio. On a quarterly basis, we validate the reasonableness of prices received from the third-party pricing services through independent price verification on a sample of investment securities in the portfolio, data integrity validation based upon comparison of current market prices to prior period market prices and analysis of overall expectations of movement in market prices based upon the changes in the related yield curves and other market factors. On an annual basis, we review the pricing methodology of the third-party pricing vendors and the results of the vendors' internal control assessments to ensure the integrity of the process that the vendor uses to develop market pricing for our investment securities portfolio.
The carrying value of our investment securities totaled $2.64 billion at December 31, 2017 , an increase of $782.2 million or 42.1% , compared to $1.86 billion at December 31, 2016 . The increase is primarily due to management's decision to increase the size of the portfolio, which was funded in part by an increase in deposits and borrowings. Late in the fourth quarter of 2017, we sold approximately $400 million of investment securities at a loss of $7.6 million following the signing of the Tax Cuts and Jobs Act as part of our treasury and tax management objectives. Following the fourth quarter of 2017 sales, but prior to December 31, 2017, we had reinvested approximately $250 million of the proceeds from the sales.
In connection with management's decision to increase the size of our investment securities portfolio during the year ended December 31, 2017, management decided to lessen its overall exposure to obligations of state and political subdivisions while increasing our positioning to amortizing mortgage related securities primarily in the form of collateralized mortgage obligations. While the carrying value of state and political subdivisions grew by $99.5 million to a total of $1.02 billion at December 31, 2017, compared to $923.0 million at December 31, 2016, the percentage of our total investments portfolio was reduced to 38.7% at December 31, 2017, compared to 49.7% at December 31, 2016. In comparison, the carrying value of collateralized mortgage obligations totaled $1.03 billion at December 31, 2017, an increase of $713.8 million , compared to $320.0 million at December 31, 2016, with growth focused primarily in mortgage related securities.
Our investment securities portfolio as of December 31, 2017 had a weighted average life of approximately 5.1 years and an effective duration of approximately 2.7 years.

47


The following table summarizes the carrying value of investment securities at December 31, 2017 , 2016 and 2015 :
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Available-for-Sale:
 
 
 
 
 
 
U.S. Treasury securities
 
$

 
$
5,793

 
$
5,765

Government sponsored agencies
 
202,916

 
215,011

 
194,989

State and political subdivisions
 
345,970

 
300,088

 
15,120

Residential mortgage-backed securities
 
150,131

 
272,282

 
187,768

Collateralized mortgage obligations
 
1,033,845

 
320,025

 
132,230

Corporate bonds
 
192,794

 
89,474

 
14,627

Preferred stock and trust preferred securities
 
37,890

 
32,291

 
3,232

Total investment securities available-for-sale
 
1,963,546

 
1,234,964

 
553,731

Held-to-Maturity:
 
 
 
 
 
 
State and political subdivisions
 
676,593

 
622,927

 
509,471

Trust preferred securities
 
500

 
500

 
500

Total investment securities held-to-maturity
 
677,093

 
623,427

 
509,971

Total investment securities
 
$
2,640,639

 
$
1,858,391

 
$
1,063,702

At December 31, 2017 , our investment securities portfolio consisted of: Government sponsored agency ("GSA") debt obligations, comprised primarily of fixed-rate instruments backed by Federal Home Loan Banks, Federal Farm Credit Banks and Student Loan Marketing Corporation, totaling $202.9 million ; state and political subdivisions debt obligations, comprised primarily of general debt obligations of issuers mostly located in the State of Michigan, totaling $1.02 billion ; residential mortgage-backed securities ("MBSs"), comprised primarily of fixed-rate instruments backed by a U.S. government agency ("Government National Mortgage Association") or government sponsored enterprises (Federal Home Loan Mortgage Corporation and Federal National Mortgage Association), totaling $150.1 million ; collateralized mortgage obligations ("CMOs"), comprised of approximately 82.0% fixed-rate and 18.0% variable-rate instruments backed by the same U.S. government agency and government sponsored enterprises as the residential MBSs, totaling $1.03 billion ; corporate bonds, comprised primarily of debt obligations of large U.S. global financial organizations, totaling $192.8 million ; and preferred stock and trust preferred securities ("TRUPs"), comprised of preferred stock debt instruments of two large regional/national banks and variable-rate TRUPs from both publicly-traded bank holding companies and small non-public bank holding companies, totaling $38.4 million . Fixed-rate instruments comprised approximately 96.0% of our investment securities portfolio at December 31, 2017 . The increase in our investment securities portfolios during the year ended December 31, 2017 is primarily due to management's decision to increase the size of the portfolio, which was funded in part by an increase in deposits and borrowings.
We record all investment securities in accordance with ASC Topic 320, Investments-Debt and Equity Securities (ASC 320), under which we are required to assess equity and debt securities that have fair values below their amortized cost basis to determine whether the decline (impairment) is other-than-temporary. An assessment is performed quarterly to determine whether unrealized losses in our investment securities portfolio are temporary or other-than-temporary by considering all reasonably available information. We review factors such as financial statements, credit ratings, news releases and other pertinent information of the underlying issuer or company to make our determination. In assessing whether a decline is other-than-temporary, management considers, among other things (i) the length of time and the extent to which the fair value has been less than the amortized cost, (ii) the financial condition and near-term prospects of the issuer, (iii) the potential for impairments in an entire industry or sub-sector and (iv) the potential for impairments in certain economically depressed geographical locations.
Our investment securities portfolio had a carrying value of $2.64 billion at December 31, 2017 , with gross unrealized losses of $35.2 million at that date. Management believes that the unrealized losses on investment securities were temporary in nature and due primarily to changes in interest rates on the investment securities and market illiquidity, and not as a result of credit-related issues. Accordingly, we believe the unrealized losses in our investment securities portfolio at December 31, 2017 were temporary in nature, and therefore, no impairment loss was recognized in our Consolidated Statement of Income in 2017 . However, other-than-temporary impairment ("OTTI") may occur in the future as a result of material declines in the fair value of investment securities resulting from market, credit, economic or other conditions. A further discussion of the assessment of potential impairment and our process that resulted in the conclusion that the impairment was temporary in nature follows.

48


At December 31, 2017 , the gross unrealized losses in our investment securities portfolio of $35.2 million were comprised as follows: state and political subdivisions securities of $22.4 million , GSA securities, residential MBSs and CMOs, combined, of $11.0 million , corporate bonds of $1.6 million and TRUPs of $0.2 million . The amortized costs and fair values of investment securities are disclosed in Note 4 to our Consolidated Financial Statements.
State and political subdivisions securities, included in our available-for-sale and held-to-maturity investment securities portfolios, had an amortized cost of $1.03 billion and gross unrealized losses of $22.4 million at December 31, 2017 . Our state and political subdivisions securities are from issuers mostly located in the State of Michigan and of which approximately 90.0% are general obligations of the issuer, meaning that repayment of these obligations is funded by general tax collections of the issuer. The gross unrealized losses were attributable to state and political subdivisions securities with an amortized cost of $809.0 million that generally mature beyond 2018 . It was our assessment that the unrealized losses on these investment securities were attributable to current market interest rates being slightly higher than the yield on these investment securities and illiquidity in the market due to the nature of a portion of these investment securities. We concluded that the unrealized losses in our state and political subdivisions securities were temporary in nature at December 31, 2017 .     
GSA securities, residential MBSs and CMOs, included in our available-for-sale investment securities portfolio, had a combined amortized cost of $1.40 billion and gross unrealized losses of $11.0 million at December 31, 2017 . Virtually all of the investment securities in these categories are backed by the full faith and credit of the U.S. government or a guarantee of a U.S. government agency or government sponsored enterprise. We determined that the unrealized losses on these investment securities were attributable to current market interest rates being higher than the yields being earned on these investment securities. We concluded that the unrealized losses in our GSA securities, residential MBSs and CMOs were temporary in nature at December 31, 2017 .
Corporate bonds included in our available-for-sale investment securities portfolio had an amortized cost of $193.2 million and gross unrealized losses of $1.6 million at December 31, 2017 . The investment securities in this category are investment grade securities and none have had recent downgrades. We determined that the unrealized losses on these investment securities were attributable to current market interest rates being higher than the yields being earned on these investment securities. We concluded that the unrealized loss was temporary in nature at December 31, 2017 .
At December 31, 2017 , we held one TRUP in our held-to-maturity investment securities portfolio, with an amortized cost of $0.5 million and gross unrealized loss of $0.1 million . This TRUP represents a 10% interest in the TRUP of a well-capitalized non-public bank holding company in Michigan. The principal of $0.5 million of this TRUP matures in 2033, with interest payments due quarterly. All scheduled interest payments on this TRUP have been made on a timely basis. We determined that the unrealized loss on this TRUP was attributable to a lack of liquidity for issuances of this size. We concluded that the unrealized loss was temporary in nature at December 31, 2017 .
At December 31, 2017 , we expected to fully recover the entire amortized cost basis of each investment security in an unrealized loss position in our investment securities portfolio at that date. Furthermore, at December 31, 2017 , we did not have the intent to sell any of our investment securities in an unrealized loss position and believed that it was more-likely-than-not that we would not have to sell any of our investment securities before a full recovery of amortized cost. However, there can be no assurance that OTTI losses will not be recognized on any investment security in the future.
Loans
Our loan portfolio is comprised of commercial, commercial real estate and real estate construction and land development loans, referred to as our commercial loan portfolio, and residential mortgage, consumer installment and home equity loans, referred to as our consumer loan portfolio. At December 31, 2017 , our loan portfolio was $14.16 billion and consisted of loans in the commercial loan portfolio totaling $8.46 billion , or 59.8% of total loans, and loans in the consumer loan portfolio totaling $5.69 billion , or 40.2% of total loans.
Chemical Bank is a full-service commercial bank and the acceptance and management of credit risk is an integral part of our business. We maintain loan policies and credit underwriting standards as part of the process of managing credit risk. These standards include making loans generally only within our market areas. Our lending markets generally consist of communities throughout Michigan and additional communities located within Northeast Ohio and Northern Indiana. Our lending philosophy is implemented through strong administrative and reporting controls. We maintain a centralized independent loan review function that monitors the approval process and ongoing asset quality of the loan portfolio.
Total loans were $14.16 billion at December 31, 2017 , an increase of $1.16 billion , or 9.0% , from total loans of $12.99 billion at December 31, 2016 . The increase in total loans during 2017 was attributable to organic loan growth of $2.29 billion , or 30.7% , partially offset by run-off in the acquired loan portfolio of $1.12 billion . Total loans increased $5.72 billion , or 79% , during 2016 , from total loans of $7.27 billion  at December 31, 2015 . The increase in total loans during 2016 was attributable to $4.88

49


billion of loans acquired in the merger with Talmer and organic loan growth of $837.2 million, or 12% . Organic loan growth during 2017 and 2016 generally occurred across all major loan categories and across all of our banking markets included as of each of those periods and was attributable to a combination of improving economic conditions and higher loan demand, as well as our increased market share in both our commercial and consumer loan portfolios.
A summary of our acquisition-related loan growth during 2016 follows:
 
 
2016
(Dollars in millions)
 
Talmer Bancorp, Inc.
(August 31, 2016)
Commercial loan portfolio:
 
 
Commercial
 
$
1,223

Commercial real estate
 
1,590

Real estate construction
 
166

Subtotal
 
2,979

Consumer loan portfolio:
 
 
Residential mortgage
 
1,532

Consumer installment
 
159

Home equity
 
212

Subtotal
 
1,903

Total loans
 
$
4,882

The following table includes the composition of our loan portfolio, by major loan category, as of December 31 for each of the past five years.
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
 
2014
 
2013
Commercial loan portfolio:
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
3,385,642

 
$
3,217,300

 
$
1,905,879

 
$
1,354,881

 
$
1,176,307

Commercial real estate:
 
 
 
 
 
 
 
 
 
 
       Owner-occupied
 
1,813,562

 
1,697,238

 
1,073,463

 
825,372

 
732,095

       Non-owner occupied
 
2,606,761

 
2,217,594

 
982,280

 
690,018

 
462,339

       Vacant land
 
80,347

 
58,308

 
56,419

 
42,258

 
38,224

Total commercial real estate
 
4,500,670

 
3,973,140

 
2,112,162

 
1,557,648

 
1,232,658

Real estate construction and land development
 
574,215

 
403,772

 
232,076

 
171,495

 
109,861

       Subtotal — commercial loan portfolio
 
8,460,527

 
7,594,212

 
4,250,117

 
3,084,024

 
2,518,826

Consumer loan portfolio:
 
 
 
 
 
 
 
 
 
 
Residential mortgage
 
3,252,487

 
3,086,474

 
1,429,636

 
1,110,390

 
960,423

Consumer installment
 
1,613,008

 
1,433,884

 
877,457

 
829,570

 
644,769

Home equity
 
829,245

 
876,209

 
713,937

 
664,246

 
523,603

       Subtotal — consumer loan portfolio
 
5,694,740

 
5,396,567

 
3,021,030

 
2,604,206

 
2,128,795

Total loans
 
$
14,155,267

 
$
12,990,779

 
$
7,271,147

 
$
5,688,230

 
$
4,647,621


A discussion of our loan portfolio by category follows.

Commercial Loan Portfolio

Our commercial loan portfolio is comprised of commercial loans, commercial real estate loans, real estate construction loans and land development loans. Our commercial loan portfolio is well diversified across business lines and has no concentration in any one industry. The commercial loan portfolio of $8.46 billion at December 31, 2017 included 144 loan relationships of $5.0 million or greater. These 144 loan relationships totaled $2.53 billion, which represented 30.0% of the commercial loan portfolio at December 31, 2017 and included 108 loan relationships that had outstanding balances of $10.0 million or higher, totaling $2.24 billion, or 26.5% of the commercial loan portfolio, at that date. We had 36 loan relationships that had outstanding balances of $20.0 million or higher, totaling $1.22 billion, or 14.5% of the commercial loan portfolio, at December 31, 2017 . We had 32

50


loan relationships at December 31, 2017 with loan balances greater than $5.0 million and less than $10.0 million, totaling $259.9 million, that had unfunded credit commitments totaling $158.9 million that, if advanced, could result in a loan relationship of $10.0 million or more.

The following table presents the contractual maturities of our $8.46 billion commercial loan portfolio at December 31, 2017 . The percentage of these loans maturing within one year was 22.3% at December 31, 2017 , while the percentage of these loans maturing beyond five years remained low at 23.6% at December 31, 2017 . At December 31, 2017 , loans in the commercial loan portfolio with maturities beyond one year totaled $6.58 billion , with 62.2% of these loans at fixed interest rates.
 
 
December 31, 2017
 
 
Due In
(Dollars in thousands)
 
1 Year
or Less
 
1 to 5
Years
 
Over 5
Years
 
Total
Loan maturities:
 
 
 
 
 
 
 
 
Commercial
 
$
1,175,608

 
$
1,766,561

 
$
443,472

 
$
3,385,641

Commercial real estate
 
580,839

 
2,583,781

 
1,336,051

 
4,500,671

Real estate construction and land development
 
128,706

 
231,557

 
213,952

 
574,215

Total
 
$
1,885,153

 
$
4,581,899

 
$
1,993,475

 
$
8,460,527

Percent of total
 
22.3
%
 
54.1
%
 
23.6
%
 
100.0
%
Interest sensitivity of above loans:
 
 
 
 
 
 
 
 
Fixed interest rates
 
$
717,547

 
$
3,074,906

 
$
1,013,538

 
$
4,805,991

Variable interest rates
 
1,167,606

 
1,506,993

 
979,937

 
3,654,536

Total
 
$
1,885,153

 
$
4,581,899

 
$
1,993,475

 
$
8,460,527

The following table presents the contractual maturities of our $7.59 billion commercial loan portfolio at December 31, 2016 .
 
 
December 31, 2016
 
 
Due In
(Dollars in thousands)
 
1 Year
or Less
 
1 to 5
Years
 
Over 5
Years
 
Total
Loan maturities:
 
 
 
 
 
 
 
 
Commercial
 
$
1,064,276

 
$
1,739,072

 
$
413,952

 
$
3,217,300

Commercial real estate
 
517,175

 
2,333,992

 
1,121,973

 
3,973,140

Real estate construction and land development
 
91,514

 
223,846

 
88,412

 
403,772

Total
 
$
1,672,965

 
$
4,296,910

 
$
1,624,337

 
$
7,594,212

Percent of total
 
22.03
%
 
56.58
%
 
21.39
%
 
100.00
%
Interest sensitivity of above loans:
 
 
 
 
 
 
 
 
Fixed interest rates
 
$
572,841

 
$
2,972,849

 
$
1,080,768

 
$
4,626,458

Variable interest rates
 
1,100,124

 
1,324,061

 
543,569

 
2,967,754

Total
 
$
1,672,965

 
$
4,296,910

 
$
1,624,337

 
$
7,594,212

Commercial loans consist of loans and lines of credit to varying types of businesses, including for profit businesses, municipalities, school districts and nonprofit organizations, for the purpose of supporting working capital and operational needs and term financing of equipment. Repayment of such loans is generally provided through operating cash flows of the borrower. Commercial loans are generally secured with inventory, accounts receivable, equipment, personal guarantees of the owner or other sources of repayment, although we may also obtain real estate as collateral.
Commercial loans were $3.39 billion at December 31, 2017 , an increase of $168.3 million , or 5.2% , from commercial loans of $3.22 billion at December 31, 2016 . Originated commercial loans grew by $506.1 million , or 26.6% , during 2017 , partially offset by run-off in the acquired portfolio of $337.7 million . Commercial loans increased $1.31 billion , or 68.8% , during 2016 from commercial loans of $1.91 billion at December 31, 2015 . Originated commercial loans grew by $380.0 million , or 25.0% , during 2016 , with the remainder of the growth attributable to the merger with Talmer completed during the year. Commercial loans represented 23.9% of our loan portfolio at December 31, 2017 , compared to 24.8% and 26.2% at December 31, 2016 and 2015 , respectively.

51


Commercial real estate loans include loans that are secured by real estate occupied by the borrower for ongoing operations, non-owner occupied real estate leased to one or more tenants and vacant land that has been acquired for investment or future land development. Commercial real estate loans were $4.50 billion at December 31, 2017 , an increase of $527.5 million , or 13.3% , from commercial real estate loans of $3.97 billion at December 31, 2016 . Loans secured by owner occupied properties, non-owner occupied properties and vacant land comprised 40.3% , 57.9% and 1.8% , respectively, of our commercial real estate loans outstanding at December 31, 2017 . Commercial real estate loans increased $1.86 billion , or 88.1% , during 2016 from commercial real estate loans of $2.11 billion at December 31, 2015 , with $1.59 billion of the growth attributable to the merger with Talmer. Commercial real estate loans represented 31.8% of our loan portfolio at December 31, 2017 , compared to 30.6% and 29.0% at December 31, 2016 and 2015 , respectively.
Commercial and commercial real estate lending are generally considered to involve a higher degree of risk than residential mortgage, consumer installment and home equity lending as they typically involve larger loan balances concentrated in a single borrower. In addition, the payment experience on loans secured by income-producing properties and vacant land loans is typically dependent on the success of the operation of the related project and is typically affected by adverse conditions in the real estate market and in the economy. We generally attempt to mitigate the risks associated with commercial and commercial real estate lending by, among other things, lending primarily in its market areas, lending across industry lines, not developing a concentration in any one line of business and using prudent loan-to-value ratios in the underwriting process. It is management's belief that our commercial and commercial real estate loan portfolios are generally well-secured.
Real estate construction loans are primarily originated for construction of commercial properties and often convert to a commercial real estate loan at the completion of the construction period. Land development loans include loans made to developers for the purpose of infrastructure improvements to vacant land to create finished marketable residential and commercial lots/land. A majority of our land development loans consist of loans to develop residential real estate. Land development loans are generally originated as interest only with the intention that the loan principal balance will be repaid through the sale of finished properties by the developers within twelve months of the completion date. Real estate construction and land development loans were $574.2 million at December 31, 2017 (comprised of approximately 90% real estate construction and 10% land development), an increase of $170.4 million , or 42.2% , compared to $403.8 million at December 31, 2016 . Real estate construction and land development loans increased $171.7 million , or 74.0% , during 2016 from real estate construction and land development loans of $232.1 million at December 31, 2015 , with $166.4 million of the growth attributable to the merger with Talmer. Real estate construction and land development loans represented 4.1% of our loan portfolio at December 31, 2017 , compared to 3.1% and 3.2% at December 31, 2016 and 2015 , respectively.    
Real estate construction and land development lending involves a higher degree of risk than commercial real estate lending and residential mortgage lending because of the uncertainties of construction, including the possibility of costs exceeding the initial estimates, the need to obtain a tenant or purchaser of the property if it will not be owner-occupied or the need to sell developed properties. We generally attempt to mitigate the risks associated with real estate construction and land development lending by, among other things, lending primarily in our market areas, using prudent underwriting guidelines and closely monitoring the construction process. At December 31, 2017 , $0.3 million , or 0.1% , of our $574.2 million of real estate construction and land development loans were considered impaired, whereby we determined it was probable that the full amount of principal and interest would not be collected on these loans in accordance with their original contractual terms. At December 31, 2016 , $0.3 million , or 0.1% of our $403.8 million of real estate construction and land development loans were considered impaired.
Consumer Loan Portfolio
Our consumer loan portfolio is comprised of residential mortgage loans, consumer installment loans and home equity loans and lines of credit.
Residential mortgage loans consist primarily of one- to four-family residential loans with fixed interest rates of fifteen years or less, with amortization periods generally from fifteen to thirty years. The loan-to-value ratio at the time of origination is generally 80% or less. Loans with more than an 80% loan-to-value ratio generally require private mortgage insurance.
Residential mortgage loans were $3.25 billion at December 31, 2017 , an increase of $166.0 million , or 5.4% , from residential mortgage loans of $3.09 billion at December 31, 2016 . Residential mortgage loans increased $1.66 billion during 2016 from residential mortgage loans of $1.43 billion at December 31, 2015 with $1.53 billion attributable to the merger with Talmer. Residential mortgage loans historically involve the least amount of credit risk in our loan portfolio. Residential mortgage loans also include loans to consumers for the construction of single family residences that are secured by these properties. Residential mortgage construction loans to consumers were $272.3 million at December 31, 2017 , compared to $169.5 million at December 31, 2016 and $62.2 million at December 31, 2015 . Residential mortgage loans represented 23.0% of our loan portfolio at December 31, 2017 , compared to 23.8% and 19.7% at December 31, 2016 and 2015 , respectively. We had residential mortgage loans with maturities beyond five years and that were at fixed interest rates totaling $495.8 million at December 31, 2017 , compared to $463.8 million at December 31, 2016 .

52


Consumer installment loans consist of relatively small loan amounts to consumers to finance personal items (primarily automobiles, recreational vehicles and marine vehicles) with the majority being indirect loans generated from dealerships. Consumer installment loans were $1.61 billion at December 31, 2017 , an increase of $179.1 million , or 12.5% , from consumer installment loans of $1.43 billion at December 31, 2016 . Consumer installment loans increased $556.4 million , or 63.4% , during 2016 from consumer installment loans of $877.5 million at December 31, 2015 with $158.8 million attributable to the merger with Talmer. At December 31, 2017 , collateral securing consumer installment loans was comprised approximately as follows: automobiles - 59.4%; recreational vehicles - 18.1%; marine vehicles - 18.3%; other collateral - 3.4%; and unsecured - 0.8%. Consumer installment loans represented 11.4% of the loan portfolio at December 31, 2017 , compared to 11.0% and 12.1% at December 31, 2016 and 2015 , respectively.
Home equity loans, including home equity lines of credit, are comprised of loans to consumers who utilize equity in their personal residence, including junior lien mortgages, as collateral to secure the loan or line of credit. Home equity loans were $829.2 million at December 31, 2017 , a decrease of $47.0 million , or 5.4% , from home equity loans of $876.2 million at December 31, 2016 . Home equity loans increased $162.3 million , or 22.7% , during 2016 from home equity loans of $713.9 million at December 31, 2015 , including $212.5 million attributable to the merger with Talmer. At December 31, 2017 , approximately 66.4% of our home equity loans were first lien mortgages and 33.6% were junior lien mortgages. Home equity loans represented 5.9% of the loan portfolio at December 31, 2017 , compared to 6.7% and 9.8% at December 31, 2016 and 2015 , respectively. Home equity lines of credit comprised $396.2 million, or 47.8%, of our home equity loans at December 31, 2017 , compared to $426.5 million, or 48.7%, of home equity loans at December 31, 2016 . The majority of our home equity lines of credit are comprised of loans with payments of interest only and original maturities of up to ten years. These home equity lines of credit include junior lien mortgages whereby the first lien mortgage is held by a nonaffiliated financial institution.
Consumer installment and home equity loans generally have shorter terms than residential mortgage loans, but generally involve more credit risk than residential mortgage lending because of the type and nature of the collateral. We experienced net credit losses on consumer installment and home equity loans totaling 20 basis points during 2017, compared to 15 basis points during 2016 . Consumer installment and home equity loans are spread across many individual borrowers, which minimizes the risk per loan transaction. We originate consumer installment and home equity loans utilizing a computer-based credit scoring analysis to supplement the underwriting process. Consumer installment and home equity lending collections are dependent on the borrowers' continuing financial stability and are more likely to be affected by adverse personal situations. Collateral values on properties securing consumer installment and home equity loans are negatively impacted by many factors, including the physical condition of the collateral and property values, although losses on consumer installment and home equity loans are often more significantly impacted by the unemployment rate and other economic conditions. The unemployment rates in Michigan, Ohio and Indiana were 4.7% , 4.7% and 3.4% , respectively, at December 31, 2017 , compared to 5.0%, 4.9% and 4.0%, respectively, at December 31, 2016 . The national average unemployment rate was 4.1% at December 31, 2017 .
Asset Quality
Summary of Impaired Assets and Past Due Loans
A loan is impaired when, based on current information and events, it is probable that we will be unable to collect all amounts due according to the contractual terms of the loan agreement. Impaired loans included nonperforming loans and all troubled debt restructurings ("TDRs").
Nonperforming assets consist of loans for which the accrual of interest has been discontinued, other real estate owned acquired through acquisitions or mergers, other real estate owned obtained through foreclosures and other repossessed assets. We do not consider accruing TDRs to be nonperforming assets. The level of nonaccrual is an important element in assessing asset quality. We transfer originated loans that are 90 days or more past due to nonaccrual status, unless we believe the loan is both well-secured and in the process of collection. For loans classified as nonaccrual, including those with modifications, we do not expect to receive all principal and interest payments, and therefore, any payments are recognized as principal reductions when received.
Acquired loans, accounted for under ASC 310-30, that are not performing in accordance with contractual terms are not reported as nonperforming because these loans are recorded in pools at their net realizable value based on the principal and interest we expect to collect on these loans.
Nonperforming assets were $71.9 million at December 31, 2017 , an increase of $10.4 million , or 16.9% , from $61.5 million at December 31, 2016 . The increase in nonperforming assets during 2017 was primarily attributable to two commercial loan credits, each greater than $5 million, added during the year, with significant collateral coverage, partially offset by a decrease in other real estate and repossessed assets. Nonperforming assets decreased $10.6 million , or 14.7% , during 2016 from $72.2 million at December 31, 2015 . Nonperforming assets represented 0.37% , 0.35% and 0.79% of total assets at December 31, 2017 , 2016 and 2015 , respectively. Our nonperforming assets are not concentrated in any one industry or any one geographical area.

53


The following table provides a five-year history of impaired assets.
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
 
2014
 
2013
Nonaccrual loans:
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
19,691

 
$
13,178

 
$
28,554

 
$
16,418

 
$
18,374

Commercial real estate
 
29,545

 
19,877

 
25,163

 
24,966

 
28,598

Real estate construction and land development
 
77

 
80

 
521

 
387

 
2,680

Total commercial loan portfolio
 
49,313

 
33,135

 
54,238

 
41,771

 
49,652

Consumer loan portfolio:
 
 
 
 
 
 
 
 
 
 
Residential mortgage
 
8,635

 
6,969

 
5,557

 
6,706

 
8,921

Consumer installment
 
842

 
879

 
451

 
500

 
676

Home equity
 
4,305

 
3,351

 
1,979

 
1,667

 
2,648

Total consumer loan portfolio
 
13,782

 
11,199

 
7,987

 
8,873

 
12,245

Total nonaccrual loans
 
63,095

 
44,334

 
62,225

 
50,644

 
61,897

Other real estate and repossessed assets
 
8,807

 
17,187

 
9,935

 
14,205

 
9,776

Total nonperforming assets
 
71,902

 
61,521

 
72,160

 
64,849

 
71,673

Accruing troubled debt restructurings
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio
 
34,484

 
45,388

 
46,141

 
44,450

 
40,253

Consumer loan portfolio
 
14,298

 
17,147

 
21,037

 
19,681

 
17,408

Total performing troubled debt restructurings
 
48,782

 
62,535

 
67,178

 
64,131

 
57,661

Total impaired assets
 
$
120,684

 
$
124,056

 
$
139,338

 
$
128,980

 
$
129,334

Accruing loans contractually past due 90 days or more as to interest or principal payments, excluding loans accounted for under ASC 310-30
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio
 
$
13

 
$
288

 
$
618

 
$
170

 
$
726

Consumer loan portfolio
 
1,364

 
995

 
1,669

 
1,903

 
1,271

Total accruing loans contractually past due 90 days or more as to interest or principal payments
 
$
1,377

 
$
1,283

 
$
2,287

 
$
2,073

 
$
1,997

Nonperforming loans as a percent of total loans
 
0.45
%
 
0.34
%
 
0.86
%
 
0.89
%
 
1.33
%
Nonperforming assets as a percent of total assets
 
0.37
%
 
0.35
%
 
0.79
%
 
0.89
%
 
1.16
%
Impaired assets as a percent of total assets
 
0.63
%
 
0.71
%
 
1.52
%
 
1.76
%
 
2.09
%
Nonaccrual loans that meet the definition of a TDR (nonaccrual TDR) totaled $29.1 million , $30.5 million , $35.9 million , $37.2 million and $37.3 million at December 31, 2017 , 2016 , 2015 , 2014 and 2013 , respectively. These loans have been modified by providing the borrower a financial concession that is intended to improve the probability of collection of the amounts due.

54


The following schedule summarizes impaired loans to commercial borrowers and the related valuation allowance at December 31, 2017 and 2016 and partial loan charge-offs (confirmed losses) taken on these impaired loans:
(Dollars in thousands)
 
Amount
 
Valuation
Allowance
 
Confirmed
Losses
 
Cumulative
Inherent
Loss Percentage
December 31, 2017
 
 
 
 
 
 
 
 
Impaired loans — originated commercial loan portfolio:
 
 
 
 
 
 
 
 
With valuation allowance and no charge-offs
 
$
48,622

 
$
4,618

 
$

 
9
%
With valuation allowance and charge-offs
 
8,591

 
919

 
9,335

 
57
%
With charge-offs and no valuation allowance
 
4,695

 

 
2,568

 
35
%
Without valuation allowance or charge-offs
 
21,889

 

 

 
%
Total impaired loans to commercial borrowers
 
$
83,797

 
$
5,537

 
$
11,903

 
18
%
 
 
 
 
 
 
 
 
 
December 31, 2016
 
 
 
 
 
 
 
 
Impaired loans — originated commercial loan portfolio:
 
 
 
 
 
 
 
 
With valuation allowance and no charge-offs
 
$
41,305

 
$
4,377

 
$

 
11
%
With valuation allowance and charge-offs
 
9,115

 
857

 
10,524

 
58
%
With charge-offs and no valuation allowance
 
4,001

 

 
6,665

 
62
%
Without valuation allowance or charge-offs
 
24,102

 

 

 
%
Total impaired loans to commercial borrowers
 
$
78,523

 
$
5,234

 
$
17,189

 
23
%
After analyzing the various components of the customer relationships and evaluating the underlying collateral of impaired loans, we determined that impaired loans in the commercial loan portfolio totaling $57.2 million at December 31, 2017 required a specific allocation of the allowance for loan losses (valuation allowance) of $5.5 million , compared to $50.4 million of impaired loans in the commercial loan portfolio at December 31, 2016 which required a valuation allowance of $5.2 million .
Nonperforming Loans
The following schedule provides the composition of nonperforming loans, by major loan category, as of December 31, 2017 and 2016 .
 
 
December 31,
 
 
2017
 
2016
(Dollars in thousands)
 
Amount
 
Percent
of Total
 
Amount
 
Percent
of Total
Commercial loan portfolio:
 
 
 
 
 
 
 
 
Commercial
 
$
19,691


31.2
%
 
$
13,178

 
29.7
%
Commercial real estate
 
29,545


46.9

 
19,877

 
44.8

Real estate construction and land development
 
77


0.1

 
80

 
0.2

Subtotal — commercial loan portfolio
 
49,313

 
78.2

 
33,135

 
74.7

Consumer loan portfolio:
 
 
 
 
 
 
 
 
Residential mortgage
 
8,635


13.7

 
6,969

 
15.7

Consumer installment
 
842


1.3

 
879

 
2.0

Home equity
 
4,305

 
6.8

 
3,351

 
7.6

Subtotal — consumer loan portfolio
 
13,782

 
21.8

 
11,199

 
25.3

Total nonperforming loans
 
$
63,095

 
100.0
%
 
$
44,334

 
100.0
%
Total nonperforming loans were $63.1 million at December 31, 2017 , an increase of $18.8 million , or 42.3% , compared to $44.3 million at December 31, 2016 . The increase in nonperforming loans during 2017 was primarily attributable to commercial real estate and commercial loans downgraded to nonaccrual status. Nonperforming loans in the commercial loan portfolio were $49.3 million at December 31, 2017 , an increase of $16.2 million, or 48.8%, from $33.1 million at December 31, 2016 . Nonperforming loans in the commercial loan portfolio comprised 78.2% of total nonperforming loans at December 31, 2017 , compared to 74.7% at December 31, 2016 . Nonperforming loans in the consumer loan portfolio were $13.8 million at December 31, 2017 , an increase of $2.6 million, or 23.1%, from $11.2 million at December 31, 2016 .

55


The following schedule summarizes changes in nonaccrual loans (including nonaccrual TDRs) during 2017 and 2016 :
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
Balance at beginning of period
 
$
44,334

 
$
62,225

Additions during period
 
57,936

 
28,263

Principal balances charged off
 
(13,392
)
 
(12,974
)
Transfers to other real estate/repossessed assets
 
(5,891
)
 
(7,046
)
Return to accrual status
 
(4,606
)
 
(6,410
)
Payments received
 
(15,286
)
 
(19,724
)
Balance at end of period
 
$
63,095

 
$
44,334

Nonperforming Loans — Commercial Loan Portfolio
The following schedule presents information related to stratification of nonperforming loans in the commercial loan portfolio by dollar amount at December 31, 2017 and 2016 .
 
 
December 31,
 
 
2017
 
2016
(Dollars in thousands)
 
Number of
Borrowers
 
Amount
 
Number of
Borrowers
 
Amount
$5,000,000 or more
 
2
 
$
10,426

 
 
$

$2,500,000 - $4,999,999
 
 

 
1
 
4,793

$1,000,000 - $2,499,999
 
7
 
10,063

 
7
 
10,526

$500,000 - $999,999
 
12
 
8,593

 
8
 
5,652

$250,000 - $499,999
 
27
 
9,473

 
10
 
3,809

Under $250,000
 
150
 
10,758

 
105
 
8,355

Total
 
198
 
$
49,313

 
131
 
$
33,135

Nonperforming commercial loans were $19.7 million at December 31, 2017 , an increase of $6.5 million , or 49.4% , from $13.2 million at December 31, 2016 . Nonperforming commercial loans comprised 0.6% of total commercial loans at December 31, 2017 , compared to 0.4% at December 31, 2016 .
Nonperforming commercial real estate loans were $29.5 million at December 31, 2017 , an increase of $9.7 million , or 48.6% , from $19.9 million at December 31, 2016 . Nonperforming commercial real estate loans comprised 0.7% of total commercial real estate loans at December 31, 2017 , compared to 0.5% at December 31, 2016 . Nonperforming commercial real estate loans secured by owner occupied real estate, non-owner occupied real estate and vacant land totaled $19.0 million, $5.3 million and $5.2 million, respectively, at December 31, 2017 . At December 31, 2017 , nonperforming commercial real estate loans were comprised of a diverse mix of commercial lines of business and were also geographically disbursed throughout our market areas. The largest concentrations of the $29.5 million in nonperforming commercial real estate loans at December 31, 2017 were two customer relationships totaling $10.3 million. One customer relationship totaling $5.2 million that was primarily secured by vacant land has been in nonperforming status for over five years. This same customer relationship had nonperforming land development loans of $0.1 million and nonperforming residential mortgage loans of $0.4 million. The other commercial customer relationship totaling $5.1 million was secured by owner occupied real estate.
Nonperforming real estate construction and land development loans were $0.1 million at both December 31, 2017 and December 31, 2016 , respectively. Nonperforming real estate construction and land development loans comprised less than 0.1% of total real estate construction and land development loans at both December 31, 2017 and 2016 .
At December 31, 2017 , nonperforming loans in the commercial loan portfolio of $1.2 million that were secured by real estate and were in various stages of foreclosure, compared to $1.7 million at December 31, 2016 .

56


Nonperforming Loans — Consumer Loan Portfolio
Nonperforming residential mortgage loans were $8.6 million at December 31, 2017 , an increase of $1.7 million , or 23.9% , from $7.0 million at December 31, 2016 . Nonperforming residential mortgage loans comprised 0.3% of total residential mortgage loans at December 31, 2017 , compared to 0.2% of total residential mortgage loans at December 31, 2016 . At December 31, 2017 , a total of $0.5 million of nonperforming residential mortgage loans were in various stages of foreclosure, compared to $1.8 million at December 31, 2016 .
Nonperforming consumer installment loans were $0.8 million at December 31, 2017 , compared to $0.9 million at December 31, 2016 . Nonperforming consumer installment loans comprised 0.05% of total consumer installment loans at December 31, 2017 compared to 0.06% at 2016 .
Nonperforming home equity loans were $4.3 million at December 31, 2017 , an increase of $1.0 million , or 28.5% , from $3.4 million at December 31, 2016 . Nonperforming home equity loans comprised 0.5% of total home equity loans at December 31, 2017 , compared to 0.4% of total home equity loans at December 31, 2016 .
Troubled Debt Restructurings (TDRs)
We assess all loan modifications to determine whether a restructuring constitutes a TDR. A restructuring is considered a TDR when a borrower demonstrates financial difficulties and for which a concession has been granted. We determined that it was probable that certain customers who were past due on their loans, if provided a modification of their loans by reducing their monthly payments, would be able to bring their loan relationships to a performing status. We believe loan modifications will potentially result in a lower level of loan losses and loan collection costs than if we proceeded immediately through the foreclosure process with these borrowers.
Accruing TDRs continue to accrue interest at the loan's original interest rate as we expect to collect the remaining principal balance on the loan. Nonaccrual loans that meet the definition of a TDR do not accrue interest as we do not expect to collect the full amount of principal and interest owed from the borrower on these loans.
The following summarizes TDRs at December 31, 2017 and 2016 :
 
 
Accruing TDRs
 
 
 
Total
(Dollars in thousands)
 
Current
 
Past Due
31-90 Days
 
Sub-
Total
 
Nonaccrual TDRs
 
December 31, 2017
 
 
Commercial loan portfolio
 
$
30,706

 
$
3,778

 
$
34,484

 
$
24,358

 
$
58,842

Consumer loan portfolio
 
13,552

 
746

 
14,298

 
4,748

 
19,046

Total TDRs
 
$
44,258

 
$
4,524

 
$
48,782

 
$
29,106

 
$
77,888

December 31, 2016
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio
 
$
43,041

 
$
2,347

 
$
45,388

 
$
25,397

 
$
70,785

Consumer loan portfolio
 
16,690

 
457

 
17,147

 
5,134

 
22,281

Total TDRs
 
$
59,731

 
$
2,804

 
$
62,535

 
$
30,531

 
$
93,066

A summary of changes in accruing TDRs in the commercial loan portfolio follows:
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
Balance at beginning of period
 
$
45,388

 
$
46,141

Additions for modifications
 
5,273

 
13,238

Principal payments and pay-offs
 
(8,530
)
 
(10,457
)
Transfers from nonaccrual status
 
3,286

 
2,045

Transfers to nonaccrual status
 
(10,933
)
 
(5,579
)
Balance at end of period
 
$
34,484

 
$
45,388


57


Other Real Estate and Repossessed Assets
Other real estate and repossessed assets are components of nonperforming assets, included in "Interest receivable and other assets" on our Consolidated Statements of Financial Position. These include other real estate (ORE), comprised of residential and commercial real estate and land development properties acquired through foreclosure or by acceptance of a deed in lieu of foreclosure, and repossessed assets, comprised of other personal and commercial assets. ORE totaled $8.2 million at December 31, 2017 , a decrease of $8.6 million , or 51.3% , from $16.8 million at December 31, 2016 . The decrease in ORE during 2017 was primarily attributable to ORE sales. Repossessed assets increased to $0.6 million at December 31, 2017 , compared to $0.4 million at December 31, 2016 .
The following schedule provides the composition of ORE at December 31, 2017 and 2016 :
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Composition of ORE:
 
 
 
 
Vacant land
 
$
2,064

 
$
5,473

Commercial real estate properties
 
3,363

 
6,812

Residential real estate properties
 
2,755

 
4,527

Total ORE
 
$
8,182

 
$
16,812

The following schedule summarizes ORE activity:
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Balance at beginning of year
 
$
16,812

 
$
9,716

 
$
13,953

Additions attributable to acquisitions (at fair value)
 

 
13,227

 
440

Additions attributable to foreclosures
 
6,905

 
9,938

 
6,957

Write-downs to fair value
 
(1,640
)
 
(636
)
 
(1,421
)
Net payments received
 
(1,064
)
 
(1,560
)
 
(45
)
Dispositions
 
(12,831
)
 
(13,873
)
 
(10,168
)
Balance at end of year
 
$
8,182

 
$
16,812

 
$
9,716

ORE is carried at the lower of cost or fair value less estimated cost to sell. We had $3.7 million in ORE at December 31, 2017 that had been held in excess of one year, of which $1.3 million had been held in excess of three years. We had $10.0 million of nonperforming loans that were in the process of foreclosure at December 31, 2017 .
All of our ORE properties have been written down to fair value through a charge-off against the allowance for loan losses at the time the loan was transferred to ORE, through a subsequent write-down, recorded as an operating expense, to recognize a further market value decline of the property after the initial transfer date, or due to recording at fair value as a result of acquisition transactions. Accordingly, at December 31, 2017 , the carrying value of ORE of $8.2 million was reflective of $6.4 million in charge-offs, write-downs and acquisition-related fair value adjustments.
During 2017 , we sold 249 ORE properties for net proceeds of $15.9 million . On an average basis, the net proceeds from these sales represented 121% of the carrying value of the property at the time of sale, with the net proceeds representing 81% of the remaining contractual loan balance at the time these loans were classified as nonperforming.
Allowance for Loan Losses
The allowance for loan losses ("allowance") provides for probable losses in the originated loan portfolio that have been identified for probable losses believed to be inherent in the loan portfolio.

58


The originated allowance is comprised of specific valuation allowances (assessed for originated loans that have known credit weaknesses and are considered impaired), pooled allowances based on assigned risk ratings and historical loan loss experience for each loan type, and a qualitative allowance based on environmental factors that take into consideration risks inherent in the originated loan portfolio that differ from historical loan loss exp erience. Our methodology for measuring the adequacy of the originated allowance is comprised of several key elements, which include a review of the loan portfolio, both individually and by category, and consideration of changes in the mix and volume of the loan portfolio, actual delinquency and loan loss experience, review of collateral values, the size and financial condition of the borrowers, industry and geographical exposures within the portfolio, economic conditions and employment levels of our local markets and other factors affecting business sectors.
The allowance for each acquired loan portfolio was not carried over on the date of each respective acquisition. Instead, the acquired loans were recorded at their estimated fair values at each acquisition date, with the estimated fair values including a component for expected credit losses. Acquired loans are subsequently evaluated for further credit deterioration in loan pools, which consist of loans with similar credit risk characteristics. If an acquired loan pool experiences a decrease in expected cash flows, as compared to those expected at the acquisition date, an allowance is established and allocated to acquired loans. The acquired allowance is calculated with the objective of maintaining a reserve sufficient to absorb losses inherent in the loan portfolio. The allowance is evaluated utilizing the key assumptions and estimates, similar to the initial estimate of fair value. Management must use judgment to develop its estimates of cash flows for acquired loans, which are impacted by many factors, including changes in property values, default rates, loss severities and prepayment speeds. As a result of the significant amount of judgment involved in estimating future cash flows expected to be collected for acquired loans, the adequacy of the allowance could be significantly impacted by changes in expected cash flows resulting from changes in credit quality of acquired loans. We had no allowance for the acquired loan portfolio at December 31, 2017 or December 31, 2016 .
We evaluate the originated and acquired allowances on a quarterly basis in an effort to ensure the level is adequate to absorb probable losses inherent in the loan portfolios. This evaluation process is inherently subjective as it requires estimates that may be susceptible to significant change and has the potential to affect net income materially. We believe that the allowances are currently maintained at an appropriate level, considering the inherent risk in the loan portfolios. Future significant adjustments to the allowances may be necessary due to changes in economic conditions, delinquencies or the level of loan losses incurred.
The following schedule summarizes information related to the allowance for loan losses:
 
 
December 31,
 (Dollars in thousands)
 
2017
 
2016
 
2015
 
2014
 
2013
Allowance for loan losses:
 
 
 
 
 
 
 
 
 
 
Originated loans
 
$
91,887

 
$
78,268

 
$
73,328

 
$
75,183

 
$
78,572

Acquired loans
 

 

 

 
500

 
500

Total
 
$
91,887

 
$
78,268

 
$
73,328

 
$
75,683

 
$
79,072

Nonperforming loans
 
$
63,095

 
$
44,334

 
$
62,225

 
$
50,644

 
$
61,897

Allowance for originated loans as a percent of:
 
 
 
 
 
 
 
 
 
 
Total originated loans
 
0.94
%
 
1.05
%
 
1.26
%
 
1.51
%
 
1.81
%
Nonperforming loans
 
146
%
 
177
%
 
118
%
 
148
%
 
127
%
Nonperforming loans, less impaired originated loans for which the expected loss has been charged-off
 
157
%
 
194
%
 
169
%
 
216
%
 
191
%

59


A summary of the activity in the allowance for loan losses for the five years ended December 31, 2017 is included in the table below.
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017

2016

2015
 
2014
 
2013
Allowance for loan losses - originated loan portfolio
 
 
 
 
 
 
 
 
 
 
Allowance for loan losses - beginning of year
 
$
78,268

 
$
73,328

 
$
75,183

 
$
78,572

 
$
83,991

Provision for loan losses
 
23,300

 
14,875

 
6,500

 
6,100

 
11,000

Loan charge-offs:
 
 
 
 
 
 
 

 
 
Commercial
 
(7,274
)
 
(6,012
)
 
(3,051
)
 
(3,169
)
 
(4,104
)
Commercial real estate
 
(1,286
)
 
(2,852
)
 
(2,693
)
 
(2,929
)
 
(7,363
)
Real estate construction and land development
 
(10
)
 
(42
)
 
(141
)
 
(301
)
 
(813
)
Residential mortgage
 
(1,206
)
 
(1,080
)
 
(2,427
)
 
(2,277
)
 
(2,878
)
Consumer installment
 
(6,281
)
 
(4,751
)
 
(4,182
)
 
(4,194
)
 
(3,993
)
Home equity
 
(810
)
 
(565
)
 
(507
)
 
(1,359
)
 
(1,995
)
Total loan charge-offs
 
(16,867
)
 
(15,302
)
 
(13,001
)
 
(14,229
)
 
(21,146
)
Recoveries of loans previously charged off:
 
 
 
 
 
 
 
 
 
 
Commercial
 
2,075

 
1,258

 
970

 
900

 
1,783

Commercial real estate
 
2,420

 
1,791

 
1,218

 
873

 
1,086

Real estate construction and land development
 

 
36

 

 
836

 
23

Residential mortgage
 
472

 
376

 
515

 
651

 
346

Consumer installment
 
2,049

 
1,703

 
1,391

 
1,279

 
1,350

Home equity
 
170

 
203

 
552

 
201

 
139

Total loan recoveries
 
7,186

 
5,367

 
4,646

 
4,740

 
4,727

Net loan charge-offs
 
(9,681
)
 
(9,935
)
 
(8,355
)
 
(9,489
)
 
(16,419
)
Allowance for loan losses - end of year
 
91,887

 
78,268

 
73,328

 
75,183

 
78,572

Allowance for loan losses - acquired loan portfolio
 
 
 
 
 
 
 
 
 
 
Allowance for loan losses - beginning of period
 

 

 
500

 
500

 
500

Provision for loan losses
 

 

 

 

 

Net loan charge-offs - acquired (commercial)
 

 

 
(500
)
 

 

Allowance for loan losses - end of period
 

 

 

 
500

 
500

Total allowance for loan losses
 
$
91,887

 
$
78,268

 
$
73,328

 
$
75,683

 
$
79,072

Net loan charge-offs as a percentage of average loans outstanding
 
0.07
%
 
0.11
%
 
0.13
%
 
0.19
%
 
0.38
%
The allocation of the allowance for loan losses in the table below is based upon ranges of estimates and is not intended to imply either limitations on the usage of the allowance or exactness of the specific amounts. The entire allowance attributable to originated loans is available to absorb future loan losses within the originated loan portfolio without regard to the categories in which the loan losses are classified. The allocation of the allowance is based upon a combination of factors, including historical loss factors, credit-risk grading, past-due experiences, and other factors, as discussed above.

60


 
 
December 31,
 
 
2017
 
2016
 
2015
 
2014
 
2013
(Dollars in thousands)
 
Allowance
Amount
 
Percent of
Loans
in Each
Category
to Total
Loans
 
Allowance
Amount
 
Percent of
Loans
in Each
Category
to Total
Loans
 
Allowance
Amount
 
Percent of
Loans
in Each
Category
to Total
Loans
 
Allowance
Amount
 
Percent of
Loans
in Each
Category
to Total
Loans
 
Allowance
Amount
 
Percent of
Loans
in Each
Category
to Total
Loans
Originated loans:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
25,329


17
%
 
$
22,388

 
14
%
 
$
21,909

 
20
%
 
$
17,951

 
22
%
 
$
18,251

 
24
%
Commercial real estate
 
35,118


19

 
25,396

 
15

 
22,810

 
20

 
23,547

 
21

 
23,753

 
23

Real estate construction and land development
 
5,686


4

 
3,417

 
2

 
2,515

 
3

 
2,658

 
3

 
2,478

 
2

Residential mortgage
 
13,375


14

 
13,760

 
11

 
14,308

 
17

 
11,286

 
18

 
12,850

 
20

Consumer Installment
 
8,577


11

 
8,907

 
10

 
5,677

 
12

 
9,411

 
14

 
8,728

 
14

Home equity
 
3,802

 
4

 
4,400

 
5

 
6,109

 
8

 
7,606

 
10

 
8,067

 
11

Unallocated
 



 

 

 

 

 
2,724

 

 
4,445

 

Subtotal — originated loans
 
91,887


69
%
 
78,268

 
57
%
 
73,328

 
80
%
 
75,183

 
88
%
 
78,572

 
94
%
Acquired loans
 


31
%
 

 
43
%
 

 
20
%
 
500

 
12
%
 
500

 
6
%
Total
 
$
91,887


100
%
 
$
78,268

 
100
%
 
$
73,328

 
100
%
 
$
75,683

 
100
%
 
$
79,072

 
100
%
Deposits
Total deposits were $13.64 billion at December 31, 2017 , an increase of $0.77 billion , or 6.0% , from total deposits at December 31, 2016 of $12.87 billion . The increase in total deposits during 2017 was attributable to growth in customer deposits, which included increases in noninterest-bearing demand deposits, savings deposits and time deposits of $644.27 million and brokered deposits of $226.8 million , partially offset by a decrease in interest-bearing demand deposits of $101.4 million . Interest and noninterest-bearing demand deposit and savings accounts were $10.11 billion at December 31, 2017 , compared to $9.86 billion at December 31, 2016 . Time and brokered deposits were $3.54 billion at December 31, 2017 , compared to $3.01 billion at December 31, 2016 .
It is our strategy to develop customer relationships that will drive core deposit growth and stability. Our competitive position within many of our market areas has historically limited our ability to materially increase core deposits without adversely impacting the weighted average cost of the deposit portfolio. While competition for core deposits remained strong throughout our markets during 2017 and 2016 , our efforts to expand deposit relationships with existing customers, our financial strength and a general trend in customers holding more liquid assets have resulted in continuing increases in customer deposits.

61


At December 31, 2017 , time deposits, which consist of certificates of deposit, including CDARs, IRA deposits and other brokered funds, totaled $3.22 billion , of which $2.17 billion have stated maturities in 2018 . We expect the majority of these maturing time deposits to be renewed by customers. The following schedule summarizes the scheduled maturities of time deposits as of December 31, 2017 :
(Dollars in thousands)
 
Amount
 
Weighted
Average
Interest Rate
2018 maturities:
 
 
 
 
First quarter
 
$
707,791

 
0.86
%
Second quarter
 
502,624

 
1.07

Third quarter
 
682,064

 
1.27

Fourth quarter
 
276,379

 
1.08

Total 2018 maturities
 
2,168,858

 
1.07

2019 maturities
 
646,514

 
1.35

2020 maturities
 
183,101

 
1.41

2021 maturities
 
134,806

 
1.55

2022 maturities and beyond
 
83,928

 
1.57

Total time deposits
 
$
3,217,207

 
1.18
%

The below table presents the maturity distribution of time deposits of $100,000 or more at December 31, 2017 . Time deposits of $100,000 or more totaled $2.20 billion and represented 16.2% of total deposits at December 31, 2017 .
 
 
December 31, 2017
(Dollars in thousands)
 
Amount
 
Percent
Maturity:
 
 
 
 
Within 3 months
 
$
548,888

 
24.9
%
After 3 but within 6 months
 
458,545

 
20.8

After 6 but within 12 months
 
668,156

 
30.3

After 12 months
 
529,133

 
24.0

Total
 
$
2,204,722

 
100.0
%
Borrowed Funds
Borrowed funds consist of securities sold under agreements to repurchase with customers, short-term borrowings and long-term borrowings. Short-term borrowings, which generally have an original term to maturity of 30 days or less, consist of short-term Federal Home Loan Bank ("FHLB") advances and federal funds purchased which are utilized to fund short-term liquidity needs. Long-term borrowings consist of securities sold under agreements to repurchase with an unaffiliated third-party financial institution, long-term FHLB advances, a non-revolving line-of-credit, a revolving line-of-credit and subordinated debt obligations.
Securities Sold Under Agreements to Repurchase with Customers
Securities sold under agreements to repurchase with customers represent funds deposited by customers that are collateralized by investment securities owned by Chemical Bank, as these deposits are not covered by Federal Deposit Insurance Corporation (FDIC) insurance. These funds have been a stable source of liquidity for Chemical Bank, much like its core deposit base, and are generally only provided to customers that have an established banking relationship with Chemical Bank. Securities sold under agreements to repurchase with customers do not qualify as sales for accounting purposes. Securities sold under agreements to repurchase with customers were $415.2 million and $343.0 million at December 31, 2017 and 2016 , respectively.

62


Short-term Borrowings
Short-term borrowings were $2.0 billion and $0.8 billion at December 31, 2017 and 2016 , respectively. Short-term borrowings increased $1.2 billion , or 142.4% , during 2017 , primarily due to the addition of short-term FHLB advances utilized to fund short-term liquidity needs resulting from loan growth and an increase in investment securities.
FHLB advances are borrowings from the Federal Home Loan Bank are generally used to fund loans and are secured by both a blanket security agreement of residential mortgage first lien and other real estate loans with an aggregate book value equal to at least 140% of the advances and FHLB capital stock owned by Chemical Bank. The carrying value of loans eligible as collateral under the blanket security agreement was $7.36 billion at December 31, 2017 . The average daily balance, average interest rate during the period and maximum month-end balance of short-term FHLB advances during the year ended December 31, 2017 was $1.6 billion, 1.18%, and $2.0 billion, respectively. The average daily balance, average interest rate during the period and maximum month-end balance of short-term FHLB advances during years ended December 31, 2016 and 2015 were $277.4 million, 0.49%, and $825.0 million and $89.2 million, 0.23% and $280.0 million, respectively. We rely on short-term FHLB advances to cover short-term liquidity needs.
Long-term Borrowings
Long-term borrowings were $372.9 million and $597.8 million at December 31, 2017 and 2016 , respectively. Long-term borrowings decreased $225.0 million , or 37.6% , during 2017 , primarily due to our decision to pay down the remaining balance on the non-revolving line-of-credit that was added in conjunction with our merger with Talmer.

A summary of the composition of long-term borrowings follows:        
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Long-term borrowings:
 
 
 
 
Long-term FHLB advances
 
$
337,204

 
$
438,538

Securities sold under agreement to repurchase
 

 
19,144

Non-revolving line-of-credit
 
19,963

 
124,625

Subordinated debt obligations
 
15,715

 
15,540

Total long-term borrowings
 
$
372,882

 
$
597,847


In conjunction with our merger with Talmer, we entered into a credit agreement of $145.0 million consisting of a $125.0 million term line-of credit and a $20.0 million revolving line-of-credit. The $20.0 million revolving line-of-credit and $105.0 million of the term line of credit was available for use at December 31, 2017 .
Securities sold under agreements to repurchase with an unaffiliated third-party financial institution represent financing arrangements that are secured by available-for-sale investment securities. These borrowings were obtained as part of our Lake Michigan acquisition and our merger with Talmer and were repaid during the year ended December 31, 2017.    
Contractual Obligations and Credit-Related Commitments
We have various financial obligations, including contractual obligations and commitments, which may require future cash payments. Refer to Notes 1, 13, 14 and 15 to our Consolidated Financial Statements for a further discussion of these contractual obligations.

63


Contractual Obligations
The following schedule summarizes noncancelable contractual obligations and future required minimum payments at December 31, 2017 .
 
 
December 31, 2017
 
 
Minimum Payments Due by Period
(Dollars in thousands)
 
Less than
1 year
 
1-3 years
 
3-5 years
 
More than
5 years
 
Total
Contractual Obligations:
 
 
Deposits with no stated maturity (1)
 
$
10,425,596

 
$

 
$

 
$

 
$
10,425,596

Time deposits with a stated maturity (1)
 
2,168,858

 
829,615

 
215,975

 
2,759

 
3,217,207

Securities sold under agreements to repurchase with customers
 
350,846

 
64,390

 

 

 
415,236

Short-term borrowings (1)
 
2,000,000

 

 

 

 
2,000,000

Long-term borrowings (1)
 
147,065

 
210,102

 

 
15,715

 
372,882

Operating leases and noncancelable contracts (2)
 
22,973

 
40,295

 
36,906

 
33,775

 
133,949

Other contractual obligations (3)
 
30,817

 
17,779

 
147

 
383

 
49,126

Total contractual obligations
 
$
15,146,155

 
$
1,162,181

 
$
253,028

 
$
52,632

 
$
16,613,996

(1)  
Deposits, short-term borrowings and long-term borrowings exclude accrued interest.
(2)  
Future minimum lease payments are reduced by $859 thousand related to sublease income to be received in the following periods: $218 thousand (less than 1 year); $430 thousand (1 to 3 years) and $211 thousand (3 to 5 years).
(3)  
Includes commitments to fund qualified low income housing and other tax investment projects, private equity capital investments and other similar types of investments.
Credit-Related Commitments
We also have credit-related commitments that may impact liquidity. The following schedule summarizes credit-related commitments and expected expiration dates by period as of December 31, 2017 .
(Dollars in thousands)
 
Less than
1 year
 
1-3 years
 
3-5 years
 
More than
5 years
 
Total
Unused commitments to extend credit:
 
 
 
 
 
 
 
 
 


Loans to commercial borrowers
 
$
992,396

 
$
641,792

 
$
215,686

 
$
450,924

 
$
2,300,798

Loans to consumer borrowers
 
231,170

 
157,792

 
139,078

 
200,677

 
728,717

Total unused commitments to extend credit
 
1,223,566

 
799,584

 
354,764

 
651,601

 
3,029,515

Undisbursed loan commitments (1)
 
571,037

 

 

 

 
571,037

Standby letters of credit
 
111,748

 
26,989

 
23,814

 
25,020

 
187,571

Total credit-related commitments
 
$
1,906,351

 
$
826,573

 
$
378,578

 
$
676,621

 
$
3,788,123

(1)  
Excludes $92.1 million of residential mortgage loan originations that were expected to be sold in the secondary market.
Because many of these commitments historically have expired without being drawn upon, the total amount of these commitments does not necessarily represent future liquidity requirements. Refer to Note 13 to our Consolidated Financial Statements for a further discussion of these obligations.
Cash Dividends
Annual cash dividends paid per common share over the past five years were as follows:
 
 
Years Ended December 31,
 
 
2017
 
2016
 
2015
 
2014
 
2013
Annual Cash Dividend (per common share)
 
$
1.10

 
$
1.06

 
$
1.00

 
$
0.94

 
$
0.87

We have paid regular cash dividends every quarter since we began operating as a bank holding company in 1973. The earnings of Chemical Bank have been the principal source of funds to pay cash dividends to shareholders. Over the long term, cash dividends to shareholders are dependent upon earnings, capital requirements, legal and regulatory restraints and other factors

64


affecting the Corporation and Chemical Bank. On January 23, 2018 , we declared a cash dividend on our common stock of $0.28 per share. The dividend will be paid on March 16, 2018 to shareholders of record as of March 2, 2018 . Refer to Note 20 to our Consolidated Financial Statements for a further discussion of factors affecting cash dividends.
Capital
Capital supports current operations and provides the foundation for future growth and expansion. Total shareholders' equity was $2.67 billion at December 31, 2017 , an increase of $87.2 million , or 3.4% , from total shareholders' equity of $2.58 billion at December 31, 2016 . Total shareholders' equity as a percentage of total assets was 13.8% at December 31, 2017 , compared to 14.9% at December 31, 2016 . Tangible equity, which is defined as total shareholders' equity less goodwill and other acquired intangible assets, totaled $1.51 billion and $1.43 billion at December 31, 2017 and 2016 , respectively. Our tangible equity to tangible assets ratio was 8.3% and 8.8% at December 31, 2017 and 2016 , respectively. Tangible equity and the tangible equity to tangible assets ratio are non-GAAP financial measures. Please refer to the section entitled "Non-GAAP Financial Measures" for a reconciliation to the closest GAAP financial measure.
Regulatory Capital
Under the regulatory "risk-based" capital guidelines in effect for both banks and bank holding companies, minimum capital levels are based upon perceived risk in the Corporation's and Chemical Bank's various asset categories. These guidelines assign risk weights to on- and off-balance sheet items in arriving at total risk-weighted assets. Regulatory capital is divided by the computed total of risk-weighted assets to arrive at the risk-based capital ratios. Risk-weighted assets for the Corporation and Chemical Bank totaled $14.74 billion and $14.70 billion , respectively, at December 31, 2017 , compared to $13.42 billion and $13.36 billion , respectively, at December 31, 2016 . The increase in risk-weighted assets during 2017 was largely attributable to originated loan growth.
In July 2013, the Federal Reserve Board and FDIC approved final rules implementing the Basel Committee on Banking Supervision's ("BCBS") capital guidelines for U.S. banks (commonly referred to as "Basel III"). Beginning January 1, 2015, the Basel III capital rules include a new minimum common equity Tier 1 capital to risk-weighted assets ("CET Tier 1") ratio of 4.5%, in addition to raising the minimum ratio of Tier 1 capital to risk-weighted assets from 4.0% to 6.0% and requiring a minimum leverage ratio of 4.0%. The Basel III capital rules also establish a new capital conservation buffer of 2.5% of risk-weighted assets, which is phased-in over a four-year period beginning January 1, 2016.
The Corporation and Chemical Bank both continue to maintain strong capital positions, which exceeded the minimum capital adequacy levels prescribed by the Board of Governors of the Federal Reserve System (Federal Reserve) at December 31, 2017 , as shown in the following schedule:
 
 
December 31, 2017
 
 
Leverage
Ratio
 
Risk-Based Capital Ratios
 
 
CET Tier 1
 
Tier 1
 
Total
Actual Capital Ratios:
 
 
 
 
 
 
 
 
Chemical Financial Corporation
 
8.3
%
 
10.2
%
 
10.2
%
 
11.0
%
Chemical Bank
 
8.4

 
10.3

 
10.3

 
11.0

Minimum required for capital adequacy purposes plus conservation buffer
 
4.0

 
5.8

 
7.3

 
9.3

Minimum required for "well-capitalized" capital adequacy purposes
 
5.0

 
6.5

 
8.0

 
10.0

As of December 31, 2017 , the Corporation and Chemical Bank's capital ratios exceeded the minimum levels required to be categorized as well-capitalized, as defined by applicable regulatory requirements. See Note 20 to our Consolidated Financial Statements for more information regarding the Corporation's and Chemical Bank's regulatory capital ratios.
Common Stock Repurchase Programs
From time to time, the board of directors approves common stock repurchase programs allowing the repurchase of shares of our common stock in the open market. The repurchased shares are available for later reissuance in connection with potential future stock dividends, employee benefit plans and other general corporate purposes. Under these programs, the timing and actual number of shares subject to repurchase are at the discretion of management and are contingent on a number of factors, including the projected parent company cash flow requirements and our share price.
In January 2008, the board of directors authorized the repurchase of up to 500,000 shares of our common stock under a stock repurchase program. In November 2011, the board of directors reaffirmed the stock buy-back authorization with the qualification that the shares may only be repurchased if the share price is below the tangible book value per share of our common

65


stock at the time of the repurchase. Since the January 2008 authorization, no shares have been repurchased. At December 31, 2017 , there were 500,000 remaining shares available for repurchase under our stock repurchase program.
Shelf Registration
On May 10, 2017, we filed an updated automatic shelf registration statement on Form S-3ASR with the Securities and Exchange Commission (SEC) for an indeterminate amount of securities, which became immediately effective. The shelf registration statement provides us with the ability to raise capital, subject to SEC rules and limitations, if the board of directors decides to do so.
Results of Operations
Overview
Net income in 2017 was $149.5 million , or $2.08 , per diluted share, compared to net income in 2016 of $108.0 million , or $2.17 per diluted share, and net income in 2015 of $86.8 million , or $2.39 per diluted share. Net income, excluding significant items, a non-GAAP financial measure, which for 2017 excludes the fourth quarter of 2017 charge to income tax expense of $46.7 million resulting from the revaluation of our net deferred tax assets completed following the signing of the Tax Cuts and Jobs Act in December 2017, merger and restructuring expenses of $28.4 million and fourth quarter of 2017 losses of $7.6 million on sales of investment securities as part of our treasury and tax management objectives, was $219.6 million , or $3.06 per diluted share, in 2017 . Net income in 2016 , excluding significant items, a non-GAAP financial measure which for 2016 excludes merger expenses of $61.1 million and a $7.4 million net gain on the sales of branches, was $143.7 million , or $2.88 per diluted share and net income in 2015 , excluding significant items, a non-GAAP financial measure which for 2015 excludes merger expenses of $7.8 million , was $92.3 million , or $2.54 per diluted share. The increase in net income in 2017 , excluding significant items, compared to 2016 , was primarily attributable to an increase in net interest income, resulting from an increase in average loans and securities and the impact of our merger with Talmer, while the increase in net income in 2016 , excluding significant items, compared to 2015 , was primarily attributable to incremental earnings resulting from our merger with Talmer.
Our return on average assets was 0.81% in 2017 , 0.90% in 2016 , and 1.02% in 2015 and our return on average shareholders' equity was 5.7% in 2017 , 7.0% in 2016 and 9.4% in 2015 . Our return on average assets, excluding the significant items described above for each period, a non-GAAP financial measure, was 1.19% in both 2017 and 2016 , and 1.09% in 2015 and our return on average shareholders' equity was 8.4% in 2017 , 9.3% in 2016 and 10.0% in 2015 .
Please refer to the section entitled "Non-GAAP Financial Measures" for a reconciliation to the most directly comparable GAAP financial measures.
Net Interest Income

Net interest income is the difference between interest income on earning assets, such as loans, investment and non-marketable equity securities and interest-bearing deposits with the Federal Reserve Bank (FRB) and other banks, and interest expense on liabilities, such as deposits and borrowings. Net interest income is our largest source of net revenue (net interest income plus noninterest income), representing 79.5% , 75.7% and 77.4% of net revenue in 2017 , 2016 and 2015 , respectively. Net interest income, on a fully taxable equivalent (FTE) basis, is the difference between interest income and interest expense adjusted for the tax benefit received on tax-exempt commercial loans and investment securities. Net interest margin (FTE) is calculated by dividing net interest income (FTE) by average interest-earning assets, annualized as applicable. Net interest spread is the difference between the average yield on interest-earning assets and the average cost of interest-bearing liabilities. Because noninterest-bearing sources of funds, or free funds (principally demand deposits and shareholders' equity), also support earning assets, the net interest margin exceeds the net interest spread.

Average Balances, Fully Tax Equivalent (FTE) Interest and Effective Yields and Rates

The following table presents the average daily balances of our major categories of assets and liabilities, interest income and expense on a fully tax equivalent (FTE) basis, average interest rates earned and paid on the assets and liabilities, net interest income (FTE), net interest spread and net interest margin for 2017 , 2016 and 2015 . The presentation of net interest income on a FTE basis is not in accordance with GAAP, but is customary in the banking industry. This non-GAAP measure ensures comparability of net interest income arising from both taxable and tax-exempt loans and investment securities. Please refer to the section entitled "Non-GAAP Financial Measures."

66


 
Years Ended December 31,
 
2017
 
2016
 
2015
(Dollars in thousands)
Average
Balance
 
Interest (FTE)
 
Effective
Yield/
Rate (1)
 
Average
Balance
 
Interest (FTE)
 
Effective
Yield/
Rate (1)
 
Average
Balance
 
Interest (FTE)
 
Effective
Yield/
Rate (1)
Assets
 
Interest-earning assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loans (2)
$
13,607,683

 
$
576,429

 
4.24
%
 
$
9,304,573

 
$
386,575

 
4.15
%
 
$
6,594,507

 
$
274,341

 
4.16
%
Taxable investment securities
1,431,167

 
31,496

 
2.20

 
706,567

 
10,989

 
1.56

 
683,612

 
8,786

 
1.29

Tax-exempt investment securities
905,831

 
28,120

 
3.10

 
595,677

 
18,929

 
3.18

 
415,092

 
13,956

 
3.36

Other interest-earning assets
157,738

 
4,924

 
3.12

 
55,341

 
1,973

 
3.57

 
34,188

 
1,648

 
4.82

Interest-bearing deposits with FRB and other banks and federal funds sold
298,006

 
4,244

 
1.42

 
194,637

 
1,555

 
0.80

 
123,735

 
510

 
0.41

Total interest-earning assets
16,400,425

 
645,213

 
3.93
%
 
10,856,795

 
420,021

 
3.87
%
 
7,851,134

 
299,241

 
3.81
%
Less: Allowance for loan losses
(82,644
)
 
 
 
 
 
(73,136
)
 
 
 
 
 
(75,378
)
 
 
 
 
Other assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash due from banks
235,621

 
 
 
 
 
186,706

 
 
 
 
 
155,109

 
 
 
 
Premises and equipment
144,114

 
 
 
 
 
118,080

 
 
 
 
 
105,904

 
 
 
 
Interest receivable and other assets
1,767,640

 
 
 
 
 
948,710

 
 
 
 
 
444,459

 
 
 
 
Total assets
$
18,465,156

 
 
 
 
 
$
12,037,155

 
 
 
 
 
$
8,481,228

 
 
 
 
Liabilities and shareholders' equity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest-bearing liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest-bearing demand deposits
$
2,753,294

 
$
4,870

 
0.18
%
 
$
2,143,064

 
$
3,277

 
0.15
%
 
$
1,661,592

 
$
1,465

 
0.09
%
Savings deposits
3,940,499

 
13,049

 
0.33

 
2,534,038

 
2,877

 
0.11

 
1,947,659

 
1,512

 
0.08

Time deposits
3,014,302

 
28,808

 
0.96

 
2,154,118

 
16,867

 
0.78

 
1,557,425

 
12,429

 
0.80

Short-term borrowings
1,978,951

 
20,321

 
1.03

 
571,510

 
1,660

 
0.29

 
420,529

 
453

 
0.11

Long-term borrowings
455,246

 
7,509

 
1.67

 
418,636

 
4,617

 
1.10

 
117,000

 
1,922

 
1.64

Total interest-bearing liabilities
12,142,292

 
74,557

 
0.61

 
7,821,366

 
29,298


0.37

 
5,704,205

 
17,781

 
0.31

Noninterest-bearing deposits
3,547,271

 

 

 
2,566,342

 

 

 
1,791,991

 

 

Total deposits and borrowed funds
15,689,563

 
74,557

 
0.48

 
10,387,708

 
29,298

 
0.28

 
7,496,196

 
17,781

 
0.24

Interest payable and other liabilities
147,731

 
 
 
 
 
102,726

 
 
 
 
 
65,704

 
 
 
 
Shareholders' equity
2,627,862

 
 
 
 
 
1,546,721

 
 
 
 
 
919,328

 
 
 
 
Total liabilities and shareholders' equity
$
18,465,156

 
 
 
 
 
$
12,037,155

 
 
 
 
 
$
8,481,228

 
 
 
 
Net Interest Spread (average yield earned minus average rate paid)
 
 
 
 
3.32
%
 
 
 
 
 
3.50
%
 
 
 
 
 
3.50
%
Net Interest Income (FTE)
 
 
$
570,656

 
 
 
 
 
$
390,723

 

 
 
 
$
281,460

 
 
Net Interest Margin (Net interest income (FTE) divided by total average interest-earning assets)
 
 
 
3.48
%
 
 
 
 
 
3.60
%
 
 
 
 
 
3.58
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation to Reported Net Interest Income
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net interest income, fully taxable equivalent (non-GAAP)
 
$
570,656

 
 
 
 
 
$
390,723

 
 
 
 
 
$
281,460

 
 
Adjustments for taxable equivalent interest (1) :
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loans
 
 
(3,301
)
 
 
 
 
 
(3,030
)
 
 
 
 
 
(2,569
)
 
 
Tax-exempt investment securities
 
 
(9,777
)
 
 
 
 
 
(6,612
)
 
 
 
 
 
(4,883
)
 
 
Total taxable equivalent interest adjustments
 
(13,078
)
 
 
 
 
 
(9,642
)
 
 
 
 
 
(7,452
)
 
 
Net interest income (GAAP)
 
 
$
557,578

 
 
 
 
 
$
381,081

 
 
 
 
 
$
274,008

 
 
Net interest margin (GAAP)
 
 
3.40
%
 
 
 
 
 
3.51
%
 
 
 
 
 
3.49
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1)     Fully taxable equivalent (FTE) basis using a federal income tax rate of 35%. The presentation of net interest income on a FTE basis is not in accordance with GAAP, but is customary in the banking industry. Please refer to the section entitled "Non-GAAP Financial Measures."
(2)     Nonaccrual loans and loans held-for-sale are included in average balances reported and are included in the calculation of yields. Also, tax equivalent interest includes net loan fees.

67


Net interest income (FTE) of $570.7 million in 2017 was $179.9 million , or 46.1% , higher than net interest income (FTE) of $390.7 million in 2016 . The increase in net interest income (FTE) in 2017 , compared to 2016 , was primarily attributable to originated loan growth, an increase in the investment securities portfolio and an increase in interest accretion from purchase accounting discounts on acquired loans. The net interest margin (FTE) was 3.48% in 2017 , compared to 3.60% in 2016 . The average yield on interest-earning assets increased six basis points to 3.93% in 2017 from 3.87% in 2016 , with the increase primarily attributable to increases and improvement in yield earned in our investment securities portfolio. Interest accretion from purchase accounting discounts on acquired loans contributed 20 basis points to the net interest margin (FTE) in 2017 , compared to nine basis points in 2016 , with the increase primarily due to the addition of the loans from our merger with Talmer in August of 2016. The average yield on loans increased nine basis points to 4.24% in 2017 from 4.15% in 2016 , primarily due to the increased benefit from interest accretion from purchase accounting discounts on acquired loans. The average cost of interest-bearing liabilities increased 24 basis points to 0.61% in 2017 from 0.37% in 2016 , primarily due to an increase in short-term borrowings and deposit rates, both resulting from a rise in market rates.
Net interest income (FTE) of $390.7 million in 2016 was $109.3 million , or 38.8% , higher than net interest income (FTE) of $281.5 million in 2015 . The increase in net interest income (FTE) in 2016 , compared to 2015 , was primarily attributable to an increase of $2.71 billion in the average volume of loans outstanding which included the impact of $4.88 billion of loans from the Talmer merger. The net interest margin (FTE) was 3.60% in 2016 , compared to 3.58% in 2015 . The average yield on interest-earning assets increased six basis points to 3.87% in 2016 from 3.81% in 2015 , with the increase primarily attributable to the benefit received from the increase in the average volume of loans outstanding. The average yield on loans decreased one basis point to 4.15% in 2016 from 4.16% in 2015 . The average cost of interest-bearing liabilities increased six basis points to 0.37% in 2016 from 0.31% in 2015 , with the increase attributable to the change in funding mix, in part due to the Talmer merger and the increase in deposit rates due to a rise in market rates.
Changes in our net interest income are influenced by a variety of factors, including changes in the level and mix of interest-earning assets and interest-bearing liabilities, current and prior years' interest rate changes, the level and direction of interest rates, the difference between short-term and long-term interest rates (the steepness of the yield curve) and the general strength of the economies in our markets. Risk management plays an important role in our level of net interest income. The ineffective management of credit risk, and more significantly interest rate risk, can adversely impact our net interest income. Management monitors our Consolidated Statement of Financial Position to reduce the potential adverse impact on net interest income caused by significant changes in interest rates. Our policies in this regard are further discussed in the section captioned "Market Risk" in Item 7A of this Annual Report.
The Federal Reserve influences the general market rates of interest, including the deposit and loan rates offered by many financial institutions. The prime interest rate, which is the rate offered on loans to borrowers with strong credit, was increased to 3.75% from the previous rate of 3.50% in December 2016, increased to 4.00% in March 2017, increased to 4.25% in June 2017, and increased again to 4.50% in December 2017. The prime interest rate has historically been 300 basis points higher than the federal funds rate. The majority of our variable interest rate loans in the commercial loan portfolio are tied to the prime rate.
We are primarily funded by core deposits, which are a lower-cost funding base than wholesale funding and historically has had a positive impact on our net interest income and net interest margin.


68


Volume and Rate Variance Analysis
The below table presents the effect of volume and rate changes on interest income and expense. Changes in volume are changes in the average balance multiplied by the previous year's average rate. Changes in rate are changes in the average rate multiplied by the average balance from the previous year. The net changes attributable to the combined impact of both rate and volume have been allocated proportionately to the changes due to volume and the changes due to rate.
 
 
2017 Compared to 2016
 
2016 Compared to 2015
 
 
Increase (Decrease)
Due to Changes in
 
Combined
Increase/
(Decrease)
 
Increase (Decrease)
Due to Changes in
 
Combined
Increase/
(Decrease)
(Dollars in thousands)
 
Average
Volume (1)
 
Average
Yield/ Rate (1)
 
 
Average
Volume
(1)
 
Average
Yield/ Rate (1)
 
Changes in Interest Income on Interest-Earning Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Loans
 
$
185,042

 
$
4,812

 
$
189,854

 
$
114,289

 
$
(2,055
)
 
$
112,234

Taxable investment securities/other assets
 
17,914

 
5,544

 
23,458

 
1,144

 
1,384

 
2,528

Tax-exempt investment securities
 
9,689

 
(498
)
 
9,191

 
5,781

 
(808
)
 
4,973

Interest-bearing deposits with the FRB and other banks
 
1,615

 
1,074

 
2,689

 
730

 
315

 
1,045

Total change in interest income on interest-earning assets
 
214,260

 
10,932

 
225,192

 
121,944

 
(1,164
)
 
120,780

Changes in Interest Expense on Interest-Bearing Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
Interest-bearing demand deposits
 
1,015

 
578

 
1,593

 
485

 
1,327

 
1,812

Savings deposits
 
3,726

 
6,446

 
10,172

 
537

 
828

 
1,365

Time deposits
 
7,995

 
3,946

 
11,941

 
4,800

 
(362
)
 
4,438

Short-term borrowings
 
13,776

 
4,885

 
18,661

 
3,265

 
(433
)
 
2,832

Long-term borrowings
 
950

 
1,942

 
2,892

 
1,007

 
62

 
1,069

Total change in interest expense on interest-bearing liabilities
 
27,462

 
17,797

 
45,259

 
10,094

 
1,422

 
11,516

Total Change in Net Interest Income (FTE) (2)
 
$
186,798

 
$
(6,865
)
 
$
179,933

 
$
111,850

 
$
(2,586
)
 
$
109,264

 
 
 
 
 
 
 
 
 
 
 
 
 
(1)    The change in interest income and interest expense due to both volume and rate has been allocated to the volume and rate changes in proportion to the
      relationship of the absolute dollar amounts of the change in each.

(2)     Fully taxable equivalent basis using a federal income tax rate of 35%. The presentation of net interest income on a FTE basis is not in accordance with
       GAAP, but is customary in the banking industry.

Provision for Loan Losses
The provision for loan losses ("provision") is an increase to the allowance, as determined by management, to provide for probable losses inherent in the originated loan portfolio and for impairment in pools of acquired loans that results from experiencing a decrease, if any, in expected cash flows of acquired loans during each reporting period. The provision was $23.3 million in 2017 , compared to $14.9 million in 2016 and $6.5 million in 2015 . The increase in the provision in 2017 , compared to 2016 , was primarily due to an increase in originated loan growth. Originated loan growth was $2.29 billion in 2017 , which was partially offset by run-off in the acquired loan portfolio of $1.12 billion during the same period. All acquired loans were recorded at their estimated fair value at each respective acquisition date without a carryover of the related allowance and, as of December 31, 2017 , no allowance was determined to be needed for acquired loans as a decrease in expected cash flows was not evident.
We experienced net loan charge-offs of $9.7 million in 2017 , compared to $9.9 million in 2016 and $8.9 million in 2015 . Net loan charge-offs as a percentage of average loans were 0.07% in 2017 , compared to 0.11% in 2016 and 0.13% in 2015 . Net loan charge-offs in the commercial loan portfolio totaled $4.1 million in 2017 , compared to $5.8 million in 2016 and $4.2 million in 2015 and represented 42.1% of total net loan charge-offs during 2017 , compared to 58.6% during 2016 and 47.4% during 2015 . Net loan charge-offs in the consumer loan portfolio totaled $5.6 million in 2017 , compared to $4.1 million in 2016 and $4.7 million in 2015 .

The provision of $23.3 million in 2017 was $13.6 million higher than 2017 net loan charge-offs, and the provision of $14.9 million in 2016 was $4.9 million higher than 2016 net loan charge-offs. The provision was higher in both 2017 and 2016 primarily related to the impact of the significant increase in originated growth in the loan portfolio in each period.

69


Noninterest Income
The following table presents the major components of noninterest income:
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Noninterest income
 
 
 
 
 
 
Service charges and fees on deposit accounts
 
$
35,001

 
$
28,136

 
$
25,481

Wealth management revenue
 
25,512

 
22,601

 
20,552

Electronic banking fees
 
24,247

 
23,433

 
19,119

Net gain on sale of loans and other mortgage
 
38,580

 
16,747

 
6,133

Change in fair value in loan servicing rights (1)
 
(6,375
)
 
5,112

 

Other fees for customer services
 
6,730

 
4,939

 
4,428

Insurance commissions
 
1,794

 
1,874

 
1,966

(Loss) gain on sale of investment securities
 
(7,388
)
 
129

 
630

Bank-owned life insurance
 
4,818

 
1,836

 
646

Rental income
 
762

 
592

 
466

Gain on sale of branch offices
 

 
7,391

 

Gain on sale of closed branch offices and other assets
 

 

 
266

Other
 
20,338

 
9,560

 
529

Total noninterest income
 
$
144,019

 
$
122,350

 
$
80,216

Significant items (2)
 
(7,556
)
 
7,391

 

Noninterest income excluding significant items (2)(3)
 
$
151,575

 
$
114,959

 
$
80,216

Noninterest income   as a percentage of:
 
 
 
 
 
 
Net revenue (net interest income plus noninterest income)
 
20.5
%
 
24.3
%
 
22.6
%
Average total assets
 
0.78
%
 
1.02
%
 
0.95
%
Net revenue, excluding significant items (2)(3)
 
21.37
%
 
23.18
%
 
22.65
%
Average total assets, excluding significant items (2)(3)
 
0.82
%
 
0.96
%
 
0.95
%
(1)
Included within the line item "Net gain on sale of loans and other mortgage banking revenue" in our Consolidated Statements of Income.
(2)
For 2017, "significant items" include the fourth quarter of 2017 losses on sales of investment securities taken as part of our treasury and tax management objectives following the signing of the Tax Cuts and Jobs Act. For 2016, "significant items" include merger expenses and net gain on the sales of branch offices.
(3)
Noninterest income, excluding significant items, as a percentage of net revenue and average total assets, are non-GAAP financial measures. See the section entitled "Non-GAAP Financial Measures."

Noninterest income was $144.0 million in 2017 , $122.4 million in 2016 and $80.2 million in 2015 . Noninterest income in 2017 included a $7.6 million loss incurred on sales of investment securities in the fourth quarter as part of our treasury and tax management objectives following the signing of the Tax Cuts and Jobs Act, noted as a significant item for 2017, and 2016 included $7.4 million of net gain on the sales of branches, noted as a significant item for 2016. Excluding these significant items in each applicable period, noninterest income increased $36.6 million , or 31.9% , in 2017 , compared to 2016 , with the increase primarily attributable to the incremental revenue resulting from the addition of Talmer into our operations in addition to organic growth in deposits and services. Noninterest income, excluding the gain on the sales of branch offices in 2016 increased $34.7 million , or 43.3% , in 2016 , compared to 2015 , with the increase primarily attributable to the incremental revenue resulting from our transactions with Talmer, Lake Michigan and Monarch.
Service charges and fees on deposit accounts, which include overdraft/non-sufficient funds fees, checking account fees and other deposit account charges, were $35.0 million in 2017 , $28.1 million in 2016 and $25.5 million in 2015 . Service charges and fees on deposit accounts increased $6.9 million , or 24.4% , in 2017 , compared to 2016 , and $2.7 million , or 10.4% , in 2016 , compared to 2015 , due primarily to additional fees earned as a result of our merger with Talmer and organic growth in customer deposit accounts. Overdraft/non-sufficient funds fees included in service charges and fees on deposit accounts were $25.1 million in 2017 , compared to $21.0 million in 2016 and $18.7 million in 2015 .
Wealth management revenue is comprised of investment fees that are generally based on the market value of assets within a trust account, custodial account fees and fees from the sale of investment products. Volatility in the equity and bond markets

70


impacts the market value of trust assets and the related investment fees. Wealth management revenue was $25.5 million in 2017 , $22.6 million in 2016 and $20.6 million in 2015 . Wealth management revenue increased $2.9 million , or 12.9% , in 2017 , compared to 2016 , and wealth management revenue increased $2.0 million , or 10.0% , in 2016 , compared to 2015 , with the increases due primarily to a combination of improving equity market performance that led to increased assets under management, growth in assets under management resulting from new customer accounts and the impact of our merger with Talmer.
At December 31, 2017 , the estimated fair value of trust assets under administration was $5.13 billion (including discretionary assets of $2.67 billion and nondiscretionary assets of $2.46 billion ), compared to $4.41 billion at December 31, 2016 (including discretionary assets of $2.43 billion and nondiscretionary assets of $1.97 billion ), and $3.71 billion at December 31, 2015 (including discretionary assets of $2.11 billion and nondiscretionary assets of $1.60 billion ). Wealth management revenue also includes fees from the sale of investment products offered through the Chemical Financial Advisors program. Fees from this program totaled $5.2 million in 2017 , compared to $4.7 million in 2016 and $3.9 million in 2015 . We had customer assets in the Chemical Financial Advisors program of $1.31 billion at December 31, 2017 , compared to $1.15 billion at December 31, 2016 and $0.87 billion at December 31, 2015 .
Electronic banking fees, which represent income earned from ATM transactions, debit card activity and internet banking fees, were $24.2 million in 2017 , $23.4 million in 2016 and $19.1 million in 2015 . Electronic banking fees increased $0.8 million , or 3.5% , in 2017 , compared to 2016 , and increased $4.3 million , or 22.6% , in 2016 , compared to 2015 . The slight increase in electronic banking fees in 2017, compared to 2016, was primarily due to a combination of a higher volume of customers due to our merger with Talmer, partially offset by a reduction in interchange fees resulting from limitations set by the Durbin amendment, which became effective for us on July 1, 2017.
Net gain on sale of loans and other mortgage banking revenue ("MBR") includes revenue from originating, selling and servicing residential mortgage loans for the secondary market and other loan sales. MBR was $32.2 million in 2017 , $21.9 million in 2016 and $6.1 million in 2015 . MBR increased $10.3 million , or 47.3% , in 2017 , compared to 2016 , due primarily to the impact of our merger with Talmer and a higher volume of loans sold in the secondary market. These increases were partially offset by the change in fair value in loan servicing rights recognized, which was a detriment of $6.4 million in 2017 , compared to income of $5.1 million in 2016 . MBR increased $15.7 million , in 2016 , compared to 2015 , due primarily to the impact of our merger with Talmer and a higher volume of loans sold in the secondary market. We sold $806.8 million of residential mortgage loans in the secondary market during 2017 , compared to $707.8 million during 2016 and $222.6 million during 2015 . At December 31, 2017 , we were servicing $7.11 billion of residential mortgage loans that had been originated in our market areas and subsequently sold in the secondary market, compared to $7.37 billion at December 31, 2016 and $2.08 billion at December 31, 2015 .
We sell residential mortgage loans in the secondary market on both a servicing retained and servicing released basis. These sales include our entering into residential mortgage loan sale agreements with buyers in the normal course of business. The agreements contain provisions that include various representations and warranties regarding the origination, characteristics and underwriting of the mortgage loans. The recourse of the buyer may result in either indemnification of the loss incurred by the buyer or a requirement for us to repurchase a loan that the buyer believes does not comply with the representations included in the loan sale agreement. Repurchase demands and loss indemnifications received are reviewed by a senior officer on a loan-by-loan basis to validate the claim made by the buyer. We maintain a reserve for probable losses expected to be incurred from loans previously sold in the secondary market. This contingent liability is based on trends in repurchase and indemnification requests, actual loss experience, information requests, known and inherent risks in the sale of loans in the secondary market and current economic conditions. We record losses resulting from the repurchase of loans previously sold in the secondary market, as well as adjustments to estimates of future probable losses, as part of its MBR in the period incurred. The reserve for probable losses was $5.3 million at December 31, 2017 , compared to $6.5 million at December 31, 2016 .
All other categories of noninterest income-other fees for customer services, insurance commissions, (loss) gain on investment securities, bank-owned life insurance, rental income, gain on sale of branch offices (in 2016), gain on sale of closed branch offices and other assets (in 2015) and other noninterest income-totaled $27.1 million in 2017 , $18.9 million in 2016 and $8.9 million in 2015 . (Loss) gain on investment securities for 2017 included the loss incurred on the sales of investment securities late in the fourth quarter of 2017 as part of our treasury and tax management objectives following the signing of the Tax Cuts and Jobs Act. Other fees for customer services include revenue from safe deposit boxes, credit card referral fees, wire transfer fees, letter of credit fees and other fees for services. The increase in all other categories of noninterest income during 2017 , compared to 2016 and 2015 , was largely attributable to incremental revenue resulting from the impact of our merger with Talmer.

71


Operating Expenses
The following table presents the major categories of operating expenses:
 
Years Ended December 31,
(Dollars in thousands)
2017
 
2016
 
2015
Operating expense
 
 
 
 
 
Salaries and wages
$
179,992

 
$
135,407

 
$
104,490

Employee benefits
33,836

 
29,806

 
23,430

Occupancy
30,554

 
23,525

 
18,213

Equipment and software
32,248

 
24,408

 
18,569

Outside processing and service fees
35,142

 
21,199

 
15,207

FDIC insurance premiums
11,190

 
7,407

 
5,485

Professional fees
11,507

 
5,832

 
4,842

Intangible asset amortization
6,089

 
5,524

 
4,389

Advertising and marketing
5,907

 
3,740

 
3,288

Postage and express mail
5,309

 
3,777

 
3,313

Training, travel and other employee expenses
6,572

 
4,025

 
3,224

Telephone
3,704

 
2,964

 
2,608

Supplies
2,614

 
2,318

 
2,216

Donations
1,775

 
1,951

 
1,375

Credit-related expenses
5,772

 
(2,701
)
 
632

Merger expenses
8,522

 
61,134

 
7,804

Restructuring expenses
19,880

 

 

Impairment of federal historic income tax credits
9,252

 

 

Other
12,129

 
8,102

 
4,809

Total operating expenses
$
421,994

 
$
338,418

 
$
223,894

Operating expenses, core(non-GAAP) (1)(2)
$
384,340

 
$
277,284

 
$
216,090

Full-time equivalent staff (at December 31)
3,010

 
3,261

 
2,116

Average assets
$18,465,156
 
$12,037,155
 
$8,481,228
Efficiency ratio - GAAP
60.1
%
 
67.2
%
 
63.2
%
Efficiency ratio - adjusted non-GAAP (2)
51.9
%
 
54.4
%
 
58.7
%
Total operating expenses as a percentage of total average assets
2.29
%
 
2.81
%
 
2.64
%
Total operating expenses as a percentage of total average assets - adjusted non-GAAP (2)
2.08
%
 
2.30
%
 
2.55
%
(1)  
Excludes certain "significant items" defined as merger expenses, restructuring expense and impairment of income tax credits for 2017 and merger expenses for 2016 and 2015.
(2)  
Please refer to the section entitled "Non-GAAP Financial Measures" for a reconciliation to the most directly comparable GAAP financial measure.

Total operating expenses were $422.0 million in 2017 , $338.4 million in 2016 and $223.9 million in 2015 . Operating expenses included $28.4 million of aggregate merger and restructuring expenses and $9.3 million of impairment taken on historic federal income tax credits placed into service in 2017 , explained further below, each noted as significant items for 2017, and $61.1 million of merger expenses in 2016 and $7.8 million of merger expenses in 2015 each noted as significant items for 2016 and 2015. Operating expenses, core, a non-GAAP financial measure that excludes these significant items for each applicable period, was $384.3 million in 2017 , an increase of $107.1 million , or 38.6% , over operating expenses, core, of $277.3 million in 2016 , due largely to incremental operating costs associated with our merger with Talmer. Operating expenses, core, increased $61.2 million , or 28.3% , in 2016 , compared to 2015 , due largely to a combination of incremental operating costs associated with our merger with Talmer and our acquisitions of Lake Michigan and Monarch.

72


Restructuring expenses of $19.9 million in 2017 were incurred as a result of our restructuring efforts that took place during the second half of the year. The restructuring efforts included an approximate 7% net reduction in total employees, the consolidation of 25 branches, the discontinuation of our title insurance services, which was operating with approximately breakeven financial results, and a reduction of resources devoted to indirect auto lending, The restructuring efforts produced more than $20 million of annualized savings, while half, or more, is planned to be reinvested in the hiring of new commercial bankers and key operational staff as well as making investment to enhance our core operating systems. Restructuring expenses primarily included $14.0 million of severance and retirement related expenses and $5.1 million of occupancy expense. There were no restructuring expenses in 2016 or 2015 .
Impairment of federal historic income tax credits of $9.3 million in 2017 was a result of federal historic tax credits placed into service. The $9.3 million of impairment, or $6.0 million net of tax, is more than offset by the benefit received on the same tax credits which resulted in a reduction of income tax expense of $7.9 million . There were no such impairment of federal historic tax credits in 2016 or 2015.
Salaries and wages were $180.0 million in 2017 , $135.4 million in 2016 and $104.5 million in 2015 . Salaries and wages expense increased $44.6 million , or 32.9% , in 2017 , compared to 2016 , and increased $30.9 million , or 29.6% , in 2016 , compared to 2015 . The increases in both 2017 and 2016 were due primarily to incremental costs associated with our merger with Talmer in addition to merit increases and market-based salary adjustments that took effect at the beginning of each year. Performance-based compensation expense was $33.8 million in 2017 , compared to $21.8 million in 2016 and $17.5 million in 2015 .
Employee benefits expense was $33.8 million in 2017 , $29.8 million in 2016 and $23.4 million in 2015 . Employee benefits expense increased $4.0 million , or 13.5% , in 2017 , compared to 2016 , due primarily to incremental costs associated with our merger with Talmer. Employee benefits expense increased $6.4 million , or 27.2% , in 2016 , compared to 2015 , due primarily to incremental costs associated with our merger and acquisition transactions, partially offset by lower pension plan expenses. Pension plan expense was a benefit of $1.5 million in 2017 , compared to expenses of $0.1 million in 2016 and $1.6 million in 2015 . The decrease in pension plan expense was largely attributable to changes in the pension plan's projected benefit obligations due to an amendment to the Chemical Financial Corporation Employees’ Pension Plan effective September 30, 2017 to cease accruing additional benefits.
Our total compensation expenses, which include salaries and wages and employee benefits, as a percentage of total operating expenses were 50.7% in 2017 , 48.8% in 2016 and 57.1% in 2015 .
Occupancy expense was $30.6 million in 2017 , $23.5 million in 2016 and $18.2 million in 2015 . Occupancy expense increased $7.0 million , or 30% , in 2017 , compared to 2016 , and increased $5.3 million , or 29% , in 2016 , compared to 2015 , primarily due to incremental operating costs associated with our merger with Talmer, partially offset by the consolidation of branches in 2017 as part of our restructuring efforts. Occupancy expense included depreciation expense on buildings of $6.9 million in 2017 , $5.5 million in 2016 and $4.8 million in 2015 .
Equipment and software expense was $32.2 million in 2017 , $24.4 million in 2016 and $18.6 million in 2015 . Equipment and software expense increased $7.8 million , or 32% , in 2017 , compared to 2016 , and increased $5.8 million , or 31.4% , in 2016 , compared to 2015 , due primarily to incremental operating costs associated with our merger with Talmer. Equipment and software expense included depreciation expense of $10.9 million in 2017 , compared to $7.7 million in 2016 and $6.2 million in 2015 .
Outside processing and service fees are primarily comprised of amounts paid to third-party vendors related to the outsourcing of certain day-to-day functions that are integral to our ability to provide services to its customers, including such things as our debit card, electronic banking and wealth management platforms. Outside processing and service fees were $35.1 million in 2017 , $21.2 million in 2016 and $15.2 million in 2015 . Outside processing and service fees increased $13.9 million , or 66% , in 2017 , compared to 2016 , and increased $6.0 million , or 39.4% , in 2016 , compared to 2015 , due largely to incremental operating costs associated with our merger with Talmer.
FDIC insurance premiums were $11.2 million in 2017 , $7.4 million in 2016 and $5.5 million in 2015 . The increase in FDIC insurance premiums in 2017 , compared to 2016 , and the increase in 2016 , compared to 2015 , was attributable to an increase in our assessment base, which consists of average consolidated total assets less average Tier 1 capital, largely resulting from our merger with Talmer, which was partially offset by reductions in our assessment rate resulting from improvement in earnings and the overall credit quality of our loan portfolio.
Professional fees were $11.5 million in 2017 , $5.8 million in 2016 and $4.8 million in 2015 . Professional fees increased $5.7 million , or 97% , in 2017 , compared to 2016 , and increased $1.0 million , or 20.4% , in 2016 , compared to 2015 , primarily due to incremental operating costs associated with the merger with Talmer and additional legal fees incurred in defense of various litigation matters.
Credit-related expenses are comprised of other real estate (ORE) net costs and loan collection costs. ORE net costs are comprised of costs to carry ORE, such as property taxes, insurance and maintenance costs, fair value write-downs after a property

73


is transferred to ORE and net gains/losses from the disposition of ORE. Loan collection costs include legal fees, appraisal fees and other costs recognized in the collection of loans with deteriorated credit quality and in the process of foreclosure. Credit-related expenses were $5.8 million in 2017 , a net benefit of $2.7 million in 2016 and an expense of $0.6 million in 2015 . Credit-related expenses increased $8.5 million in 2017 , compared to 2016 , primarily due to a lower net gain on sale of ORE and an increase in incremental operating costs associated with additional properties added in our merger with Talmer. Credit-related expenses decreased $3.3 million in 2016 , compared to 2015 , due to $2.0 million in higher net gains on the sale of ORE properties and a reduction of $0.9 million in ORE operating and loan collection costs. We recognized net gains on the sale of ORE properties of $1.4 million in 2017 , $4.7 million in 2016 and $2.7 million in 2015 . ORE operating and loan collection costs were $6.7 million in 2017 , $3.0 million in 2016 and $3.3 million in 2015 .
All other categories of operating expenses totaled $44.1 million in 2017 , $32.4 million in 2016 and $25.2 million in 2015 . All other categories of operating expenses increased $11.7 million , or 36% , in 2017 , compared to 2016 , and increased $7.2 million , or 28.5% , in 2016 , compared to 2015 , due largely to incremental costs associated with our merger with Talmer.
Our efficiency ratio, which measures total operating expenses divided by the sum of net interest income (FTE) and noninterest income, was 60.1% in 2017 , 67.2% in 2016 and 63.2% in 2015 . Our adjusted efficiency ratio, a non-GAAP financial measure that excludes merger expenses, restructuring expenses, the change in fair value in loan servicing rights, amortization of intangibles, impairment of historic income tax credits, net interest income FTE adjustment, gains on sales of branches, loss/gain from sale of investment securities and closed branch locations, was 51.9% in 2017 , 54.4% in 2016 and 58.7% in 2015 . Please refer to the section entitled "Non-GAAP Financial Measures."
Income Taxes
During the fourth quarter 2017 , "H.R.1", referred to as the "Tax Cuts and Jobs Act" was signed into law. The Tax Cuts and Jobs Act, among other items, reduces the corporate income tax rate from a maximum rate of 35% to a flat tax rate of 21% effective January 1, 2018. Accounting guidance requires the effects of changes in tax law be recognized and recorded in the interim period in which the law is enacted. As such, our deferred tax assets and liabilities which were previously valued at a federal rate of 35% were revalued to the current enacted federal tax rate of 21% . The impact of the Tax Cuts and Jobs Act resulted in a $46.7 million increase to income tax expense related to continuing operations as a result of the revaluation of the net deferred tax asset of $46.0 million and an acceleration of amortization expense on the low income housing tax credit investment portfolio of $0.7 million.
In addition to the reduction in the statutory corporate income tax rate and revaluation of deferred taxes, the Tax Cuts and Jobs Act provides for several additional provisions that may impact us in future years, including the following:
FDIC Insurance Premiums: The new law limits the amount of FDIC insurance premiums a bank with over $10 billion in consolidated assets may take as a deduction for tax purposes.
Employee Compensation: The Act eliminates certain performance-based exceptions to IRC Section 162(m) for publicly-held corporations. This new provision also clarifies the definition of a "covered person" falling under the limitations defined in IRC Section 162(m).
Business Meals and Entertainment Expenses: Certain provisions governing the deductibility of business meals and entertainment expenses, whether partially or in full, have changed or been eliminated.
Acquired Asset Expensing: The Act provides for immediate expensing of the full cost of certain qualified business assets, in this case both new and used property, placed in service on or after September 27, 2017 through January 1, 2023.
Corporate Alternative Minimum Tax: The new law prospectively repeals the corporate alternative minimum tax (AMT) and allows for the use of any previously recorded AMT credit carryovers against future taxable income. Unused AMT credit carryover may become partially or fully refundable over multiple years from 2018 to 2022.
Our effective federal income tax rate was 41.7% in 2017 , 28.0% in 2016 and 29.9% in 2015 . The fluctuations in our effective federal income tax rate reflect changes each year in the proportion of interest income exempt from federal taxation, nondeductible transaction costs and other nondeductible expenses relative to pretax income and tax credits. The increase in our effective federal income tax rate in 2017 , compared to 2016 , was primarily due to the $46.7 million charge to income tax expense from continuing operations resulting from the impact of the Tax Cuts and Jobs Act discussed previously. Additionally, the increase was also impacted by $7.9 million of tax benefit received from federal historic tax credits placed into service during 2017 and growth in lending on real estate projects that receive either low income housing or historic tax credits. The income tax benefit

74


from the federal historic tax credit placed into service were partially offset by impairment recorded on the same tax credits included within other operating expenses.
The decrease in the effective federal income tax rate in 2016 , compared to 2015 , was due primarily to an increase in available tax credits resulting from investments in qualified affordable housing and other tax credit projects obtained as part of our Lake Michigan transaction, tax benefits attributable to share-based compensation payments and additional tax-exempt interest income obtained through our merger with Talmer. See Note 16 to our Consolidated Financial Statements for additional details on income taxes. We had no uncertain tax positions during the three years ended December 31, 2017 .
Liquidity
Liquidity risk is the potential that we will be unable to meet our obligations as they come due because of an inability to liquidate assets or obtain adequate funding (referred to as "funding liquidity risk") or that we cannot easily unwind or offset specific exposures without significantly lowering market prices because of inadequate market depth or market disruptions (referred to as "market liquidity risk").
Funding liquidity risk is managed to ensure stable, reliable and cost-effective sources of funds are available to satisfy deposit withdrawals and lending and investment opportunities. The ability of a financial institution to meet its current financial obligations is a function of its balance sheet structure, its ability to liquidate assets and its access to alternative sources of funds. Our funding needs are managed by maintaining a level of liquid funds through our asset/liability management process. Our largest sources of liquidity on a consolidated basis are our deposits from consumer, business and municipal customers within our local markets, principal payments on loans, maturing investment securities, cash held at the FRB and unpledged investment securities available-for-sale. Total deposits increased $0.77 billion during 2017 , compared to 2016, and increased $5.42 billion during 2016 , compared to 2015. The increase in deposits during 2017 was primarily due to growth in customer deposits, which includes noninterest-bearing demand deposits, savings deposits and time deposits, of $644.3 million , partially offset by a decrease in interest-bearing demand deposits of $101.4 million . The increase in deposits in 2016 was primarily attributable to $5.29 billion of deposits acquired in our merger with Talmer, which included $403.2 million of brokered deposits. Our loan-to-deposit ratio increased to 100.7% at December 31, 2017 from 98.3% at December 31, 2016 as a result of loans increasing $1.16 billion , or 9.0% , during 2017 . We had $143.7 million of cash deposits held at the FRB at December 31, 2017 , compared to $52.1 million at December 31, 2016 . At December 31, 2017 , we had unpledged investment securities available-for-sale with an amortized cost of $782.5 million and available unused wholesale sources of liquidity, including FHLB advances and borrowings from the discount window of the FRB.
Chemical Bank is a member of the FHLB and as such has access to short-term and long-term advances from the FHLB that are generally secured by residential mortgage first lien loans. The Corporation had short-term and long-term FHLB advances outstanding of $2.3 billion at December 31, 2017 . Additional borrowing availability from the FHLB, which is subject to certain requirements, was $193.5 million at December 31, 2017 . The Corporation can also borrow from the FRB's discount window to meet short-term liquidity requirements. These borrowings are required to be secured by investment securities and/or certain loan types, with each category of assets carrying various borrowing capacity percentages. At December 31, 2017 , we maintained an unused borrowing capacity of $114.0 million with the FRB's discount window based upon pledged collateral as of that date. We also had the ability to borrow an additional $425.0 million of federal funds from multiple third-party financial institutions at December 31, 2017 . In addition, we have a credit agreement of $145.0 million consisting of a $125.0 million term line-of-credit and a $20.0 million revolving line-of-credit. The $20.0 million revolving line-of-credit and $105.0 million of the term line of credit was available for use at December 31, 2017 . It is management's opinion that our borrowing capacity could be expanded, if deemed necessary, as we have additional borrowing capacity available at the FHLB and we have a significant amount of additional assets that could be used as collateral at the FRB's discount window.
We manage our liquidity position to provide the cash necessary to pay dividends to shareholders, invest in new subsidiaries, enter new banking markets, pursue investment opportunities and satisfy other operating requirements. Our primary source of liquidity is dividends from Chemical Bank.
Federal and state banking laws place certain restrictions on the amount of dividends that a bank may pay to its parent company. During the year ended December 31, 2017 , Chemical Bank paid $165.0 million in dividends to the Corporation, and the Corporation paid cash dividends to shareholders of $78.5 million . During 2016 , Chemical Bank paid $110.5 million in dividends to the Corporation and the Corporation paid cash dividends to shareholders of $49.4 million . The earnings of Chemical Bank are the principal source of funds to pay cash dividends to our shareholders. Chemical Bank had net income of $162.7 million during the year ended December 31, 2017 , compared to net income of $129.1 million during the year ended December 31, 2016 . Over the long term, cash dividends to shareholders are dependent upon earnings, capital requirements, regulatory restraints and other factors affecting Chemical Bank.

75


The following liquidity ratios compare certain assets and liabilities to total deposits or total assets.
 
 
December 31,
 
 
2017
 
2016
 
2015
Investment securities available-for-sale to total deposits
 
14.4
%
 
9.6
%
 
7.4
%
Loans to total deposits (1)
 
100.7

 
98.3

 
93.8

Interest-earning assets to total assets
 
88.6

 
87.4

 
91.3

Interest-bearing deposits to total deposits
 
72.7

 
74.0

 
74.1

(1)  
For liquidity purposes, securities sold under agreements to repurchase with customers are treated similarly to deposits and are included in this calculation.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
Market risk is the risk to a financial institutions' condition resulting from adverse movements in market rates or prices, including, but not limited to, interest rates, foreign exchange rates, commodity prices, or equity prices. Interest rate risk, a form of market risk, is the current and prospective risk to earnings or capital arising from movement in interest rates. Interest rate risk is due to the difference in the repricing and maturity dates between financial assets and funding sources, as well as changes in the relationship between benchmark rate indices used to reprice various assets and liabilities, product options available to customers, competitive pressures and other variables. Our net interest income is largely dependent upon the effective management of interest rate risk. Our goal is to avoid a significant decrease in net interest income, and thus an adverse impact on our profitability in periods of changing interest rates. Sensitivity of earnings to interest rate changes arises when yields on assets change differently from the interest costs on liabilities. Interest rate sensitivity is determined by the amount of interest-earning assets and interest-bearing liabilities repricing within a specific time period and the magnitude by which interest rates change on the various types of interest-earning assets and interest-bearing liabilities. The management of interest rate sensitivity includes monitoring the maturities and repricing opportunities of interest-earning assets and interest-bearing liabilities. Our interest rate risk is managed through policies and risk limits approved by the boards of directors of the Corporation and Chemical Bank and an Asset and Liability Committee ("ALCO"). The ALCO, which is comprised of executive and senior management from various areas of the Corporation and Chemical Bank, including finance, lending, investments and deposit gathering, meets regularly to execute asset and liability management strategies. The ALCO establishes guidelines and monitors the sensitivity of earnings to changes in interest rates. The goal of the ALCO process is to manage the impact on net interest income and the net present value of future cash flows of probable changes in interest rates within authorized risk limits.
The primary technique we utilize to measure our interest rate risk is simulation analyses. Simulation analyses forecast the effects on the balance sheet structure and net interest income under a variety of scenarios that incorporate changes in interest rates, the shape of the U.S. Treasury yield curve, interest rate relationships and the mix of assets and liabilities and loan prepayments. These forecasts are compared against net interest income projected in a stable interest rate environment. While many assets and liabilities reprice either at maturity or in accordance with their contractual terms, several balance sheet components demonstrate characteristics that require an evaluation to more accurately reflect their repricing behavior. Key assumptions in the simulation analysis include prepayments on loans, probable calls of investment securities, changes in market conditions, loan volumes and loan pricing, deposit sensitivity and customer preferences. These assumptions are inherently uncertain as they are subject to fluctuation and revision in a dynamic environment. As a result, the simulation analysis cannot precisely forecast the impact of rising and falling interest rates on net interest income. Actual results will differ from simulated results due to many other factors, including changes in balance sheet components, interest rate changes, changes in market conditions and management strategies.
Our interest rate sensitivity is estimated by first forecasting the next twelve months of net interest income under an assumed environment of constant market interest rates. Next, we compare the results of various simulation analyses to the constant interest rate forecast (base case). At December 31, 2017 and 2016 , we projected the change in net interest income during the next twelve months assuming short-term market interest rates were to uniformly and gradually increase or decrease by up to 200 basis points in a parallel fashion over the entire yield curve during the same time period. Additionally, we projected the change in net interest income of an immediate 400 basis point increase in market interest rates at December 31, 2017 and 2016 . We did not project an immediate 400 basis point decrease in interest rates as the likelihood of a decrease of this size was considered unlikely given prevailing interest rate levels. These projections were based on our assets and liabilities remaining static over the next twelve months, while factoring in probable calls and prepayments of certain investment securities and residential mortgage and consumer loans. The ALCO regularly monitors our forecasted net interest income sensitivity to ensure that it remains within established limits.

76


A summary of our interest rate sensitivity at December 31, 2017 and 2016 follows:
 
Gradual Change
 
Immediate
Change
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Twelve month interest rate change projection (in basis points)
-200
 
-100
 
 
+100
 
+200
 
+400
Percent change in net interest income vs. constant rates
(3.6
)%
 
(1.2
)%
 
%
 
0.9
 %
 
(2.1
)%
 
(4.2
)%
December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
Twelve month interest rate change projection (in basis points)
-200
 
-100
 
0
 
+100
 
+200
 
+400
Percent change in net interest income vs. constant rates
(3.9
)%
 
(0.9
)%
 
%
 
(1.4
)%
 
(2.6
)%
 
(6.8)%
At December 31, 2017 , our model simulations projected that 200 and 400 basis point increases in interest rates would result in negative variances in net interest income of 2.1% and 4.2% , respectively, while the 100 basis point increase would result in a positive variance in net interest income of 0.9% , relative to the base case over the next twelve-month period. At December 31, 2017 , our model simulations also projected that decreases in interest rates of 100 and 200 basis points would result in negative variances in net interest income of 1.2% and 3.6% , respectively, relative to the base case over the next twelve-month period. At December 31, 2016 , the model simulations projected that 100, 200 and 400 basis point increases in interest rates would result in negative variances in net interest income of 1.4% , 2.6% and 6.8% , respectively, relative to the base case over the next twelve-month period, while decreases in interest rates of 100 and 200 basis points would result in negative variances in net interest income of 0.9% and 3.9% , respectively, relative to the base case over the next twelve-month period. The likelihood of a decrease in interest rates beyond 100 basis points at December 31, 2017 and 2016 was considered to be unlikely given prevailing interest rate levels.
Our model simulations at December 31, 2017 for a 200 basis point increase in interest rates resulted in a negative variance in net interest income, relative to the base case, primarily due to our deployment of excess cash and maturing variable-rate investment securities into fixed-rate loans during 2017 . While the model simulations projected a negative variance for a 200 basis point increase, our net interest income is still projected to be higher if interest rates were to rise 200 basis points due to the higher yield being earned on the funds deployed into loans compared to maintaining these funds at the FRB earning 25-50 basis points or investing in lower yielding variable-rate investment securities. The model simulations at December 31, 2017 for an immediate 400 basis point increase in interest rates also resulted in a negative variance in net interest income, relative to the base case, due to the loan portfolio being primarily comprised of fixed-rate loans, while a majority of our customer deposit accounts are interest-rate sensitive.


77


Item 8. Financial Statements and Supplementary Data.


Report of Independent Registered Public Accounting Firm
The Shareholders and Board of Directors
Chemical Financial Corporation:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated statements of financial position of Chemical Financial Corporation and subsidiaries (the Corporation) as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income, changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Corporation as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Corporation’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 28, 2018 expressed an unqualified opinion on the effectiveness of the Corporation’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Corporation’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Corporation in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ KPMG LLP

We have served as the Corporation's auditor since 2006.

Detroit, Michigan
February 28, 2018


78


Chemical Financial Corporation
Consolidated Statements of Financial Position
 
(Dollars in thousands, except per share data)
 
December 31, 2017
 
December 31, 2016
Assets
 
 
 
 
Cash and cash equivalents:
 
 
 
 
Cash and cash due from banks
 
226,003

 
$
237,758

Interest-bearing deposits with the Federal Reserve Bank and other banks
 
229,988

 
236,644

Total cash and cash equivalents
 
455,991

 
474,402

Investment securities:
 
 
 
 
Available-for-sale, at fair value
 
1,963,546

 
1,234,964

Held-to-maturity, at amortized cost (fair value of $662,906 and $608,531, respectively)
 
677,093

 
623,427

Total investment securities
 
2,640,639

 
1,858,391

Loans held-for-sale, at fair value
 
52,133

 
81,830

Loans
 
14,155,267

 
12,990,779

Allowance for loan losses
 
(91,887
)
 
(78,268
)
Net loans
 
14,063,380

 
12,912,511

Premises and equipment
 
126,896

 
145,012

Loan servicing rights ($63,841 and $48,085 measured at fair value, respectively)
 
63,841

 
58,315

Goodwill
 
1,134,568

 
1,133,534

Other intangible assets
 
34,271

 
40,211

Interest receivable and other assets
 
709,154

 
650,973

Total assets
 
$
19,280,873

 
$
17,355,179

Liabilities
 
 
 
 
Deposits:
 
 
 
 
Noninterest-bearing
 
3,725,779

 
$
3,341,520

Interest-bearing
 
9,917,024

 
9,531,602

Total deposits
 
13,642,803

 
12,873,122

Interest payable and other liabilities
 
181,203

 
134,637

Securities sold under agreements to repurchase with customers
 
415,236

 
343,047

Short-term borrowings
 
2,000,000

 
825,000

Long-term borrowings
 
372,882

 
597,847

Total liabilities
 
16,612,124

 
14,773,653

Shareholders' equity
 
 
 
 
Preferred stock, no par value:
 
 
 
 
Authorized – 2,000,000 shares at 12/31/17 and 12/31/16, none issued
 

 

Common stock, $1.00 par value per share:
 
 
 
 
Authorized — 135,000,000 shares at 12/31/17 and 100,000,000 shares at 12/31/16
 
 
 
 
Issued and outstanding — 71,207,114 shares at 12/31/17 and 70,599,133 shares at 12/31/16
 
71,207

 
70,599

Additional paid-in capital
 
2,203,637

 
2,210,762

Retained earnings
 
419,403

 
340,201

Accumulated other comprehensive loss
 
(25,498
)
 
(40,036
)
Total shareholders' equity
 
2,668,749


2,581,526

Total liabilities and shareholders' equity
 
$
19,280,873

 
$
17,355,179

See accompanying notes to Consolidated Financial Statements.

79


Chemical Financial Corporation
Consolidated Statements of Income
 
 
Year Ended December 31,
(Dollars in thousands, except per share data)
2017
 
2016
 
2015
Interest income
 
 
 
 
 
Interest and fees on loans
$
573,128

 
$
383,545

 
$
271,772

Interest on investment securities:
 
 
 
 
 
Taxable
31,496

 
10,989

 
8,786

Tax-exempt
18,343

 
12,317

 
9,073

Dividends on nonmarketable equity securities
4,924

 
1,973

 
1,648

Interest on deposits with the Federal Reserve Bank, other banks and Federal funds sold
4,244

 
1,555

 
510

Total interest income
632,135

 
410,379

 
291,789

Interest expense
 
 
 
 
 
Interest on deposits
46,727

 
23,021

 
15,406

Interest on short-term borrowings
20,321

 
1,660

 
453

Interest on long-term borrowings
7,509

 
4,617

 
1,922

Total interest expense
74,557

 
29,298

 
17,781

Net interest income
557,578

 
381,081

 
274,008

Provision for loan losses
23,300

 
14,875

 
6,500

Net interest income after provision for loan losses
534,278

 
366,206

 
267,508

Noninterest income
 
 
 
 
 
Service charges and fees on deposit accounts
35,001

 
28,136

 
25,481

Wealth management revenue
25,512

 
22,601

 
20,552

Other charges and fees for customer services
32,771

 
30,246

 
25,513

Net gain on sale of loans and other mortgage banking revenue
32,205

 
21,859

 
6,133

Net (loss) gain on sale of investment securities
(7,388
)
 
129

 
630

Net gain on sale of branch offices

 
7,391

 

Other
25,918

 
11,988

 
1,907

Total noninterest income
144,019

 
122,350

 
80,216

Operating expenses
 
 
 
 
 
Salaries, wages and employee benefits
213,828

 
165,213

 
127,920

Occupancy
30,554

 
23,525

 
18,213

Equipment and software
32,248

 
24,408

 
18,569

Outside processing and service fees
35,142

 
21,199

 
15,207

Merger expenses
8,522

 
61,134

 
7,804

Restructuring expenses
19,880

 

 

Other
81,820

 
42,939

 
36,181

Total operating expenses
421,994

 
338,418

 
223,894

Income before income taxes
256,303

 
150,138

 
123,830

Income tax expense
106,780

 
42,106

 
37,000

Net income
$
149,523

 
$
108,032

 
$
86,830

Earnings per common share:
 
 
 
 
 
Basic
$
2.11

 
$
2.21

 
$
2.41

Diluted
2.08

 
2.17

 
2.39

Cash dividends declared per common share
1.10

 
1.06

 
1.00


See accompanying notes to Consolidated Financial Statements.


80


Chemical Financial Corporation
Consolidated Statements of Comprehensive Income
 
 
Year Ended December 31,
(Dollars in thousands)
2017
 
2016
 
2015
Net Income
$
149,523

 
$
108,032

 
$
86,830

Other Comprehensive Income (Loss), Net of Tax:
 
 
 
 
 
Unrealized holding gains (losses) on securities available-for-sale arising during the period
1,269

 
(18,723
)
 
(1,952
)
Reclassification adjustment for gains and losses on realized income
7,388

 
(129
)
 
(630
)
Tax effect
(3,029
)
 
6,598

 
904

Net unrealized gains (losses) on securities available-for-sale, net of tax
5,628

 
(12,254
)
 
(1,678
)
Unrealized gains on interest rate swaps designated as cash flow hedges
4,263

 

 

Reclassification adjustment for losses included in net income
1,633

 

 

Tax effect
(2,064
)
 

 

Net unrealized gains on interest rate swaps designated as cash flow hedges, net of tax
3,832

 

 

Plan remeasurement
13,011

 
(707
)
 

Adjustment for pension and other postretirement benefits
1,752


2,630

 
7,845

Tax effect
(5,167
)
 
(673
)
 
(2,746
)
Net adjustment for pension and other postretirement benefits
9,596

 
1,250

 
5,099

Other comprehensive income (loss), net of tax
19,056

 
(11,004
)
 
3,421

Total comprehensive income, net of tax
$
168,579

 
$
97,028

 
$
90,251



See accompanying notes to Consolidated Financial Statements.


81


Chemical Financial Corporation
Consolidated Statements of Changes in Shareholders’ Equity

 
(Dollars in thousands)
Common
Stock
 
Additional
Paid in
Capital
 
Retained
Earnings
 
Accumulated Other
Comprehensive
Income (Loss)
 
Total Shareholders' Equity
Balances at December 31, 2014
$
32,774

 
$
565,166

 
$
231,646

 
$
(32,453
)
 
$
797,133

Comprehensive income
 
 
 
 
86,830

 
3,421

 
90,251

Cash dividends declared and paid of $1.00 per share
 
 
 
 
(36,918
)
 
 
 
(36,918
)
Issuance of common stock and common stock equivalents in business combinations
5,183

 
154,721

 
 
 
 
 
159,904

Net shares issued under share-based compensation plans
200

 
1,926

 
 
 
 
 
2,126

Share-based compensation expense
11

 
3,467

 
 
 
 
 
3,478

Balances at December 31, 2015
38,168

 
725,280

 
281,558

 
(29,032
)
 
1,015,974

Comprehensive income
 
 
 
 
108,032

 
(11,004
)
 
97,028

Cash dividends declared and paid of $1.06 per share
 
 
 
 
(49,389
)
 
 
 
(49,389
)
Issuance of common stock and common stock equivalents in business combinations
32,074

 
1,472,737

 
 
 
 
 
1,504,811

Net shares issued under share-based compensation plans
351

 
(701
)
 
 
 
 
 
(350
)
Share-based compensation expense
6

 
13,446

 
 
 
 
 
13,452

Balances at December 31, 2016
70,599

 
2,210,762

 
340,201

 
(40,036
)
 
2,581,526

Cumulative effect adjustment of change in accounting policy, net of tax impact (1)

 
 
 
 
3,659

 
 
 
3,659

Comprehensive income
 
 
 
 
149,523

 
19,056

 
168,579

Cash dividends declared and paid of $1.10 per share
 
 
 
 
(78,498
)
 
 
 
(78,498
)
Issuance of common stock and common stock equivalents in business combinations

 

 
 
 
 
 

Net shares issued under share-based compensation plans
608

 
(24,471
)
 
 
 
 
 
(23,863
)
Share-based compensation expense

 
17,346

 
 
 
 
 
17,346

Reclassification of certain income tax effects (2)  
 
 
 
 
4,518

 
(4,518
)
 

Balances at December 31, 2017
$
71,207

 
$
2,203,637

 
$
419,403

 
$
(25,498
)
 
$
2,668,749

(1)  
Refer to Note 1, Summary of Significant Accounting Policies and Note 9, Loan Servicing Rights, for further details on the changes in accounting policy.
(2)  
The reclassification from accumulated other comprehensive income (loss) to retained earnings was due to the early adoption of ASU 2018-02, refer to Note 1 for further details on the adoption.

See accompanying notes to Consolidated Financial Statements.


82


Chemical Financial Corporation
Consolidated Statements of Cash Flows
 
Year Ended December 31,
(Dollars in thousands)
2017
 
2016
 
2015
Cash flows from operating activities
 
 
 
 
 
Net income
$
149,523

 
$
108,032

 
$
86,830

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

Provision for loan losses
23,300

 
14,875

 
6,500

Gains on sales of loans
(31,734
)
 
(15,686
)
 
(6,354
)
Proceeds from sales of loans
838,549

 
723,521

 
228,995

Loans originated for sale
(772,968
)
 
(534,422
)
 
(220,765
)
Net losses (gains) on sale of investment securities
7,388

 
(129
)
 
(630
)
Net gains from sales/writedowns of other real estate and repossessed assets
(1,017
)
 
(5,212
)
 
(2,681
)
Depreciation of premises and equipment
17,722

 
13,270

 
11,028

Amortization of intangible assets
6,090

 
10,046

 
8,444

Additions to loan servicing rights
(8,745
)
 
(4,333
)
 
(1,476
)
Valuation change in loan servicing rights
8,880

 
(4,585
)
 
(200
)
Net amortization of premiums and discounts on investment securities
19,262

 
9,713

 
6,007

Share-based compensation expense
17,346

 
13,452

 
3,478

Deferred income tax expense
93,184

 
24,091

 
5,700

Net increase in interest receivable and other assets
(151,531
)
 
(25,606
)
 
(19,027
)
Net increase (decrease) in interest payable and other liabilities
59,760

 
(46,449
)
 
(2,800
)
Net cash from operating activities
275,009

 
280,578

 
103,049

Cash flows from investing activities
 
 
 
 
 
Investment securities — available-for-sale:
 
 
 
 
 
Proceeds from maturities, calls and principal reductions
318,952

 
248,772

 
212,051

Proceeds from sales and redemptions
409,220

 
41,446

 
40,301

Purchases
(1,480,524
)
 
(187,702
)
 

Investment securities — held-to-maturity:
 
 
 
 
 
Proceeds from maturities, calls and principal reductions
93,600

 
90,933

 
87,189

Purchases
(141,489
)
 
(206,023
)
 
(279,226
)
Net increase in loans
(1,189,865
)
 
(860,135
)
 
(493,776
)
Proceeds from sales of other real estate and repossessed assets
19,879

 
22,147

 
16,653

Purchases of premises and equipment, net of disposals
(12,852
)
 
(18,098
)
 
(8,527
)
Cash acquired, net of cash paid, in business combinations

 
325,714

 
16,551

Net cash used in investing activities
(1,983,079
)
 
(542,946
)
 
(408,784
)
Cash flows from financing activities
 
 
 
 
 
Net increase in interest- and noninterest-bearing demand deposits and savings accounts
243,110

 
672,584

 
479,386

Net increase (decrease) in time deposits
526,571

 
(550,847
)
 
(170,598
)
Net increase (decrease) in securities sold under agreements to repurchase with customers and other short-term borrowings
1,247,189

 
401,144

 
(31,268
)
Proceeds from issuance of long-term borrowings

 
375,000

 
125,000

Repayment of long-term borrowings
(224,850
)
 
(351,018
)
 
(6,000
)
Cash dividends paid
(78,498
)
 
(49,389
)
 
(36,918
)
Proceeds from directors' stock plans and exercise of stock options, net of shares withheld
3,991

 
1,572

 
2,473

Cash paid for payroll taxes upon conversion of share-based awards
(27,854
)
 
(1,065
)
 
(571
)
Net cash from financing activities
1,689,659

 
497,981

 
361,504

Net increase (decrease) in cash and cash equivalents
(18,411
)
 
235,613

 
55,769

Cash and cash equivalents at beginning of year
474,402

 
238,789

 
183,020

Cash and cash equivalents at end of year
$
455,991

 
$
474,402

 
$
238,789

Supplemental disclosures of cash flow information:
 
 
 
 
 
Interest paid
$
73,643

 
$
25,460

 
$
16,958

Net income tax payments
2,252

 
22,200

 
41,450

Non-cash activities:
 
 
 
 
 
Loans transferred to other real estate and repossessed assets
11,546

 
12,970

 
9,329

Net transfer of loans held-for-sale to loans held- for-investment
(4,150
)
 
(289
)
 

Closed branch offices transferred to other assets
13,246

 
4,846

 
2,692

Business combinations:
 
 
 
 
 
Fair value of tangible assets acquired (noncash)
420

 
6,371,781

 
1,282,420

Goodwill, loan servicing rights and other identifiable intangible assets acquired
1,034

 
908,217

 
118,744

Liabilities assumed
1,454

 
6,100,901

 
1,258,051

Common stock and stock options issued

 
1,504,811

 
159,904

See accompanying notes to Consolidated Financial Statements.

83

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017


Note 1: Summary of Significant Accounting Policies
Nature of Operations
Chemical Financial Corporation ("Corporation" or "Chemical") operates in a single operating segment — commercial banking. The Corporation is a financial holding company, headquartered in Midland, Michigan, that operates through one commercial bank, Chemical Bank. Chemical Bank operates within Michigan, Northeast Ohio and Northern Indiana as a Michigan state-chartered commercial bank. Chemical Bank operates through an internal organizational structure of seven regional banking units and offers a full range of traditional banking and fiduciary products and services to the residents and business customers in the Corporation's geographical market areas. The products and services offered by the regional banking units, through branch banking offices, are generally consistent throughout the Corporation, as is the pricing of those products and services. The marketing of products and services throughout the Corporation's regional banking units is generally uniform, as many of the markets served by the regional banking units overlap. The distribution of products and services is generally uniform throughout the Corporation's regional banking units and is achieved primarily through retail branch banking offices, automated teller machines and electronically accessed banking products.
The Corporation's primary sources of revenue are interest from its loan products and investment securities, service charges and fees from customer deposit accounts, wealth management revenue, net gain on sale of loans and other mortgage banking revenue.
Basis of Presentation and Principles of Consolidation
The accounting and reporting policies of the Corporation and its subsidiaries have been prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), Securities and Exchange Commission ("SEC") rules and interpretive releases and prevailing practices within the banking industry. The Consolidated Financial Statements of the Corporation include the accounts of the Corporation and its wholly owned subsidiaries. All significant income and expenses are recorded on the accrual basis. Intercompany accounts and transactions have been eliminated in preparing the Consolidated Financial Statements.
Use of Estimates
Management makes estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying footnotes. Estimates that are particularly susceptible to significant change include the determination of the allowance for loan losses, expected cash flows from acquired loans, income and other taxes the valuation of loan servicing rights. Actual results could differ from these estimates.
Business Combinations
Pursuant to the guidance of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 805, Business Combinations ("ASC 805"), the Corporation recognizes assets acquired, including identified intangible assets, and the liabilities assumed in acquisitions at their fair values as of the acquisition date, with the acquisition-related transaction and restructuring costs expensed in the period incurred.
See Note 2 for further information regarding the Corporation's mergers and acquisitions.
Cash and Cash Equivalents
For purposes of reporting cash flows, cash and cash equivalents include cash on hand and interest-bearing deposits held at the Federal Reserve Bank ("FRB").
Investment Securities
Investment securities include investments in debt, trust preferred and preferred stock securities. Investment securities are accounted for in accordance with ASC Topic 320, Investments — Debt and Equity Securities ("ASC 320"), which requires investments to be classified within one of three categories (trading, held-to-maturity or available-for-sale). The Corporation held no trading investment securities at December 31, 2017 or 2016 .
Designation as an investment security held-to-maturity is based on the Corporation's intent and ability to hold the security to maturity. Investment securities held-to-maturity are carried at amortized cost, adjusted for purchase price premiums and accretion of discounts. Investment securities that are not held-to-maturity are accounted for as securities available-for-sale, and are stated at estimated fair value, with the aggregate unrealized gains and losses classified as a component of accumulated other comprehensive income (loss), net of income taxes. Realized gains and losses on the sale of investment securities charges are determined using

84

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

the specific identification method and are included within noninterest income in the Consolidated Statements of Income. Premiums and discounts on investment securities are amortized over the estimated lives of the related investment securities based on the effective interest yield method and are included in interest income in the Consolidated Statements of Income.
The Corporation assesses equity and debt securities that have fair values below amortized cost basis to determine whether declines (impairment) are other-than-temporary. If the Corporation intends to sell an impaired security or it is more-likely-than-not that the Corporation will be required to sell an impaired security prior to the recovery of its amortized cost, an other-than-temporary impairment ("OTTI") write-down is recognized in earnings equal to the entire difference between the investment security's amortized cost basis and its fair value. In assessing whether OTTI exists, management considers, among other things, (i) the length of time and the extent to which the fair value has been less than cost, (ii) the financial condition and near-term prospects of the issuer, (iii) the potential for impairments in an entire industry or sub-sector and (iv) the potential for impairments in certain economically depressed geographical locations. For the years ended December 31, 2017 , 2016 and 2015 , the Corporation did not recognize OTTI.
Nonmarketable Equity Securities
The Corporation is required to hold non-marketable equity securities, comprised of Federal Home Loan Bank of Indianapolis ("FHLB") and FRB stock, as a condition of membership. These securities are accounted for at cost, which equals par or redemption value, and included in "interest receivable and other assets" on the Consolidated Statements of Financial Position. These securities do not have a readily determinable fair value as their ownership is restricted and there is no market for these securities. These securities can only be redeemed or sold at their par value and only to the respective issuing government supported institution or to another member institution. FHLB stock can only be redeemed upon giving a five year written notice and FRB stock can only be redeemed upon giving six months written notice, with no more than 25.0% eligible for redemption in any calendar year. The Corporation records these non-marketable equity securities as a component of other assets and they are periodically evaluated for impairment. Management considers these non-marketable equity securities to be long-term investments. Accordingly, when evaluating these securities for impairment, management considers the ultimate recoverability of the par value rather than recognizing temporary declines in value, if applicable. The estimated loss is recognized as a loss from equity investments in other noninterest income in the Consolidated Statements of Income. The Corporation's ownership of FHLB stock totaled $112.0 million at December 31, 2017 and $58.0 million at December 31, 2016 . The Corporation's ownership of FRB stock totaled $68.1 million at December 31, 2017 and $39.4 million at December 31, 2016 .
Loans Held for Sale
Mortgage and construction loans intended for sale in the secondary market are carried at fair value based on the Corporation's election of the fair value option. The estimated fair value of loans held for sale are based on quoted market prices for securities backed by similar types of loans, where available, or by discounting estimated cash flows using observable inputs inclusive of interest rates, prepayment speeds and loss assumptions for similar collateral. The fair value includes the servicing value of the loans as well as any accrued interest. These loans are sold both with servicing rights retained and with servicing rights released.
Originated Loans Held for Investment
Originated loans include the Corporation's entire portfolio loans held for investment, excluding loans acquired in business combinations, as further discussed below. Originated loans are stated at their principal amount outstanding, net of unearned income, charge-offs and unamortized deferred fees and costs. Loan interest income is recognized on the accrual basis. Deferred loan fees and costs are amortized over the loan term based on the level-yield method. Net loan commitment fees are deferred and amortized into fee income on a straight-line basis over the commitment period.
If a loan is transferred from the loan held for investment portfolio to the held for sale portfolio, any write-down in the carrying amount of the loan at the date of transfer is recorded as a charge-off. The loans are transferred at fair value determined using the same methods described above for held for sale loans. When loans classified as held for investment are transferred to loans held for sale due to a change in intent, cash flows associated with the loans will be classified in the Consolidated Statements of Cash Flows as operating or investing, as appropriate, in accordance with the initial classification of the loans.
The past due status of a loan is based on the loan's contractual terms. A loan is placed in nonaccrual status (accrual of interest is discontinued) when principal or interest is past due 90 days or when doubt exists as to the ultimate collection of principal or interest, unless the loan is both well-secured and in the process of collection, or earlier when, in the opinion of management, there is sufficient reason to doubt the collectibility of principal or interest. Interest previously accrued, but not collected, is reversed and charged against interest income at the time the loan is placed in nonaccrual status. Subsequent receipts of interest while a loan is in nonaccrual status are recorded as a reduction of principal. Loans are returned to accrual status when principal and interest

85

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

payments are brought current and are anticipated to be fully collectible, payments have been received consistently for a period of time (generally six months) and collectibility is no longer in doubt.
Loans Acquired in a Business Combination
Loans acquired in a business combination ("acquired loans") consist of loans acquired on August 31, 2016 in the merger with Talmer, on May 31, 2015 in the acquisition of Lake Michigan Financial Corporation ("Lake Michigan"), on April 1, 2015 in the acquisition of Monarch Community Bancorp, Inc. ("Monarch"), on October 31, 2014 in the acquisition of Northwestern Bancorp, Inc. ("Northwestern"), and on April 30, 2010 in the acquisition of O.A.K. Financial Corporation ("OAK"). Acquired loans were recorded at fair value at the date of acquisition, without a carryover of the associated allowance for loan losses related to these loans.
The Corporation accounts for acquired loans, which are recorded at fair value at acquisition using an estimate of cash flows deemed to be collectible and an accretable yield, in accordance with ASC Topic 310-30, Loans and Debt Securities Acquired with Deteriorated Credit Quality ("ASC 310-30"). ASC 310-30 allows investors to aggregate loans acquired into loan pools that have common risk characteristics and thereby use a composite interest rate and expectation of cash flows expected to be collected for the loan pools. Under the provisions of ASC 310-30, the Corporation aggregated acquired loans into pools within each merger or acquisition based upon common risk characteristics, including types of loans, commercial type loans with similar risk grades and whether loans were performing or nonperforming. A pool is considered a single unit of accounting for the purposes of applying the guidance prescribed in ASC 310-30. A loan will be removed from a pool of acquired loans only if the loan is sold, foreclosed, paid off or written off, and will be removed from the pool at the carrying value. The estimate of expected credit losses was determined based on due diligence performed by executive and senior officers of the Corporation, with assistance from third-party consultants. The Corporation estimated the cash flows expected to be collected over the life of the pools of loans at acquisition and estimates expected cash flows quarterly thereafter, based on a set of assumptions including expectations as to default rates, prepayment rates and loss severities. The Corporation must make numerous assumptions, interpretations and judgments using internal and third-party credit quality information to determine whether it is probable that the Corporation will be able to collect all contractually required payments. This is a point in time assessment and inherently subjective due to the nature of the available information and judgment involved.
The calculation of the fair value of the acquired loan pools entails estimating the amount and timing of cash flows attributable to both principal and interest expected to be collected on such loan pools and then discounting those cash flows at market interest rates. The excess of a loan pool's expected cash flows at the acquisition date over its estimated fair value is referred to as the "accretable yield," which is recognized into interest income over the estimated remaining life of the loan pool on a level-yield basis. The difference between a loan pool's contractually required principal and interest payments at the acquisition date and the cash flows expected to be collected at the acquisition date is referred to as the "nonaccretable difference," which includes an estimate of future credit losses expected to be incurred over the estimated life of the loan pool and interest payments that are not expected to be collected. Decreases to the expected cash flows in each loan pool in subsequent periods will require the Corporation to record a provision for loan losses and establish an allowance for loan loss. Improvements in expected cash flows in each loan pool in subsequent periods will result in reversing a portion of the nonaccretable difference, which is then classified as part of the accretable yield and subsequently recognized into interest income over the estimated remaining life of the loan pool.
Loans Modified Under Troubled Debt Restructurings
Loans modified under TDRs involve granting a concession to a borrower who is experiencing financial difficulty. Concessions generally include modifications to original loan terms, including changes to a loan's payment schedule, principal forgiveness, interest rate reductions, or other actions intended to minimize our economic loss and to avoid foreclosure or repossession of the collateral, if applicable, which generally would not otherwise be considered. The Corporation's TDRs include accruing TDRs, which consist of originated loans that continue to accrue interest as the Corporation expects to collect the remaining principal and interest on the loan, and nonaccrual TDRs, which include originated loans that are in a nonaccrual status and are no longer accruing interest, as the Corporation does not expect to collect the full amount of principal and interest owed from the borrower on these loans. All TDRs are accounted for as impaired loans and are included in the Corporation's analysis of the allowance for loan losses. A TDR that has been renewed by a borrower who is no longer experiencing financial difficulty and which yields a market rate of interest at the time of a renewal is no longer reported as a TDR, but only if they have been refinanced or restructured at market terms and qualify as a new loan.
Loans in the Corporation's commercial loan portfolio (comprised of commercial, commercial real estate, real estate construction and land development loans) that meet the definition of a TDR generally consist of loans where the Corporation has allowed borrowers to defer scheduled principal payments and make interest-only payments for a specified period of time at the stated interest rate of the original loan agreement or reduced payments due to a moderate extension of the loan's contractual term.

86

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

If the Corporation does not expect to collect all principal and interest on the loan, the modified loan is classified as a nonaccrual TDR and impairment is measured based on collateral values, if the loan is collateral dependent. If the Corporation does not expect to incur a loss on the loan based on its assessment of the borrowers' expected cash flows, as the pre- and post-modification effective yields are approximately the same, the loan is current and a six-month payment history has been sustained, the loan is classified as an accruing TDR. Since no loss is expected to be incurred on these loans, no additional provision for loan losses has been recognized for these loans and they continue to accrue interest at their contractual interest rate. Accruing TDRs are transferred to nonaccrual status if they become 90 days past due as to principal or interest payments or if it is probable that any remaining principal and interest payments due on the loan will not be collected in accordance with the modified terms of the loan. If accruing TDRs are deemed to be collateral dependent, they are measured based on collateral values.
Loans in the Corporation's consumer loan portfolio (comprised of residential mortgage, consumer installment and home equity loans) that meet the definition of a TDR include a concession that reduces a borrower's monthly payments by decreasing the interest rate charged on the loan for a specified period of time (generally 24 months) under a formal modification agreement. The Corporation recognizes an additional provision for loan losses related to impairment on these loans on an individual basis based on the present value of expected future cash flows discounted at the loan's original effective interest rate. These loans continue to accrue interest at their effective interest rate, which consists of contractual interest under the terms of the modification agreement in addition to an adjustment for the accretion of computed impairment. TDRs are placed on nonaccrual status if they become 90 days past due as to principal or interest payments, or sooner if conditions warrant and measure impairment based on collateral values, if the loan is collateral dependent.
Impaired Loans
Impaired loans include loans on nonaccrual status and TDRs. Loans are considered impaired when based on current information and events it is probable the Corporation will be unable to collect all amounts due in accordance with the original contractual terms of the loan agreements. Impaired loans are accounted for at the lower of the present value of expected cash flows discounted at the loan's original effective interest rate or the estimated fair value of the collateral, if the loan is collateral dependent. When the present value of expected cash flows or the fair value of collateral of an impaired loan in the originated loan portfolio is less than the amount of unpaid principal outstanding on the loan, the principal balance of the loan is reduced to its carrying value through either a specific allowance for loan losses or a partial charge-off of the loan balance.
Nonperforming Loans
Nonperforming loans are comprised of loans for which the accrual of interest has been discontinued (nonaccrual loans, including nonaccrual TDRs).
Acquired loans that were classified as nonperforming loans prior to being acquired and acquired loans that are not performing in accordance with contractual terms subsequent to acquisition are not classified as nonperforming loans subsequent to acquisition because the loans are recorded in pools at net realizable value based on the principal and interest the Corporation expects to collect on such loans. They continue to earn interest from accretable yield, independent of performance in accordance of their contractual terms, and are expected to be fully collected under the new carrying values of such loans (that is, the new cost basis arising out of purchase accounting).

Allowance for Loan Losses

The allowance for credit losses ("allowance") consists of two components: the allowance for loan losses (including both the originated and acquired loan portfolios) and the reserve for unfunded credit commitments. Unfunded credit commitments include items such as letters of credit, financial guarantees and binding unfunded loan commitments. The allowance represents management’s estimate of probable credit losses inherent in the loan and credit commitment portfolios as of period end.

The allowance is calculated with the objective of maintaining a reserve sufficient to absorb losses inherent in the loan portfolio. The determination of the amount of the allowance requires significant judgment and the use of estimates related to the amount and timing of expected cash flows on acquired loans and impaired loans, collateral values on impaired loans, and estimated losses on pools of homogeneous loans based on historical loss experience, and consideration of current economic trends and conditions, all of which may be susceptible to significant change. The principal assumption used in deriving the allowance is the estimate of a loss percentage for each type of loan.

In determining the allowance for the originated loan portfolio and the related provision for loan losses, the Corporation considers three principal elements: (i) valuation allowances based upon probable losses identified during the review of impaired loans, (ii) reserves, by loan classes, on all other loans based on a six-year historical loan loss experience, loan loss trends and

87

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

giving consideration to estimated loss emergence periods, and (iii) a reserve for qualitative factors that take into consideration risks inherent in the originated loan portfolio that differ from historical loan loss experience.
    
The first element reflects the Corporation's estimate of probable losses based upon the systematic review of individually impaired loans in the originated loan portfolio. These estimates are based upon a number of objective factors, such as payment history, financial condition of the borrower and discounted collateral exposure. The Corporation measures the investment in an impaired loan based on one of three methods: the loan's observable market price; the fair value of the collateral; or the present value of expected future cash flows discounted at the loan's effective interest rate. Loans in the commercial loan portfolio that were in nonaccrual status (including nonaccrual TDRs) were valued based on the fair value of the collateral securing the loan, while accruing TDRs in the commercial loan portfolio and consumer loans were valued based on the present value of expected future cash flows discounted at the loan's effective interest rate. It is the Corporation's general policy to obtain new appraisals at initial impairment and updated when deemed necessary on nonaccrual loans in the commercial loan portfolio. Appraisals on nonaccrual loans in the consumer loan portfolio are updated at initial impairment and when deemed necessary where there is a delay in the foreclosure process. When the Corporation determines that the fair value of the collateral is less than the carrying value of an impaired loan and a portion is deemed not collectible, the portion of the impairment that is deemed not collectible is charged off (confirmed loss) and deducted from the allowance. The remaining carrying value of the impaired loan is classified as a nonperforming loan. When the Corporation determines that the fair value of the collateral is less than the carrying value of an impaired loan but believes it is probable it will recover this impairment, the Corporation establishes a valuation allowance for such impairment.
The second element is determined by assigning allocations based principally upon a six -year average of loss experience for each class of loan. Average losses may be adjusted based on current loan loss experience, delinquency trends, estimated loss emergence periods and other industry specific environmental factors. This component considers the lagging impact of historical charge-off ratios in periods where future loan charge-offs are expected to increase or decrease, trends in delinquencies and nonaccrual loans, the changing portfolio mix in terms of collateral, average loan balance, loan growth and the degree of seasoning in the various loan portfolios. Loan loss analyses are performed quarterly and certain inputs and parameters are updated as necessary to reflect the current credit environment.
The third element is based on qualitative factors that cannot be associated with a specific credit or loan class and reflects an attempt to ensure that the overall allowance appropriately reflects additional losses that are inherent in the Corporation's loan portfolio. Determination of the probable losses inherent in the portfolio, which are not necessarily captured by the allocation methodology discussed above, involves the exercise of judgment. This qualitative portion of the allowance is judgmentally determined and generally serves to compensate for the uncertainty in estimating inherent losses, particularly in times of changing economic conditions, and also considers the inherent judgment associated with risk rating commercial loans. The qualitative portion of the allowance also takes into consideration, among other things, economic conditions within our geographic areas and nationwide, including unemployment levels, industry-wide and Corporation specific loan delinquency rates, changes in composition of and growth in the Corporation's loan portfolio and changing commercial and residential real estate values.

Consumer loans secured by real estate are charged-off to the estimated fair value of the collateral when a loss is confirmed or at 180 days past due, whichever is sooner. Loss confirming events include, but are not limited to, bankruptcy (unsecured), continued delinquency, foreclosure or receipt of an asset valuation indicating a collateral deficiency and the asset is the sole source of repayment. For consumer loans not secured by real estate, the charge-off is taken upon confirmation or 120 days past due.

Commercial loans are evaluated on a loan level basis and either charged-off or written down to net realizable value if a loss confirming event has occurred. Loss confirming events include, but are not limited to, bankruptcy (unsecured), continued delinquency, foreclosure, or receipt of an asset valuation indicating a collateral deficiency and that asset is the sole source of repayment.

Although the Corporation allocates portions of the allowance to specific loans and loan types, the entire allowance attributable to originated loans is available for any loan losses that occur in the originated portfolio. Loans that are deemed not collectible are charged off and reduce the allowance. The provision for loan losses and recoveries on loans previously charged off increase the allowance. Collection efforts may continue and recoveries may occur after a loan is charged off.

Acquired loans are aggregated into pools based upon common risk characteristics. An allowance may be recorded related to an acquired loan pool if it experiences a decrease in expected cash flows, as compared to those projected at the acquisition date. On a quarterly basis, the expected future cash flow of each pool is estimated based on various factors, including changes in property values of collateral dependent loans, default rates, loss severities and prepayment speeds. Decreases in estimates of expected cash

88

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

flows within a pool generally result in a charge to the provision for loan losses and a corresponding increase in the allowance allocated to acquired loans for the particular pool. Increases in estimates of expected cash flows within a pool generally result in a reduction in the allowance allocated to acquired loans for the particular pool, if applicable, and then an adjustment to the accretable yield for the pool, which will increase amounts recognized in interest income in subsequent periods.

Various regulatory agencies, as an integral part of their examination processes, periodically review the allowance. Such agencies may require additions to the allowance, based on their judgment, reflecting information available to them at the time of their examinations.

Mortgage Banking Operations

The Corporation generally sells conforming long-term fixed interest rate mortgage loans it originates in the secondary market. Gains on the sales of these loans are determined using the specific identification method. The Corporation sells residential mortgage loans in the secondary market on either a servicing retained or released basis.

The Corporation elected the fair value measurement option, as prescribed by ASC Topic 820, Fair Value Measurements and Disclosures ("ASC 820"), for all residential mortgage loans held-for-sale originated on or after July 1, 2012. This election allows for a more effective offset of the changes in fair value of residential mortgage loans held-for-sale and the derivative instruments used to economically hedge them without having to apply complex hedge accounting provisions. Residential mortgage loans held-for-sale are carried at fair value, with changes in fair value recorded through earnings. Residential mortgage loan commitments, forward commitments, are generally entered into at the time customer applications are accepted to protect the value of the mortgage loans from increases in market interest rates during the period held and are generally settled with the investor in the secondary market within 90 days after entering into the forward commitment.

Forward loan commitments are accounted for as derivatives and recorded at fair value, with changes in fair value recorded through earnings. The Corporation recognizes revenue associated with the expected future cash flows of servicing loans for loans held-for-sale at the time a forward loan commitment is made to originate a held-for-sale loan, as required under SEC Staff Accounting Bulletin No. 109, Written Loan Commitments Recorded at Fair Value through Earnings.

The Corporation purchases and originates loans for sale to the secondary market and sell the loans on either a servicing retained or servicing-released basis. If we retain the right to service the loan, a loan servicing rights ("LSRs") is created at the time of sale which is recorded at fair value. Effective January 1, 2017, the Corporation elected to account for all LSRs previously accounted for under the lower of cost or fair value method under the fair value method. Management believes this election will provide more comparable results to peers as many of those within our industry group account for loan servicing rights under the fair value method. The change in accounting policy in the first quarter of 2017 resulted in a cumulative adjustment to increase retained earnings in the amount of $3.7 million , net of taxes.

LSRs are established and recorded at the estimated fair value by calculating the present fair value of estimated future net servicing cash flows. To determine the fair value of LSRs, the Corporation uses an independent third party valuation model requiring the incorporation of assumptions that market participants would use in estimating future net servicing income, which include estimates of prepayment speeds, discount rate, cost to service and escrow account earnings. Changes in the fair value of LSRs directly impact earnings. Servicing income is recognized in net gain on sale of loans and other mortgage banking revenue in the Consolidated Statements of Income when earned and is offset by the fair value of LSRs.

Derivatives
The Corporation enters into derivative to manage the fair value changes, exposure to fluctuations exposed to price and interest rate risk, facilitate asset/liability management, minimize the variability of future cash flows on long-term debt, and to provide a service to certain qualifying customers to help facilitate their respective risk management strategies ("customer-initiated derivatives"). All derivatives are recognized on the Consolidated Statements of Financial Condition as other assets and liabilities, as applicable, at their estimated fair value. For derivatives designated as qualified cash flow hedges, changes in the fair value of the derivatives, to the extent effective as a hedge, are recorded in accumulated other comprehensive income, net of income taxes, and reclassified into earnings concurrently with the earnings of the hedged item. For customer-initiated and mortgage banking derivatives, changes in the fair value of the derivative are recognized immediately in earnings.


89

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Interest rate swaps are entered into in order to economically hedge the effect of changes and to mitigate the impact of fluctuations in interest rate volatility to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts. These derivatives are designated as cash flow hedges. Accordingly, the effective portion of changes in the fair value of interest rate swaps are recorded in accumulated other comprehensive income on the Consolidated Statement of Financial Condition and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Any ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. The Corporation expects the hedges to remain highly effective during the remaining terms of the swaps. Interest rate swaps, are valued based on quoted prices for similar assets in an active market with inputs that are observable.
     
The Corporation utilizes interest rate derivatives to provide a service to certain qualifying customers to help facilitate their respective risk management strategies, customer-initiated derivatives. Therefore, these derivatives are not used to manage interest rate risk in the Corporation's assets or liabilities. The Corporation generally takes offsetting positions with dealer counterparties to mitigate the valuation risk of the customer-initiated derivatives. Income primarily results in the spread between the customer derivatives and offsetting dealer positions. The gains or losses derived from changes in fair value are recognized in current earnings during the period of change in other noninterest income on the Consolidated Statements of Income. The Corporation calculates a credit valuation adjustment by applying a credit spread for the counterparty or the Corporation, as appropriate, to the total expected exposure of the derivative after considering collateral and other master netting arrangements.
    
The Corporation additionally has written and purchased option derivatives consisting of instruments to facilitate an equity-linked time deposit product (the "Power Equity CD"). The Power Equity CD is a time deposit that provides the purchaser a guaranteed return of principal at maturity plus a potential equity return (a written option), while the Corporation receives a known stream of funds based on the equity return (a purchased option). The written and purchased options are mirror derivative instruments which are carried at fair value on the Consolidated Statements of Financial Position.

Premises and Equipment

Land is carried at cost. Premises and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method with useful lives ranging from 25 to 40 years for buildings and three to ten years for all other depreciable assets. Maintenance and repairs are charged to expense as incurred.

Other Real Estate Owned and Repossessed Assets

Other real estate owned ("ORE") and repossessed assets represent property acquired by the Corporation as part of an acquisition or subsequently through the loan foreclosure or repossession process, or any other resolution activity that results in partial or total satisfaction of problem loans. ORE is primarily comprised of commercial and residential real estate properties, including vacant land and development properties, obtained in partial or total satisfaction of loan obligations. The acquired properties are recorded at fair value at the date of acquisition. Losses arising at the time of acquisition of properties not acquired as part of an acquisition are charged against the allowance for loan and lease losses. Foreclosed properties are initially recorded at the lower of cost, or the estimated fair value of the property, less estimated costs to sell, based upon the property's appraised value at the date of transfer to ORE and management's estimate of the fair value of the collateral, establishing a new cost basis. Any difference between the net realizable value of the property and the carrying value of the loan is charged to the allowance for loan losses. Subsequently, all other real estate owned is valued at the lower of cost or fair value, less estimated costs to sell, based on periodic valuations performed by management, with any difference between the net realizable value of the property and the carrying value of the loan charged to the allowance for loan losses. If fair value declines subsequent to foreclosure, a valuation allowance is recorded through expense. Subsequent write-downs, for amounts not expected to be recovered, in the carrying value of other real estate owned and repossessed asset properties that may be required are expensed as incurred. Improvements to the properties may be capitalized if the improvements contribute to the overall value of the property. Improvement amounts may not be capitalized in excess of the net realizable value of the property. Any gains or losses realized at the time of disposal are reflected in other noninterest expense on the Consolidated Statements of Income. Other real estate owned and repossessed assets totaling $8.8 million and $17.2 million at December 31, 2017 and 2016 , respectively, was included in "Interest receivable and other assets" in the Consolidated Statements of Financial Position.

Goodwill

Goodwill is not amortized, but rather is subject to impairment tests annually or more frequently if triggering events occur and indicate potential impairment. The Corporation's annual goodwill impairment assessment was performed as of October 31,

90

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

2017 . The Corporation elected to utilize the qualitative assessment of goodwill impairment allowed under ASC Topic 350-20, Goodwill ("ASC 350-20") that became acceptable as a result of FASB Accounting Standards Update ("ASU") 2011-08, Testing Goodwill for Impairment. In accordance with ASC 350-20, the Corporation assessed qualitative factors to determine whether it is more likely than not that the fair value of its reporting units were less than their carrying amounts.

In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Corporation assesses relevant events and circumstances, including macroeconomic conditions, industry and market considerations, overall financial performance, changes in the composition or carrying amount of assets and liabilities, the market price of the Corporation's common stock, and other relevant factors. Based on the qualitative assessment performed, the Corporation determined that no goodwill impairment was evident as of the October 31, 2017 assessment date. The Corporation also determined that no triggering events occurred that indicated impairment from the most recent assessment date through December 31, 2017 and that the Corporation's goodwill was not impaired at December 31, 2017 .

Other Intangible Assets

Intangible assets consist of core deposit intangible assets and non-compete intangible assets. Core deposit intangible assets arose as the result of business combinations or other acquisitions and are amortized over periods ranging from 10 to 15 years , primarily on an accelerated basis, as applicable. Non-compete intangible assets arose as the result of business combinations and are amortized over the period of the non-compete agreements. Intangible assets are tested for impairment on an annual basis in accordance with ASC Topic 350, "Intangibles-Goodwill and Other."

Share-based Compensation

The Corporation grants stock options, Time-Based Restricted Stock Units ("TRSUs"), Performance-Based Restricted Stock Units ("PRSUs"), and other stock awards to certain executive and senior management employees. The Corporation accounts for share-based compensation expense using the modified-prospective transition method. Under that method, compensation expense is recognized for stock options based on the estimated grant date fair value as computed using the Black-Scholes option pricing model and the probability of issuance. The Corporation accounts for stock awards based on the closing stock price of the Corporation's common stock on the date the award is granted. The fair values of stock options, stock awards and restricted stock awards are recognized as compensation expense on a straight-line basis over the requisite service period. The Corporation accounts for PRSUs based on the closing stock price of the Corporation's common stock on the date of grant, discounted by the present value of estimated future dividends to be declared over the requisite performance or service period. The fair value of PRSUs is recognized as compensation expense over the expected requisite performance period, or requisite service period for awards with multiple performance and service conditions. The Corporation accounts for TRSUs based on the closing stock price of the Corporation's common stock on the date of grant, as these awards accrue dividend equivalents equal to the amount of any cash dividends that would have been payable to a shareholder owning the number of shares of the Corporation's common stock represented by the TRSUs. The fair value of the TRSUs is recognized as compensation expense over the requisite service period.

Bank-Owned Life Insurance

The Corporation has life insurance policies on certain key officers of Chemical Bank. The majority of the bank-owned life insurance policies of the Corporation were obtained through its acquisition of Lake Michigan and the merger with Talmer. Bank-owned life insurance is recorded at the cash surrender value, net of surrender charges, and is included within "Interest receivable and other assets" on the Consolidated Statements of Financial Position and tax-exempt income from the periodic changes in the cash surrender values are recorded as "Other noninterest income" on the Consolidated Statements of Income. The total cash surrender value of our bank owned life insurance policies totaled $147.6 million and $143.7 million at December 31, 2017 and 2016 , respectively. Bank owned life insurance income was $4.8 million , $1.8 million and $0.6 million for the years ended December 31, 2017 , 2016 and 2015 , respectively.


91

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Securities Sold Under Agreements to Repurchase with Customers

Securities sold under agreements to repurchase with customers are collateralized financing transactions and the obligations to repurchase securities sold are reflected as a liability in the accompanying Consolidated Statements of Financial Position. The dollar amount of the securities underlying the agreements remains in the Corporation's investment securities portfolio. The Corporation's securities sold under agreements to repurchase with customers are considered a stable source of liquidity, much like its core deposit base, and are generally only provided to customers that have an established banking relationship with Chemical Bank.

Short-term Borrowings

Short-term borrowings are comprised of short-term FHLB advances with original scheduled maturities of one year or less. From time to time, the Corporation may also utilized federal funds purchased, which represent unsecured borrowings from nonaffiliated third-party financial institutions, generally on an overnight basis, to cover short-term liquidity needs.

Long-term Borrowings

Long-term borrowings are comprised of securities sold under agreements to repurchase with an unaffiliated third-party financial institution, a secured non-revolving line-of-credit with an unaffiliated third-party financial institution, subordinated debentures and long-term FHLB advances. Securities sold under agreements to repurchase are collateralized financing transactions and the obligations to repurchase securities sold are reflected as a liability in the accompanying Consolidated Statements of Financial Position. The dollar amount of the securities underlying the agreements remains in the Corporation's investment securities portfolio.

FHLB advances, both short-term and long-term, are borrowings from the FHLB to fund short-term liquidity needs as well as a portion of the loan and investment securities portfolios. These advances are secured, under a blanket security agreement, by first lien residential mortgage loans with an aggregate book value equal to at least 140.0% of the FHLB advances and the FHLB stock owned by the Corporation. FHLB advances with an original maturity of one year or less are classified as short-term and FHLB advances with an original maturity of more than one year are classified as long-term.

Fair Value Measurements

Fair value for assets and liabilities measured at fair value on a recurring or nonrecurring basis refers to the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants in the market in which the reporting entity transacts such sales or transfers based on the assumptions market participants would use when pricing an asset or liability. Assumptions are developed based on prioritizing information within a fair value hierarchy that gives the highest priority to quoted prices in active markets and the lowest priority to unobservable data, such as the reporting entity's own data.

The Corporation may choose to measure eligible items at fair value at specified election dates. Unrealized gains and losses on items for which the fair value measurement option has been elected are reported in earnings at each subsequent reporting date. At December 31, 2017 and 2016 , the Corporation had elected the fair value option on all of its residential mortgage loans held-for-sale. In addition, the Corporation elected to account for loan servicing rights under the fair value method effective January 1, 2017. The Corporation has not elected the fair value option for any other financial assets or liabilities as of December 31, 2017 .

Pension and Postretirement Benefit Plan Actuarial Assumptions

The Corporation's defined benefit pension, supplemental pension and postretirement benefit obligations and related costs are calculated using actuarial concepts and measurements. Two critical assumptions, the discount rate and the expected long-term rate of return on plan assets, are important elements of expense and/or benefit obligation measurements. Other assumptions involve employee demographic factors such as retirement patterns, mortality, turnover and the rate of future compensation increases, as well as future health care costs. The Corporation evaluates all assumptions annually.

The discount rate enables the Corporation to state expected future benefit payments as a present value on the measurement date. The Corporation determined the discount rate at December 31, 2017 and 2016 by utilizing the results from a discount rate model that involves selecting a portfolio of bonds to settle the projected benefit payments of each plan.


92

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

To determine the expected long-term rate of return on defined benefit pension plan assets, the Corporation considers the current asset allocation of the defined benefit pension plan, as well as historical and expected returns on each asset class. A lower expected rate of return on defined benefit pension plan assets will increase pension expense.

The Corporation recognizes the over- or under-funded status of a plan within "Interest receivable and other assets" or "Interest payable and other liabilities" in the Consolidated Statements of Financial Position as measured by the difference between the fair value of the plan assets and the projected benefit obligation. Unrecognized prior service costs and actuarial gains and losses are recognized as a component of accumulated other comprehensive income (loss). The Corporation measures defined benefit plan assets and obligations as of December 31.

Advertising Costs

Advertising costs are expensed as incurred. Advertising and marketing expense was $5.9 million , $3.7 million and $3.3 million for the years ended December 31, 2017 , 2016 and 2015 , respectively.

Income and Other Taxes

The Corporation is subject to the income and other tax laws of the United States, the States of Michigan, Ohio and Indiana and other states where nexus has been created. These laws are complex and are subject to different interpretations by the taxpayer and the various taxing authorities. In determining the provision for income and other taxes, management must make judgments and estimates about the application of these inherently complex laws, related regulations and case law. In the process of preparing the Corporation's tax returns, management attempts to make reasonable interpretations of enacted tax laws. These interpretations are subject to challenge by the tax authorities upon audit or to reinterpretation based on management's ongoing assessment of facts and evolving case law.

The Corporation and its subsidiaries file a consolidated federal income tax return. The provision for federal income taxes is based on income and expenses, as reported in the Consolidated Financial Statements, rather than amounts reported on the Corporation's federal income tax return. The difference between the federal statutory income tax rate and the Corporation's effective federal income tax rate is primarily a function of the proportion of the Corporation's interest income exempt from federal taxation, nondeductible interest expense and other nondeductible expenses relative to pretax income and tax credits. When income and expenses are recognized in different periods for tax purposes than for book purposes, deferred tax assets and liabilities are recognized for the future tax consequences attributable to the temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Differences in the tax and book carrying amounts of assets and liabilities can also be generated when the Corporation acquires other banks or bank branches. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date of the change. On December 22, 2017, H.R.1, commonly referred to as the "Tax Cuts and Jobs Act" was signed into law. The Tax Cuts and Jobs Act, among other items, reduces the corporate income tax rate from 35% to 21%, effective January 1, 2018. As such, the Corporation completed a revaluation of the net deferred tax assets and estimated a reduction in the Corporation's deferred tax asset as of December 31, 2017 .

On a quarterly basis, management assesses the reasonableness of its effective federal tax rate based upon its estimate of taxable income and the applicable taxes expected for the full year. Deferred tax assets and liabilities are reassessed on a quarterly basis, including the need for a valuation allowance for deferred tax assets.

Uncertain income tax positions are evaluated to determine whether it is more-likely-than-not that a tax position will be sustained upon examination based on the technical merits of the tax position. If a tax position is more-likely-than-not to be sustained, a tax benefit is recognized for the amount that is greater than 50.0% likely to be realized. Reserves for contingent income tax liabilities attributable to unrecognized tax benefits associated with uncertain tax positions are reviewed quarterly for adequacy based upon developments in tax law and the status of audits or examinations. The Corporation had no contingent income tax liabilities recorded at December 31, 2017 and 2016 .

Investments in Qualified Affordable Housing Projects, Federal Historic Projects and New Market Tax Credits

The Corporation invests in qualified affordable housing projects, federal historic projects, and new market projects for the purpose of community reinvestment and obtaining tax credits. Return on the Corporation's investment in these projects comes

93

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

in the form of the tax credits and tax losses that pass through to the Corporation. The carrying value of the investments is reflected in "Interest receivable and other assets" on the Consolidated Statements of Financial Position. The Corporation utilizes the proportional amortization method to account for investments in qualified affordable housing projects and the equity method to account for investments in other tax credit projects. Management analyzes these investments for potential impairment when events or changes in circumstances indicate that it is more-likely-than-not that the carrying amount of the investment will not be realized. An impairment loss is measured as the amount by which the carrying amount of an investment exceeds its fair value.

Under the proportional amortization method, the Corporation amortizes the initial cost of the investment in proportion to the tax credits and other tax benefits. Under the equity method, the Corporation's share of the earnings or losses is included in "Other operating expenses" on the Consolidated Statements of Income. The Corporation's unfunded equity contributions relating to investments in qualified affordable housing projects, federal historic tax projects and new market projects is recorded in "Interest payable and other liabilities" on the Consolidated Statements of Financial Position.

Earnings Per Share

The Corporation applies the two-class method of computing earnings per share as the Corporation has unvested restricted stock awards which qualify as participating securities. Under this calculation, all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends are considered participating securities and earnings per share is determined according to dividends declared and participating right in undistributed earnings.

Accumulated Other Comprehensive Income (Loss)

Comprehensive income of the Corporation includes net income and adjustments to shareholders' equity for changes in unrealized gains and losses on investment securities available-for-sale and changes in the net actuarial gain/loss for the Corporation's defined benefit pension and postretirement plans, net of income taxes. The Corporation presents "Comprehensive income" as a component in the Consolidated Statements of Changes in Shareholders' Equity and the components of other comprehensive income separately in the Consolidated Statements of Comprehensive Income.

Reclassifications

Certain amounts appearing in the Consolidated Financial Statements and notes thereto for prior periods have been reclassified to conform to the current presentation. The reclassification had no effect on net income or shareholders’ equity as previously reported.

Adopted Accounting Pronouncements

Stock Compensation

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"), which simplifies the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures and statutory holding requirements, as well as classification on the statement of cash flows. ASU 2016-09 is effective for public companies for interim and annual periods beginning after December 15, 2016 with early adoption permitted for any interim or annual period. If an entity early adopts the amendments, any adjustment should be reflected as of the beginning of the fiscal year. The Corporation elected to early adopt ASU 2016-09 during the fourth quarter of 2016. All quarters during the year ended December 31, 2016 have been adjusted as a result of this adoption.

Prior to adoption of ASU 2016-09, all excess tax benefits resulting from the exercise or settlement of share-based payment transactions were recognized in additional-paid-in-capital ("APIC") and accumulated in an APIC pool, while tax deficiencies were either offset against the APIC pool or recognized in the income statement if no APIC pool was available. The new guidance eliminates additions to the APIC pool and all excess tax benefits and deficiencies are recognized as an income tax benefit or expense in the income statement prospectively. Accordingly, periods prior to January 1, 2016 have not been adjusted.

94

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Investment Securities

The Corporation elected to early adopt ASU No. 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities ("ASU 2017-08") during the second quarter of 2017. The guidance in ASU 2017-08 shortens the amortization period for certain callable debt securities that are held at a premium to the earliest call date. Debt securities held at a discount will continue to be amortized as a yield adjustment over the life of the instrument. The early adoption of ASU 2017-08 in the second quarter of 2017 did not have a material impact on the Consolidated Financial Statements.

Accumulated Other Comprehensive Income (Loss)

The Corporation elected to early adopt ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02") during the fourth quarter 2017. In February 2018, the FASB issued ASU 2018-02, which requires deferred tax liabilities and assets to be adjusted for the effect of a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date and permitted early adoption. The Corporation elected to early adopt ASU 2018-02 during the fourth quarter of 2017 and an election was made to reclassify the income tax effects of the Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The early adoption of ASU 2018-02, resulted in a $4.5 million reclassification from accumulated other comprehensive income to retained earnings related to the income tax effects of the Tax Cuts and Jobs Act.


Note 2: Mergers and Acquisitions

Merger with Talmer Bancorp, Inc.

On August 31, 2016, the Corporation completed the merger with Talmer for total consideration of $1.61 billion . As a result of the merger, the Corporation issued 32.1 million shares of its common stock based on an exchange ratio where each Talmer shareholder received 0.4725 shares of the Corporation's common stock, and $ 1.61 in cash, for each share of Talmer common stock. In conjunction with the merger, the Corporation entered into and drew on a $125.0 million credit facility, which is described in more detail in Note 15. The proceeds from the credit facility were used to pay off the Corporation's $25.0 million line-of-credit and a $ 37.5 million line-of-credit of Talmer, with the remaining proceeds used to partially fund the cash portion of the merger consideration. The Corporation incurred $8.5 million and $61.1 million of merger and acquisition-related transaction expenses during the years ended December 31, 2017 and 2016 , respectively. As a result of the merger, Talmer Bank and Trust became a wholly-owned subsidiary of the Corporation. Talmer Bank and Trust was consolidated with and into Chemical Bank during the fourth quarter of 2016.


95

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The Company determined that the merger with Talmer constitutes a business combination as defined by ASC 805. Accordingly, the assets acquired and liabilities assumed were recorded at their fair values on the date of acquisition. Fair values were determined in accordance with the guidance provided in ASC Topic 820, Fair Value Measurements, as of the merger date as presented in the following table.
(Dollars in thousands)
 
 
Consideration paid:
 
 
Stock
 
$
1,504,811

Cash
 
107,638

Total consideration
 
1,612,449

 
 
 
Fair value of identifiable assets acquired (1) :
 
 
Cash and cash equivalents
 
433,352

Investment securities:
 
 
Available-for-sale
 
808,894

Held-to-maturity
 
1,657

Loans held-for-sale
 
244,916

Loans
 
4,882,402

Premises and equipment
 
38,793

Loan servicing rights
 
42,462

Other intangible assets
 
19,088

Interest receivable and other assets (2)
 
395,539

Total identifiable assets acquired
 
6,867,103

 
 
 
Fair value of liabilities assumed (1) :
 
 
Noninterest-bearing deposits
 
1,236,902

Interest-bearing deposits
 
4,057,716

Interest payable and other liabilities (2)
 
100,936

Securities sold under agreements to repurchase with customers
 
19,704

Short-term borrowings
 
387,500

Long-term borrowings
 
299,597

Total liabilities assumed
 
6,102,355

 
 
 
Fair value of net identifiable assets acquired
 
764,748

Goodwill resulting from acquisition (2)
 
$
847,701

(1)  
All amounts were previously reported in the Corporation's Annual Report on Form 10-K for the year ended December 31, 2016, with the exception of interest receivable and other assets and interest payable and other liabilities.
(2)  
Includes adjustments to the fair value as a result of additional valuation information obtained during the third quarter of 2017, including the corresponding tax effects.

During the third quarter of 2017, prior to August 31, 2017, additional valuation information was obtained related to the fair value of certain liabilities and deferred tax assets, which resulted in an adjustment to goodwill acquired in the Talmer transaction. The adjustment recorded during the third quarter of 2017 resulted in a $1.0 million increase to the amount of goodwill recorded for the Talmer transaction.


96

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Information regarding loans accounted for under ASC 310-30 at the merger date is as follows:
(Dollars in thousands)
 
 
Accounted for under ASC 310-30:
 
 
Contractual cash flows
 
$
5,968,488

Contractual cash flows not expected to be collected (nonaccretable difference)
 
223,959

Expected cash flows
 
5,744,529

Interest component of expected cash flows (accretable yield)
 
862,127

Fair value at acquisition
 
$
4,882,402


Acquisition of Lake Michigan Financial Corporation

On May 31, 2015, the Corporation acquired all of the outstanding stock of Lake Michigan Financial Corporation (Lake Michigan) for total consideration of $187.4 million , which included stock consideration of $132.9 million and cash consideration of $54.5 million . As a result of the acquisition, the Corporation issued approximately 4.3 million shares of its common stock, based on an exchange ratio of 1.326 shares of its common stock, and paid $16.64 in cash, for each share of Lake Michigan common stock outstanding. Lake Michigan, a bank holding company which owned The Bank of Holland and The Bank of Northern Michigan, provided traditional banking services and products with five banking offices in Holland, Grand Haven, Grand Rapids, Petoskey and Traverse City, Michigan. The Bank of Holland and the Bank of Northern Michigan were consolidated with and into Chemical Bank on November 13, 2015.

At the acquisition date, Lake Michigan added total assets of $1.24 billion , including total loans of $985.5 million , and total deposits of $924.7 million to the Consolidated Statement of Financial Position. The Corporation recorded $101.1 million of goodwill, which was primarily attributable to the synergies and economies of scale expected from combining the operations of the Corporation and Lake Michigan. In addition, the Corporation recorded $8.6 million of core deposit and other intangible assets in conjunction with the acquisition.

The results of the merged Lake Michigan operations are presented in the Consolidated Financial Statements from the date of acquisition. Acquisition-related expenses associated with the Lake Michigan transaction totaled $5.5 million during 2015.

The summary computation of the purchase price, including adjustments to reflect Lake Michigan's assets acquired and liabilities assumed at fair value and the allocation of the purchase price to the net assets of Lake Michigan, is presented below.

(Dollars in thousands)
 
 
Stock
 
$
132,916

Cash
 
54,478

Total consideration
 
187,394

 
 
 
Net assets acquired:
 
 
Lake Michigan shareholders' equity
 
$
89,280

Adjustments to reflect fair value of net assets acquired:
 
 
Loans
 
(22,600
)
Allowance for loan losses
 
15,888

Premises and equipment
 
(5,031
)
Core deposit intangibles
 
8,003

Deferred tax assets, net
 
4,096

Deposits and borrowings, net
 
(3,182
)
Other assets and other liabilities
 
(121
)
Fair value of adjusted net assets acquired
 
86,333

Goodwill recognized as a result of the Lake Michigan transaction
 
$
101,061


97

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Allocation of Purchase Price

The following schedule summarizes the acquisition date fair values of assets acquired and liabilities assumed from Lake Michigan:
(Dollars in thousands)
 
 
Assets
 
 
Cash and cash equivalents
 
$
39,301

Investment securities
 
66,699

Loans
 
985,542

Premises and equipment
 
10,975

Deferred tax asset, net
 
16,715

Goodwill
 
101,061

Core deposit intangible asset
 
8,003

Bank-owned life insurance
 
23,844

Other assets
 
37,695

Assets acquired, at fair value
 
1,289,835

Liabilities
 
 
Deposits
 
924,697

Short-term borrowings
 
30,000

Other borrowings
 
124,857

Other liabilities
 
22,887

Total liabilities acquired, at fair value
 
1,102,441

Total purchase price
 
$
187,394


Information regarding loans accounted for under ASC 310-30 at the merger date is as follows:
(Dollars in thousands)
 
 
Accounted for under ASC 310-30:
 
 
Contractual cash flows
 
$
1,198,388

Contractual cash flows not expected to be collected (nonaccretable difference)
 
22,600

Expected cash flows
 
1,175,788

Interest component of expected cash flows (accretable yield)
 
190,246

Fair value at acquisition
 
$
985,542


Acquisition of Monarch Community Bancorp, Inc.

On April 1, 2015, the Corporation acquired all of the outstanding stock of Monarch Community Bancorp, Inc. (Monarch) in an all-stock transaction valued at $27.2 million . As a result of the acquisition, the Corporation issued 860,575 shares of its common stock based on an exchange ratio of 0.0982 shares of its common stock for each share of Monarch common stock outstanding. Monarch, a bank holding company, owned Monarch Community Bank, which operated five full service branch offices in Coldwater, Marshall, Hillsdale and Union City, Michigan. Monarch Community Bank was consolidated with and into Chemical Bank on May 8, 2015.

At the acquisition date, Monarch added total assets of $182.8 million , including total loans of $121.8 million , and total deposits of $144.3 million to the Consolidated Statement of Financial Position. In connection with the acquisition of Monarch, the Corporation recorded $5.3 million of goodwill, which was primarily attributable to the synergies and economies of scale expected from combining the operations of the Corporation and Monarch. In addition, the Corporation recorded $1.9 million of core deposit intangible assets in conjunction with the acquisition.    


98

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The results of the merged Monarch operations are presented in the Consolidated Financial Statements from the date of acquisition. The disclosure of Monarch's post-acquisition revenue and net income is not practical due to the combining of Monarch's operations with and into Chemical Bank during the second quarter of 2015. Acquisition-related expenses associated with the Monarch transaction totaled $2.3 million during 2015.    

The summary computation of the purchase price, including adjustments to reflect Monarch's assets acquired and liabilities assumed at fair value and the allocation of the purchase price to the net assets of Monarch is presented below.
(Dollars in thousands)
 
 
Stock
 
$
26,988

Cash
 
203

Total consideration
 
$
27,191

 
 
 
Net assets acquired:
 
 
Monarch shareholders' equity
 
$
15,270

Adjustments to reflect fair value of net assets acquired:
 
 
Loans
 
(7,150
)
Allowance for loan losses
 
2,128

Deferred tax assets, net:
 
 
Net operating loss carryforward
 
7,900

Other
 
1,826

Premises and equipment
 
(415
)
Core deposit intangibles
 
1,930

Mortgage servicing rights
 
315

Other assets and other liabilities
 
48

Fair value of adjusted net assets acquired
 
21,852

Goodwill recognized as a result of the Monarch transaction
 
$
5,339

    

99

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Allocation of Purchase Price

The following schedule summarizes the revised acquisition date estimated fair values, including the adjustments to the fair values identified and recorded from the acquisition date through December 31, 2015, of assets acquired and liabilities assumed from Monarch.
(Dollars in thousands)
 
 
Assets
 
 
Cash and cash equivalents
 
$
32,171

Loans
 
121,783

Premises and equipment
 
3,019

Deferred tax assets, net
 
 
Net operating loss carryforward
 
7,900

Other
 
2,392

Interest receivable and other assets
 
6,972

Goodwill
 
5,339

Core deposit intangibles
 
1,930

Mortgage servicing rights
 
1,284

Assets acquired, at fair value
 
182,790

Liabilities
 
 
Deposits
 
144,300

FHLB advances
 
8,000

Interest payable and other liabilities
 
3,299

Total liabilities acquired, at fair value
 
155,599

Total purchase price
 
$
27,191


Information regarding loans accounted for under ASC 310-30 at the merger date is as follows:
(Dollars in thousands)
 
 
Accounted for under ASC 310-30:
 
 
Contractual cash flows
 
$
166,797

Contractual cash flows not expected to be collected (nonaccretable difference)
 
7,100

Expected cash flows
 
159,697

Interest component of expected cash flows (accretable yield)
 
37,914

Fair value at acquisition
 
$
121,783


The outstanding contractual principal balance and the carrying amount of the Monarch acquired loan portfolio were $ 76.0 million and $ 70.8 million , respectively, at December 31, 2017 , compared to $92.4 million and $86.4 million , respectively, at December 31, 2016 .

Unaudited Pro Forma Combined Results of Operations

The following unaudited pro forma financial information presents the consolidated results of operation of the Corporation and Talmer as if the merger had occurred as of January 1, 2015 and Lake Michigan and Monarch as if the acquisitions had occurred as of January 1, 2014. The unaudited pro forma combined results of operations are presented solely for information purposes and are not intended to represent or be indicative of the consolidated results of operations that Chemical would have reported had these transactions been completed as of the dates and for the periods presented, nor are they necessarily indicative of future results. In particular, no adjustments have been made to eliminate the amount of Talmer's, Lake Michigan's or Monarch's provision for loan losses incurred prior to the acquisition date that would not have been necessary had the acquired loans been recorded at fair value as of the beginning of each period indicated. In accordance with Article 11 of SEC Regulation S-X, transaction costs directly attributable to the acquisitions have been excluded.

100

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

   
 
Years ended December 31,
    (In thousands, except per share data)
 
2017
 
2016
 
2015
Net interest and other income
 
$
701,597

 
$
492,323

 
$
654,962

Net Income
 
149,523

 
115,847

 
142,504

Earnings per share:
 
 
 
 
 
 
Basic
 
$
2.11

 
$
1.65

 
$
2.03

Diluted
 
$
2.08

 
$
1.62

 
$
2.01


Note 3: Fair Value Measurements

Fair value, as defined by GAAP, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. The price in the principal (or most advantageous) market used to measure the fair value of the asset or liability is not adjusted for transaction costs. An orderly transaction is a transaction that assumes exposure to the market for a period prior to the measurement date to allow for market activities that are usual and customary for transactions involving such assets and liabilities; it is not a forced transaction. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact and (iv) willing to transact.

The Corporation utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Investment securities — available-for-sale, loans held-for-sale, loan servicing rights and derivatives are recorded at fair value on a recurring basis. Additionally, the Corporation may be required to record other assets, such as impaired loans, goodwill, other intangible assets, other real estate and repossessed assets, at fair value on a nonrecurring basis. These nonrecurring fair value adjustments typically involve the application of lower of cost or market accounting or write-downs of individual assets.

The Corporation determines the fair value of its financial instruments based on a three-level hierarchy established by GAAP. The classification and disclosure of assets and liabilities within the hierarchy is based on whether the inputs to the valuation methodology used for measurement are observable or unobservable. Observable inputs reflect market-derived or market-based information obtained from independent sources, while unobservable inputs reflect management's estimates about market data. The three levels of inputs that may be used to measure fair value within the GAAP hierarchy are as follows:

Level 1
Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 valuations for the Corporation include U.S. Treasury securities that are traded by dealers or brokers in active over-the-counter markets. Valuations are obtained from a third-party pricing service for these investment securities.

Level 2
    Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Level 2 valuations for the Corporation include government sponsored agency securities, including securities issued by the Federal Home Loan Bank, Federal Home Loan Mortgage Corporation, Federal National Mortgage Association, Federal Farm Credit Bank, Student Loan Marketing Corporation and the Small Business Administration, securities issued by certain state and political subdivisions, residential mortgage-backed securities, collateralized mortgage obligations, corporate bonds, preferred stock and available-for-sale trust preferred securities. Valuations are obtained from a third-party pricing service for these investment securities. Additionally included in Level 2 valuations are loans held-for-sale and derivative assets and liabilities.

Level 3
Valuation is generated from model-based techniques that use at least one significant assumption not observable in the market. These unobservable assumptions reflect estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models, yield curves and similar techniques. The determination of fair value requires management judgment or estimation and generally is corroborated by external data, which includes third-party pricing services. Level 3 valuations for the Corporation include securities issued by certain state and political subdivisions, held-to-maturity trust preferred investment securities, impaired loans, goodwill, core deposit intangible assets, non-compete intangible assets, LSRs and other real estate and repossessed assets.

101

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017


A description of the valuation methodologies used for instruments measured at fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy, is set forth below. These valuation methodologies were applied to all of the Corporation's financial assets and financial liabilities carried at fair value and all financial instruments disclosed at fair value. Transfers of asset or liabilities between levels of the fair value hierarchy are recognized at the beginning of the reporting period, when applicable.

In general, fair value is based upon quoted market prices, where available. If quoted market prices are not available, fair value is based upon third-party pricing services when available. Fair value may also be based on internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be required to record financial instruments at fair value. Any such valuation adjustments are applied consistently over time. The Corporation's valuation methodologies may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values.

While management believes the Corporation's valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Furthermore, the fair value amounts may change significantly after the date of the statement of financial position from the amounts reported in the Consolidated Financial Statements and related notes.

Assets and Liabilities Recorded at Fair Value on a Recurring Basis

Investment securities: Investment securities classified as available-for-sale are recorded at fair value on a recurring basis. Fair value measurement is based upon quoted prices, if available. If quoted prices are not available, fair values are generally measured using independent pricing models or other model-based valuation techniques that include market inputs, such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, reference data and industry and economic events.

Loans held-for-sale: The Corporation has elected the fair value option for all loans held-for-sale. Accordingly, loans held-for-sale are recorded at fair value on a recurring basis. The fair values of loans held-for-sale are based on the market price for similar loans sold in the secondary market, and therefore, are classified as Level 2 valuations.

Loan servicing rights: Effective January 1, 2017, the Corporation elected to account for all LSRs under the fair value measurement method. LSRs acquired related to the merger with Talmer effective August 31, 2016 were also previously accounted for under the fair value measurement method based on accounting election. A third party valuation model is used to determine the fair value at the end of each reporting period utilizing a discounted cash flow analysis using interest rates and prepayment speed assumptions currently quoted for comparable instruments and a discount rate determined by management. Because of the nature of the valuation inputs, the Corporation classifies loan servicing rights as Level 3. Refer to Note 9, “Loan Servicing Rights”, for the assumptions included in the valuation of loan servicing rights.

Derivatives: The Corporation enters into interest rate lock commitments with prospective borrowers to be sold into the secondary market and forward commitments for the future delivery of mortgage loans to third party investors, which are carried at fair value on a recurring basis. The fair value of these commitments is based on the fair value of related mortgage loans determined using observable market data. Interest rate lock commitments are adjusted for expectations of exercise and funding. This adjustment is not considered to be a material input. The Corporation classifies interest rate lock commitments and forward contracts related to mortgage loans to be delivered for sale as recurring Level 2.
 
Derivative instruments held or issued for risk management or customer-initiated activities are traded in over-the counter markets where quoted market prices are not readily available. Fair value for over-the-counter derivative instruments is measured on a recurring basis using third party models that use primarily market observable inputs, such as yield curves and option volatilities.  The fair value for these derivatives may include a credit valuation adjustment that is determined by applying a credit spread for the counterparty or the Corporation, as appropriate, to the total expected exposure of the derivative after considering collateral and other master netting arrangements. These adjustments, which are considered Level 3 inputs, are based on estimates of current credit spreads to evaluate the likelihood of default. The Corporation assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions at both December 31, 2017 and 2016 and it was determined that the credit valuation adjustments were not significant to the overall valuation of its derivatives. As a result, the Corporation classifies

102

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

its risk management interest rate swaps designated as cash flow hedges and customer-initiated derivatives valuations in Level 2 of the fair value hierarchy.

Foreign exchange forward and option contracts are entered into primarily to accommodate the needs of the customer. These derivatives are not designated as hedging. Fair value of foreign exchange forward and option contracts are measured on a recurring basis using third party models that use primarily market observable inputs, such as yield curves and option volatilities. The Corporation classifies its foreign exchange forward and option contracts in Level 2 of the fair value hierarchy.

Written and purchased option derivatives consist of instruments to facilitate an equity-linked time deposit product (the "Power Equity CD"). The Power Equity CD is a time deposit that provides the purchaser a guaranteed return of principal at maturity plus a potential equity return, while the Corporation receives a known stream of funds based on equity returns. The written and purchased options are mirror derivative instruments which are carried at fair value on the Consolidated Statements of Financial Position. Fair value measurements for the Power Equity CD are determined using quoted prices of underlying stocks, along with other terms and features of the derivative instrument. As a result, the Power Equity CD derivatives are classified as Level 2 valuations.

Disclosure of Recurring Basis Fair Value Measurements

For assets and liabilities measured at fair value on a recurring basis, quantitative disclosures about the fair value measurements for each major category of assets and liabilities follow:
(Dollars in thousands)
 
Quoted Prices
In Active
Markets for
Identical
Assets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
December 31, 2017
 
 
 
 
 
 
 
 
Investment securities — available-for-sale:
 
 
 
 
 
 
 
 
Government sponsored agencies
 
$

 
$
202,916

 
$

 
$
202,916

State and political subdivisions
 

 
345,970

 

 
345,970

Mortgage-backed securities
 

 
150,131

 

 
150,131

Collateralized mortgage obligations
 

 
1,033,845

 

 
1,033,845

Corporate bonds
 

 
192,794

 

 
192,794

Preferred stock and trust preferred securities
 

 
37,890

 

 
37,890

Total investment securities — available-for-sale
 

 
1,963,546

 

 
1,963,546

Loans held-for-sale
 

 
52,133

 

 
52,133

Loan servicing rights
 

 

 
63,841

 
63,841

Derivative assets:
 
 
 
 
 
 
 
 
Customer-initiated derivatives
 

 
9,376

 

 
9,376

Interest rate lock commitments
 

 
1,222

 

 
1,222

Power Equity CD
 

 
2,184

 

 
2,184

Risk management derivatives
 

 
5,899

 

 
5,899

Total derivatives
 

 
18,681

 

 
18,681

Total assets at fair value
 
$

 
$
2,034,360

 
$
63,841

 
$
2,098,201

Derivative liabilities:
 
 
 
 
 
 
 
 
Customer-initiated derivatives
 
$

 
$
10,139

 
$

 
$
10,139

Forward contracts related to mortgage loans to be delivered for sale
 

 
34

 

 
34

Power Equity CD
 

 
2,184

 

 
2,184

Total derivatives
 

 
12,357

 

 
12,357

Total liabilities at fair value
 
$

 
$
12,357

 
$

 
$
12,357


103

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

(Dollars in thousands)
 
Quoted Prices
In Active
Markets for
Identical
Assets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
December 31, 2016
 
 
 
 
 
 
 
 
Investment securities — available-for-sale:
 
 
 
 
 
 
 
 
U.S. Treasury securities
 
$
5,793

 
$

 
$

 
$
5,793

Government sponsored agencies
 

 
215,011

 

 
215,011

State and political subdivisions
 

 
300,088

 

 
300,088

Residential mortgage-backed securities
 

 
272,282

 

 
272,282

Collateralized mortgage obligations
 

 
320,025

 

 
320,025

Corporate bonds
 

 
89,474

 

 
89,474

Preferred stock and trust preferred securities
 

 
32,291

 

 
32,291

Total investment securities — available-for-sale
 
5,793

 
1,229,171

 

 
1,234,964

Loans held-for-sale
 

 
81,830

 

 
81,830

Loan servicing rights
 

 

 
48,085

 
48,085

Derivative assets:
 
 
 
 
 
 
 


Customer-initiated derivatives
 

 
4,406

 

 
4,406

Forward contracts related to mortgage loans to be delivered for sale
 

 
635

 

 
635

Interest rate lock commitments
 

 
956

 

 
956

Power Equity CD
 

 
2,218

 

 
2,218

Total derivatives
 

 
8,215

 

 
8,215

Total assets at fair value
 
$
5,793

 
$
1,319,216

 
$
48,085

 
$
1,373,094

Derivative liabilities:
 
 
 
 
 
 
 
 
Customer-initiated derivatives
 

 
4,141

 

 
4,141

Power Equity CD
 

 
2,218

 

 
2,218

Total derivatives
 

 
6,359

 

 
6,359

Total liabilities at fair value
 
$

 
$
6,359

 
$

 
$
6,359


There were no transfers between levels within the fair value hierarchy during the year ended December 31, 2017 .

The following table summarizes the changes in Level 3 assets measured at fair value on a recurring basis.
 
 
Year Ended December 31,
 
 
2017
 
2016
(Dollars in thousands)
 
Loan servicing rights
Balance, beginning of period
 
$
48,085

 
$

Additions due to acquisition
 

 
42,462

Transfer in based on new accounting policy election (1)
 
15,891

 

Gains (losses):
 
 

 
 
Recorded in earnings (realized):
 
 
 
 
Recorded in "Net gain on sale of loans and other mortgage banking revenue"
 
(8,880
)
 
4,593

New originations
 
8,745

 
1,030

Balance, end of period
 
$
63,841

 
$
48,085

(1)  
Refer to Note 1, Basis of Presentation and Significant Accounting Policies, for further details.


104

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The Corporation has elected the fair value option for loans held-for-sale. These loans are intended for sale and the Corporation believes that the fair value is the best indicator of the resolution of these loans. Interest income is recorded based on the contractual terms of the loans in accordance with the Corporation's policy on loans held for investment in “Interest and fees on loans” in the Consolidated Statements of Income. There were no loans held-for-sale that were on nonaccrual status or 90 days past due and on accrual status as of December 31, 2017 and 2016 .
 
The aggregate fair value, contractual balance (including accrued interest), and gain or loss for loans held-for-sale carried at fair value option was as follows:
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Aggregate fair value
 
$
52,133

 
$
81,830

Contractual balance
 
50,597

 
81,009

Unrealized gain (loss)
 
1,536

 
821

 
The total amount of gains (losses) from loans held-for-sale included in the Consolidated Statements of Income was as follows:
 
 
Year Ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Interest income (1)
 
$
2,540

 
$
1,606

 
$
83

Change in fair value (2)
 
715

 
39

 
(61
)
Net gain on sales of loans (2)
 
31,734

 
15,686

 
6,354

Total included in earnings
 
$
34,989

 
$
17,331

 
$
6,376

(1)  
Included in "Interest and fees on loans" in the Consolidated Statements of Income.
(2)  
Included in "Net gain on sale of loans and other mortgage banking revenue" in the Consolidated Statements of Income.

Assets and Liabilities Recorded at Fair Value on a Nonrecurring Basis

Investment securities : Investment securities classified as held to maturity are recorded at fair value if the value is below amortized cost and the Corporation has determined that such unrealized loss is an other-than-temporary impairment. Fair value measurement is based upon quoted prices, if available. If quoted prices are not available, fair values are generally measured using independent pricing models or other model-based valuation techniques that include market inputs, such as benchmark yields, reported trades, broker dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, reference data and industry and economic events.     

Impaired Loans: The Corporation does not record loans held for investment at fair value on a recurring basis. However, from time to time, a loan is considered impaired and an allocation of the allowance (valuation allowance) may be established or a portion of the loan is charged off. Loans for which it is probable that payment of interest and principal will not be made in accordance with the contractual terms of the loan agreement are considered impaired. The fair value of impaired loans is estimated using one of several methods, including the loan's observable market price, the fair value of the collateral or the present value of the expected future cash flows discounted at the loan's effective interest rate. Those impaired loans not requiring a valuation allowance represent loans for which the fair value of the expected repayments or collateral exceed the remaining carrying amount of such loans. Impaired loans where a valuation allowance is established or a portion of the loan is charged off based on the fair value of collateral are subject to nonrecurring fair value measurement and require classification in the fair value hierarchy. The Corporation records impaired loans as Level 3 valuations as there is generally no observable market price or management determines the fair value of the collateral is further impaired below the independent appraised value. When management determines the fair value of the collateral is further impaired below the appraised value, discounts ranging between 20% and 30% of the appraised value are used depending on the nature of the collateral and the age of the most recent appraisal.

Goodwill: Goodwill is subject to impairment testing on an annual basis. The assessment of goodwill for impairment requires a significant degree of judgment. In the event the assessment indicates that it is more-likely-than-not that the fair value is less than the carrying value, the asset is considered impaired and recorded at fair value. Goodwill that is impaired and subject to nonrecurring fair value measurements is a Level 3 valuation. At December 31, 2017 and 2016 , no goodwill was impaired.


105

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Other intangible assets: Other intangible assets consist of core deposit intangible assets and non-compete intangible assets. These items are recorded at fair value when initially recorded. Subsequently, core deposit intangible assets and non-compete intangible assets are amortized primarily on an accelerated basis over periods ranging from ten to fifteen years for core deposit intangible assets and 1 year for non-compete intangible assets and are subject to impairment testing whenever events or changes in circumstances indicate that the carrying amount exceeds the fair value of the asset. If core deposit intangible asset or non-compete intangible asset impairment is identified, the Corporation classifies impaired core deposit intangible assets and impaired non-compete intangible assets subject to nonrecurring fair value measurements as Level 3 valuations. At December 31, 2017 and 2016 , there was no impairment identified for core deposit intangible assets or non-compete intangible assets.

Loan servicing rights: Prior to January 1, 2017, LSRs originated by the Corporation and those acquired in acquisitions of other institutions prior to the merger with Talmer were accounted for under the amortization method. The fair value of these LSRs were initially estimated using a model that calculates the net present value of estimated future cash flows using various assumptions, including prepayment speeds, the discount rate and servicing costs. If the valuation model reflects a value less than the carrying value, LSRs are adjusted to fair value, as determined by the model, through a valuation allowance. The Corporation classifies the LSRs subject to nonrecurring fair value measurements as Level 3 valuations. At December 31, 2016 , the Corporation recognized a valuation allowance of $8 thousand related to impairment within certain pools attributable to the Corporation's servicing portfolios. As a result, the LSRs related to these servicing portfolios were considered to be recorded at fair value on a nonrecurring basis as of December 31, 2016 .

Other real estate owned and repossessed assets : The carrying amounts for other real estate and repossessed assets are reported in the Consolidated Statements of Financial Position under "Interest receivable and other assets." Other real estate and repossessed assets include real estate and other types of assets repossessed by the Corporation. Other real estate and repossessed assets are recorded at the lower of cost or fair value upon the transfer of a loan to other real estate and repossessed assets and, subsequently, continue to be measured and carried at the lower of cost or fair value. Fair value is based upon independent market prices, appraised values of the property or management's estimation of the value of the property. The Corporation records other real estate and repossessed assets as Level 3 valuations as management generally determines that the fair value of the property is impaired below the appraised value. When management determines the fair value of the property is further impaired below appraised value, discounts ranging between 20% and 30% of the appraised value are used depending on the nature of the property and the age of the most recent appraisal.

Disclosure of Nonrecurring Basis Fair Value Measurements

For assets measured at fair value on a nonrecurring basis, quantitative disclosures about fair value measurements for each major category of assets follow:
(Dollars in thousands)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
December 31, 2017
 
 
 
 
Impaired loans
 
$
70,619

 
$
70,619

Other real estate and repossessed assets
 
2,899

 
2,899

Total
 
$
73,518

 
$
73,518

December 31, 2016
 
 
 
 
Impaired loans
 
$
62,184

 
$
62,184

Other real estate and repossessed assets
 
1,386

 
1,386

Loan servicing rights
 
2

 
2

Total
 
$
63,572

 
$
63,572

There were no liabilities recorded at fair value on a nonrecurring basis at December 31, 2017 and 2016 .

106

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following table presents additional information about the significant unobservable inputs used in the fair value measurement of financial assets measured on a nonrecurring basis that were categorized within the Level 3 of the fair value hierarchy:
(Dollars in thousands)
 
Fair Value at December 31, 2017
 
Valuation Technique
 
Significant Unobservable Inputs
 
Range
Impaired loans
 
$
70,619

 
Appraisal of collateral
 
Discount for type of collateral and age of appraisal
 
20%-30%
Other real estate and repossessed assets
 
2,899

 
Appraisal of property
 
Discount for type of property and age of appraisal
 
20%-30%
Disclosures About Fair Value of Financial Instruments

GAAP requires disclosures about the estimated fair value of the Corporation's financial instruments, including those financial assets and liabilities that are not measured and reported at fair value on a recurring or nonrecurring basis. However, the method of estimating fair value for certain financial instruments, such as loans, that are not required to be measured on a recurring or nonrecurring basis, as prescribed by FASB ASC Topic 820, " Fair Value Measurement ", does not incorporate the exit-price concept of fair value. The Corporation utilized the fair value hierarchy in computing the fair values of its financial instruments. In cases where quoted market prices were not available, the Corporation employed present value methods using unobservable inputs requiring management's judgment to estimate the fair values of its financial instruments, which are considered Level 3 valuations. These Level 3 valuations are affected by the assumptions made and, accordingly, do not necessarily indicate amounts that could be realized in a current market exchange. It is also the Corporation's general practice and intent to hold the majority of its financial instruments until maturity and, therefore, the Corporation does not expect to realize the estimated amounts disclosed.

The methodologies for estimating the fair value of financial assets and financial liabilities on a recurring or nonrecurring basis are discussed above. At December 31, 2017 and 2016 , the estimated fair values of cash and cash equivalents, interest receivable and interest payable approximated their carrying values at those dates. The methodologies for other financial assets and financial liabilities follow.

Investment securities — held-to-maturity: Fair value measurement for investment securities — held-to-maturity fair values are measured using independent pricing models or other model-based valuation techniques that include market inputs such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, reference data and industry and economic events. Fair value measurements using Level 2 valuations of investment securities — held-to-maturity include investment securities issued by state and political subdivisions. Level 3 valuations include trust preferred investment securities.

Nonmarketable equity securities: Fair value measurements of nonmarketable equity securities, which consist of Federal Home Loan Bank (FHLB) and Federal Reserve Bank (FRB) stock, are based on their redeemable value, which is cost. The market for these securities is restricted to the issuer of the stock and subject to impairment evaluation. It is not practicable to determine the fair value of these securities within the fair value hierarchy due to the restrictions placed on their transferability.

Loans: The fair values of loans that are not considered impaired are estimated using a discounted cash flow model. The cash flows take into consideration current portfolio interest rates and repricing characteristics as well as assumptions relating to prepayment speeds. The discount rates take into consideration the current market interest rate environment, a credit risk component based on the credit characteristics of each loan portfolio, and a liquidity premium reflecting the liquidity or illiquidity of the market. The fair value measurements for loans are Level 3 valuations.

Bank-owned life insurance: Life insurance policies are held on certain officers. The carrying value of these policies approximate fair value as it is based on the cash surrender value adjusted for other charges or amounts due that are probable at settlement. As such, the Corporation classifies the estimated fair value of bank-owned life insurance as Level 2. Bank-owned life insurance is recorded within "Interest receivable and other assets."

Deposits: The fair values of deposit accounts without defined maturities, such as interest-and noninterest-bearing checking, savings and money market accounts, are estimated to be the amounts payable on demand. The fair values for variable-interest rate time deposits with defined maturities approximate their carrying amounts. Fair value measurements for fixed-interest rate time

107

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

deposits with defined maturities are based on the discounted value of contractual cash flows, using the Corporation's interest rates currently being offered for deposits of similar maturities, and are therefore classified as Level 2 valuations. However, if the estimated fair value is less than the carrying value, the carrying value is reported as the fair value.

Securities sold under agreements to repurchase: Fair value measurements are based on the present value of future estimated cash flows using current interest rates offered to the Corporation under similar terms and are Level 2 valuations.

Short-term borrowings: Short-term borrowings consist of short-term FHLB advances. Fair value measurements for short-term borrowings are based on the present value of future estimated cash flows using current interest rates offered to the Corporation for debt with similar terms and are Level 2 valuations.

Lon g -term borrowings: Long-term borrowings consist of long-term FHLB advances, securities sold under agreements to repurchase with an unaffiliated financial institution, a term line-of-credit and subordinated debt obligations. Fair value measurements for long-term borrowings are based on the present value of future estimated cash flows using current interest rates offered to the Corporation for debt with similar terms and are therefore classified as Level 2 valuations.

Financial guarantees: The Corporation's unused commitments to extend credit, standby letters of credit and loan commitments have no carrying amount and have been estimated to have no realizable fair value. Historically, a majority of the unused commitments to extend credit have not been drawn upon and, generally, the Corporation does not receive fees in connection with these commitments other than standby letter of credit fees, which are not significant.

A summary of carrying amounts and estimated fair values of the Corporation's financial instruments not recorded at fair value in their entirety on a recurring basis on the Consolidated Statements of Financial Position was as follows:
 
 
 
 
December 31,
 
 
Level in Fair Value Measurement Hierarchy
 
2017
 
2016
(Dollars in thousands)
 
 
Carrying
Amount
 
Fair
Value
 
Carrying
Amount
 
Fair
Value
Financial assets:
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
Level 1
 
$
455,991

 
$
455,991

 
$
474,402

 
$
474,402

Investment securities:
 
 
 
 
 
 
 
 
 
 
Held-to-maturity
 
Level 2
 
676,593

 
662,516

 
622,927

 
608,221

Held-to-maturity
 
Level 3
 
500

 
390

 
500

 
310

Nonmarketable equity securities
 
Level 2
 
180,091

 
180,091

 
97,350

 
97,350

Net loans (1)
 
Level 3
 
14,063,380

 
14,114,545

 
12,912,511

 
13,069,315

Interest receivable
 
Level 2
 
50,710

 
50,710

 
42,235

 
42,235

  Bank-owned life insurance
 
Level 2
 
147,584

 
147,584

 
143,718

 
143,718

Financial liabilities:
 
 
 
 
 
 
 
 
 
 
Deposits:
 
 
 
 
 
 
 
 
 
 
Deposits without defined maturities
 
Level 2
 
$
10,425,596

 
$
10,425,596

 
$
9,862,755

 
$
9,862,755

Time deposits
 
Level 2
 
3,217,207

 
3,225,847

 
3,010,367

 
3,010,048

Total deposits
 
 
 
13,642,803

 
13,651,443

 
12,873,122

 
12,872,803

Interest payable
 
Level 2
 
6,329

 
6,329

 
5,415

 
5,415

Securities sold under agreements to repurchase with customers
 
Level 2
 
415,236

 
415,236

 
343,047

 
343,047

Short-term borrowings
 
Level 2
 
2,000,000

 
1,999,137

 
825,000

 
825,000

Long-term borrowings
 
Level 2
 
372,882

 
367,984

 
597,847

 
591,227

(1)  
Included $70.6 million and $62.2 million of impaired loans recorded at fair value on a nonrecurring basis at December 31, 2017 and 2016 , respectively.



108

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 4: Investment Securities
The following is a summary of the amortized cost and fair value of investment securities available-for-sale and investment securities held-to-maturity at December 31, 2017 and 2016 :
 
 
Investment Securities Available-for-Sale
(Dollars in thousands)
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Fair
Value
December 31, 2017
 
 
 
 
 
 
 
 
Government sponsored agencies
 
$
203,099

 
$
765

 
$
948

 
$
202,916

State and political subdivisions
 
350,088

 
310

 
4,428

 
345,970

Residential mortgage-backed securities
 
151,752

 
5

 
1,626

 
150,131

Collateralized mortgage obligations
 
1,042,240

 
89

 
8,484

 
1,033,845

Corporate bonds
 
193,230

 
1,156

 
1,592

 
192,794

Preferred stock and trust preferred securities
 
36,237

 
1,715

 
62

 
37,890

Total
 
$
1,976,646

 
$
4,040

 
$
17,140

 
$
1,963,546

December 31, 2016
 
 
 
 
 
 
 
 
U.S. Treasury securities
 
$
5,788

 
$
5

 
$

 
$
5,793

Government sponsored agencies
 
216,890

 
189

 
2,068

 
215,011

State and political subdivisions
 
311,704

 
163

 
11,779

 
300,088

Residential mortgage-backed securities
 
276,162

 
112

 
3,992

 
272,282

Collateralized mortgage obligations
 
323,965

 
63

 
4,003

 
320,025

Corporate bonds
 
90,859

 
16

 
1,401

 
89,474

Preferred stock and trust preferred securities
 
31,353

 
1,018

 
80

 
32,291

Total
 
$
1,256,721

 
$
1,566

 
$
23,323

 
$
1,234,964

 
 
Investment Securities Held-to-Maturity
(Dollars in thousands)
 
Amortized
Cost
 
Unrecognized
Gains
 
Unrecognized
Losses
 
Fair
Value
December 31, 2017
 
 
 
 
 
 
 
 
State and political subdivisions
 
$
676,593

 
$
3,856

 
$
17,933

 
$
662,516

Trust preferred securities
 
500

 

 
110

 
390

Total
 
$
677,093

 
$
3,856

 
$
18,043

 
$
662,906

December 31, 2016
 
 
 
 
 
 
 
 
State and political subdivisions
 
$
622,927

 
$
2,648

 
$
17,354

 
$
608,221

Trust preferred securities
 
500

 

 
190

 
310

Total
 
$
623,427

 
$
2,648

 
$
17,544

 
$
608,531

The majority of the Corporation's residential mortgage-backed securities and collateralized mortgage obligations are backed by a U.S. government agency (Government National Mortgage Association) or a government sponsored enterprise (Federal Home Loan Mortgage Corporation or Federal National Mortgage Association).
Proceeds from sales of securities and the associated gains and losses recorded in earnings are listed below:
 
 
For the years ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Proceeds
 
$
409,220

 
$
41,446

 
$
40,301

Gross gains
 
178

 
325

 
631

Gross losses
 
(7,566
)
 
(196
)
 
(1
)

109

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following is a summary of the amortized cost and fair value of investment securities at December 31, 2017 , by maturity, for both available-for-sale and held-to-maturity investment securities. The maturities of residential mortgage-backed securities and collateralized mortgage obligations are based on scheduled principal payments. The maturities of all other debt securities are based on final contractual maturity.
 
 
December 31, 2017
(Dollars in thousands)
 
Amortized Cost
 
Fair Value
Investment Securities Available-for-Sale:
 
 
 
 
Due in one year or less
 
$
300,364

 
$
298,644

Due after one year through five years
 
751,998

 
746,082

Due after five years through ten years
 
616,027

 
611,822

Due after ten years
 
306,868

 
305,174

Preferred stock
 
1,389

 
1,824

Total
 
$
1,976,646

 
$
1,963,546

Investment Securities Held-to-Maturity:
 
 
 
 
Due in one year or less
 
$
89,359

 
$
89,149

Due after one year through five years
 
237,113

 
233,022

Due after five years through ten years
 
152,299

 
148,185

Due after ten years
 
198,322

 
192,550

Total
 
$
677,093

 
$
662,906

Securities with a carrying value of $937.2 million and $794.0 million were pledged at December 31, 2017 and 2016 , respectively, to secure borrowings and deposits.
At December 31, 2017 and 2016 , there were no holdings of securities of any one issuer, other than U.S. government and its agencies, in an amount greater than 10% of shareholders' equity.
    

110

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following schedule summarizes information for both available-for-sale and held-to-maturity investment securities with gross unrealized losses at December 31, 2017 and 2016 , aggregated by category and length of time that individual securities have been in a continuous unrealized loss position. As of December 31, 2017 , the Corporation's securities portfolio consisted of 2,329 securities, 1,518 of which were in an unrealized loss position.
 
 
Less Than 12 Months
 
12 Months or More
 
Total
(Dollars in thousands)
 
Fair
Value
 
Gross
Unrealized
Losses
 
Fair
Value
 
Gross
Unrealized
Losses
 
Fair
Value
 
Gross
Unrealized
Losses
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
Government sponsored agencies
 
$
63,818

 
$
510

 
$
24,621

 
$
438

 
$
88,439

 
$
948

State and political subdivisions
 
437,407

 
12,268

 
349,242

 
10,093

 
786,649

 
22,361

Residential mortgage-backed securities
 
93,508

 
383

 
56,576

 
1,243

 
150,084

 
1,626

Collateralized mortgage obligations
 
713,525

 
7,235

 
73,707

 
1,249

 
787,232

 
8,484

Corporate bonds
 
71,447

 
1,138

 
47,878

 
454

 
119,325

 
1,592

Preferred stock and trust preferred securities
 

 

 
11,164

 
172

 
11,164

 
172

Total
 
$
1,379,705

 
$
21,534

 
$
563,188

 
$
13,649

 
$
1,942,893

 
$
35,183

December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
Government sponsored agencies
 
$
105,702

 
$
1,707

 
$
15,023

 
$
361

 
$
120,725

 
$
2,068

State and political subdivisions
 
758,063

 
28,158

 
26,810

 
975

 
784,873

 
29,133

Residential mortgage-backed securities
 
244,239

 
3,992

 

 

 
244,239

 
3,992

Collateralized mortgage obligations
 
279,001

 
3,778

 
14,754

 
225

 
293,755

 
4,003

Corporate bonds
 
80,536

 
1,401

 

 

 
80,536

 
1,401

Preferred stock and trust preferred securities
 
10,699

 
80

 
310

 
190

 
11,009

 
270

Total
 
$
1,478,240

 
$
39,116

 
$
56,897

 
$
1,751

 
$
1,535,137

 
$
40,867

An assessment is performed quarterly by the Corporation to determine whether unrealized losses in its investment securities portfolio are temporary or other-than-temporary by carefully considering all reasonably available information. The Corporation reviews factors such as financial statements, credit ratings, news releases and other pertinent information of the underlying issuer or company to make its determination. Management did not believe any individual unrealized loss on any investment security at December 31, 2017 , represented an other-than-temporary impairment (OTTI) as the unrealized losses for these securities resulted primarily from changes in benchmark U.S. Treasury interest rates and not credit issues. Management believed that the unrealized losses on investment securities at December 31, 2017 were temporary in nature and due primarily to changes in interest rates and reduced market liquidity and not as a result of credit-related issues.
At December 31, 2017 , the Corporation did not have the intent to sell any of its impaired investment securities and believed that it was more-likely-than-not that the Corporation will not have to sell any such investment securities before a full recovery of amortized cost. Accordingly, at December 31, 2017 , the Corporation believed the impairments in its investment securities portfolio were temporary in nature. However, there is no assurance that OTTI may not occur in the future.
Note 5: Loans
Loan portfolio segments are defined as the level at which an entity develops and documents a systematic methodology to determine its allowance. The Corporation has two loan portfolio segments (commercial loans and consumer loans) that it uses in determining the allowance. Both quantitative and qualitative factors are used by management at the loan portfolio segment level in determining the adequacy of the allowance for the Corporation. Classes of loans are a disaggregation of an entity's loan portfolio segments. Classes of loans are defined as a group of loans which share similar initial measurement attributes, risk characteristics and methods for monitoring and assessing credit risk. The Corporation has six classes of loans, which are set forth below.

111

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Commercial  — Loans and lines of credit to varying types of businesses, including municipalities, school districts and nonprofit organizations, for the purpose of supporting working capital, operational needs and term financing of equipment. Repayment of such loans is generally provided through operating cash flows of the business. Commercial loans are predominately secured by equipment, inventory, accounts receivable, personal guarantees of the owner and other sources of repayment, although the Corporation may also secure commercial loans with real estate.
Commercial real estate  — Loans secured by real estate occupied by the borrower for ongoing operations, non-owner occupied real estate leased to one or more tenants and vacant land that has been acquired for investment or future land development.
Real estate construction and land development  — Real estate construction loans represent secured loans for the construction of business properties. Real estate construction loans often convert to a commercial real estate loan at the completion of the construction period. Land development loans represent secured development loans made to borrowers for the purpose of infrastructure improvements to vacant land to create finished marketable residential and commercial lots/land. Most land development loans are originated with the intention that the loans will be paid through the sale of developed lots/land by the developers within twelve months of the completion date. Land development loans at December 31, 2017 and 2016 were primarily comprised of loans to develop residential properties.
Residential mortgage  — Loans secured by one - to four -family residential properties, generally with fixed interest rates for periods of fifteen years or less. The loan-to-value ratio at the time of origination is generally 80% or less. Residential mortgage loans with a loan-to-value ratio of more than 80% generally require private mortgage insurance.
Consumer installment  — Loans to consumers primarily for the purpose of acquiring automobiles, recreational vehicles and personal watercraft and comprised primarily of indirect loans purchased from dealers. These loans consist of relatively small amounts that are spread across many individual borrowers.
Home equity  — Loans and lines of credit whereby consumers utilize equity in their personal residence, generally through a second mortgage, as collateral to secure the loan.

112

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Commercial, commercial real estate, real estate construction and land development loans are referred to as the Corporation's commercial loan portfolio, while residential mortgage, consumer installment and home equity loans are referred to as the Corporation's consumer loan portfolio. A summary of the Corporation's loans follows:
(Dollars in thousands)
 
Originated
 
Acquired (1)
 
Total loans
December 31, 2017
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
Commercial
 
$
2,407,606

 
$
978,036

 
$
3,385,642

Commercial real estate
 
2,751,425

 
1,749,245

 
4,500,670

Real estate construction and land development
 
498,155

 
76,060

 
574,215

Subtotal
 
5,657,186

 
2,803,341

 
8,460,527

Consumer loan portfolio:
 
 
 
 
 
 
Residential mortgage
 
1,967,857

 
1,284,630

 
3,252,487

Consumer installment
 
1,510,540

 
102,468

 
1,613,008

Home equity
 
611,846

 
217,399

 
829,245

Subtotal
 
4,090,243

 
1,604,497

 
5,694,740

Total loans (2)
 
$
9,747,429

 
$
4,407,838

 
$
14,155,267

December 31, 2016
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
Commercial
 
$
1,901,526

 
$
1,315,774

 
$
3,217,300

Commercial real estate
 
1,921,799

 
2,051,341

 
3,973,140

Real estate construction and land development
 
281,724

 
122,048

 
403,772

Subtotal
 
4,105,049

 
3,489,163

 
7,594,212

Consumer loan portfolio:
 
 
 
 
 
 
Residential mortgage
 
1,475,342

 
1,611,132

 
3,086,474

Consumer installment
 
1,282,588

 
151,296

 
1,433,884

Home equity
 
595,422

 
280,787

 
876,209

Subtotal
 
3,353,352

 
2,043,215

 
5,396,567

Total loans (2)
 
$
7,458,401

 
$
5,532,378

 
$
12,990,779

(1)  
Acquired loans are accounted for under ASC 310-30.
(2)  
Reported net of deferred costs totaling $26.1 million and $14.8 million at December 31, 2017 and 2016 , respectively.

The Corporation acquired loans at fair value as of the acquisition date, which includes loans acquired in the acquisitions of Talmer, Lake Michigan Financial Corporation ("Lake Michigan"), Monarch Community Bancorp, Inc. ("Monarch"), Northwestern Bancorp, Inc. ("Northwestern") and O.A.K. Financial Corporation ("OAK"). Acquired loans are accounted for under ASC 310-30 which recognizes the expected shortfall of expected future cash flows, as compared to the contractual amount due, as nonaccretable discount. Any excess of the net present value of expected future cash flows over the acquisition date fair value is recognized as the accretable discount, or accretable yield. The accretable discount is recognized over the expected remaining life of the acquired loans on a pool basis. In the event an acquired loan is renewed or extended, the loan continues to be accounted for as an acquired loan on a pool basis in accordance with ASC 310-30.

113

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Activity for the accretable yield is as follows:
(Dollars in thousands)
 
Talmer
 
Lake Michigan
 
Monarch
 
North-western
 
OAK
 
Total
Year Ended December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
Balance at beginning of period
 
$
798,210

 
$
121,416

 
$
27,182

 
$
69,847

 
$
23,316

 
$
1,039,971

Accretion recognized in interest income
 
(175,678
)
 
(29,077
)
 
(4,533
)
 
(20,318
)
 
(12,563
)
 
(242,169
)
Net reclassification (to) from nonaccretable difference (1)
 
108,821

 
2,785

 
(153
)
 
11,285

 
6,357

 
129,095

Balance at end of period
 
$
731,353

 
$
95,124

 
$
22,496

 
$
60,814

 
$
17,110

 
$
926,897

Year Ended December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
Balance at beginning of period
 
$

 
$
152,999

 
$
34,558

 
$
82,623

 
$
28,077

 
$
298,257

Addition attributable to acquisitions
 
862,127

 

 

 

 

 
862,127

Additions (reductions) (1)
 

 
(3,552
)
 
(1,908
)
 
(6,985
)
 
1,091

 
(11,354
)
Accretion recognized in interest income
 
(63,917
)
 
(33,031
)
 
(5,468
)
 
(15,791
)
 
(13,352
)
 
(131,559
)
Net reclassification (to) from nonaccretable difference (1)
 

 
5,000

 

 
10,000

 
7,500

 
22,500

Balance at end of period
 
$
798,210

 
$
121,416

 
$
27,182

 
$
69,847

 
$
23,316

 
$
1,039,971

Year Ended December 31, 2015
 
 
 
 
Balance at beginning of period
 
$

 
$

 
$

 
$
104,675

 
$
33,286

 
$
137,961

Addition attributable to acquisitions
 

 
190,246

 
37,914

 

 

 
228,160

Additions (reductions) (1)
 

 
(12,991
)
 
1,336

 
(3,396
)
 
6,601

 
(8,450
)
Accretion recognized in interest income
 

 
(24,256
)
 
(4,692
)
 
(18,656
)
 
(11,810
)
 
(59,414
)
Net reclassification (to) from nonaccretable difference (1)
 

 

 

 

 

 

Balance at end of period
 
$

 
$
152,999

 
$
34,558

 
$
82,623

 
$
28,077

 
$
298,257

(1)  
The net reclassification results from changes in expected cash flows of the acquired loans which may include increases in the amount of contractual principal and interest expected to be collected due to improvement in credit quality, increases in balances outstanding from advances, renewals, extensions and interest rates; as well as reductions in contractual principal and interest expected to be collected due to credit deterioration, payoffs, and decreases in interest rates.
Chemical Bank has extended loans to its directors, executive officers and their affiliates. These loans were made in the ordinary course of business upon normal terms, including collateralization and interest rates prevailing at the time, and did not involve more than the normal risk of repayment by the borrower. The aggregate loans outstanding to the directors, executive officers and their affiliates totaled $3.8 million at December 31, 2017 and $23.9 million at December 31, 2016 . During 2017 and 2016 , there were $44.1 million and $33.8 million , respectively, of new loans and other additions, while repayments and other reductions totaled $64.2 million and $31.6 million , respectively.
Loans held-for-sale, comprised of fixed-rate residential mortgage loans, were $52.1 million at December 31, 2017 and $81.8 million at December 31, 2016 . The Corporation sold loans totaling $806.8 million in 2017 , $707.8 million in 2016 and $222.6 million in 2015 .
Credit Quality Monitoring
The Corporation maintains loan policies and credit underwriting standards as part of the process of managing credit risk. These standards include making loans generally only within the Corporation's market areas. The Corporation's lending markets generally consist of communities throughout Michigan and additional communities located within northwest Ohio and northern Indiana.
The Corporation, through Chemical Bank, has a commercial loan portfolio approval process involving underwriting and individual and group loan approval authorities to consider credit quality and loss exposure at loan origination. The loans in the Corporation's commercial loan portfolio are risk rated at origination based on the grading system set forth below. The approval authority of relationship managers is established based on experience levels, with credit decisions greater than $1.25 million requiring credit officer approval and credit decisions greater than $3.0 million requiring group loan authority approval, except for

114

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

six executive and senior officers who have varying loan limits up to $8.0 million . With respect to the group loan authorities, Chemical Bank has various regional loan committees that meet weekly to consider loan ranging in amounts from $3.0 million to $7.0 million , and a senior loan committee, consisting of certain executive and senior officers, that meets weekly to consider loans ranging in amounts from $5.0 million up to Chemical Bank's internal lending limit, depending on risk rating and credit action required. Credit decisions exceeding Chemical Bank's internal lending limit require the approval of the board of directors.
The majority of the Corporation's consumer loan portfolio is comprised of secured loans that are relatively small. The Corporation's consumer loan portfolio has a centralized approval process which utilizes standardized underwriting criteria. The ongoing measurement of credit quality of the consumer loan portfolio is largely done on an exception basis. If payments are made on schedule, as agreed, then no further monitoring is performed. However, if delinquency occurs, the delinquent loans are turned over to the Corporation's collection department for resolution, resulting in repossession or foreclosure if payments are not brought current. Credit quality for the entire consumer loan portfolio is measured by the periodic delinquency rate, nonaccrual amounts and actual losses incurred.
Loans in the commercial loan portfolio tend to be larger and more complex than those in the consumer loan portfolio, and therefore, are subject to more intensive monitoring. All loans in the commercial loan portfolio have an assigned relationship manager, and most borrowers provide periodic financial and operating information that allows the relationship managers to stay abreast of credit quality during the life of the loans. The risk ratings of loans in the commercial loan portfolio are reassessed at least annually, with loans below an acceptable risk rating reassessed more frequently and reviewed by various loan committees within the Corporation at least quarterly.
The Corporation maintains a centralized independent loan review function that monitors the approval process and ongoing asset quality of the loan portfolio, including the accuracy of loan grades. The Corporation also maintains an independent appraisal review function that participates in the review of all appraisals obtained by the Corporation for loans in the commercial loan portfolio.
Credit Quality Indicators
Commercial Loan Portfolio
Risk categories for the Corporation's commercial loan portfolio establish the credit quality of a borrower by measuring liquidity, debt capacity, coverage and payment behavior as shown in the borrower's financial statements. The risk categories also measure the quality of the borrower's management and the repayment support offered by any guarantors. Risk categories for the Corporation's commercial loan portfolio are described as follows:
Pass: Includes all loans without weaknesses or potential weaknesses identified in the categories of special mention, substandard or doubtful. 
Special Mention: Loans with potential credit weakness or credit deficiency, which, if not corrected, pose an unwarranted financial risk that could weaken the loan by adversely impacting the future repayment ability of the borrower.
Substandard: Loans with a well-defined weakness, or weaknesses, such as loans to borrowers who may be experiencing losses from operations or inadequate liquidity of a degree and duration that jeopardizes the orderly repayment of the loan. Substandard loans also are distinguished by the distinct possibility of loss in the future if these weaknesses are not corrected.
Doubtful: Loans with all the characteristics of a loan classified as Substandard, with the added characteristic that credit weaknesses make collection in full highly questionable and improbable. The primary source of repayment is nonexistent and there is doubt as to the value of the secondary source of repayments. A doubtful asset has a high probability of total or substantial loss, but because of pending events that may strengthen the asset, its classification as loss is deferred.

Loss: An asset classified as loss is considered uncollectible and of such little value that the continuance as a bankable asset is not warranted. This classification does not mean that an asset has absolutely no recovery or salvage value, but rather that it is not practical or desirable to defer writing off this basically worthless asset even through partial recovery may occur in the future.


115

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following schedule presents the recorded investment of loans in the commercial loan portfolio by credit risk categories at December 31, 2017 and 2016 :
(Dollars in thousands)
 
Pass
 
Special Mention
 
Substandard
 
Doubtful
 
Total
December 31, 2017
 
 
 
 
 
 
 
 
 
 
Originated Portfolio:
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
2,316,464

 
$
41,059

 
$
50,083

 
$

 
$
2,407,606

Commercial real estate
 
2,677,579

 
24,204

 
49,642

 

 
2,751,425

Real estate construction and land development
 
494,528

 
837

 
2,790

 

 
498,155

Subtotal
 
5,488,571

 
66,100

 
102,515

 

 
5,657,186

Acquired Portfolio:
 
 
 
 
 
 
 
 
 
 
Commercial
 
873,861

 
68,418

 
35,539

 
218

 
978,036

Commercial real estate
 
1,603,685

 
67,970

 
76,803

 
787

 
1,749,245

Real estate construction and land development
 
72,346

 
2,218

 
1,496

 

 
76,060

Subtotal
 
2,549,892

 
138,606

 
113,838

 
1,005

 
2,803,341

Total
 
$
8,038,463

 
$
204,706

 
$
216,353

 
$
1,005

 
$
8,460,527

December 31, 2016
 
 
 
 
 
 
 
 
 
 
Originated Portfolio:
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
1,803,750

 
$
44,809

 
$
51,898

 
$
1,069

 
$
1,901,526

Commercial real estate
 
1,849,315

 
36,981

 
35,502

 
1

 
1,921,799

Real estate construction and land development
 
280,968

 
157

 
599

 

 
281,724

Subtotal
 
3,934,033

 
81,947

 
87,999

 
1,070

 
4,105,049

Acquired Portfolio:
 
 
 
 
 
 
 
 
 
 
Commercial
 
1,218,848

 
46,643

 
50,283

 

 
1,315,774

Commercial real estate
 
1,897,011

 
61,441

 
92,636

 
253

 
2,051,341

Real estate construction and land development
 
117,505

 
1,982

 
2,561

 

 
122,048

Subtotal
 
3,233,364

 
110,066

 
145,480

 
253

 
3,489,163

Total
 
$
7,167,397

 
$
192,013

 
$
233,479

 
$
1,323

 
$
7,594,212

Consumer Loan Portfolio
The Corporation evaluates the credit quality of loans in the consumer loan portfolio based on the performing or nonperforming status of the loan. Loans in the consumer loan portfolio that are performing in accordance with original contractual terms and are less than 90 days past due and accruing interest are considered to be in a performing status, while those that are in nonaccrual status, contractually past due 90 days or more as to interest or principal payments are considered to be in a nonperforming status. Loans accounted for under ASC 310-30, "Acquired loans", that are not performing in accordance with contractual terms are not reported as nonperforming because these loans are recorded in pools at their net realizable value based on the principal and interest the Corporation expects to collect on these loans.

116

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following schedule presents the recorded investment of loans in the consumer loan portfolio based on loans in a performing status and loans in a nonperforming status at December 31, 2017 and 2016 :
(Dollars in thousands)
 
Residential mortgage
 
Consumer
installment
 
Home equity
 
Total consumer
December 31, 2017
 
 
 
 
 
 
 
 
Originated Portfolio:
 
 
 
 
 
 
 
 
Performing
 
$
1,959,222

 
$
1,509,698

 
$
607,541

 
$
4,076,461

Nonperforming
 
8,635

 
842

 
4,305

 
13,782

Subtotal
 
1,967,857

 
1,510,540

 
611,846

 
4,090,243

Acquired Loans
 
1,284,630

 
102,468

 
217,399

 
1,604,497

Total
 
$
3,252,487

 
$
1,613,008

 
$
829,245

 
$
5,694,740

December 31, 2016
 
 
 
 
 
 
 
 
Originated Portfolio:
 
 
 
 
 
 
 
 
Performing
 
$
1,468,373

 
$
1,281,709

 
$
592,071

 
$
3,342,153

Nonperforming
 
6,969

 
879

 
3,351

 
11,199

Subtotal
 
1,475,342

 
1,282,588

 
595,422

 
3,353,352

Acquired Loans
 
1,611,132

 
151,296

 
280,787

 
2,043,215

Total
 
$
3,086,474

 
$
1,433,884

 
$
876,209

 
$
5,396,567


Nonperforming Assets and Past Due Loans

Nonperforming assets consist of loans for which the accrual of interest has been discontinued, other real estate owned acquired through acquisitions, other real estate owned obtained through foreclosure and other repossessed assets.

Loans are considered past due or delinquent when the contractual principal or interest due in accordance with the terms of the loan agreement or any portion thereof remains unpaid after the due date of the scheduled payments. Loans outside of those accounted for under ASC 310-30 are classified as nonaccrual when, in the opinion of management, collection of principal or interest is doubtful. The accrual of interest is discontinued when a loan is placed in nonaccrual status and any payments received reduce the carrying value of the loan. A loan may be placed back on accrual status if all contractual payments have been received and collection of future principal and interest payments are no longer doubtful. Acquired loans that are not performing in accordance with contractual terms are not reported as nonperforming because these loans are recorded in pools at their net realizable value based on the principal and interest the Corporation expects to collect on these loans.


117

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

A summary of nonperforming assets follows:
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Nonperforming assets
 
 
 
 
Nonaccrual loans:
 
 
 
 
Commercial
 
$
19,691

 
$
13,178

Commercial real estate
 
29,545

 
19,877

Real estate construction and land development
 
77

 
80

Residential mortgage
 
8,635

 
6,969

Consumer installment
 
842

 
879

Home equity
 
4,305

 
3,351

Total nonaccrual loans
 
63,095

 
44,334

Other real estate owned and repossessed assets
 
8,807

 
17,187

Total nonperforming assets
 
$
71,902

 
$
61,521

Accruing loans contractually past due 90 days or more as to interest or principal payments, excluding acquired loans accounted for under ASC 310-30
 
 
 
 
Commercial
 
$

 
$
11

Commercial real estate
 
13

 
277

Residential mortgage
 

 

Home equity
 
1,364

 
995

Total accruing loans contractually past due 90 days or more as to interest or principal payments, excluding acquired loans accounted for under ASC 310-30
 
$
1,377

 
$
1,283

    
The Corporation's nonaccrual loans at December 31, 2017 and 2016 included $29.1 million and $30.5 million , respectively, of nonaccrual TDRs.
There was no interest income recognized on nonaccrual loans during 2017 , 2016 and 2015 while the loans were in nonaccrual status. During 2017 , 2016 and 2015 , the Corporation recognized $1.3 million , $0.4 million and $0.9 million , respectively, of interest income on these loans while they were in an accruing status. Additional interest income that would have been recorded on nonaccrual loans had they been current in accordance with their original terms was $3.1 million in 2017 , $2.9 million in 2016 and $3.2 million in 2015 . During 2017 , 2016 and 2015 , the Corporation recognized interest income of $2.6 million , $3.9 million and $3.9 million , respectively, on performing TDRs.
The Corporation had $4.2 million of residential mortgage loans that were in the process of foreclosure at December 31, 2017 , compared to $7.3 million at December 31, 2016 .

118

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Loan delinquency, excluding acquired loans accounted for under ASC 310-30, was as follows:
(Dollars in thousands)
 
30-59
days
past due
 
60-89
days
past due
 
90 days or more past due
 
Total past due
 
Current
 
Total loans
 
90 days or more past due and still accruing
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Originated Portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
13,906

 
$
3,766

 
$
9,494

 
$
27,166

 
$
2,380,440

 
$
2,407,606

 
$

Commercial real estate
 
9,380

 
1,562

 
5,873

 
16,815

 
2,734,610

 
2,751,425

 
13

Real estate construction and land development
 

 

 

 

 
498,155

 
498,155

 

Residential mortgage
 
2,795

 
1,415

 
858

 
5,068

 
1,962,789

 
1,967,857

 

Consumer installment
 
3,324

 
442

 
226

 
3,992

 
1,506,548

 
1,510,540

 

Home equity
 
2,319

 
1,301

 
2,196

 
5,816

 
606,030

 
611,846

 
1,364

Total
 
$
31,724

 
$
8,486

 
$
18,647

 
$
58,857

 
$
9,688,572

 
$
9,747,429

 
$
1,377

December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Originated Portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
10,421

 
$
4,842

 
$
3,641

 
$
18,904

 
$
1,882,622

 
$
1,901,526

 
$
11

Commercial real estate
 
6,551

 
1,589

 
5,165

 
13,305

 
1,908,494

 
1,921,799

 
277

Real estate construction and land development
 
2,721

 
499

 

 
3,220

 
278,504

 
281,724

 

Residential mortgage
 
3,147

 
62

 
1,752

 
4,961

 
1,470,381

 
1,475,342

 

Consumer installment
 
3,991

 
675

 
238

 
4,904

 
1,277,684

 
1,282,588

 

Home equity
 
3,097

 
893

 
2,349

 
6,339

 
589,083

 
595,422

 
995

Total
 
$
29,928

 
$
8,560

 
$
13,145

 
$
51,633

 
$
7,406,768

 
$
7,458,401

 
$
1,283


119

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Impaired Loans
A loan is impaired when, based on current information and events, it is probable that the Corporation will be unable to collect all amounts due according to the contractual terms of the loan agreement. Impaired loans include nonperforming loans and all TDRs. Impaired loans are accounted for at the lower of the present value of expected cash flows or the estimated fair value of the collateral. When the present value of expected cash flows or the fair value of the collateral of an impaired loan not accounted for under ASC 310-30 is less than the amount of unpaid principal outstanding on the loan, the recorded principal balance of the loan is reduced to its carrying value through either a specific allowance for loan loss or a partial charge-off of the loan balance.
The following schedules present impaired loans by classes of loans at December 31, 2017 and December 31, 2016 :
(Dollars in thousands)
 
Recorded
investment
 
Unpaid
principal
balance
 
Related
valuation
allowance
December 31, 2017
 
 
 
 
 
 
Impaired loans with a valuation allowance:
 
 
 
 
 
 
Commercial
 
$
28,897

 
$
31,655

 
$
2,296

Commercial real estate
 
28,003

 
34,580

 
3,227

Real estate construction and land development
 
313

 
313

 
14

Residential mortgage
 
15,872

 
15,872

 
1,487

Consumer installment
 
966

 
966

 
120

Home equity
 
4,570

 
4,570

 
858

Subtotal
 
78,621

 
87,956

 
8,002

Impaired loans with no related valuation allowance:
 
 
 
 
 
 
Commercial
 
8,504

 
9,291

 

Commercial real estate
 
18,080

 
19,861

 

Real estate construction and land development
 

 

 

Residential mortgage
 
4,902

 
4,902

 

Consumer installment
 

 

 

Home equity
 
1,770

 
1,770

 

Subtotal
 
33,256

 
35,824

 

Total impaired loans:
 
 
 
 
 
 
Commercial
 
37,401

 
40,946

 
2,296

Commercial real estate
 
46,083

 
54,441

 
3,227

Real estate construction and land development
 
313

 
313

 
14

Residential mortgage
 
20,774

 
20,774

 
1,487

Consumer installment
 
966

 
966

 
120

Home equity
 
6,340

 
6,340

 
858

Total
 
$
111,877

 
$
123,780

 
$
8,002


120

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

    
(Dollars in thousands)
 
Recorded
investment
 
Unpaid
principal
balance
 
Related
valuation
allowance
December 31, 2016
 
 
Impaired loans with a valuation allowance:
 
 
 
 
 
 
Commercial
 
$
28,925

 
$
33,209

 
$
3,128

Commercial real estate
 
21,318

 
27,558

 
2,102

Real estate construction and land development
 
177

 
177

 
4

Residential mortgage
 
20,864

 
20,864

 
3,528

Consumer installment
 
879

 
879

 
240

Home equity
 
2,577

 
2,577

 
390

Subtotal
 
74,740

 
85,264

 
9,392

Impaired loans with no related valuation allowance:
 
 
 
 
 
 
Commercial
 
7,435

 
11,153

 

Commercial real estate
 
20,588

 
23,535

 

Real estate construction and land development
 
80

 
80

 

Residential mortgage
 
3,252

 
3,252

 

Consumer installment
 

 

 

Home equity
 
774

 
774

 

Subtotal
 
32,129

 
38,794

 

Total impaired loans:
 
 
 
 
 
 
Commercial
 
36,360

 
44,362

 
3,128

Commercial real estate
 
41,906

 
51,093

 
2,102

Real estate construction and land development
 
257

 
257

 
4

Residential mortgage
 
24,116

 
24,116

 
3,528

Consumer installment
 
879

 
879

 
240

Home equity
 
3,351

 
3,351

 
390

Total
 
$
106,869

 
$
124,058

 
$
9,392


121

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following schedule presents additional information regarding impaired loans by classes of loans segregated by those requiring a valuation allowance and those not requiring a valuation allowance at December 31, 2017 , 2016 and 2015 and the respective interest income amounts recognized:
 
 
For the years ended December 31,
 
 
2017
 
2016
 
2015
(Dollars in thousands)
 
Average annual recorded investment
 
Interest income recognized while on impaired status
 
Average annual recorded investment
 
Interest income recognized while on impaired status
 
Average annual recorded investment
 
Interest income recognized while on impaired status
Impaired loans with a valuation allowance:
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
$
25,099

 
$
939

 
$
7,829

 
$

 
$
9,511

 
$

Commercial real estate
 
19,983

 
677

 
5,658

 

 
2,918

 

Real estate construction and land development
 
175

 
10

 
19

 

 

 

Residential mortgage
 
16,390

 
538

 
23,958

 
1,285

 
20,661

 
1,312

Consumer installment
 
744

 
4

 
359

 

 

 

Home equity
 
4,201

 
82

 
1,759

 

 

 

Subtotal
 
66,592

 
2,250

 
39,582

 
1,285

 
33,090

 
1,312

Impaired loans with no related valuation allowance:
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
10,196

 
28

 
29,559

 
1,343

 
27,778

 
1,005

Commercial real estate
 
24,658

 
245

 
41,646

 
1,236

 
50,079

 
1,547

Real estate construction and land development
 
78

 

 
585

 
22

 
889

 
25

Residential mortgage
 
4,622

 
38

 
1,519

 

 
6,027

 

Consumer installment
 
205

 

 

 

 
448

 

Home equity
 
1,392

 
14

 
555

 

 
1,872

 

Subtotal
 
41,151

 
325

 
73,864

 
2,601

 
87,093

 
2,577

Total impaired loans:
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
35,295

 
967

 
37,388

 
1,343

 
37,289

 
1,005

Commercial real estate
 
44,641

 
922

 
47,304

 
1,236

 
52,997

 
1,547

Real estate construction and land development
 
253

 
10

 
604

 
22

 
889

 
25

Residential mortgage
 
21,012

 
576

 
25,477

 
1,285

 
26,688

 
1,312

Consumer installment
 
949

 
4

 
359

 

 
448

 

Home equity
 
5,593

 
96

 
2,314

 

 
1,872

 

Total
 
$
107,743

 
$
2,575

 
$
113,446

 
$
3,886

 
$
120,183

 
$
3,889

The difference between an impaired loan's recorded investment and the unpaid principal balance for originated loans represents a partial charge-off resulting from a confirmed loss due to the value of the collateral securing the loan being below the loan balance and management's assessment that full collection of the loan balance is not likely.
Impaired loans included $48.8 million and $62.5 million at December 31, 2017 and December 31, 2016 , respectively, of accruing TDRs.

122

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Loans Modified Under Troubled Debt Restructurings (TDRs)    
The following tables present the recorded investment of loans modified into TDRs during the years ended December 31, 2017 , 2016 and 2015 by type of concession granted. In cases where more than one type of concession was granted, the loans were categorized based on the most significant concession.
 
Concession type
 
 
 
 
(Dollars in thousands)
Principal
deferral
 
Principal
reduction
 
A/B Note Restructure (1)
 
Interest
rate
 
Forbearance
agreement
 
Total
number
of loans
 
Pre-
modification
recorded
investment
 
Post-
modification
recorded
investment
For the year ended December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
$
2,308

 
$

 
$

 
$
1,827

 
$
2,176

 
36

 
$
6,416

 
$
6,311

Commercial real estate
706

 

 

 
338

 
953

 
16

 
2,097

 
1,997

Real estate construction and land development
35

 

 

 

 

 
1

 
36

 
35

Subtotal
3,049

 

 

 
2,165

 
3,129

 
53

 
8,549

 
8,343

Consumer loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Residential mortgage
297

 

 

 
383

 

 
11

 
763

 
680

Consumer installment
118

 
37

 

 
37

 

 
34

 
208

 
192

Home equity
389

 

 

 
52

 

 
14

 
537

 
441

Subtotal
804

 
37

 

 
472

 

 
59

 
1,508

 
1,313

Total loans
$
3,853

 
$
37

 
$

 
$
2,637

 
$
3,129

 
112

 
$
10,057

 
$
9,656

For the year ended December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
$
11,533

 
$
1,527

 
$
43

 
$

 
$
1,750

 
54

 
$
14,853

 
$
14,853

Commercial real estate
2,993

 
1,866

 

 

 

 
16

 
4,859

 
4,859

Subtotal
14,526

 
3,393

 
43

 

 
1,750

 
70

 
19,712

 
19,712

Consumer loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Residential mortgage
477

 

 

 

 

 
4

 
477

 
477

Consumer installment
87

 

 

 

 

 
14

 
87

 
87

Home equity
179

 

 

 
364

 

 
10

 
543

 
543

Subtotal
743

 

 

 
364

 

 
28

 
1,107

 
1,107

Total loans
$
15,269

 
$
3,393

 
$
43

 
$
364

 
$
1,750

 
98

 
$
20,819

 
$
20,819

For the year ended December 31, 2015
 
 
 
 
 
 
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
$
6,031

 
$

 
$

 
$
117

 
$
5,298

 
53

 
$
11,446

 
$
11,446

Commercial real estate
5,904

 
450

 

 
102

 
740

 
21

 
7,196

 
7,196

Real estate construction and land development
705

 

 

 

 

 
3

 
705

 
705

Subtotal
12,640

 
450

 

 
219

 
6,038

 
77

 
19,347

 
19,347

Consumer loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Residential mortgage
1,246

 

 

 
635

 

 
20

 
1,881

 
1,881

Consumer installment
210

 

 

 

 

 
19

 
210

 
210

Home equity
1,110

 

 

 
46

 

 
26

 
1,158

 
1,156

Subtotal
2,566

 

 

 
681

 

 
65

 
3,249

 
3,247

Total loans
$
15,206

 
$
450

 
$

 
$
900

 
$
6,038

 
142

 
$
22,596

 
$
22,594

(1)  
Loan restructurings whereby the original loan is restructured into two notes: an "A" note, which generally reflects the portion of the modified loans which is expected to be collected: and a "B" note, which is fully charged off.

123

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The pre-modification and post-modification recorded investment represents amounts as of the date of loan modification. The difference between the pre-modification and post-modification recorded investment of residential mortgage TDRs represents impairment recognized by the Corporation through the provision for loan losses computed based on a loan's post-modification present value of expected future cash flows discounted at the loan's original effective interest rate.

The following schedule presents the Corporation's TDRs at December 31, 2017 and 2016 :
(Dollars in thousands)
 
Accruing
 TDRs
 
Nonaccrual TDRs
 
Total
December 31, 2017
 
 
 
 
 
 
Commercial loan portfolio
 
$
34,484

 
$
24,358

 
$
58,842

Consumer loan portfolio
 
14,298

 
4,748

 
19,046

Total
 
$
48,782

 
$
29,106

 
$
77,888

December 31, 2016
 
 
 
 
 
 
Commercial loan portfolio
 
$
45,388

 
$
25,397

 
$
70,785

Consumer loan portfolio
 
17,147

 
5,134

 
22,281

Total
 
$
62,535

 
$
30,531

 
$
93,066


The following schedule includes TDRs for which there was a payment default during the years ended December 31, 2017 , 2016 and 2015 , whereby the borrower was past due with respect to principal and/or interest for 90 days or more, and the loan became a TDR during the twelve-month period prior to the default:
 
 
For the years ended December 31,
 
 
2017
 
2016
 
2015
 
 
Number of loans
 
Principal balance at year end
 
Number of loans
 
Principal balance at year end
 
Number of loans
 
Principal balance at year end
(Dollars in thousands)
 
 
 
 
 
 
Commercial loan portfolio:
 
 
 
 
 
 
 
 
 
 
 
 
Commercial
 
5
 
$
1,617

 
 
$

 
1
 
$
1,206

Commercial real estate
 
 

 
2
 
1,721

 
5
 
1,016

Subtotal - commercial loan portfolio
 
5
 
1,617

 
2
 
1,721

 
6
 
2,222

Consumer loan portfolio (residential mortgage)
 
17
 
434

 
14
 
259

 
3
 
65

Total
 
22
 
$
2,051

 
16
 
$
1,980

 
9
 
$
2,287

At December 31, 2017 , commitments to lend additional funds to borrowers whose terms have been modified in TDRs totaled $2.0 million .

124

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Allowance for Loan Losses
The following schedule presents, by loan portfolio segment, the changes in the allowance for the originated loan portfolio for the years ended December 31, 2017 , 2016 and 2015 .
(Dollars in thousands)
 
Commercial
loan
portfolio
 
Consumer
loan
portfolio
 
Unallocated
 
Total
Originated Loan Portfolio
 
 
 
 
 
 
 
 
Changes in allowance for loan losses for the year ended December 31, 2017:
 
 
 
 
Beginning balance
 
$
51,201

 
$
27,067

 
$

 
$
78,268

Provision for loan losses
 
19,007

 
4,293

 

 
23,300

Charge-offs
 
(8,570
)
 
(8,297
)
 

 
(16,867
)
Recoveries
 
4,495

 
2,691

 

 
7,186

Ending balance
 
$
66,133

 
$
25,754

 
$

 
$
91,887

Changes in allowance for loan losses for the year ended December 31, 2016:
 
 
 
 
Beginning balance
 
$
47,234

 
$
26,094

 
$

 
$
73,328

Provision (benefit) for loan losses
 
9,788

 
5,087

 

 
14,875

Charge-offs
 
(8,906
)
 
(6,396
)
 

 
(15,302
)
Recoveries
 
3,085

 
2,282

 

 
5,367

Ending balance
 
$
51,201

 
$
27,067

 
$

 
$
78,268

Changes in allowance for loan losses for the year ended December 31, 2015:
 
 
 
 
Beginning balance
 
$
44,156

 
$
28,803

 
$
2,724

 
$
75,683

Provision (benefit) for loan losses
 
7,275

 
1,949

 
(2,724
)
 
6,500

Charge-offs
 
(6,385
)
 
(7,116
)
 

 
(13,501
)
Recoveries
 
2,188

 
2,458

 

 
4,646

Ending balance
 
$
47,234

 
$
26,094

 
$

 
$
73,328


125

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following schedule presents by loan portfolio segment, details regarding the balance in the allowance and the recorded investment in loans at December 31, 2017 and 2016 by impairment evaluation method.
(Dollars in thousands)
 
Commercial
Loan
Portfolio
 
Consumer
Loan
Portfolio
 
Total
Allowance for loan losses balance at December 31, 2017 attributable to:
Loans individually evaluated for impairment
 
$
5,537

 
$
2,465

 
$
8,002

Loans collectively evaluated for impairment
 
60,596

 
23,289

 
83,885

Loans accounted for under ASC 310-30
 

 

 

Total
 
$
66,133

 
$
25,754

 
$
91,887

Recorded investment (loan balance) at December 31, 2017:
Loans individually evaluated for impairment
 
$
83,797

 
$
28,080

 
$
111,877

Loans collectively evaluated for impairment
 
5,573,389

 
4,062,163

 
9,635,552

Loans accounted for under ASC 310-30
 
2,803,341

 
1,604,497

 
4,407,838

Total
 
$
8,460,527

 
$
5,694,740

 
$
14,155,267

Allowance for loan losses balance at December 31, 2016 attributable to:
 
 
Loans individually evaluated for impairment
 
$
5,234

 
$
4,158

 
$
9,392

Loans collectively evaluated for impairment
 
45,967

 
22,909

 
68,876

Loans accounted for under ASC 310-30
 

 

 

Total
 
$
51,201

 
$
27,067

 
$
78,268

Recorded investment (loan balance) at December 31, 2016:
 
 
Loans individually evaluated for impairment
 
$
78,523

 
$
28,346

 
$
106,869

Loans collectively evaluated for impairment
 
4,026,526

 
3,325,006

 
7,351,532

Loans accounted for under ASC 310-30
 
3,489,163

 
2,043,215

 
5,532,378

Total
 
$
7,594,212

 
$
5,396,567

 
$
12,990,779

Note 6: Premises and Equipment
The following table summarizes premises and equipment:
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Land and land improvements
 
$
31,427

 
$
36,185

Buildings
 
130,028

 
144,155

Furniture and equipment
 
100,932

 
91,963

Total
 
262,387

 
272,303

Less accumulated depreciation
 
(135,491
)
 
(127,291
)
Premises and equipment, net
 
$
126,896

 
$
145,012

The Corporation leases certain branch properties and equipment under operating leases. Net rent expense was $6.4 million , $3.3 million and $1.7 million for the years ended December 31, 2017 , 2016 and 2015 , respectively.
During the years ended December 31, 2017 and 2016 the Corporation transferred $13.2 million and $4.8 million from premises and equipment to other assets, respectively, due to branch or building operation closings/consolidations.

126

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017


Note 7: Other Real Estate Owned and Repossessed Assets
 
Changes in other real estate owned and repossessed assets, included in interest receivable and other assets on the Consolidated Statements of Financial Position, were as follows:
(Dollars in thousands)
 
Other real estate
 owned
 
Repossessed
assets
Balance at January 1, 2015
 
$
13,953

 
$
252

Additions due to acquisitions
 
440

 

Other additions (1)
 
6,957

 
2,372

Net payments received
 
(45
)
 
(22
)
Disposals
 
(10,168
)
 
(2,383
)
Write-downs
 
(1,421
)
 

Balance at December 31, 2015
 
$
9,716

 
$
219

Additions due to acquisitions
 
13,227

 
313

Other additions (1)
 
9,938

 
3,032

Net payments received
 
(1,560
)
 
(763
)
Disposals
 
(13,873
)
 
(2,426
)
Write-downs
 
(636
)
 

Balance at December 31, 2016
 
$
16,812

 
$
375

Other additions (1)
 
6,905

 
4,641

Net payments received
 
(1,064
)
 

Disposals
 
(12,831
)
 
(4,391
)
Write-downs
 
(1,640
)
 

Balance at December 31, 2017
 
$
8,182

 
$
625

(1)  
Includes loans transferred to other real estate owned and other repossessed assets.

At December 31, 2017 the Corporation had $0.5 million of other real estate owned and repossessed assets as a result of obtaining physical possession in accordance with ASU No. 2014-04, Reclassification of Residential Real Estate Collateralized Consumer Mortgage Loans Upon Foreclosure. In addition, there were $4.2 million of consumer mortgage loans secured by residential real estate properties for which formal foreclosure proceedings are in process, as of December 31, 2017 .    

127

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Income and expenses related to other real estate owned and repossessed assets, recorded as a component of “Other expense” in the Consolidated Statements of Income, were as follows:
(Dollars in thousands)
 
Other real estate
 owned
 
Repossessed
assets
For the year ended December 31, 2017
 
 

 
 

Net gain (loss) on sale
 
$
3,038

 
$
(381
)
Write-downs
 
(1,640
)
 

Net operating expenses
 
(1,981
)
 
(41
)
Total
 
$
(583
)
 
$
(422
)
For the year ended December 31, 2016
 
 
 
 
Net gain (loss) on sale
 
$
5,325

 
$
523

Write-downs
 
(636
)
 

Net operating expenses
 
(740
)
 
(60
)
Total
 
$
3,949

 
$
463

For the year ended December 31, 2015
 
 
 
 
Net gain (loss) on sale
 
$
4,128

 
$
(26
)
Write-downs
 
(1,421
)
 

Net operating expenses
 
(1,604
)
 
(19
)
Total
 
$
1,103

 
$
(45
)

Note 8: Goodwill
Goodwill was $1.13 billion for both December 31, 2017 and 2016 . Goodwill recorded is primarily attributable to the synergies and economies of scale expected from combining the operations of the Corporation and acquired and merged organizations. The Corporation recorded goodwill in the amount of $847.7 million related to the merger with Talmer completed on August 31, 2016. During 2015, the Corporation acquired Lake Michigan and Monarch, which resulted in the recognition of goodwill for each transaction of $101.1 million and $5.3 million , respectively.    
Goodwill is not amortized but is subject to impairment testing annually as of October 31 and on an interim basis if events or changes in circumstances indicate assets might be impaired. Impairment exists when the carrying value of goodwill exceeds its fair value. The Corporation’s most recent annual goodwill impairment review performed as of October 31, 2017 did not indicate that an impairment of goodwill existed. The Corporation also determined that no triggering events have occurred that indicated impairment from the most recent valuation date through December 31, 2017 and that the Corporation's goodwill was no t impaired at December 31, 2017 .

Note 9: Loan Servicing Rights

LSRs are created as a result of selling residential mortgage and commercial real estate loans in the secondary market while retaining the right to service these loans and receive servicing income over the life of the loan, and from acquisitions of other banks that had LSRs. Loans serviced for others are not reported as assets in the Consolidated Statements of Financial Position.     
The Corporation elected to account for LSRs acquired related to the merger with Talmer under the fair value measurement method. Prior to January 1, 2017, the Corporation accounted for all other LSRs at the lower of cost or fair value ("Amortized LSRs"). The Corporation elected as of January 1, 2017 to account for all previously Amortized LSRs under the fair value measurement method. This change in accounting policy resulted in a cumulative adjustment to retained earnings as of January 1, 2017 in the amount of $3.7 million . For further information on this election, refer to Note 1, Basis of Presentation and Significant Accounting Policies.


128

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

LSRs are established and recorded at the estimated fair value by calculating the present value of estimated future net servicing cash flows, taking into consideration actual and expected mortgage loan prepayment rates, discount rates, servicing costs, and other economic factors, which are determined based on current market conditions. The following table represents the activity for LSRs and the related fair value changes:
(Dollars in thousands)
 
Commercial
Real Estate
 
Mortgage
 
Total
For the year ended December 31, 2017
 
 
 
 
 
 
Fair value, beginning of period
 
$
344

 
$
47,741

 
$
48,085

Transfers in based on new accounting policy election
 

 
15,891

 
15,891

Additions from loans sold with servicing retained
 
188

 
8,557

 
8,745

Changes in fair value due to:
 
 
 
 
 


Reductions from pay-offs, pay downs and run-off
 
(105
)
 
(2,400
)
 
(2,505
)
Changes in estimates of fair value (1)
 

 
(6,375
)
 
(6,375
)
Fair value, end of period
 
$
427

 
$
63,414

 
$
63,841

Principal balance of loans serviced
 
$
40,316

 
$
7,068,431

 
$
7,108,747

For the year ended December 31, 2016
 
 

 
 

 
 

Fair value, beginning of period
 
$

 
$

 
$

Acquired in Talmer Bancorp, Inc. merger
 
365

 
42,097

 
42,462

Additions from loans sold with servicing retained
 

 
1,030

 
1,030

Changes in fair value due to:
 
 
 
 
 


Reductions from pay-offs, pay downs and run-off
 
(17
)
 
(502
)
 
(519
)
Changes in estimates of fair value (1)
 
(4
)
 
5,116

 
5,112

Fair value, end of period
 
$
344

 
$
47,741

 
$
48,085

Principal balance of loans serviced under the fair value measurement method
 
$
64,756

 
$
5,235,415

 
$
5,300,171

(1) Represents estimated LSR value change resulting primarily from market-driven changes in interest rates and prepayments. Included
in "Net gain on sale of loans and other mortgage banking revenue" in the Consolidated Statements of Income.

The following shows the net carrying value and fair value of LSRs and the total loans that the Corporation serviced for others accounted for at the lower of cost or fair value for the years ended December 31, 2016 and 2015:        
 
 
Years Ended December 31,
(Dollars in thousands)
 
2016
 
2015
Net carrying value of LSRs
 
$
10,230

 
$
11,122

Fair value of LSRs
 
$
15,891

 
$
15,542

Valuation allowance
 
$
8

 
$

Loans serviced for others that have servicing rights capitalized
 
$
2,074,057

 
$
2,082,899


Activity for LSRs accounted for at the lower of cost or fair value and the related valuation allowance for the years ended December 31, 2016 and 2015 are as follows:
 
 
Years Ended December 31,
(Dollars in thousands)
 
2016
 
2015
Balance at beginning of period
 
$
11,122

 
$
12,217

Acquired through acquisitions
 

 
1,284

Additions
 
3,303

 
1,476

Amortization
 
(4,187
)
 
(4,055
)
Change in valuation allowance
 
(8
)
 
200

Balance at end of period
 
$
10,230

 
$
11,122



129

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Expected and actual loan prepayment speeds are the most significant factors driving the fair value of loan servicing rights. The following table presents assumptions utilized in determining the fair value of loan servicing rights as of December 31, 2017 and 2016 .
 
 
Mortgage
As of December 31, 2017
 
 

Prepayment speed
 
0.00 - 38.8%

Weighted average ("WA") discount rate
 
10.1
%
Cost to service/per year
 
$
66

WA Ancillary income/per year
 
$
31

WA float range
 
1.6
%
As of December 31, 2016
 
 

Prepayment speed
 
0.00 - 99.8%

WA discount rate
 
10.1
%
Cost to service/per year
 
$65-$90

Ancillary income/per year
 
$
28

WA float range
 
1.0
%

The Corporation realized total loan servicing fee income of $18.2 million , $8.7 million and $5.4 million for the years ended December 31, 2017 , 2016 and 2015 , respectively, recorded as a component of "Net gain on sale of loans and other mortgage banking revenue" in the Consolidated Statements of Income.

Note 10: Other Intangible Assets

The following table shows the net carrying value of the Corporation's other intangible assets.
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Core deposit intangible assets
 
$
34,259

 
$
40,211

Non-compete intangible assets
 
12

 

Total other intangible assets
 
$
34,271

 
$
40,211


Core Deposit Intangible Assets

The Corporation recorded core deposit intangible assets associated with each of its acquisitions. Core deposit intangible assets are amortized on an accelerated basis over their estimated useful lives and have an estimated remaining weighted-average useful life of 7.5 years as of December 31, 2017 .

The following table sets forth the carrying amount and accumulated amortization of core deposit intangible assets that are amortizable and arose from business combinations or other acquisitions:
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Gross carrying amount
 
$
59,143

 
$
59,143

Accumulated amortization
 
24,884

 
18,932

Net carrying amount
 
$
34,259

 
$
40,211


Amortization expense recognized on core deposit intangible assets was $6.0 million , $5.2 million and $4.1 million for the years ended December 31, 2017 , 2016 and 2015 , respectively.

130

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The estimated future amortization expense on core deposit intangible assets for the next five years is as follows:
(Dollars in thousands)
Estimated
amortization
expense
2018
$
5,703

2019
5,441

2020
4,850

2021
4,471

2022
4,218


Note 11: Derivative Instruments and Balance Sheet Offsetting

In the normal course of business, the Corporation enters into various transactions involving derivative instruments to manage exposure to fluctuations in interest rates and to meet the financing needs of customers (customer-initiated derivatives).  These financial instruments involve, to varying degrees, elements of market and credit risk. Market and credit risk are included in the determination of fair value.
 
Commitments to fund mortgage loans (interest rate locks) to be sold into the secondary market and forward commitments for the future delivery of mortgage loans to third party investors are considered derivatives. It is the Corporation’s practice to enter into forward commitments for the future delivery of mortgage loans when interest rate lock commitments are entered into in order to economically hedge the effect of changes in interest rates resulting from its commitments to fund the loans.
     
The Corporation enters into interest rate derivatives to provide a service to certain qualifying customers to help facilitate their respective risk management strategies, customer-initiated derivatives, and, therefore, are not used for interest rate risk management purposes. These derivatives primarily consist of interest rate swaps, interest rate caps and floors, and foreign exchange contracts. The Corporation generally takes offsetting positions with dealer counterparts to mitigate the inherent risk. Income primarily results from the spread between the customer derivative and the offsetting dealer positions. Gains and losses on customer-related derivatives are included in other noninterest income.

The Corporation utilizes interest rate swaps for risk management purposes to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. These interest rate swaps designated as cash flow hedges are used to manage differences in the amount, timing and duration of the Corporation's known or expected cash receipts and its known or expected cash payments principally related to certain variable rate borrowings. The Corporation assesses the effectiveness of each hedging relationship by comparing the changes in cash flows of the derivative instruments with the changes in cash flows of the designated hedged transactions. The effective portion of changes in fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (loss) and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Any ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. The Corporation expects the hedges to remain highly effective during the remaining terms of the swaps.

The Corporation additionally has written and purchased option derivatives consisting of instruments to facilitate an equity-linked time deposit product (the "Power Equity CD"). The Power Equity CD is a time deposit that provides the purchaser a guaranteed return of principal at maturity plus a potential equity return (a written option), while the Corporation receives a known stream of funds based on the equity return (a purchased option). The written and purchased options are mirror derivative instruments which are carried at fair value on the Consolidated Statements of Financial Position.
 

131

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following table presents the notional amount and fair value of the Corporation’s derivative instruments held or issued in connection with customer-initiated and mortgage banking activities. 
 
December 31,
 
2017
 
2016
 
 
 
Fair Value
 
 
 
Fair Value
(Dollars in thousands)
Notional
Amount (1)
 
Gross
Derivative
Assets (2)
 
Gross
Derivative
Liabilities
(2)
 
Notional
Amount (1)
 
Gross
Derivative
Assets (2)
 
Gross
Derivative
Liabilities
(2)
Risk management purposes:
 
 
 
 
 
 
 
 
 
 
 
Derivatives designated as hedging instruments:
 
 
 
 
 
 
 
 
 
 
 
Interest rate swaps
$
620,000

 
$
5,899

 
$

 
$

 
$

 
$

Total risk management purposes
620,000

 
5,899

 

 

 

 

Customer-initiated and mortgage banking derivatives:
 

 
 

 
 

 
 

 
 

 
 

Customer-initiated derivatives
1,365,119

 
9,376

 
10,139

 
600,598

 
4,406

 
4,141

Foreign exchange forwards (3)

 

 

 

 

 

Forward contracts related to mortgage loans to be delivered for sale
115,996

 

 
34

 
140,155

 
635

 

Interest rate lock commitments
71,003

 
1,222

 

 
76,034

 
956

 

Power Equity CD
38,807

 
2,184

 
2,184

 
36,807

 
2,218

 
2,218

Total customer-initiated and mortgage banking derivatives
1,590,925

 
12,782

 
12,357

 
853,594

 
8,215

 
6,359

Total gross derivatives
$
2,210,925

 
$
18,681

 
$
12,357

 
$
853,594

 
$
8,215

 
$
6,359

(1)  
Notional or contract amounts, which represent the extent of involvement in the derivatives market, are used to determine the contractual cash flows required in accordance with the terms of the agreement. These amounts are typically not exchanged, significantly exceed amounts subject to credit or market risk and are not reflected in the Consolidated Statements of Financial Position.
(2)  
Derivative assets are included within "Interest receivable and other assets" and derivative liabilities are included within "Interest Payable and other liabilities" on the Consolidated Statements of Financial Position. Included in the fair value of the derivative assets are credit valuation adjustments for counterparty credit risk totaling $809 thousand at December 31, 2017 and $99 thousand at December 31, 2016 .
(3)  
The foreign exchange forwards that were entered into during the year ended December 31, 2017 had matured as of December 31, 2017 .
 
In the normal course of business, the Corporation may decide to settle a forward contract rather than fulfill the contract.  Cash received or paid in this settlement manner is included in "Net gain (loss) on sale of loans and other mortgage banking revenue" in the Consolidated Statements of Income and is considered a cost of executing a forward contract.

The following table presents the net gains (losses) related to derivative instruments reflecting the changes in fair value.
 
 
 
 
For the years ended December 31,
(Dollars in thousands)
 
Location of Gain (Loss)
 
2017
 
2016
 
2015
Forward contracts related to mortgage loans to be delivered for sale
 
Net gain (loss) on sale of loans and other mortgage banking revenue
 
$
(669
)
 
$
692

 
$
193

Interest rate lock commitments
 
Net gain (loss) on sale of loans and other mortgage banking revenue
 
266

 
(1,356
)
 
(132
)
Customer-initiated derivatives
 
Other noninterest income
 
(1,028
)
 
581

 

Total gain (loss) recognized in income
 
 
 
$
(1,431
)
 
$
(83
)
 
$
61



132

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

     The following table presents the net gains (losses) recorded in accumulated other comprehensive income and the Consolidated Statements of Income relating to interest rate swaps designated as cash flow hedges for the year ended December 31, 2017 . The Corporation first began entering into interest rate swaps designated as cash flow hedges during the year ended December 31, 2017.
(Dollars in thousands)
 
Amount of gain (loss) recognized in other comprehensive income (Effective portion)
 
Amount of gain (loss) reclassified from other comprehensive income to interest income or expense (Effective portion)
 
Amount of gain (loss) recognized in other noninterest income (Ineffective portion)
Year Ended December 31, 2017
 
 
 
 
 
 
Interest rate swaps designated as cash flow hedges
 
$
4,263

 
$
(1,633
)
 
$
(3
)
    
At December 31, 2017 , the Corporation expected $0.3 million of unrealized income to be reclassified as a decrease to interest expense during the following twelve months.

Methods and assumptions used by the Corporation in estimating the fair value of its forward contracts, interest rate lock commitments and customer-initiated derivatives are discussed in Note 3.

Balance Sheet Offsetting
 
Certain financial instruments, including customer-initiated derivatives and interest rate swaps, may be eligible for offset in the Consolidated Statements of Financial Position and/or subject to master netting arrangements or similar agreements. The Corporation is party to master netting arrangements with its financial institution counterparties; however, the Corporation does not offset assets and liabilities under these arrangements for financial statement presentation purposes based on an accounting policy election. The tables below present information about the Corporation’s financial instruments that are eligible for offset.

 
 
 
 
 
 
 
 
Gross amounts not offset in the
statements of financial position
 
 
(Dollars in thousands)
 
Gross
amounts
recognized
 
Gross amounts
offset in the
statements of
financial condition
 
Net amounts
presented in the
statements of
financial position
 
Financial
instruments
 
Collateral
(received)/posted
 
Net
Amount
December 31, 2017
 
 

 
 

 
 

 
 

 
 

 
 

Offsetting derivative assets
 
 

 
 

 
 

 
 

 
 

 
 

Derivative assets
 
$
15,228

 
$

 
$
15,228

 
$

 
$

 
$
15,228

Offsetting derivative liabilities
 
 
 
 
 
 
 
 
 
 
Derivative liabilities
 
10,139

 

 
10,139

 

 
1,081

 
9,058

December 31, 2016
 
 

 
 

 
 

 
 

 
 

 
 

Offsetting derivative assets
 
 

 
 

 
 

 
 

 
 

 
 

Derivative assets
 
$
4,405

 
$

 
$
4,405

 
$

 
$

 
$
4,405

Offsetting derivative liabilities
 
 

 
 

 
 

 
 

 
 

Derivative liabilities
 
4,141

 

 
4,141

 

 
2,550

 
1,591



Note 12: Investments in Qualified Affordable Housing Projects, Federal Historic Projects and New Market Tax Credits

The Corporation invests in qualified affordable housing projects, federal historic projects, and new market projects for the purpose of community reinvestment and obtaining tax credits. Return on the Corporation's investment in these projects comes in the form of the tax credits and tax losses that pass through to the Corporation. The carrying value of the investments is reflected in "Interest receivable and other assets" on the Consolidated Statements of Financial Position. The Corporation utilizes the proportional amortization method to account for investments in qualified affordable housing projects and the equity method to account for investments in other tax credit projects.


133

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Under the proportional amortization method, the Corporation amortizes the initial cost of the investment in proportion to the tax credits and other tax benefits. The Corporation recognized additional income tax expense attributable to the amortization of investments in qualified affordable housing projects of $3.4 million , $2.6 million and $1.3 million during the years ended December 31, 2017 , 2016 and 2015 , respectively. The Corporation's remaining investment in qualified affordable housing projects accounted for under the proportional amortization method totaled $51.4 million at December 31, 2017 and $29.5 million  at December 31, 2016 .

Under the equity method, the Corporation's share of the earnings or losses is included in "Other operating expenses" on the Consolidated Statements of Income. The Corporation's remaining investment in new market projects accounted for under the equity method totaled $17.3 million and $10.9 million at December 31, 2017 and 2016 , respectively.

The Corporation's unfunded equity contributions relating to investments in qualified affordable housing projects, federal historic tax projects and new market projects is recorded in "Interest payable and other liabilities" on the Consolidated Statements of Financial Position. The Corporation's remaining unfunded equity contributions totaled $48.1 million and $16.0 million at December 31, 2017 and 2016 , respectively.

Management analyzes these investments for potential impairment when events or changes in circumstances indicate that it is more-likely-than-not that the carrying amount of the investment will not be realized. An impairment loss is measured as the amount by which the carrying amount of an investment exceeds its fair value. During the year ended December 31, 2017 , multiple federal housing tax credits were placed into service resulting in income tax benefit of $7.9 million , partially offset by i mpairment expense of $9.3 million , $6.0 million net of tax, recorded in "other noninterest expense." There was no impairment losses recognized as of December 31, 2016 .

The Corporation consolidates variable interest entities ("VIEs") in which it is the primary beneficiary. In general, a VIE is an entity that either (i) has an insufficient amount of equity to carry out its principal activities without additional subordinated financial support, (ii) has a group of equity owners that are unable to make significant decisions about its activities or (iii) has a group of equity owners that do not have the obligation to absorb losses or the right to receive returns as generated by its operations. If any of these characteristics are present, the entity is subject to a variable interest consolidation model, and consolidation is based on variable interests, not on ownership of the entity's outstanding voting stock. Variable interests are defined as contractual, ownership, or other monetary interests in an entity that change with fluctuations in the entity's net asset value. The primary beneficiary consolidates the VIE. The primary beneficiary is defined as the enterprise that has the power to direct the activities and absorb losses or the right to receive benefits. The Corporation is a significant limited partner in the qualified affordable housing, federal historic and new market projects it has invested in . These projects meet the definition of VIEs. However, the Corporation is not the primary beneficiary of any of the VIEs in which it holds a limited partnership interest; therefore, the VIEs are not consolidated in the Consolidated Financial Statements.
Note 13: Commitments, Contingencies and Guarantees
Commitments
In the normal course of business, the Corporation offers a variety of financial instruments containing credit risk that are not required to be reflected in the Consolidated Statements of Financial Position. These financial instruments include outstanding commitments to extend credit, approved but undisbursed loans (undisbursed loan commitments), credit lines, commercial letters of credit and standby letters of credit. The Corporation has risk management policies to identify, monitor and limit exposure to credit risk. To mitigate credit risk for these financial guarantees, the Corporation generally determines the need for specific covenant, guarantee and collateral requirements on a case-by-case basis, depending on the nature of the financial instrument and the customer's creditworthiness.
At December 31, 2017 and 2016 , the Corporation had $187.6 million and $118.9 million , respectively, of outstanding financial and performance standby letters of credit. The majority of these standby letters of credit are collateralized. The Corporation determined that there were no potential losses from standby letters of credit at December 31, 2017 and 2016 .
Commitments to extend credit are agreements to lend to a customer provided there is no violation of any condition established in the commitment. Commitments generally have fixed expiration dates or other termination clauses and may not require payment of a fee. Since many commitments expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements. The Corporation evaluates each customer's creditworthiness on an individual basis. The amount of collateral obtained, if deemed necessary by the Corporation upon extension of credit, is based on management's

134

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

credit evaluation of the counterparty. The collateral held varies, but may include securities, real estate, accounts receivable, inventory, plant or equipment. Unfunded commitments under commercial lines of credit, revolving credit lines and overdraft protection agreements are included in commitments to extend credit. These lines of credit are generally not collateralized, usually do not contain a specified maturity date and may be drawn upon only to the total extent to which the Corporation is committed. At December 31, 2017 and 2016 , the Corporation had $3.03 billion and $2.70 billion , respectively, of commitments to extend credit. The Corporation had undisbursed loan commitments of $571.0 million and $578.2 million at December 31, 2017 and 2016 , respectively. Undisbursed loan commitments are not included in loans on the Consolidated Statements of Financial Position. The majority of undisbursed loan commitments will be funded and convert to a portfolio loan within a one year period.
The allowance for credit losses on lending-related commitments included $1.2 million and $1.3 million at December 31, 2017 and 2016 , respectively, for probable credit losses inherent in the Corporation's unused commitments and was recorded in "Interest payable and other liabilities" in the Consolidated Statements of Financial Position.     
Contingencies and Guarantees
The Corporation has originated and sold certain loans, and additionally acquired the potential liability for those historical originated and sold loans by Talmer, for which the buyer has limited recourse to us in the event the loans do not perform as specified in the agreements. These loans had an outstanding balance of $13.3 million and $16.9 million at December 31, 2017 and 2016 , respectively. The maximum potential amount of undiscounted future payments that the Corporation could be required to make in the event of nonperformance by the borrower totaled $12.8 million and $16.1 million at December 31, 2017 and 2016 , respectively. In the event of nonperformance, the Corporation has rights to the underlying collateral securing the loans. At both December 31, 2017 and 2016 , the Corporation had recorded a liability of $0.2 million , in connection with the recourse agreements, recorded in "Interest payable and other liabilities" in the Consolidated Statements of Financial Position.
Representations and Warranties
In connection with the Corporation's mortgage banking loan sales, and the historical sales of merged or acquired entities, the Corporation makes certain representations and warranties that the loans meet certain criteria, such as collateral type and underwriting standards. The Corporation may be required to repurchase individual loans and/or indemnify the purchaser against losses if the loan fails to meet established criteria. At December 31, 2017 and 2016 , respectively, the liability recorded in connection with these representations and warranties totaled $5.3 million and $6.5 million , respectively.
A summary of the reserve for representations and warranties of the Corporation is as follows:
 
For the years ended December 31,
(Dollars in thousands)
2017
 
2016
 
2015
Reserve balance at beginning of period
$
6,459

 
$
4,048

 
$
3,000

Addition of fair value of representations and warranties due to mergers and acquisitions

 
3,100

 
1,712

Reserve reduction
(1,095
)
 
(580
)
 

Charge-offs
(15
)
 
(109
)
 
(664
)
Ending reserve balance
$
5,349

 
$
6,459

 
$
4,048

Reserve balance:
 
 
 
 
 
Liability for specific claims
531

 
730

 

General allowance
4,818

 
5,729

 
4,048

Total reserve balance
$
5,349

 
$
6,459

 
$
4,048

Operating Leases and Other Noncancelable Contractual Obligations
The Corporation has operating leases and other noncancelable contractual obligations on buildings, equipment, computer software and other expenses that will require annual payments through 2034 , including renewal option periods for those building leases that the Corporation expects to renew.

135

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Future minimum lease payments for operating leases and other noncancelable contractual obligations are as follows:
(Dollars in thousands)
Future Minimum
Lease Payments (1)
Years ending December 31,
 

2018
$
22,973

2019
21,487

2020
18,808

2021
16,794

2022
20,112

Thereafter
33,775

Total
$
133,949

(1)  
Future minimum lease payments are reduced by $0.9 million related to sublease income to be received within the next five years.

Minimum payments include estimates, where applicable, of estimated usage and annual Consumer Price Index increases of approximately 2.1% . Total expense recorded under operating leases and other noncancelable contractual obligations was $30.8 million in 2017 , compared to $20.4 million in 2016 and $15.6 million in 2015 .
Legal Proceedings
The Corporation and Chemical Bank are subject to various pending or threatened legal proceedings arising out of the normal course of business and related to our merger and acquisition history.
The Corporation assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Corporation will incur a loss and the amount of the loss can be reasonably estimated, the Corporation records a liability in the Consolidated Financial Statements. While the ultimate liability with respect to these litigation matters and claims cannot be determined at this time, in the opinion of management, the ultimate disposition of these matters is not expected to have a material adverse effect on the financial position or results of operations of the Corporation.

136

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 14: Deposits

A summary of deposits follows:
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Noninterest-bearing demand
 
$
3,725,779

 
$
3,341,520

Savings
 
1,697,762

 
1,662,115

Interest-bearing demand
 
2,724,415

 
2,825,801

Money market accounts
 
1,957,909

 
2,033,319

Brokered deposits
 
453,227

 
226,429

Other time deposits
 
3,083,711

 
2,783,938

Total deposits
 
$
13,642,803

 
$
12,873,122

    
Excluded from total deposits are demand deposit account overdrafts (overdrafts) which have been classified as loans. At December 31, 2017 and 2016 , overdrafts totaled $5.9 million and $5.0 million , respectively.

Deposits from executive officers, directors, principal shareholders and their related interests were $10.6 million at December 31, 2017 .

Time deposits, including certificates of deposit and certain individual retirement account deposits, of $250 thousand or more totaled $1.6 billion and $975.4 million at December 31, 2017 and 2016 , respectively. At December 31, 2017 , the scheduled maturities of time deposits for the next five years were as follows:

(Dollars in thousands)
 
2018
$
2,168,858

2019
646,514

2020
183,101

2021
134,806

2022
81,169

Thereafter
2,759

Total
$
3,217,207


137

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 15: Borrowings
A summary of the Corporation's short- and long-term borrowings follows:
 
 
December 31,
 
 
2017
 
2016
(Dollars in thousands)
 
Amount
 
Weighted Average Rate (1)
 
Amount
 
Weighted Average Rate (1)
Securities sold under agreements to repurchase with customers:
 
 
 
 
 
 
 
 
Securities sold under agreements to repurchase with customers
 
$
415,236

 
0.44
%
 
$
343,047

 
0.16
%
Short-term borrowings:
 
 
 
 
 
 
 
 
FHLB advances: 1.25% - 1.50% fixed-rate notes
 
2,000,000

 
1.39

 
825,000

 
0.65

Long-term borrowings:
 
 
 
 
 
 
 
 
FHLB advances: 0.92% - 2.60% fixed-rate notes due 2018 to 2020 (2)
 
337,204

 
1.26

 
438,538

 
1.24

Securities sold under agreements to repurchase (3)
 

 

 
19,144

 
3.17

Line-of-credit: floating-rate based on one-month LIBOR plus 1.75%
 
19,963

 
3.10

 
124,625

 
2.52

Subordinated debt obligations: floating-rate based on three-month LIBOR plus 1.45% - 2.85% due 2034 to 2035 (4)
 
11,425

 
3.69

 
11,285

 
3.14

Subordinated debt obligations: floating-rate based on three-month LIBOR plus 3.25% due in 2032 (5)
 
4,290

 
4.59

 
4,255

 
4.25

Total long-term borrowings
 
372,882

 
1.47

 
597,847

 
1.63

Total short-term and long-term borrowings
 
$
2,788,118

 
1.26
%
 
$
1,765,894

 
0.89
%
(1)  
Weighted average rate presented is the contractual rate which excludes premiums and discounts related to purchase accounting.
(2)  
The December 31, 2017 balance includes advances payable of $337.0 million and purchase accounting premiums of $0.2 million . The December 31, 2016 balance includes advances payable of $437.8 million and purchase accounting premiums of $0.7 million .
(3)  
The December 31, 2016 balance includes advance payable of $19.0 million and purchase accounting premiums of $0.1 million .
(4)  
The December 31, 2017 balance includes advances payable of $15.0 million and purchase accounting discounts of $3.6 million . The December 31, 2016 balance includes advance payable of $15.0 million and purchase accounting premiums of $3.7 million .
(5)  
The December 31, 2017 balance includes advances payable of $5.0 million and purchase accounting discounts of $0.7 million . The December 31, 2016 balance includes advance payable of $5.0 million and purchase accounting premiums of $0.7 million .

Chemical Bank is a member of the FHLB, which provides short- and long-term funding collateralized by mortgage related assets to its members. Each advance is payable at its maturity date, with a prepayment penalty for fixed-rate advances. The Corporation's FHLB advances, including both short-term and long-term, require monthly interest payments and are collateralized by commercial and residential mortgage loans totaling $7.36 billion as of December 31, 2017 . The Corporation's additional borrowing availability through the FHLB, subject to the FHLB's credit requirements and policies and based on the amount of FHLB stock owned by the Corporation, was $193.5 million at December 31, 2017 .

In conjunction with the merger with Talmer, the Corporation entered into a credit agreement of $145.0 million consisting of a $125.0 million term line-of credit and a $20.0 million revolving line-of-credit. The Corporation drew $125.0 million on the term line-of-credit to pay off the Corporation's prior $25.0 million line-of-credit and a $37.5 million line-of-credit acquired in the merger with Talmer, with the remaining proceeds used to partially fund the cash portion of the merger consideration. The line-of-credit agreement contains covenants related to certain thresholds that must be maintained related to the nonperforming assets to tangible capital ratio, the loan loss reserve to nonperforming loan ratio, the liquidity ratio and return on average assets. The Corporation was in compliance with all of the covenants at December 31, 2017 .

138

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

At December 31, 2017 , the contractual principal payments due and the amortization/accretion of purchase accounting adjustments for the remaining maturities of long-term debt over the next five years and thereafter are as follows:
(Dollars in thousands)
Long-term Debt by Maturity
Years Ending December 31,
 
2018
$
147,065

2019
100,058

2020
110,044

2021

2022

Thereafter
15,715

Total
$
372,882


Note 16: Income Taxes
The current and deferred components of the provision for income taxes were as follows:
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Current income tax expense (benefit)
 
 
 
 
 
 
Federal
 
$
14,665

 
$
19,144

 
$
31,300

State
 
20

 
(423
)
 

Total current income tax expense
 
14,685

 
18,721

 
31,300

Deferred expense (benefit)
 
 
 
 
 
 
Federal
 
92,636

 
23,649

 
5,700

State
 
548

 
442

 

Total deferred income tax expense (benefit)
 
93,184

 
24,091

 
5,700

Change in valuation allowance
 
(1,089
)
 
(706
)
 

Income tax provision
 
$
106,780

 
$
42,106

 
$
37,000


139

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

A reconciliation of expected income tax expense at the federal statutory income tax rate and the amounts recorded in the Consolidated Financial Statements were as follows:
 
 
Years Ended December 31,
 
 
2017
 
2016
 
2015
(Dollars in thousands)
 
Amount
 
Rate
 
Amount
 
Rate
 
Amount
 
Rate
Tax at statutory rate
 
$
89,706

 
35.0
 %
 
$
52,548

 
35.0
 %
 
$
43,341

 
35.0
 %
Changes resulting from:
 
 
 
 
 
 
 
 
 
 
 
 
Tax-exempt interest income
 
(9,001
)
 
(3.5
)
 
(5,320
)
 
(3.5
)
 
(3,943
)
 
(3.2
)
State taxes, net of federal benefit
 
369

 
0.1

 
13

 

 

 

Change in valuation allowance
 
(1,089
)
 
(0.4
)
 
(706
)
 
(0.5
)
 

 

Bank-owned life insurance adjustments
 
(1,696
)
 
(0.7
)
 
(832
)
 
(0.6
)
 
(124
)
 
(0.1
)
Director plan change in control
 

 

 
(508
)
 
(0.3
)
 

 

Income tax credits, net
 
(11,449
)
 
(4.4
)
 
(2,454
)
 
(1.6
)
 
(2,557
)
 
(2.1
)
Nondeductible transaction expenses
 
156

 
0.1

 
2,100

 
1.4

 
411

 
0.3

Tax benefits in excess of compensation costs on share-based payments (1)
 
(5,886
)
 
(2.3
)
 
(2,240
)
 
(1.5
)
 

 

Impact of the Tax Cuts and Jobs Act (2)
 
46,660

 
18.2

 

 

 

 

Other, net
 
(990
)
 
(0.4
)
 
(495
)
 
(0.4
)
 
(128
)
 

Income tax expense
 
$
106,780

 
41.7
 %
 
$
42,106

 
28.0
 %
 
$
37,000

 
29.9
 %
(1)  
The years ended December 31, 2017 and 2016 reflect the adoption of ASU 2016-09, as of January 1, 2016, which results in excess tax benefits recognized within "Income tax expense" rather than previously recognized directly into equity with "Additional paid-in-capital." Refer to Note 1, Summary of Significant Accounting Policies, for further details.
(2)  
The year ended December 31, 2017 included the impact of the enactment of H.R.1 (the "Tax Cuts and Jobs Act"), which required a revaluation of net deferred tax assets and liabilities, see below for further details.

On December 22, 2017, H.R.1 (known as the "Tax Cuts and Jobs Act") was signed into law. Among other provisions, the Tax Cuts and Jobs Act, reduces the statutory corporate income tax rate from a maximum rate of 35% to flat tax rate of 21% , effective January 1, 2018. ASC Topic 740 requires the recognition of the effects of tax law changes be recorded in the period in which the law is enacted. Therefore, the Corporation's deferred tax assets and liabilities which were previously valued at a federal rate of 35% , were revalued to the current enacted federal tax rate of 21% . The impact of the Tax Cuts and Jobs Act resulted in a $46.7 million increase to income tax expense related to continuing operations as a result of the revaluation of the net deferred tax asset of $46.0 million and an acceleration of amortization expense on the low income housing tax credit investment portfolio of $0.7 million .

The SEC issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act, thereby allowing a measurement period to reflect provisional adjustments as information becomes available. The measurement period includes the Tax Cuts and Jobs Acts' enactment date up until one year after. The Corporation does not have any provisional adjustments to its net deferred tax asset as a result of the tax reform at December 31, 2017 under Staff Accounting Bulletin No. 118, but the Corporation will have adjustments in 2018 to reflect the impact of the rate reduction on various deferred items that management reasonably estimated at December 31, 2017 and will true up with the filing of the 2017 tax return in 2018.
    

140

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows:
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Deferred tax assets:
 
 
 
 
Allowance for loan losses
 
$
20,446

 
$
45,763

Acquisition-related fair value adjustments
 
27,607

 
54,704

Accrued stock-based compensation
 
4,082

 
18,891

Loss and tax credit carry forwards
 
57,969

 
76,446

Depreciation
 
2,954

 
11,270

Nonaccrual loan interest
 
6,155

 
9,465

Accrued expense
 
9,200

 
20,858

Other
 
9,127

 
15,751

Total deferred tax assets
 
137,540

 
253,148

Deferred tax liabilities:
 
 
 
 
Loan servicing rights
 
13,446

 
20,450

Core deposit intangible assets
 
6,022

 
11,844

Goodwill
 
4,076

 
6,373

Prepaid expenses
 
7,390

 
4,873

Other
 
7,735

 
2,762

Total deferred tax liabilities
 
38,669

 
46,302

Net deferred tax asset before valuation allowance
 
98,871

 
206,846

Valuation allowance
 
(1,150
)
 
(2,239
)
Net deferred tax asset
 
$
97,721

 
$
204,607

On August 31, 2016, the Corporation merged with Talmer and recorded $151.9 million in deferred tax assets, net of valuation allowance. In connection with the merger, Talmer incurred an ownership change within the meaning of Section 382 of the Internal Revenue Code ("IRC"). At August 31, 2016, Talmer had $102.8 million in gross federal net operating loss carry forwards, $88.7 million in gross realized built-in loss carry forwards, $1.0 million in federal tax credit carry forwards that expire from 2026 through 2035, and $14.9 million in federal alternative minimum tax credits with an indefinite life.

The valuation allowance against the Corporation’s deferred tax assets at December 31, 2017 totaled $1.2 million and included $0.6 million due to IRC Section 382 limitations on the utilization of pre-ownership change loss and tax credit carry forwards associated with Talmer’s previously acquired entities and $0.6 million due to management’s estimate of capital loss carry forwards more likely than not to expire unutilized. Actual outcomes could vary from the Corporation's current estimates, resulting in future increases or decreases in the valuation allowance and corresponding future tax expense or benefit.

Due to the substantial equity value of Talmer at the time of the ownership change, the entity was deemed to be in a net unrealized built-in gain position which allows for the utilization of certain carry forward attributes. Therefore, no additional valuation allowance was established against Talmer's net deferred tax assets.


141

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following table is a summary of the loss attributes, Section 382 limitations, and tax expiration periods as of December 31, 2017 .
 
From the Acquisition of:
 
 
 
 
 
 
 
 
 
Talmer's Prior Ownership Changes
 
 
 
 
(Dollars in thousands)
Talmer
 
Monarch
 
First Place Holdings/First Place Bank
 
Talmer West Bank
 
First of Huron Corp./Signature Bank
 
From 2009 Ownership change
 
Not Limited by Section 382
 
Total
Tax Loss and Credit Carryforwards as of 12/31/17:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Years Expiring (except AMT Credits)
2032-2034
 
2026-2034
 
2027-2031
 
2028-2032
 
2029-2032
 
2027-2029
 
2036
 
 
Annual Section 382 limitation-base (1)
$
34,668

 
$
673

 
$
6,650

 
$
3,028

 
$
365

 
$
145

 
$

 
$ N/A

Gross Federal Net Operating Losses

 
15,047

 

 
47,284

 
649

 
1,740

 

 
64,720

Gross Capital Losses

 

 

 

 

 

 

 

Realized Built-in Losses

 

 
68,356

 
8,936

 

 

 

 
77,292

Business Tax Credits
170

 
1,651

 
781

 

 

 

 
912

 
3,514

Less amounts not recorded due to Sec 382 Limitation

 
(1,738
)
 
(65
)
 
(3,218
)
 

 
(145
)
 

 
(5,166
)
Alternative Minimum Tax Credits - no expiration
12,473

 
106

 
2,115

 

 
303

 

 
10,832

 
25,829

Valuation Allowance

 

 

 
(585
)
 

 

 
(565
)
 
(1,150
)
(1)  
In respect to the Monarch and Talmer acquisitions, in addition to the statutory "base" Section 382 limitation, recognized built in gain increases the Section 382 limitation during the five year period beginning on the acquisition date. The Corporation estimates that the recognized built in gain will total $2.8 million and $253.2 million for the Monarch and Talmer acquisitions, respectively.

Management concluded that no valuation allowance was necessary on the remainder of the Corporation's net deferred tax assets at December 31, 2017 and 2016 . This determination was based on the Corporation's history of pre-tax and taxable income over the prior three years, as well as management's expectations for sustainable profitability in the future. Management monitors deferred tax assets quarterly for changes affecting the ability to realize and the valuation allowance could be adjusted in future periods.
At December 31, 2017 , the Corporation had approximately $36.0 million of bad debt reserve in equity for which no provision for federal income taxes was recorded. This amount represents Talmer's qualifying thrift bad debt reserve at December 31, 1987 through its acquisition of First Place Bank, which is only required to be recaptured into taxable income if certain events occur. At December 31, 2017 , the potential tax on the above amount was approximately $7.5 million . The Corporation does not intend to take any action that would result in a recapture of any portion of its bad debt reserve.
The Corporation's federal tax return for the years ended December 31, 2014 to present are open to potential examination. Talmer amended its four federal tax returns for the years 2011, 2012, 2013 and 2014 to reflect the impact of changes to First Place Bank due to an IRS settlement in January of 2016. These four amendments were selected for audit which concluded with no changes and all expected refunds were received in 2017.The Corporation's most significant states of operation, Michigan and Ohio, do not impose income-based taxes on financial institutions. The Corporation and/or its subsidiaries are subject to immaterial amounts of income tax in various other states, with varying years open to potential examination. The Corporation received notice in February 2018 that Talmer Bancorp's Ohio Financial Institutions tax has been selected for audit for the years ended December 31, 2013, 2014 and 2015.
The Corporation had no unrecognized tax benefits at December 31, 2017 or 2016 and does not expect to record unrecognized tax benefits of any significance during the next twelve months. The Corporation recognizes interest and/or penalties related to income tax matters in income tax expense, when applicable. There were no liabilities accrued for interest and/or penalties at December 31, 2017 or 2016 .

142

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 17: Share-Based Compensation
The Corporation maintains share-based compensation plans under which it periodically grants share-based awards for a fixed number of shares to certain officers of the Corporation. The fair value of share-based awards is recognized as compensation expense over the requisite service or performance period. During the years ended December 31, 2017 , 2016 and 2015 , share-based compensation expense related to share-based awards totaled $17.3 million , $14.7 million and $3.7 million , respectively. The excess tax benefit realized from shared-based compensation transactions during the years ended December 31, 2017 , 2016 and 2015 was $6.1 million , $2.2 million and $0.5 million , respectively.
During the year ended December 31, 2017 , the Corporation granted options to purchase 132,414 shares of common stock, 169,252 restricted stock units and 72,537 shares of common stock to certain officers of the Corporation.
On April 26, 2017, the shareholders of the Corporation approved the Stock Incentive Plan of 2017, which provides for 1,750,000 shares of the Corporation's common stock to be made available for future equity-based awards and canceled the amount of shares available for future grant under prior share-based compensation plans. At December 31, 2017 , there were 1,681,101 shares of common stock available for future grants under the Stock Incentive Plan of 2017.
Stock Options
The Corporation issues stock options to certain officers from time to time. The exercise price on stock options equals the current market price of the Corporation's common stock on the date of grant and stock options expire ten years from the date of grant. Stock options granted after 2012 vest ratably over a five -year period. Stock options granted prior to 2013 generally vest ratably over a three -year period. Stock options granted prior to 2016 fully vested upon completion of the merger with Talmer. Stock options assumed by the Corporation in the merger with Talmer were fully vested prior to assumption.
The following summarizes information about stock options outstanding and exercisable at December 31, 2017 :
 
 
Options outstanding
 
Options exercisable
Range of
exercise
prices
per share
 
Number
outstanding
 
Weighted
average
exercise
price
per share
 
Weighted
average
contractual
term
(in years)
 
Number
exercisable
 
Weighted
average
exercise
price
per share
 
Weighted
average
contractual
term
(in years)
$11.09 - 12.80
 
32,691

 
$
12.37

 
2.93
 
32,691

 
$
12.37

 
2.93
$13.20 - 16.24
 
136,604

 
15.94

 
4.92
 
136,604

 
15.94

 
4.92
$19.97 - 21.10
 
49,546

 
20.36

 
2.62
 
49,546

 
20.36

 
2.62
$23.78 - 25.14
 
232,582

 
24.56

 
4.33
 
232,582

 
24.56

 
4.33
$29.45 - 32.81
 
537,893

 
31.68

 
7.62
 
290,534

 
30.72

 
7.15
$46.95 - 53.72
 
121,602

 
53.40

 
9.25
 
38,091

 
53.72

 
9.23
$11.09 - 53.72
 
1,110,918

 
$
29.56

 
6.42
 
780,048

 
$
25.99

 
5.56
The intrinsic value of all outstanding in-the-money stock options and exercisable in-the-money stock options was $26.6 million and $21.4 million , respectively, at December 31, 2017 . The aggregate intrinsic values of outstanding and exercisable options at December 31, 2017 were calculated based on the closing market price of the Corporation's common stock on December 31, 2017 of $53.47 per share less the exercise price. Options with intrinsic values less than zero, or "out-of-the-money" options, are not included in the aggregate intrinsic value reported. The total intrinsic value of stock options for the years ended December 31, 2016 and 2015 was $80.4 million and $7.6 million , respectively.


143

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

A summary of activity for the Corporation's stock options as of and during the years ended December 31, 2017 , 2016 and 2015 is presented below:
 
 
Non-vested
stock options outstanding
 
Stock options outstanding
 
 
Number of
options
 
Weighted-
average
exercise
price
per share
 
Weighted-
average
grant date
fair value
per share
 
Number of
options
 
Weighted-
average
exercise
price
per share
Outstanding at December 31, 2014
 
432,199

 
$
26.75

 
$
8.30

 
1,037,311

 
$
25.90

Granted
 
244,165

 
30.18

 
8.40

 
244,165

 
30.18

Acquired
 

 

 

 
132,883

 
12.93

Exercised
 

 

 

 
(310,985
)
 
25.10

Vested
 
(150,224
)
 
25.57

 
7.80

 

 

Forfeited/expired
 
(46,385
)
 
27.99

 
8.50

 
(48,635
)
 
28.18

Outstanding at December 31, 2015
 
479,755

 
$
28.75

 
$
8.49

 
1,054,739

 
$
25.38

Granted
 
441,167

 
32.81

 
6.15

 
441,167

 
32.81

Acquired
 

 

 

 
1,466,408

 
15.08

Exercised
 

 

 

 
(450,296
)
 
20.02

Vested
 
(454,360
)
 
28.74

 
8.49

 

 

Forfeited/expired
 
(58,623
)
 
31.10

 
7.17

 
(58,623
)
 
31.10

Outstanding at December 31, 2016
 
407,939

 
$
32.81

 
$
6.15

 
2,453,395

 
$
21.41

Granted
 
132,414

 
53.43

 
9.94

 
132,414

 
53.43

Exercised
 

 

 

 
(1,427,159
)
 
17.50

Vested
 
(161,751
)
 
37.73

 
7.07

 

 

Forfeited/expired
 
(47,732
)
 
37.55

 
7.03

 
(47,732
)
 
37.55

Outstanding at December 31, 2017
 
330,870

 
$
37.97

 
$
7.09

 
1,110,918

 
$
29.56

Exercisable/vested at December 31, 2017
 
 
 
 
 
 
 
780,048

 
$
25.99

Total cash received from option exercises during the years ended December 31, 2017 , 2016 and 2015 was $3.2 million , $2.7 million and $2.3 million , respectively, resulting in the issuance of 621,355 shares, 229,055 shares and 134,659 shares, respectively.
At December 31, 2017 , unrecognized compensation expense related to stock options totaled $1.9 million and is expected to be recognized over a remaining weighted average period of 3.5 years.
The fair value of the stock options granted during the years ended December 31, 2017 , 2016 and 2015 were estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions.
 
 
2017
 
2016
 
2015
Expected dividend yield
 
3.31
%
 
3.30
%
 
3.50
%
Risk-free interest rate
 
2.05
%
 
1.39
%
 
1.78
%
Expected stock price volatility
 
26.7
%
 
27.9
%
 
39.1
%
Expected life of options — in years
 
6.0

 
6.5

 
7.0

Weighted average fair value of options granted
 
$9.94
 
$6.15
 
$8.40
The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and the expected life of the options granted. Expected stock volatility was based on historical volatility of the Corporation's common stock over the expected life of the option. The expected life of options represents the period of time that options granted are expected to be outstanding and is based primarily upon historical experience, including option exercise behavior.

144

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Because of the unpredictability of the assumptions required, the Black-Scholes (or any other valuation) model is incapable of accurately predicting the Corporation's common stock price or of placing an accurate present value on options to purchase its stock. In addition, the Black-Scholes model was designed to approximate value for types of options that are very different from those issued by the Corporation. In spite of any theoretical value that may be placed on a stock option grant, no value is possible under options issued by the Corporation without an increase in the market price per share of the Corporation's common stock over the market price per share of the Corporation's common stock at the date of grant.
Restricted Stock Units
The Corporation grants Performance-Based Restricted Stock Units ("PRSUs") and Time-Based Restricted Stock Units ("TRSUs") (collectively referred to as RSUs) to certain officers from time to time. The PRSUs vest based on the Corporation achieving certain performance target levels and the grantee completing the requisite service period. The PRSUs are eligible to vest from 0.5 x to 1.5 x the number of units originally granted depending on which, if any, of the performance target levels are met. However, if the minimum performance target levels are not achieved, no shares will become vested or be issued for that respective year's PRSUs. The TRSUs vest upon satisfaction of a service condition. Upon achievement of the performance target level and/or satisfaction of a service condition, as applicable, the RSUs are converted into shares of the Corporation's common stock on a one-to-one basis. Compensation expense related to RSUs is recognized over the expected requisite performance or service period, as applicable.
A summary of the activity for RSUs during the year ended December 31, 2017 is presented below:
 
 
Number of
units
 
Weighted-average
grant date fair value per unit
Outstanding at December 31, 2016
 
298,357

 
$
32.81

Granted
 
169,252

 
51.93

Converted into shares of common stock
 
(75,639
)
 
30.73

Forfeited/expired
 
(11,030
)
 
47.62

Outstanding at December 31, 2017
 
380,940

 
$
41.29

At December 31, 2017 , unrecognized compensation expense related to RSUs totaled $9.0 million and is expected to be recognized over a remaining weighted average period of 2.7 years .
Restricted Stock Awards
The Corporation assumed restricted stock awards in the merger with Talmer that vest upon completion of future service requirements. The fair value of these awards is equal to the market price of the Corporation's common stock at the date the awards were assumed with the portion of the fair value related to post-combination service. The Corporation recognizes stock-based compensation expense over the vesting period, using the straight-lined method, based upon the number of shares of restricted stock ultimately expected to vest. If an individual that has been awarded restricted stock awards terminates their employment prior to the end of the vesting period, the unvested portion of the stock is forfeited, with certain exceptions.
The following table provides information regarding nonvested restricted stock awards:
Nonvested restricted stock awards
 
Number of awards
 
Weighted-average acquisition-date fair value
Nonvested at January 1, 2017
 
365,891

 
$
46.23

Vested
 
(277,821
)
 
46.23

Forfeited
 
(4,842
)
 
46.23

Nonvested at December 31, 2017
 
83,228

 
$
46.23

At December 31, 2017 , unrecognized compensation expense related to nonvested restricted stock awards totaled $2.2 million and is expected to be recognized over a remaining weighted average period of 1.1 years .

145

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 18: Retirement Plans
The Corporation's retirement plans include a qualified defined benefit pension plan, a nonqualified pension plan, a nonqualified postretirement benefit plan, a 401(k) savings plan, and a multi-employer defined benefit plan.
Qualified Defined Benefit Pension Plan
The Chemical Financial Corporation Employees’ Pension Plan (the "Pension Plan") is a qualified defined benefit, noncontributory pension plan, which provides for postretirement pension benefits for certain salaried employees of the Corporation and its subsidiary, Chemical Bank. Benefits under the Pension Plan were partially frozen effective June 30, 2006. Under the partial freeze of the Pension Plan, benefits for employees with less than 15 years of service or whose combined age plus years of service were less than 65 at June 30, 2006, were based on years of vested service at June 30, 2006 and generally the average of the employee's salary for the five years ended June 30, 2006. In addition, no employee hired after January 1, 2006 was eligible to participate in the Pension Plan. Effective September 30, 2017, the Pension and Compensation Committee approved an amendment to the Pension Plan to cease accruing additional benefits under the existing pension benefit formula after the effective date and all accrued benefits were frozen. Retirement benefits under the Pension Plan are based on years of vested service at September 30, 2017, up to a maximum of thirty years, and the employee's average annual pay for the five highest consecutive years during the ten years preceding September 30, 2017, except for employees whose benefits were previously frozen during 2006.
Pension Plan benefits are the present value of estimated future periodic payments that are attributable to services rendered by the employees to the valuation date. Benefits include the benefits expected to be paid to (a) retired or terminated employees or their beneficiaries and (b) present employees or their beneficiaries.
The freeze of the Pension Plan effective September 30, 2017, required a remeasurement of the plan's projected benefit obligation. The combined impact of the remeasurement, an increase in fair value of underlying assets, the impact of the freeze and changes to participant's status as a result of the Corporation's restructuring efforts during the year ended December 31, 2017, resulted in an increase of the funded status of the Pension Plan. A discount rate of 3.68% was utilized to remeasure the projected benefit obligation as of December 31, 2017. There was less than $0.1 million of curtailment cost to the Corporation as a result of the amendment. The Pension Plan is fully funded as of December 31, 2017 . At December 31, 2017 , the Corporation had 100  employees who had accrued benefits under the Pension Plan, which contributions are intended to provide benefits attributable to service-to-date employees.
Pension Plan expense was a benefit of $1.5 million in 2017 , compared to expenses of $0.1 million in 2016 and $1.6 million in 2015 .
Nonqualified Pension Plan
The Corporation has a supplemental defined benefit nonqualified pension plan, the Chemical Financial Corporation Supplemental Pension Plan ("SERP"). The Corporation established the SERP to provide payments to certain executive officers of the Corporation, as determined by the Compensation and Pension Committee. The Internal Revenue Code limits both the amount of eligible compensation for benefit calculation purposes and the amount of annual benefits that may be paid from a tax-qualified retirement plan. The SERP was designed to provide benefits to which executive officers of the Corporation would have been entitled, calculated under the provisions of the Pension Plan, as if the limits imposed by the Internal Revenue Code did not apply. The SERP is an unfunded plan and, therefore, has no assets.
Effective September 30, 2017, the Pension and Compensation Committee approved a curtailment to the SERP, due to the retirement of the final remaining participant in the SERP. The curtailment, in addition to changes in valuation of liabilities, resulted in a reduction in obligation during the year ended December 31, 2017. As of December 31, 2017 , a $2.4 million liability included in other liabilities was recorded in the Consolidated Statements of Financial Position related to the SERP. As of December 31, 2017 , the SERP had no active participants.
Nonqualified Postretirement Benefit Plan
The Corporation has a nonqualified postretirement benefit plan ("Postretirement Plan") that provides medical and dental benefits, upon retirement, to a limited number of active and retired employees. The majority of the retirees are required to make contributions toward the cost of their benefits based on their years of credited service and age at retirement. Beginning January 1, 2012, the Corporation amended the Postretirement Plan to extend coverage to employees who were at least age 50 as of January 1, 2012. These employees must also retire at age 60 or older, have at least twenty-five years of service with the Corporation and be participating in the active employee group health insurance plan in order to be eligible to participate in the Corporation's Postretirement Plan. Eligible employees may also cover their spouse until age 65 as long as the spouse is not offered health insurance coverage through his or her employer. Employees and their spouses eligible to participate in the Postretirement Plan will be required

146

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

to make contributions toward the cost of their benefits upon retirement, with the contribution levels designed to cover the projected overall cost of these benefits over the long-term. Retiree contributions are generally adjusted annually. The accounting for these postretirement benefits anticipates changes in future cost-sharing features such as retiree contributions, deductibles, copayments and coinsurance. The Corporation reserves the right to amend, modify or terminate these benefits at any time.
401(k) Savings Plan
The Corporation's 401(k) Savings Plan provides an employer match, in addition to a 4.0% contribution for all employees, with the exception of employees participating the Pension Plan discussed above, during the time period they were eligible to earn service credits. The 401(k) Savings Plan is available to all regular employees and provides employees with tax deferred salary deductions and alternative investment options. The Corporation matches 50.0% of the participants' elective deferrals on the first 4.0% of the participants' base compensation up to the maximum amount allowed under the Internal Revenue Code. The 401(k) Savings Plan provides employees with the option to invest in the Corporation's common stock. The Corporation's match under the 401(k) Savings Plan was $2.9 million in 2017 , $3.0 million in 2016 and $1.6 million in 2015 . Employer contributions to the 401(k) Savings Plan for the 4.0% benefit for employees totaled $6.2 million in 2017 , $3.5 million in 2016 and $3.1 million in 2015 . The combined amount of the employer match and 4.0% contribution to the 401(k) Savings Plan totaled $9.1 million in 2017 , $6.5 million in 2016 and $4.7 million in 2015 .
Multi-Employer Defined Benefit Plan
In conjunction with the April 1, 2015 acquisition of Monarch, the Corporation acquired a participation in the Pentegra Defined Benefit Plan for Financial Institutions (Pentegra DB Plan), a qualified defined benefit plan. Employee benefits for Monarch employees under the Pentegra DB Plan were frozen effective April 1, 2004. The Pentegra DB Plan operates as a multi-employer plan for accounting purposes and as a multiple employer plan under the Employee Retirement Income Security Act of 1974 and the Internal Revenue Code (IRC). The Pentegra DB Plan is a single plan under IRC Section 413(c) and, as a result, all the plan's assets stand behind all of the plan's liabilities. Accordingly, contributions made by a participating employer may be used to provide benefits to participants of other participating employers. No contributions were made to the Pentegra DB Plan during the years ended December 31, 2017 and 2016 .
The Pentegra DB Plan's Employer Identification Number is 13-5645888 and the Plan Number is 333. Financial information for the Pentegra DB Plan, which maintains a June 30 year end, is made available through the public Form 5500 which is available by April 15th of the year following the plan year end. The Pentegra DB Plan was fully funded as of its most recent year end. The Corporation's allocation of assets and liabilities in the Pentegra DB Plan totaled $3.7 million and $2.6 million respectively, as of December 31, 2017 , and the Corporation's allocation of assets comprised 0.1% of the plan's total assets at that date.

147

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Benefit Obligations and Plan Expenses
The following schedule sets forth the changes in the projected benefit obligation and plan assets of the Corporation's Plans:
 
 
Pension Plan
 
Postretirement Plan
 
SERP
(Dollars in thousands)
 
2017
 
2016
 
2017
 
2016
 
2017
 
2016
Projected benefit obligation:
 
 
 
 
 
 
 
 
 
 
 
 
Benefit obligation at beginning of year
 
$
123,968

 
$
119,873

 
$
2,601

 
$
3,247

 
$
2,567

 
$
2,160

Service cost
 
639

 
1,041

 
5

 
9

 
61

 
77

Interest cost
 
4,966

 
5,335

 
94

 
132

 
69

 
92

Settlement and other charges (1)
 

 

 

 

 

 
(264
)
Net actuarial loss (gain)
 
10,131

 
2,684

 
10

 
(478
)
 
(274
)
 
536

Benefits paid
 
(6,432
)
 
(4,965
)
 
(198
)
 
(309
)
 

 
(34
)
Curtailment
 
(11,911
)
 

 

 

 

 

Benefit obligation at end of year
 
121,361

 
123,968

 
2,512

 
2,601

 
2,423

 
2,567

Fair value of plan assets:
 
 
 
 
 
 
 
 
 
 
 
 
Fair value of plan assets at beginning of year
 
132,751

 
126,930

 

 

 

 

Actual return on plan assets
 
19,582

 
10,786

 

 

 

 

Employer contributions
 

 

 
198

 
309

 

 

Benefits paid
 
(6,432
)
 
(4,965
)
 
(198
)
 
(309
)
 

 

Fair value of plan assets at end of year
 
145,901

 
132,751

 

 

 

 

Funded (unfunded) status at December 31
 
$
24,540

 
$
8,783

 
$
(2,512
)
 
$
(2,601
)
 
$
(2,423
)
 
$
(2,567
)
Accumulated benefit obligation
 
$
121,361

 
$
115,418

 
$
2,512

 
$
2,601

 
$
2,423

 
$
2,567

(1)  
The settlement and other charges relate to the change in control as a result of the merger with Talmer as of August 31, 2016.

The Corporation did not make a contribution to the Pension Plan in either 2017 or 2016 . The Corporation is not required to make a contribution to the Pension Plan in 2018 .

148

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Weighted-average rate assumptions of the Corporation's Plans follow:
 
 
Pension Plan
 
Postretirement Plan
 
SERP
 
 
2017
 
2016
 
2015
 
2017
 
2016
 
2015
 
2017
 
2016
 
2015
Discount rate used in determining benefit obligation — December 31
 
3.68
%
 
4.22
%
 
4.55
%
 
3.41
%
 
3.79
%
 
4.23
%
 
3.38
%
 
3.63
%
 
4.51
%
Discount rate used in determining expense
 
4.22

 
4.55

 
4.15

 
3.79

 
4.23

 
3.75

 

 
4.51

 
4.07

Discount rate used in determining expense — prior to remeasurement
 
3.81

 

 

 

 

 

 
3.63

 
2.87

 

Expected long-term return on Pension Plan assets
 
6.75

 
6.75

 
6.75

 

 

 

 

 

 

Rate of compensation increase used in determining benefit obligation — December 31
 

 
3.50

 
3.50

 

 

 

 

 
3.50

 
3.50

Rate of compensation increase used in determining pension expense
 
3.50

 
3.50

 
3.50

 

 

 

 
3.50

 
3.50

 
3.50

Year 1 increase in cost of postretirement benefits
 

 

 

 
6.5

 
7.0

 
7.5

 

 

 

Net periodic pension cost (income) of the Corporation's Plans was as follows for the years ended December 31:
 
 
Pension Plan
 
Postretirement Plan
 
SERP
(Dollars in thousands)
 
2017
 
2016
 
2015
 
2017
 
2016
 
2015
 
2017
 
2016
 
2015
Service cost
 
$
639

 
$
1,041

 
$
1,021

 
$
5

 
$
9

 
$
16

 
$
61

 
$
77

 
$
70

Interest cost
 
4,966

 
5,335

 
5,242

 
94

 
132

 
133

 
69

 
92

 
85

Expected return on plan assets
 
(8,938
)
 
(8,562
)
 
(8,645
)
 

 

 

 

 

 

Amortization of prior service credit
 

 

 
(5
)
 

 
117

 
130

 

 

 

Amortization of net actuarial loss (gain)
 
1,837

 
2,259

 
3,962

 
(162
)
 
(100
)
 
(1
)
 
77

 
78

 
262

Curtailment
 
1

 

 

 

 

 

 

 

 

Settlement (1)
 

 

 

 

 

 

 
322

 
120

 

Net cost (income)
 
$
(1,495
)
 
$
73

 
$
1,575

 
$
(63
)
 
$
158

 
$
278

 
$
529

 
$
367

 
$
417

(1)  
The settlement charge relates to the settlement of liabilities under the SERP for the retirement of the plan participant during the third quarter of 2017 and the change in control as a result of the merger with Talmer as of August 31, 2016.


149

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The following schedule presents estimated future benefit payments for the next 10 years under the Corporation's Plans for retirees already receiving benefits and future retirees, assuming they retire and begin receiving unreduced benefits as soon as they are eligible:
(Dollars in thousands)
 
Pension Plan
 
Postretirement Plan
 
SERP
2018
 
$
6,001

 
$
230

 
$
2,063

2019
 
6,297

 
230

 
22

2020
 
6,392

 
231

 
22

2021
 
6,657

 
230

 
22

2022
 
6,787

 
227

 
22

2023 - 2027
 
35,689

 
973

 
107

Total
 
$
67,823

 
$
2,121

 
$
2,258

For measurement purposes for the Postretirement Plan, the annual rates of increase in the per capita cost of covered health care benefits and dental benefits for 2018 were each assumed at 7.5% . These rates were assumed to decrease gradually to 5.0% in 2020 and remain at that level thereafter.
The assumed health care and dental cost trend rates could have a significant effect on the amounts reported for the Postretirement Plan. A one percentage-point change in these rates would have the following effects:
 
 
One Percentage-Point
(Dollars in thousands)
 
Increase
 
Decrease
Effect on total of service and interest cost components in 2016
 
$
8

 
$
(8
)
Effect on postretirement benefit obligation as of December 31, 2016
 
196

 
(177
)
Pension Plan Assets
The assets of the Pension Plan are invested by the Wealth Management department of Chemical Bank. The investment policy and allocation of the assets of the pension trust were approved by the Compensation and Pension Committee of the board of directors of the Corporation.
The Pension Plan's primary investment objective is long-term growth coupled with income. In consideration of the Pension Plan's fiduciary responsibilities, emphasis is placed on quality investments with sufficient liquidity to meet benefit payments and plan expenses, as well as providing the flexibility to manage the investments to accommodate current economic and financial market conditions. To meet the Pension Plan's long-term objective within the constraints of prudent management, target ranges have been set for the three primary asset classes: an equity securities range from 40.0% to 70.0% , a debt securities range from 20.0% to 60.0% , and a cash and cash equivalents and other range from 0.0% to 10.0% . Modest asset positions outside of these targeted ranges may occur due to the repositioning of assets within industries or other activity in the financial markets. Equity securities are primarily comprised of both individual securities and equity-based mutual funds, invested in either domestic or international markets. The stocks are diversified among the major economic sectors of the market and are selected based on balance sheet strength, expected earnings growth, the management team and position within their industries, among other characteristics. Debt securities are comprised of U.S. dollar denominated bonds issued by the U.S. Treasury, U.S. government agencies and investment grade bonds issued by corporations. The notes and bonds purchased are primarily rated "A" or better by the major bond rating companies from diverse industries.

150

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The Pension Plan's asset allocation by asset category was as follows:
  
 
December 31,
Asset Category
 
2017
 
2016
Equity securities
 
68
%
 
69
%
Debt securities
 
28

 
29

Other
 
4

 
2

Total
 
100
%
 
100
%
The following schedule sets forth the fair value of the Pension Plan's assets and the level of the valuation inputs used to value those assets at December 31, 2017 and 2016 :
(Dollars in thousands)
 
Quoted Prices
In Active
Markets for
Identical
Assets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
December 31, 2017
 
 
 
 
 
 
 
 
Cash
 
$
5,238

 
$

 
$

 
$
5,238

Equity securities:
 

 

 

 

U.S. large- and mid-cap stocks (1)
 
68,909

 

 

 
68,909

U.S. small-cap mutual funds
 
5,377

 

 

 
5,377

International large-cap mutual funds
 
18,341

 

 

 
18,341

Emerging markets mutual funds
 
7,363

 

 

 
7,363

Debt securities:
 

 

 

 

U.S. Treasury and government sponsored agency bonds and notes
 

 
548

 

 
548

Mutual funds (3)
 
40,046

 

 

 
40,046

Other
 
79

 

 

 
79

Total
 
$
145,353

 
$
548

 
$

 
$
145,901

December 31, 2016
 
 
 
 
 
 
 
 
Cash
 
$
2,825

 
$

 
$

 
$
2,825

Equity securities:
 
 
 
 
 
 
 
 
U.S. large- and mid-cap stocks (1)
 
55,389

 

 

 
55,389

U.S. small-cap mutual funds
 
5,687

 

 

 
5,687

International large-cap mutual funds
 
13,701

 

 

 
13,701

Emerging markets mutual funds
 
5,147

 

 

 
5,147

Chemical Financial Corporation common stock
 
11,412

 

 

 
11,412

Debt securities:
 
 
 
 
 
 
 
 
U.S. Treasury and government sponsored agency bonds and notes
 

 
806

 

 
806

Corporate bonds (2)
 

 
1,503

 

 
1,503

Mutual funds (3)
 
36,220

 

 

 
36,220

Other
 
61

 

 

 
61

Total
 
$
130,442

 
$
2,309

 
$

 
$
132,751

(1)  
Comprised of common stocks and mutual funds traded on U.S. Exchanges whose issuers had market capitalizations exceeding $3 billion .
(2)  
Comprised of investment grade bonds of U.S. issuers from diverse industries.
(3)  
Comprised primarily of fixed-income bonds issued by the U.S. Treasury and government sponsored agencies and bonds of U.S. and foreign issuers from diverse industries.

151

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

At December 31, 2017 and 2016 , equity securities included zero and 210,663  shares, respectively, of the Corporation's common stock. During both 2017 and 2016 , cash dividends of $0.2 million were paid on the Corporation's common stock held by the Pension Plan. The fair value of the Corporation's common stock held in the Pension Plan was zero at December 31, 2017 and $11.4 million at December 31, 2016 , which represented zero and 8.6% of Pension Plan assets at December 31, 2017 and 2016 , respectively.
Accumulated Other Comprehensive Loss
The following sets forth the changes in accumulated other comprehensive income (loss), net of tax, related to the Corporation's Pension Plan, Postretirement Plan and SERP during 2017 :
(Dollars in thousands)
 
Pension
Plan
 
Postretirement
Plan
 
SERP
 
Total
Accumulated other comprehensive income (loss) at beginning of year
 
$
(26,123
)
 
$
724

 
$
(495
)
 
$
(25,894
)
Comprehensive income (loss) adjustment:
 

 

 

 
 
Prior service costs (credits)
 

 

 

 

Net actuarial (income) loss
 
1,528

 
(112
)
 
229

 
1,645

Curtailment
 
7,742

 

 

 
7,742

Settlement (1)
 

 

 
209

 
209

Comprehensive income (loss) adjustment
 
9,270

 
(112
)
 
438

 
9,596

Reclassification of certain income tax effects  (2)
 
(3,630
)
 
132

 
(12
)
 
(3,510
)
Accumulated other comprehensive income (loss) at end of year
 
$
(20,483
)
 
$
744

 
$
(69
)
 
$
(19,808
)
(1)  
The settlement charge relates to the settlement of liabilities under the SERP for the retirement of the plan participant during the third quarter of 2017.    
(2)  
The reclassification from accumulated other comprehensive income (loss) to retained earnings was due to the early adoption of ASU 2018-02, see Note 1 for further information.

The estimated income (loss) that will be amortized from accumulated other comprehensive income (loss) into net periodic cost, net of tax, in 2018 is as follows:
(Dollars in thousands)
 
Pension
Plan
 
Postretirement
Plan
 
SERP
 
Total
Prior service (costs) credits
 
$

 
$

 
$

 
$

Net gain (loss)
 
(561
)
 
113

 

 
(448
)
Total
 
$
(561
)
 
$
113

 
$

 
$
(448
)

152

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 19: Equity
Common Stock Repurchase Programs
From time to time, the board of directors of the Corporation approves common stock repurchase programs allowing management to repurchase shares of the Corporation's common stock in the open market. The repurchased shares are available for later reissuance in connection with potential future stock dividends, the Corporation's dividend reinvestment plan, employee benefit plans and other general corporate purposes. Under these programs, the timing and actual number of shares subject to repurchase are at the discretion of management and are contingent on a number of factors, including the projected parent company cash flow requirements and the Corporation's market price per share.
In January 2008, the board of directors of the Corporation authorized the repurchase of up to 500,000  shares of the Corporation's common stock under a stock repurchase program. In November 2011, the board of directors of the Corporation reaffirmed the stock buy-back authorization with the qualification that the shares may only be repurchased if the share price is below the tangible book value per share of the Corporation's common stock at the time of the repurchase. Since the January 2008 authorization, no shares have been repurchased. At December 31, 2017 , there were 500,000 remaining shares available for repurchase under the Corporation's stock repurchase programs.
Shelf Registration
On May 10, 2017, the Corporation filed an automatic shelf registration statement on Form S-3ASR with the SEC for an indeterminate amount of securities, which became immediately effective. The shelf registration statement provides the Corporation with the ability to raise capital, subject to SEC rules and limitations, if the board of directors of the Corporation decides to do so.
Preferred Stock
On April 20, 2015, the shareholders of the Corporation approved an amendment to the restated articles of incorporation which eliminated and replaced the previous class of 200,000  shares of preferred stock, approved by shareholders on April 20, 2009, with a new class of 2,000,000 shares of preferred stock. As of December 31, 2017 , no shares of preferred stock were issued and outstanding.
Common Stock
On July 19, 2016, the shareholders of the Corporation approved an amendment to the restated articles of incorporation to increase the number of authorized shares of common stock from 60,000,000 to 100,000,000 in anticipation of the merger with Talmer.
On April 26, 2017, the shareholders of the Corporation approved an amendment to the restated articles of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 135,000,000 .
Note 20: Regulatory Capital and Reserve Requirements
Federal and state banking regulations place certain restrictions on the transfer of assets, in the form of dividends, loans, or advances, from Chemical Bank to the Corporation. As of December 31, 2017 , substantially all of the assets of Chemical Bank were restricted from transfer to the Corporation in the form of loans or advances. Dividends from the bank are the principal source of funds for the Corporation. In addition to the statutory limits, the Corporation considers the overall financial and capital position of the bank prior to making any cash dividend decisions.
Banking regulations require that banks maintain cash reserve balances in vault cash, with the Federal Reserve Bank, or with certain other qualifying banks. The aggregate average amount of the regulatory balances required to be maintained by Chemical Bank during 2017 and 2016 were $71.7 million and $52.3 million , respectively. During 2017 , Chemical Bank satisfied its regulatory reserve requirements by maintaining a combination of vault cash balances and cash held with the FRB in excess of regulatory reserve requirements. Chemical Bank was not required to maintain compensating balances with correspondent banks during 2017 or 2016 .

153

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The Corporation and Chemical Bank are subject to various regulatory capital requirements administered by federal banking agencies. Under these capital requirements, Chemical Bank must meet specific capital guidelines that involve quantitative measures of assets and certain off-balance sheet items as calculated under regulatory accounting practices. In addition, capital amounts and classifications are subject to qualitative judgments by regulators. Failure to meet minimum capital requirements can initiate certain mandatory and possibly additional discretionary actions by regulators that, if undertaken, could have a direct material effect on the Consolidated Financial Statements. Management believes as of December 31, 2017 , the Corporation and Chemical Bank met all capital adequacy requirements to which they are subject.
Quantitative measures established by regulation to ensure capital adequacy require minimum ratios of Tier 1 capital to average assets (Leverage Ratio) and Common Equity Tier 1, Tier 1 and Total capital to risk-weighted assets. These capital guidelines assign risk weights to on- and off- balance sheet items in arriving at total risk-weighted assets. Minimum capital levels are based upon the perceived risk of various asset categories and certain off-balance sheet instruments. Risk-weighted assets for the Corporation and Chemical Bank totaled $14.74 billion and $14.70 billion , respectively, at December 31, 2017 , compared to $13.42 billion and $13.36 billion at December 31, 2016 , respectively.
Effective January 1, 2015, the Corporation adopted the Basel III regulatory capital framework as approved by federal banking agencies, which is subject to a multi-year phase-in period. The adoption of this new framework modified the calculation of the various capital ratios, added a new ratio, common equity tier 1, and revised the adequately and well capitalized thresholds. In addition, Basel III establishes a new capital conservation buffer of 2.5% of risk-weighted assets, which is phased-in over a four-year period beginning January 1, 2016. The capital conservation buffer for 2017 is 1.25% and was 0.625% for 2016. The Corporation has elected to opt-out of including accumulated other comprehensive income in common equity tier 1 capital.
At December 31, 2017 and 2016 , Chemical Bank's capital ratios exceeded the quantitative capital ratios required for an institution to be considered "well-capitalized." Significant factors that may affect capital adequacy include, but are not limited to, a disproportionate growth in assets versus capital and a change in mix or credit quality of assets. There are no conditions or events since that notification that management believes have changed the institutions' category.

154

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

The summary below compares the actual capital amounts and ratios with the quantitative measures established by regulation to ensure capital adequacy:
 
 
Actual
 
Minimum Required
for Capital Adequacy
Purposes
 
Minimum Required for Capital Adequacy Purposes Plus Capital Conservation Buffer
 
Required to be Well
Capitalized Under
Prompt Corrective 
Action Regulations
(Dollars in thousands)
 
Capital
Amount
 
Ratio
 
Capital
Amount
 
Ratio
 
Capital
Amount
 
Ratio
 
Capital
Amount
 
Ratio
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Capital to Risk-Weighted Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
$
1,614,046

 
11.0
%
 
$
1,179,076

 
8.0
%
 
$
1,363,307

 
9.3
%
 
N/A

 
N/A

Chemical Bank
 
1,613,087

 
11.0

 
1,176,361

 
8.0

 
1,360,167

 
9.3

 
$
1,470,451

 
10.0
%
Tier 1 Capital to Risk-Weighted Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
1,498,463

 
10.2

 
884,307

 
6.0

 
1,068,538

 
7.3

 
N/A

 
N/A

Chemical Bank
 
1,513,219

 
10.3

 
882,271

 
6.0

 
1,066,077

 
7.3

 
1,176,361

 
8.0

Common Equity Tier 1 Capital to Risk-Weighted Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
1,498,463

 
10.2

 
663,230

 
4.5

 
847,461

 
5.8

 
N/A

 
N/A

Chemical Bank
 
1,513,219

 
10.3

 
661,703

 
4.5

 
845,509

 
5.8

 
955,793

 
6.5

Leverage Ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
1,498,463

 
8.3

 
720,890

 
4.0

 
720,890

 
4.0

 
N/A

 
N/A

Chemical Bank
 
1,513,219

 
8.4

 
720,043

 
4.0

 
720,043

 
4.0

 
900,053

 
5.0

December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Capital to Risk-Weighted Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
$
1,543,018

 
11.5
%
 
$
1,073,431

 
8.0
%
 
$
1,157,293

 
8.6
%
 
N/A

 
N/A

Chemical Bank
 
1,608,980

 
12.0

 
1,068,560

 
8.0

 
$
1,152,041

 
8.6

 
$
1,335,700

 
10.0
%
Tier 1 Capital to Risk-Weighted Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
1,441,209

 
10.7

 
805,073

 
6.0

 
888,935

 
6.6

 
N/A

 
N/A

Chemical Bank
 
1,522,711

 
11.4

 
801,420

 
6.0

 
884,901

 
6.6

 
1,068,560

 
8.0

Common Equity Tier 1 Capital to Risk-Weighted Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
1,441,209

 
10.7

 
603,805

 
4.5

 
687,667

 
5.1

 
N/A

 
N/A

Chemical Bank
 
1,522,711

 
11.4

 
601,065

 
4.5

 
684,546

 
5.1

 
868,205

 
6.5

Leverage Ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporation
 
1,441,209

 
9.0

 
643,603

 
4.0

 
643,603

 
4.0

 
N/A

 
N/A

Chemical Bank
 
1,522,711

 
9.5

 
641,457

 
4.0

 
641,457

 
4.0

 
801,822

 
5.0


During the years ended December 31, 2017 , 2016 and 2015 , Chemical Bank paid dividends to the Corporation totaling $165.0 million , $110.5 million and $56.9 million , respectively.

On January 23, 2018 , a cash dividend on the Corporation's common stock of $0.28 per share was declared. The dividend will be paid on March 16, 2018 to shareholders of record as of March 2, 2018 .




155

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 21: Parent Company Only Financial Statements
Condensed financial statements of Chemical Financial Corporation (parent company) only follow:

Condensed Statements of Financial Position
 
 
December 31,
(Dollars in thousands)
 
2017
 
2016
Assets
 
 
 
 
Cash at subsidiary bank
 
$
5,761

 
$
16,851

Investment in subsidiaries
 
2,673,858

 
2,654,458

Premises and equipment
 
3,931

 
4,051

Goodwill
 
1,092

 
1,092

Deferred tax asset
 
7,203

 
30,715

Other assets
 
31,459

 
32,869

Total assets
 
$
2,723,304

 
$
2,740,036

Liabilities
 
 
 
 
Other liabilities
 
$
18,877

 
$
18,345

Non-revolving line-of-credit
 
19,963

 
124,625

Subordinated debentures
 
15,715

 
15,540

Total liabilities
 
54,555

 
158,510

Shareholders' equity
 
2,668,749

 
2,581,526

Total liabilities and shareholders' equity
 
$
2,723,304

 
$
2,740,036

Condensed Statements of Income
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Income
 
 
 
 
 
 
Cash dividends from subsidiaries
 
$
165,000

 
$
110,450

 
$
56,860

Other income
 
921

 
151

 
144

Total income
 
165,921

 
110,601

 
57,004

Expenses
 
 
 
 
 
 
Interest expense
 
3,076

 
1,816

 
761

Operating expenses
 
23,298

 
30,589

 
7,794

Total expenses
 
26,374

 
32,405

 
8,555

Income before income taxes and equity in undistributed net income of subsidiaries
 
139,547

 
78,196

 
48,449

Income tax benefit
 
12,670

 
11,378

 
2,582

Equity in undistributed net (loss) income of subsidiaries
 
(2,694
)
 
18,458

 
35,799

Net income
 
$
149,523

 
$
108,032

 
$
86,830








156

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Condensed Statements of Cash Flows
 
 
Years Ended December 31,
(Dollars in thousands)
 
2017
 
2016
 
2015
Cash Flows From Operating Activities
 
 
 
 
 
 
Net income
 
$
149,523

 
$
108,032

 
$
86,830

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
 
Share-based compensation expense
 
17,346

 
13,452

 
3,478

Depreciation of premises and equipment
 
408

 
355

 
318

Equity in undistributed net loss (income) of subsidiaries
 
2,694

 
(18,458
)
 
(35,799
)
Net decrease in other assets
 
1,410

 
9,752

 
2,873

Net increase (decrease) in other liabilities
 
25,178

 
(11,830
)
 
(19,033
)
Net cash provided by operating activities
 
196,559

 
101,303

 
38,667

Cash Flows From Investing Activities
 
 
 
 
 
 
Cash paid, net of cash assumed, in business combinations
 

 
(107,622
)
 
(45,267
)
Purchases of premises and equipment, net
 
(288
)
 
(774
)
 
(320
)
Net cash used in investing activities
 
(288
)
 
(108,396
)
 
(45,587
)
Cash Flows From Financing Activities
 
 
 
 
 
 
Cash dividends paid
 
(78,498
)
 
(49,389
)
 
(36,918
)
Proceeds from issuance of common stock, net of issuance costs
 

 

 

Repayment of subordinated debt obligations
 

 
(18,558
)
 

Repayments of other borrowings
 
(105,000
)
 
(62,500
)
 

Proceeds from issuance of other borrowings
 

 
125,000

 
25,000

Proceeds from directors' stock purchase plan and exercise of stock options
 
3,991

 
1,572

 
2,473

Cash paid for payroll taxes upon conversion of restricted stock units
 
(27,854
)
 
(1,065
)
 
(571
)
Net cash used in financing activities
 
(207,361
)
 
(4,940
)
 
(10,016
)
Net decrease in cash and cash equivalents
 
(11,090
)
 
(12,033
)
 
(16,936
)
Cash and cash equivalents at beginning of year
 
16,851

 
28,884

 
45,820

Cash and cash equivalents at end of year
 
$
5,761

 
$
16,851

 
$
28,884

 
 
 
 
 
 
 
Business combinations:
 
 
 
 
 
 
Fair value of assets acquired (noncash)
 
$

 
$
46,898

 
$
10,304

Liabilities assumed
 

 
58,309

 
42,019

Common stock and stock options issued
 

 
1,504,811

 
159,904


157

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 22: Earnings Per Common Share
The two-class method is used in the calculation of basic and diluted earnings per share.  Under the two-class method, earnings available to common shareholders for the period are allocated between common shareholders and participating securities according to dividends declared (or accumulated) and participating rights in undistributed earnings.
Average shares of common stock for diluted net income per common share include shares to be issued upon the exercise of stock options granted under the Corporation’s share-based compensation plans, restricted stock units that may be converted to stock, restricted stock awards and stock to be issued under the deferred stock compensation plan for non-employee directors.
The factors used in the earnings per share computation follow: 
 
 
For the years ended December 31,
(In thousands, except per share data)
 
2017
 
2016
 
2015
Net income
 
$
149,523

 
$
108,032

 
$
86,830

  Net income allocated to participating securities
 
495

 
166

 

Net income allocated to common shareholders (1)
 
$
149,028

 
$
107,866

 
$
86,830

Weighted average common shares - issued
 
71,103

 
49,091

 
36,081

  Average unvested restricted share awards
 
(238
)
 
(139
)
 

Weighted average common shares outstanding - basic
 
70,865

 
48,952

 
36,081

Effect of dilutive securities
 
 
 
 
 
 
  Weighted average common stock equivalents
 
648

 
651

 
272

Weighted average common shares outstanding - diluted
 
71,513

 
49,603

 
36,353

EPS available to common shareholders
 
 
 
 
 
 
  Basic earnings per common share
 
$
2.11

 
$
2.21

 
$
2.41

  Diluted earnings per common share
 
$
2.08

 
$
2.17

 
$
2.39

(1)  
Net income allocated to common shareholders for basic and diluted earnings per share may differ under the two-class method as a result of adding common share equivalents for options and warrants to dilutive shares outstanding, which alters the ratio used to allocate net income to common shareholders and participating securities for the purposes of calculating diluted earnings per share.

For the effect of dilutive securities, the assumed average stock valuation is $50.26 per share, $40.58 per share and $32.17 per share for the years ended December 31, 2017 , 2016 and 2015 , respectively.
    
The average number of exercisable employee stock option awards outstanding that were "out-of-the-money," whereby the option exercise price per share exceeded the market price per share and, therefore, were not included in the computation of diluted earnings per common share because they would have been anti-dilutive, totaled 107,272 for the year ended December 31, 2017 , 0 for the year ended December 31, 2016 and 54,771 for the year ended December 31, 2015 .


158

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 23: Accumulated Other Comprehensive Loss
The following table summarizes the changes within each component of accumulated other comprehensive income (loss), net of related tax benefit/expense for the years ended December 31, 2017 , 2016 and 2015 :
(Dollars in thousands)
 
Unrealized gains
(losses) on securities
available-for-sale,
net of tax
 
Defined Benefit Pension Plans
 
Unrealized gains (losses) on cash flow hedges, net of tax
 
Total
For the year ended December 31, 2017
 
 
 
 
 
 
 
 
Beginning balance
 
$
(14,142
)
 
$
(25,894
)
 
$

 
$
(40,036
)
Other comprehensive loss before reclassifications
 
826

 
8,457

 
2,771

 
12,054

Amounts reclassified from accumulated other comprehensive income
 
4,802

 
1,139

 
1,061

 
7,002

Net current period other comprehensive income (loss)
 
5,628

 
9,596

 
3,832

 
19,056

Reclassification of certain deferred tax effects (1)
 
(1,834
)
 
(3,510
)
 
826

 
(4,518
)
Ending balance
 
$
(10,348
)
 
$
(19,808
)
 
$
4,658

 
$
(25,498
)
For the year ended December 31, 2016
 
 
 
 
 
 
 
 
Beginning balance
 
$
(1,888
)
 
$
(27,144
)
 
$

 
$
(29,032
)
Other comprehensive income (loss) before reclassifications
 
(12,170
)
 
(229
)
 

 
(12,399
)
Amounts reclassified from accumulated other comprehensive income
 
(84
)
 
1,479

 

 
1,395

Net current period other comprehensive income (loss)
 
(12,254
)
 
1,250

 

 
(11,004
)
Ending balance
 
$
(14,142
)
 
$
(25,894
)
 
$

 
$
(40,036
)
For the year ended December 31, 2015
 
 
 
 
 
 
 
 
Beginning balance
 
$
(210
)
 
$
(32,243
)
 
$

 
$
(32,453
)
Other comprehensive income (loss) before reclassifications
 
(1,269
)
 
2,443

 

 
1,174

Amounts reclassified from accumulated other comprehensive income
 
(409
)
 
2,656

 

 
2,247

Net current period other comprehensive income (loss)
 
(1,678
)
 
5,099

 

 
3,421

Ending balance
 
$
(1,888
)
 
$
(27,144
)
 
$

 
$
(29,032
)
(1)  
The reclassification from accumulated other comprehensive income (loss) to retained earnings was due to the early adoption of ASU 2018-02, see Note 1 for further information.

The following table summarizes the amounts reclassified out of each component of accumulated other comprehensive income (loss) for the years ended December 31, 2017, 2016 and 2015:
(Dollars in thousands)
 
Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)
 
Affected Line Item in the Income Statement
 
 
December 31, 2017
 
December 31, 2016
 
December 31, 2015
 
 
Gains and losses on available-for-sale securities
 
$
(7,388
)
 
$
129

 
$
630

 
Net gain on sale of investment securities (noninterest income)
 
 
2,586

 
(45
)
 
(221
)
 
Income tax (expense)/benefit
 
 
$
(4,802
)
 
$
84

 
$
409

 
Net Income
Amortization of defined benefit pension plan items
 
$
(1,752
)
 
$
(2,276
)
 
$
(4,086
)
 
Salaries, wages and employee benefits (operating expenses)
 
 
613

 
797

 
1,430

 
Income tax (expense)/benefit
 
 
$
(1,139
)
 
$
(1,479
)
 
$
(2,656
)
 
Net Income
Gains and losses on cash flow hedges
 
1,633

 

 

 
Interest on short-term borrowings (interest expense)
 
 
(572
)
 

 

 
Income tax (expense)/benefit
 
 
$
1,061

 
$

 
$

 
Net Income (loss)

159

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

Note 24: Summary of Quarterly Statements of Income (Unaudited)
The following is a summary of the unaudited quarterly results of operation for the years ended December 31, 2017 , 2016 and 2015 . In the opinion of management, the information reflects all adjustments that are necessary for the fair presentation of the results of operations for the periods presented.
   
 
2017
(Dollars in thousands, except per share data)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Interest income
 
$
142,896

 
$
155,133

 
$
164,944

 
$
169,162

 
$
632,135

Interest expense
 
12,799

 
17,185

 
21,316

 
23,257

 
74,557

Net interest income
 
130,097

 
137,948

 
143,628

 
145,905

 
557,578

Provision for loan losses
 
4,050

 
6,229

 
5,499

 
7,522

 
23,300

Noninterest income
 
38,010

 
41,568

 
32,122

 
32,319

 
144,019

Operating expenses
 
104,196

 
98,237

 
119,539

 
100,022

 
421,994

Income before income taxes
 
59,861

 
75,050

 
50,712

 
70,680

 
256,303

Income tax expense
 
12,257

 
23,036

 
10,253

 
61,234

 
106,780

Net income
 
$
47,604

 
$
52,014

 
$
40,459

 
$
9,446

 
$
149,523

Net income per common share:
 
 
 
 
 
 
 
 
 
 
Basic
 
$
0.67

 
$
0.73

 
$
0.57

 
$
0.13

 
$
2.11

Diluted
 
0.67

 
0.73

 
0.56

 
0.13

 
2.08

Cash dividends declared per common share
 
0.27

 
0.27

 
0.28

 
0.27

 
1.10

   
 
2016
(Dollars in thousands, except per share data)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Interest income
 
$
79,464

 
$
82,937

 
$
103,562

 
$
144,416

 
$
410,379

Interest expense
 
5,134

 
5,442

 
6,753

 
11,969

 
29,298

Net interest income
 
74,330

 
77,495

 
96,809

 
132,447

 
381,081

Provision for loan losses
 
1,500

 
3,000

 
4,103

 
6,272

 
14,875

Noninterest income
 
19,419

 
20,897

 
27,770

 
54,264

 
122,350

Operating expenses
 
58,887

 
59,085

 
106,144

 
114,302

 
338,418

Income before income taxes
 
33,362

 
36,307

 
14,332

 
66,137

 
150,138

Income tax expense
 
9,757

 
10,532

 
2,848

 
18,969

 
42,106

Net income
 
$
23,605

 
$
25,775

 
$
11,484

 
$
47,168

 
$
108,032

Net income per common share:
 
 
 
 
 
 
 
 
 
 
Basic
 
$
0.61

 
$
0.67

 
$
0.23

 
$
0.67

 
$
2.21

Diluted
 
0.60

 
0.67

 
0.23

 
0.66

 
2.17

Cash dividends declared per common share
 
0.26

 
0.26

 
0.27

 
0.27

 
1.06


160

Chemical Financial Corporation
Notes to Consolidated Financial Statements
December 31, 2017

 
 
2015
(Dollars in thousands, except per share data)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Interest income
 
$
62,630

 
$
69,679

 
$
78,851

 
$
80,629

 
$
291,789

Interest expense
 
3,450

 
3,944

 
5,234

 
5,153

 
17,781

Net interest income
 
59,180

 
65,735

 
73,617

 
75,476

 
274,008

Provision for loan losses
 
1,500

 
1,500

 
1,500

 
2,000

 
6,500

Noninterest income
 
19,275

 
20,674

 
20,215

 
20,052

 
80,216

Operating expenses
 
51,020

 
56,785

 
58,265

 
57,824

 
223,894

Income before income taxes
 
25,935

 
28,124

 
34,067

 
35,704

 
123,830

Income tax expense
 
8,100

 
9,100

 
9,600

 
10,200

 
37,000

Net income
 
$
17,835

 
$
19,024

 
$
24,467

 
$
25,504

 
$
86,830

Net income per common share:
 
 
 
 
 
 
 
 
 
 
Basic
 
$
0.54

 
$
0.54

 
$
0.64

 
$
0.67

 
$
2.41

Diluted
 
0.54

 
0.54

 
0.64

 
0.66

 
2.39

Cash dividends declared per common share
 
0.24

 
0.24

 
0.26

 
0.26

 
1.00


 


161


Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Disclosure Controls and Procedures
The Corporation's management is responsible for establishing and maintaining effective disclosure controls and procedures, as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (Exchange Act). An evaluation was performed under the supervision and with the participation of the Corporation's management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Corporation's disclosure controls and procedures as of the end of the period covered by this Annual Report. Based on and as of the time of that evaluation, the Corporation's management, including the Chief Executive Officer and Chief Financial Officer, concluded that the Corporation's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Corporation in the reports it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SECs rules and forms.
Changes in Internal Controls Over Financial Reporting
There were no changes to the Corporation's internal controls over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the fourth quarter ended December 31, 2017 that materially affected, or are reasonably likely to materially affect, the Corporation's internal controls over financial reporting.

162


MANAGEMENT'S ASSESSMENT AS TO THE EFFECTIVENESS
OF INTERNAL CONTROL OVER FINANCIAL REPORTING

Management of the Corporation is responsible for establishing and maintaining effective internal control over financial reporting that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. The system of internal control over financial reporting as it relates to the financial statements is evaluated for effectiveness by management and tested for reliability through a program of internal audits. Actions are taken to correct potential deficiencies as they are identified. Any system of internal control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and misstatements due to error or fraud may occur and not be detected. Also, because of changes in conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance with respect to financial reporting and financial statement preparation.
Management assessed the Corporation's system of internal control over financial reporting as of December 31, 2017 , as required by Section 404 of the Sarbanes-Oxley Act of 2002. Management's assessment is based on the criteria for effective internal control over financial reporting as described in "Internal Control — Integrated Framework (2013)" issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has concluded that, as of December 31, 2017 , its system of internal control over financial reporting was effective and meets the criteria of the "Internal Control — Integrated Framework (2013)." The Corporation's independent registered public accounting firm that audited the Consolidated Financial Statements included in this annual report has issued an attestation report on the Corporation's internal control over financial reporting as of December 31, 2017 .
 
/s/ David T. Provost
 
/s/ Dennis L. Klaeser
David T. Provost
 
Dennis L. Klaeser
Chief Executive Officer and President
 
Executive Vice President and Chief Financial Officer
 
 
February 28, 2018
 
February 28, 2018

163


Report of Independent Registered Public Accounting Firm
The Shareholders and Board of Directors
Chemical Financial Corporation:

Opinion on Internal Control Over Financial Reporting

We have audited Chemical Financial Corporation and subsidiaries’ (the Corporation) internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Corporation maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of the Corporation as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income, changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements), and our report dated February 28, 2018 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Corporation’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Assessment as to the Effectiveness of Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Corporation’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Corporation in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Detroit, Michigan
February 28, 2018


164


Item 9B. Other Information.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

Given the timing of the following events, the following information is included in this Annual Report on Form 10-K pursuant to Item 5.02 of Form 8-K, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers" in lieu of filing a Form 8-K.

Appointment of Principal Accounting Officer

On February 27, 2018, our board of directors appointed Kathleen S. Wendt as Chief Accounting Officer of the Corporation. In this role, she will serve as our principal accounting officer, a role previously held by Dennis L. Klaeser, our Executive Vice President and Chief Financial Officer. Ms. Wendt will report to Mr. Klaeser.

Ms. Wendt, age 44, has served as Executive Vice President and Chief Accounting Officer of the Corporation since October 2017. Ms. Wendt served as Chief Accounting Officer and an Executive Managing Director of Talmer Bancorp, Inc. from June 2011 until its merger with the Corporation on August 31, 2016. She served as First Senior Vice President and Chief Accounting Officer of Chemical Bank following the merger with Talmer Bancorp, Inc. until March 2017. Ms. Wendt is a certified public accountant with experience in financial reporting, accounting policy and the management of controls over financial reporting. Ms. Wendt served in a number of positions with Comerica Incorporated, a financial institution with more than $60 billion in total assets, from May 2003 until June 2011, including as Senior Vice President, Director of External Reporting and Senior Vice President, Director of Accounting Policy and Financial Procedures and Controls. Before that, Ms. Wendt served as an Assurance Manager at PricewaterhouseCoopers located in Chicago, Illinois and Zurich, Switzerland. Ms. Wendt is a member of the Executive Leadership Team and the Senior Leadership Team of Chemical Bank.

Adoption of Annual Cash Incentive Plan

On February 27, 2018, based on the recommendation of our Compensation and Pension Committee (the “Compensation Committee”), our board of directors approved the Chemical Financial Corporation Executive Annual Incentive Plan (the “annual Incentive Plan”). Under the Annual Incentive Plan, each year, the Committee will select key performance objectives from a set of key measurable performance goals which include, but are not limited to, the following items (each, a “Performance Measure” and collectively, the “Performance Measures”), which will be used to determine the actual cash incentive payment to be awarded to participants in the plan upon the achievement of the Performance Measures:

Cash earnings;
Cash earnings per share (reflecting dilution of the Company’s common stock as the Committee deems appropriate and, if the Committee so determines, net of or including dividends);
Cash earnings return on equity;
Cash flow;
Cash flow return on capital;
Customer satisfaction, satisfaction based on specified objective goals or a Company-sponsored customer survey;
Deposit growth;
Economic value added measurements;
Efficiency ratio;
Employee turnover;
Expense or cost levels;
Interest income;
Loan growth;
Margins;
Market share or market penetration with respect to specific designated products or services, product or service groups and/or specific geographic areas;
Net income (before or after taxes, interest, depreciation, and/or amortization);
Net income per share;
Net interest income;
Noninterest income;
Operating efficiency;
Operating income;

165


Operating income per share;
Operating income return on equity;
Productivity ratios;
Reduction of losses, loss ratios, expense ratios or fixed costs;
Return on assets;
Return on capital;
Return on equity;
Share price (including without limitation growth measures, total shareholder return or comparison to indices);
Specified objective social goals; and
Such other business criteria as the Committee may determine to be appropriate, which may include financial and nonfinancial performance goals.

Each year, the Compensation Committee will select eligible executives who will participate in the Annual Incentive Plan and will set the amount of each participant’s Threshold Award, Target Award and Maximum Award (each as defined in the Annual Incentive Plan) that can be awarded under the Annual Incentive Plan, determined as a percentage of the participant’s base salary. As noted above, the Compensation Committee will also establish one or more Performance Measures and a formula to determine the amount of the award that will be earned at different levels of achievement of the Performance Measures.

The Annual Incentive Plan is administered by the Compensation Committee, which has full authority, among other things, to designate participants; construe and interpret the plan; waive, prospectively or retroactively, any conditions of or rights of the Corporation under any award; increase or decrease the payout due under any award; and make all other determinations and take all other actions necessary under the plan. Under the Annual Incentive Plan, except as may otherwise be approved by the Compensation Committee or as specifically set forth in a written employment agreement between a participant and the Corporation, no incentive payment will be awarded under the Annual Incentive Plan if the participant is not employed in good standing on the date payment is made for a particular performance period.

The foregoing description of the Annual Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the Annual Incentive Plan, which is incorporated herein by reference as Exhibit 10.9.

New Employment Agreement with David T. Provost

On February 27, 2018, we entered into a new executive employment agreement with David T. Provost, our Chief Executive Officer and President, who will continue to serve in these roles under his new employment agreement.

The employment agreement has an initial term of two years commencing on March 1, 2018, that automatically renews for successive one year periods, until either party provides advance written notice of non-renewal at least 30 days before an anniversary of the March 1 effective date. Under the employment agreement, his current base salary of $1.00 will be increased to $950,000 effective July 1, 2018. Mr. Provost’s base salary will be reviewed by the Compensation Committee at least annually and can be increased in the Committee’s sole discretion. In addition to base salary, he is:

eligible to participate in our annual bonus and equity programs for senior executives;
entitled to an annual taxable stipend to cover deduction for other benefits under our group health care plan in the amount of $20,000;
entitled to a monthly automobile allowance of $900; and
eligible for reimbursement for membership in two country clubs of his selection.

The employment agreement provides that if he is terminated by us for any reason other than for “cause” or because of his “disability,” or if he terminates his employment for “good reason,” each as defined in the employment agreement, then he is entitled to receive severance pay in the amount of two times his then current base salary (with base salary calculated as at least $950,000), plus two times the average of his bonuses under our annual cash incentive plan for each of the three most recently completed calendar years, including complete calendar years with Talmer Bank and Trust (with each bonus calculated as the higher of the actual bonus or $1.5 million). We will also pay Mr. Provost a lump sum equal to 24 times his monthly contribution towards COBRA for employee dependent health, prescription drug and dental coverage elections under our employee benefit plans providing such benefits, minus the COBRA administrative cost (whether or not he elects COBRA). In addition, all equity-based awards previously granted to Mr. Provost that remain outstanding on the termination date will be treated as follows:

all unvested stock options will immediately vest, and together with other vested stock options, will remain exercisable for a period of three years from termination;
all outstanding time-based restricted stock units will automatically vest; and

166


all performance-based restricted stock units will automatically vest at the applicable target level.

Our decision not to renew the term of his employment agreement will also constitute our termination of his employment without cause. I n the event of his death, his outstanding equity-based awards will vest as outlined above.

The severance payments and vesting of equity awards is conditioned upon Mr. Provost executing a mutually agreeable release of claims, in substantially the form attached to his employment agreement. His employment agreement also requires the he keep corporate information confidential. In addition, he is subject to provisions related to non-competition and non-solicitation of customers and employees for a period of 24-months following termination of his employment.

The foregoing description of Mr. Provost’s executive employment agreement does not purport to be complete and is qualified in its entirety by reference to his executive employment agreement, which is incorporated herein by reference as Exhibit 10.25.

Change in Control Agreement with Robert S. Rathbun

On February 27, 2018, we entered into a change in control agreement with Robert S. Rathbun. Under the agreement, if within six months before a change in control (as defined in the agreement) or within two years after a change in control, Mr. Rathbun is terminated by us other than for “cause” (as defined in the agreement), disability or death, or if he terminates his employment for “good reason” (as defined in the agreement), he will be entitled to a lump sum payment in the amount of one times the sum of his base salary plus the average of his bonuses under our annual executive incentive plan for each of the three most recently completed calendar years. We will also pay Mr. Rathbun a lump sum payment equal to 12 times his monthly contribution towards his then current employee and dependent health, prescription drug and dental coverage elections. In addition, all equity-based awards previously granted to Mr. Rathbun that remain outstanding on his termination date will be treated as follows:

all unvested stock options will immediately vest, and together with other vested stock options, will remain exercisable for a period of three years from termination;
all outstanding time-based restricted stock units will automatically vest; and
all performance-based restricted stock units will remain outstanding, subject to their original performance goals, and the restrictions will not lapse until such goals have been attained, at which time the restrictions will lapse at the relevant performance level attained, as if Mr. Rathbun had remained employed through the last day of the performance period.

We have also agreed to provide Mr. Rathbun executive-level outplacement services for up to 12 months after his termination.

The severance payments are conditioned on Mr. Rathbun executing a mutually agreeable release of claims, in substantially the form attached to the agreement. His agreement also requires him to keep corporate information confidential. In addition, he is subject to provisions related to non-competition and non-solicitation of customers and employees for a period of 12-months following termination of his employment.

The foregoing description of the change in control agreement does not purport to be complete and is qualified in its entirety by reference to Mr. Rathbun’s change in control agreement, which is incorporated herein by reference as Exhibit 10.29.

Long-Term Incentive Plan Awards

On February 27, 2018, the following awards of restricted stock units were made to our named executive officers in accordance with the terms of the Chemical Financial Corporation Stock Incentive Plan of 2017 (the “Equity Plan”).

Executive Officer
 
Number of Time-Vested
Restricted Stock Units
 
Number of Performance-Based Restricted Stock Units (1)
David T. Provost
 
21,417

 
34,689

Dennis L. Klaeser
 
7,139

 
11,563

Robert S. Rathbun
 
1,060

 
1,717

Thomas W. Kohn
 
725

 
522

(1)
Amount shown is the target amount of the award. The range of performance-based restricted stock units actually earned can be in the range of 0% of target for below threshold performance, to 50% of target for threshold performance, to 150% of target for maximum performance.

167


The Compensation Committee of our board of directors, consistent with its historical practices of providing long term equity compensation as a portion of overall executive compensation, approved the awards of restricted stock units to each of our named executive officers.

Under the terms of the time-vested restricted stock unit agreements (“TRSUs), the restricted stock units vest in equal installments on the first, second, third, fourth and fifth anniversaries of the February 27, 2018 grant date, based on the named executive officer’s continued employment. The TRSUs will have all non-cash dividend and all liquidation rights with respect to shares of our common stock and each named executive officer will receive a number of restricted stock units equal to the number of shares of our common stock (including fractions of a share) that have a market value equal to the amount of any cash dividends that would have been payable to a shareholder owning the number of shares of common stock represented by restricted stock units subject to the agreement on each dividend payment date.

Under the terms of the performance-based restricted stock unit agreements (“PRSUs”), the restricted stock units vest based on the Corporation’s achievement of performance targets determined by the Compensation Committee during the performance period at a threshold, target and maximum performance level, if the named executive officer remains employed through the restricted period.

Both the TRSU agreement and PRSU agreement provide that, unless otherwise provided in another written agreement with the executive, in the event of the executive’s termination without cause by us, or if the executive terminates his or her employment for “good reason,” or if the executive dies or is disabled, or if the executive provides one year written notice before his or her intended retirement, then executive will be issued (a) with respect to TRSUs, a pro rata number of TRSUs determined based on the number of months that have passed since the last annual vesting date, or if no vesting date has occurred, the grant date, and (b) with respect to PRSUs, a pro rata number of PRSUs granted at the target (100%) level determined based on the number of months that have elapsed between the first day of the Performance Period (as defined in the agreement) and the effective date of the executive’s termination.

Both the TRSU agreement and PRSU agreement also provide that, unless otherwise provided in another written agreement with the executive, in the event of a change in control (as set forth therein), and the awards are assumed by the surviving entity, then (a) with respect to TRSUs, if within two years of the change in control, the executive is terminated without cause by us or the executive terminates his or her employment for good reason, all unvested TRSUs will vest, and (b) with respect to PRSUs, the PRSUs will be fixed at the target (100%) performance level and will vest as of the end of the performance period; provided that, if within two years of the change in control, the executive is terminated without cause by us or the executive terminates his or her employment for good reason, all unvested PRSUs will immediately vest at the target (100%) performance level. If the TRSU and PRSU agreements are not assumed by the surviving entity, each agreement contains a provision for the awards to be paid in cash, as follows:

with respect to TRSUs, the market value of all TRSUs outstanding as of the change in control will be paid in cash, subject to the same vesting schedule; provided that, if within two years of the change in control, the executive is terminated without cause by us or the executive terminates his or her employment for good reason, then the cash value of the TRSUs will be paid at termination; and
with respect to PRSUs, the market value of the target (100%) number of PRSUs outstanding as of the change in control will be paid in cash at the end of the performance period; provided that, if within two years of the change in control, the executive is terminated without cause by us or the executive terminates his or her employment for good reason, then the cash value of the PRSUs will be paid at termination.

A copy of the Equity Plan is filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed with the SEC on May 10, 2017. The foregoing description of the restricted stock unit agreements does not purport to be complete and is qualified in its entirety by reference to the form of TRSU agreement and the form of PRSU agreement, each of which is incorporated herein by reference as Exhibits 10.31 and 10.30, respectively.

Item 8.01 Other Events.

Given the timing of the following event, the following information is included in this Annual Report on Form 10-K pursuant to Item 8.01 of Form 8-K, "Other Events" in lieu of filing a Form 8-K.

On February 27, 2018, we entered into a new executive employment agreement with Gary Torgow, the Executive Chairman of our board of directors, who will continue to serve in this role under his new employment agreement, which is substantially similar to Mr. Provost’s new employment agreement described above.


168


The foregoing description of Mr. Torgow’s executive employment agreement does not purport to be complete and is qualified in its entirety by reference to his executive employment agreement, which is incorporated herein by reference as Exhibit 10.27.

PART III.
Item 10. Directors, Executive Officers and Corporate Governance.
Information required by this item is set forth under the subheadings "Nominees for Election as Directors" and "Board Committees," and the headings "Executive Officers" and "Section 16(a) Beneficial Ownership Reporting Compliance" in our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders to be filed with the SEC not later than 120 days after December 31, 2017 and is here incorporated by reference.
We have adopted a Code of Ethics for Senior Financial Officers and Members of Senior Leadership, which applies to the Chief Executive Officer and the Chief Financial Officer, as well as all other senior financial and accounting officers. The Code of Ethics is posted on our website at www.chemicalbank.com. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver of, a provision of the Code of Ethics by posting such information on our website at www.chemicalbank.com.
Item 11. Executive Compensation.
Information required by this item is set forth under the headings "Executive Compensation," "Director Compensation," "Compensation and Pension Committee Report" and under the subheading "Compensation Committee Interlocks and Insider Participation" in our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders to be filed with the SEC not later than 120 days after December 31, 2017 and is here incorporated by reference.


169


Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item is set forth under the heading "Ownership of Chemical Financial Common Stock" in our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders to be filed with the SEC not later than 120 days after December 31, 2017 and is here incorporated by reference.
The following table presents information about our equity compensation plans as of December 31, 2017 :
 
 
Equity Compensation Plan Information
 
Plan category
 
Number of Securities to be Issued upon Exercise of Outstanding Options,
Warrants and Rights
(a)
 
Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)
 
Number of Securities
Remaining Available for Future Issuance under Equity Compensation Plans
(excluding Securities Reflected in Column (a))
(c)
 
Equity compensation plans approved by security holders (1)
 
941,623

 
$
32.13

 
1,941,843

(3)
Equity compensation plans not approved by security holders (2)
 
169,295

 
$
15.25

 

 
Total
 
1,110,918

 
$
29.56

 
1,941,843

 
(1)
Consists of the Chemical Financial Corporation Stock Incentive Plan of 2006 ("2006 Plan"), the Chemical Financial Corporation Stock Incentive Plan of 2012 ("2012 Plan"), the Chemical Financial Corporation Stock Incentive Plan of 2015 ("2015 Plan"), the Chemical Financial Corporation Stock Incentive Plan of 2017 ("2017 Plan") and the Chemical Financial Corporation Directors' Deferred Stock Plan. Stock options or other awards may no longer be granted under the 2006 Plan, the 2012 Plan, or the 2015 Plan.
(2)
At December 31, 2017 , equity compensation plans not approved by shareholders consisted of the Talmer Bancorp, Inc. 2009 Equity Incentive Plan ("TLMR Equity Incentive Plan"), the Lake Michigan Financial Corporation Stock Incentive Plan of 2003 and the Lake Michigan Financial Corporation Stock Incentive Plan of 2012 (collectively referred to as the "LMFC Stock Incentive Plans"). The TLMR Equity Incentive Plan granted non-statutory stock options that were awarded at the fair value of Talmer Bancorp, Inc. common stock on the date of grant. Effective as of the Corporation's merger with Talmer Bancorp, Inc. on August 31, 2016, each option outstanding under the TLMR Equity Incentive Plan ceased to represent a stock option for TLMR common stock and was converted into a stock option for common stock of the Corporation. The LMFC Stock Incentive Plans granted non-statutory stock options that were awarded at the fair value of Lake Michigan Financial Corporation common stock on the date of grant. Effective as of the Corporation's acquisition of Lake Michigan Financial Corporation on May 31, 2015, each option outstanding under the LMFC Stock Incentive Plans ceased to represent a stock option for LMFC common stock and was converted into a stock option for common stock of the Corporation. Payment for the exercise of an option at the time of exercise may be made in the form of shares of the Corporation’s common stock having a market value equal to the exercise price of the option at the time of exercise, or in cash. There are no further stock options or other awards available for grant under the TLMR Equity Incentive Plan or the LMFC Stock Incentive Plans. As of December 31, 2017 , there were 138,324 options to purchase the Corporation's common stock under the TLMR Equity Incentive Plan with a weighted average exercise price of $15.36 per share and 30,971 options to purchase the Corporation's common stock outstanding under the LMFC Stock Incentive Plans with a weighted average exercise price of $14.76 per share.
(3)
Represents 1,681,101 remaining available shares for future grant under the 2017 Plan and 259,651 remaining shares available for future issuance under the Directors' Deferred Stock Plan.
Each plan listed above contains customary anti-dilution provisions that are applicable in the event of a stock split or certain other changes in the capitalization of Chemical Financial Corporation.

Item 13. Certain Relationships and Related Transactions and Director Independence.
The information required by this item is set forth under the subheadings "Board Committees" and "Transactions with Related Persons" in our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders to be filed with the SEC not later than 120 days after December 31, 2017 and is here incorporated by reference.

Item 14. Principal Accountant Fees and Services.
The information required by this item is set forth under the heading "Independent Registered Public Accounting Firm" and subheading "Audit Committee" in our definitive Proxy Statement for our 2018 Annual Meeting of Shareholders to be filed with the SEC not later than 120 days after December 31, 2017 and is here incorporated by reference.

170



PART IV.
Item 15. Exhibits and Financial Statement Schedules.
(a)  (1)   Financial Statements.  The following documents are filed as part of Item 8 of this Annual Report:
Report of Independent Registered Public Accounting Firm
Consolidated Statements of Financial Position as of December 31, 2017 and 2016
Consolidated Statements of Income for each of the three years in the period ended December 31, 2017
Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2017
Consolidated Statements of Changes in Shareholders' Equity for each of the three years in the period ended December 31, 2017
Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2017
Notes to Consolidated Financial Statements

(2)
Financial Statement Schedules.  The schedules for the Corporation are omitted because of the absence of conditions under which they are required, or because the information is set forth in the Consolidated Financial Statements or the Notes thereto.
(3)
Exhibits.  The following lists the Exhibits to the Annual Report on Form 10-K:
Number
 
Exhibit
3.1 *
 
3.2
 
4.1
 

4.2
 
4.3
 
Long-Term Debt. The registrant has outstanding long-term debt which at the time of this Annual Report does not exceed 10% of the registrant's total consolidated assets. The registrant agrees to furnish copies of the agreements defining the rights of holders of such long-term debt to the SEC upon request.
10.1 *†
 

10.2 *†
 

10.3 *†
 

10.4 *†
 

10.5 *†
 
10.6 *†
 

10.7 *†
 

10.8 *†
 

10.9 †
 

10.10 *†
 

171


10.11 *†
 

10.12 *†
 

10.13 *†
 

10.14 *†#
 

10.15 †+
 

10.16 †^
 
10.17 †^
 
10.18 †
 
10.19 *†
 

10.20 *†
 

10.21 *†
 

10.22 *†
 

10.23 *†

 

10.24 †
 

10.25 †
 

10.26 †
 
10.27 †
 
10.28 †
 
10.29 †
 

10.30 †
 
21
 
23.1
 
23.2
 
24
 
31.1
 
31.2
 
32
 
99.1
 
101.1
 
Interactive Data File.
* Incorporated by reference. Copies of these Exhibits have been filed with the SEC. Exhibits that are not incorporated by reference

172


are filed with this Annual Report.
These agreements are management contracts or compensation plans or arrangements required to be filed as Exhibits to this Form 10-K.
# Exhibit 10.14 was superseded and replaced with the Offer Letter Agreement dated November 3, 2017 here incorporated by reference as Exhibit 10.22, except for the covenant not to compete in Section 13 of Exhibit 10.14, which remains in force and effect, and was reduced to six months.
+ Exhibit 10.15 was superseded and replaced with the Employment Agreement dated July [__], 2017 and filed herewith as Exhibit 10.18.
^ Exhibits 10.16 and 10.17 were superseded and replaced with the Employment Agreements dated August 9, 2017 here incorporated by reference as Exhibits 10.20 and 10.21, respectively.

The index of exhibits and any exhibits filed as part of the 2017 Form 10-K are accessible at no cost on our web site at www.chemicalbank.com in the "Investor Information" section, at www.edocumentview.com/chfc and through the United States Securities and Exchange Commission's web site at www.sec.gov . We will furnish a copy of any exhibit listed above to any shareholder at a cost of 30 cents per page upon written request to Dennis L. Klaeser, Chief Financial Officer, Chemical Financial Corporation, 235 East Main Street, Midland, P.O. Box 569, Michigan 48640-0569.

173


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 28, 2018 .
CHEMICAL FINANCIAL CORPORATION

/s/ David T. Provost 
David T. Provost
Chief Executive Officer and President
(Principal Executive Officer)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 28, 2018 by the following persons on behalf of the registrant and in the capacities indicated.
OFFICERS:
 
/s/ David T. Provost 
David T. Provost
Chief Executive Officer and President
(Principal Executive Officer)

/s/ Dennis L. Klaeser                
Dennis L. Klaeser
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

/s/ Kathleen S. Wendt                   
Kathleen S. Wendt
Executive Vice President and Chief Accounting Officer
(Principal Accounting Officer)

The following Directors of Chemical Financial Corporation executed a power of attorney appointing Dennis L. Klaeser their attorney-in-fact, empowering him to sign this report on their behalf.
James R. Fitterling
Ronald A. Klein
Richard M. Lievense
Barbara J. Mahone
John E. Pelizzari
Thomas C. Shafer
Larry D. Stauffer
Jeffrey L. Tate
Gary Torgow
Arthur A. Weiss
Franklin C. Wheatlake
 
/s/ Dennis L. Klaeser
By Dennis L. Klaeser
Attorney-in-fact

174


EXHIBIT 3.2


BYLAWS


OF


CHEMICAL FINANCIAL CORPORATION
(as amended through January 23, 2018)


ARTICLE I

OFFICES

1.01    PRINCIPAL OFFICE. The principal office of the corporation shall be at such place within the state of Michigan as the Board of Directors shall determine from time to time.

1.02    OTHER OFFICES. The corporation may also have offices at such other places as the Board of Directors from time to time determines or the business of the corporation requires.


ARTICLE II

SEAL

2.01    SEAL. The corporation shall have a seal in such form as the Board of Directors may from time to time determine. The seal may be used by causing it or a facsimile to be impressed, affixed, reproduced or otherwise.


ARTICLE III

CAPITAL STOCK

3.01    ISSUANCE OF SHARES. The shares of capital stock of the corporation shall be issued in such amounts, at such times, for such consideration and on such terms and conditions as the Board shall deem advisable, subject to the provisions of the Articles of Incorporation of the corporation and the further provisions of these Bylaws, and subject also to any requirements or restrictions imposed by the laws of the State of Michigan.

3.02    CERTIFICATES FOR SHARES. The shares of the corporation may be represented by certificates signed by the Chair of the Board, President or a Vice President and by the Treasurer, Assistant Treasurer, Secretary or Assistant Secretary of the corporation, and may be sealed with the seal of the corporation or a facsimile thereof. The signatures of the officers may be facsimiles if the certificate is countersigned by a transfer agent or registered by a registrar other than the corporation itself or its employee. In case an officer who has signed or whose facsimile signature has been placed upon a certificate ceases to be such officer before the certificate is issued, it may be issued by the corporation with the same effect as if he were such officer at the date of issuance. A certificate representing shares shall state upon its face that the corporation is formed under the laws of the State of Michigan; the name of the person to whom it is issued; the number and class of shares, and the designation of the series, if any, which the certificate represents; the par value of each share represented by the certificate, or a statement that the shares are without par value; and such other provisions as may be required by the laws of the State of Michigan. The Board of Directors may authorize the issuance of some or all of the shares of any class or series of stock of the corporation without certificates.

3.03    TRANSFER OF SHARES. The shares of the capital stock of the corporation are transferable only on the books of the corporation and, if such shares are certificated, upon surrender of the certificate therefor, properly endorsed for transfer, and the presentation of such evidences of ownership and validity of the assignment as the corporation may require.

3.04    REGISTERED SHAREHOLDERS. The corporation shall be entitled to treat the person in whose name any share of stock is registered as the owner thereof for purposes of dividends and other distributions in the course of business, or in





the course of recapitalization, consolidation, merger, reorganization, sale of assets, liquidation or otherwise and for the purpose of votes, approvals and consents by shareholders, and for the purpose of notices to shareholders, and for all other purposes whatever, and shall not be bound to recognize any equitable or other claim to or interest in such shares on the part of any other person, whether or not the corporation shall have notice thereof, save as expressly required by the laws of the State of Michigan.

3.05    LOST OR DESTROYED CERTIFICATES. Upon the presentation to the corporation of a proper affidavit attesting the loss, destruction or mutilation of any certificate or certificates for shares of stock of the corporation, the Board of Directors shall direct the issuance of a new certificate or certificates to replace the certificates so alleged to be lost, destroyed or mutilated. The Board of Directors may require as a condition precedent to the issuance of new certificates any or all of the following: (a) presentation of additional evidence or proof of the loss, destruction or mutilation claimed; (b) advertisement of loss in such manner as the Board of Directors may direct or approve; (c) a bond or agreement of indemnity, in such form and amount and with such sureties, or without sureties, as the Board of Directors may direct or approve; (d) the order or approval of a court or judge.


ARTICLE IV

SHAREHOLDERS AND MEETINGS OF SHAREHOLDERS

4.01    PLACE OF MEETINGS. All meetings of shareholders shall be held at the principal office of the corporation or at such other place as shall be determined by the Board of Directors and stated in the notice of meeting.

4.02    ANNUAL MEETING. The annual meeting of the shareholders of the corporation shall be held on the third Monday of the fourth calendar month after the end of the corporation’s fiscal year at 2 o’clock in the afternoon, or on such other date and time as shall be determined by the Board of Directors prior to the end of the second calendar quarter. Directors shall be elected at each annual meeting and such other business transacted as may come before the meeting.

4.03    SPECIAL MEETINGS. Special meetings of shareholders may be called by the Board of Directors, the Chair of the Board (if such office is filled) or the President and shall be called by the President or Secretary at the written request of shareholders holding a majority of the shares of stock of the corporation outstanding and entitled to vote. The request shall state the purpose or purposes for which the meeting is to be called.

4.04    NOTICE OF MEETING OF SHAREHOLDERS. Notwithstanding anything to the contrary in these bylaws (including Article VI, Section 6.01), written notice of each meeting of shareholders, stating the time, place, if any, and purposes thereof, shall be given to each shareholder entitled to vote at the meeting not less than ten nor more than sixty days before the date fixed for the meeting, either personally, by mail, or, if authorized by the Board of Directors, by a form of electronic transmission to which the shareholder has consented. For the purposes of these Bylaws, “electronic transmission” means any form of communication that does not directly involve the physical transmission of paper, that creates a record that may be retained and retrieved by the recipient, and that may be reproduced in paper form by the recipient through an automated process. Notice of a meeting need not be given to any shareholder who signs a waiver of notice before or after the meeting. Attendance of a shareholder at a meeting shall constitute both: (a) a waiver of notice or defective notice except when the shareholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to holding the meeting or transacting any business because the meeting has not been lawfully called or convened, and (b) a waiver of objection to consideration of a particular matter at the meeting that is not within the purpose or purposes described in the meeting notice, except when the shareholder objects to considering the matter when it is presented.

4.05    RECORD DATES. The Board of Directors, the Chair of the Board (if such office is filled) or the President may fix in advance a date as the record date for the purpose of determining shareholders entitled to notice of and to vote at a meeting of shareholders or an adjournment thereof, or to express consent or to dissent from a proposal without a meeting, or for the purpose of determining shareholders entitled to receive payment of a dividend or allotment of a right, or for the purpose of any other action. The date fixed shall not be more than 60 nor less than 10 days before the date of the meeting, nor more than 60 days before any other action. In such case only such shareholder as shall be shareholders of record on the date so fixed shall be entitled to notice of and to vote at such meeting or adjournment therefor, or to express consent or to dissent from such proposal, or to receive payment of such dividend or to receive such allotment of rights, or to participate in any other action, as the case may be, notwithstanding any transfer of any stock on the books of the corporation, or otherwise, after any such record date. Nothing in this Bylaw shall affect the rights of a shareholder and his or her transferee or transferor as between themselves.

4.06    LIST OF SHAREHOLDERS. The Secretary of the corporation or the agent of the corporation having charge of the stock transfer records for shares of the corporation shall make and certify a complete list of the shareholders entitled to vote at a shareholders’ meeting or any adjournment thereof. The list shall be arranged alphabetically within each class and series, with





the address of, and the number of shares held by, each shareholder; be produced at the time and place of the meeting; be subject to inspection by any shareholder during the whole time of the meeting; and be prima facie evidence as to who are the shareholders entitled to examine the list or vote at the meeting.

4.07    QUORUM. Unless a greater or lesser quorum is required in the Articles of Incorporation or by the laws of the State of Michigan, the shareholders present at a meeting in person or by proxy who, as of the record date for such meeting, were holders of a majority of the outstanding shares of the corporation entitled to vote at the meeting shall constitute a quorum at the meeting. Whether or not a quorum is present, a meeting of shareholders may be adjourned by a vote of the shares present in person or by proxy. When the holders of a class or series of shares are entitled to vote separately on an item of business, this Bylaw applies in determining the presence of a quorum of such class or series for transaction of such item of business.

4.08    PROXIES. A shareholder entitled to vote at a meeting of shareholders or to express consent or dissent without a meeting may authorize one or more other persons to act for him or her by proxy. The following methods constitute a valid means by which a shareholder may grant authority to another person to act as proxy: (a) The execution of a writing authorizing another person or persons to act for the shareholder as proxy. Execution may be accomplished by the shareholder or by an authorized officer, director, employee, or agent signing the writing or causing his or her signature to be affixed to the writing by any reasonable means including, but not limited to, facsimile signature; and (b) Transmitting or authorizing the transmission by electronic transmission to the person who will hold the proxy or to a proxy solicitation firm, proxy support service organization, or similar agent fully authorized by the person who will hold the proxy to receive that transmission. Any electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the shareholder. If an electronic transmission is determined to be valid, the inspectors, or, if there are no inspectors, the persons making the determination shall specify the information upon which they relied.

4.09    INSPECTORS OF ELECTION. The Board of Directors, in advance of a shareholders’ meeting, may appoint one or more inspectors to act at the meeting or any adjournment thereof. If inspectors are not so appointed, the person presiding at the shareholders’ meeting may, and on request of a shareholder entitled to vote thereat shall, appoint one or more inspectors. In case a person appointed fails to appear or act, the vacancy may be filled by appointment made by the Board of Directors in advance of the meeting or at the meeting by the person presiding thereat. If appointed, the inspectors shall determine the number of shares outstanding and the voting power of each, the shares represented at the meeting, the existence of a quorum and the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine challenges and questions arising in connection with the right to vote, count and tabulate votes, ballots or consents, determine the result, and do such acts as are proper to conduct the election or vote with fairness to all shareholders. On request of the person presiding at the meeting or a shareholder entitled to vote thereat, the inspectors shall make and execute a written report to the person presiding at the meeting of any of the facts found by them and matters determined by them. The report shall be prima facie evidence of the facts stated and of the vote as certified by the inspectors.

4.10    VOTING. Each outstanding share is entitled to one vote on each matter submitted to a vote, unless otherwise provided in the Articles of Incorporation. Votes shall be cast in writing, signed by the shareholder or his or her proxy. When an action, other than the election of directors, is to be taken by a vote of the shareholders, it shall be authorized by a majority of the votes cast by the holders of shares entitled to vote thereon, unless a greater plurality is required by the Articles of Incorporation or by the laws of the State of Michigan. Except as otherwise provided by the Articles of Incorporation, directors shall be elected by a plurality of the votes cast at any election.

4.11    SHAREHOLDER PROPOSALS. Except as otherwise provided by statute, the corporation’s Articles of Incorporation or these Bylaws:

(a)
No matter may be presented for shareholder action at an annual or special meeting of shareholders unless such matter is: (i) specified in the notice of the meeting (or any supplement to the notice) given by or at the direction of the Board of Directors; (ii) otherwise presented at the meeting by or at the direction of the Board of Directors; (iii) properly presented for action at the meeting by a shareholder in accordance with the notice provisions set forth in this Section and any other applicable requirements; or (iv) a procedural matter presented, or accepted for presentation, by the Chair in his or her sole discretion

(b)
For a matter to be properly presented by a shareholder, the shareholder must have given timely notice of the matter in writing to the Secretary of the corporation. To be timely, the notice must be delivered to or mailed to and received at the principal executive offices of the corporation not less than 120 calendar days prior to the date corresponding to the date of the corporation’s proxy statement or notice of meeting released to shareholders in connection with the last preceding annual meeting of shareholders





in the case of an annual meeting (unless the corporation did not hold an annual meeting within the last year, or if the date of the upcoming annual meeting changed by more than thirty days from the date of the last preceding meeting, then the notice must be delivered or mailed and received not more than ten days after the earlier of the date of the notice of the meeting or public disclosure of the date of the meeting), and not more than ten days after the earlier of the date of the notice of the meeting or public disclosure of the date of the meeting in the case of a special meeting. The notice by the shareholder must set forth: (i) a brief description of the matter the shareholder desires to present for shareholder action; (ii) the name and record address of the shareholder proposing the matter for shareholder action; (iii) the class and number of shares of capital stock of the corporation that are beneficially owned by the shareholder; and (iv) any material interest of the shareholder in the matter proposed for shareholder action. For purposes of this Section, “public disclosure” means disclosure in a press release reported by the Dow Jones News Service, Associated Press or other comparable national financial news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15 of the Securities Exchange Act of 1934, as amended.

(c)
Except to the extent that a shareholder proposal submitted pursuant to this Section is not made available at the time of mailing, the notice of the purposes of the meeting shall include the name and address of and the number of shares of the voting security held by the proponent of each shareholder proposal

(d)
Notwithstanding the above, if the shareholder desires to require the corporation to include the shareholder’s proposal in the corporation’s proxy materials, matters and proposals submitted for inclusion in the corporation’s proxy materials shall be governed by the solicitation rules and regulations of the Securities Exchange Act of 1934, as amended, including without limitation Rule 14a-8.


ARTICLE V

DIRECTORS

5.01    NUMBER. The business and affairs of the corporation shall be managed by a Board of not less than five (5) nor more than twenty-five (25) directors as shall be fixed from time to time by the Board of Directors. The directors need not be residents of Michigan or shareholders of the corporation.

5.02    ELECTION, RESIGNATION AND REMOVAL. Directors shall be elected at each annual meeting of the shareholders, each to hold office until the next annual meeting of shareholders and until his or her successor is elected and qualified, or until his or her resignation or removal. A director may resign by written notice to the corporation. The resignation is effective upon its receipt by the corporation or a subsequent time as set forth in the notice of resignation. A director or the entire Board of Directors may be removed, with or without cause, by vote of the holders of a majority of the shares entitled to vote at an election of directors.

5.03    NOMINATIONS OF DIRECTOR CANDIDATES.

(a)
Nominations of candidates for election to the Board of Directors of the corporation at any annual meeting of shareholders or at any special meeting of shareholders called for election of directors (an “Election Meeting”) may be made by the Board of Directors or by a shareholder of record of shares of a class entitled to vote at such Election Meeting.

(b)
Nominations made by the Board of Directors shall be made at a meeting of the Board of Directors, or by written consent of directors in lieu of a meeting, not less than ten days prior to the date of an Election Meeting; provided, that approval by the Board of Directors of the corporation’s proxy statement with respect to an Election Meeting in which nominees for director are named shall constitute the nominations of the Board of Directors.

(c)
A shareholder of record of shares of a class entitled to vote at an Election Meeting may make a nomination at an Election Meeting if, and only if, such shareholder shall have first delivered, not less than 120 days prior to the date of the Election Meeting in the case of an annual meeting, and not more than seven days following the date of notice of the Election Meeting in the case of a special meeting, a notice to the Secretary of the corporation setting forth with respect to each proposed nominee: (i) the name, age, business address and residence address of such nominee; (ii) the principal occupation or employment





of such nominee; (iii) the number of shares of capital stock of the corporation which are beneficially owned by such nominee; (iv) a statements that such nominee is willing to be nominated and to serve if elected; and (v) such other information concerning such nominee as would be required under the rules of the Securities and Exchange Commission to be provided in a proxy statement soliciting proxies for the election of such nominee.

(d)
If the chair of the Election Meeting determines that a nomination was not made in accordance with the foregoing procedures, such nomination shall be void and all votes cast in favor of election of a person so nominated shall be disregarded.

5.04    VACANCIES. Vacancies in the Board of Directors occurring by reason of death, resignation, removal, increase in the number of directors or otherwise shall be filled by the affirmative vote of a majority of the remaining directors though less than a quorum of the Board of Directors, unless filled by proper action of the shareholders of the corporation. Each person so elected shall be a director for a term of office continuing only until the next election of directors by the shareholders.

5.05    ANNUAL MEETING. The Board of Directors shall meet each year following the annual meeting of the shareholders, for the purpose of election of officers and consideration of such business that may properly be brought before the meeting.

5.06    REGULAR AND SPECIAL MEETINGS. Regular meetings of the Board of Directors may be held at such times and places as the majority of the directors may from time to time determine at a prior meeting or as shall be directed or approved by the vote or written consent of all the directors. Special meetings of the Board may be called by the Chair of the Board (if such office is filled) or the President and shall be called by the President or Secretary upon the written request of any two directors.

5.07    NOTICES. No notice shall be required for annual or regular meetings of the Board or for adjourned meetings, whether regular or special. Three days’ written notice shall be given for special meetings of the Board, and such notice shall state the time, place and purpose or purposes of the meeting.

5.08    QUORUM. A majority of the Board of Directors then in office, or of the members of a committee thereof, constitutes a quorum for the transaction of business. The vote of a majority of the directors present at any meeting at which there is a quorum shall be the acts of the Board or of the committee, except as a larger vote may be required by the laws of the State of Michigan. A member of the Board or of a committee designated by the Board may participate in a meeting by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other. Participation in a meeting in this manner constitutes presence in person at the meeting.

5.09    EXECUTIVE AND OTHER COMMITTEES. The Board of Directors may, by resolution passed by a majority of the whole Board, appoint three or more members of the Board as an executive committee to exercise all powers and authorities of the Board in management of the business and affairs of the corporation, provided, however, that such committee shall not have power or authority to:

(a)
amend the Articles of Incorporation;

(b)
adopt an agreement of merger or consolidation;

(c)
recommend to shareholders the sale, lease or exchange of all or substantially all of the corporation’s property and assets;

(d)
recommend to shareholders a dissolution of the corporation or revocation of a dissolution;

(e)
amend these Bylaws;

(f)
fill vacancies in the Board;

(g)
fix the compensation of the directors for serving on the Board or on a committee; or

(h)
unless expressly authorized by the Board, declare a dividend or authorize the issuance of stock.






The Board of Directors from time to time may, by like resolution, appoint such other committees of one or more directors to have such authority as shall be specified by the Board in the resolution making such appointments. The Board of Directors may designate one or more directors as alternate members of any committee who may replace an absent or disqualified member at any meeting thereof.

5.10    DISSENTS. A director who is present at a meeting of the Board of Directors, or a committee thereof of which he or she is a member, at which action on a corporate matter is taken is presumed to have concurred in that action unless his or her dissent is entered in the minutes of the meeting or unless he or she files his or her written dissent to the action with the person acting as secretary of the meeting before the adjournment thereof or shall forward such dissent by registered mail to the Secretary of the corporation promptly after the adjournment of the meeting. Such right to dissent does not apply to a director who voted in favor of such action. A director who is absent from a meeting of the Board, or a committee thereof of which he or she is a member, at which any such action is taken is presumed to have concurred in the action unless he or she files his or her written dissent with the Secretary of the corporation within a reasonable time after he or she has knowledge of the action.

5.11    COMPENSATION. The Board of Directors, by affirmative vote of a majority of directors in office and irrespective of any personal interest of any of them, may establish reasonable compensation of directors for services to the corporation as directors or officers.


ARTICLE VI

NOTICES, WAIVERS OF NOTICE AND MANNER OF ACTING

6.01    NOTICES. All notices of meetings required to be given to shareholders, directors or any committee of directors may be given by mail or by electronic transmission to any shareholder, director or committee member at his or her last address as it appears on the books of the corporation. Such notice shall be deemed to be given at the time when the same shall be mailed or otherwise dispatched.

6.02    WAIVER OF NOTICE. Notice of the time, place and purpose of any meeting of shareholders, directors or committee of directors may be waived in writing or by electronic transmission, either before or after the meeting, or in such other manner as may be permitted by the laws of the State of Michigan. Attendance of a person at any meeting of shareholders, in person or by proxy, or at any meeting of directors or of a committee of directors, constitutes a waiver of notice of the meeting except when the person attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

6.03    ACTION WITHOUT A MEETING. Any action required or permitted at any meeting of shareholders or directors or committee of directors may be taken without a meeting, without prior notice and without a vote, if all of the shareholders or directors or committee members entitled to vote thereon consent thereto in writing.


ARTICLE VII

OFFICERS

7.01    NUMBER. The Board of Directors shall elect or appoint a Chair of the Board, a Chief Executive Officer, a President, a Secretary, a Treasurer, and one or more other officers as the Board of Directors may from time to time determine. The Chair of the Board, the President and the Chief Executive Officer, if such person is not also the President, shall be members of the Board of Directors. Any two or more offices, except those of President and Vice President and those of Chief Executive Officer and Vice President, may be held by the same person, but no officer shall execute, acknowledge or verify an instrument in more than one capacity.

7.02    TERM OF OFFICE, RESIGNATION AND REMOVAL. The Chair of the Board and each officer shall hold office for the term for which he or she is elected or appointed and until his or her successor is elected or appointed and qualified, or until his or her resignation or removal. The Chair of the Board and any officer may resign by written notice to the corporation. The resignation is effective upon its receipt by the corporation or at a subsequent time specified in the notice of resignation. An officer may be removed with or without cause. The removal of an officer shall be without prejudice to his or her contract rights, if any. The election or appointment of an officer does not of itself create contract rights.






7.03    VACANCIES. The Board of Directors may fill any vacancies in the Chair of the Board position or any office occurring for whatever reason.

7.04    AUTHORITY. The Chair of the Board and all officers, employees and agents of the corporation shall have such authority and perform such duties in the conduct and management of the business and affairs of the corporation as may be designated by the Board of Directors and these Bylaws.


ARTICLE VIII

DUTIES OF OFFICERS

8.01    CHAIR OF THE BOARD. The Chair of the Board shall preside at all meetings of the shareholders and of the Board of Directors at which he or she is present. He or she shall have such other duties and powers as may be imposed upon or given to him or her by the Board of Directors.

8.02    CHIEF EXECUTIVE OFFICER. The Chief Executive Officer shall see that all orders and resolutions of the Board are carried into effect, and he or she shall have the general and active powers of supervision and management usually vested in the chief executive officer of a corporation, including the authority to vote all securities of other corporations and business organizations which are held by the corporation. In the absence or disability of the Chair of the Board, he or she also shall perform the duties and execute the powers of the Chair of the Board as set forth in these Bylaws.

8.03    PRESIDENT. The President shall have such duties as may be assigned to him or her from time to time by the Chief Executive Officer or the Board of Directors. The President may also be the Chief Executive Officer. In the absence or disability of the Chief Executive Officer, the President shall perform the duties and execute the powers of the Chief Executive Officer as set forth in these Bylaws.

8.04    VICE PRESIDENTS. The Vice Presidents, in order of their seniority based upon executive title, shall, in the absence or disability of the President, perform his or her duties and exercise his or her powers and shall perform such other duties as the Board of Directors, the Chief Executive Officer or the President may from time to time prescribe.

8.05    SECRETARY. The Secretary shall attend all meetings of the Board of Directors and of shareholders and shall record all votes and minutes of all proceedings in a book to be kept for that purpose. He or she shall give or cause to be given notice of all meetings of the shareholders and of the Board of Directors. He or she shall keep in safe custody the seal of the corporation, if any, and, when authorized by the Board, affix the same to any instrument requiring it, and when so affixed it shall be attested by his or her signature, or by the signature of the Treasurer or an Assistant Secretary. The Secretary may delegate any of his or her duties, powers and authorities to one or more Assistant Secretaries, unless such delegation is disapproved by the Board.

8.06    TREASURER. The Treasurer shall have the custody of the corporate funds and securities; shall keep full and accurate accounts of receipts and disbursements in books of the corporation; and shall deposit all moneys and other valuable effects in the name and to the credit of the corporation in such depositories as may be designated by the Board of Directors. He or she shall render to the Chief Executive Officer, the President and directors, whenever they may require it, an account of his or her transactions as Treasurer and of the financial condition of the corporation. The Treasurer may delegate any of his or her duties, powers and authorities to one or more Assistant Treasurers unless such delegation be disapproved by the Board of Directors. The Board of Directors may designate the individual who serves as Treasurer to also serve as Chief Financial Officer of the corporation, .

8.07    ASSISTANT SECRETARIES AND TREASURERS. The Assistant Secretaries, in the order of their seniority based upon executive title, shall perform the duties and exercise the powers and authorities of the Secretary in case of his or her absence or disability. The Assistant Treasurers, in the order of their seniority based upon executive title, shall perform the duties and exercise the powers and authorities of the Treasurer in case of his or her absence or disability. The Assistant Secretaries and Assistant Treasurers shall also perform such duties as may be delegated to them by the Secretary and Treasurer, respectively, and also such duties as the Chief Executive Officer, the President, or the Board of Directors may prescribe.

8.08    OTHER OFFICERS. The Board of Directors may, from time to time, appoint such other officers of the corporation as the Board of Directors may consider appropriate. Such officers shall perform such duties and exercise such authority as the Board of Directors may prescribe.






8.09    EXECUTIVE OFFICERS. The Chief Executive Officer, President, Secretary and Treasurer, together with such other officers specifically designated by the Board of Directors, shall be known as the executive officers and shall have all of the usual powers and shall perform all of the usual duties incident to their respective offices.


ARTICLE IX

SPECIAL CORPORATE ACTS

9.01    ORDERS FOR PAYMENT OF MONEY. All checks, drafts, notes, bonds, bills of exchange and orders for payment of money of the corporation shall be signed by such officer or officers or such other person or persons as the Board of Directors may from time to time designate.

9.02    CONTRACTS AND CONVEYANCES. The Board of Directors of the corporation may in any instance designate the officer and/or agent who shall have authority to execute any contract, conveyance, mortgage or other instrument on behalf of the corporation, or may ratify or confirm any execution. When the execution of any instrument has been authorized without specification of the executing officers or agents, any executive officer of the corporation may execute the same in the name and on behalf of this corporation and may affix the corporate seal thereto.


ARTICLE X

BOOKS AND RECORDS

10.01    MAINTENANCE OF BOOKS AND RECORDS. The proper officers and agents of the corporation shall keep and maintain such books, records and accounts of the corporation’s business and affairs, minutes of the proceedings of its shareholders, Board and committees, if any, and such stock ledgers and lists of shareholders, as the Board of Directors shall deem advisable, and as shall be required by the laws of the State of Michigan and other states or jurisdictions empowered to impose such requirements. Books, records and minutes may be kept within or without the State of Michigan in a place which the Board shall determine.

10.02    RELIANCE ON BOOKS AND RECORDS. In discharging his or her duties, a director or an officer of the corporation, when acting in good faith, may rely upon the opinion of counsel for the corporation, upon the report of an independent appraiser selected with reasonable care by the Board, or upon financial statements of the corporation represented to him or her to be correct by the President or the officer of the corporation having charge of its books of account, or stated in a written report by an independent public or certified public accountant or firm of such accountants fairly to reflect the financial condition of the corporation.


ARTICLE XI

INDEMNIFICATION

11.01    INDEMNIFICATION. The corporation shall provide indemnification to persons who serve or have served as directors, officers, employees or agents of the corporation, and to persons who serve or have served at the request of the corporation as directors, officers, employees, partners or agents of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise, whether for profit or not, to the fullest extent permitted by the Michigan Business Corporation Act, as the same now exists or may hereafter be amended.


ARTICLE XII

AMENDMENTS

12.01    AMENDMENTS. The Bylaws of the corporation may be amended, altered or repealed, in whole or in part, by the shareholders or by the Board of Directors at any meeting duly held in accordance with these Bylaws, provided that notice of the meeting includes notice of the proposed amendment, alternative or repeal.





Exhibit 10.9

CHEMICAL FINANCIAL CORPORATION EXECUTIVE ANNUAL INCENTIVE PLAN

SECTION 1: Establishment & Purpose.
1.1      Establishment of Plan . The Company hereby establishes this Chemical Financial Corporation Executive Annual Incentive Plan for its corporate and Subsidiary employees.
1.2      Purpose of Plan. The purpose of this Plan is to advance the interests of the Company and its Subsidiaries by attracting and retaining executives, and by stimulating the efforts of such executives to contribute to the continued success and growth of the business of the Company and its Subsidiaries. This Plan is further intended to provide flexibility to the Company and its Subsidiaries in structuring long-term incentive compensation to appropriately balance risk and reward, ensure compatibility with effective controls and risk-management, and to align Awards with the interests of its shareholders. Awards under this Plan are payable in cash or other property, but not the equity securities of the Company or its Subsidiaries.
SECTION 2: Definitions.
The following words have the following meanings unless a different meaning plainly is required by the context:
2.1      Act means the Securities Exchange Act of 1934, as amended.
2.2     “ Award ” means a right granted to a Participant to receive an incentive payment, in cash or other property, upon the achievement of certain Performance Measures designated as provided in this Plan.
2.3     “ Base Salary ” means a Participant’s annualized base salary as of the last day of the applicable Performance Period or, if earlier, the date the Participant terminates employment if payment is made under Section 4.2(b) on account of death, Disability or retirement.
2.4      Board means the Board of Directors of the Company.
2.5      Code means the Internal Revenue Code of 1986, as amended. Each reference in this Plan to a section or sections of the Code, unless otherwise noted, shall be deemed to include a reference to the rules and regulations issue under such section or sections of the Code.
2.6     “ Committee ” means the Compensation and Pension Committee of the Board or such other committee as the Board may designate from time to time. The Committee shall consist of at least two members of the Board and all of its members shall be “non-employee directors” as defined in Rule 16b-3 issued under the Act.
2.7      Company means Chemical Financial Corporation, a Michigan corporation, and its successors and assigns.
2.8     “ Disability ” means an inability of a Participant to perform his or her employment duties due to physical or mental disability for a continuous period of one hundred eighty (180) days or longer and the Participant is eligible for benefits under the Company’s or a Subsidiary’s long-term disability policy.
2.9     “ Executive ” means an executive employee of the Company or one of its Subsidiaries.
2.10 Maximum Award means a dollar amount or a percentage of Base Salary, as determined by the Committee for each Performance Period, which represents the payment that the Participant will earn if the maximum level of the Performance Measures is achieved.
2.11 “ Participants means any Executive of the Company who is designated by the Committee as a Participant in this Plan. Members of the Board of Directors of the Company who are not also Executives of the Company are not eligible to participate in





this Plan. A person who is hired by the Company, or promoted to a position in which he is eligible to be a Participant, during a Performance Period may also be designated by the Committee at the time of hire or promotion as a Participant, in which event the Performance Period for such Participant shall be the portion of the Performance Period remaining after the person is designated a Participant.
2.12 Performance Measures means the performance goals selected for each Participant with respect to each Performance Period, the achievement of which shall determine the amount of the Participant’s Award for the Performance Period. The Performance Measures may include any of the criteria listed below:
(a)
Cash earnings;
(b)
Cash earnings per share (reflecting dilution of the Company’s common stock as the Committee deems appropriate and, if the Committee so determines, net of or including dividends);
(c)
Cash earnings return on equity;
(d)
Cash flow;
(e)
Cash flow return on capital;
(f)
Customer satisfaction, satisfaction based on specified objective goals or a Company-sponsored customer survey;
(g)
Deposit growth;
(h)
Economic value added measurements;
(i)
Efficiency ratio;
(j)
Employee turnover;
(k)
Expense or cost levels;
(l)
Interest income;
(m)
Loan growth;
(n)
Margins;
(o)
Market share or market penetration with respect to specific designated products or services, product or service groups and/or specific geographic areas;
(p)
Net income (before or after taxes, interest, depreciation, and/or amortization);
(q)
Net income per share;
(r)
Net interest income;
(s)
Noninterest income;
(t)
Operating efficiency;
(u)
Operating income;
(v)
Operating income per share;
(w)
Operating income return on equity;
(x)
Productivity ratios;
(y)
Reduction of losses, loss ratios, expense ratios or fixed costs;
(z)
Return on assets;
(aa)
Return on capital;
(bb)
Return on equity;
(cc)
Share price (including without limitation growth measures, total shareholder return or comparison to indices);
(dd)
Specified objective social goals; and
(ee)
Such other business criteria as the Committee may determine to be appropriate, which may include financial and nonfinancial performance goals.
One or more Performance Measures may, in the Committee’s sole discretion and provided that the Committee determines that it does not encourage the applicable Participant to expose the Company or its Subsidiaries to imprudent risks that may pose a threat to the safety and soundness of the Company or its Subsidiaries: (i) be linked to the Participant’s business unit, a Subsidiary or the Company as a whole, or any combination of the foregoing, or to such Participant’s areas of responsibility; (ii) be compared to pre-determined levels, as the Committee may deem appropriate, or compared to the performance of a pre-established peer group, or published or special index that the Committee, in its sole discretion, deems appropriate; or (iii) include subjective determinations by the Committee or the Participant’s superiors.
The Committee shall adjust any Performance Measure to the extent necessary to prevent dilution or enlargement of an Award as a result of extraordinary events or circumstances, as determined by the Committee in its sole discretion, or to exclude the effects of extraordinary, unusual, or non-recurring items, such as (a) asset write-downs, (b) litigation or claim judgments or settlements, (c) changes in tax laws, accounting principles, or other laws or provisions affecting reported results, (d) any reorganization and restructuring programs, (e) extraordinary nonrecurring items as described in Financial Accounting Standards Board Accounting Standards Codification Topic 225-20 and/or in management’s discussion and analysis of financial condition and results of operations





appearing in the Company’s annual report to shareholders for the applicable fiscal year, (f) acquisitions, mergers, or divestitures (including non-recurring transaction-related expenses); (g) securities offerings; (h) accounting changes, (i) amortization of goodwill or other intangible assets, (j) discontinued operations, and (k) other special charges or extraordinary items as approved by the Committee, in its sole discretion.
2.13 “ Performance Period means each consecutive twelve (12)-month period commencing on the first day of each calendar or fiscal year during the term of this Plan, or a portion of such twelve-month period with respect to an Executive who becomes a Participant during such period, or such other period as determined by the Committee.
2.14 “ Plan means this Chemical Financial Corporation Annual Incentive Plan.
2.15 “ Target Award means a dollar amount or a percentage of Base Salary determined by the Committee for each Performance Period, which represents the payment that the Participant will earn if the target level of the Performance Measures is achieved.
2.16 “ Threshold Award means a dollar amount or a percentage of Base Salary, as determined by the Committee for each Performance Period, which represents the payment that the Participant will earn if the threshold level of the Performance Measures is achieved.
SECTION 3: Administration.
3.1      Power and Authority of Committee . The Plan shall be administered by the Committee. The Committee shall have full power and authority, subject to all applicable provisions of this Plan and applicable law, to
(a)
establish, amend, suspend or waive such rules and regulations and appoint such agents as it deems necessary or advisable for the proper administration of this Plan,
(b)
construe, interpret and administer this Plan and any instrument or agreement relating to this Plan, including correcting any defect, supplying any omission or reconciling any inconsistency in the manner and to the extent it shall deem desirable to carry this Plan into effect,
(c)
waive, prospectively or retroactively, any conditions of or rights of the Company under any Award,
(d)
increase or decrease the payout due under any Award, and
(d)
make all other determinations and take all other actions necessary or advisable for the administration of this Plan.
Unless otherwise expressly provided in this Plan, each determination made and each action taken by the Committee pursuant to this Plan or any instrument or agreement relating to this Plan shall be within the sole discretion of the Committee, may be made at any time and shall be final, binding and conclusive for all purposes on all persons, including, but not limited to, Participants and Executives of the Company or its Subsidiaries, and their legal representatives and beneficiaries.
3.2      Delegation . The Committee may delegate its powers and duties under this Plan, to designate Executives who will be eligible for Awards and the Performance Measures and other terms of such Awards, and/or to approve achievement of the applicable Performance Measures, to one or more officers of the Company or its Subsidiaries or a committee of such officers, subject to such terms, conditions and limitations as the Committee may establish in its sole discretion; provided, however , that no such officer shall have powers with respect to his or her own Award. The Committee initially delegates such powers and duties under this Plan with respect to Executives who are not officers of the Company, to its Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, and its highest ranking Human Resources Officer, each of whom may exercise such powers individually until such time as the Committee acts to modify or terminate such delegation.
3.3      Determinations at the Outset of Each Performance Period . Prior to the start of or during each Performance Period, the Committee shall:
(a)
designate Executives who will become Participants for such Performance Period;
(b)
establish a Threshold Award, Target Award and Maximum Award for each Participant; and





(c)
with respect to each Participant, establish one or more Performance Measures and a formula to determine the amount of the Award that will be earned at different levels of achievement of the Performance Measures.
3.4      Approval. Following the close of each Performance Period and prior to payment of any amount to any Participant under this Plan, the Committee must approve which of the applicable Performance Measures for that Performance Period have been achieved and the attainment of all other factors upon which any payments to a Participant for that Performance Period are to be based and the corresponding Award amounts. Such approval shall be made in time to permit payments to be made not later than the fifteenth (15th) day of the third (3rd) calendar month following the end of the Performance Period.
SECTION 4: Incentive Payment.
Subject to the provisions of this Plan, each Participant shall receive an incentive payment for each Performance Period in the amount determined by the extent to which his or her Performance Measures have been achieved under the terms of his or her Award, subject to the limitations set forth below:
(a)      Discretionary Increase or Reduction. Subject to the provisions of Section 2.13 relating to Performance Measures, the Committee shall retain sole and absolute discretion to increase or reduce the amount of any incentive payment otherwise payable to any Participant under this Plan.
(b)      Continued Employment. Except as otherwise approved by the Committee or specifically set forth in a written employment agreement between the Executive and the Company or its Subsidiaries in effect on the date of such payment, no incentive payment under this Plan with respect to a Performance Period shall be paid or owed to a Participant who is not employed in good standing, as determined by the Committee, on the date payment is made for a Performance Period under Section 5.1.
(c)     Regulatory Action. Awards will not be earned or paid, regardless of achievement of Performance Measures, (i) to the extent that any regulatory agency issues a formal, written enforcement action, memorandum of understanding or other directive action that, or a regulation, prohibits or limits the eligibility of the Executive for or pay out of the Award to the Executive under the Plan, or (ii) if, after a review of the Company’s or its Subsidiaries’ credit quality measures, the Committee considers it imprudent to provide or pay out the Award under the Plan.
(d)     Ethical Obligations. The Company and its Subsidiaries are committed to doing business in an honest and ethical manner and to complying with all applicable laws and regulations. Participant actions are expected to comply with the policies established by the Company and its Subsidiaries, including their Codes of Ethics and Insider Trading Policies. The Committee may determine, on a case-by-case basis, any reductions or eliminations of incentive payments under this Plan due to violations of policies or noncompliance.
(e)     Clawback . The Participant agrees to repay any compensation previously paid or otherwise made available to the Participant under this Plan to the extent required by the Company’s clawback policy, as it may be amended from time to time. The Participant acknowledges the rights of the Company and its Subsidiaries to make deductions from the Participant’s compensation and to engage in any legal or equitable action or proceeding in order to enforce the provisions of this Section.
SECTION 5: Benefit Payments.
5.1      Time and Form of Payments . All payments of Awards pursuant to this Plan shall be made not later than the fifteenth (15th) day of the third (3rd) month following the end of the Performance Period; provided that the Committee may permit Participants to elect to defer payment of their Awards pursuant to a timely election made pursuant to a deferred compensation plan established by the Company that satisfies the requirements of Section 409A of the Code.
5.2      Nontransferability. Except as otherwise determined by the Committee, no right to any incentive payment under this Plan, whether payable in cash or property, shall be transferable by a Participant other than by will or by the laws of descent and distribution; provided, however, that if so determined by the Committee, a Participant may, in the manner established by the Committee, designate a beneficiary or beneficiaries to exercise the rights of the Participant and receive any cash or property due under the Participant’s Award upon the death of the Participant. No right to any incentive payment under this Plan may be pledged, attached or otherwise encumbered, and any purported pledge, attachment or encumbrance thereof shall be void and unenforceable against the Company.





5.3      Other Restrictions. The Committee may impose other restrictions on any Award, or any cash or property acquired in connection with an Award, as the Committee deems advisable, including, without limitation, holding periods or further transfer restrictions, forfeiture provisions, and restrictions under applicable federal or state securities laws.
5.4      Tax Withholding . The Company or its Subsidiaries shall be entitled to withhold and deduct from future wages of a Participant (or from other amounts that may be due and owing to a Participant from the Company or a Subsidiary), or make other arrangements for the collection of, all legally required amounts necessary to satisfy any and all federal, state, local and foreign withholding and employment-related tax requirements attributable to an Award. The Company may also require a Participant promptly to remit the amount of such withholding to the Company or its Subsidiaries before taking any action with respect to an Award. The Company may establish such rules and procedures concerning timing of any withholding election as it deems appropriate. Notwithstanding any action taken or not taken by the Company or its Subsidiaries, the Participant shall remain solely liable for all taxes due with respect to his or her Award.
SECTION 6: Amendment and Termination .
Except to the extent prohibited by applicable law and unless otherwise expressly provided in this Plan, the Board may amend, alter, suspend, discontinue or terminate this Plan, and the Committee may amend or cancel any Award, except that no such amendment, alteration, suspension, discontinuation or termination shall be made that would violate the rules or regulations of the NASDAQ Stock Market or any other securities rules and regulations that are applicable to the Company.
Unless earlier terminated by the Board, this Plan shall expire ten (10) years after its Effective Date and no Awards shall be granted thereafter (although any Awards outstanding at such time shall remain outstanding and subject to this Plan until they are paid out or otherwise cancelled as provided in this Plan).
SECTION 7: General Provisions.
7.1      Effective Date. This Plan was approved by the Board to be effective as of January 1, 2018.
7.2      Term of this Plan. This Plan shall continue indefinitely until otherwise terminated pursuant to Section 6. No right to receive an incentive payment shall be granted after the termination of this Plan. However, unless otherwise expressly provided in this Plan, any right to receive an incentive payment theretofore granted may extend beyond the termination of this Plan, and the authority of the Board and the Committee and its delegates to amend or otherwise administer this Plan shall extend beyond the termination of this Plan.
7.3      Headings. Headings are given to the Sections and subsections of this Plan solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Plan or any provision thereof .
7.4      Applicability to Successors. This Plan shall be binding upon and inure to the benefit of the Company and each Participant, and the successors and assigns of the Company, and the beneficiaries, personal representatives and heirs of each Participant. If the Company becomes a party to any merger, consolidation or reorganization, this Plan shall remain in full force and effect as an obligation of the Company or its successors in interest.
7.5      Employment Rights and Other Benefit Programs. The provisions of this Plan shall not give any Participant any right to be retained in the employment of the Company or its Subsidiaries. In the absence of any specific agreement to the contrary, this Plan shall not affect any right of the Company, or of any Subsidiary, to terminate, with or without cause, any Participant’s employment or service at any time. This Plan shall not replace any contract of employment, whether oral or written, between the Company or its Subsidiaries and any Participant, but shall be considered a supplement thereto. This Plan is in addition to, and not in lieu of, any other employee benefit plan or program in which any Participant may be or become eligible to participate by reason of employment with the Company or its Subsidiaries. No compensation or benefit awarded to or realized by any Participant under this Plan shall be included for the purpose of computing such Participant’s compensation under any compensation-based retirement, disability, or similar plan of the Company or any Subsidiary unless required by law or otherwise provided by such other plan.
7.6      No Trust or Fund Created. This Plan shall not create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Subsidiary and a Participant or any other person. To the extent that any





person acquires a right to receive payments from the Company or any Subsidiary pursuant to this Plan, such right shall be no greater than the right of any unsecured general creditor of the Company or of any Subsidiary.
7.7      Governing Law. The validity, construction and effect of this Plan or any incentive payment payable under this Plan shall be determined in accordance with the laws of the State of Michigan.
7.8      Severability. If any provision of this Plan is, becomes, or is deemed to be invalid, illegal or unenforceable in any jurisdiction, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of this Plan, such provision shall be stricken as to such jurisdiction, and the remainder of this Plan shall remain in full force and effect.
7.9      Certain Tax Matters. No payments are intended to constitute deferred compensation subject to Section 409A of the Code, unless a Participant elects to defer a payment pursuant to a deferred compensation plan that is intended to comply with such Code Section.
This Plan is being executed, on behalf of the Board, by the undersigned duly-authorized officer of the Company.

CHEMICAL FINANCIAL CORPORATION

/s/ David T. Provost 
David T. Provost
Chief Executive Officer and President
(Principal Executive Officer)





Exhibit 10.15
    
EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made by CHEMICAL FINANCIAL CORPORATION, a Michigan corporation (the “Corporation”) and THOMAS C. SHAFER (“Executive”). The parties agree as follows.
WHEREAS, the Board of Directors of the Corporation believes that the future services of Executive as provided in this Agreement will be of great value to the Corporation; and
WHEREAS, the Corporation owns and operates a wholly owned subsidiary, Chemical Bank (“Bank”), which is engaged in the general business of banking; and
WHEREAS, the Board of Directors of the Corporation has determined that it is in the best interests of the Corporation, its shareholders and the Bank to secure Executive’s continued services and to ensure Executive’s continued dedication and objectivity in the event of any potential or occurrence of, or negotiation or other action that could lead to, or create the possibility of, a Change in Control (as hereafter defined) of the Corporation, without concern as to whether Executive might be hindered or distracted by personal uncertainties and risks created by any such possible Change in Control, and to encourage Executive’s full attention and dedication to the Corporation and the Bank, the Board of Directors has authorized the Corporation to enter into this Agreement; and
WHEREAS, Executive is willing to serve in the employ of the Corporation and the Bank on a full-time basis as an at-will employee as provided in this Agreement.
NOW, THEREFORE, the parties agree as follows.
1.      Effective Date and Term. This Agreement will take effect as of the Effective Time of the Corporation’s acquisition of Talmer Bancorp, Inc. (“Talmer”), as defined in the Agreement and Plan of Merger dated as of January 25, 2016, between Chemical and Talmer (the “Merger Agreement”) (“Effective Date”). If the merger of the Corporation and Talmer does not close, this Agreement shall be null and void. The initial term of this Agreement shall be two years, and, at the end of the initial term, the term shall automatically be extended by another year on each anniversary of the Effective Date unless either party gives the other notice (as provided in Section 15) of intention to terminate this Agreement at least thirty (30) days before an anniversary of the Effective Date, in which case this Agreement shall terminate at the end of the then-current term without any further extension; provided, however, that:
(a)      except for termination as provided above pursuant to notice from Executive to the Corporation, this Agreement will not terminate during an “Active Change in Control Proposal Period” (as defined in Section 10), even if the Corporation has given Executive notice of intention to terminate this Agreement;
(b)      except for termination as provided above pursuant to notice from Executive to the Corporation, upon the occurrence of a “Change in Control” (as defined in Section 9), the term of this Agreement shall automatically be extended until the second anniversary of the effective date of the Change in Control, even if the Corporation has given notice of intention to terminate this Agreement; and





(c)      termination of this Agreement shall not affect the obligations of either party accrued before termination of this Agreement, including Executive’s obligations under Sections 11, 12 and 13.
2.      Employment. Executive will serve as: (A) Executive Vice President Director of Regional & Community Banking of the Corporation; (the “principal position”); and (B) in such positions with Affiliates (defined for purposes of this Agreement as any organizations controlling, controlled by or under common control with the Corporation) as reasonably requested by the Corporation, provided that the duties of such positions are consistent with Executive’s responsibilities in Executive’s principal position (together, the “Employment”). As used in this Agreement, the term “Corporation” includes the Bank, unless the context clearly requires otherwise.
Executive will serve the Corporation and the Bank well and faithfully during the Employment and will devote Executive’s best reasonable full time business efforts to the Employment, except that Executive may engage in civic and professional activities, service on boards of directors, and similar activities as long as such activities do not constitute a conflict of interest or impair Executive’s performance of the duties of the Employment. The Employment may be terminated during the term of this Agreement as provided in Sections 4 and 5.
3.      Compensation. Executive will be compensated during the Employment as follows:
(a)      Salary. Executive’s annual salary (“Salary”) will be $425,000.00, prorated for any partial year, subject to required payroll deductions and payable in weekly, bi-weekly or semi-monthly installments pursuant to the Corporation’s normal payroll practices. Such Salary shall be subject to review annually commencing in 2017 and will be subject to adjustment pursuant to the Corporation’s normal procedures.
(b)      Bonus. In 2016, Executive will continue to participate in the Talmer annual bonus plan. Beginning in 2017, Executive will participate in any bonus programs for senior executives of the Corporation or the Bank, at a level commensurate with Executive’s principal position. For 2017, Executive’s target bonus will be 60% of Salary based on 70% of the corporate performance goals and 30% of your individual performance goals. Executive’s actual bonus for 2017 may exceed or fall below 60% of Salary based on actual performance as compared to target. Such bonus amount and performance goals shall be subject to review annually commencing in 2018 and will be subject to adjustment pursuant to the Corporation’s normal procedures.
(c)      Equity Plans. Executive will participate in any stock option or other equity based compensation programs (“Equity Plans”) offered by the Corporation, at a level commensurate with Executive’s principal position. On or as soon as administratively feasible after the Effective Time, the Corporation will issue Executive restricted stock units under the Corporation’s Stock Incentive Plan of 2015 that are equal in value to 70% of Executive’s Salary, 30% of which will be stock options, 60% of which will be Performance Share Units (“PSUs”) and 10% of which will be Time Restricted Share Units (“TRSUs”). TRSUs will vest on the fifth anniversary of the award date. The PSUs will vest based on the Corporation’s performance goals as determination for purposes of the Corporation’s awards issued in February 2016.
(d)      Fringe Benefits. Executive will participate in health and dental, life insurance, short and long term disability insurance, retirement and other employee fringe benefit programs covering the Corporation’s salaried employees as a group, and in any programs applicable to senior executives of the Corporation or the Bank. The terms of applicable insurance policies and benefit plans in effect





from time to time will govern with regard to specific issues of coverage and benefit eligibility. All benefit programs are subject to change from time to time in the Corporation’s discretion, except that Executive will at all times receive the following specific benefits:
i. Thirty (30) days of paid time off per year, to be taken in the year earned, and which may not be accumulated or carried forward except as permitted by Corporation policy. Such paid time off shall be subject to review annually commencing in 2017 and Executive’s days of paid time off per year shall be subject to adjustment pursuant to the Corporation’s normal procedures.

ii. Reimbursement of expenses incurred to purchase or lease an executive automobile not to exceed $900.00 per month. Executive will be responsible for payment of all other expenses related to the automobile, such as fuel expenses, automobile insurance, maintenance and repair costs. Such automobile expense reimbursement shall be subject to review annually commencing in 2017 and subject to adjustment pursuant to the Corporation’s normal procedures.

iii. Reimbursement of up to $15,750 per year for country club membership dues. Reimbursement is to be paid according to the Corporation’s standard reimbursement policies and procedures, but not later than March 15 of the year following the year in which the expense was incurred.

(e)      Business Expenses. The Corporation will reimburse Executive for reasonable ordinary and necessary business expenses incurred in the course of the Employment, for fees and expenses of Executive’s attendance in the course of the Employment at banking related conventions and similar events, for reasonable professional association and seminar expenses, and for any additional expenses authorized by the Corporation, subject to Executive’s submission of proper documentation for tax and accounting purposes. Reimbursement under this section and Sections 3(d)(ii)-(iv) will be paid within thirty (30) days after Executive submits documentation as provided by this Section, provided that payments may not be made after March 15 of the calendar year following the calendar year in which the expenses were incurred.
4.      Termination of the Employment Without Severance Pay. Executive shall not be entitled to any further compensation from the Corporation or any Affiliate after termination of the Employment as permitted by this Section 4, except (A) unpaid Salary installments through the Employment termination date, (B) any vested benefits accrued as of the date of termination of the Employment under the terms of any written Corporation or Bank employment, compensation or benefit program; and (C) any rights of Executive to indemnification under the provisions of the Articles of Incorporation or Bylaws of the Corporation or the Bank or any indemnification agreement entered into between Executive and the Corporation or any Affiliate (together, the “Vested Rights”).
(a)      Death. The Employment will terminate automatically upon Executive’s death.
(b)      Disability. The Corporation may terminate the Employment due to Executive’s “Permanent Disability”, as defined and provided for in this Section 4(b). If Executive has been unable by reason of physical or mental disability to properly perform Executive’s duties hereunder for a period of one hundred eighty (180) days, the Corporation may give Executive notice of its intention to terminate the Employment due to Permanent Disability. If Executive wishes to contest the existence





of termination due to Permanent Disability, he must give the Corporation notice of Executive’s disagreement within ten (10) days after receipt of the notice from the Corporation, and he must promptly submit to examination by three physicians who are reasonably acceptable to both Executive and the Corporation (with consultation from other physicians as determined by those three). If (A) within sixty (60) days after receipt by Executive of the notice from the Corporation, two of such physicians shall issue their written statement to the effect that in their opinion, based on their diagnosis, Executive is capable of resuming Executive’s employment and devoting Executive’s full time and energy to discharging Executive’s duties within sixty (60) days after the date of such statement, and (B) Executive does in fact within such sixty (60) day period resume the Employment and properly perform Executive’s duties hereunder, then the Employment shall not be terminated due to Permanent Disability. It is understood that the Corporation has the right to terminate the Employment due to Executive’s disability without meeting the standards in this Section 4(b), but in that event the termination shall be deemed to be a termination of the Employment pursuant to Section 5(a).
(c)      Termination by Corporation for Cause. The Corporation may terminate the Employment for “Cause”, defined as (i) removal by order of a regulatory agency having jurisdiction over the Corporation or the Bank, (ii) Executive’s conviction of, or plea of no contest to, a felony, (iii) Executive’s gross misconduct, or (iv) Executive’s willful and repeated failure to perform Executive’s duties under this Employment Agreement. The Corporation may only terminate the Employment for Cause under (iii) and (iv) above if the failure has not been cured by Executive within thirty (30) days after the Corporation gives notice thereof to Executive; it being expressly understood that negligence or bad judgment shall not constitute “Cause” so long as such act or omission shall be without intent of personal profit and is reasonably believed by Executive to be in or not adverse to the best interests of the Corporation.
(d)      Discretionary Termination by Executive. Executive may terminate the Employment at will, with at least thirty (30) days advance notice. If Executive gives such notice of termination, the Corporation may (but need not) relieve Executive of some or all of Executive’s offices and responsibilities for part or all of such notice period, provided that Executive’s Salary and benefits are continued for the lesser of thirty (30) days or the remaining period of the Employment.
(e)      Termination of Employment after Termination of This Agreement. If Executive continues to be employed by the Corporation or the Bank after termination of this Agreement as provided in Section 1, Executive’s employment shall be terminable by either party at will without any Severance Pay.
5.      Termination With Severance Pay. Executive shall not be entitled to any further compensation from the Corporation or any Affiliate after termination of the Employment as permitted by this Section 5, except (A) Vested Rights; and (B) Severance Pay under Section 6 or the Change in Control Severance under Section 7, whichever is applicable.
(a)      Discretionary Termination by Corporation. The Corporation may terminate the Employment during the term of this Agreement at will, with at least thirty (30) days advance notice to Executive. Any termination of Executive’s Employment by the Corporation under Section 4 that is found not to meet the standards of such Section will be considered to have been a termination under this Section 5(a).
(b)      Termination by Executive for Good Reason . Executive may terminate the Employment during the term of this Agreement for “Good Reason” if there is a material negative change to the employment relationship between Executive and the Corporation because: (i) Executive





is removed from any of Executive’s principal positions; (ii) the status, authority or responsibility of Executive’s principal positions is materially diminished; (iii) Executive’s Salary as then in effect is materially reduced without a corresponding reduction in the salaries of the Corporation and Bank’s other executives, (iv) the Corporation requires Executive be based in a facility that is more than sixty (60) miles from the facility where Executive is located immediately prior to the relocation or any substantial increase in the business travel required of Executive; or (v) any material breach by the Corporation or the Bank, or any successor, of its obligations to Executive under this Agreement.
Executive may not terminate the employment for “Good Reason” unless:
A.      Executive notifies the CEO in writing, within 60 days after Executive becomes aware of the act or omission constituting Good Reason, that the act or omission in question constitutes Good Reason and explaining why Executive considers it to constitute Good Reason;
B.      the Corporation fails, within 30 days after notice from Executive under A. above, to revoke the action or correct the omission and make Executive whole; and
C.      Executive gives notice of termination within 30 days after expiration of the 30-day period under B. above.
6.      Severance Pay. The Corporation will pay and provide Executive with the payments and benefit continuation provided in this Section 6 (“Severance Pay”) if Executive’s Employment is terminated during the term of this Agreement as provided in Section 5 in a manner that constitutes a “separation from service” as that term is defined by Section 409A of the Internal Revenue Code of 1986 (the “Code”) and Executive is not entitled to the Change in Control Severance under Section 7. If Executive becomes entitled to Severance Pay under this Section 6, and subsequently becomes entitled to the Change in Control Severance under Section 7, the amount of the lump sum Cash Payment under Section 7(a) shall be reduced by the amount of Severance Pay already received by Executive under this Section 6, and no further Severance Pay will be payable under this Section 6.
(a) Amount and Duration of Severance Pay. Subject to the other provisions of this Section, Severance Pay will consist of:
i.      Severance. Payment of an amount equal to one times the sum of (A) Executive’s then-current Salary (disregarding any reduction in Salary that constitutes Good Reason) and (B) the sum of Executive’s cash bonuses under the Corporation’s [executive annual incentive plan] for each of the most recent three complete calendar years of Executive’s employment by the Corporation (or such lesser number of complete calendar years as Executive has been employed by the Corporation) divided by three (or the lesser number of complete calendar years for which Executive has been employed by the Corporation), payable in equal installments over fifty-two (52) weeks following the week in which the Employment terminates (the “Severance Pay Period”) pursuant to the Corporation’s normal payroll process, subject to required payroll withholding;
ii.      Health Coverage Payment. The Corporation will pay Executive a lump sum equal to twelve (12) times the Corporation’s monthly contribution towards Executive’s then current employee and dependent health, prescription drug and dental coverage elections, payable in the first payroll occurring on or after the tenth business day after the date Executive’s Employment terminates, subject to required payroll withholding. If Executive is not enrolled





in the Corporation’s health, prescription drug and dental plans, then the monthly contribution will be based on the Corporation’s contribution towards family coverage for such plans determined at the time employment terminates. Although the right to payment under this paragraph is based on the Corporation’s health, prescription drug and/or dental plan at the time employment terminates and is intended to fund payment for health coverage, the payment is not required to be used for health coverage and Executive may use the payment for any purpose;
iii.      Acceleration of Vesting . Effective at the time of termination of employment, all unvested stock options and stock previously issued to Executive as to which rights of ownership are subject to forfeiture shall immediately vest; all risk of forfeiture of the ownership of stock or stock options and restrictions on the exercise of options shall lapse; and, Executive shall be entitled to exercise any or all options, such that the underlying shares will be considered outstanding at the time of the termination of employment; and
iv.      Outplacement Services . The Corporation will provide Executive with executive-level outplacement services through an outplacement services firm selected by the Company with the Executive’s approval, which shall not be withheld if the firm selected is reputable, for a period not to exceed twelve (12) months after Executive’s termination date. The timing of outplacement services to be received shall be determined by the Executive, provided that all costs under this subsection must be incurred, and all applicable payments to the outplacement firm made, within twelve months following Executive’s termination of employment.
Executive will receive the Severance Pay provided in Section 6(a) notwithstanding any other earnings that Executive may have, and subject to offset only as provided in Section 6(c). If Executive dies during the Severance Pay Period, the Severance Pay under Section 6(a) will continue for the remainder of the Severance Pay Period for the benefit of Executive’s designated beneficiary (or Executive’s estate if Executive fails to designate a beneficiary).
(b)      Conditions to Severance Pay. To be eligible for Severance Pay, Executive must meet the following conditions: (i) Executive must comply with Executive’s obligations under this Agreement that continue after termination of the Employment; (ii) Executive must promptly sign and continue to honor a release, in form acceptable to the Corporation, of any and all claims arising out of or relating to Executive’s employment or its termination and that Executive might otherwise have against the Corporation, the Corporation’s Affiliates, or any of their officers, directors, employees and agents, provided that the release will not waive Executive’s right to claims or rights related to (A) this Agreement; (B) unpaid salary through the employment termination date; (C) unpaid expense reimbursements for authorized business expenses incurred before the employment termination date; (D) any Equity Plan benefits; (E) benefit plans (for example to convert life insurance); (F) any rights under the terms of any qualified retirement plan covering Executive; and (G) rights of indemnification under the Corporation’s Articles of Incorporation or Bylaws or any indemnification agreement entered into between Executive and the Corporation or any Affiliate (in addition, the release does not affect Executive’s right to cooperate in an investigation by the Equal Employment Opportunity Commission), (iii) Executive must resign upon written request by Corporation from all positions with or representing the Corporation or any Affiliate, including but not limited to, membership on boards of directors; and (iv) Executive must provide the Corporation for a period of six (6) months after the Employment termination date with consulting services regarding matters within the scope of Executive’s former duties upon request by the Corporation’s Chief Executive Officer; provided, however, that Executive will only be required to provide those services by telephone at Executive’s





reasonable convenience and without substantial interference with Executive’s other activities or commitments.
(c)      Reductions to Severance Pay. The Severance Pay due to Executive under Section 6(a)(i) for any week will be reduced (but not below zero) by: (i) any disability benefits to which Executive is entitled for that week under any disability insurance policy or program of the Corporation or any Affiliate (including but not limited to worker’s disability compensation); (ii) any severance pay payable to Executive under any other agreement or Corporation policy; (iii) any payment due to Executive under the Federal Worker Adjustment and Retraining Notification Act or any comparable state statute or local ordinance; and (iv) up to $5,000 of expenses owed by Executive to the Corporation from debt incurred in the ordinary course of the service relationship.
(d)      Delay in Payment to a Specified Employee . Notwithstanding any other timing provision in this Section 6, if, at the time any payment that is not exempt from Section 409A would commence due to a separation from service, and Executive is a “specified employee” as that term is defined by Section 409A of the Code, then no such payment under this Agreement may be paid before the date that is six months after Executive’s separation from service (or, if earlier, the individual’s death). Payments that are not exempt from Section 409A and that Executive would otherwise have been entitled during those six months will be accumulated and paid on the first payroll date after six months following Executive’s separation from service (or, if earlier, the individual’s death). All payments that are exempt from Section 409A, or that would otherwise be made more than six months following Executive’s separation from service, will be made in accordance with the general timing provisions described above.
7.      Change in Control Severance. The Corporation will make the payments provided for in this Section 7 if Executive’s Employment is terminated under Section 5 during the term of this Agreement in a manner that constitutes a “separation from service” as that term is defined by Section 409A of the Code, and such termination of Employment occurs either (i) within two years after the date of a Change in Control or (ii) within six months before the date of a Change in Control.
(a)      Amount and Payment of Cash Payment. The Corporation will make a cash payment (the “Cash Payment”) to Executive in an amount equal to one times the sum of (A) Executive’s then-current Salary (disregarding any reduction in Salary that constitutes Good Reason) and (B) the sum of Executive’s cash bonuses under the Corporation’s [executive annual incentive plan] for each of the most recent three complete calendar years of Executive’s employment by the Corporation (or such lesser number of complete calendar years as Executive has been employed by the Corporation) divided by three (or the lesser number of complete calendar years for which Executive has been employed by the Corporation). The Cash Payment shall be paid to Executive in a single lump sum in the first payroll occurring on or after the tenth business day after the date Executive’s Employment terminates. If Executive dies after becoming entitled to the Cash Payment but before it has been paid in full, any remaining Cash Payments will be made to Executive’s designated beneficiary (or Executive’s estate if Executive fails to designate a beneficiary).
(b)      Health Coverage Payment. The Corporation will pay Executive a lump sum equal to twelve (12) times the Corporation’s monthly contribution towards Executive’s then current employee and dependent health, prescription drug and dental coverage elections, payable in the first payroll occurring on or after the tenth business day after the date Executive’s Employment terminates, subject to required payroll withholding. If Executive is not enrolled in the Corporation’s health, prescription drug and dental plans, then the monthly contribution will be based on the Corporation’s contribution towards family coverage for such plans determined at the time employment terminates.





Although the right to payment under this paragraph is based on the Corporation’s health, prescription drug and/or dental plan at the time employment terminates and is intended to fund payment for health coverage, the payment is not required to be used for health coverage and Executive may use the payment for any purpose.
(c)      Acceleration of Vesting . Effective at the time of termination of employment, all unvested stock options and stock previously issued to Executive as to which rights of ownership are subject to forfeiture shall immediately vest; all risk of forfeiture of the ownership of stock or stock options and restrictions on the exercise of options shall lapse; and, Executive shall be entitled to exercise any or all options, such that the underlying shares will be considered outstanding at the time of the termination of employment.
(d)      Outplacement Services . The Corporation will provide Executive with executive-level outplacement services through an outplacement services firm selected by the Company with the Executive’s approval, which shall not be withheld if the firm selected is reputable, for a period not to exceed twelve (12) months after Executive’s termination date. The timing of outplacement services to be received shall be determined by the Executive, provided that all costs under this subsection must be incurred, and all applicable payments to the outplacement firm made, within twelve months following Executive’s termination of employment.
(d)      Reductions to Cash Payment. Executive will receive the Cash Payment notwithstanding any other earnings that Executive may have and without offset of any kind except required payroll deductions.
8.      Parachute Cap. Notwithstanding anything in this Agreement to the contrary, any payment, benefit, or amount payable or benefit to be provided to Executive, whether pursuant to this Agreement or otherwise, that is a “Parachute Payment” as defined in Section 280G(b)(2) of the Internal Revenue Code (the “Code”), will be reduced to the extent necessary so that the benefits payable or to be provided to Executive under this Agreement that are treated as Parachute Payments as well as any payments or benefits provided outside of this Agreement that are so treated will not cause the Corporation or any Affiliate to have paid an “Excess Parachute Payment” as defined in Section 280G(b)(1) of the Code. If it is established that an “Excess Parachute Payment” has occurred or will occur under this Agreement or otherwise, any remaining Parachute Payments to be made will be reduced to ensure that the total payments to Executive do not exceed 2.99 times Executive’s “base amount” as defined in Section 280G(b)(3) of the Code. The lump sum cash severance payment under Section 7(a) will be reduced to comply with this Section 8 only to the extent necessary to ensure that the total payments to Executive do not exceed 2.99 times Executive’s “base amount” as defined in Section 280G(b)(3) of the Code.
9.      Definition of Change in Control. As used in this Agreement, the term “Change in Control” means any of the occurrences listed in (a) below, subject to (b) below.
(a)      A Change in Control means the occurrence of a change in the ownership of effective control of the Corporation or a change in the ownership of a substantial portion of the assets of the Corporation as provided by Treasury Regulation § 1.409A-3(i)(5), which includes the occurrence of any of the following events:
(i)      The acquisition, by a person or persons acting as a group, of stock of the Corporation that together with stock held by such person or group constitutes more than 50% of the total fair market value or total voting power of the stock of the Corporation.





(ii)      The majority of members of the Board of Directors of the Corporation are replaced during any twelve month period by directors whose appointment or election is not endorsed by a majority of the members of the Board of Directors prior to the date of appointment or election.
(iii)      The acquisition, by a person or persons acting as a group, of the Corporation’s assets that have a total gross fair market value equal to or exceeding 50% of the total gross fair market value of the Corporation’s assets in a single transaction or within a twelve month period ending with the most recent acquisition. For the purpose of this section, gross fair market value means the value of the assets of the Corporation, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.
The parties agree that the merger between the Corporation and Talmer pursuant to the Merger Agreement does not constitute a Change in Control under this Agreement and does not trigger any payments that may otherwise be required by this Section and Executive waives any right to any payment under this Agreement as a result of that merger.
(b)      Notwithstanding the foregoing, no trust department or designated fiduciary or other trustee of such trust department of the Corporation or a subsidiary of the Corporation, or other similar fiduciary capacity of the Corporation with direct voting control of the stock shall be treated as a person or group within the meaning of subsection (a)(i) hereof. Further, no profit-sharing, employee stock ownership, employee stock purchase and savings, employee pension, or other employee benefit plan of the Corporation or any of its subsidiaries, and no trustee of any such plan in its capacity as such trustee, shall be treated as a person or group within the meaning of subsection (a)(i) hereof.
10.      Definition of “Active Change in Control Proposal Period”. As used in this Agreement the term “Active Change in Control Proposal Period” shall mean any period:
(a)      during which the Board of Directors of the Corporation has authorized solicitation by the Corporation of offers for a transaction which, if consummated, would constitute a Change in Control; or
(b)      during which the Corporation has received a proposal for a transaction which, if consummated, would constitute a Change in Control, and the Board of Directors has not determined to reject such proposal without any counter-offer or further discussions; or
(c)      during which any proxy solicitation or tender offer with regard to the securities of the Corporation is ongoing, if the intent of such proxy solicitation or tender offer is to cause the Corporation to solicit offers for or enter into a transaction that would constitute a Change in Control.
11.      Confidentiality, Return of Property. Executive has obtained and may obtain confidential information concerning the business, operations, financial affairs, organizational and personnel matters, policies, procedures and other non-public matters of Corporation and its Affiliates, and those of third-parties that is not generally disclosed to persons not employed by Corporation or its subsidiaries. Such information (referred to herein as the “Confidential Information”) may have been or may be provided in written form or orally. Executive shall not disclose to any other person the Confidential Information at any time during or after termination of the Employment, except that during the Employment Executive may use and disclose Confidential Information as reasonably required by the Employment. Upon termination of the Employment, Executive will deliver to the Corporation any and all property owned or leased by the Corporation or any Affiliate and any and all Confidential Information (in whatever form) including without limitation all customer





lists and information, financial information, business notes, business plans, documents, keys, credit cards and other Corporation-provided equipment. Executive’s commitments in this Section will continue in effect after termination of the Employment and after termination of this Agreement. The parties agree that any breach of Executive’s covenants in this Section would cause the Corporation irreparable harm, and that injunctive relief would be appropriate.
12.      Inventions, Discoveries and Improvements. Executive hereby agrees to assign and transfer to the Corporation, its successors and assigns, Executive’s entire right, title and interest in and to any and all inventions, discoveries, trade secrets and improvements thereto which he may discover to develop, either solely or jointly with others, during Executive’s employment hereunder and for a period of one year after termination of such employment, which would relate in any way to the business of the Corporation or any Affiliate of the Corporation, together with all rights to letters patent, copyrights or trademarks which may be granted with respect thereto. Immediately upon making or developing any invention, discovery, trade secret or improvement thereto, Executive shall notify the Corporation thereof and shall execute and deliver to the Corporation, without further compensation, such documents as may be necessary to assign and transfer to the Corporation Executive’s entire right, title and interest in and to such invention, discovery, trade secret or improvement thereto, and to prepare or prosecute applications for letters patent with respect to the same in the name of the Corporation. Executive’s obligations under this Section 12 shall continue in effect, as to inventions, discoveries and improvements covered by this Section 12, notwithstanding any termination of the employment or this Agreement.
13.      Noncompetition and Nonsolicitation.
(a)      In view of Executive’s importance to the success of the Corporation, Executive and Corporation agree that the Corporation would likely suffer significant harm from Executive’s competing with Corporation during the Employment and for some period of time thereafter. Accordingly, Executive agrees that Executive shall not engage in competitive activities either: (A) while employed by Corporation; or (B) if Executive’s Employment is terminated during the term of this Agreement, during the Restricted Period (as defined below). Executive shall be deemed to engage in competitive activities if he shall, without the prior written consent of the Corporation, (i) in any county in which the Corporation has a branch office, ATM, loan processing center or any other facility, and all contiguous counties, (including the municipalities therein), render services directly or indirectly, as an employee, officer, director, consultant, advisor, partner or otherwise, for any organization or enterprise which competes directly or indirectly with the business of Corporation or any of its Affiliates in providing financial products or services (including, without limitation, banking, insurance, or securities products or services) to consumers and businesses, or (ii) directly or indirectly acquires any financial or beneficial interest in (except as provided in the next sentence) any organization which conducts or is otherwise engaged in a business or enterprise in any county in which the Corporation has a branch office, ATM, loan processing center or any other facility, and all contiguous counties, (including all municipalities therein) which competes directly or indirectly with the business of Corporation or any of its Affiliates in providing financial products or services (including, without limitation, banking, insurance or securities products or services) to consumers and businesses. Notwithstanding the preceding sentence, Executive shall not be prohibited from owning less than 1 percent of any class of publicly traded securities of a competitor. For purposes of this Section 13 the term “Restricted Period” shall equal twelve (12) months, commencing as of the date of termination of Executive’s Employment during the term of this Agreement.
(b)      While employed by Corporation and during the Restricted Period, Executive agrees that Executive shall not, in any manner directly (i) solicit by mail, by telephone, by personal meeting, or by any other means, any customer or prospective customer of Corporation to whom Executive





provided services, or for whom Executive transacted business, or whose identity become known to Executive in connection with Executive’s services to Corporation (including employment with or services to any predecessor or successor entities), to transact business with a person or an entity other than the Corporation or its Affiliates or reduce or refrain from doing any business with the Corporation or its Affiliates or (ii) interfere with or damage (or attempt to interfere with or damage) any relationship between Corporation or any of its Affiliates and any such customer or prospective customer, or any shareholder of the Corporation. The term “solicit” as used in this Section 13 means any communication of any kind whatsoever, inviting, encouraging or requesting any person to take or refrain from taking any action with respect to the business of Corporation or any of its Affiliates.
(c)      While employed by Corporation and during the Restricted Period, Executive agrees that Executive shall not, in any manner directly solicit any person who is an employee of Corporation or any of its Affiliates to apply for or accept employment or a business opportunity with any other person or entity.
(d)      The parties agree that nothing herein shall be construed to limit or negate the common law of torts or trade secrets where it provides broader protection than that provided herein.
(e)      If Executive’s Employment is terminated during the term of this Agreement, Executive’s obligations under this Section shall survive termination of this Agreement.
14.      Successors; Binding Agreement.
(a)      This Agreement shall not be terminated by any merger or consolidation of the Corporation whereby the Corporation is or is not the surviving or resulting corporation or as a result of any transfer of all or substantially all of the assets of the Corporation. In the event of any such merger, consolidation, or transfer of assets, the provisions of this Agreement shall be binding upon the surviving or resulting corporation or the person or entity to which such assets are transferred.
(b)      The Corporation agrees that concurrently with any merger, consolidation or transfer of assets constituting a Change in Control, it will cause any successor or transferee unconditionally to assume, by written instrument delivered to Executive (or Executive’s beneficiary or estate), all of the obligations of the Corporation hereunder. Failure of the Corporation to obtain such assumption prior to the effective date of any Change in Control shall be a material breach of the Corporation’s obligations to Executive under this Agreement.
(c)      This Agreement shall inure to the benefit of and be enforceable by Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive shall die while any amounts would be payable to Executive hereunder had Executive continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to such person or persons appointed in writing by Executive to receive such amounts or, if no person is so appointed, to Executive’s estate.
15.      Notice. For purposes of this Agreement, all notices and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given when delivered or received by facsimile transmission or five (5) days after deposit in the United States mail, certified and return receipt requested, postage prepaid, addressed as follows:
If to the Corporation:      Chemical Financial Corporation
Attn:CEO         





333 East Main Street, P.O. Box 569
Midland, Michigan 48640-0569     

If to Executive:      Thomas C. Shafer
________________         
________________         
Either party may change its address for notices by notice to the other party.
16.      Amendment and Waiver. No provisions of this Agreement may be amended, modified, waived or discharged unless the waiver, modification, or discharge is authorized by the Corporation’s Board of Directors, or a committee of the Board of Directors, and is agreed to in a writing signed by Executive and by the CEO. No waiver by either party at any time of any breach or non-performance of this Agreement by the other party shall be deemed a waiver of any prior or subsequent breach or non-performance.
17.      Severability. The invalidity or unenforceability of any provision of this Agreement will not affect the validity or enforceability of any other provision of this Agreement, which will remain in full force and effect. If a court of competent jurisdiction ever determines that any provision of this Agreement (including, but not limited to, all or any part of the non-competition covenant in this Agreement) is unenforceable as written, the parties intend that the provision shall be deemed narrowed or revised in that jurisdiction (as to geographic scope, duration, or any other matter) to the extent necessary to allow enforcement of the provision. The revision shall thereafter govern in that jurisdiction, subject only to any allowable appeals of that court decision.
18.      Entire Agreement. No agreements or representations, oral or otherwise, express or implied, with respect to Executive’s Employment with the Corporation or any of the subjects covered by this Agreement have been made by either party that are not set forth expressly in this Agreement, and this Agreement supersedes any pre-existing employment agreements and any other agreements on the subjects covered by this Agreement, including your Employment Agreement dated May 17, 2010, as amended, with Talmer (as successor to First Michigan Bancorp, Inc.) and Bank (as successor to First Michigan Bank) (the “Talmer Employment Agreement”) which you agree terminates as of the Effective Time of the Merger; provided, however, (i) the “Change in Control Payment” under Section 9 of the Talmer Employment Agreement shall continue to be due and payable pursuant to the transactions contemplated by the Merger Agreement, and (ii) the provisions of Section 12 of the Talmer Employment Agreement (concerning “Excise Tax Payment”) shall continue in full force and effect; provided, however, except as expressly modified hereby, this Agreement shall not affect Executive’s rights under any retirement and health and welfare plans in which Executive participates which are maintained by the Corporation or its Affiliates.
19.      Governing Law. The validity, interpretation, and construction of this Agreement are to be governed by Michigan laws, without regard to choice of law rules. The parties agree that any judicial action involving a dispute arising under this Agreement will be filed, heard and decided in the Midland County Circuit Court. The parties agree that they will subject themselves to the personal jurisdiction and venue of either court, regardless of where Executive or the Corporation may be located at the time any action may be commenced. The parties agree that the locations specified above are mutually convenient forums and that each of the parties conducts business in Midland County.
20.      Section 409A. This Agreement is intended to be exempt from Section 409A of the Internal Revenue Code partially as an involuntary separation pay plan as that term is understood under Treasury Regulation § 1.409A-1(b)(9) and partially as providing for short-term deferrals as that term is understood under Treasury Regulation § 1.409A-1(b)(4) and shall be interpreted and operated consistently with those





intentions. To the extent Section 409A is found to be applicable to this Agreement, this Agreement is to be interpreted to comply with Section 409A and shall be interpreted and operated consistently with those intentions, including but not limited to, any applicable six-month delay in payment if Executive is a specified employee of the Corporation.
21.      Counterparts. This Agreement may be signed in original or by fax in counterparts, each of which shall be deemed an original, and together the counterparts shall constitute one complete document.
Signature Page to Follow
The parties made this Agreement effective as of the Effective Date in Section 1.

CHEMICAL BANK
By ___/s/ David B. Ramaker______________________
David B. Ramaker, Chairman, Chief Executive Officer and President

Date:      August 31, 2016         

CHEMICAL FINANCIAL CORPORATION
By _____/s/ David B. Ramaker____________________
David B. Ramaker, Chairman, Chief Executive Officer and President
    
Date:      August 31, 2016    
    
EXECUTIVE
_/s/ Thomas C. Shafer_______________________________
Thomas C. Shafer     
        
Date:      August 31, 2016         












Exhibit 10.18

EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement (the “ Agreement ”) is entered into as of July 1, 2017, by and between Chemical Financial Corporation (“ Chemical ”), and Thomas C. Shafer (the “ Executive ”).
Recitals
WHEREAS , Chemical owns and operates a wholly-owned subsidiary, Chemical Bank (the “ Bank ”), which is engaged in the general business of banking; and
WHEREAS, The Board of Directors (the “ Board ”) of Chemical believes that it is in the best interest of Chemical and its shareholders to secure Executive’s services to encourage Executive’s full dedication to Chemical and the Bank and to ensure Executive’s continued dedication and objectivity in the event of any Change in Control, as defined herein; and
WHEREAS, Executive acknowledges and agrees that pursuant to his employment with the Bank and Chemical he has acquired and shall continue to acquire a considerable amount of knowledge and goodwill with respect to the business of Chemical and the Bank that would be detrimental to Chemical and the Bank if used by Executive to compete with Chemical and the Bank; and
WHEREAS, Chemical wishes to protect its investment in its business, employees, customer relationships and confidential information by requiring Executive to abide by certain restrictive covenants regarding confidentiality, non-competition, non-solicitation and other matters, as set forth herein; and
WHEREAS , the Board of Chemical desires to employ Executive in the positions set forth below, and Executive desires to be employed in and serve in such positions, on the terms and conditions set forth in this Agreement; and
NOW, THEREFORE , in consideration of the foregoing, the mutual agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1. Employment; Term. Chemical hereby employs Executive under the terms of this Agreement, and Executive hereby accepts such employment terms for an initial two (2) year period commencing July 1, 2017 (the “ Effective Date ”) and ending June 30, 2019 (the “ Initial Term ”), unless sooner terminated as provided in Section 5 below. This Agreement automatically shall renew on each anniversary of the Effective Date for successive one (1) year periods, unless either party provides the other party with written notice of intention to terminate this Agreement (in accordance with Section 12(d)), at least thirty (30) days before an anniversary of the Effective Date, in which case this Agreement shall terminate at the end of the then-current two-year Term, without any further extension; provided, however, that:

(a) except for termination as provided above pursuant to written notice from Executive to Chemical, this Agreement shall not terminate during an Active Change in Control Proposal Period even if Chemical has given Executive notice of its intention to terminate this Agreement. As used in this Agreement the term “ Active Change in Control Proposal Period ” shall mean any period:

(i) during which the Board of Chemical has authorized Chemical’s solicitation of offers for a transaction which, if consummated, would constitute a Change in Control; or

(ii) during which Chemical has received a proposal for a transaction which, if consummated, would constitute a Change in Control, and the Board of Chemical has not determined to reject such proposal without any counter-offer or further discussions; or

(iii) during which any proxy solicitation or tender offer with regard to the securities of Chemical is ongoing, if the intent of such proxy solicitation or tender offer is to cause Chemical to solicit offers for or enter into a transaction that would constitute a Change in Control;

(b) except for termination as provided above pursuant to written notice from Executive to Chemical upon the occurrence of a “ Change in Control ” (as defined in Section 6(iv)), the Term of this Agreement shall automatically be extended





until the second anniversary of the effective date of the Change in Control, even if Chemical has given notice of its intent to terminate this Agreement; and

(c) termination of this Agreement shall not affect the obligations of either party accrued before termination of the Agreement, including Executive’s obligations under Sections 6 through 12.

The Initial Term and all renewals together shall constitute the “ Term ” of this Agreement.

2. Position; Duties. Executive shall serve as: (A) the Bank’s Chief Executive Officer (his principal position); (B) Vice Chair of Chemical; (C) in such positions with Affiliates as are reasonably requested by Chemical’s Board; provided that the duties of such positions are consistent with Executive’s responsibilities in Executive’s principal position; and (D) to the extent appointed or elected, as a director on the Boards of both Chemical and the Bank, which positions in the aggregate shall constitute Executive’s employment hereunder (“ Employment ”). Executive shall perform the services customarily associated with the aforementioned positions and as otherwise may be assigned to Executive from time to time by Chemical’s Board. Executive shall devote the majority of his business time to the affairs of the Bank and Chemical and to his duties hereunder; provided, however, Executive may engage in civic and professional activities, service on boards of directors and similar activities, as long as such activities do not constitute a conflict of interest or impair Executive’s performance to the Bank and Chemical. Executive shall perform his Employment duties diligently and to the best of his ability, in compliance with the policies and procedures of Chemical and the Bank, and the laws and regulations that apply to the business of Chemical and the Bank. For purposes of this Agreement, “ Chemical ” includes the Bank, unless the context clearly requires otherwise, and the term “ Affiliate ” means any organization controlling, controlled by or under common control with Chemical.

3. Compensation and Benefits. As compensation for the services to be rendered by Executive under this Agreement, Chemical shall provide Executive with the following compensation and benefits during the Employment Term:

(a) Base Salary. Chemical shall pay Executive an initial annual base salary (“ Base Salary ”) of seven hundred and fifty thousand dollars ($750,000), prorated for any partial year, subject to required payroll deductions and tax withholdings, payable in weekly, bi-weekly or semi-monthly installments in accordance with Chemical’s normal payroll practices. Executive’s Base Salary shall be subject to annual review commencing in 2018 and shall be subject to adjustment pursuant to Chemical’s normal procedures.

(b) Bonus. Executive shall be eligible to participate in annual bonus programs for senior executives of Chemical or the Bank, as applicable, at a level commensurate with Executive’s principal position. The initial annual target for Executive’s bonus compensation shall be ninety percent (90%) of Executive’s Base Salary.

(c) Equity Plans . Executive shall participate in any stock option, performance share unit, time restricted stock unit or other equity-based compensation programs (“ Equity Plans ”) offered by Chemical, at a level commensurate with Executive’s principal position. The initial annual target for Executive’s Equity Plan awards shall be one hundred and ten percent (110%) of Executive’s Base Salary.

(d) Fringe Benefits. Executive shall participate in health and dental, life insurance, short and long term disability insurance, retirement and other employee fringe benefit programs covering Chemical’s salaried employees as a group, and in any programs applicable to senior executives of Chemical or the Bank, as applicable. The terms of applicable insurance policies and benefit plans in effect from time to time shall govern with regard to specific issues of coverage and benefit eligibility. All benefit programs are subject to change from time to time in Chemical’s discretion, except that Executive shall at all times receive the following specific benefits:

(i) Paid Time Off . Executive shall receive thirty (30) days of paid time off per year, to be taken in the year earned, and which may not be accumulated or carried forward except as permitted by Chemical policy. Such paid time off shall be subject to review annually commencing in 2018. Executive’s days of paid time off per year shall be subject to adjustment pursuant to Chemical’s normal procedures.

(ii) Automobile. Executive shall receive a monthly stipend of nine hundred dollars ($900) per month to purchase or lease an executive automobile. Executive shall be responsible for payment of all other expenses related to the automobile, such as fuel expenses, automobile insurance, maintenance and repair costs. The automobile stipend shall be reviewed annually commencing in 2018 and subject to adjustment pursuant to Chemical’s normal procedures.

(iii) Club Dues . Executive shall be reimbursed up to twenty-five thousand dollars ($25,000) per year for country club membership dues in accordance with Chemical’s standard reimbursement policies and procedures.






(e) Tax Withholdings. Chemical shall withhold from any amounts payable under this Agreement such federal, state and local taxes as Chemical determines are required to be withheld pursuant to applicable law.

4. Reimbursement of Expenses. Chemical shall reimburse Executive for all reasonable ordinary and necessary business expenses incurred by Executive in connection with the performance of his duties hereunder, including but not limited to Executive’s fees and expenses for attendance at banking-related conventions and similar events, reasonable professional association and seminar expenses and other expenses authorized by Chemical, upon submission of proper documentation for tax and accounting purposes in compliance with Chemical’s reimbursement policies in effect from time to time. Such reimbursements shall be made promptly but in no event later than March 15 following the calendar year in which an expense is incurred. For purposes of reimbursements subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “ Code ”), the amount of expenses eligible for reimbursement during one (1) year shall not affect expenses eligible for reimbursement in any other year, and such amount is not subject to liquidation or exchange for another benefit.

5. Termination. Executive’s Employment under this Agreement shall terminate as of the earliest termination date to occur, as set forth below (“ Termination Date ”):

(a) Death. Automatically effective upon Executive’s death.

(b) Disability. By Chemical, effective upon written notice to Executive in the event of Executive’s permanent and total disability, as defined in this Section 5(b) (“ Disability ”). Executive shall be deemed to have incurred a Disability if he is unable by reason of physical or mental disability to properly perform his duties hereunder for a period of one hundred and eighty (180) days. If Executive wishes to contest his termination due to Disability, he must give Chemical written notice of his disagreement within ten (10) days after receipt of the Disability notice from Chemical, and he must promptly submit to examination by a physician who is reasonably acceptable to both Executive and Chemical (with consultation from other physicians as determined by the physician). If (i) within sixty (60) days after receipt by Executive of the Disability notice from Chemical, the physician issues a written statement to the effect that in the physician’s opinion, Executive is capable of resuming Executive’s Employment and devoting Executive’s full time and energy to discharging Executive’s duties within sixty (60) days after the date of such statement, and (ii) Executive does in fact within such sixty (60) day period resume Employment and properly perform Executive’s duties hereunder, then Executive’s Employment shall not be terminated due to Disability. It is understood that Chemical has the right to terminate Executive’s Employment due to Disability without meeting the standards in this Section 5(b), and in such event the termination shall be deemed to be a Termination Without Cause pursuant to Section 5(d).

(c) For Cause. By Chemical, effective upon written notice to Executive for Cause, unless specified otherwise below. For purposes of this Agreement, “ Cause ” means: (i) Executive’s removal by order of a regulatory agency having jurisdiction over Chemical or the Bank; (ii) Executive’s material breach of any provision in this Agreement; if the breach is curable, it shall constitute Cause only if it continues uncured for a period of twenty (20) days after Executive’s receipt of written notice of such breach by Chemical; (iii) Executive’s failure or refusal, in any material manner to perform all lawful services required of him in his Employment positions with Chemical, which failure or refusal continues for more than twenty (20) days after Executive’s receipt of written notice of such deficiency; (iv) Executive’s commission of fraud, embezzlement, theft, or a crime constituting moral turpitude, whether or not involving Chemical or the Bank, which in the reasonable good faith judgment of Chemical’s Board, renders Executive’s continued employment harmful to Chemical; (v) Executive’s misappropriation of the assets of Chemical or the Bank or property, including without limitation, obtaining material reimbursement through financial vouchers or expense reports; or (vi) Executive’s conviction or the entry of a plea of guilty or no contest by Executive with respect to any felony or other crime which, in the reasonable good faith judgment of Chemical’s Board, adversely affects Chemical, and its reputation.

(d) Without Cause. By Chemical, effective upon thirty (30) days’ written notice to Executive at any time for any reason other than for death, Cause or Executive’s Disability (“ Termination Without Cause ”).

(e) Resignation. By Executive, effective upon thirty (30) days’ written notice to Chemical at any time for any reason.

(f) Good Reason . By Executive, effective as set forth below. For purposes of this Agreement, “ Good Reason ” means the occurrence of any of the following events without the written consent of Executive:

(i) any material reduction in Executive’s Base Salary, as it may be adjusted from time to time, without a corresponding reduction in the base salaries of the other executives of Chemical and the Bank;

(ii) any material reduction in the status, position or responsibilities of Executive;





(iii) any requirement by Chemical (without Executive’s consent) that Executive be principally based at any office or location more than sixty (60) miles from Executive’s principal work location as of the effective date of this Agreement; or

(iv) any material breach of this Agreement by Chemical or the Bank.

Notwithstanding the foregoing, if Executive fails to give Chemical written notice of his intention to terminate Employment with Chemical for Good Reason within sixty (60) days following Executive’s knowledge of any Good Reason event and a period of thirty (30) days in which Chemical may remedy the event alleged to constitute Good Reason, and if Executive has not Separated from Service (as defined in Section 6(f)(2)) within sixty (60) days following expiration of Chemical’s cure period, the event shall not constitute Good Reason, and Executive shall have no right to terminate employment for Good Reason as a result of such event.
(g) During any notice period under Sections 5(c), 5(d), 5(e) or 5(f), Chemical may, in its sole discretion, relieve Executive of some or all of his duties during the notice period, but Chemical shall continue to provide Executive with his full salary, compensation, equity vesting, and benefits during such period.

6.
Effect of Termination.

(a) Employment Termination Following Termination of this Agreement . If Executive continues to be employed by Chemical or the Bank after termination of this Agreement due to non-renewal as described in Section 1, Executive’s Employment may be terminated by either party at will, and severance shall be determined based on Chemical’s severance guidelines as in effect at such time and not the “Severance” described in Section 6(c) hereunder.

(b) Termination of Employment Without Severance . In the event of termination due to death, Disability, Cause, or resignation, Executive (or Executive’s estate, as applicable), shall not be entitled to any further compensation from Chemical, the Bank or any Affiliate after termination of Employment, except (a) unpaid Base Salary through the Employment Termination Date; (b) any vested benefits accrued as of Executive’s Termination Date under the terms of any written Chemical or Bank employment, compensation or benefit program, including certain rights to equity-based awards in the event of death, as described in Section 6(c)(iii) below; and (c) any rights of Executive to indemnification under the provisions of the Articles of Incorporation or Bylaws of Chemical or the Bank or any indemnification agreement entered into between Executive and Chemical, the Bank or any Affiliate.

(c) Separation Benefits upon Certain Terminations.

(i) Termination Without Cause. Upon Termination Without Cause, Executive shall be entitled to the following Severance benefits (“ Severance ”).

(A) Severance Pay . If Chemical terminates Executive’s Employment pursuant to a Termination Without Cause and Executive is not entitled to Change in Control Severance under Section 6(c)(iv) below, Executive shall be entitled to receive Severance pay in the amount of two (2) times the sum of (1) Executive’s then Base Salary, disregarding any Base Salary reduction due to a Good Reason termination, plus (2) the average of Executive’s bonuses under Chemical’s annual executive incentive plan for each of the three (3) most recent complete calendar years of Executive’s employment with Chemical (or the lesser number of complete calendar years that Executive has been employed by Chemical), payable in equal installments over one hundred and four (104) weeks; subject to installment payment adjustments, as applicable, to comply with Code Section 409A (“ Severance Pay ”). Severance provided hereunder is conditioned upon Executive and Chemical executing a mutually agreeable release of claims, in substantially the form attached hereto as Appendix A (the “ Release ”), which is enforceable within sixty (60) days following Executive’s Termination Date. Subject to any delayed payment due to Executive’s status as a “Specified Employee” under Code Section 409A and as described more fully in Section 6(f) below, the Severance shall be payable to Executive over time in accordance with Chemical’s payroll practices and procedures, beginning on the first pay date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, payments shall commence on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may begin the payments earlier if such commencement does not violate Code Section 409A. Notwithstanding the foregoing, if Executive is entitled to receive the Severance but violates any provisions of Sections 8 through 10 hereof after termination of Employment, Chemical shall be entitled to immediately stop paying any further installments of Severance and shall have any other remedies, including claw back, that may be available to Chemical in law or at equity.






(B) Health Coverage Payment . Chemical shall pay Executive a lump sum stipend equal to twenty four (24) times Executive’s monthly contribution towards Executive’s then current employee and dependent health, prescription drug and dental coverage elections, conditioned on Executive’s execution of the Release described herein that becomes irrevocable within sixty (60) days following Executive’s Termination Date, with the stipend payable on the first payroll date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. If Executive is not enrolled in Chemical’s health, prescription drug and dental plans, the monthly contribution shall be based on Executive’s contribution towards family coverage for such plans determined at the time Employment terminates. Although the right to payment under this paragraph is based on Executive’s health, prescription drug and/or dental plan at the time Executive’s Employment terminates and is intended to fund payment for health coverage, the payment is not required to be used for health coverage and Executive may use the payment for any purpose.

(C) Equity-Based Awards . Effective upon expiration of the Release revocation period described in Section 6(c)(i)(A) above, all equity-based awards previously granted to Executive and outstanding at the time of his Employment Termination Date shall be treated as follows: (i) all unvested stock options immediately shall vest, become exercisable and together with Executive’s other vested, unexercised stock options, remain exercisable until the earlier of their original term and three (3) years following Executive’s Employment Termination Date; (ii) all outstanding time-based restricted stock units automatically shall vest and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; (iii) all performance-based stock units (“PSUs”), shall remain outstanding subject to their original performance goals, and the restrictions under each such grant shall not lapse until Chemical’s Compensation and Pension Committee has determined that the applicable performance goals have been attained and the level to which such goals were attained, at which time the restrictions shall lapse on the number of units corresponding to the level of the attained performance, as if Executive had remained employed by Chemical through the last day of the applicable performance period, and such units shall become convertible into Chemical’s Common Stock, with settlement to occur as soon as administratively feasible, on the same date as settlement occurs for the other holders of PSUs for the applicable performance period; and (iv) any other equity-based awards shall vest in accordance with the terms of the applicable equity-based plan or grant agreement.

(D) Outplacement Services . Chemical shall provide Executive with executive-level outplacement services through an outplacement services firm selected by Chemical with Executive’s approval, which approval shall not be withheld if the firm selected is reputable, for a period not to exceed twelve (12) months after Executive’s Termination Date. The timing of outplacement services shall be determined by Executive, provided that all costs under this subsection must be incurred, and all applicable payments to the outplacement firm made, within twelve (12) months following Executive’s Employment Termination Date.

(ii) Termination for Good Reason . Executive may terminate employment for Good Reason and receive the same benefits as Termination Without Cause in Section 6(c)(i), subject to the same Release and payment timing restrictions as a Termination Without Cause.

(iii) Death . For avoidance of doubt, the termination of Executive’s employment as a result of death shall not constitute a Termination Without Cause triggering the rights described in Section 6(c)(i); provided, however, that Executive’s outstanding equity-based awards shall be treated in accordance with Section 6(c)(i)(C) above, with Executive’s personal representative signing the Release on behalf of Executive’s estate and Executive’s equity-based awards being exercised by, or paid to, Executive’s personal representative or such other successor in interest to Executive, as applicable.

(iv) Change in Control Termination Without Cause . If Executive incurs a Termination Without Cause within either (A) two (2) years following the date of a Change in Control, or (B) within six (6) months before the date of a Change in Control, Executive shall be entitled to Change in Control Severance, as described below (“ Change in Control Severance ”). For purposes of this Agreement, “ Change in Control” shall be defined as the occurrence of any of the following events: (1) the acquisition by a person or persons acting as a group, of Chemical stock that together with stock held by such person or group constitutes more than fifty percent (50%) of the total fair market value or total voting power of the stock of Chemical; (2) the majority of the members of Chemical’s Board are replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of appointment or election; or (3) the acquisition, by a person or persons acting as a group, of Chemical’s assets that have a total gross fair market value equal to or exceeding fifty percent (50%) of the total gross fair market value of Chemical’s assets in a single transaction or within a 12-month period ending with the most recent acquisition. For purposes of this





Section, gross fair market value means the value of Chemical’s assets, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. Notwithstanding the foregoing, no trust department or designated fiduciary or other trustee of such trust department of Chemical or a subsidiary of Chemical, or other similar fiduciary capacity of Chemical with direct voting control of the stock shall be treated as a person or group within the meaning of subsection (1) hereof. Further, no profit sharing, employee stock ownership, employee stock purchase and savings, employee pension, or other employee benefit plan of Chemical or any of its subsidiaries, and no trustee of any such plan in its capacity as such trustee, shall be treated as a person or group within the meaning of subsection (1) hereof.

(A) Change in Control Severance Pay . If Executive incurs a Change in Control Termination Without Cause, Executive shall be entitled to receive Change in Control Severance in the amount of two (2) times the sum of (1) Executive’s then Base Salary, disregarding any Base Salary reduction due to a Good Reason termination, plus (2) the average of Executive’s bonuses under Chemical’s annual executive incentive plan for each of the three (3) most recent complete calendar years of Executive’s employment with Chemical (or the lesser number of complete calendar years that Executive has been employed by Chemical), payable in one (1) lump sum cash payment (“ Change in Control Severance Pay ”). The amount shall be reduced by any Severance Pay previously received by Executive under Section 6(c)(i)(A). The Change in Control Severance Pay is conditioned upon Executive and Chemical executing a mutually agreeable release of claims, in substantially the form attached hereto as Appendix A (the “ Release ”), which is enforceable within sixty (60) days following Executive’s Termination Date. Subject to any delayed payment due to Executive’s status as a “Specified Employee” under Code Section 409A, if applicable, and as described more fully in Section 6(f) below, the Change in Control Severance Pay shall be payable to Executive on the first pay date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. Notwithstanding the foregoing, if Executive is entitled to Change in Control Severance but violates any provisions of Sections 8 through 10 hereof after termination of Employment, Chemical shall have any remedies, including claw back, that may be available to Chemical in law or at equity.

(B) Health Coverage Payment . Chemical shall pay Executive a lump sum stipend equal to twenty four (24) times Executive’s monthly contribution towards Executive’s then current employee and dependent health, prescription drug and dental coverage elections, conditioned on Executive’s execution of the Release described herein that becomes irrevocable within sixty (60) days following Executive’s Termination Date, with the stipend payable on the first payroll date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. If Executive is not enrolled in Chemical’s health, prescription drug and dental plans, the monthly contribution shall be based on Executive’s contribution towards family coverage for such plans determined at the time Employment terminates. Although the right to payment under this paragraph is based on Executive’s health, prescription drug and/or dental plan at the time Executive’s Employment terminates and is intended to fund payment for health coverage, the payment is not required to be used for health coverage and Executive may use the payment for any purpose.

(C) Equity-Based Awards . Effective upon expiration of the Release revocation period described in Section 6(c)(iv)(A) above, all equity-based awards previously granted to Executive and outstanding at the time of his Employment Termination Date shall be treated as follows: (i) all unvested stock options immediately shall vest, become exercisable and together with Executive’s other vested, unexercised stock options, remain exercisable until the earlier of their original term and three (3) years following Executive’s Employment Termination Date; (ii) all outstanding time-based restricted stock units automatically shall vest and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; (iii) all performance-based stock units (“PSUs”), shall remain outstanding, subject to their original performance goals, and the restrictions under each such grant shall not lapse until Chemical’s Compensation and Pension Committee has determined that the applicable performance goals have been attained and the level to which such goals were attained, at which time the restrictions shall lapse on the number of units corresponding to the level of the attained performance, as if Executive had remained employed by Chemical through the last day of the applicable performance period, and such units shall become convertible into Chemical’s Common Stock, with settlement to occur as soon as administratively feasible, on the same date as settlement occurs for the other holders of PSUs for the applicable performance period; and (iv) any other equity-based awards shall vest in accordance with the terms of the applicable equity-based plan or grant agreement.






(D) Outplacement Services . Chemical shall provide Executive with executive-level outplacement services through an outplacement services firm selected by Chemical with Executive’s approval, which approval shall not be withheld if the firm selected is reputable, for a period not to exceed twelve (12) months after Executive’s Termination Date. The timing of outplacement services shall be determined by Executive, provided that all costs under this subsection must be incurred, and all applicable payments to the outplacement firm made, within twelve (12) months following Executive’s termination of Employment.

(d) Conditions to Severance . To be eligible for Severance, Executive must meet the following conditions: (i) Executive must comply with Executive’s obligations under this Agreement and that continue after termination of Employment; (ii) Executive must promptly sign and continue to honor the Release referenced above, in a form acceptable to Chemical, of any and all claims arising out of or relating to Executive’s employment or its termination and any and all claims that Executive might otherwise have against Chemical, the Bank, Chemical’s Affiliates, or any of their officers, directors, employees and agents, provided that the Release shall not waive Executive’s right to claims or rights related to (A) this Agreement; (B) unpaid Base Salary through the Employment Termination Date; (C) unpaid expense reimbursements for authorized business expenses incurred before the Employment Termination Date; (D) any Equity Plan benefits; (E) benefit plans (for example to convert life insurance); (F) any rights under the terms of any qualified retirement plan covering Executive; and (G) rights of indemnification under Chemical’s or the Bank’s Articles of Incorporation or Bylaws, as applicable, or any indemnification agreement entered into between Executive and Chemical, the Bank or any Affiliate (in addition, the Release does not affect Executive’s right to cooperate in an investigation by the Equal Employment Opportunity Commission); (iii) Executive must resign upon written request by Chemical from all positions with or representing Chemical, the Bank or any Affiliate, including but not limited to, membership on boards of directors; and (iv) Executive must provide Chemical and the Bank for a period of six (6) months after the Employment Termination Date with consulting services regarding matters within the scope of Executive’s former duties upon request by Chemical’s Chief Executive Officer; provided, however, that Executive only shall be required to provide those services by telephone at Executive’s reasonable convenience and without substantial interference with Executive’s other activities or commitments.

(e) Golden Parachute Cap . Notwithstanding anything in this Agreement to the contrary, any payment or benefit to be provided to Executive, whether pursuant to this Agreement or otherwise, that is a “ Parachute Payment ” as defined in Code Section 280G(b)(2), shall be reduced to the extent necessary so that the benefits payable or to be provided to Executive under this Agreement that are Parachute Payments, as well as any Parachute Payments provided outside of this Agreement shall not cause Chemical, the Bank or any Affiliate to have paid an “ Excess Parachute Payment ” as defined in Code Section 280G(b)(1). If it is established that an Excess Parachute Payment has occurred or shall occur under this Agreement or otherwise, any remaining Parachute Payments shall be reduced (cash payments first) to ensure that the total payments to Executive do not exceed 2.99 times Executive’s “ Base Amount ” as defined in Code Section 280G(b)(3).

(f) Application of Internal Revenue Code Section 409A.

(i) All payments and benefits provided under this Agreement are intended to be exempt from, or in accordance with, Code Section 409A, and the Agreement is to be interpreted accordingly. Each installment payment is intended to constitute a separate benefit and terms such as “employment termination,” “termination from employment” or like terms are intended to constitute a Separation from Service, as defined below. To the extent exempt from Code Section 409A, payments are intended to be exempt under the short term deferral exemption, or exempt or partially exempt under the involuntary separation pay plan exemption. Notwithstanding the forgoing, neither Chemical, the Bank nor any Affiliate has responsibility for any taxes, penalties or interest incurred by Executive in connection with payments and benefits provided under this Agreement, including any imposed by Code Section 409A.

(ii) Despite other payment timing provisions in this Agreement, any payments and benefits provided under this Section 6 that constitute nonqualified deferred compensation that are subject to Code Section 409A, shall not commence in connection with Executive’s termination of Employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (a “ Separation from Service). However, if Chemical determines that the Severance is subject to Code Section 409A, and Executive is a “ Specified Employee ” (as defined under Code Section 409A) at the time of Separation from Service, then, solely to the extent necessary to avoid adverse tax consequences to Executive under Code Section 409A, the timing of any Severance payments shall be delayed until the earlier to occur of: (i) the date that is six (6) months and one (1) day after Executive’s Separation from Service, or (ii) the date of Executive’s death (such applicable date, the “ Specified Employee Initial Payment Date ”), and Chemical (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Severance payments that Executive otherwise would have received through the Specified Employee Initial Payment Date if the commencement of Severance had not been so delayed pursuant to this Section, and (B) commence paying the balance of the Severance in accordance with the applicable payment schedules set forth in this Agreement.






(g) No Further Obligations. Except as expressly provided above or as otherwise required by law, Chemical shall have no obligations to Executive in the event of the termination of this Agreement for any reason.

7. Representations of Executive. Executive represents and warrants that he is not obligated or restricted under any agreement (including any non-competition or confidentiality agreement), judgment, decree, order or other restraint of any kind that could impair his ability to perform the duties and obligations required hereunder. Executive further agrees that he shall not divulge to Chemical, the Bank or any Affiliate any confidential information and/or trade secrets belonging to others, including Executive’s former employers, nor shall Chemical, the Bank or an Affiliate seek to elicit from Executive such information. Consistent with the foregoing, Executive shall not provide to Chemical, the Bank or an Affiliate, nor shall they request, any documents or copies of documents containing such information.

8. Confidential Information.

(a) Executive acknowledges that Chemical and the Bank have and shall give Executive access to certain highly-sensitive, confidential, and proprietary information belonging to Chemical, the Bank, their Affiliates or third parties who may have furnished such information under obligations of confidentiality, relating to and used in Chemical’s Business (collectively, “ Confidential Information ”). Executive acknowledges that, unless otherwise available to the public, Confidential Information includes, but is not limited to, the following categories of confidential or proprietary information and material financial statements and information; budgets, forecasts, and projections; business and strategic plans; marketing, sales, and distribution strategies; research and development projects; records relating to any intellectual property developed by, owned by, controlled, or maintained by Chemical, the Bank or their Affiliates; information related to Chemical’s, the Bank’s or their Affiliates’ inventions, research, products, designs, methods, formulae, techniques, systems, processes; customer lists; non-public information relating to Chemical’s, the Bank’s or their Affiliates’ customers, suppliers, distributors, or investors; the specific terms of Chemical’s, the Bank’s or their Affiliates’ agreements or arrangements, whether oral or written, with any customer, supplier, vendor, or contractor with which Chemical, the Bank or their Affiliates may be associated from time to time; and any and all information relating to the operation of Chemical’s, the Bank’s or their Affiliates’ business which Chemical, the Bank or their Affiliates may from time to time designate as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by Chemical, the Bank or their Affiliates as confidential or proprietary. Confidential Information encompasses all formats in which information is preserved, whether electronic, print, or any other form, including all originals, copies, notes, or other reproductions or replicas thereof.

(b) Confidential Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Executive or other violation of this Agreement; or (iii) is disclosed to Executive by a third party under no obligation to maintain the confidentiality of the information.

(c) Executive acknowledges that Confidential Information owned or licensed by Chemical, the Bank or their Affiliates is unique, valuable, proprietary and confidential; derives independent actual or potential commercial value from not being generally known or available to the public; and is subject to reasonable efforts to maintain its secrecy. Executive hereby relinquishes, and agrees that he shall not at any time claim, any right, title or interest of any kind in or to any Confidential Information.

(d) During and after his employment with Chemical and the Bank, Executive shall hold in trust and confidence all Confidential Information, and shall not disclose any Confidential Information to any person or entity, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical. Executive further agrees that during and after his employment with Chemical and the Bank, Executive shall not use any Confidential Information for the benefit of any third party, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical.

(e) The restrictions in Section 8(d) above shall not apply to any information to the extent that Executive is required to disclose such information by law, provided that Executive (i) notifies Chemical of the existence and terms of such obligation, (ii) gives Chemical a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure, and (iii) only discloses that information actually required to be disclosed.

(f) Return of Property. Upon request by Chemical during Employment and automatically and immediately at termination of Employment, Executive shall return to Chemical all Confidential Information in any form (including all copies and reproductions thereof) and all other property whatsoever of Chemical and the Bank in his possession or under his control. If requested by Chemical, Executive shall certify in writing that all such materials have been returned to Chemical. Executive also expressly agrees that immediately upon the termination of his Employment with Chemical for any reason, Executive shall cease using any secure website, computer systems, e-mail system, or phone system or voicemail service provided by Chemical or the Bank for the use of their employees.






9. Assignment of Inventions.

(a) Executive agrees that all developments or inventions (including without limitation any and all software programs (source and object code), algorithms and applications, concepts, designs, discoveries, improvements, processes, techniques, know-how and data) that result from work performed by Executive for Chemical, the Bank and their Affiliates, whether or not patentable or registrable under copyright or similar statutes or subject to analogous protection (“ Inventions ”), shall be the sole and exclusive property of Chemical or its nominees, and Executive shall and hereby does assign to Chemical all rights in and to such Inventions upon the creation of any such Invention, including, without limitation: (i) patents, patent applications and patent rights throughout the world; (ii) rights associated with works of authorship throughout the world, including copyrights, copyright applications, copyright registrations, mask work rights, mask work applications and mask work registrations; (iii) rights relating to the protection of trade secrets and confidential information throughout the world; (iv) rights analogous to those set forth herein and any other proprietary rights relating to intangible property; and (v) divisions, continuations, renewals, reissues and extensions of the foregoing (as applicable), now existing or hereafter filed, issued or acquired (collectively, the “ IP Rights ”).

(b) For avoidance of doubt, if any Inventions fall within the definition of “work made for hire” as such term is defined in 17 U.S.C. § 101, such Inventions shall be considered “work made for hire” and the copyright of such Inventions shall be owned solely and exclusively by Chemical. If any Invention does not fall within such definition of “work made for hire” then Executive’s right, title and interest in and to such Inventions shall be assigned to Chemical pursuant to Section 9(a) above.

(c) Chemical and its nominees shall have the right to use and/or to apply for statutory or common law protections for such Inventions in any and all countries. Executive further agrees, at Chemical’s expense, to: (i) reasonably assist Chemical in obtaining and from time to time enforcing such IP Rights relating to Inventions, and (ii) execute and deliver to Chemical or its nominee upon reasonable request all such documents as Chemical or its nominee may reasonably determine are necessary or appropriate to effect the purposes of this Section 9, including assignments of inventions. Such documents may be necessary to: (A) vest in Chemical or its nominee clear and marketable title in and to Inventions; (B) apply for, prosecute and obtain patents, copyrights, mask works rights and other rights and protections relating to Inventions; or (C) enforce patents, copyrights, mask works rights and other rights and protections relating to Inventions. Executive’s obligations pursuant to this Section 9 shall continue beyond the termination of Executive’s employment with Chemical. If Chemical is unable for any reason to secure Executive’s signature to any lawful and necessary document required to apply for or execute any patent, trademark, copyright or other applications with respect to any Inventions (including renewals, extensions, continuations, divisions or continuations in part thereof), Executive hereby irrevocably designates and appoints Chemical and its then current Chief Executive Officer as Executive’s agent and attorney-in-fact to act for and in behalf and instead of Executive, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents, trademarks, copyrights or other rights thereon with the same legal force and effect as if executed by Executive.

(d) The obligations of Executive under Section 9(a) above shall not apply to any Invention that Executive developed entirely on his own time without using Chemical’s equipment, supplies, facility or trade secret information, except for those Inventions that (i) relate to Chemical’s business or actual or demonstrably anticipated research or development, or (ii) result from any work performed by Executive for Chemical or the Bank. Executive shall bear the burden of proof in establishing the applicability of this subsection to a particular circumstance.

10. Non-Competition and Non-Solicitation.

(a) Purpose. Executive understands and agrees that the purpose of this Section 10 is solely to protect Chemical’s legitimate business interests, including, but not limited to its confidential and proprietary information, customer relationships and goodwill, and Chemical’s competitive advantage. Therefore, Executive agrees to be subject to restrictive covenants under the following terms.

(b) Definitions. As used in this Agreement, the following terms have the meanings given to such terms below.

(i) Business ” means the business(es) in which Chemical, the Bank or their Affiliates were engaged in at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(ii) Customer ” means any person or entity who is or was a customer, supplier or client of Chemical, the Bank or their Affiliates with whom Executive had any contact or association for any reason and with whom Executive had dealings on behalf of Chemical, the Bank or their Affiliates in the course of his employment with Chemical and the Bank.






(iii) Chemical Employee ” means any person who is or was an employee of Chemical, the Bank or their Affiliates at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(iv) Restricted Period ” means the period during Executive’s employment with Chemical and for twenty-four (24) months from and after Executive’s applicable Termination Date; provided, however, that this period shall be tolled and shall not run during any time Executive is in violation of this Section 10, it being the intent of the parties that the Restricted Period shall be extended for any period of time in which Executive is in violation of this Section 10.

(v) Restricted Territory ” means Michigan or any other state in which Chemical, the Bank or any Affiliate operates a banking, insurance or securities products and services institution at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(c) Non-Competition. During the Restricted Period, Executive shall not in the Restricted Area, on his own behalf or on behalf of any other person:

(i)
assist or have an interest in (whether or not such interest is active), whether as partner, investor, stockholder, officer, director or as any type of principal whatever, any person, firm, partnership, association, corporation or business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business; provided, however, that Executive shall be permitted to make passive investments in the stock of any publicly traded business (including a competitive business), as long as the stock investment in any competitive business does not rise above one percent (1%) of the outstanding shares of such business; or

(ii)
enter into the employment of or act as an independent contractor or agent for or advisor or consultant to, any person, firm, partnership, association, corporation, business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business, or is a governmental regulator agency of the Business.

(d) Non-Solicitation. During the Restricted Period, Executive shall not, directly or indirectly, on Executive’s own behalf or on behalf of any other party:

(i)
Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert, or encourage any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical, the Bank or their Affiliates;

(ii)
Accept as a customer any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical, the Bank or their Affiliates;

(iii)
Induce, encourage, or attempt to induce or encourage any Customer to purchase or accept products or services that are similar to or competitive with those offered by Chemical, the Bank or their Affiliates from any person or entity (other than Chemical, the Bank or their Affiliates ) engaging in the Business;

(iv)
Induce, encourage, or attempt to induce or encourage any Customer to reduce, limit, or cancel its business with Chemical, the Bank or their Affiliates; or

(v)
Solicit, induce, or attempt to solicit or induce any employee of Chemical, the Bank or their Affiliates to terminate employment with Chemical, the Bank or their Affiliates.

(e) Reasonableness of Restrictions. Executive acknowledges and agrees that the restrictive covenants in this Agreement (i) are essential elements of Executive’s employment by Chemical and the Bank and are reasonable given Executive’s access to Chemical’s the Bank’s and their Affiliates’ Confidential Information and the substantial knowledge and goodwill Executive shall acquire with respect to the business of Chemical, the Bank and their Affiliates as a result of his employment with Chemical and the Bank, and the unique and extraordinary services to be provided by Executive to Chemical and the Bank; and (ii) are reasonable in time, territory, and scope, and in all other respects.






(f) Preserve Livelihood. Executive represents that his experience, capabilities and personal assets are such that this Agreement does not deprive him from either earning a livelihood in the unrestricted business activities which remain open to him or from otherwise adequately and appropriately supporting himself and his family.

(g) Judicial Modification. Should any part or provision of this Section 10 be held invalid, void, or unenforceable in any court of competent jurisdiction, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement. The parties further agree that if any portion of this Section 10 is found to be invalid or unenforceable by a court of competent jurisdiction because its duration, territory, or other restrictions are deemed to be invalid or unreasonable in scope, the invalid or unreasonable terms shall be replaced by terms that such court deems valid and enforceable and that come closest to expressing the intention of such invalid or unenforceable terms.

11. Enforcement. Executive acknowledges and agrees that Chemical shall suffer irreparable harm in the event that Executive breaches any of Executive’s obligations under Sections 8, 9, or 10 of this Agreement and that monetary damages would be inadequate to compensate Chemical for such breach. Accordingly, Executive agrees that, in the event of a breach by Executive of any of Executive’s obligations under Sections 8, 9, or 10 of this Agreement, Chemical shall be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief, and expedited discovery for the purpose of seeking relief, in order to prevent or to restrain any such breach. Chemical shall be entitled to recover its costs incurred in connection with any action to enforce Sections 8, 9, or 10 of this Agreement, including reasonable attorneys’ fees and expenses.

12. Miscellaneous.

(a) Entire Agreement. This Agreement, when aggregated with the attached Release, as applicable, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements (whether written or oral and whether express or implied) between the parties to the extent related to such subject matter.

(b) Successors and Assigns.

(i)
This Agreement shall not be terminated by any merger or consolidation of Chemical or the Bank whereby Chemical or the Bank is not the surviving or resulting corporation, or as a result of any transfer of all or substantially all of the assets of Chemical or the Bank. In the event of any such merger, consolidation or transfer of assets, the provisions of this Agreement shall be binding upon the surviving or resulting corporation or the person or entity to which such assets are transferred.

(ii)
Chemical agrees that concurrently with any merger, consolidation or transfer of assets constituting a Change in Control, it shall cause any successor or transferee unconditionally to assume, by written instrument delivered to Executive (or Executive’s beneficiary or estate), all of Chemical’s obligations hereunder. Failure of Chemical to obtain such assumption prior to the effective date of any Change in Control shall be a material breach of Chemical’s obligations to Executive under this Agreement.

(iii)
This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors, permitted assigns and, in the case of Executive, heirs, executors, and/or personal representatives. Executive may not assign, delegate or otherwise transfer any of Executive’s rights, interests or obligations in this Agreement. If Executive shall die while any amounts would be payable to Executive hereunder had Executive continued to live, all such amounts unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to such person or persons appointed in writing by Executive to receive such amounts or, if no such person is appointed, to Executive’s estate.

(c) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement.

(d) Notices. Any notice pursuant to this Agreement must be in writing and shall be deemed effectively given to the other party on (i) the date it is actually delivered by overnight courier service (such as FedEx) or personal delivery of such notice in person, or (ii) three (3) days after mailing by certified or registered U.S. mail, return receipt requested; in each case the appropriate address shown below (or to such other address as a party may designate by notice to the other party):







If to Executive:                Thomas C. Shafer
                        
If to Chemical and the Bank:        Chemical Financial Corporation                                            2301 West Big Beaver Road
Troy, MI 48084
Attention: Chief Executive Officer
    
(e) Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the amendment is authorized by Chemical’s Board or a committee of Chemical’s Board, is in writing and signed by Chemical and Executive. No waiver of any provision of this Agreement shall be valid unless the waiver is in writing and signed by the waiving party. The failure of a party at any time to require performance of any provision of this Agreement shall not affect such party’s rights at a later time to enforce such provision. No waiver by a party of any breach of this Agreement shall be deemed to extend to any other breach hereunder or affect in any way any rights arising by virtue of any other breach.

(f) Severability. Each provision of this Agreement is severable from every other provision of this Agreement. Any provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable shall not affect the validity or enforceability of any other provision. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable.

(g) Construction. The section headings in this Agreement are inserted for convenience only and are not intended to affect the interpretation of this Agreement. Any reference in this Agreement to any “Section” refers to the corresponding Section of this Agreement. The word “including” in this Agreement means “including without limitation.” This Agreement shall be construed as if drafted jointly by Chemical, the Bank and Executive, and no presumption or burden of proof shall arise favoring or disfavoring Chemical, the Bank or Executive by virtue of the authorship of any provision in this Agreement. All words in this Agreement shall be construed to be of such gender or number as the circumstances require.

(h) Survival. The terms of Sections 6, 7, 8, 9, 10, 11 and 12 shall survive the termination of this Agreement for any reason.

(i) Remedies Cumulative. The rights and remedies of the parties under this Agreement are cumulative (not alternative) and in addition to all other rights and remedies available to such parties at law, in equity, by contract or otherwise.

(j) Venue. Executive, Chemical and the Bank agree that the exclusive forum for resolving any disputes between the parties related to the Agreement shall be arbitration before the American Arbitration Association applying the Employment Arbitration Rules and Mediation Procedures as amended and effective November 1, 2009. The Arbitrator shall be empowered to grant any legal or equitable relief available to the parties, including interim equitable relief as set forth in the Optional Rules for Emergency Measures of Protection. Any award of the Arbitration may be enforced through proceedings in a court of competent jurisdiction.

(k) Governing Law. This Agreement shall be governed by the laws of the State of Michigan without giving effect to any choice or conflict of law principles of any jurisdiction.


[Signatures are on the Next Page]






IN WITNESS WHEREOF , the parties hereto have executed and delivered this Agreement as set forth below.

 
 
 
Date:
October 16, 2017
/s/ Thomas C. Shafer
 
 
Thomas C. Shafer
Executive
 
 
 
 
 
 
Date:
October 16, 2017
/s/ Gary Torgow
 
 
Gary Torgow
Chairman of the Board of Directors
Chemical Financial Corporation
 
 
 
Date:
October 16, 2017
/s/ Franklin C. Wheatlake
 
 
Franklin C. Wheatlake
Lead Independent Director
Chemical Financial Corporation






APPENDIX A
EMPLOYMENT AGREEMENT RELEASE
THIS RELEASE AGREEMENT (the “Release”) is made as of the ____ day of _______, 20__, by and between Chemical Financial Corporation (“Chemical”), Chemical Bank (“Bank”) and Thomas C. Shafer (the “Executive”) (in the aggregate, the “Parties”).
WHEREAS , Chemical, the Bank and Executive have entered into an Employment Agreement dated as of July 1, 2017, (the “Employment Agreement”), pursuant to which Executive is entitled to receive certain additional compensation upon termination of Executive’s employment with Chemical Without Cause or for Good Reason (all as defined in the Employment Agreement); and
WHEREAS , Executive’s receipt of the additional compensation under the Employment Agreement is conditioned upon the execution of this Release that is mutually acceptable to the Parties; and
WHEREAS, Executive’s employment with Chemical and the Banks has been/shall be terminated effective ______________ __, 20__ [Without Cause] [due to Good Reason by the Executive];
NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed between the Parties as follows:
1.      Additional Compensation . Subject to the terms and conditions hereof, Chemical shall pay Executive the additional compensation set forth in Section 6 of the Employment Agreement, net of applicable withholding taxes, commencing after the expiration of the waiting period set forth herein and in accordance with the terms of the Employment Agreement.
2.      Release.
(a)    In exchange for the good and valuable consideration set forth herein, Executive agrees for himself, his heirs, administrators, representatives, executors, successors and assigns (“Releasors”), to irrevocably and unconditionally release, waive and forever discharge any and all manner of action, causes of action, claims, rights, promises, charges, suits, damages, debts, lawsuits, liabilities, rights, due controversies, charges, complaints, remedies, losses, demands, obligations, costs, expenses, fees (including, without limitation attorneys’ fees), or any and all other liabilities or claims of whatsoever nature, whether arising in contract, tort, or any other theory of action, whether arising in law or in equity, whether known or unknown, choate or inchoate, matured or unmatured, contingent or fixed, liquidated or unliquidated, accrued or unaccrued, asserted or unasserted, including, but not limited to, any claim and/or claim of damages or other relief for tort, breach of contract, personal injury, negligence, age discrimination under The Age Discrimination In Employment Act of 1967 (as amended), employment discrimination prohibited by other federal, state or local laws including sex, race, national origin, marital status, age, handicap, height, weight, or religious discrimination, and any other claims of unlawful employment practices or any other unlawful criterion or circumstance which Executive and Releasors had, now have, or may have in the future against each or any of Chemical, its parent, divisions, affiliates and related companies or entities, regardless of its or their form of business organization (the “Company Entities”), any predecessors, successors, joint ventures, and parents of any Company Entity, and any and all of their respective past or present directors, officers, shareholders, partners, employees, consultants, independent contractors, trustees, administrators, insurers, agents, attorneys, representative and fiduciaries, successors and assigns including without limitation all persons acting by, through, under or in concert with any of them (all collectively, the “Released Parties’) arising out of or relating to his employment relationship with Chemical, its predecessors, successors or affiliates and the termination thereof. Executive understands that he does not waive rights or claims that may arise after the date of this Release.
(b)    Executive acknowledges that he has read this Release carefully and understands all of its terms.
(c)    Executive understands and agrees that he has been advised to consult with an attorney prior to executing this Release.
(d)    Executive understands that he is entitled to consider this Release for at least [twenty-one (21)][forty-five] days before signing the Release. However, after due deliberation, Executive may elect to sign this Release without availing himself of the opportunity to consider its provisions for at least [twenty-one (21)][forty-five] days. Executive hereby acknowledges that any decision to shorten the time for considering this Release prior to signing it is voluntary, and such decision is not induced by or through fraud, misrepresentation, or a threat to withdraw or alter the provisions set forth in this Release in the event Executive elected to consider this Release for at least [twenty-one (21)][forty-five] days prior to signing the Release.





(e)    Executive understands that he may revoke this Release as it relates to any potential claim that could be brought or filed under the Age Discrimination in Employment Act 29 U.S.C. §§ 621-634, within seven (7) days after the date on which he signs this Release, and that this Release as it relates to such a claim does not become effective until the expiration of the seven (7) day period. In the event that Executive wishes to revoke this Release within the seven (7) day period, Executive understands that he must provide such revocation in writing to the then Chief Executive Officer at the address set forth below.
(f)    In agreeing to sign this Release, Executive is doing so voluntarily and agrees that he has not relied on any oral statements or explanations made by Chemical, the Bank or their representatives.
(g)    This Release shall not be construed as an admission of wrongdoing by either Executive, Chemical or the Bank.
3.      Notices . Every notice relating to this Release shall be in writing and if given by mail shall be given by registered or certified mail with return receipt requested. All notices to Chemical and the Bank shall be delivered to Chemical’s Chief Executive Officer at Chemical Financial Corporation, 2301 W. Big Beaver Rd, Troy, MI 48084. All notices by Chemical and the Bank to Executive shall be delivered to Executive personally or addressed to Executive at Executive’s last residence address as then contained in the records of Chemical, the Bank or such other address as Executive may designate. Either party by notice to the other may designate a different address to which notices shall be addressed. Any notice given by Chemical and the Bank to Executive at Executive’s last designated address shall be effective to bind any other person who shall acquire rights hereunder.
4.      Governing Law . To the extent not preempted by Federal law, this Release shall be governed by and construed in accordance with the laws of the State of Michigan, without giving effect to conflicts of laws.
5.      Counterparts . This Release may be executed in two (2) or more counterparts, all of which when taken together shall be considered one (1), and the same Release and shall become effective when the counterparts have been signed by each party and delivered to the other party; it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.
6.      Entire Agreement . This Release, when aggregated with the Employment Agreement [Note: Add any other documents, as applicable], contains the entire understanding of the parties with respect to the subject matter hereof and together supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Release.
IN WITNESS WHEREOF, the parties hereto have executed this Release as of the day and year first written above.
 
 
 
Date:
 
 
 
 
Thomas C. Shafer
Executive
 
 
 
 
 
 
Date:
 
 
 
 
 
 
 
 
Date:
 
 
 
 
 








WAIVER OF [21][45] DAY NOTICE PERIOD
I have been provided with the General Release Agreement (“Agreement”) between Chemical Financial Corporation (collectively with the Bank and all of their affiliates, “Chemical”) and Thomas C. Shafer (“Executive”).
I understand that I have [twenty-one (21)][forty-five (45)] days from the date the Agreement was presented to me to consider whether or not to sign the Agreement. I further understand that I have the right to seek counsel prior to signing the Agreement.
I am knowingly and voluntarily signing and returning the Agreement prior to the expiration of the [twenty-one (21)-day][forty-five (45)-day] consideration period. I understand that I have seven (7) days from signing the Agreement to revoke the Agreement, by delivering a written notice of revocation to the Chief Executive Officer, Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084.
 
 
 
Date:
 
 
 
 
Thomas C. Shafer
Executive
 
 
 







Exhibit 10.24


CHANGE IN CONTROL AGREEMENT

This Change in Control Agreement (the “ Agreement ”) is entered into as of February 27, 2018, by and between Chemical Financial Corporation (“ Chemical ”), Chemical Bank (the “ Bank ”) and Robert Rathbun (the “ Executive ”).

Recitals

WHEREAS , Chemical believes that the establishment and maintenance of sound and vital management of Chemical is essential to the protection and enhancement of the interests of Chemical and Chemical’s shareholders;

WHEREAS, Chemical also recognizes the possibility of a Change in Control (as defined herein), with the attendant uncertainties and risks that might result in the departure or distraction of Chemical’s key employees to Chemical’s detriment;

WHEREAS, Chemical has determined that it is appropriate to take steps to induce key employees to remain with Chemical, and to reinforce and encourage their continued attention and dedication, when faced with the possibility of a Change in Control; and

NOW, THEREFORE , in consideration of the foregoing, the mutual agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.
Definitions.

(a) “Affiliate” any organization controlling, controlled by or under common control with Chemical.

(b) “Bank” means Chemical Bank.

(c) “Base Salary” means Executive’s annual base compensation as in effect immediately prior to Executive’s Termination Date, disregarding any base salary reduction due to a Good Reason event, as described below.

(d) “Board” means the Board of Directors of Chemical

(e) “Bonus” means a payment under Chemical’s Annual Executive Incentive Plan.

(f) “Cause” means (i) Executive’s removal by order of a regulatory agency having jurisdiction over Chemical or the Bank; (ii) Executive’s material breach of any provision in this Agreement; if the breach is curable, it shall constitute Cause only if it continues uncured for a period of twenty (20) days after Executive’s receipt of written notice of such breach by Chemical; (iii) Executive’s failure or refusal, in any material manner to perform all lawful services required of him in his employment positions with Chemical, which failure or refusal continues for more than twenty (20) days after Executive’s receipt of written notice of such deficiency; (iv) Executive’s commission of fraud, embezzlement, theft, or a crime constituting moral turpitude, whether or not involving Chemical or the Bank, which in the reasonable good faith judgment of Chemical’s Board, renders Executive’s continued employment harmful to Chemical; (v) Executive’s misappropriation of the assets of Chemical or the Bank or their property, including without limitation, obtaining material reimbursement through financial vouchers or expense reports; or (vi) Executive’s conviction or the entry of a plea of guilty or no contest by Executive with respect to any felony or other crime which, in the reasonable good faith judgment of Chemical’s Board, adversely affects Chemical, and its reputation.

(g) “Change in Control” means the occurrence of any of the following events: (i) the acquisition by a person or persons acting as a group, of Chemical stock that together with stock held by such person or group constitutes more than fifty percent (50%) of the total fair market value or total voting power of the stock of Chemical; (ii) the majority of the members of Chemical’s Board are replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of appointment or election; or (iii) the acquisition, by a person or persons acting as a group, of Chemical’s assets that have a total gross fair market value equal to or exceeding fifty percent (50%) of the total gross fair market value of Chemical’s assets in a single transaction or within a 12-month period ending with the most recent acquisition. For purposes of this Section, gross fair market value means the value of Chemical’s assets, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. Notwithstanding the foregoing, no trust department or designated fiduciary or other trustee of such trust department of Chemical or a subsidiary of Chemical, or other similar fiduciary capacity of Chemical with direct voting control of the stock shall be treated as a person or group within the





meaning of subsection (i) hereof. Further, no profit sharing, employee stock ownership, employee stock purchase and savings, employee pension, or other employee benefit plan of Chemical or any of its subsidiaries, and no trustee of any such plan in its capacity as such trustee, shall be treated as a person or group within the meaning of subsection (i) hereof.

(h) “Code” means the Internal Revenue Code of 1986, as amended.

(i) “Equity Plans” means any stock option, performance share unit, time restricted stock unit or other equity-based compensation programs offered by Chemical.

(j) “Fringe Benefits” means health and dental, life insurance, short and long term disability insurance, retirement and other employee fringe benefit programs covering Chemical’s salaried employees as a group, and in any programs applicable to senior executives of Chemical or the Bank, as applicable.

(k) “Good Reason” means the occurrence of any of the following events without the written consent of Executive:

(i) any material reduction in Executive’s Base Salary, as it may be adjusted from time to time, without a corresponding reduction in the base salaries of the other executives of Chemical and the Bank;

(ii) any material reduction in the status, position or responsibilities of Executive;

(iii) any requirement by Chemical (without Executive’s consent) that Executive be principally based at any office or location more than sixty (60) miles from Executive’s principal work location as of the effective date of this Agreement; or

(iv) any material breach of this Agreement by Chemical or the Bank.

Notwithstanding the foregoing, if Executive fails to give Chemical written notice of Executive’s intention to terminate employment with Chemical for Good Reason within sixty (60) days following Executive’s knowledge of any Good Reason event and a period of thirty (30) days in which Chemical may remedy the event alleged to constitute Good Reason, and if Executive has not Separated from Service (as defined below) within sixty (60) days following expiration of Chemical’s cure period, the event shall not constitute Good Reason, and Executive shall have no right to terminate employment for Good Reason as a result of such event.
(l) “Release” means Executive’s waiver and release of claims against Chemical and the Bank, as described in Section 2(a).

(m) “Separation from Service” means the definition set forth in Section 5(b).

(n) “Termination Date” means the date on which Executive incurs a Separation of Service.

(o) “Termination Without Cause” means (a) Executive’s Separation from Service by Chemical for reasons other than Cause, disability, death, or voluntary termination of employment by Executive or (b) Good Reason Termination by Executive.

2. Change in Control Termination Without Cause . If Executive incurs a Termination Without Cause within either (a) two (2) years following the date of a Change in Control, or (b) within six (6) months before the date of a Change in Control, Executive shall be entitled to Change in Control Severance, as described below (“ Change in Control Severance ”).

(a) Change in Control Severance Pay . If Executive incurs a Change in Control Termination Without Cause, Executive shall be entitled to receive Change in Control Severance Pay in the amount of one (1) times the sum of (i) Executive’s then Base Salary, disregarding any Base Salary reduction due to a Good Reason termination, plus (ii) the average of Executive’s Bonuses under Chemical’s Annual Executive Incentive Plan for each of the three (3) most recent complete calendar years of Executive’s employment with Chemical (or the lesser number of complete calendar years that Executive has been employed by Chemical), payable in one (1) lump sum cash payment (“ Change in Control Severance Pay ”). The amount shall be reduced by any severance previously received by Executive under any other Chemical severance arrangement. The Change in Control Severance Pay is conditioned upon Executive and Chemical executing a mutually agreeable release of claims, in substantially the form attached hereto as Appendix A (the “ Release ”), which is enforceable within sixty (60) days following Executive’s Termination Date. Subject to any delayed payment due to Executive’s status as a “Specified Employee” under Code Section 409A, if applicable, and as described more fully in Section 5(b) below, the Change in Control Severance Pay shall be payable to Executive on the first pay date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that





Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. Notwithstanding the foregoing, if Executive is entitled to Change in Control Severance but violates any provisions of Sections 7 through 9 hereof after termination of employment, Chemical shall have any remedies, including claw back, that may be available to Chemical in law or at equity.

(b) Health Coverage Payment . Chemical shall pay Executive a lump sum stipend equal to twelve (12) times Executive’s monthly contribution towards Executive’s then current employee and dependent health, prescription drug and dental coverage elections, conditioned on Executive’s execution of the Release described herein that becomes irrevocable within sixty (60) days following Executive’s Termination Date, with the stipend payable on the first payroll date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. If Executive is not enrolled in Chemical’s health, prescription drug and dental plans, the monthly contribution shall be based on Executive’s contribution towards family coverage for such plans determined at the time employment terminates. Although the right to payment under this paragraph is based on Executive’s health, prescription drug and/or dental plan at the time Executive’s employment terminates and is intended to fund payment for health coverage, the payment is not required to be used for health coverage and Executive may use the payment for any purpose.

(c) Equity-Based Awards . Effective upon expiration of the Release revocation period described in Section 2(a) above, all equity-based awards previously granted to Executive and outstanding at the time of his Termination Date shall be treated as follows: (i) all unvested stock options immediately shall vest, become exercisable and together with Executive’s other vested, unexercised stock options, remain exercisable until the earlier of their original term and three (3) years following Executive’s Termination Date; (ii) all outstanding time-based restricted stock units automatically shall vest and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; (iii) all performance-based stock units (“PSUs”), shall remain outstanding, subject to their original performance goals, and the restrictions under each such grant shall not lapse until Chemical’s Compensation and Pension Committee has determined that the applicable performance goals have been attained and the level to which such goals were attained, at which time the restrictions shall lapse on the number of units corresponding to the level of the attained performance, as if Executive had remained employed by Chemical through the last day of the applicable performance period, and such units shall become convertible into Chemical’s Common Stock, with settlement to occur as soon as administratively feasible, on the same date as settlement occurs for the other holders of PSUs for the applicable performance period; and (iv) any other equity-based awards shall vest in accordance with the terms of the applicable equity-based plan or grant agreement.

(d) Outplacement Services . Chemical shall provide Executive with executive-level outplacement services through an outplacement services firm selected by Chemical with Executive’s approval, which approval shall not be withheld if the firm selected is reputable, for a period not to exceed twelve (12) months after Executive’s Termination Date. The timing of outplacement services shall be determined by Executive, provided that all costs under this subsection must be incurred, and all applicable payments to the outplacement firm made, within twelve (12) months following Executive’s Termination Date.

3. Conditions to Change in Control Severance . To be eligible for Change in Control Severance, Executive must meet the following conditions: (i) Executive must comply with Executive’s obligations under this Agreement that continue after termination of employment; (ii) Executive must promptly sign and continue to honor the Release referenced above, in a form acceptable to Chemical, of any and all claims arising out of or relating to Executive’s employment or its termination and any and all claims that Executive might otherwise have against Chemical, the Bank, Chemical’s Affiliates, or any of their officers, directors, employees and agents, provided that the Release shall not waive Executive’s right to claims or rights related to (A) this Agreement; (B) unpaid Base Salary through his Termination Date; (C) unpaid expense reimbursements for authorized business expenses incurred before the employment Termination Date; (D) any Equity Plan benefits; (E) benefit plans (for example to convert life insurance); (F) any rights under the terms of any qualified retirement plan covering Executive; and (G) Executive’s rights of indemnification under Chemical’s or the Bank’s Articles of Incorporation or Bylaws, as applicable, or any indemnification agreement entered into between Executive and Chemical, the Bank or any Affiliate (in addition, the Release does not affect Executive’s right to cooperate in an investigation by the Equal Employment Opportunity Commission); (iii) Executive must resign upon written request by Chemical from all positions with or representing Chemical, the Bank or any Affiliate, including but not limited to, membership on boards of directors; and (iv) Executive must provide Chemical for a period of six (6) months after his employment Termination Date with consulting services regarding matters within the scope of Executive’s former duties upon request of the Chief Executive Officer; provided, however, that Executive only shall be required to provide those services by telephone at Executive’s reasonable convenience and without substantial interference with Executive’s other activities or commitments.






4. Golden Parachute Cap . Notwithstanding anything in this Agreement to the contrary, any payment or benefit to be provided to Executive, whether pursuant to this Agreement or otherwise, that is a “ Parachute Payment ” as defined in Code Section 280G(b)(2), shall be reduced to the extent necessary so that the benefits payable or to be provided to Executive under this Agreement that are Parachute Payments, as well as any Parachute Payments provided outside of this Agreement shall not cause Chemical, the Bank or any Affiliate to have paid an “ Excess Parachute Payment ” as defined in Code Section 280G(b)(1). If it is established that an Excess Parachute Payment has occurred or shall occur under this Agreement or otherwise, any remaining Parachute Payments shall be reduced (cash payments first) to ensure that the total payments to Executive do not exceed 2.99 times Executive’s “ Base Amount ” as defined in Code Section 280G(b)(3).

5. Application of Internal Revenue Code Section 409A.

(a) All payments and benefits provided under this Agreement are intended to be exempt from, or in accordance with, Code Section 409A, and the Agreement is to be interpreted accordingly. Each installment payment is intended to constitute a separate benefit and terms such as “employment termination,” “termination from employment” or like terms are intended to constitute a “Separation from Service,” as defined below. To the extent payments or benefits hereunder are exempt from Code Section 409A, such payments or benefits are intended to be exempt under the short term deferral exemption, or exempt or partially exempt under the involuntary separation pay plan exemption. Notwithstanding the forgoing, neither Chemical, the Bank nor any Affiliate has responsibility for any taxes, penalties or interest incurred by Executive in connection with payments and benefits provided under this Agreement, including any imposed by Code Section 409A.

(b) Despite other payment timing provisions in this Agreement, any payments and benefits provided hereunderunder that constitute nonqualified deferred compensation that are subject to Code Section 409A, shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “Separation from Service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (a “ Separation from Service ). However, if Chemical determines that the Change in Control severance is subject to Code Section 409A, and Executive is a “ Specified Employee ” (as defined under Code Section 409A) at the time of Separation from Service, then, solely to the extent necessary to avoid adverse tax consequences to Executive under Code Section 409A, the timing of any Change in Control Severance payments or benefits shall be delayed until the earlier to occur of: (i) the date that is six (6) months and one (1) day after Executive’s Separation from Service, or (ii) the date of Executive’s death (such applicable date, the “ Specified Employee Initial Payment Date ”), and Chemical (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Change in Control Severance payments or benefits that Executive otherwise would have received through the Specified Employee Initial Payment Date if the commencement of such Change in Control Severance had not been so delayed pursuant to this Section, and (B) commence paying the balance of the payments and benefits in accordance with the applicable payment schedules set forth in this Agreement.

6. Further obligations. Except as expressly provided above or as otherwise required by law, Chemical shall have no obligations to Executive in the event of the termination of this Agreement for any reason.

7. Confidential Information.

(a) Executive acknowledges that Chemical and the Bank have and shall give Executive access to certain highly-sensitive, confidential, and proprietary information belonging to Chemical, the Bank, their Affiliates or third parties who may have furnished such information under obligations of confidentiality, relating to and used in Chemical’s Business, as defined below (collectively, “ Confidential Information ”). Executive acknowledges that, unless otherwise available to the public, Confidential Information includes, but is not limited to, the following categories of confidential or proprietary information and material financial statements and information; budgets, forecasts, and projections; business and strategic plans; marketing, sales, and distribution strategies; research and development projects; records relating to any intellectual property developed by, owned by, controlled, or maintained by Chemical, the Bank or their Affiliates; information related to Chemical’s, the Bank’s or their Affiliates’ inventions, research, products, designs, methods, formulae, techniques, systems, processes; customer lists; non-public information relating to Chemical’s, the Bank’s or their Affiliates’ customers, suppliers, distributors, or investors; the specific terms of Chemical’s, the Bank’s or their Affiliates’ agreements or arrangements, whether oral or written, with any customer, supplier, vendor, or contractor with which Chemical, the Bank or their Affiliates may be associated from time to time; and any and all information relating to the operation of Chemical’s, the Bank’s or their Affiliates’ business which Chemical, the Bank or their Affiliates may from time to time designate as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by Chemical, the Bank or their Affiliates as confidential or proprietary. Confidential Information encompasses all formats in which information is preserved, whether electronic, print, or any other form, including all originals, copies, notes, or other reproductions or replicas thereof.





(b) Confidential Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Executive or other violation of this Agreement; or (iii) is disclosed to Executive by a third party under no obligation to maintain the confidentiality of the information.

(c) Executive acknowledges that Confidential Information owned or licensed by Chemical, the Bank or their Affiliates is unique, valuable, proprietary and confidential; derives independent actual or potential commercial value from not being generally known or available to the public; and is subject to reasonable efforts to maintain its secrecy. Executive hereby relinquishes, and agrees that he shall not at any time claim, any right, title or interest of any kind in or to any Confidential Information.

(d) During and after his employment with Chemical and the Bank, Executive shall hold in trust and confidence all Confidential Information, and shall not disclose any Confidential Information to any person or entity, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical. Executive further agrees that during and after his employment with Chemical and the Bank, Executive shall not use any Confidential Information for the benefit of any third party, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical.

(e) The restrictions in this Section shall not apply to any information to the extent that Executive is required to disclose such information by law, provided that Executive (i) notifies Chemical of the existence and terms of such obligation, (ii) gives Chemical a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure, and (iii) only discloses that information actually required to be disclosed.

(f) Return of Property. Upon request by Chemical during employment and automatically and immediately at employment termination, Executive shall return to Chemical all Confidential Information in any form (including all copies and reproductions thereof) and all other property whatsoever of Chemical and the Bank in his possession or under his control. If requested by Chemical, Executive shall certify in writing that all such materials have been returned to Chemical. Executive also expressly agrees that immediately upon termination of his employment with Chemical for any reason, Executive shall cease using any secure website, computer systems, e-mail system, or phone system or voicemail service provided by Chemical or the Bank for the use of their employees.

8. Assignment of Inventions.

(a) Executive agrees that all developments or inventions (including without limitation any and all software programs (source and object code), algorithms and applications, concepts, designs, discoveries, improvements, processes, techniques, know-how and data) that result from work performed by Executive for Chemical, the Bank and their Affiliates, whether or not patentable or registrable under copyright or similar statutes or subject to analogous protection (“ Inventions ”), shall be the sole and exclusive property of Chemical or its nominees, and Executive shall and hereby does assign to Chemical all rights in and to such Inventions upon the creation of any such Invention, including, without limitation: (i) patents, patent applications and patent rights throughout the world; (ii) rights associated with works of authorship throughout the world, including copyrights, copyright applications, copyright registrations, mask work rights, mask work applications and mask work registrations; (iii) rights relating to the protection of trade secrets and confidential information throughout the world; (iv) rights analogous to those set forth herein and any other proprietary rights relating to intangible property; and (v) divisions, continuations, renewals, reissues and extensions of the foregoing (as applicable), now existing or hereafter filed, issued or acquired (collectively, the “ IP Rights ”).

(b) For avoidance of doubt, if any Inventions fall within the definition of “work made for hire” as such term is defined in 17 U.S.C. § 101, such Inventions shall be considered “work made for hire” and the copyright of such Inventions shall be owned solely and exclusively by Chemical. If any Invention does not fall within such definition of “work made for hire” then Executive’s right, title and interest in and to such Inventions shall be assigned to Chemical pursuant to Section 8(a) above.

(c) Chemical and its nominees shall have the right to use and/or to apply for statutory or common law protections for such Inventions in any and all countries. Executive further agrees, at Chemical’s expense, to: (i) reasonably assist Chemical in obtaining and from time to time enforcing such IP Rights relating to Inventions, and (ii) execute and deliver to Chemical or its nominee upon reasonable request all such documents as Chemical or its nominee may reasonably determine are necessary or appropriate to effect the purposes of this Section 8, including assignments of inventions. Such documents may be necessary to: (A) vest in Chemical or its nominee clear and marketable title in and to Inventions; (B) apply for, prosecute and obtain patents, copyrights, mask works rights and other rights and protections relating to Inventions; or (C) enforce patents, copyrights, mask works rights and other rights and protections relating to Inventions. Executive’s obligations pursuant to this Section 8 shall continue beyond the termination of Executive’s employment with Chemical. If Chemical is unable for any reason to secure Executive’s signature to any lawful and necessary document required to apply for or execute any patent, trademark, copyright or other applications with respect to any Inventions (including renewals, extensions, continuations, divisions or continuations in part





thereof), Executive hereby irrevocably designates and appoints Chemical and its then current Chief Executive Officer as Executive’s agent and attorney-in-fact to act for and in behalf and instead of Executive, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents, trademarks, copyrights or other rights thereon with the same legal force and effect as if executed by Executive.

(d) The obligations of Executive under this Section 8 shall not apply to any Invention that Executive developed entirely on his own time without using Chemical’s equipment, supplies, facility or trade secret information, except for those Inventions that (i) relate to Chemical’s business or actual or demonstrably anticipated research or development, or (ii) result from any work performed by Executive for Chemical or the Bank. Executive shall bear the burden of proof in establishing the applicability of this subsection to a particular circumstance.

9. Non-Competition and Non-Solicitation.

(a) Purpose. Executive understands and agrees that the purpose of this Section 9 is solely to protect Chemical’s legitimate business interests, including, but not limited to its confidential and proprietary information, customer relationships and goodwill, and Chemical’s competitive advantage. Therefore, Executive agrees to be subject to restrictive covenants under the following terms.

(b) Definitions. As used in this Agreement, the following terms have the meanings given to such terms below.

(i) Business ” means the business(es) in which Chemical, the Bank or their Affiliates were engaged in at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(ii) Customer ” means any person or entity who is or was a customer, supplier or client of Chemical, the Bank or their Affiliates with whom Executive had any contact or association for any reason and with whom Executive had dealings on behalf of Chemical, the Bank or their Affiliates in the course of his employment with Chemical and the Bank.

(iii) Chemical Employee ” means any person who is or was an employee of Chemical, the Bank or their Affiliates at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(iv) Restricted Period ” means the period during Executive’s employment with Chemical and for twelve (12) months from and after Executive’s applicable Termination Date; provided, however, that this period shall be tolled and shall not run during any time Executive is in violation of this Section 9, it being the intent of the parties that the Restricted Period shall be extended for any period of time in which Executive is in violation of this Section 9.

(v) Restricted Territory ” means Michigan or any other state in which Chemical, the Bank or any Affiliate operates a banking, insurance or securities products and services institution at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(c) Non-Competition. During the Restricted Period, Executive shall not in the Restricted Area, on his own behalf or on behalf of any other person:

(i) assist or have an interest in (whether or not such interest is active), whether as partner, investor, stockholder, officer, director or as any type of principal whatever, any person, firm, partnership, association, corporation or business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business; provided, however, that Executive shall be permitted to make passive investments in the stock of any publicly traded business (including a competitive business), as long as the stock investment in any competitive business does not rise above one percent (1%) of the outstanding shares of such business; or

(ii) enter into the employment of or act as an independent contractor or agent for or advisor or consultant to, any person, firm, partnership, association, corporation, business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business, or is a governmental regulator agency of the Business.

(d) Non-Solicitation. During the Restricted Period, Executive shall not, directly or indirectly, on Executive’s own behalf or on behalf of any other party:






(i) Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert, or encourage any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical, the Bank or their Affiliates;

(ii) Accept as a customer any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical, the Bank or their Affiliates;

(iii) Induce, encourage, or attempt to induce or encourage any Customer to purchase or accept products or services that are similar to or competitive with those offered by Chemical, the Bank or their Affiliates from any person or entity (other than Chemical, the Bank or their Affiliates ) engaging in the Business;

(iv) Induce, encourage, or attempt to induce or encourage any Customer to reduce, limit, or cancel its business with Chemical, the Bank or their Affiliates; or

(v) Solicit, induce, or attempt to solicit or induce any employee of Chemical, the Bank or their Affiliates to terminate employment with Chemical, the Bank or their Affiliates.

(e) Reasonableness of Restrictions. Executive acknowledges and agrees that the restrictive covenants in this Agreement (i) are essential elements of Executive’s employment by Chemical and the Bank and are reasonable given Executive’s access to Chemical’s the Bank’s and their Affiliates’ Confidential Information and the substantial knowledge and goodwilll Executive shall acquire with respect to the business of Chemical, the Bank and their Affiliates as a result of his employment with Chemical and the Bank, and the unique and extraordinary services to be provided by Executive to Chemical and the Bank; and (ii) are reasonable in time, territory, and scope, and in all other respects.

(f) Preserve Livelihood. Executive represents that his experience, capabilities and personal assets are such that this Agreement does not deprive him from either earning a livelihood in the unrestricted business activities which remain open to him or from otherwise adequately and appropriately supporting himself and his family.

(g) Judicial Modification. Should any part or provision of this Section 9 be held invalid, void, or unenforceable in any court of competent jurisdiction, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement. The parties further agree that if any portion of this Section 9 is found to be invalid or unenforceable by a court of competent jurisdiction because its duration, territory, or other restrictions are deemed to be invalid or unreasonable in scope, the invalid or unreasonable terms shall be replaced by terms that such court deems valid and enforceable and that come closest to expressing the intention of such invalid or unenforceable terms.

10. Disparagement. Executive agrees not to disparage Chemical, the Bank and their Affiliates following his Termination Date.

11. Enforcement. Executive acknowledges and agrees that Chemical shall suffer irreparable harm in the event that Executive breaches any of Executive’s obligations under Sections 7, 8, 9, or 10 of this Agreement and that monetary damages would be inadequate to compensate Chemical for such breach. Accordingly, Executive agrees that, in the event of a breach by Executive of any of Executive’s obligations under Sections 7, 8, 9, or 10 of this Agreement, Chemical shall be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief, and expedited discovery for the purpose of seeking relief, in order to prevent or to restrain any such breach. Chemical shall be entitled to recover its costs incurred in connection with any action to enforce Sections 7, 8, 9, or 10 of this Agreement, including reasonable attorneys’ fees and expenses.

12. Miscellaneous.

(a) Entire Agreement. This Agreement, when aggregated with the attached Release, as applicable, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements (whether written or oral and whether express or implied) between the parties to the extent related to such subject matter. The foregoing notwithstanding, the letter agreement between the Bank and the Executive dated November 3, 2017 and effective November 13, 2017 (the “Letter Agreement”), continues in full force and effect, except that the Change in Control provisions in the Letter Agreement are superseded in their entirety by this Agreement.






(b) Successors and Assigns.

(i) This Agreement shall not be terminated by any merger or consolidation of Chemical or the Bank whereby Chemical or the Bank is not the surviving or resulting corporation, or as a result of any transfer of all or substantially all of the assets of Chemical or the Bank. In the event of any such merger, consolidation or transfer of assets, the provisions of this Agreement shall be binding upon the surviving or resulting corporation or the person or entity to which such assets are transferred.

(ii) Chemical agrees that concurrently with any merger, consolidation or transfer of assets constituting a Change in Control, it shall cause any successor or transferee unconditionally to assume, by written instrument delivered to Executive (or Executive’s beneficiary or estate), all of Chemical’s obligations hereunder. Failure of Chemical to obtain such assumption prior to the effective date of any Change in Control shall be a material breach of Chemical’s obligations to Executive under this Agreement.

(iii) This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors, permitted assigns and, in the case of Executive, heirs, executors, and/or personal representatives. Executive may not assign, delegate or otherwise transfer any of Executive’s rights, interests or obligations in this Agreement. If Executive shall die while any amounts would be payable to Executive hereunder had Executive continued to live, all such amounts unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to such person or persons appointed in writing by Executive to receive such amounts or, if no such person is appointed, to Executive’s estate.

(c) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement.

(d) Notices. Any notice pursuant to this Agreement must be in writing and shall be deemed effectively given to the other party on (i) the date it is actually delivered by overnight courier service (such as FedEx) or personal delivery of such notice in person, or (ii) three (3) days after mailing by certified or registered U.S. mail, return receipt requested; in each case the appropriate address shown below (or to such other address as a party may designate by notice to the other party):

If to Executive:                Robert S. Rathbun
                        

If to Chemical and the Bank:        Chemical Financial Corporation                                            2301 West Big Beaver Road
Troy, MI 48084
Attention: Chief Executive Officer
    
(e) Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the amendment is authorized by Chemical’s Board or a committee of Chemical’s Board, is in writing and signed by Chemical and Executive. No waiver of any provision of this Agreement shall be valid unless the waiver is in writing and signed by the waiving party. The failure of a party at any time to require performance of any provision of this Agreement shall not affect such party’s rights at a later time to enforce such provision. No waiver by a party of any breach of this Agreement shall be deemed to extend to any other breach hereunder or affect in any way any rights arising by virtue of any other breach.

(f) Severability. Each provision of this Agreement is severable from every other provision of this Agreement. Any provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable shall not affect the validity or enforceability of any other provision. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable.

(g) Construction. The section headings in this Agreement are inserted for convenience only and are not intended to affect the interpretation of this Agreement. Any reference in this Agreement to any “Section” refers to the corresponding Section of this Agreement. The word “including” in this Agreement means “including without limitation.” This Agreement shall be construed as if drafted jointly by Chemical, the Bank and Executive, and no presumption or burden of proof shall arise favoring or disfavoring Chemical, the Bank or Executive by virtue of the authorship of any provision in this Agreement. All words in this Agreement shall be construed to be of such gender or number as the circumstances require.






(h) Survival. The terms of Sections 7, 8, 9, 10, 11 and 12 shall survive the termination of this Agreement for any reason.

(i) Remedies Cumulative. The rights and remedies of the parties under this Agreement are cumulative (not alternative) and in addition to all other rights and remedies available to such parties at law, in equity, by contract or otherwise.

(j) Venue. Executive, Chemical and the Bank agree that the exclusive forum for resolving any disputes between the parties related to the Agreement shall be arbitration before the American Arbitration Association applying the Employment Arbitration Rules and Mediation Procedures as amended and effective November 1, 2009. The Arbitrator shall be empowered to grant any legal or equitable relief available to the parties, including interim equitable relief as set forth in the Optional Rules for Emergency Measures of Protection. Any award of the Arbitration may be enforced through proceedings in a court of competent jurisdiction.

(k) Governing Law. This Agreement shall be governed by the laws of the State of Michigan without giving effect to any choice or conflict of law principles of any jurisdiction.



[Signatures are on the Next Page]






IN WITNESS WHEREOF , the parties hereto have executed and delivered this Agreement as set forth below.
 
 
 
Date:
February 27, 2018
/s/ Robert S. Rathbun
 
 
Robert S.Rathbun
Executive Vice President
Retail & Regional President of the East Region
Chemical Bank
 
 
 
 
 
 
Date:
February 27, 2018
/s/ David T. Provost
 
 
David T. Provost
Chief Executive Officer and President
Chemical Financial Corporation
 
 
 
Date:
February 27, 2018
/s/ Thomas C. Shafer
 
 
Thomas C. Shafer
Chief Executive Officer and President
Chemical Bank








APPENDIX A

CHANGE IN CONTROL AGREEMENT RELEASE

THIS RELEASE AGREEMENT (the “Release”) is made as of the ____ day of _______, 20__, by and between Chemical Financial Corporation (“Chemical”), Chemical Bank (“Bank”) and __________ _. __________ (the “Executive”) (in the aggregate, the “Parties”).

WHEREAS , Chemical, the Bank and Executive have entered into a Change in Control Agreement dated as of February __, 2018 (the “Change in Control Agreement”), pursuant to which Executive is entitled to receive certain additional compensation upon termination of Executive’s employment with Chemical pursuant to a Change in Control (all as defined in the Change in Control Agreement); and

WHEREAS , Executive’s receipt of the additional compensation under the Change in Control Agreement is conditioned upon the execution of this Release that is mutually acceptable to the Parties; and

WHEREAS, Executive’s employment with Chemical and the Bank has been/shall be terminated effective ______________ __, 20__ [Without Cause] [due to Good Reason by the Executive];

NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed between the Parties as follows:

1.      Additional Compensation . Subject to the terms and conditions hereof, Chemical shall pay Executive the additional compensation set forth in Section 2 of the Change in Control Agreement, net of applicable withholding taxes, commencing after the expiration of the waiting period set forth herein and in accordance with the terms of the Change in Control Agreement.

2.      Release.

(a)    In exchange for the good and valuable consideration set forth herein, Executive agrees for himself, his heirs, administrators, representatives, executors, successors and assigns (“Releasors”), to irrevocably and unconditionally release, waive and forever discharge any and all manner of action, causes of action, claims, rights, promises, charges, suits, damages, debts, lawsuits, liabilities, rights, due controversies, charges, complaints, remedies, losses, demands, obligations, costs, expenses, fees (including, without limitation attorneys’ fees), or any and all other liabilities or claims of whatsoever nature, whether arising in contract, tort, or any other theory of action, whether arising in law or in equity, whether known or unknown, choate or inchoate, matured or unmatured, contingent or fixed, liquidated or unliquidated, accrued or unaccrued, asserted or unasserted, including, but not limited to, any claim and/or claim of damages or other relief for tort, breach of contract, personal injury, negligence, age discrimination under The Age Discrimination In Employment Act of 1967 (as amended), employment discrimination prohibited by other federal, state or local laws including sex, race, national origin, marital status, age, handicap, height, weight, or religious discrimination, and any other claims of unlawful employment practices or any other unlawful criterion or circumstance which Executive and Releasors had, now have, or may have in the future against each or any of Chemical, its parent, divisions, affiliates and related companies or entities, regardless of its or their form of business organization (the “Company Entities”), any predecessors, successors, joint ventures, and parents of any Company Entity, and any and all of their respective past or present directors, officers, shareholders, partners, employees, consultants, independent contractors, trustees, administrators, insurers, agents, attorneys, representative and fiduciaries, successors and assigns including without limitation all persons acting by, through, under or in concert with any of them (all collectively, the “Released Parties’) arising out of or relating to his employment relationship with Chemical, its predecessors, successors or affiliates and the termination thereof. Executive understands that he does not waive rights or claims that may arise after the date of this Release.

(b)    Executive acknowledges that he has read this Release carefully and understands all of its terms.

(c)    Executive understands and agrees that he has been advised to consult with an attorney prior to executing this Release.

(d)    Executive understands that he is entitled to consider this Release for at least [twenty-one (21)][forty-five (45)] days before signing the Release. However, after due deliberation, Executive may elect to sign this Release without availing himself of the opportunity to consider its provisions for at least [twenty-one (21)][forty-five (45)] days. Executive hereby acknowledges that any decision to shorten the time for considering this Release prior to signing it is voluntary, and such decision is not induced





by or through fraud, misrepresentation, or a threat to withdraw or alter the provisions set forth in this Release in the event Executive elected to consider this Release for at least [twenty-one (21)][forty-five (45)] days prior to signing the Release.

(e)    Executive understands that he may revoke this Release as it relates to any potential claim that could be brought or filed under the Age Discrimination in Employment Act 29 U.S.C. §§ 621-634, within seven (7) days after the date on which he signs this Release, and that this Release as it relates to such a claim does not become effective until the expiration of the seven (7) day period. In the event that Executive wishes to revoke this Release within the seven (7) day period, Executive understands that he must provide such revocation in writing to the then Chief Executive Officer at the address set forth below.

(f)    In agreeing to sign this Release, Executive is doing so voluntarily and agrees that he has not relied on any oral statements or explanations made by Chemical, the Bank or their representatives.

(g)    This Release shall not be construed as an admission of wrongdoing by either Executive, Chemical or the Bank.

3.      Notices . Every notice relating to this Release shall be in writing and if given by mail shall be given by registered or certified mail with return receipt requested. All notices to Chemical and the Bank shall be delivered to Chemical’s Chief Executive Officer at Chemical Financial Corporation, 2301 W. Big Beaver Rd, Troy, MI 48084. All notices by Chemical and the Bank to Executive shall be delivered to Executive personally or addressed to Executive at Executive’s last residence address as then contained in the records of Chemical, the Bank or such other address as Executive may designate. Either party by notice to the other may designate a different address to which notices shall be addressed. Any notice given by Chemical and the Bank to Executive at Executive’s last designated address shall be effective to bind any other person who shall acquire rights hereunder.

4.      Governing Law . To the extent not preempted by Federal law, this Release shall be governed by and construed in accordance with the laws of the State of Michigan, without giving effect to conflicts of laws.

5.      Counterparts . This Release may be executed in two (2) or more counterparts, all of which when taken together shall be considered one (1), and the same Release and shall become effective when the counterparts have been signed by each party and delivered to the other party; it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.

6.      Entire Agreement . This Release, when aggregated with the Change in Control Agreement and any applicable Equity Plans contains the entire understanding of the parties with respect to the subject matter hereof and together supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Release.

IN WITNESS WHEREOF, the parties hereto have executed this Release as of the day and year first written above.
 
 
 
Date:
 
 
 
 
Robert S.Rathbun
Executive Vice President
Retail & Regional President of the East Region
Chemical Bank
 
 
 
 
 
 
Date:
 
 
 
 
 
 
 
 
Date:
 
 
 
 
 








WAIVER OF [21][45] DAY NOTICE PERIOD

I have been provided with the General Release Agreement (“Agreement”) between Chemical Financial Corporation (collectively with the Bank and all of their affiliates, “Chemical”) and _________ __. __________ (“Executive”).

I understand that I have [twenty-one (21)][forty-five (45)] days from the date the Agreement was presented to me to consider whether or not to sign the Agreement. I further understand that I have the right to seek counsel prior to signing the Agreement.

I am knowingly and voluntarily signing and returning the Agreement prior to the expiration of the [twenty-one (21)-day][forty-five (45)-day] consideration period. I understand that I have seven (7) days from signing the Agreement to revoke the Agreement, by delivering a written notice of revocation to the Chief Executive Officer, Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084.

 
 
 
Date:
 
 
 
 
Robert S.Rathbun
Executive Vice President
Retail & Regional President of the East Region
Chemical Bank
 
 
 





Exhibit 10.25


EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement (the “ Agreement ”) is entered into as of February 27, 2018 (the “ Execution Date ”), by and between Chemical Financial Corporation (“ Chemical ”), and David T. Provost (the “ Executive ”).
Recitals
WHEREAS , Chemical desires to continue the employment of Executive in the positions of Chief Executive Officer, President and member of Chemical’s Board of Directors (the “ Board ”), and Executive desires to accept continuing employment in such positions, on the terms and conditions set forth in this Agreement; and
WHEREAS, Executive acknowledges and agrees that pursuant to his employment with Chemical, he has acquired and shall continue to acquire a considerable amount of knowledge and goodwill with respect to Chemical’s business that would be detrimental to Chemical if used by Executive to compete with Chemical and recognizes Chemical's need to protect its business interests through restrictive covenants;
NOW, THEREFORE , in consideration of the foregoing, the mutual agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1.
Employment; Term. Subject to the terms and conditions of this Agreement, Chemical hereby employs Executive under the terms of this Agreement, and Executive hereby accepts such employment terms for an initial two (2) year period commencing March 1, 2018 (the “ Effective Date ”) and ending February 29, 2020 (the “ Initial Term ”), unless sooner terminated as provided in Section 5 below. This Agreement automatically shall renew on each anniversary of the Effective Date for successive one (1) year periods, unless either party provides the other party with written notice of intention to terminate this Agreement (in accordance with Section 12(d)), at least thirty (30) days before an anniversary of the Effective Date, in which case the Agreement shall terminate at the end of the then-current Term, without any further extension; provided, however, that termination of this Agreement shall not affect the obligations of either party accrued before termination of the Agreement, including Executive’s obligations under Sections 6 through 12. The Initial Term and all renewals together shall constitute the “ Term ” of this Agreement.

2.
Position; Duties. Executive shall continue to serve as Chemical’s Chief Executive Officer, President and a member of the Board and shall perform such services for Chemical as are customarily associated with such positions and as otherwise may be assigned to Executive from time to time by Chemical’s Board, including positions with Chemical’s Affiliates as directed by the Board. Executive shall devote the majority of his business time to the affairs of Chemical and to his duties hereunder; provided, however, Executive may engage in civic and professional activities, service on boards of directors and similar activities, as long as such activities do not constitute a conflict of interest or impair Executive’s performance of services to Chemical. Executive shall perform his Chemical employment duties diligently and to the best of his ability, in compliance with Chemical’s policies and procedures, and the laws and regulations that apply to Chemical’s business. For purposes of this Agreement, “ Chemical ” includes Chemical Bank, unless the context clearly requires otherwise, and the term “ Affiliate ” means any organization controlling, controlled by or under common control with Chemical.

3.
Compensation and Benefits. As compensation for the services to be rendered by Executive under this Agreement, Chemical shall provide the following compensation and benefits during Executive’s employment Term:

(a)
Base Salary. Chemical shall pay Executive an annual base salary of one dollar ($1.00) (the “ Base Salary ”), which shall be paid on the first regular pay date after September 1 each year; provided, however, that effective July 1, 2018, Executive’s Base Salary shall be increased to nine hundred and fifty thousand dollars ($950,000), prorated for any partial year, subject to required payroll deductions and tax withholdings, payable in weekly, bi-weekly or semi-monthly installments in accordance with Chemical’s normal payroll practices. Executive’s Base Salary shall be reviewed from time to time by the Board (and no less often than annually) beginning in 2019 and may be increased in the sole discretion of the Compensation Committee of the Board (the “ Compensation Committee ”).

(b)
Bonus and Equity Programs. Executive shall be eligible to participate in Chemical’s annual bonus and equity programs for senior executives, based upon Executive’s and Chemical’s achievement of certain individual and corporate goals as established by Chemical’s Compensation Committee.






(c)
Paid Time Off . Executive shall receive thirty (30) days of paid time off per year, to be taken in the year earned, and which may not be accumulated or carried forward except as permitted by Chemical policy. Such paid time off shall be subject to review annually commencing in 2019. Executive’s days of paid time off per year shall be subject to adjustment pursuant to Chemical’s normal procedures.

(d)
Additional Stipend. Executive shall receive an annual taxable stipend to be used for health care payments or for any other purpose in the amount of $20,000, as may be adjusted from time to time, payable in accordance with Chemical’s normal payroll practices. The stipend shall terminate effective June 30, 2018.

(e)
Auto Allowance . Executive shall receive a monthly auto allowance of nine hundred dollars ($900.00), as may be adjusted from time to time, payable in accordance with Chemical’s normal payroll practices.

(f)
Club Dues . Executive shall be reimbursed for memberships in two (2) country clubs of his selection in accordance with Chemical’s standard reimbursement policies and procedures.

(g)
General Benefits. Executive shall be entitled to such other benefits, and to participate in such benefit plans, as are generally made available to similarly situated executives of Chemical from time to time, subject to Chemical’s policies, and the terms and conditions of any applicable benefit plans. Nothing in this Agreement shall be deemed to alter Chemical’s rights to modify or terminate any such plans or programs in its sole discretion.

(h)
Tax Withholdings. Chemical shall withhold from any amounts payable under this Agreement such federal, state and local taxes as Chemical determines are required to be withheld pursuant to applicable law.

4.
Reimbursement of Expenses. Chemical shall reimburse Executive for all reasonable ordinary and necessary business expenses incurred by Executive in connection with the performance of his duties hereunder, including but not limited to Executive’s fees and expenses for attendance at banking-related conventions and similar events, reasonable professional association and seminar expenses and other expenses authorized by Chemical, upon submission of proper documentation for tax and accounting purposes in compliance with Chemical’s reimbursement policies in effect from time to time. Such reimbursements shall be made promptly but in no event later than the last day of the calendar year following the calendar year in which an expense is incurred. For purposes of reimbursements subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “ Code ”), the amount of expenses eligible for reimbursement during one (1) year shall not affect the expenses eligible for reimbursement in any other year, and is not subject to liquidation or exchange for another benefit.

5.
Termination. Executive’s employment under this Agreement shall terminate as of the earliest Termination Date to occur. Executive’s “ Termination Date ” shall be as follows:

(a)
Death. Automatically effective upon Executive’s death.

(b)
Disability. By Chemical, effective upon written notice to Executive in the event of Executive’s permanent and total disability, as defined under Chemical’s long-term disability plan in effect at such time (“ Disability ”).

(c)
For Cause. By Chemical, effective upon written notice to Executive for Cause, unless otherwise specified in this Section 5(c). For purposes of this Agreement, “ Cause ” means: (i) Executive’s material breach of any provision in this Agreement; if the breach is curable, it shall constitute Cause only if it continues uncured for a period of twenty (20) days after Executive’s receipt of written notice of such breach by Chemical; (ii) Executive’s failure or refusal, in any material manner to perform all lawful services required of him in his employment position with Chemical, which failure or refusal continues for more than twenty (20) days after Executive’s receipt of written notice of such deficiency; (iii) Executive’s commission of fraud, embezzlement, theft, or a crime constituting moral turpitude, whether or not involving Chemical, which in the reasonable good faith judgment of the Board, renders Executive’s continued employment harmful to Chemical; (iv) Executive’s misappropriation of Chemical’s assets or property, including without limitation, obtaining material reimbursement through financial vouchers or expense reports; or (v) Executive’s conviction or the entry of a plea of guilty or no contest by Executive with respect to any felony or other crime which, in the reasonable good faith judgment of the Board, adversely affects Chemical, its reputation.

(d)
Without Cause. By Chemical, effective upon thirty (30) days’ written notice to Executive at any time for any reason other than for Cause or Executive’s Disability (“ Termination Without Cause ”). Chemical’s decision not to renew the Term of this Agreement also shall constitute a Termination Without Cause.






(e)
Resignation. By Executive, effective upon thirty (30) days’ written notice to Chemical at any time for any reason.

(f)
Good Reason . By Executive, in the event of Good Reason, as defined below. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following events without the written consent of Executive:

(i)
any material reduction in Executive’s base salary (if more than one dollar ($1.00) annually), as it may be adjusted from time to time

(ii)
any material reduction in the status, position or responsibilities of Executive, including Executive’s continuing services as a director on the Board;

(iii)
any requirement by Chemical (without Executive’s consent) that Executive be principally based at any office or location more than fifty (50) miles from Executive’s principal work location as of the effective date of this Agreement; or

(iv)
any material breach of this Agreement by Chemical.

Notwithstanding the foregoing, if Executive fails to give Chemical written notice of his intention to terminate employment with Chemical for Good Reason within ninety (90) days following Executive’s knowledge of any Good Reason event and a period of thirty (30) days in which Chemical may remedy the event alleged to constitute Good Reason, and if Executive has not Separated from Service (as defined herein) within sixty (60) days following expiration of Chemical’s cure period, the event shall not constitute Good Reason, and Executive shall have no right to terminate employment for Good Reason as a result of such event.
(g)
During any notice period under Sections 5(c), 5(d), or 5(e), Chemical may, in its sole discretion, relieve Executive of some or all of his duties during the notice period, but Chemical shall continue to provide Executive with his full salary, compensation, equity vesting, and benefits during such period.

6.
Effect of Termination.

(a)
Generally. When Executive’s employment with Chemical is terminated for any reason, Executive, or his estate, as the case may be, shall be entitled to receive the compensation and benefits earned through the applicable Termination Date, along with reimbursement for any approved business expenses that Executive has timely submitted for reimbursement in accordance with Chemical’s expense reimbursement policy or practice. In the event of employment termination due to death, Executive’s estate shall be entitled to rights to certain equity-based awards described in Section 6(b)(i)(C) below. Upon employment termination for any reason, Executive shall retain his rights to indemnification under the provisions of the Articles of Incorporation or Bylaws of Chemical, the Bank or any Affiliate.

(b)
Separation Benefits upon Certain Terminations.

(i)
Termination Without Cause.

(A)
Severance Pay . If Chemical terminates Executive’s employment pursuant to a Termination Without Cause, Executive shall be entitled to receive severance pay in the amount of two (2) times Executive’s then Base Salary (with Base Salary calculated as the higher of nine hundred and fifty thousand dollars ($950,000) or his actual Base Salary, disregarding any Base Salary reduction due to a Good Reason termination), plus two (2) times the average of Executive’s bonuses under Chemical’s annual executive incentive plan for each of the three (3) most recent complete calendar years of Executive’s employment with Chemical (including for such purpose, complete calendar years with Talmer Bank and Trust, if applicable), and with each bonus calculated as the higher of the actual bonus, or one million five hundred thousand dollars ($1,500,000) per year (the “ Severance Pay ”). The Severance Pay provided hereunder is conditioned upon Executive and Chemical executing a mutually agreeable release of claims, in substantially the form attached hereto as Appendix A (the “ Release ”), which is enforceable within sixty (60) days following Executive’s Termination Date. Unless specified otherwise herein and subject to any delayed payment due to Executive’s status as a “Specified Employee” under Code Section 409A as described more fully in Section 6(c) below, the Severance Pay shall be payable to Executive in equal installments over one hundred and four (104) weeks, in accordance with Chemical’s payroll practices and procedures, beginning on the first pay date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans two (2) calendar years, payments





shall commence on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may begin the payments earlier if such commencement does not violate Code Section 409A. If Executive requests that his Severance Pay be paid directly to one or more specified charities, Chemical agrees to comply with such request. Notwithstanding the foregoing, if Executive is entitled to receive the Severance Pay but violates any provisions of Sections 8 through 10 hereof after termination of employment, Chemical shall be entitled to immediately stop paying any further installments of the Severance Pay and shall have any other remedies, including claw back, that may be available to Chemical in law or at equity.

(B)
Health Coverage Payment . Chemical shall pay Executive a lump sum stipend equal to twenty-four (24) times Executive’s monthly contribution towards COBRA for employee and dependent health, prescription drug and dental coverage elections under Chemical’s employee benefit plans providing such benefits, minus the COBRA administrative cost (whether or not Executive elects COBRA), based on Executive’s elections in effect on Executive’s Termination Date, conditioned on Executive’s execution of the Release described herein that becomes irrevocable within sixty (60) days following Executive’s Termination Date, with the stipend payable on the first payroll date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the sixty (60) day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. If Executive is not enrolled in Chemical’s health, prescription drug and dental plans, the monthly contribution shall be based on Executive’s contributions towards family coverage for such plans, determined at Executive’s Termination Date. Although the payment under this paragraph is based on Chemical’s health, prescription drug and/or dental plans in effect on Executive’s Termination Date and is intended to fund payment for health coverage, the payment is not required to be used for health coverage, and Executive may use the payment for any purpose.

(C)
Equity-Based Awards . Effective upon expiration of the Release revocation period described in Section 6(b)(i)(A) above, all then outstanding equity-based awards granted to Executive prior to the Execution Date of this Agreement shall be administered in accordance with the terms of the applicable equity-based plan or grant agreements, and all equity-based awards granted to Executive on and after the Effective Date of this Agreement and outstanding as of his Termination Date shall be treated as follows: (i) all unvested stock options immediately shall vest, become exercisable and together with Executive’s other vested, unexercised stock options, remain exercisable until the earlier of their original term and three (3) years following Executive’s Termination Date; (ii) all outstanding time-based restricted stock units automatically shall vest and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; (iii) all performance-based stock units (“ PSU s”) shall vest at one hundred percent (100%) of the applicable target level and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; and (iv) any other equity-based awards shall vest in accordance with the terms of the applicable equity-based plan or grant agreement.

(D)
Golden Parachute Cap . Notwithstanding anything in this Section 6(b)(i) to the contrary, any payment or benefit to be provided to Executive, whether pursuant to this Agreement or otherwise, that is a “ Parachute Payment ” as defined in Code Section 280G(b)(2), shall be reduced to the extent necessary so that the benefits payable or to be provided to Executive under this Agreement that are Parachute Payments, as well as any Parachute Payments provided outside of this Agreement shall not cause Chemical or any Affiliate to have paid an “ Excess Parachute Payment ” as defined in Code Section 280G(b)(1). If it is established that an Excess Parachute Payment has occurred or shall occur under this Agreement or otherwise, any remaining Parachute Payments shall be reduced to ensure that the total payments to Executive do not exceed 2.99 times Executive’s “ Base Amount ” as defined in Code Section 280G(b)(3).

(ii)
Termination for Good Reason . Executive may terminate employment for Good Reason and receive the same benefits as Termination Without Cause, subject to the same Release and payment timing restrictions as a Termination Without Cause.

(iii)
Death . For avoidance of doubt, the termination of Executive’s employment as a result of his death shall not constitute a Termination Without Cause triggering the rights described in this Section 6(b); provided, however, that Executive’s outstanding equity-based awards shall be treated in accordance with Section 6(b)(i)(C) above, with Executive’s representative signing the Release on behalf of Executive’s estate, and





Executive’s equity-based awards being exercised by, or paid to, Executive’s personal representative or such other successor in interest to Executive, as applicable.

(c)
Application of Internal Revenue Code Section 409A.

(i)
All payments and benefits provided under this Agreement are intended to be exempt from, or in accordance with, Code Section 409A, and the Agreement is to be interpreted accordingly. Each installment payment is intended to constitute a separate benefit and terms such as “employment termination,” “termination from employment” or like terms are intended to constitute a Separation from Service, as defined below. To the extent exempt from Code Section 409A, payments are intended to be exempt under the short term deferral exemption or partially exempt under the involuntary separation pay plan exemption. Notwithstanding the forgoing, Chemical has no responsibility for any taxes, penalties or interest incurred by Executive in connection with payments and benefits provided under this Agreement, including any imposed by Code Section 409A.

(ii)
Despite other payment timing provisions in this Agreement, any payments and benefits provided under this Section 6 that constitute nonqualified deferred compensation that are subject to Code Section 409A, shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (a “ Separation from Service”). However, if Chemical determines that the Severance is subject to Code Section 409A, and Executive is a “ Specified Employee ” (as defined under Code Section 409A) at the time of Separation from Service, then, solely to the extent necessary to avoid adverse tax consequences to Executive under Code Section 409A, the timing of the Severance payments shall be delayed until the earlier to occur of: (i) the date that is six (6) months and one (1) day after Executive’s Separation from Service, or (ii) the date of Executive’s death (such applicable date, the “ Specified Employee Initial Payment Date ”), and Chemical (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Severance payments that Executive otherwise would have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance had not been so delayed pursuant to this Section, and (B) commence paying the balance of the Severance in accordance with the applicable payment schedules set forth in this Agreement.

(d)
No Further Obligations. Except as expressly provided above or as otherwise required by law, Chemical shall have no obligations to Executive in the event of the termination of this Agreement for any reason.

7.
Representations of Executive. Executive represents and warrants that he is not obligated or restricted under any agreement (including any non-competition or confidentiality agreement), judgment, decree, order or other restraint of any kind that could impair his ability to perform the duties and obligations required hereunder. Executive further agrees that he shall not divulge to Chemical any confidential information and/or trade secrets belonging to others, including Executive’s former employers, nor shall Chemical seek to elicit from Executive such information. Consistent with the foregoing, Executive shall not provide to Chemical, and Chemical shall not request, any documents or copies of documents containing such information.

8.
Confidential Information.

(a)
Executive acknowledges that Chemical has and shall give Executive access to certain highly-sensitive, confidential, and proprietary information belonging to Chemical, its Affiliates or third parties who may have furnished such information under obligations of confidentiality, relating to and used in Chemical’s Business (collectively, “ Confidential Information ”). Executive acknowledges that, unless otherwise available to the public, Confidential Information includes, but is not limited to, the following categories of confidential or proprietary information and material: financial statements and information; budgets, forecasts, and projections; business and strategic plans; marketing, sales, and distribution strategies; research and development projects; records relating to any intellectual property developed by, owned by, controlled, or maintained by Chemical or its Affiliates; information related to Chemical’s or its Affiliates’ inventions, research, products, designs, methods, formulae, techniques, systems, processes; customer lists; non-public information relating to Chemical’s or its Affiliates’ customers, suppliers, distributors, or investors; the specific terms of Chemical’s or its’ Affiliates’ agreements or arrangements, whether oral or written, with any customer, supplier, vendor, or contractor with which Chemical or its Affiliates may be associated from time to time; and any and all information relating to the operation of Chemical’s or its Affiliates’ business which Chemical or its Affiliates may from time to time designate as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by





Chemical or its Affiliates as confidential or proprietary. Confidential Information encompasses all formats in which information is preserved, whether electronic, print, or any other form, including all originals, copies, notes, or other reproductions or replicas thereof.

(b)
Confidential Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Executive or other violation of this Agreement; or (iii) is disclosed to Executive by a third party under no obligation to maintain the confidentiality of the information.

(c)
Executive acknowledges that Confidential Information owned or licensed by Chemical or its Affiliates is unique, valuable, proprietary and confidential; derives independent actual or potential commercial value from not being generally known or available to the public; and is subject to reasonable efforts to maintain its secrecy. Executive hereby relinquishes, and agrees that he shall not at any time claim, any right, title or interest of any kind in or to any Confidential Information.

(d)
During and after his employment with Chemical, Executive shall hold in trust and confidence all Confidential Information, and shall not disclose any Confidential Information to any person or entity, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical. Executive further agrees that during and after his employment with Chemical, Executive shall not use any Confidential Information for the benefit of any third party, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical.

(e)
The restrictions in Section 8(d) above shall not apply to any information to the extent that Executive is required to disclose such information by law, provided that Executive (i) notifies Chemical of the existence and terms of such obligation, (ii) gives Chemical a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure, and (iii) only discloses that information actually required to be disclosed.

(f)
Return of Property. Upon request by Chemical during employment and automatically and immediately at termination of his employment, Executive shall return to Chemical all Confidential Information in any form (including all copies and reproductions thereof) and all other property whatsoever of Chemical in his possession or under his control. If requested by Chemical, Executive shall certify in writing that all such materials have been returned to Chemical. Executive also expressly agrees that immediately upon the termination of his employment with Chemical for any reason, Executive shall cease using any secure website, computer systems, e-mail system, or phone system or voicemail service provided by Chemical for the use of its employees.

9.
Assignment of Inventions.

(a)
Executive agrees that all developments or inventions (including without limitation any and all software programs (source and object code), algorithms and applications, concepts, designs, discoveries, improvements, processes, techniques, know-how and data) that result from work performed by Executive for Chemical and its Affiliates, whether or not patentable or registrable under copyright or similar statutes or subject to analogous protection (“ Inventions ”), shall be the sole and exclusive property of Chemical or its nominees, and Executive shall and hereby does assign to Chemical all rights in and to such Inventions upon the creation of any such Invention, including, without limitation: (i) patents, patent applications and patent rights throughout the world; (ii) rights associated with works of authorship throughout the world, including copyrights, copyright applications, copyright registrations, mask work rights, mask work applications and mask work registrations; (iii) rights relating to the protection of trade secrets and confidential information throughout the world; (iv) rights analogous to those set forth herein and any other proprietary rights relating to intangible property; and (v) divisions, continuations, renewals, reissues and extensions of the foregoing (as applicable), now existing or hereafter filed, issued or acquired (collectively, the “ IP Rights ”).

(b)
For avoidance of doubt, if any Inventions fall within the definition of “work made for hire” as such term is defined in 17 U.S.C. § 101, such Inventions shall be considered “work made for hire” and the copyright of such Inventions shall be owned solely and exclusively by Chemical. If any Invention does not fall within such definition of “work made for hire” then Executive’s right, title and interest in and to such Inventions shall be assigned to Chemical pursuant to Section 9(a) above.

(c)
Chemical and its nominees shall have the right to use and/or to apply for statutory or common law protections for such Inventions in any and all countries. Executive further agrees, at Chemical’s expense, to: (i) reasonably





assist Chemical in obtaining and from time to time enforcing such IP Rights relating to Inventions, and (ii) execute and deliver to Chemical or its nominee upon reasonable request all such documents as Chemical or its nominee may reasonably determine are necessary or appropriate to effect the purposes of this Section 9, including assignments of inventions. Such documents may be necessary to: (1) vest in Chemical or its nominee clear and marketable title in and to Inventions; (2) apply for, prosecute and obtain patents, copyrights, mask works rights and other rights and protections relating to Inventions; or (3) enforce patents, copyrights, mask works rights and other rights and protections relating to Inventions. Executive’s obligations pursuant to this Section 9 shall continue beyond the termination of Executive’s employment with Chemical. If Chemical is unable for any reason to secure Executive’s signature to any lawful and necessary document required to apply for or execute any patent, trademark, copyright or other applications with respect to any Inventions (including renewals, extensions, continuations, divisions or continuations in part thereof), Executive hereby irrevocably designates and appoints Chemical and its then current Chairman of the Board as Executive’s agent and attorney-in-fact to act for and in behalf and instead of Executive, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents, trademarks, copyrights or other rights thereon with the same legal force and effect as if executed by Executive.

(d)
The obligations of Executive under Section 9(a) above shall not apply to any Invention that Executive developed entirely on his own time without using Chemical’s equipment, supplies, facility or trade secret information, except for those Inventions that (i) relate to Chemical’s business or actual or demonstrably anticipated research or development, or (ii) result from any work performed by Executive for Company. Executive shall bear the burden of proof in establishing the applicability of this subsection to a particular circumstance.

10.
Non-Competition and Non-Solicitation.

(a)
Purpose. Executive understands and agrees that the purpose of this Section 10 is solely to protect Chemical’s legitimate business interests, including, but not limited to its confidential and proprietary information, customer relationships and goodwill, and Chemical’s competitive advantage. Therefore, Executive agrees to be subject to restrictive covenants under the following terms.

(b)
Definitions. As used in this Agreement, the following terms have the meanings given to such terms below.

(i)
Business ” means the business(es) in which Chemical or its Affiliates were engaged in at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(ii)
Customer ” means any person or entity who is or was a customer, supplier or client of Chemical or its Affiliates with whom Executive had any contact or association for any reason and with whom Executive had dealings on behalf of Chemical or its Affiliates in the course of his employment with Chemical.

(iii)
Chemical Employee ” means any person who is or was an employee of Chemical or its Affiliates at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(iv)
Restricted Period ” means the period during Executive’s employment with Chemical and for twenty-four (24) months from and after Executive’s applicable Termination Date; provided, however, that this period shall be tolled and shall not run during any time Executive is in violation of this Section 10, it being the intent of the parties that the Restricted Period shall be extended for any period of time in which Executive is in violation of this Section 10.

(v)
Restricted Territory ” means Michigan or any other state in which Chemical or any Affiliate operates a banking, insurance or securities products and services institution at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(c)
Non-Competition. During the Restricted Period, Executive shall not in the Restricted Area, on his own behalf or on behalf of any other person:

(i)
assist or have an interest in (whether or not such interest is active), whether as partner, investor, stockholder, officer, director or as any type of principal whatever, any person, firm, partnership, association, corporation or business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in





the planning or development stage) that competes in any manner with the Business; provided, however, that Executive shall be permitted to make passive investments in the stock of any publicly traded business (including a competitive business), as long as the stock investment in any competitive business does not rise above five percent (5%) of the outstanding shares of such business; or

(ii)
enter into the employment of or act as an independent contractor or agent for or advisor or consultant to, any person, firm, partnership, association, corporation, business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business, or is a governmental regulator agency of the Business.

(d)
Non-Solicitation. During the Restricted Period, Executive shall not, directly or indirectly, on Executive’s own behalf or on behalf of any other party:

(i)
Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert, or encourage any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical or its Affiliates;

(ii)
Accept as a customer any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical or its Affiliates;

(iii)
Induce, encourage, or attempt to induce or encourage any Customer to purchase or accept products or services that are similar to or competitive with those offered by Chemical or its Affiliates from any person or entity (other than Chemical or its Affiliates ) engaging in the Business;

(iv)
Induce, encourage, or attempt to induce or encourage any Customer to reduce, limit, or cancel its business with Chemical or its Affiliates; or

(v)
Solicit, induce, or attempt to solicit or induce any Chemical Employee to terminate employment with Chemical or its Affiliates. Notwithstanding the foregoing, Executive may solicit a former employee of Chemical, who at the time of the solicitation had been involuntarily terminated by Chemical without cause, even if such former employee of Chemical was employed by Chemical at, or during the twelve (12) month period immediately prior to Executive’s Termination Date.

(e)
Reasonableness of Restrictions. Executive acknowledges and agrees that the restrictive covenants in this Agreement (i) are essential elements of Executive’s employment by Chemical and are reasonable given Executive’s access to Chemical’s and its Affiliates’ Confidential Information and the substantial knowledge and goodwilll Executive shall acquire with respect to the business of Chemical and its Affiliates as a result of his employment with Chemical, and the unique and extraordinary services to be provided by Executive to Chemical; and (ii) are reasonable in time, territory, and scope, and in all other respects.

(f)
Preserve Livelihood. Executive represents that his experience, capabilities and personal assets are such that this Agreement does not deprive him from either earning a livelihood in the unrestricted business activities which remain open to him or from otherwise adequately and appropriately supporting himself and his family.

(g)
Judicial Modification. Should any part or provision of this Section 10 be held invalid, void, or unenforceable in any court of competent jurisdiction, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement. The parties further agree that if any portion of this Section 10 is found to be invalid or unenforceable by a court of competent jurisdiction because its duration, territory, or other restrictions are deemed to be invalid or unreasonable in scope, the invalid or unreasonable terms shall be replaced by terms that such court deems valid and enforceable and that come closest to expressing the intention of such invalid or unenforceable terms.

11.
Enforcement. Executive acknowledges and agrees that Chemical shall suffer irreparable harm in the event that Executive breaches any of Executive’s obligations under Sections 8, 9, or 10 of this Agreement and that monetary damages would be inadequate to compensate Chemical for such breach. Accordingly, Executive agrees that, in the event of a breach by Executive of any of Executive’s obligations under Sections 8, 9, or 10 of this Agreement, Chemical shall be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief, and expedited discovery for the purpose of seeking relief, in order to prevent or to restrain any such breach. Chemical shall be entitled to recover its





costs incurred in connection with any action to enforce Sections 8, 9, or 10 of this Agreement, including reasonable attorneys’ fees and expenses.

12.
Miscellaneous.

(a)
Entire Agreement. This Agreement, when aggregated with the attached Release, as applicable, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements (whether written or oral and whether express or implied) between the parties to the extent related to such subject matter, including Executive’s employment agreements with Chemical dated January 25, 2016 and August 9, 2017.

(b)
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors, permitted assigns and, in the case of Executive, heirs, executors, and/or personal representatives. Chemical may freely assign or transfer this Agreement to an affiliated company or to a successor following a merger, consolidation, sale of assets or equity, or other business transaction. Executive may not assign, delegate or otherwise transfer any of Executive’s rights, interests or obligations in this Agreement.

(c)
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement.

(d)
Notices. Any notice pursuant to this Agreement must be in writing and shall be deemed effectively given to the other party on (i) the date it is actually delivered by overnight courier service (such as FedEx) or personal delivery of such notice in person, or (ii) three (3) days after mailing by certified or registered U.S. mail, return receipt requested; in each case the appropriate address shown below (or to such other address as a party may designate by notice to the other party):
        
If to Executive:            David T. Provost
                            
If to Chemical:            Chemical Financial Corporation                                            2301 West Big Beaver Road
Troy, MI 48084
Attention: Chairman of the Board
    
(e)
Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the amendment is in writing and signed by Chemical and Executive. No waiver of any provision of this Agreement shall be valid unless the waiver is in writing and signed by the waiving party. The failure of a party at any time to require performance of any provision of this Agreement shall not affect such party’s rights at a later time to enforce such provision. No waiver by a party of any breach of this Agreement shall be deemed to extend to any other breach hereunder or affect in any way any rights arising by virtue of any other breach.

(f)
Severability. Each provision of this Agreement is severable from every other provision of this Agreement. Any provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable shall not affect the validity or enforceability of any other provision. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable.

(g)
Construction. The section headings in this Agreement are inserted for convenience only and are not intended to affect the interpretation of this Agreement. Any reference in this Agreement to any “Section” refers to the corresponding Section of this Agreement. The word “including” in this Agreement means “including without limitation.” This Agreement shall be construed as if drafted jointly by Chemical and Executive and no presumption or burden of proof shall arise favoring or disfavoring Chemical or Executive by virtue of the authorship of any provision in this Agreement. All words in this Agreement shall be construed to be of such gender or number as the circumstances require.

(h)
Survival. The terms of Sections 6, 7, 8, 9, 10, 11 and 12 shall survive the termination of this Agreement for any reason.






(i)
Remedies Cumulative. The rights and remedies of the parties under this Agreement are cumulative (not alternative) and in addition to all other rights and remedies available to such parties at law, in equity, by contract or otherwise.

(j)
Venue. Executive and the Corporation agree that the exclusive forum for resolving any disputes between the parties related to Release Agreement shall be arbitration before the American Arbitration Association applying the Employment Arbitration Rules and Mediation Procedures as amended and effective November 1, 2009. The Arbitrator shall be empowered to grant any legal or equitable relief available to the parties, including interim equitable relief as set forth in the Optional Rules for Emergency Measures of Protection. Any award of the Arbitration may be enforced through proceedings in a court of competent jurisdiction.

(k)
Governing Law. This Agreement shall be governed by the laws of the State of Michigan without giving effect to any choice or conflict of law principles of any jurisdiction.


[Signatures are on the Next Page]






IN WITNESS WHEREOF , the parties hereto have executed and delivered this Agreement as of the date first written above.

 
 
 
Date:
February 27, 2018
/s/ David T. Provost
 
 
David T. Provost,
Executive
 
 
 
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
Date:
February 27, 2018
/s/ Thomas C. Shafer
 
 
Thomas C. Shafer
Vice Chairman of Chemical Financial Corporation
 
 
 




    





APPENDIX A
EMPLOYMENT AGREEMENT RELEASE
THIS RELEASE AGREEMENT (the “ Release ”) is made as of the ____ day of _______, 20__, by and between Chemical Financial Corporation (“ Chemical ”) and David T. Provost (the “ Executive ”) (in the aggregate, the “ Parties ”).
WHEREAS , Chemical and Executive have entered into an Employment Agreement dated as of February 27, 2018, (the “Employment Agreement”), pursuant to which Executive is entitled to receive certain additional compensation upon termination of Executive’s employment with Chemical Without Cause or for Good Reason (all as defined in the Employment Agreement); and
WHEREAS , Executive’s receipt of the additional compensation under the Employment Agreement is conditioned upon the execution of this Release that is mutually acceptable to both Parties; and
WHEREAS, Executive’s employment with Chemical has been/shall be terminated effective ______________ __, 20__ [Without Cause], [due to Good Reason by the Executive];
NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed between the Parties as follows:
1.      Additional Compensation . Subject to the terms and conditions hereof, Chemical shall pay Executive the additional compensation set forth in Section 6 of the Employment Agreement, net of applicable withholding taxes, commencing after the expiration of the waiting period set forth herein and in accordance with the terms of the Employment Agreement.
2.      Release.
(a)    In exchange for the good and valuable consideration set forth herein, Executive agrees for himself, his heirs, administrators, representatives, executors, successors and assigns (“Releasors”), to irrevocably and unconditionally release, waive and forever discharge any and all manner of action, causes of action, claims, rights, promises, charges, suits, damages, debts, lawsuits, liabilities, rights, due controversies, charges, complaints, remedies, losses, demands, obligations, costs, expenses, fees (including, without limitation attorneys’ fees), or any and all other liabilities or claims of whatsoever nature, whether arising in contract, tort, or any other theory of action, whether arising in law or in equity, whether known or unknown, choate or inchoate, matured or unmatured, contingent or fixed, liquidated or unliquidated, accrued or unaccrued, asserted or unasserted, including, but not limited to, any claim and/or claim of damages or other relief for tort, breach of contract, personal injury, negligence, age discrimination under The Age Discrimination In Employment Act of 1967 (as amended), employment discrimination prohibited by other federal, state or local laws including sex, race, national origin, marital status, age, handicap, height, weight, or religious discrimination, and any other claims of unlawful employment practices or any other unlawful criterion or circumstance which Executive and Releasors had, now have, or may have in the future against each or any of Chemical, its parent, divisions, affiliates and related companies or entities, regardless of its or their form of business organization (the “ Company Entities ”), any predecessors, successors, joint ventures, and parents of any Company Entity, and any and all of their respective past or present directors, officers, shareholders, partners, employees, consultants, independent contractors, trustees, administrators, insurers, agents, attorneys, representative and fiduciaries, successors and assigns including without limitation all persons acting by, through, under or in concert with any of them (all collectively, the “ Released Parties” ) arising out of or relating to his employment relationship with Chemical, its predecessors, successors or affiliates and the termination thereof; provided, however, that Executive expressly does not release his rights to indemnification under the provisions of the Articles of Incorporation or Bylaws of Chemical, the Bank or any indemnification agreement entered into between Executive and Chemical, the Bank or any Affiliates. Executive understands that he does not waive rights or claims that may arise after the date of this Release.
(b)    Executive acknowledges that he has read this Release carefully and understands all of its terms.
(c)    Executive understands and agrees that he has been advised to consult with an attorney prior to executing this Release.
(d)    Executive understands that he is entitled to consider this Release for at least twenty-one (21) days before signing the Release. However, after due deliberation, Executive may elect to sign this Release without availing himself of the opportunity to consider its provisions for at least twenty-one (21) days. Executive hereby acknowledges that any decision to shorten the time for considering this Release prior to signing it is voluntary, and such decision is not induced by or through fraud, misrepresentation,





or a threat to withdraw or alter the provisions set forth in this Release in the event Executive elected to consider this Release for at least twenty-one (21) days prior to signing the Release.
(e)    Executive understands that he may revoke this Release as it relates to any potential claim that could be brought or filed under the Age Discrimination in Employment Act 29 U.S.C. §§ 621-634, within seven (7) days after the date on which he signs this Release, and that this Release as it relates to such a claim does not become effective until the expiration of the seven (7) day period. In the event that Executive wishes to revoke this Release within the seven (7) day period, Executive understands that he must provide such revocation in writing to the then Chairman of the Board at Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084.
(f)    In agreeing to sign this Release, Executive is doing so voluntarily and agrees that he has not relied on any oral statements or explanations made by Chemical or its representatives.
(g)    This Release shall not be construed as an admission of wrongdoing by either Executive or Chemical.
3.      Notices . Every notice relating to this Release shall be in writing and if given by mail shall be given by registered or certified mail with return receipt requested. All notices to Chemical shall be delivered to the Chairman of the Board of Chemical at Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084. All notices by Chemical to Executive shall be delivered to Executive personally or addressed to Executive at Executive’s last residence address as then contained in the records of Chemical or such other address as Executive may designate. Either party by notice to the other may designate a different address to which notices shall be addressed. Any notice given by Chemical to Executive at Executive’s last designated address shall be effective to bind any other person who shall acquire rights hereunder.
4.      Governing Law . To the extent not preempted by Federal law, this Release shall be governed by and construed in accordance with the laws of the State of Michigan, without giving effect to conflicts of laws.
5.      Counterparts . This Release may be executed in two (2) or more counterparts, all of which when taken together shall be considered one (1), and the same Release and shall become effective when the counterparts have been signed by each party and delivered to the other party; it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.
6.      Entire Agreement . This Release, when aggregated with the Employment Agreement [Note: Add any other documents, as applicable], contains the entire understanding of the parties with respect to the subject matter hereof and together supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Release.
IN WITNESS WHEREOF, the parties hereto have executed this Release as of the day and year first written above.
 
 
 
 
 
 
 
 
David T. Provost,
Executive
 
 
 
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
 
 
 
 
By:
 
 
Its:
 






WAIVER OF 21 DAY NOTICE PERIOD
I have been provided with the General Release Agreement (“ Agreement ”) between Chemical Financial Corporation (collectively with all of its affiliates, the “Corporation”) and David T. Provost (“ Executive ”).
I understand that I have twenty-one (21) days from the date the Agreement was presented to me to consider whether or not to sign the Agreement. I further understand that I have the right to seek counsel prior to signing the Agreement.
I am knowingly and voluntarily signing and returning the Agreement prior to the expiration of the twenty-one (21)-day consideration period. I understand that I have seven (7) days from signing the Agreement to revoke the Agreement, by delivering a written notice of revocation to the Chairman of the Board, Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084.
 
 
 
Dated:
 
 
 
 
David T. Provost,
Executive
 
 
 
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
 
 
 
 
By:
 
 
Its:
 







Exhibit 10.26
PHILANTHROPY AGREEMENT
THIS AGREEMENT (the “ Agreement ”) between Chemical Financial Corporation (“ Chemical ” ) and David T. Provost (the “ Executive ”) is entered into as of February 27, 2018.
WHEREAS , Executive currently serves as Chemical’s Chief Executive Officer, President and member of Chemical’s Board of Directors (the “ Board ”); and
WHEREAS, Chemical recognizes Executive’s long and distinguished history of strong philanthropy to the community that Chemical serves; and
WHEREAS , in the event Executive’s employment with Chemical and services on Chemical’s Board are terminated and Executive receives a cash severance benefit in connection with his separation from service, Chemical desires to make the charitable contribution described below in recognition of Executive’s extraordinary philanthropy to the community;
NOW, THEREFORE , in consideration of the foregoing, Chemical agrees as follows:
If, Executive’s services to Chemical are involuntarily terminated Without Cause or for Good Reason, both as defined in the employment agreement between Chemical and Executive in effect at such time (the “ Employment Agreement ”), Chemical, in recognition of Executive’s voluntary generosity shown to the community over a long period of time, shall donate to the Community Foundation of Southeastern Michigan, a cash, lump sum payment within sixty (60) calendar days following Executive’s separation from service with Chemical (the “ Donation ”). The amount of such Donation shall equal the lesser of: (i) the total amount of any cash Severance Pay (as defined in the Employment Agreement) that Executive is entitled to receive under the Employment Agreement, and (ii) the dollar amount of his Severance Pay that Executive directs to be paid to the Community Foundation of Southeastern Michigan. Chemical and Executive agree that the Donation is not compensation to Executive for any services that Executive has provided to Chemical, is not due and would not otherwise have been paid to or at the direction of Executive, and Executive shall receive no economic benefit whatsoever as a result of the Donation.
This Agreement shall be binding upon any successor to Chemical. The Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same Agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement. No amendment of any provision of this Agreement shall be valid unless the amendment is in writing and signed by Chemical and Executive.
This Agreement is hereby executed as of the date set forth above.
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
 
By:
/s/ Thomas C. Shafer
 
 
Thomas C. Shafer
 
Its:
Vice Chairman of Chemical Financial Corporation
 
 
 
 
 
/s/ David T. Provost
 
 
David T. Provost, Executive
 
 
 





Exhibit 10.27

EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement (the “ Agreement ”) is entered into as of February 27, 2018 (the “ Execution Date ”), by and between Chemical Financial Corporation (“ Chemical ”), and Gary Torgow (the “ Executive ”).
Recitals
WHEREAS , Chemical desires to continue the employment of Executive in the position of Executive Chairman of the Board of Directors of Chemical (the “ Board ”), and Executive desires to accept continuing employment in such position, on the terms and conditions set forth in this Agreement; and
WHEREAS, Executive acknowledges and agrees that pursuant to his employment with Chemical he has acquired and shall continue to acquire a considerable amount of knowledge and goodwill with respect to Chemical’s business that would be detrimental to Chemical if used by Executive to compete with Chemical and recognizes Chemical's need to protect its business interests through restrictive covenants;
NOW, THEREFORE , in consideration of the foregoing, the mutual agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1.
Employment; Term. Subject to the terms and conditions of this Agreement, Chemical hereby employs Executive under the terms of this Agreement, and Executive hereby accepts such employment terms for an initial two (2) year period commencing March 1, 2018 (the “ Effective Date ”) and ending February 29, 2020 (the “ Initial Term ”), unless sooner terminated as provided in Section 5 below. This Agreement automatically shall renew on each anniversary of the Effective Date for successive one (1) year periods, unless either party provides the other party with written notice of intention to terminate this Agreement (in accordance with Section 12(d)), at least thirty (30) days before an anniversary of the Effective Date, in which case the Agreement shall terminate at the end of the then-current Term, without any further extension; provided, however, that termination of this Agreement shall not affect the obligations of either party accrued before termination of the Agreement, including Executive’s obligations under Sections 6 through 12. The Initial Term and all renewals together shall constitute the “ Term ” of this Agreement.

2.
Position; Duties. Executive shall continue to serve as Chemical’s Executive Chairman of the Board and shall perform such services for Chemical as are customarily associated with such position and as otherwise may be assigned to Executive from time to time by Chemical’s Board. Executive shall devote the majority of his business time to the affairs of Chemical and to his duties hereunder; provided, however, Executive may engage in civic and professional activities, service on boards of directors and similar activities, as long as such activities do not constitute a conflict of interest or impair Executive’s performance of services to Chemical. Executive shall perform his Chemical employment duties diligently and to the best of his ability, in compliance with Chemical’s policies and procedures, and the laws and regulations that apply to Chemical’s business. For purposes of this Agreement, “ Chemical ” includes Chemical Bank, unless the context clearly requires otherwise, and the term “ Affiliate ” means any organization controlling, controlled by or under common control with Chemical.

3.
Compensation and Benefits. As compensation for the services to be rendered by Executive under this Agreement, Chemical shall provide the following compensation and benefits during Executive’s employment Term:

(a) Base Salary. Chemical shall pay Executive an annual base salary of one dollar ($1.00) (the “ Base Salary ”), which shall be paid on the first regular pay date after September 1 each year; provided, however, that effective July 1, 2018, Executive’s Base Salary shall be increased to nine hundred and fifty thousand dollars ($950,000), prorated for any partial year, subject to required payroll deductions and tax withholdings, payable in weekly, bi-weekly or semi-monthly installments in accordance with Chemical’s normal payroll practices. Executive’s Base Salary shall be reviewed from time to time by the Board (and no less often than annually) beginning in 2019 and may be increased in the sole discretion of the Compensation Committee of the Board (the “ Compensation Committee ”).

(b) Bonus and Equity Programs. Executive shall be eligible to participate in Chemical’s annual bonus and equity programs for senior executives, based upon Executive’s and Chemical’s achievement of certain individual and corporate goals as established by Chemical’s Compensation Committee.






(c) Paid Time Off . Executive shall receive thirty (30) days of paid time off per year, to be taken in the year earned, and which may not be accumulated or carried forward except as permitted by Chemical policy. Such paid time off shall be subject to review annually commencing in 2019. Executive’s days of paid time off per year shall be subject to adjustment pursuant to Chemical’s normal procedures.

(d) Additional Stipend. Executive shall receive an annual taxable stipend to be used for health care payments or for any other purpose in the amount of $20,000, as may be adjusted from time to time, payable in accordance with Chemical’s normal payroll practices. The stipend shall terminate effective June 30, 2018.

(e) Auto Allowance . Executive shall receive a monthly auto allowance of nine hundred dollars ($900.00), as may be adjusted from time to time, payable in accordance with Chemical’s normal payroll practices.

(f) Club Dues . Executive shall be reimbursed for memberships in two (2) country clubs of his selection in accordance with Chemical’s standard reimbursement policies and procedures.

(g) General Benefits. Executive shall be entitled to such other benefits, and to participate in such benefit plans, as are generally made available to similarly situated executives of Chemical from time to time, subject to Chemical’s policies, and the terms and conditions of any applicable benefit plans. Nothing in this Agreement shall be deemed to alter Chemical’s rights to modify or terminate any such plans or programs in its sole discretion.

(h) Tax Withholdings. Chemical shall withhold from any amounts payable under this Agreement such federal, state and local taxes as Chemical determines are required to be withheld pursuant to applicable law.

4.
Reimbursement of Expenses. Chemical shall reimburse Executive for all reasonable ordinary and necessary business expenses incurred by Executive in connection with the performance of his duties hereunder, including but not limited to Executive’s fees and expenses for attendance at banking-related conventions and similar events, reasonable professional association and seminar expenses and other expenses authorized by Chemical, upon submission of proper documentation for tax and accounting purposes in compliance with Chemical’s reimbursement policies in effect from time to time. Such reimbursements shall be made promptly but in no event later than the last day of the calendar year following the calendar year in which an expense is incurred. For purposes of reimbursements subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “ Code ”), the amount of expenses eligible for reimbursement during one (1) year shall not affect the expenses eligible for reimbursement in any other year, and is not subject to liquidation or exchange for another benefit.

5.
Termination. Executive’s employment under this Agreement shall terminate as of the earliest Termination Date to occur. Executive’s “ Termination Date ” shall be as follows:

(a) Death. Automatically effective upon Executive’s death.

(b) Disability. By Chemical, effective upon written notice to Executive in the event of Executive’s permanent and total disability, as defined under Chemical’s long-term disability plan in effect at such time (“ Disability ”).

(c) For Cause. By Chemical, effective upon written notice to Executive for Cause, unless otherwise specified in this Section 5(c). For purposes of this Agreement, “ Cause ” means: (i) Executive’s material breach of any provision in this Agreement; if the breach is curable, it shall constitute Cause only if it continues uncured for a period of twenty (20) days after Executive’s receipt of written notice of such breach by Chemical; (ii) Executive’s failure or refusal, in any material manner to perform all lawful services required of him in his employment position with Chemical, which failure or refusal continues for more than twenty (20) days after Executive’s receipt of written notice of such deficiency; (iii) Executive’s commission of fraud, embezzlement, theft, or a crime constituting moral turpitude, whether or not involving Chemical, which in the reasonable good faith judgment of the Board, renders Executive’s continued employment harmful to Chemical; (iv) Executive’s misappropriation of Chemical’s assets or property, including without limitation, obtaining material reimbursement through financial vouchers or expense reports; or (v) Executive’s conviction or the entry of a plea of guilty or no contest by Executive with respect to any felony or other crime which, in the reasonable good faith judgment of the Board, adversely affects Chemical, its reputation.

(d) Without Cause. By Chemical, effective upon thirty (30) days’ written notice to Executive at any time for any reason other than for Cause or Executive’s Disability (“ Termination Without Cause ”). Chemical’s decision not to renew the Term of this Agreement also shall constitute a Termination Without Cause.






(e) Resignation. By Executive, effective upon thirty (30) days’ written notice to Chemical at any time for any reason.

(f) Good Reason . By Executive, in the event of Good Reason, as defined below. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following events without the written consent of Executive:

(i) any material reduction in Executive’s base salary (if more than one dollar ($1.00) annually), as it may be adjusted from time to time;

(ii) any material reduction in the status, position or responsibilities of Executive, including Executive’s continuing services as Executive Chairman of the Board;

(iii) any requirement by Chemical (without Executive’s consent) that Executive be principally based at any office or location more than fifty (50) miles from Executive’s principal work location as of the effective date of this Agreement; or

(iv) any material breach of this Agreement by Chemical.

Notwithstanding the foregoing, if Executive fails to give Chemical written notice of his intention to terminate employment with Chemical for Good Reason within ninety (90) days following Executive’s knowledge of any Good Reason event and a period of thirty (30) days in which Chemical may remedy the event alleged to constitute Good Reason, and if Executive has not Separated from Service (as defined herein) within sixty (60) days following expiration of Chemical’s cure period, the event shall not constitute Good Reason, and Executive shall have no right to terminate employment for Good Reason as a result of such event.
(g) During any notice period under Sections 5(c), 5(d), or 5(e), Chemical may, in its sole discretion, relieve Executive of some or all of his duties during the notice period, but Chemical shall continue to provide Executive with his full salary, compensation, equity vesting, and benefits during such period.

6.
Effect of Termination.

(a) Generally. When Executive’s employment with Chemical is terminated for any reason, Executive, or his estate, as the case may be, shall be entitled to receive the compensation and benefits earned through the applicable Termination Date, along with reimbursement for any approved business expenses that Executive has timely submitted for reimbursement in accordance with Chemical’s expense reimbursement policy or practice. In the event of employment termination due to death, Executive’s estate shall be entitled to rights to certain equity-based awards described in Section 6(b)(i)(C) below. Upon employment termination for any reason, Executive shall retain his rights to indemnification under the provisions of the Articles of Incorporation or Bylaws of Chemical, the Bank or any Affiliate.

(b) Separation Benefits upon Certain Terminations.

(i) Termination Without Cause.

(A) Severance Pay . If Chemical terminates Executive’s employment pursuant to a Termination Without Cause, Executive shall be entitled to receive severance pay in the amount of two (2) times Executive’s then Base Salary (with Base Salary calculated as the higher of nine hundred and fifty thousand dollars ($950,000) or his actual Base Salary, disregarding any Base Salary reduction due to a Good Reason termination), plus two (2) times the average of Executive’s bonuses under Chemical’s annual executive incentive plan for each of the three (3) most recent complete calendar years of Executive’s employment with Chemical (including for such purpose, complete calendar years with Talmer Bank and Trust, if applicable), and with each bonus calculated as the higher of the actual bonus, or one million five hundred thousand dollars ($1,500,000) per year (the “ Severance Pay ”). The Severance Pay provided hereunder is conditioned upon Executive and Chemical executing a mutually agreeable release of claims, in substantially the form attached hereto as Appendix A (the “ Release ”), which is enforceable within sixty (60) days following Executive’s Termination Date. Unless specified otherwise herein and subject to any delayed payment due to Executive’s status as a “Specified Employee” under Code Section 409A as described more fully in Section 6(c) below, the Severance Pay shall be payable to Executive in equal installments over one hundred and four (104) weeks, in accordance with Chemical’s payroll practices and procedures, beginning on the first pay date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the 60-day period spans





two (2) calendar years, payments shall commence on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may begin the payments earlier if such commencement does not violate Code Section 409A. If Executive requests that his Severance Pay be paid directly to one or more specified charities, Chemical agrees to comply with such request. Notwithstanding the foregoing, if Executive is entitled to receive the Severance Pay but violates any provisions of Sections 8 through 10 hereof after termination of employment, Chemical shall be entitled to immediately stop paying any further installments of the Severance Pay and shall have any other remedies, including claw back, that may be available to Chemical in law or at equity.

(B) Health Coverage Payment . Chemical shall pay Executive a lump sum stipend equal to twenty-four (24) times Executive’s monthly contribution towards COBRA for employee and dependent health, prescription drug and dental coverage elections under Chemical’s employee benefit plans providing such benefits, minus the COBRA administrative cost (whether or not Executive elects COBRA), based on Executive’s elections in effect on Executive’s Termination Date, conditioned on Executive’s execution of the Release described herein that becomes irrevocable within sixty (60) days following Executive’s Termination Date, with the stipend payable on the first payroll date after sixty (60) days have lapsed following Executive’s Separation from Service, provided that if the sixty (60) day period spans two (2) calendar years, the payment shall be made on the first pay date in the second calendar year and provided further that Chemical, in its sole discretion, may make the payment earlier if such commencement does not violate Code Section 409A. If Executive is not enrolled in Chemical’s health, prescription drug and dental plans, the monthly contribution shall be based on Executive’s contributions towards family coverage for such plans determined at Executive’s Termination Date. Although the payment under this paragraph is based on Chemical’s health, prescription drug and/or dental plans in effect on Executive’s Termination Date and is intended to fund payment for health coverage, the payment is not required to be used for health coverage, and Executive may use the payment for any purpose.

(C) Equity-Based Awards . Effective upon expiration of the Release revocation period described in Section 6(b)(i)(A) above, all then outstanding equity-based awards granted to Executive prior to the Execution Date of this Agreement shall be administered in accordance with the terms of the applicable equity-based plan or grant agreements, and all equity-based awards granted to Executive on and after the Effective Date of this Agreement and outstanding as of his Termination Date shall be treated as follows: (i) all unvested stock options immediately shall vest, become exercisable and together with Executive’s other vested, unexercised stock options, remain exercisable until the earlier of their original term and three (3) years following Executive’s Termination Date; (ii) all outstanding time-based restricted stock units automatically shall vest and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; (iii) all performance-based stock units (“ PSUs ”) shall vest at one hundred percent (100%) of the applicable target level and be convertible into Chemical’s Common Stock, with settlement to occur within seven (7) days thereafter; and (iv) any other equity-based awards shall vest in accordance with the terms of the applicable equity-based plan or grant agreement.

(D) Golden Parachute Cap . Notwithstanding anything in this Section 6(b)(i) to the contrary, any payment or benefit to be provided to Executive, whether pursuant to this Agreement or otherwise, that is a “ Parachute Payment ” as defined in Code Section 280G(b)(2), shall be reduced to the extent necessary so that the benefits payable or to be provided to Executive under this Agreement that are Parachute Payments, as well as any Parachute Payments provided outside of this Agreement shall not cause Chemical or any Affiliate to have paid an “ Excess Parachute Payment ” as defined in Code Section 280G(b)(1). If it is established that an Excess Parachute Payment has occurred or shall occur under this Agreement or otherwise, any remaining Parachute Payments shall be reduced to ensure that the total payments to Executive do not exceed 2.99 times Executive’s “ Base Amount ” as defined in Code Section 280G(b)(3).

(ii) Termination for Good Reason . Executive may terminate employment for Good Reason and receive the same benefits as Termination Without Cause, subject to the same Release and payment timing restrictions as a Termination Without Cause.

(iii) Death . For avoidance of doubt, the termination of Executive’s employment as a result of his death shall not constitute a Termination Without Cause triggering the rights described in this Section 6(b); provided,





however, that Executive’s outstanding equity-based awards shall be treated in accordance with Section 6(b)(i)(C) above, with Executive’s representative signing the Release on behalf of Executive’s estate, and Executive’s equity-based awards being exercised by, or paid to, Executive’s personal representative or such other successor in interest to Executive, as applicable.

(c) Application of Internal Revenue Code Section 409A.

(i) All payments and benefits provided under this Agreement are intended to be exempt from, or in accordance with, Code Section 409A, and the Agreement is to be interpreted accordingly. Each installment payment is intended to constitute a separate benefit and terms such as “employment termination,” “termination from employment” or like terms are intended to constitute a Separation from Service, as defined below. To the extent exempt from Code Section 409A, payments are intended to be exempt under the short term deferral exemption or partially exempt under the involuntary separation pay plan exemption. Notwithstanding the forgoing, Chemical has no responsibility for any taxes, penalties or interest incurred by Executive in connection with payments and benefits provided under this Agreement, including any imposed by Code Section 409A.

(ii) Despite other payment timing provisions in this Agreement, any payments and benefits provided under this Section 6 that constitute nonqualified deferred compensation that are subject to Code Section 409A, shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (a “ Separation from Service”). However, if Chemical determines that the Severance is subject to Code Section 409A, and Executive is a “ Specified Employee ” (as defined under Code Section 409A) at the time of Separation from Service, then, solely to the extent necessary to avoid adverse tax consequences to Executive under Code Section 409A, the timing of the Severance payments shall be delayed until the earlier to occur of: (i) the date that is six (6) months and one (1) day after Executive’s Separation from Service, or (ii) the date of Executive’s death (such applicable date, the “ Specified Employee Initial Payment Date ”), and Chemical (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Severance payments that Executive otherwise would have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance had not been so delayed pursuant to this Section, and (B) commence paying the balance of the Severance in accordance with the applicable payment schedules set forth in this Agreement.

(d) No Further Obligations. Except as expressly provided above or as otherwise required by law, Chemical shall have no obligations to Executive in the event of the termination of this Agreement for any reason.

7.
Representations of Executive. Executive represents and warrants that he is not obligated or restricted under any agreement (including any non-competition or confidentiality agreement), judgment, decree, order or other restraint of any kind that could impair his ability to perform the duties and obligations required hereunder. Executive further agrees that he shall not divulge to Chemical any confidential information and/or trade secrets belonging to others, including Executive’s former employers, nor shall Chemical seek to elicit from Executive such information. Consistent with the foregoing, Executive shall not provide to Chemical, and Chemical shall not request, any documents or copies of documents containing such information.

8.
Confidential Information.

(a) Executive acknowledges that Chemical has and shall give Executive access to certain highly-sensitive, confidential, and proprietary information belonging to Chemical, its Affiliates or third parties who may have furnished such information under obligations of confidentiality, relating to and used in Chemical’s Business (collectively, “ Confidential Information ”). Executive acknowledges that, unless otherwise available to the public, Confidential Information includes, but is not limited to, the following categories of confidential or proprietary information and material: financial statements and information; budgets, forecasts, and projections; business and strategic plans; marketing, sales, and distribution strategies; research and development projects; records relating to any intellectual property developed by, owned by, controlled, or maintained by Chemical or its Affiliates; information related to Chemical’s or its Affiliates’ inventions, research, products, designs, methods, formulae, techniques, systems, processes; customer lists; non-public information relating to Chemical’s or its Affiliates’ customers, suppliers, distributors, or investors; the specific terms of Chemical’s or its’ Affiliates’ agreements or arrangements, whether oral or written, with any customer, supplier, vendor, or contractor with which Chemical or its Affiliates may be associated from time to time; and any and all information relating to the operation of Chemical’s or its Affiliates’ business which Chemical or its Affiliates may from time to time designate as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by Chemical





or its Affiliates as confidential or proprietary. Confidential Information encompasses all formats in which information is preserved, whether electronic, print, or any other form, including all originals, copies, notes, or other reproductions or replicas thereof.

(b) Confidential Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Executive or other violation of this Agreement; or (iii) is disclosed to Executive by a third party under no obligation to maintain the confidentiality of the information.

(c) Executive acknowledges that Confidential Information owned or licensed by Chemical or its Affiliates is unique, valuable, proprietary and confidential; derives independent actual or potential commercial value from not being generally known or available to the public; and is subject to reasonable efforts to maintain its secrecy. Executive hereby relinquishes, and agrees that he shall not at any time claim, any right, title or interest of any kind in or to any Confidential Information.

(d) During and after his employment with Chemical, Executive shall hold in trust and confidence all Confidential Information, and shall not disclose any Confidential Information to any person or entity, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical. Executive further agrees that during and after his employment with Chemical, Executive shall not use any Confidential Information for the benefit of any third party, except in the course of performing duties assigned by Chemical or as authorized in writing by Chemical.

(e) The restrictions in Section 8(d) above shall not apply to any information to the extent that Executive is required to disclose such information by law, provided that Executive (i) notifies Chemical of the existence and terms of such obligation, (ii) gives Chemical a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure, and (iii) only discloses that information actually required to be disclosed.

(f) Return of Property. Upon request by Chemical during employment and automatically and immediately at termination of his employment, Executive shall return to Chemical all Confidential Information in any form (including all copies and reproductions thereof) and all other property whatsoever of Chemical in his possession or under his control. If requested by Chemical, Executive shall certify in writing that all such materials have been returned to Chemical. Executive also expressly agrees that immediately upon the termination of his employment with Chemical for any reason, Executive shall cease using any secure website, computer systems, e-mail system, or phone system or voicemail service provided by Chemical for the use of its employees.

9.
Assignment of Inventions.

(a) Executive agrees that all developments or inventions (including without limitation any and all software programs (source and object code), algorithms and applications, concepts, designs, discoveries, improvements, processes, techniques, know-how and data) that result from work performed by Executive for Chemical and its Affiliates, whether or not patentable or registrable under copyright or similar statutes or subject to analogous protection (“ Inventions ”), shall be the sole and exclusive property of Chemical or its nominees, and Executive shall and hereby does assign to Chemical all rights in and to such Inventions upon the creation of any such Invention, including, without limitation: (i) patents, patent applications and patent rights throughout the world; (ii) rights associated with works of authorship throughout the world, including copyrights, copyright applications, copyright registrations, mask work rights, mask work applications and mask work registrations; (iii) rights relating to the protection of trade secrets and confidential information throughout the world; (iv) rights analogous to those set forth herein and any other proprietary rights relating to intangible property; and (v) divisions, continuations, renewals, reissues and extensions of the foregoing (as applicable), now existing or hereafter filed, issued or acquired (collectively, the “ IP Rights ”).

(b) For avoidance of doubt, if any Inventions fall within the definition of “work made for hire” as such term is defined in 17 U.S.C. § 101, such Inventions shall be considered “work made for hire” and the copyright of such Inventions shall be owned solely and exclusively by Chemical. If any Invention does not fall within such definition of “work made for hire” then Executive’s right, title and interest in and to such Inventions shall be assigned to Chemical pursuant to Section 9(a) above.
(c) Chemical and its nominees shall have the right to use and/or to apply for statutory or common law protections for such Inventions in any and all countries. Executive further agrees, at Chemical’s expense, to: (i) reasonably assist Chemical in obtaining and from time to time enforcing such IP Rights relating to Inventions, and (ii) execute and deliver to Chemical or its nominee upon reasonable request all such documents as Chemical or its nominee may reasonably determine are necessary or appropriate to effect the purposes of this Section 9, including assignments of inventions. Such documents may be necessary to: (1) vest in Chemical or its nominee clear and marketable title in and to Inventions; (2)





apply for, prosecute and obtain patents, copyrights, mask works rights and other rights and protections relating to Inventions; or (3) enforce patents, copyrights, mask works rights and other rights and protections relating to Inventions. Executive’s obligations pursuant to this Section 9 shall continue beyond the termination of Executive’s employment with Chemical. If Chemical is unable for any reason to secure Executive’s signature to any lawful and necessary document required to apply for or execute any patent, trademark, copyright or other applications with respect to any Inventions (including renewals, extensions, continuations, divisions or continuations in part thereof), Executive hereby irrevocably designates and appoints Chemical and its then current Chief Executive Officer as Executive’s agent and attorney-in-fact to act for and in behalf and instead of Executive, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents, trademarks, copyrights or other rights thereon with the same legal force and effect as if executed by Executive.

(d) The obligations of Executive under Section 9(a) above shall not apply to any Invention that Executive developed entirely on his own time without using Chemical’s equipment, supplies, facility or trade secret information, except for those Inventions that (i) relate to Chemical’s business or actual or demonstrably anticipated research or development, or (ii) result from any work performed by Executive for Company. Executive shall bear the burden of proof in establishing the applicability of this subsection to a particular circumstance.

10.
Non-Competition and Non-Solicitation.

(a) Purpose. Executive understands and agrees that the purpose of this Section 10 is solely to protect Chemical’s legitimate business interests, including, but not limited to its confidential and proprietary information, customer relationships and goodwill, and Chemical’s competitive advantage. Therefore, Executive agrees to be subject to restrictive covenants under the following terms.

(b) Definitions. As used in this Agreement, the following terms have the meanings given to such terms below.

(i) Business ” means the business(es) in which Chemical or its Affiliates were engaged in at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(ii) Customer ” means any person or entity who is or was a customer, supplier or client of Chemical or its Affiliates with whom Executive had any contact or association for any reason and with whom Executive had dealings on behalf of Chemical or its Affiliates in the course of his employment with Chemical.

(iii) Chemical Employee ” means any person who is or was an employee of Chemical or its Affiliates at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(iv) Restricted Period ” means the period during Executive’s employment with Chemical and for twenty-four (24) months from and after Executive’s applicable Termination Date; provided, however, that this period shall be tolled and shall not run during any time Executive is in violation of this Section 10, it being the intent of the parties that the Restricted Period shall be extended for any period of time in which Executive is in violation of this Section 10.

(v) Restricted Territory ” means Michigan or any other state in which Chemical or any Affiliate operates a banking, insurance or securities products and services institution at the time of, or during the twelve (12) month period prior to, the applicable Termination Date.

(c) Non-Competition. During the Restricted Period, Executive shall not in the Restricted Area, on his own behalf or on behalf of any other person:

(i) assist or have an interest in (whether or not such interest is active), whether as partner, investor, stockholder, officer, director or as any type of principal whatever, any person, firm, partnership, association, corporation or business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business; provided, however, that Executive shall be permitted to make passive investments in the stock of any publicly traded business (including a competitive business), as long as the stock investment in any competitive business does not rise above five percent (5%) of the outstanding shares of such business; or






(ii) enter into the employment of or act as an independent contractor or agent for or advisor or consultant to, any person, firm, partnership, association, corporation, business organization, entity or enterprise that is or is about to become directly or indirectly engaged in, any business or activity (whether such enterprise is in operation or in the planning or development stage) that competes in any manner with the Business, or is a governmental regulator agency of the Business.

(d) Non-Solicitation. During the Restricted Period, Executive shall not, directly or indirectly, on Executive’s own behalf or on behalf of any other party:

(i) Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert, or encourage any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical or its Affiliates;

(ii) Accept as a customer any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by Chemical or its Affiliates;

(iii) Induce, encourage, or attempt to induce or encourage any Customer to purchase or accept products or services that are similar to or competitive with those offered by Chemical or its Affiliates from any person or entity (other than Chemical or its Affiliates ) engaging in the Business;

(iv) Induce, encourage, or attempt to induce or encourage any Customer to reduce, limit, or cancel its business with Chemical or its Affiliates; or

(v) Solicit, induce, or attempt to solicit or induce any Chemical Employee to terminate employment with Chemical or its Affiliates. Notwithstanding the foregoing, Executive may solicit a former employee of Chemical, who at the time of the solicitation had been involuntarily terminated by Chemical without cause, even if such former employee of Chemical was employed by Chemical at, or during the twelve (12) month period immediately prior to Executive’s Termination Date.

(e) Reasonableness of Restrictions. Executive acknowledges and agrees that the restrictive covenants in this Agreement (i) are essential elements of Executive’s employment by Chemical and are reasonable given Executive’s access to Chemical’s and its Affiliates’ Confidential Information and the substantial knowledge and goodwilll Executive shall acquire with respect to the business of Chemical and its Affiliates as a result of his employment with Chemical, and the unique and extraordinary services to be provided by Executive to Chemical; and (ii) are reasonable in time, territory, and scope, and in all other respects.

(f) Preserve Livelihood. Executive represents that his experience, capabilities and personal assets are such that this Agreement does not deprive him from either earning a livelihood in the unrestricted business activities which remain open to him or from otherwise adequately and appropriately supporting himself and his family.

(g) Judicial Modification. Should any part or provision of this Section 10 be held invalid, void, or unenforceable in any court of competent jurisdiction, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement. The parties further agree that if any portion of this Section 10 is found to be invalid or unenforceable by a court of competent jurisdiction because its duration, territory, or other restrictions are deemed to be invalid or unreasonable in scope, the invalid or unreasonable terms shall be replaced by terms that such court deems valid and enforceable and that come closest to expressing the intention of such invalid or unenforceable terms.

11.
Enforcement. Executive acknowledges and agrees that Chemical shall suffer irreparable harm in the event that Executive breaches any of Executive’s obligations under Sections 8, 9, or 10 of this Agreement and that monetary damages would be inadequate to compensate Chemical for such breach. Accordingly, Executive agrees that, in the event of a breach by Executive of any of Executive’s obligations under Sections 8, 9, or 10 of this Agreement, Chemical shall be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief, and expedited discovery for the purpose of seeking relief, in order to prevent or to restrain any such breach. Chemical shall be entitled to recover its costs incurred in connection with any action to enforce Sections 8, 9, or 10 of this Agreement, including reasonable attorneys’ fees and expenses.

12.
Miscellaneous.






(a) Entire Agreement. This Agreement, when aggregated with the attached Release, as applicable, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements (whether written or oral and whether express or implied) between the parties to the extent related to such subject matter, including Executive’s employment agreements with Chemical dated January 25, 2016 and August 9, 2017.

(b) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors, permitted assigns and, in the case of Executive, heirs, executors, and/or personal representatives. Chemical may freely assign or transfer this Agreement to an affiliated company or to a successor following a merger, consolidation, sale of assets or equity, or other business transaction. Executive may not assign, delegate or otherwise transfer any of Executive’s rights, interests or obligations in this Agreement.

(c) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement.

(d) Notices. Any notice pursuant to this Agreement must be in writing and shall be deemed effectively given to the other party on (i) the date it is actually delivered by overnight courier service (such as FedEx) or personal delivery of such notice in person, or (ii) three (3) days after mailing by certified or registered U.S. mail, return receipt requested; in each case the appropriate address shown below (or to such other address as a party may designate by notice to the other party):

If to Executive:            Gary Torgow
                        

If to Chemical:            Chemical Financial Corporation                                            2301 West Big Beaver Road
Troy, MI 48084
Attention: Chief Executive Officer
    
(e) Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the amendment is in writing and signed by Chemical and Executive. No waiver of any provision of this Agreement shall be valid unless the waiver is in writing and signed by the waiving party. The failure of a party at any time to require performance of any provision of this Agreement shall not affect such party’s rights at a later time to enforce such provision. No waiver by a party of any breach of this Agreement shall be deemed to extend to any other breach hereunder or affect in any way any rights arising by virtue of any other breach.

(f) Severability. Each provision of this Agreement is severable from every other provision of this Agreement. Any provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable shall not affect the validity or enforceability of any other provision. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable.

(g) Construction. The section headings in this Agreement are inserted for convenience only and are not intended to affect the interpretation of this Agreement. Any reference in this Agreement to any “Section” refers to the corresponding Section of this Agreement. The word “including” in this Agreement means “including without limitation.” This Agreement shall be construed as if drafted jointly by Chemical and Executive and no presumption or burden of proof shall arise favoring or disfavoring Chemical or Executive by virtue of the authorship of any provision in this Agreement. All words in this Agreement shall be construed to be of such gender or number as the circumstances require.

(h) Survival. The terms of Sections 6, 7, 8, 9, 10, 11 and 12 shall survive the termination of this Agreement for any reason.

(i) Remedies Cumulative. The rights and remedies of the parties under this Agreement are cumulative (not alternative) and in addition to all other rights and remedies available to such parties at law, in equity, by contract or otherwise.

(j) Venue. Executive and the Corporation agree that the exclusive forum for resolving any disputes between the parties related to Release Agreement shall be arbitration before the American Arbitration Association applying the Employment Arbitration Rules and Mediation Procedures as amended and effective November 1, 2009. The Arbitrator shall be empowered to grant any legal or equitable relief available to the parties, including interim equitable relief as set





forth in the Optional Rules for Emergency Measures of Protection. Any award of the Arbitration may be enforced through proceedings in a court of competent jurisdiction.

(k) Governing Law. This Agreement shall be governed by the laws of the State of Michigan without giving effect to any choice or conflict of law principles of any jurisdiction.


[Signatures are on the Next Page]





IN WITNESS WHEREOF , the parties hereto have executed and delivered this Agreement as of the date first written above.

 
 
 
Date:
February 27, 2018
/s/ Gary Torgow
 
 
Gary Torgow
Executive
 
 
 
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
Date:
February 27, 2018
/s/ Thomas C. Shafer
 
 
Thomas C. Shafer
Vice Chairman of Chemical Financial Corporation
 
 
 




    





APPENDIX A
EMPLOYMENT AGREEMENT RELEASE
THIS RELEASE AGREEMENT (the “ Release ”) is made as of the ____ day of _______, 20__, by and between Chemical Financial Corporation (“ Chemical ”) and Gary Torgow (the “ Executive ”) (in the aggregate, the “ Parties ”).
WHEREAS , Chemical and Executive have entered into an Employment Agreement dated as of February 27, 2018, (the “ Employment Agreement ”), pursuant to which Executive is entitled to receive certain additional compensation upon termination of Executive’s employment with Chemical Without Cause or for Good Reason (all as defined in the Employment Agreement); and
WHEREAS , Executive’s receipt of the additional compensation under the Employment Agreement is conditioned upon the execution of this Release that is mutually acceptable to both Parties; and
WHEREAS, Executive’s employment with Chemical has been/shall be terminated effective ______________ __, 20__ [Without Cause], [due to Good Reason by the Executive];
NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed between the Parties as follows:
1.      Additional Compensation . Subject to the terms and conditions hereof, Chemical shall pay Executive the additional compensation set forth in Section 6 of the Employment Agreement, net of applicable withholding taxes, commencing after the expiration of the waiting period set forth herein and in accordance with the terms of the Employment Agreement.
2.      Release.
(a)    In exchange for the good and valuable consideration set forth herein, Executive agrees for himself, his heirs, administrators, representatives, executors, successors and assigns (“Releasors”), to irrevocably and unconditionally release, waive and forever discharge any and all manner of action, causes of action, claims, rights, promises, charges, suits, damages, debts, lawsuits, liabilities, rights, due controversies, charges, complaints, remedies, losses, demands, obligations, costs, expenses, fees (including, without limitation attorneys’ fees), or any and all other liabilities or claims of whatsoever nature, whether arising in contract, tort, or any other theory of action, whether arising in law or in equity, whether known or unknown, choate or inchoate, matured or unmatured, contingent or fixed, liquidated or unliquidated, accrued or unaccrued, asserted or unasserted, including, but not limited to, any claim and/or claim of damages or other relief for tort, breach of contract, personal injury, negligence, age discrimination under The Age Discrimination In Employment Act of 1967 (as amended), employment discrimination prohibited by other federal, state or local laws including sex, race, national origin, marital status, age, handicap, height, weight, or religious discrimination, and any other claims of unlawful employment practices or any other unlawful criterion or circumstance which Executive and Releasors had, now have, or may have in the future against each or any of Chemical, its parent, divisions, affiliates and related companies or entities, regardless of its or their form of business organization (the “ Company Entities ”), any predecessors, successors, joint ventures, and parents of any Company Entity, and any and all of their respective past or present directors, officers, shareholders, partners, employees, consultants, independent contractors, trustees, administrators, insurers, agents, attorneys, representative and fiduciaries, successors and assigns including without limitation all persons acting by, through, under or in concert with any of them (all collectively, the “ Released Parties ”) arising out of or relating to his employment relationship with Chemical, its predecessors, successors or affiliates and the termination thereof’ provided, however, that Executive expressly does not release his rights to indemnification under the provisions of the Articles of Incorporation or Bylaws of Chemical, the Bank or any indemnification agreement entered into between Executive and Chemical, the Bank or any Affiliates. Executive understands that he does not waive rights or claims that may arise after the date of this Release.
(b)    Executive acknowledges that he has read this Release carefully and understands all of its terms.
(c)    Executive understands and agrees that he has been advised to consult with an attorney prior to executing this Release.
(d)    Executive understands that he is entitled to consider this Release for at least twenty-one (21) days before signing the Release. However, after due deliberation, Executive may elect to sign this Release without availing himself of the opportunity to consider its provisions for at least twenty-one (21) days. Executive hereby acknowledges that any decision to shorten the time for considering this Release prior to signing it is voluntary, and such decision is not induced by or through fraud, misrepresentation,





or a threat to withdraw or alter the provisions set forth in this Release in the event Executive elected to consider this Release for at least twenty-one (21) days prior to signing the Release.
(e)    Executive understands that he may revoke this Release as it relates to any potential claim that could be brought or filed under the Age Discrimination in Employment Act 29 U.S.C. §§ 621-634, within seven (7) days after the date on which he signs this Release, and that this Release as it relates to such a claim does not become effective until the expiration of the seven (7) day period. In the event that Executive wishes to revoke this Release within the seven (7) day period, Executive understands that he must provide such revocation in writing to the then Chief Executive Officer at Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084.
(f)    In agreeing to sign this Release, Executive is doing so voluntarily and agrees that he has not relied on any oral statements or explanations made by Chemical or its representatives.
(g)    This Release shall not be construed as an admission of wrongdoing by either Executive or Chemical.
3.      Notices . Every notice relating to this Release shall be in writing and if given by mail shall be given by registered or certified mail with return receipt requested. All notices to Chemical shall be delivered to Chemical’s Chief Executive Officer at Chemical Financial Corporation, 2301 W. Big Beaver Rd, Troy, MI 48084. All notices by Chemical to Executive shall be delivered to Executive personally or addressed to Executive at Executive’s last residence address as then contained in the records of Chemical or such other address as Executive may designate. Either party by notice to the other may designate a different address to which notices shall be addressed. Any notice given by Chemical to Executive at Executive’s last designated address shall be effective to bind any other person who shall acquire rights hereunder.
4.      Governing Law . To the extent not preempted by Federal law, this Release shall be governed by and construed in accordance with the laws of the State of Michigan, without giving effect to conflicts of laws.
5.      Counterparts . This Release may be executed in two (2) or more counterparts, all of which when taken together shall be considered one (1), and the same Release and shall become effective when the counterparts have been signed by each party and delivered to the other party; it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.
6.      Entire Agreement . This Release, when aggregated with the Employment Agreement [Note: Add any other documents, as applicable], contains the entire understanding of the parties with respect to the subject matter hereof and together supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Release.
IN WITNESS WHEREOF, the parties hereto have executed this Release as of the day and year first written above.
 
 
 
 
 
 
 
 
Gary Torgow,
Executive
 
 
 
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
 
 
 
 
By:
 
 
Its:
 






WAIVER OF 21 DAY NOTICE PERIOD
I have been provided with the General Release Agreement (“ Agreement ”) between Chemical Financial Corporation (collectively with all of its affiliates, the “ Corporation ”) and Gary Torgow (“ Executive ”).
I understand that I have twenty-one (21) days from the date the Agreement was presented to me to consider whether or not to sign the Agreement. I further understand that I have the right to seek counsel prior to signing the Agreement.
I am knowingly and voluntarily signing and returning the Agreement prior to the expiration of the twenty-one (21)-day consideration period. I understand that I have seven (7) days from signing the Agreement to revoke the Agreement, by delivering a written notice of revocation to the Chief Executive Officer, Chemical Financial Corporation, 2301 W. Big Beaver Rd., Troy, MI 48084.
 
 
 
Dated:
 
 
 
 
Gary Torgow,
Executive
 
 
 
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
 
 
 
 
By:
 
 
Its:
 





Exhibit 10.28

PHILANTHROPY AGREEMENT
THIS AGREEMENT (the “ Agreement ”) between Chemical Financial Corporation (“ Chemical ” ) and Gary Torgow (the “ Executive ”) is entered into as of February 27, 2018.
WHEREAS, Executive currently serves as Executive Chairman of Chemical’s Board of Directors (the “ Board ”); and
WHEREAS , Chemical recognizes Executive’s long and distinguished history of strong philanthropy to the community that Chemical serves; and
WHEREAS , in the event Executive’s services as Executive Chairman of the Board are terminated and Executive receives a cash severance benefit in connection with his separation from service, Chemical desires to make the charitable contribution described below in recognition of Executive’s extraordinary philanthropy to the community;
NOW, THEREFORE , in consideration of the foregoing, Chemical agrees as follows:
If, Executive’s services to Chemical as Chairman of the Board are terminated Without Cause or for Good Reason, both as defined in the employment agreement between Executive and Chemical in effect at such time (the “ Employment Agreement ”), Chemical, in recognition of Executive’s voluntary generosity shown to the community over a long period of time, shall donate to the Community Foundation of Southeastern Michigan a cash, lump sum payment within sixty (60) calendar days following Executive’s separation from service with Chemical (the “ Donation )”. The amount of such Donation shall equal the lesser of: (i) the total amount of any cash Severance Pay (as defined in the Employment Agreement) that Executive is entitled to receive under the Employment Agreement, and (ii) the dollar amount of his Severance Pay that Executive directs to be paid to the Community Foundation of Southeastern Michigan. Chemical and Executive agree that the Donation is not compensation to Executive for any services that Executive has provided to Chemical, is not due and would not otherwise have been paid to or at the direction of Executive, and Executive shall receive no economic benefit whatsoever as a result of the Donation.
This Agreement shall be binding upon any successor to Chemical. The Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same Agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement. No amendment of any provision of this Agreement shall be valid unless the amendment is in writing and signed by Chemical and Executive.
This Agreement is hereby executed as of the date set forth above.
 
 
CHEMICAL FINANCIAL CORPORATION
 
 
 
 
By:
/s/ Thomas C. Shafer
 
 
Thomas C. Shafer
 
Its:
Vice Chairman of Chemical Financial Corporation
 
 
 
 
 
/s/ Gary Torgow
 
 
Gary Torgow, Executive
 
 
 






Exhibit 10.29



CHEMICAL FINANCIAL CORPORATION
___________
<NAME>
<###> Units

RESTRICTED STOCK UNIT AGREEMENT
PURSUANT TO
STOCK INCENTIVE PLAN OF 2017
Performance-Based Restricted Stock Units
____________

This Restricted Stock Unit Agreement (“Agreement”) is made as of [Insert Date of Grant] (the “Grant Date”), between CHEMICAL FINANCIAL CORPORATION (the “Corporation”), and the Grantee named above (“Grantee”).

The Chemical Financial Corporation Stock Incentive Plan of 2017 (the “Plan”) is administered by the Compensation and Pension Committee of the Corporation’s Board of Directors (the “Committee”). The Committee has determined that Grantee is eligible to participate in the Plan. The Committee has awarded restricted stock units to Grantee, subject to the terms and conditions set forth in this Agreement and in the Plan.

Grantee acknowledges receipt of a copy of the Plan and the [_____] Summary Plan Description and accepts this restricted stock unit award subject to all of the terms, conditions, and pro-visions of this Agreement and the Plan.

1.      Award . Corporation hereby awards to Grantee <###> restricted stock units, subject to the restrictions imposed under this Agreement and the Plan (the “Restricted Stock Units” or “PRSUs”). Each Restricted Stock Unit is initially equal to one share of common stock, $1.00 par value, of the Corporation (“Common Stock”) and is convertible into Common Stock pursuant to the formula determined by the Committee and attached as Exhibit A , subject to vesting as set forth below.

2.      Transferability . Until the Restricted Stock Units vest as set forth in Section 3 below, the Plan provides that interests in Restricted Stock Units under this Agreement are generally not transferable by Grantee except by will or according to the laws of descent and distribution, and further provides that all rights with respect to the Restricted Stock Units are exercisable during Grantee’s lifetime only by Grantee, Grantee’s guardian, or legal representative.

3.      Vesting . Except as otherwise provided in this Agreement, the calculation of Restricted Stock Units earned pursuant to this Agreement shall occur based on the Corporation’s achievement of performance targets determined by the Committee and attached as Exhibit A for the Performance Period (as defined in Exhibit A ). Restricted Stock Units shall vest, to the extent earned, upon the conclusion of the Restricted Period (as defined below). The “Restricted Period” shall begin on the first day of the Performance Period and shall end on the date of the issuance of the audit opinion with respect to the Corporation’s consolidated financial statements for the year ending on the last day of the Performance Period, but in no event later than March 5 th of the year following the last day of the Performance Period. Restricted Stock Units are unvested under the Plan and under this Agreement until the end of the Restricted Period. Upon vesting, Restricted Stock Units will be settled as soon as administratively feasible, but no later than March 15 of the year following the last day of the Performance Period.






4.      Termination of Employment . Subject to Section 11 below, if the Grantee’s employment with the Corporation or any of its Subsidiaries is terminated during any Restricted Period by the Corporation without cause, or if Grantee terminates employment due to Good Reason, or if the Grantee dies or becomes Disabled during any Restricted Period, then Grantee shall be issued within thirty (30) days following the effective date of the termination of Grantee’s employment the (i) Target (100%) number of PRSUs set forth in Section 1 of this Agreement, multiplied by (ii) the quotient of (x) the number of full months that have elapsed between the first day of the Performance Period and the effective date of the Grantee’s termination and (y) the total number of full months in the respective Performance Period. If the Grantee’s employment is terminated due to Retirement, and if the Grantee has given the Corporation written notice of the Grantee’s intended date of Retirement at least one year in advance of such intended date of Retirement, then Grantee shall be issued within thirty (30) days following the effective date of the termination of Grantee’s employment the (i) Target (100%) number of Restricted Stock Units set forth in Section 1 of this Agreement, multiplied by (ii) the quotient of (x) the number of full months that have elapsed between the first day of the Performance Period and the effective date of the Grantee’s termination and (y) the total number of full months in the respective Performance Period. If the Grantee does not provide such one year advanced notice of the Grantee’s intended date of Retirement, then all Restricted Stock Units still subject to restrictions at the date of such Retirement shall automatically be forfeited. Any unvested Restricted Stock Units shall be forfeited upon termination of employment by the Corporation for cause or voluntary termination of employment by the Grantee, except as provided herein.

5.      Employment by Corporation . The award of Restricted Stock Units under this Agreement shall not impose upon the Corporation or any Subsidiary any obligation to retain Grantee in its employ for any given period or upon any specific terms of employment. The Corporation or any Subsidiary may at any time dismiss Grantee from employment, free from any liability or claim under the Plan or this Agreement, unless otherwise expressly provided in any written agreement with Grantee.

6.      Shareholder Rights . During the Restricted Period, Grantee shall have all non-cash dividend and all liquidation rights with respect to shares of Common Stock subject to the Restricted Stock Units held by Grantee as if Grantee held unrestricted Common Stock. Any non-cash dividends or distributions paid with respect to shares of Common Stock subject to unvested Restricted Stock Units shall be subject to the same restrictions and vesting schedule as the shares to which such dividends or distributions relate. Grantee shall have no voting rights with respect to shares of Common Stock underlying Restricted Stock Units unless and until such shares are reflected as issued and outstanding on the Corporation’s stock ledger.

7.      Illegality. The Corporation will not be obligated to issue any shares to the Grantee under this agreement, if the issuance of such shares shall constitute a violation by the Grantee or the Corporation of any provision of any law, order or regulation of any governmental authority.

8.      Certifications. The Grantee acknowledges that he or she has been furnished and has read the [____] Summary Plan Description relating to the Plan. The Grantee shall not resell or distribute the shares received upon vesting of the Restricted Stock Units in compliance with such conditions as the Corporation may reasonably specify to ensure compliance with federal and state securities laws and other Corporation policies, including stock ownership guidelines, if applicable.

9.      Withholding . The Corporation or one of its Subsidiaries shall be entitled to (a) withhold and deduct from Grantee’s future wages (or from other amounts that may be due and owing to Grantee from Corporation or a Subsidiary), or make other arrangements for the collection of, all legally required amounts necessary to satisfy any and all federal, state, and local withholding and employment-related tax requirements attributable to the Restricted Stock Unit award under this Agreement, including, without limitation, the award or vesting of, or payments of dividends with respect to, the Restricted Stock Units; or (b) require Grantee promptly to remit the amount of such withholding to the Corporation or a Subsidiary before taking any action with respect to the Restricted Stock Units. Unless the Committee provides otherwise, withholding may be satisfied by withholding Common Stock to be received or by delivery to the Corporation or a Subsidiary of previously owned Common Stock of the Corporation.






10.      Effective Date . This award of Restricted Stock Units shall be effective as of the date first set forth above.

11. Change in Control.

11 . 1      Restricted Stock Units Assumed or Substituted by Surviving Entity . If the Restricted Stock Units granted hereunder are assumed by the surviving entity or otherwise equitably converted or substituted in connection with a Change in Control, such Restricted Stock Units shall be fixed at an amount equal to the Target (100%) number of PRSUs set forth in Section 1 above, and will be fully vested at the end of the Performance Period and settled as soon as administratively feasible, but no later than March 15 of the year following the last day of the Performance Period; provided that, if sooner than the end of the Performance Period, if on or within two years after the effective date of the Change in Control, Grantee’s employment is involuntarily terminated other than for cause or the Grantee terminates employment for Good Reason, the Target (100%) number of PRSUs set forth in Section 1 of this Agreement shall immediately vest and be settled within thirty (30) days following the effective date of the termination of Grantee’s employment.

11.2      Restricted Stock Units Not Assumed or Substituted by Surviving Entity . With respect to Restricted Stock Units that are not assumed by the surviving entity or otherwise equitably converted or substituted in connection with the Change in Control in a manner approved by the Committee or the Board, then upon the occurrence of a Change in Control the market value of the Target (100%) number of PRSUs set forth in Section 1 above shall be determined as of the date of the Change in Control (the “PRSU Amount”). The PRSU Amount will be paid in cash (without interest) to Grantee as soon as administratively feasible after the conclusion of the Performance Period. If, on or within two years after the effective date of the Change in Control, and sooner than the end of the Performance Period, Grantee’s employment is involuntarily terminated other than for cause or the Grantee terminates employment for Good Reason, then the PRSU Amount shall be paid to the Grantee within thirty (30) days following the effective date of the termination of Grantee’s employment.

12.      Definitions . Capitalized terms not defined herein shall be as defined in the Plan. For purposes of this Agreement, the following term has the following definition:

(a)      Change in Control ,” means an occurrence of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A issued under the Act. Without limiting the inclusiveness of the definition in the preceding sentence, a Change in Control of the Corporation shall be deemed to have occurred as of the first day that any one or more of the following conditions is satisfied: (a) any Person is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Corporation representing 25% or more of the combined voting power of the Corporation’s then outstanding securities; (b) the failure at any time of the Continuing Directors to constitute at least a majority of the Board; or (c) any of the following occur: (i) any merger or consolidation of the Corporation, other than a merger or consolidation in which the voting securities of the Corporation immediately prior to the merger or consolidation continue to represent (either by remaining outstanding or being converted into securities of the surviving entity) 40% or more of the combined voting power of the Corporation or surviving entity immediately after the merger or consolidation with another entity; (ii) any sale, exchange, lease, mortgage, pledge, transfer or other disposition (in a single transaction or a series of related transactions) of assets or earning power aggregating more than 40% of the assets or earning power of the Corporation on a consolidated basis; (iii) any complete liquidation or dissolution of the Corporation; (iv) any reorganization, reverse stock split or recapitalization of the Corporation which would result in a Change in Control as otherwise defined in this Plan; or (v) any transaction or series of related transactions having, directly or indirectly, the same effect as any of the foregoing.
    
13.      Amendment . This Agreement shall not be modified except in a writing executed by the parties hereto.






14.      Agreement Controls . The Plan is incorporated in this Agreement by reference. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the provisions of the Agreement shall control. Furthermore, in the event of any conflict between the terms of this Agreement or the terms of the Plan and any written employment agreement with the Grantee, the provisions of the written employment agreement shall control. For the avoidance of doubt, and in furtherance of the foregoing sentence, to the extent that any defined term in this Agreement, such as “Change in Control” or any undefined term such as “cause,” is defined differently in any written employment agreement with the Grantee, the definition of any such term as set forth in such written employment agreement shall control.
  






* * *


This grant of Restricted Stock Units has been issued by the Corporation by authority of its Compensation and Pension Committee.

                    
CHEMICAL FINANCIAL CORPORATION
“Corporation”

                            
__________________________________            
By: David T. Provost                 
Its: CEO & President                  
                                            



___________________________________            
Signature     
Name:

“Grantee”
                        







Exhibit 10.30

CHEMICAL FINANCIAL CORPORATION
___________
<NAME>
<###> Units

RESTRICTED STOCK UNIT AGREEMENT
PURSUANT TO
STOCK INCENTIVE PLAN OF 2017
Time-Based Restricted Stock Units

____________


This Restricted Stock Unit Agreement (“Agreement”) is made as of [Insert Date of Grant] (the “Grant Date”), between CHEMICAL FINANCIAL CORPORATION (the “Corporation”), and the Grantee named above (“Grantee”).

The Chemical Financial Corporation Stock Incentive Plan of 2017 (the “Plan”) is administered by the Compensation and Pension Committee of the Corporation’s Board of Directors (the “Committee”). The Committee has determined that Grantee is eligible to participate in the Plan. The Committee has awarded restricted stock units to Grantee, subject to the terms and conditions set forth in this Agreement and in the Plan.

Grantee acknowledges receipt of a copy of the Plan and the [ ] Summary Plan Description and accepts this restricted stock unit award subject to all of the terms, conditions, and pro-visions of this Agreement and the Plan.

1.      Award . Corporation hereby awards to Grantee <###> restricted stock units, subject to the restrictions imposed under this Agreement and the Plan (the “Restricted Stock Units” or “TRSUs”). Each Restricted Stock Unit is initially equal to one share of common stock, $1.00 par value, of the Corporation (“Common Stock”) and is convertible into one share of Common Stock, subject to vesting as set forth below.

2.      Transferability . Until the Restricted Stock Units vest as set forth in Section 3 below, the Plan provides that interests in Restricted Stock Units under this Agreement are generally not transferable by Grantee except by will or according to the laws of descent and distribution, and further provides that all rights with respect to the Restricted Stock Units are exercisable during Grantee’s lifetime only by Grantee, Grantee’s guardian or legal representative.

3.      Vesting . Except as otherwise provided in this Agreement, the vesting of Restricted Stock Units earned pursuant to this Agreement shall occur based on the continued employment of the Grantee as determined by the Committee and the vesting schedule attached as Exhibit A . The periods during which Restricted Stock Units are unvested under the Plan and under this Agreement shall be known as the “Restricted Period(s).” The Restricted Period(s) shall lapse upon the date or dates identified in Exhibit A . Upon vesting, Restricted Stock Units will be settled as soon as administratively feasible within thirty (30) days following the date of vesting.

4.      Termination of Employment . Subject to Section 11 below, if the Grantee’s employment with the Corporation or any of its Subsidiaries is terminated during any Restricted Period by the Corporation without cause, or if Grantee terminates employment due to Good Reason, or if the Grantee dies or becomes Disabled during any Restricted Period, then Grantee shall be issued within thirty (30) days following the effective date of the termination of Grantee’s employment (i) the number of unvested TRSUs as of the effective date of the of the termination, multiplied by (ii) the quotient of (x) the number of full months that have elapsed since the most recent annual vesting date, or if no vesting date has occurred, the Grant Date, and the effective date of the Grantee’s termination, and (y) the total number of full





months remaining in the vesting period since the most recent annual vesting date, or if no vesting date has occurred, the Grant Date. If the Grantee’s employment is terminated due to Retirement, and if the Grantee has given the Corporation written notice of the Grantee’s intended date of Retirement at least one year in advance of such intended date of Retirement, then Grantee shall be issued within thirty (30) days following the effective date of the termination of Grantee’s employment (i) the number of unvested TRSUs as of the effective date of the of the termination, multiplied by (ii) the quotient of (x) the number of full months that have elapsed since the most recent annual vesting date, or if no vesting date has occurred, the Grant Date, and the effective date of the Grantee’s termination, and (y) the total number of full months remaining in the vesting period since the most recent annual vesting date, or if no vesting date has occurred, the Grant Date; provided that, if the Grantee does not provide such one year advanced notice of the Grantee’s intended date of Retirement, then all Restricted Stock Units still subject to restrictions at the date of such Retirement shall automatically be forfeited. Any unvested Restricted Stock Units shall be forfeited upon termination of employment by the Corporation for cause or voluntary termination of employment by the Grantee.

5.      Employment by Corporation . The award of Restricted Stock Units under this Agreement shall not impose upon the Corporation or any Subsidiary any obligation to retain Grantee in its employ for any given period or upon any specific terms of employment. The Corporation or any Subsidiary may at any time dismiss Grantee from employment, free from any liability or claim under the Plan or this Agreement, unless otherwise expressly provided in any written agreement with Grantee.

6.      Shareholder Rights . During the Restricted Period, Grantee shall have all non-cash dividend and all liquidation rights with respect to shares of Common Stock subject to the Restricted Stock Units held by Grantee as if Grantee held unrestricted Common Stock. In addition, Grantee shall receive a number of Restricted Stock Units equal to the number of shares of Common Stock (including fractions of a share) that have a Market Value equal to the amount of any cash dividends that would have been payable to a shareholder owning the number of shares of Common Stock represented by Restricted Stock Units subject to this Agreement on each dividend payment date (“Dividend Equivalents”). A n y dividend equivalents, non-cash dividends or distributions paid with respect to shares of Common Stock subject to unvested Restricted Stock Units shall be subject to the same restrictions and vesting schedule as the shares to which such dividend equivalents, dividends or distributions relate. Grantee shall have no voting rights with respect to shares of Common Stock underlying Restricted Stock Units unless and until such shares are reflected as issued and outstanding on Corporation’s stock ledger.

7.      Illegality. The Corporation will not be obligated to issue any shares to the Grantee under this Agreement, if the issuance of such shares shall constitute a violation by the Grantee or the Corporation of any provision of any law, order or regulation of any governmental authority.

8.      Certifications. The Grantee acknowledges that he or she has been furnished and has read the [ ] Summary Plan Description relating to the Plan. The Grantee shall not resell or distribute the shares received upon vesting of the Restricted Stock Units in compliance with such conditions as the Corporation may reasonably specify to ensure compliance with federal and state securities laws and other Corporation policies, including stock ownership guidelines, if applicable.

9.      Withholding . The Corporation or one of its Subsidiaries shall be entitled to (a) withhold and deduct from Grantee’s future wages (or from other amounts that may be due and owing to Grantee from Corporation or a Subsidiary), or make other arrangements for the collection of, all legally required amounts necessary to satisfy any and all federal, state, and local withholding and employment-related tax requirements attributable to the Restricted Stock Units awarded under this Agreement, including, without limitation, the award or vesting of, or payments of dividends with respect to, the Restricted Stock Units; or (b) require Grantee promptly to remit the amount of such withholding to the Corporation or a Subsidiary before taking any action with respect to the Restricted Stock Units. Unless the Committee provides otherwise, withholding may be satisfied by withholding Common Stock to be received or by delivery to the Corporation or a Subsidiary of previously owned Common Stock of the Corporation.

10.      Effective Date . This award of Restricted Stock Units shall be effective as of the date first set forth above.






11.      Change in Control.     

11 . 1      Restricted Stock Units Assumed or Substituted by Surviving Entity . With respect to Restricted Stock Units assumed by the surviving entity or otherwise equitably converted or substituted in connection with a Change in Control in a manner approved by the Committee or the Board, if on or within two years after the effective date of the Change in Control, a Grantee’s employment is involuntarily terminated other than for cause or the Grantee terminates employment for Good Reason, then all remaining time-based vesting restrictions on that Grantee’s outstanding Restricted Stock Units shall lapse and be settled within thirty (30) days following the effective date of the termination of Grantee’s employment.

11.2      Restricted Stock Units Not Assumed or Substituted by Surviving Entity . With respect to Restricted Stock Units that are not assumed by the surviving entity or otherwise equitably converted or substituted in connection with the Change in Control in a manner approved by the Committee or the Board, then upon the occurrence of a Change in Control the market value of all time-based Restricted Stock Units that were outstanding immediately before the effective time of the Change in Control shall be determined as of the date of the Change in Control (the “TRSU Amount”). The TRSU Amount shall remain subject to the vesting schedule of the applicable time-based Restricted Stock Units and will be paid in cash (without interest) to Grantee when the applicable Restricted Stock Units Awards otherwise would have vested if the Grantee remains employed with the surviving entity at that time. If, on or within two years after the effective date of the Change in Control, Grantee’s employment is involuntarily terminated other than for cause or the Grantee terminates employment for Good Reason, then the entire remaining TRSU Amount shall be paid to the Grantee within thirty (30) days following the effective date of the termination of Grantee’s employment.

11.3      Definitions . Capitalized terms not defined herein shall be as defined in the Plan. For purposes of this Agreement, the following term has the following definition:

(a)      Change in Control ,” means an occurrence of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A issued under the Act. Without limiting the inclusiveness of the definition in the preceding sentence, a Change in Control of the Corporation shall be deemed to have occurred as of the first day that any one or more of the following conditions is satisfied: (a) any Person is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Corporation representing 25% or more of the combined voting power of the Corporation’s then outstanding securities; (b) the failure at any time of the Continuing Directors to constitute at least a majority of the Board; or (c) any of the following occur: (i) any merger or consolidation of the Corporation, other than a merger or consolidation in which the voting securities of the Corporation immediately prior to the merger or consolidation continue to represent (either by remaining outstanding or being converted into securities of the surviving entity) 40% or more of the combined voting power of the Corporation or surviving entity immediately after the merger or consolidation with another entity; (ii) any sale, exchange, lease, mortgage, pledge, transfer or other disposition (in a single transaction or a series of related transactions) of assets or earning power aggregating more than 40% of the assets or earning power of the Corporation on a consolidated basis; (iii) any complete liquidation or dissolution of the Corporation; (iv) any reorganization, reverse stock split or recapitalization of the Corporation which would result in a Change in Control as otherwise defined in this Plan; or (v) any transaction or series of related transactions having, directly or indirectly, the same effect as any of the foregoing.

12.      Amendment . This Agreement shall not be modified except in a writing executed by the parties hereto.

13.      Agreement Controls . The Plan is incorporated in this Agreement by reference. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the provisions of the Agreement shall control. Furthermore, in the event of any conflict between the terms of this Agreement or the terms of the Plan and any written employment agreement with the Grantee, the provisions of the written employment agreement shall control. For the avoidance of doubt, and in furtherance of the foregoing sentence, to the extent that any defined term in this Agreement, such as “Change in Control” or any undefined term such as “cause,” is defined differently in any written employment agreement with the Grantee, the definition of any such term as set forth in such written employment agreement shall control.






* * *

This grant of Restricted Stock Units has been issued by the Corporation by authority of its Compensation and Pension Committee.

                    
CHEMICAL FINANCIAL CORPORATION
“Corporation”         

                        
________________________________________
By: David T. Provost                                               Its: CEO & President
                        
            

“Grantee”


_________________________________________        
Signature     
Name:









EXHIBIT 21


SUBSIDIARIES OF
CHEMICAL FINANCIAL CORPORATION


Subsidiaries
 
Ownership
Percentage
 
State or Other Jurisdiction
of Incorporation
 
 
 
 
 
Chemical Bank
 
(1)
 
Michigan
CFC Financial Services, Inc.
 
 
 
 
also operates under d/b/a
Chemical Financial Advisors
 
(2)
 
Michigan
CFC Title Services, Inc.
 
(1)
 
Michigan
CFC Capital, Inc.
 
(2)
 
Michigan
First of Huron Capital Trust I
 
(1)
 
Delaware
First Place Capital Trust
 
(1)
 
Delaware
First Place Capital Trust II
 
(1)
 
Delaware
First Place Capital Trust III
 
(1)
 
Delaware
InSite Capital, LLC
 
(1)
 
Michigan
Port Huron CDE, LLC
 
(2)
 
Michigan
 
 
 
 
 

(1)
100% owned by Chemical Financial Corporation.
(2)
100% owned by Chemical Bank.





EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm


The Board of Directors
Chemical Financial Corporation


We consent to the incorporation by reference in the registration statement (No. 333‑217834) on Form S-3, and (Nos. 333-133962, 333-157569, 333-166377, 333-181140, 333-202555, 333-203742, 333-210520, 333-217836, and 333-217837) on Form S-8 of Chemical Financial Corporation of our reports dated February 28, 2018 , with respect to the consolidated statements of financial position of Chemical Financial Corporation as of December 31, 2017 and 2016 , and the related consolidated statements of income, comprehensive income, changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017 , and the related notes (collectively, the consolidated financial statements), and the effectiveness of internal control over financial reporting as of December 31, 2017 , which reports appear in the December 31, 2017 annual report on Form 10‑K of Chemical Financial Corporation.

/s/ KPMG LLP

Detroit, Michigan
February 28, 2018








EXHIBIT 23.2

Consent of Independent Registered Public Accounting Firm
 

The Board of Directors
Chemical Financial Corporation



We hereby consent to the incorporation by reference in the Registration Statement No. 333-157569 on Form S-8 dated February 27, 2009 of our report dated February 28, 2018 with respect to the financial statements of the Chemical Financial Corporation Directors' Deferred Stock Plan included in Exhibit 99.1 of this Annual Report (Form 10-K) as of December 31, 2017 and 2016 and the related statements of income and changes in plan equity for each of the three years in the period ended December 31, 2017 filed with the Securities and Exchange Commission.


/s/ Andrews Hooper Pavlik PLC

Saginaw, Michigan
February 28, 2018










EXHIBIT 24

LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 20, 2017
/s/ James R. Fitterling
 
(signature)
 
 
 
James R. Fitterling
 
(type or print name)










LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Ronald A. Klein
 
(signature)
 
 
 
Ronald A. Klein
 
(type or print name)








LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Richard M. Lievense
 
(signature)
 
 
 
Richard M. Lievense
 
(type or print name)












LIMITED POWER OF ATTORNEY
 
The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 29, 2017
/s/ Barbara J. Mahone
 
(signature)
 
 
 
Barbara J. Mahone
 
(type or print name)







LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 22, 2017
/s/ John E. Pelizzari
 
(signature)
 
 
 
John E. Pelizzari

 
(type or print name)







LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ David T. Provost
 
(signature)
 
 
 
David T. Provost

 
(type or print name)







LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Thomas C. Shafer
 
(signature)
 
 
 
Thomas C. Shafer
 
(type or print name)






LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Larry D. Stauffer
 
(signature)
 
 
 
Larry D. Stauffer
 
(type or print name)






LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Jeffrey L. Tate
 
(signature)
 
 
 
Jeffrey L. Tate
 
(type or print name)






LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  February 20, 2018
/s/ Gary Torgow
 
(signature)
 
 
 
Gary Torgow
 
(type or print name)






 
LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Arthur A. Weiss
 
(signature)
 
 
 
Arthur A. Weiss
 
(type or print name)







LIMITED POWER OF ATTORNEY

The undersigned, in his or her capacity as a director or officer, or both, of Chemical Financial Corporation, does hereby appoint David T. Provost and Dennis L. Klaeser, or either of them, his or her attorneys or attorney, with full power of substitution, to execute in his or her name an Annual Report of Chemical Financial Corporation on Form 10-K for its fiscal year ended December 31, 2017 , and any amendments to that report, and to file the same, including all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission. Each attorney shall have power and authority to do and perform in the name and on behalf of the undersigned, in any and all capacities, every act to be done in the premises as fully and to all intents and purposes as the undersigned could do in person, and the undersigned hereby ratifies and approves the acts of such attorneys.



Dated:  December 12, 2017
/s/ Franklin C. Wheatlake
 
(signature)
 
 
 
Franklin C. Wheatlake
 
(type or print name)






EXHIBIT 31.1

CERTIFICATIONS

I, David T. Provost, certify that:
1.
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2017 of Chemical Financial Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 
Date:
February 28, 2018
/s/ David T. Provost
 
 
David T. Provost
Chief Executive Officer and President
Chemical Financial Corporation

EXHIBIT 31.2

CERTIFICATIONS

I, Dennis L. Klaeser, certify that:
1.
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2017 of Chemical Financial Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
February 28, 2018
/s/ Dennis L. Klaeser
 
 
Dennis L. Klaeser
Executive Vice President and Chief Financial Officer
Chemical Financial Corporation

EXHIBIT 32
CERTIFICATION
Pursuant to 18 U.S.C. § 1350, each of the undersigned hereby certifies in his or her capacity as an officer of Chemical Financial Corporation (the "Corporation") that the Corporation’s Annual Report on Form 10-K for the year ended December 31, 2017 fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition of the Corporation at the end of such period and the results of operations of the Corporation for such period.
 


Dated:
February 28, 2018
/s/ David T. Provost
 
 
David T. Provost
Chief Executive Officer and President
 
 
 
Dated:
February 28, 2018
/s/ Dennis L. Klaeser
 
 
Dennis L. Klaeser
Executive Vice President and Chief Financial Officer



 
A signed original of this written statement required by Section 906 has been provided to Chemical Financial Corporation and will be retained by Chemical Financial Corporation and furnished to the Securities and Exchange Commission or its staff upon request.








EXHIBIT 99.1










 



Financial Statements
With Report of Independent Registered Public Accounting Firm



Chemical Financial Corporation
Directors' Deferred Stock Plan


December 31, 2017






Report of Independent Registered Public Accounting Firm



Plan Administrator
Chemical Financial Corporation
Directors' Deferred Stock Plan

Opinion on the Financial Statements

We have audited the accompanying statements of financial condition of the Chemical Financial Corporation Directors' Deferred Stock Plan as of December 31, 2017 and 2016 and the related statements of income and changes in plan equity for each of the three years in the period ended December 31, 2017 , and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Plan, as of December 31, 2017 and 2016, and the results of its operations for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Plan in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of the Plan's internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purposes of expressing an opinion on the effectiveness of the Plan's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material mistatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.




/s/ Andrews Hooper Pavlik PLC

Andrews Hooper Pavlik PLC

We have served as the Plan's auditor since 2008.

Saginaw, Michigan
February 28, 2018


1


Chemical Financial Corporation
Directors' Deferred Stock Plan


Statements of Financial Condition

 
 
December 31,
 
 
2017
 
2016
Assets
 
 
 
 
Cash
 
$

 
$
64,100

Common stock receivable of Chemical Financial Corporation, at fair value (28,699 shares at a cost of $1,437,094 at December 31, 2017 and 880 shares at a cost of $47,451 at December 31, 2016)
 
1,534,558

 
47,649

Total Assets
 
$
1,534,558

 
$
111,749

Plan Equity
 
 
 
 
Plan equity (20 participants at December 31, 2017 and 19 participants at December 31, 2016)
 
$
1,534,558

 
$
111,749



See accompanying notes.




2


Chemical Financial Corporation
Directors' Deferred Stock Plan


Statements of Income and Changes in Plan Equity

 
 
Years Ended December 31,
 
 
2017
 
2016
 
2015
Additions:
 
 
 
 
 
 
    Participant contributions
 
$
1,303,750

 
$
569,400

 
$
420,050

    Dividend equivalents
 
21,793

 
67,788

 
76,024

 
 
1,325,543

 
637,188

 
496,074

 
 
 
 
 
 
 
Plan distributions
 

 
(4,128,269
)
 
(106,700
)
 
 
 
 
 
 
 
Net realized and unrealized appreciation in fair value of common stock receivable
 
97,266

 
805,900

 
314,740

Net increase (decrease)
 
1,422,809

 
(2,685,181
)
 
704,114

Plan equity at beginning of period
 
111,749

 
2,796,930

 
2,092,816

Plan equity at end of period
 
$
1,534,558

 
$
111,749

 
$
2,796,930



See accompanying notes.



3


Chemical Financial Corporation
Directors' Deferred Stock Plan

Notes to Financial Statements
Note 1 - Description of the Plan
The Chemical Financial Corporation Directors' Deferred Stock Plan (Plan) became effective on April 21, 2008. The Plan, which was approved by the shareholders of Chemical Financial Corporation (Corporation), is an unfunded supplemental nonqualified deferred compensation plan designed to provide benefits to each non-employee director (Director) of the Corporation and the Corporation's subsidiary bank, Chemical Bank. The Plan provides for a maximum of 400,000 shares of the Corporation's $1.00 par value common stock (Common Stock), subject to adjustments for certain changes in the capital structure of the Corporation as defined in the Plan (including stock dividends and stock splits), to be available under the Plan.
Under the Plan, Directors are required to defer fifty percent, or such greater percentage as determined by the board of directors of the Corporation, of their annual retainer in the form of investment in stock units representing Common Stock. The remaining part of the annual retainer may, at each Director's option, be deferred and invested in stock units representing Common Stock. In addition, all meeting and other director fees may, at each Director's option, be deferred and invested in stock units representing Common Stock. Directors opting to defer the remaining portion of their annual retainer and/or other fees earned as a Director must elect to do so at the beginning of each calendar year. The election is not revocable once the year of election begins and can only be revoked or modified for future years if done so before the start of any future calendar year.
The portion of the annual retainer deferred under the Plan is credited on the books of the Corporation to an account established for that Director and converted to a number of stock units equal to the cash amount of the deferred portion of the annual retainer divided by the fair market value of one share of Common Stock on the date the annual retainer is paid. Other fees deferred under the Plan are credited to that Director's account and converted to a number of stock units equal to the cash amount of the deferred portion of other fees earned divided by the fair market value of one share of Common Stock on the next date the Corporation pays its quarterly cash dividend. The Plan also provides for dividend equivalents to be credited to each Director's account on each date the Corporation pays its quarterly cash dividend. Dividend equivalents are calculated by multiplying the Corporation's dividend rate by the number of stock units credited in each Director's account as of the date the Corporation pays its quarterly cash dividend. The Plan also provides for an appropriate credit to each Director's account for stock dividends, stock splits or other distributions of Common Stock by the Corporation.
Directors are eligible for participation in the Plan on the first day of an individual's term as a Director. Elective deferrals must be made within the first 30 days of eligibility in order for an individual to participate in the first calendar year of eligibility. Otherwise, the deferral election will be effective at the beginning of the next calendar year. All annual retainer and director fees contributed to the Plan and dividend equivalents credited to each Director's account are vested immediately. Directors will cease to be eligible to participate in the Plan upon their termination of service on the board of directors of the Corporation. Upon termination of service, death, a change in control of the Corporation or termination of the Plan, a Director will receive a number of shares of Common Stock and cash in lieu of fractional shares equal to the number of stock units in their account. Distributions from the Plan will be made in the form of either a single lump-sum or in five annual installments.
The Plan had 259,651 shares and 287,471 shares as of December 31, 2017 and 2016 , respectively, of Common Stock available for future issuance. There were no shares distributed from the Plan during 2017 . A total of 94,977 shares of Common Stock were distributed from the Plan during 2016 . The Plan considers the common stock receivable at year-end to be issued.


4


Chemical Financial Corporation
Directors' Deferred Stock Plan

Notes to Financial Statements (continued)
Note 1 - Description of the Plan (continued)
The Corporation reserves the right to terminate or amend the Plan at any time, provided, however, that no termination or amendment shall affect or diminish any Director's right to the benefit of contributions made by him/her prior to the date of such amendment or termination.
The Plan is not qualified under Sections 401(a) or 501(a) of the Internal Revenue Code of 1986 (IRC), as amended. The Plan does not provide for income taxes because any income is taxable to the participants. Directors participating in the Plan must treat, as ordinary taxable income, the fair market value of shares of Common Stock received at the time of distribution from the Plan or upon failure of the Plan to meet the requirements of IRC Section 409A.
Note 2 - Summary of Accounting Policies
Cash
Amounts reported as cash represent fees deferred under the Plan that have been credited to a Director's account but have not been converted to stock units. These fees will be converted to stock units on the next date the Corporation pays its quarterly cash dividend.
The fair value of cash approximates its carrying value and is classified as Level 1 in accordance with the United States generally accepted accounting principles (GAAP) fair value measurement hierarchy.
Valuation of Common Stock Receivable
The Plan's common stock receivable is recorded at the fair value per share of Common Stock multiplied by the number of shares receivable at the valuation date. Fair value is based on the closing price of Common Stock at year end ( $53.47 per share at December 31, 2017 and $54.17 per share at December 31, 2016 ).
In accordance with GAAP, the valuation of common stock receivable is measured at fair value on a recurring basis using Level 1 inputs based on quoted prices from The NASDAQ Stock Market ® .
Contributions
Participant contributions represent annual retainer and/or fees earned and deferred by Directors during the year and are accounted for on the accrual basis.
Income
Dividend equivalents are accrued on the date the Corporation pays its quarterly cash dividend.
Operating Expenses
All expenses of the Plan and its administration are paid by the Corporation.
Related Party Transactions
Substantially all transactions and balances of the Plan are considered related party transactions.

5